PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30719209-7	2019	Meanwhile, down-regulation of RasGRF2 and treatment of cells with the EGFR-targeted tyrosine kinase inhibitor (TKI) lapatinib strongly attenuated the growth of otherwise EGFR-TKI resistant AnxA6 high TNBC cells.	Lapatinib	116-125	epidermal growth factor receptor	Mus musculus	70-74
30719209-7	2019	Meanwhile, down-regulation of RasGRF2 and treatment of cells with the EGFR-targeted tyrosine kinase inhibitor (TKI) lapatinib strongly attenuated the growth of otherwise EGFR-TKI resistant AnxA6 high TNBC cells.	Lapatinib	116-125	epidermal growth factor receptor	Mus musculus	170-174
30719209-7	2019	Meanwhile, down-regulation of RasGRF2 and treatment of cells with the EGFR-targeted tyrosine kinase inhibitor (TKI) lapatinib strongly attenuated the growth of otherwise EGFR-TKI resistant AnxA6 high TNBC cells.	Lapatinib	116-125	annexin A6	Mus musculus	189-194
30655674-1	2019	Aim: To evaluate efficacy and safety of lapatinib or trastuzumab alone or both plus chemotherapy for the treatment of breast cancer patients with positive HER-2 expression.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-160
30545388-10	2018	RESULTS: We observed that trastuzumab and lapatinib upregulate Irf6 in ErbB2-positive human breast tumor cells and that neoadjuvant trastuzumab-based therapies tend to upregulate Irf6 in human breast tumors.	Lapatinib	42-51	interferon regulatory factor 6	Homo sapiens	179-183
30413412-5	2019	We report here that efferocytosis cleared apoptotic tumor cells in residual disease of lapatinib-treated HER2+ mammary tumors in MMTV-Neu mice, increased immunosuppressive cytokines, myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg).	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
30500458-20	2019	Moreover, lapatinib and neratinib are FDA-approved small molecule ErbB2/HER2 antagonists used in the treatment of selected breast cancer patients.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71
30500458-20	2019	Moreover, lapatinib and neratinib are FDA-approved small molecule ErbB2/HER2 antagonists used in the treatment of selected breast cancer patients.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
30508379-5	2018	In vitro experiments exhibited that most of tested compounds suppressed tumor cell proliferation more strongly than Gefitinib and Lapatinib (dual inhibitor of EGFR/HER2) as controls.	Lapatinib	130-139	epidermal growth factor receptor	Homo sapiens	159-163
30687062-0	2018	Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease.	Lapatinib	27-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
30687062-4	2018	Objectives: To evaluate the efficacy of the combined HER2-targeted agents, trastuzumab and lapatinib, as maintenance therapy in one patient.	Lapatinib	91-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
30545388-10	2018	RESULTS: We observed that trastuzumab and lapatinib upregulate Irf6 in ErbB2-positive human breast tumor cells and that neoadjuvant trastuzumab-based therapies tend to upregulate Irf6 in human breast tumors.	Lapatinib	42-51	interferon regulatory factor 6	Homo sapiens	63-67
30545388-10	2018	RESULTS: We observed that trastuzumab and lapatinib upregulate Irf6 in ErbB2-positive human breast tumor cells and that neoadjuvant trastuzumab-based therapies tend to upregulate Irf6 in human breast tumors.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-76
30174304-5	2018	Finally, we show that cyclocreatine in combination with the HER2 kinase inhibitor lapatinib reduces the growth of a trastuzumab-resistant HER2+ patient-derived xenograft.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
30544991-6	2018	DRAIC was also investigated in the Oncomine database and we found that DRAIC expression predicted patients" response to paclitaxel and FEC as well as lapatinib, which are commonly used therapy options for breast cancer.	Lapatinib	150-159	downregulated RNA in cancer, inhibitor of cell invasion and migration	Homo sapiens	0-5
30174304-5	2018	Finally, we show that cyclocreatine in combination with the HER2 kinase inhibitor lapatinib reduces the growth of a trastuzumab-resistant HER2+ patient-derived xenograft.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
30591093-5	2018	We found that activation of HER2 and protein kinase B (AKT) were key factors in inducing intrinsic and acquired lapatinib-resistant gastric cancer cell lines, and that AUY922 effectively suppressed activation of both HER2 and AKT in acquired lapatinib-resistant gastric cancer cell lines.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
30338368-7	2018	After treatment of BT474 cells by lapatinib, as a tyrosine kinase inhibitor (TKI), the signaling pathway of EGFR/HER2 heterodimer was significantly inhibited, which resulted in a decrease in Ca2+ entry into the cytoplasm and fluorescence emission decreased.	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	108-112
30338368-7	2018	After treatment of BT474 cells by lapatinib, as a tyrosine kinase inhibitor (TKI), the signaling pathway of EGFR/HER2 heterodimer was significantly inhibited, which resulted in a decrease in Ca2+ entry into the cytoplasm and fluorescence emission decreased.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
30591093-0	2018	HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.	Lapatinib	60-69	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
30591093-0	2018	HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
30591093-5	2018	We found that activation of HER2 and protein kinase B (AKT) were key factors in inducing intrinsic and acquired lapatinib-resistant gastric cancer cell lines, and that AUY922 effectively suppressed activation of both HER2 and AKT in acquired lapatinib-resistant gastric cancer cell lines.	Lapatinib	112-121	AKT serine/threonine kinase 1	Homo sapiens	55-58
30591093-1	2018	Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-40
30591093-1	2018	Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
30591093-5	2018	We found that activation of HER2 and protein kinase B (AKT) were key factors in inducing intrinsic and acquired lapatinib-resistant gastric cancer cell lines, and that AUY922 effectively suppressed activation of both HER2 and AKT in acquired lapatinib-resistant gastric cancer cell lines.	Lapatinib	242-251	erb-b2 receptor tyrosine kinase 2	Homo sapiens	217-221
30591093-1	2018	Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
30591093-5	2018	We found that activation of HER2 and protein kinase B (AKT) were key factors in inducing intrinsic and acquired lapatinib-resistant gastric cancer cell lines, and that AUY922 effectively suppressed activation of both HER2 and AKT in acquired lapatinib-resistant gastric cancer cell lines.	Lapatinib	242-251	AKT serine/threonine kinase 1	Homo sapiens	226-229
30591093-7	2018	Dual inhibition of the HSP90 and HER2 signaling pathways could represent a potent therapeutic strategy to treat HER2-positive gastric cancer with intrinsic and acquired resistance to lapatinib.	Lapatinib	183-192	heat shock protein 90 alpha family class A member 1	Homo sapiens	23-28
30591093-7	2018	Dual inhibition of the HSP90 and HER2 signaling pathways could represent a potent therapeutic strategy to treat HER2-positive gastric cancer with intrinsic and acquired resistance to lapatinib.	Lapatinib	183-192	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
30458861-5	2018	RESULTS: Silencing JAM-A enhanced the anti-proliferative effects of anti-HER2 treatments in trastuzumab- and lapatinib-resistant breast cancer cells and further reduced HER2 protein expression and Akt phosphorylation in drug-treated cells.	Lapatinib	109-118	F11 receptor	Homo sapiens	19-24
30398082-1	2018	AIM: HER2 testing is necessary in the context of therapy with trastuzumab, pertuzumab, lapatinib and neratinib.	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
31223207-3	2018	Improved HER2 targeting agents such as trastuzumab, pertuzumb, lapatinib and ado-trastuzumab emtansine are available.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
30893699-1	2019	BACKGROUND: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine combined with HER2-directed agents such as trastuzumab and lapatinib is supported by some evidence.	Lapatinib	195-204	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-64
30893699-1	2019	BACKGROUND: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine combined with HER2-directed agents such as trastuzumab and lapatinib is supported by some evidence.	Lapatinib	195-204	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
30893699-1	2019	BACKGROUND: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine combined with HER2-directed agents such as trastuzumab and lapatinib is supported by some evidence.	Lapatinib	195-204	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30246405-3	2018	The aim of this study was to examine the anti-tumour effect of lapatinib, a tyrosine kinase inhibitor of HER2, on canine TCC cell lines in vitro and in vivo.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	105-109
30246405-6	2018	Lapatinib inhibited phosphorylation of HER2 and cell growth in a dose-dependent manner.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	39-43
30246405-12	2018	These findings suggest that lapatinib exerts anti-tumour effects on canine TCC cells by inhibiting HER2 signalling and inducing cell cycle arrest.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	99-103
30458861-5	2018	RESULTS: Silencing JAM-A enhanced the anti-proliferative effects of anti-HER2 treatments in trastuzumab- and lapatinib-resistant breast cancer cells and further reduced HER2 protein expression and Akt phosphorylation in drug-treated cells.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
30542510-6	2018	Significantly, we use in vitro and in vivo methods to show that staurosporine synergizes with the HER2 inhibitor lapatinib to restore sensitivity toward HER2 inhibition in a HER2 inhibitor resistant breast cancer model.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
30542510-6	2018	Significantly, we use in vitro and in vivo methods to show that staurosporine synergizes with the HER2 inhibitor lapatinib to restore sensitivity toward HER2 inhibition in a HER2 inhibitor resistant breast cancer model.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
30542510-6	2018	Significantly, we use in vitro and in vivo methods to show that staurosporine synergizes with the HER2 inhibitor lapatinib to restore sensitivity toward HER2 inhibition in a HER2 inhibitor resistant breast cancer model.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
30021909-4	2018	Small-molecule EGFR kinase inhibitors (erlotinib, lapatinib) also dramatically sensitized to navitoclax-mediated apoptosis, and this was associated with markedly increased proteasome-dependent degradation of MCL1.	Lapatinib	50-59	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	208-212
29902299-1	2018	Importance: Dual anti-HER2 blockade increased the rate of pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial, and high immune gene expression was associated with pCR in all treatment arms.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
30297650-6	2018	Her2-positive OE19 EAC cells showed an induction in autophagic flux upon treatment with the small molecule Her2 inhibitor Lapatinib.	Lapatinib	122-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
30243723-0	2018	Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.	Lapatinib	67-76	p21 (RAC1) activated kinase 2	Homo sapiens	34-38
30243723-0	2018	Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
30243723-2	2018	Lapatinib has been widely used as a HER2-targeted therapy, however, a number of patients develop lapatinib resistance and still suffer from poor prognosis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
30243723-2	2018	Lapatinib has been widely used as a HER2-targeted therapy, however, a number of patients develop lapatinib resistance and still suffer from poor prognosis.	Lapatinib	97-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
30243723-6	2018	Finally, we identified PAK2 as a therapeutic target from the network analysis and validated that PAK2 knockdown and PAK inhibitor treatment resensitize the lapatinib resistant cells to lapatinib.	Lapatinib	156-165	p21 (RAC1) activated kinase 2	Homo sapiens	23-27
30243723-6	2018	Finally, we identified PAK2 as a therapeutic target from the network analysis and validated that PAK2 knockdown and PAK inhibitor treatment resensitize the lapatinib resistant cells to lapatinib.	Lapatinib	156-165	p21 (RAC1) activated kinase 2	Homo sapiens	97-101
30243723-6	2018	Finally, we identified PAK2 as a therapeutic target from the network analysis and validated that PAK2 knockdown and PAK inhibitor treatment resensitize the lapatinib resistant cells to lapatinib.	Lapatinib	185-194	p21 (RAC1) activated kinase 2	Homo sapiens	23-27
30243723-6	2018	Finally, we identified PAK2 as a therapeutic target from the network analysis and validated that PAK2 knockdown and PAK inhibitor treatment resensitize the lapatinib resistant cells to lapatinib.	Lapatinib	185-194	p21 (RAC1) activated kinase 2	Homo sapiens	97-101
30243723-7	2018	This results suggest that PAK2 is a potent therapeutic target to overcome acquired lapatinib resistance in HER2-positive breast cancer cells.	Lapatinib	83-92	p21 (RAC1) activated kinase 2	Homo sapiens	26-30
30243723-7	2018	This results suggest that PAK2 is a potent therapeutic target to overcome acquired lapatinib resistance in HER2-positive breast cancer cells.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
30017980-2	2018	Theoretical studies have been carried out to try to clarify the structural and energetic details linked to acquired resistance to Gefitinib, Erlotinib or Lapatinib, however, some of these studies are contradictory with each other and with experimental reports and did not mention whether the study was performed by considering the inactive or active EGFR states.	Lapatinib	154-163	epidermal growth factor receptor	Homo sapiens	350-354
30017980-3	2018	In this study, we combined structural data and molecular dynamic simulations coupled to a molecular mechanics generalized Born surface area approach to provide insight into the binding mechanism between three FDA-approved drugs (Erlotinib, Gefitinib and Lapatinib) that target the wild-type and T790M, L858R and L858R/T790M mutants of EGFR.	Lapatinib	254-263	epidermal growth factor receptor	Homo sapiens	335-339
30294606-3	2018	The HERACLES trial at four Italian academic cancer centers has confirmed the effectiveness of dual blockage of HER2 with trastuzumab plus lapatinib in patients with heavily pretreated HER2-positive mCRC, refractory to the anti-EGFR antibodies cetuximab or panitumumab.	Lapatinib	138-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
30334236-3	2018	More recently, and in the metastatic setting, dual HER2-targeted therapy-beyond that of trastuzumab alone, and in combination with monoclonal antibodies such as pertuzumab and tyrosine kinase inhibitors such as lapatinib-has shown a survival benefit.	Lapatinib	211-220	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
30305055-0	2018	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
30305055-0	2018	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.	Lapatinib	38-47	TNF superfamily member 10	Homo sapiens	136-141
30305055-1	2018	BACKGROUND: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
30305055-3	2018	Induction of apoptotic cell death is a key mechanism of action of lapatinib in HER2-positive breast cancer cells.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
30305055-6	2018	We identified alterations in members of the BCL-2 family of proteins, in particular MCL-1 and BAX, which may play a role in resistance to lapatinib.	Lapatinib	138-147	BCL2 apoptosis regulator	Homo sapiens	44-49
30305055-6	2018	We identified alterations in members of the BCL-2 family of proteins, in particular MCL-1 and BAX, which may play a role in resistance to lapatinib.	Lapatinib	138-147	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	84-89
30305055-6	2018	We identified alterations in members of the BCL-2 family of proteins, in particular MCL-1 and BAX, which may play a role in resistance to lapatinib.	Lapatinib	138-147	BCL2 associated X, apoptosis regulator	Homo sapiens	94-97
30305055-9	2018	Interestingly, we also found that the development of acquired resistance to lapatinib resulted in acquired sensitivity to TRAIL in SKBR3-L cells.	Lapatinib	76-85	TNF superfamily member 10	Homo sapiens	122-127
30301790-4	2018	Compared to HER2 amplification alone, in both patients and cultured cell lines, the co-occurrence of HER2 mutation and amplification was associated with poor response to trastuzumab and lapatinib, the standard-of-care anti-HER2 agents.	Lapatinib	186-195	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
30301790-4	2018	Compared to HER2 amplification alone, in both patients and cultured cell lines, the co-occurrence of HER2 mutation and amplification was associated with poor response to trastuzumab and lapatinib, the standard-of-care anti-HER2 agents.	Lapatinib	186-195	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
30297650-6	2018	Her2-positive OE19 EAC cells showed an induction in autophagic flux upon treatment with the small molecule Her2 inhibitor Lapatinib.	Lapatinib	122-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
29701763-0	2018	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.	Lapatinib	197-206	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-6
30105460-0	2018	Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-98
30105460-0	2018	Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	103-107
30105460-2	2018	Lapatinib inhibits both EGFR and HER2neu.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	24-28
30105460-2	2018	Lapatinib inhibits both EGFR and HER2neu.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-40
29678476-1	2018	BACKGROUND: Lapatinib is an oral small molecule tyrosine kinase epidermal growth factor receptor-1/HER2 inhibitor that crosses the blood-brain barrier and is active against central nervous system (CNS) metastases.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
29908185-0	2018	Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
29895705-5	2018	This increase in membrane JAGGED1 is associated with higher NOTCH receptor expression, activation, and enrichment of CSCs in vitro and in vivo Importantly, lapatinib treatment results in growth arrest and cell death of JAGGED1 low-expressing cells while the JAGGED1 high-expressing cells continue to cycle.	Lapatinib	156-165	jagged canonical Notch ligand 1	Homo sapiens	26-33
29895705-5	2018	This increase in membrane JAGGED1 is associated with higher NOTCH receptor expression, activation, and enrichment of CSCs in vitro and in vivo Importantly, lapatinib treatment results in growth arrest and cell death of JAGGED1 low-expressing cells while the JAGGED1 high-expressing cells continue to cycle.	Lapatinib	156-165	jagged canonical Notch ligand 1	Homo sapiens	219-226
29895705-5	2018	This increase in membrane JAGGED1 is associated with higher NOTCH receptor expression, activation, and enrichment of CSCs in vitro and in vivo Importantly, lapatinib treatment results in growth arrest and cell death of JAGGED1 low-expressing cells while the JAGGED1 high-expressing cells continue to cycle.	Lapatinib	156-165	jagged canonical Notch ligand 1	Homo sapiens	219-226
30227653-0	2018	Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines.	Lapatinib	30-39	epidermal growth factor receptor	Homo sapiens	15-19
29908185-3	2018	Lapatinib is a dual tyrosin kinase inhibitor of EGFR and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	48-52
29908185-3	2018	Lapatinib is a dual tyrosin kinase inhibitor of EGFR and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
29908185-11	2018	Flowcytometric analysis and immunoflurescence study using cleaved PARP antibody demonstrated the enhanced apoptotic potential of PEGylated liposomes of lapatinib.	Lapatinib	152-161	collagen type XI alpha 2 chain	Homo sapiens	66-70
29908185-13	2018	Hence, the PEGylated liposomal formulation of lapatinib can be used as a therapeutic strategy against HER2 positive breast cancer either alone or in combination with conventional anticancer agents and hormonal therapies.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
30181930-1	2018	Background: Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
30279968-0	2018	Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib.	Lapatinib	157-166	calpain 1	Mus musculus	22-31
30279968-0	2018	Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib.	Lapatinib	157-166	calpain 2	Mus musculus	36-45
30279968-4	2018	Furthermore, capns1 knockout in a tumor derived cell line correlated with enhanced sensitivity to the chemotherapeutic doxorubicin and the HER2/EGFR tyrosine kinase inhibitor lapatinib.	Lapatinib	175-184	calpain, small subunit 1	Mus musculus	13-19
30279968-4	2018	Furthermore, capns1 knockout in a tumor derived cell line correlated with enhanced sensitivity to the chemotherapeutic doxorubicin and the HER2/EGFR tyrosine kinase inhibitor lapatinib.	Lapatinib	175-184	erb-b2 receptor tyrosine kinase 2	Mus musculus	139-143
29909520-3	2018	The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer.	Lapatinib	59-68	epidermal growth factor receptor	Homo sapiens	104-136
29909520-3	2018	The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer.	Lapatinib	59-68	epidermal growth factor receptor	Homo sapiens	138-142
29909520-3	2018	The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-188
29909520-3	2018	The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	190-194
29909520-10	2018	The phosphorylated EGFR and HER2 as well as the activation of downstream molecules MAPKs and AKT significantly decreased when exposed to lapatinib and paclitaxel.	Lapatinib	137-146	epidermal growth factor receptor	Homo sapiens	19-23
29909520-10	2018	The phosphorylated EGFR and HER2 as well as the activation of downstream molecules MAPKs and AKT significantly decreased when exposed to lapatinib and paclitaxel.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
29948766-0	2018	Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.	Lapatinib	10-19	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	56-80
29948766-2	2018	Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients.	Lapatinib	44-53	epidermal growth factor receptor	Homo sapiens	58-62
29948766-2	2018	Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-68
29948766-2	2018	Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients.	Lapatinib	44-53	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	137-161
29948766-2	2018	Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients.	Lapatinib	44-53	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	163-166
29948766-16	2018	CONCLUSIONS: These data suggest that lapatinib may have growth-inhibitory effects on meningiomas in NF2 patients, and support prospective studies of lapatinib for NF2 patients with progressive meningiomas.	Lapatinib	37-46	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	100-103
29948766-16	2018	CONCLUSIONS: These data suggest that lapatinib may have growth-inhibitory effects on meningiomas in NF2 patients, and support prospective studies of lapatinib for NF2 patients with progressive meningiomas.	Lapatinib	149-158	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	163-166
30123134-12	2018	In validating experiments, combination of Lapatinib and all-trans retinoic acid (ATRA) synergistically suppresses cell growth, and accompanied by decreased expression of MYC.	Lapatinib	42-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	170-173
30125265-0	2018	Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	31-63
30125265-0	2018	Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	65-69
30125265-0	2018	Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	75-80
30125265-1	2018	BACKGROUND The aim of this study was to evaluate the effect of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER-2, on the radiosensitivity of murine bladder tumor line-2 (MBT-2) cells in vitro and in vivo.	Lapatinib	63-72	epidermal growth factor receptor	Mus musculus	94-126
30125265-1	2018	BACKGROUND The aim of this study was to evaluate the effect of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER-2, on the radiosensitivity of murine bladder tumor line-2 (MBT-2) cells in vitro and in vivo.	Lapatinib	63-72	epidermal growth factor receptor	Mus musculus	128-132
30125265-1	2018	BACKGROUND The aim of this study was to evaluate the effect of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER-2, on the radiosensitivity of murine bladder tumor line-2 (MBT-2) cells in vitro and in vivo.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Mus musculus	138-143
30125265-6	2018	RESULTS Lapatinib pretreatment, combined with radiation, decreased MBT-2 cell survival, and suppressed radiation-activated levels of p-EGFR and p-HER-2.	Lapatinib	8-17	epidermal growth factor receptor	Mus musculus	135-139
30125265-6	2018	RESULTS Lapatinib pretreatment, combined with radiation, decreased MBT-2 cell survival, and suppressed radiation-activated levels of p-EGFR and p-HER-2.	Lapatinib	8-17	erb-b2 receptor tyrosine kinase 2	Mus musculus	146-151
30125265-10	2018	CONCLUSIONS Lapatinib treatment enhanced the radiation sensitivity in an in vitro and in vivo murine bladder cancer model by decreasing radiation-mediated EGFR and HER-2 activation, and by causing DNA damage leading to cell apoptosis.	Lapatinib	12-21	epidermal growth factor receptor	Mus musculus	155-159
30125265-10	2018	CONCLUSIONS Lapatinib treatment enhanced the radiation sensitivity in an in vitro and in vivo murine bladder cancer model by decreasing radiation-mediated EGFR and HER-2 activation, and by causing DNA damage leading to cell apoptosis.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Mus musculus	164-169
30086790-15	2018	Correlation of PCBP1 with p27 is also found in the tamoxifen, doxorubincin and lapatinib resistant breast cancer cells of GEO database.	Lapatinib	79-88	poly(rC) binding protein 1	Homo sapiens	15-20
30086790-15	2018	Correlation of PCBP1 with p27 is also found in the tamoxifen, doxorubincin and lapatinib resistant breast cancer cells of GEO database.	Lapatinib	79-88	cyclin dependent kinase inhibitor 1B	Homo sapiens	26-29
29698927-1	2018	BACKGROUND: For human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) with progression on trastuzumab-based therapy, continuing trastuzumab beyond progression and switching to lapatinib combined with chemotherapy are both valid options.	Lapatinib	210-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-56
29698927-1	2018	BACKGROUND: For human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) with progression on trastuzumab-based therapy, continuing trastuzumab beyond progression and switching to lapatinib combined with chemotherapy are both valid options.	Lapatinib	210-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
29786108-9	2018	Therefore, it was concluded that miR-494 inhibited the CIC phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2-positive gastric cancer.	Lapatinib	96-105	microRNA 494	Homo sapiens	33-40
29786108-9	2018	Therefore, it was concluded that miR-494 inhibited the CIC phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2-positive gastric cancer.	Lapatinib	96-105	fibroblast growth factor receptor 2	Homo sapiens	120-125
29786108-0	2018	miR-494 inhibits cancer-initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2-positive gastric cancer.	Lapatinib	78-87	microRNA 494	Homo sapiens	0-7
29786108-9	2018	Therefore, it was concluded that miR-494 inhibited the CIC phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2-positive gastric cancer.	Lapatinib	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
29786108-0	2018	miR-494 inhibits cancer-initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2-positive gastric cancer.	Lapatinib	78-87	fibroblast growth factor receptor 2	Homo sapiens	106-111
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	epidermal growth factor receptor	Homo sapiens	37-41
29786108-2	2018	Lapatinib, a potent ATP-competitive inhibitor, is a small, orally active molecule, which inhibits the tyrosine kinases of HER2 and epidermal growth factor receptor type 1.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
29786108-3	2018	The activation of receptor tyrosine kinases can contribute to lapatinib resistance in HER2-positive gastric cancer.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
29786108-4	2018	The aim of the present study was to explore the effects of miR-494 and FGFR2 in regulation of cancer-initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2-positive gastric cancer.	Lapatinib	158-167	microRNA 494	Homo sapiens	59-66
29786108-4	2018	The aim of the present study was to explore the effects of miR-494 and FGFR2 in regulation of cancer-initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2-positive gastric cancer.	Lapatinib	158-167	fibroblast growth factor receptor 2	Homo sapiens	71-76
29786108-4	2018	The aim of the present study was to explore the effects of miR-494 and FGFR2 in regulation of cancer-initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2-positive gastric cancer.	Lapatinib	158-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-175
29786108-7	2018	The overexpression of FGFR2 promoted the generation of cancer-initiating cells (CICs) and resistance to lapatinib in HER2-positive gastric cancer YCC1 cells.	Lapatinib	104-113	fibroblast growth factor receptor 2	Homo sapiens	22-27
29786108-7	2018	The overexpression of FGFR2 promoted the generation of cancer-initiating cells (CICs) and resistance to lapatinib in HER2-positive gastric cancer YCC1 cells.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
29786108-8	2018	In addition, it was observed that overexpression of microRNA (miR)-494 downregulated the protein expression of FGFR2, inhibited the formation of CICs and reversed lapatinib resistance in YCC1-F cells (HER2-positive, FGFR2 overexpressing and lapatinib-resistant gastric cancer cells).	Lapatinib	163-172	microRNA 494	Homo sapiens	52-70
29786108-8	2018	In addition, it was observed that overexpression of microRNA (miR)-494 downregulated the protein expression of FGFR2, inhibited the formation of CICs and reversed lapatinib resistance in YCC1-F cells (HER2-positive, FGFR2 overexpressing and lapatinib-resistant gastric cancer cells).	Lapatinib	241-250	microRNA 494	Homo sapiens	52-70
30083253-5	2018	Results: Preclinical studies showed KW-2450 and lapatinib act synergistically to induce in vitro apoptosis and inhibit growth of HER2-positive MDA-MB-361 and BT-474 breast cancer cell lines.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	epidermal growth factor receptor	Homo sapiens	49-81
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	epidermal growth factor receptor	Homo sapiens	83-87
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-94
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 3	Homo sapiens	96-101
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 4	Homo sapiens	103-108
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
29845287-3	2018	The results of reverse transcription-quantitative polymerase chain reaction demonstrated that administration of lapatinib and PI3K inhibitors decreased the mRNA expression of TS and E2F1, a transcription factor that promotes TS gene expression, in SKBR3 and T47D cell lines.	Lapatinib	112-121	thymidylate synthetase	Homo sapiens	175-177
29902719-2	2018	Guided by the binding mode of the marketed dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors based on the 6-phenylthieno[2,3-d]pyrimidine as a core scaffold and hinge binder.	Lapatinib	69-78	epidermal growth factor receptor	Homo sapiens	48-52
29902719-2	2018	Guided by the binding mode of the marketed dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors based on the 6-phenylthieno[2,3-d]pyrimidine as a core scaffold and hinge binder.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
29902719-2	2018	Guided by the binding mode of the marketed dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors based on the 6-phenylthieno[2,3-d]pyrimidine as a core scaffold and hinge binder.	Lapatinib	69-78	epidermal growth factor receptor	Homo sapiens	111-115
29902719-2	2018	Guided by the binding mode of the marketed dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors based on the 6-phenylthieno[2,3-d]pyrimidine as a core scaffold and hinge binder.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
29902719-5	2018	Additionally, 27b efficiently thwarted the proliferation of lapatinib-resistant human non-small lung carcinoma (NCI-H1975) cells, harboring T790 M mutation, with IC50 of 4.2 muM.	Lapatinib	60-69	latexin	Homo sapiens	174-177
29271513-0	2018	Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.	Lapatinib	42-51	checkpoint kinase 1	Homo sapiens	0-4
29271513-0	2018	Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
29271513-3	2018	In this study, we explored the effect of ATR/Chk1 pathway on regulating lapatinib sensitivity in human epidermal growth factor receptor-2 (HER2)-positive gastric cancer cell lines.	Lapatinib	72-81	ATR serine/threonine kinase	Homo sapiens	41-44
29271513-3	2018	In this study, we explored the effect of ATR/Chk1 pathway on regulating lapatinib sensitivity in human epidermal growth factor receptor-2 (HER2)-positive gastric cancer cell lines.	Lapatinib	72-81	checkpoint kinase 1	Homo sapiens	45-49
29271513-3	2018	In this study, we explored the effect of ATR/Chk1 pathway on regulating lapatinib sensitivity in human epidermal growth factor receptor-2 (HER2)-positive gastric cancer cell lines.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-137
29271513-3	2018	In this study, we explored the effect of ATR/Chk1 pathway on regulating lapatinib sensitivity in human epidermal growth factor receptor-2 (HER2)-positive gastric cancer cell lines.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
29271513-5	2018	Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
29271513-5	2018	Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells.	Lapatinib	15-24	epidermal growth factor receptor	Homo sapiens	59-63
29271513-5	2018	Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells.	Lapatinib	15-24	epidermal growth factor receptor	Homo sapiens	85-117
29271513-5	2018	Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells.	Lapatinib	15-24	epidermal growth factor receptor	Homo sapiens	119-123
29271513-5	2018	Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
29271513-6	2018	In NCI-N87 cells, lapatinib induced G1 arrest and reduced Chk1 phosphorylation through inhibiting the expression of DNA topoisomerase 2-binding protein 1 (TopBP1).	Lapatinib	18-27	checkpoint kinase 1	Homo sapiens	58-62
29271513-6	2018	In NCI-N87 cells, lapatinib induced G1 arrest and reduced Chk1 phosphorylation through inhibiting the expression of DNA topoisomerase 2-binding protein 1 (TopBP1).	Lapatinib	18-27	DNA topoisomerase II binding protein 1	Homo sapiens	116-153
29271513-6	2018	In NCI-N87 cells, lapatinib induced G1 arrest and reduced Chk1 phosphorylation through inhibiting the expression of DNA topoisomerase 2-binding protein 1 (TopBP1).	Lapatinib	18-27	DNA topoisomerase II binding protein 1	Homo sapiens	155-161
29271513-8	2018	Inhibition of Chk1 phosphorylation enhanced the lapatinib sensitivity of MKN7 cells, which was shown by potentiated anti-proliferative effect, G1 arrest, downregulation of phosphorylated AKT and ERK along with aggravated DNA damage.	Lapatinib	48-57	checkpoint kinase 1	Homo sapiens	14-18
29271513-8	2018	Inhibition of Chk1 phosphorylation enhanced the lapatinib sensitivity of MKN7 cells, which was shown by potentiated anti-proliferative effect, G1 arrest, downregulation of phosphorylated AKT and ERK along with aggravated DNA damage.	Lapatinib	48-57	AKT serine/threonine kinase 1	Homo sapiens	187-190
29271513-8	2018	Inhibition of Chk1 phosphorylation enhanced the lapatinib sensitivity of MKN7 cells, which was shown by potentiated anti-proliferative effect, G1 arrest, downregulation of phosphorylated AKT and ERK along with aggravated DNA damage.	Lapatinib	48-57	mitogen-activated protein kinase 1	Homo sapiens	195-198
29271513-9	2018	In addition, increased Chk1 phosphorylation in NCI-N87 cells attenuated lapatinib-induced anti-proliferative effect and G1 arrest, and abrogated reduced phosphorylated AKT and ERK.	Lapatinib	72-81	checkpoint kinase 1	Homo sapiens	23-27
29271513-9	2018	In addition, increased Chk1 phosphorylation in NCI-N87 cells attenuated lapatinib-induced anti-proliferative effect and G1 arrest, and abrogated reduced phosphorylated AKT and ERK.	Lapatinib	72-81	mitogen-activated protein kinase 1	Homo sapiens	176-179
29271513-10	2018	Taken together, our study provides a novel mechanism for regulating lapatinib sensitivity in HER2 positive gastric cancer cells, suggesting a new strategy in clinical treatment.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
29845287-0	2018	Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2-positive breast cancer.	Lapatinib	20-29	E2F transcription factor 1	Homo sapiens	69-73
29845287-0	2018	Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2-positive breast cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
29845287-1	2018	The human epidermal growth factor receptor 2 (HER2)-targeting agent, lapatinib, combined with oral fluoropyrimidine capecitabine, has been previously demonstrated to be an effective treatment option for patients with trastuzumab-resistant HER2-positive metastatic breast cancer.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-44
29845287-1	2018	The human epidermal growth factor receptor 2 (HER2)-targeting agent, lapatinib, combined with oral fluoropyrimidine capecitabine, has been previously demonstrated to be an effective treatment option for patients with trastuzumab-resistant HER2-positive metastatic breast cancer.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50
29845287-1	2018	The human epidermal growth factor receptor 2 (HER2)-targeting agent, lapatinib, combined with oral fluoropyrimidine capecitabine, has been previously demonstrated to be an effective treatment option for patients with trastuzumab-resistant HER2-positive metastatic breast cancer.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	239-243
29445928-13	2018	CONCLUSIONS: This study confirmed the therapeutic impact of lapatinib, trastuzumab, and paclitaxel therapy for each ER- and ER+ subgroup of HER2+ patients.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-144
29845287-3	2018	The results of reverse transcription-quantitative polymerase chain reaction demonstrated that administration of lapatinib and PI3K inhibitors decreased the mRNA expression of TS and E2F1, a transcription factor that promotes TS gene expression, in SKBR3 and T47D cell lines.	Lapatinib	112-121	E2F transcription factor 1	Homo sapiens	182-186
29845287-3	2018	The results of reverse transcription-quantitative polymerase chain reaction demonstrated that administration of lapatinib and PI3K inhibitors decreased the mRNA expression of TS and E2F1, a transcription factor that promotes TS gene expression, in SKBR3 and T47D cell lines.	Lapatinib	112-121	thymidylate synthetase	Homo sapiens	225-227
29845287-4	2018	Furthermore, treatment with lapatinib and PI3K inhibitors also suppressed the mRNA expression of ribonucleotide reductase M1 subunit (RRM1), an important determinant of gemcitabine resistance, and DNA topoisomerase II-alpha (TOP2A), a molecular target of anthracyclines, in SKBR3 and T47D cell lines.	Lapatinib	28-37	ribonucleotide reductase catalytic subunit M1	Homo sapiens	97-138
29845287-4	2018	Furthermore, treatment with lapatinib and PI3K inhibitors also suppressed the mRNA expression of ribonucleotide reductase M1 subunit (RRM1), an important determinant of gemcitabine resistance, and DNA topoisomerase II-alpha (TOP2A), a molecular target of anthracyclines, in SKBR3 and T47D cell lines.	Lapatinib	28-37	DNA topoisomerase II alpha	Homo sapiens	225-230
29845287-5	2018	Western blot analysis further demonstrated that the phosphorylation of Akt was inhibited by lapatinib, and the results of the MTT assay revealed that the combination of lapatinib with either 5-FU or gemcitabine demonstrated synergistic antitumor effects, whereas a combinatory treatment of lapatinib with epirubicin, a typical anthracycline drug, exhibited antagonistic antitumor effects in HER2-positive breast cancer cells.	Lapatinib	92-101	AKT serine/threonine kinase 1	Homo sapiens	71-74
29845287-5	2018	Western blot analysis further demonstrated that the phosphorylation of Akt was inhibited by lapatinib, and the results of the MTT assay revealed that the combination of lapatinib with either 5-FU or gemcitabine demonstrated synergistic antitumor effects, whereas a combinatory treatment of lapatinib with epirubicin, a typical anthracycline drug, exhibited antagonistic antitumor effects in HER2-positive breast cancer cells.	Lapatinib	169-178	AKT serine/threonine kinase 1	Homo sapiens	71-74
29845287-5	2018	Western blot analysis further demonstrated that the phosphorylation of Akt was inhibited by lapatinib, and the results of the MTT assay revealed that the combination of lapatinib with either 5-FU or gemcitabine demonstrated synergistic antitumor effects, whereas a combinatory treatment of lapatinib with epirubicin, a typical anthracycline drug, exhibited antagonistic antitumor effects in HER2-positive breast cancer cells.	Lapatinib	169-178	erb-b2 receptor tyrosine kinase 2	Homo sapiens	391-395
29845287-5	2018	Western blot analysis further demonstrated that the phosphorylation of Akt was inhibited by lapatinib, and the results of the MTT assay revealed that the combination of lapatinib with either 5-FU or gemcitabine demonstrated synergistic antitumor effects, whereas a combinatory treatment of lapatinib with epirubicin, a typical anthracycline drug, exhibited antagonistic antitumor effects in HER2-positive breast cancer cells.	Lapatinib	169-178	AKT serine/threonine kinase 1	Homo sapiens	71-74
29845287-5	2018	Western blot analysis further demonstrated that the phosphorylation of Akt was inhibited by lapatinib, and the results of the MTT assay revealed that the combination of lapatinib with either 5-FU or gemcitabine demonstrated synergistic antitumor effects, whereas a combinatory treatment of lapatinib with epirubicin, a typical anthracycline drug, exhibited antagonistic antitumor effects in HER2-positive breast cancer cells.	Lapatinib	169-178	erb-b2 receptor tyrosine kinase 2	Homo sapiens	391-395
29845287-6	2018	These results indicate that the synergistic antitumor effects exhibited by combinatory treatment of lapatinib with capecitabine may be induced via the suppression of E2F1-mediated TS expression.	Lapatinib	100-109	E2F transcription factor 1	Homo sapiens	166-170
29941010-10	2018	Sequencing of the progressing metastasis allowed the identification of the ERBB2 L869R mutation previously associated with resistance to lapatinib in vitro.These results support further clinical investigation aiming to demonstrate that ERBB2-mutational driven therapy can improve patient care irrespective of histology.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-80
29950679-5	2018	The JNMF detected known associations between biomarkers and drugs such as BRAF mutation with PLX4720 and HER2 amplification with lapatinib.	Lapatinib	129-138	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	74-78
29950679-5	2018	The JNMF detected known associations between biomarkers and drugs such as BRAF mutation with PLX4720 and HER2 amplification with lapatinib.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
29941010-10	2018	Sequencing of the progressing metastasis allowed the identification of the ERBB2 L869R mutation previously associated with resistance to lapatinib in vitro.These results support further clinical investigation aiming to demonstrate that ERBB2-mutational driven therapy can improve patient care irrespective of histology.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	236-241
29799521-0	2018	Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-60
29963236-8	2018	Several HER3 mutants (F94L, G284R, D297Y, T355I, and E1261A) acquired a gain-of-function phenotype in MCF10AHER2 cells and were resistant to lapatinib.	Lapatinib	141-150	erb-b2 receptor tyrosine kinase 3	Homo sapiens	8-12
29879129-3	2018	Our previous studies have shown that our HER2 siRNA nanoparticles could overcome intrinsic and acquired resistance to trastuzumab and lapatinib in HER2-positive breast cancers.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
29879129-3	2018	Our previous studies have shown that our HER2 siRNA nanoparticles could overcome intrinsic and acquired resistance to trastuzumab and lapatinib in HER2-positive breast cancers.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
29879129-8	2018	HER2 ablation with HER2 siRNA prevented reactivation of HER2 signaling that was observed in cells resistant to lapatinib.	Lapatinib	111-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
29879129-8	2018	HER2 ablation with HER2 siRNA prevented reactivation of HER2 signaling that was observed in cells resistant to lapatinib.	Lapatinib	111-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
29879129-8	2018	HER2 ablation with HER2 siRNA prevented reactivation of HER2 signaling that was observed in cells resistant to lapatinib.	Lapatinib	111-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
29751334-2	2018	The development of the anti-HER2 class of drugs, first with trastuzumab, followed closely by lapatinib, pertuzumab, and T-DM1, has improved outcomes dramatically.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
29772459-7	2018	In this article we review the role of currently available or investigational HER2 tyrosine kinase inhibitors: lapatinib, neratinib, afatinib and tucatinib in the treatment of brain metastases in HER2-positive breast cancer patients.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
29426804-8	2018	A lower risk of infection is reported for anti-ErbB2/HER2 monoclonal antibodies (trastuzumab and pertuzumab) and ErbB receptor tyrosine kinase inhibitors (including dual-EGFR/ErbB2 inhibitors such as lapatinib or neratinib) compared to conventional chemotherapy, presumably as a result of the decreased occurrence of drug-induced neutropaenia.	Lapatinib	200-209	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
29426804-8	2018	A lower risk of infection is reported for anti-ErbB2/HER2 monoclonal antibodies (trastuzumab and pertuzumab) and ErbB receptor tyrosine kinase inhibitors (including dual-EGFR/ErbB2 inhibitors such as lapatinib or neratinib) compared to conventional chemotherapy, presumably as a result of the decreased occurrence of drug-induced neutropaenia.	Lapatinib	200-209	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
29426804-8	2018	A lower risk of infection is reported for anti-ErbB2/HER2 monoclonal antibodies (trastuzumab and pertuzumab) and ErbB receptor tyrosine kinase inhibitors (including dual-EGFR/ErbB2 inhibitors such as lapatinib or neratinib) compared to conventional chemotherapy, presumably as a result of the decreased occurrence of drug-induced neutropaenia.	Lapatinib	200-209	epidermal growth factor receptor	Homo sapiens	47-51
29615437-5	2018	Human AO substrates identified contained unsubstituted diazanaphthalene moieties (A77-01, INCB 28060, ML-347, LDN-193189, and SB-525334), 4-aminoquinazoline cores (lapatinib, lapatinib M1, and CL-387785), and terminal pyridine and pyrimidine groups (imatinib, bafetinib, and AMG 900).	Lapatinib	164-173	aldehyde oxidase 1	Homo sapiens	6-8
29615437-5	2018	Human AO substrates identified contained unsubstituted diazanaphthalene moieties (A77-01, INCB 28060, ML-347, LDN-193189, and SB-525334), 4-aminoquinazoline cores (lapatinib, lapatinib M1, and CL-387785), and terminal pyridine and pyrimidine groups (imatinib, bafetinib, and AMG 900).	Lapatinib	175-184	aldehyde oxidase 1	Homo sapiens	6-8
29799521-9	2018	Indeed, HSF1 inhibition simultaneously downregulated ERBB2, adaptive RTKs and mutant p53, and its combination with lapatinib prevented development of lapatinib resistance in vitro.	Lapatinib	150-159	heat shock transcription factor 1	Homo sapiens	8-12
29799521-10	2018	Thus, the kinome adaptation in lapatinib-resistant ERBB2-positive breast cancer cells is governed, at least in part, by HSF1-mediated heat shock pathway, providing a novel potential intervention strategy to combat resistance.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-56
29799521-10	2018	Thus, the kinome adaptation in lapatinib-resistant ERBB2-positive breast cancer cells is governed, at least in part, by HSF1-mediated heat shock pathway, providing a novel potential intervention strategy to combat resistance.	Lapatinib	31-40	heat shock transcription factor 1	Homo sapiens	120-124
29963251-4	2018	We previously reported that oncosuppressive miR-205 targets HER3, thus increasing the responsiveness to TKIs lapatinib and gefitinib in preclinical models.	Lapatinib	109-118	microRNA 205	Homo sapiens	44-51
29963251-4	2018	We previously reported that oncosuppressive miR-205 targets HER3, thus increasing the responsiveness to TKIs lapatinib and gefitinib in preclinical models.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 3	Homo sapiens	60-64
29977173-1	2018	High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib).	Lapatinib	293-302	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-59
29977173-1	2018	High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib).	Lapatinib	293-302	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
29977173-1	2018	High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib).	Lapatinib	293-302	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-159
29799521-1	2018	Despite success of ERBB2-targeted therapies such as lapatinib, resistance remains a major clinical concern.	Lapatinib	52-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-24
29799521-6	2018	We found that multiple adaptive RTKs are activated in lapatinib-resistant cells in vivo, some of which have been previously described (Axl, MET) and some were novel (PDGFRalpha, PDGFRbeta, VEGFR1, MUSK, NFGR).	Lapatinib	54-63	AXL receptor tyrosine kinase	Homo sapiens	135-138
29799521-6	2018	We found that multiple adaptive RTKs are activated in lapatinib-resistant cells in vivo, some of which have been previously described (Axl, MET) and some were novel (PDGFRalpha, PDGFRbeta, VEGFR1, MUSK, NFGR).	Lapatinib	54-63	platelet derived growth factor receptor alpha	Homo sapiens	166-176
29799521-6	2018	We found that multiple adaptive RTKs are activated in lapatinib-resistant cells in vivo, some of which have been previously described (Axl, MET) and some were novel (PDGFRalpha, PDGFRbeta, VEGFR1, MUSK, NFGR).	Lapatinib	54-63	fms related receptor tyrosine kinase 1	Homo sapiens	189-195
29799521-6	2018	We found that multiple adaptive RTKs are activated in lapatinib-resistant cells in vivo, some of which have been previously described (Axl, MET) and some were novel (PDGFRalpha, PDGFRbeta, VEGFR1, MUSK, NFGR).	Lapatinib	54-63	muscle associated receptor tyrosine kinase	Homo sapiens	197-201
29799521-7	2018	Strikingly, all lapatinib-resistant cells show chronically activated HSF1 and its transcriptional targets, heat shock proteins (HSPs), and, as a result, superior tolerance to proteotoxic stress.	Lapatinib	16-25	heat shock transcription factor 1	Homo sapiens	69-73
29799521-8	2018	Importantly, lapatinib-resistant tumors and cells retained sensitivity to Hsp90 and HSF1 inhibitors, both in vitro and in vivo, thus providing a unifying and actionable therapeutic node.	Lapatinib	13-22	heat shock protein 90 alpha family class A member 1	Homo sapiens	74-79
29799521-8	2018	Importantly, lapatinib-resistant tumors and cells retained sensitivity to Hsp90 and HSF1 inhibitors, both in vitro and in vivo, thus providing a unifying and actionable therapeutic node.	Lapatinib	13-22	heat shock transcription factor 1	Homo sapiens	84-88
28786423-2	2018	HLA-DRB1*07:01 carriage was associated with serum alanine aminotransferase (ALT) elevations in lapatinib-treated patients (odds ratio 6.5, P=3 x 10-26, n=4482) and the risk and severity of ALT elevation for lapatinib-treated patients was higher in homozygous than heterozygous HLA-DRB1*07:01 genotype carriers.	Lapatinib	207-216	glutamic--pyruvic transaminase	Homo sapiens	50-74
28786423-0	2018	Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.	Lapatinib	53-62	major histocompatibility complex, class II, DR beta 1	Homo sapiens	24-32
28786423-3	2018	A higher ALT case incidence plus weaker HLA association observed during concurrent administration of lapatinib and taxane suggested a subset of liver injury in this combination group that was HLA-DRB1*07:01 independent.	Lapatinib	101-110	major histocompatibility complex, class II, DR beta 1	Homo sapiens	40-43
28786423-0	2018	Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.	Lapatinib	146-155	major histocompatibility complex, class II, DR beta 1	Homo sapiens	24-32
28786423-1	2018	HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cancer (adjuvant lapatinib and/or trastuzumab treatment optimisation).	Lapatinib	73-82	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8
28786423-1	2018	HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cancer (adjuvant lapatinib and/or trastuzumab treatment optimisation).	Lapatinib	139-148	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8
28786423-1	2018	HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cancer (adjuvant lapatinib and/or trastuzumab treatment optimisation).	Lapatinib	139-148	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8
28786423-2	2018	HLA-DRB1*07:01 carriage was associated with serum alanine aminotransferase (ALT) elevations in lapatinib-treated patients (odds ratio 6.5, P=3 x 10-26, n=4482) and the risk and severity of ALT elevation for lapatinib-treated patients was higher in homozygous than heterozygous HLA-DRB1*07:01 genotype carriers.	Lapatinib	95-104	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8
28786423-3	2018	A higher ALT case incidence plus weaker HLA association observed during concurrent administration of lapatinib and taxane suggested a subset of liver injury in this combination group that was HLA-DRB1*07:01 independent.	Lapatinib	101-110	major histocompatibility complex, class II, DR beta 1	Homo sapiens	192-200
28786423-2	2018	HLA-DRB1*07:01 carriage was associated with serum alanine aminotransferase (ALT) elevations in lapatinib-treated patients (odds ratio 6.5, P=3 x 10-26, n=4482) and the risk and severity of ALT elevation for lapatinib-treated patients was higher in homozygous than heterozygous HLA-DRB1*07:01 genotype carriers.	Lapatinib	95-104	glutamic--pyruvic transaminase	Homo sapiens	50-74
28786423-2	2018	HLA-DRB1*07:01 carriage was associated with serum alanine aminotransferase (ALT) elevations in lapatinib-treated patients (odds ratio 6.5, P=3 x 10-26, n=4482) and the risk and severity of ALT elevation for lapatinib-treated patients was higher in homozygous than heterozygous HLA-DRB1*07:01 genotype carriers.	Lapatinib	95-104	major histocompatibility complex, class II, DR beta 1	Homo sapiens	277-285
28786423-5	2018	Robust ALT elevation risk estimates for HLA-DRB1*07:01 may support causality discrimination and safety risk management during the use of lapatinib combination therapy for the treatment of metastatic breast cancer.	Lapatinib	137-146	major histocompatibility complex, class II, DR beta 1	Homo sapiens	40-48
28786423-2	2018	HLA-DRB1*07:01 carriage was associated with serum alanine aminotransferase (ALT) elevations in lapatinib-treated patients (odds ratio 6.5, P=3 x 10-26, n=4482) and the risk and severity of ALT elevation for lapatinib-treated patients was higher in homozygous than heterozygous HLA-DRB1*07:01 genotype carriers.	Lapatinib	207-216	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8
29712619-3	2018	Here, we show that lapatinib, an ATP-competitive inhibitor of HER2, is able to induce proliferation cooperatively with the HER3 ligand neuregulin.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
30057690-7	2018	Therapeutic targeting of HER3 includes abrogating its dimerization partners" kinase activity using small molecule inhibitors (lapatinib, erlotinib, gefitinib, afatinib, neratinib) or direct targeting of its extracellular domain.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 3	Homo sapiens	25-29
29930721-0	2018	The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
29930721-0	2018	The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.	Lapatinib	19-28	nitric oxide synthase 2	Homo sapiens	84-88
29930721-1	2018	Rationale: Lapatinib (LAP) is a crucial alternative to trastuzumab upon the onset of drug resistance during treatment of metastatic human epidermal growth factor receptor 2-positive breast cancer.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-172
29930721-1	2018	Rationale: Lapatinib (LAP) is a crucial alternative to trastuzumab upon the onset of drug resistance during treatment of metastatic human epidermal growth factor receptor 2-positive breast cancer.	Lapatinib	22-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-172
28833867-2	2018	In the EMILIA trial of T-DM1 vs capecitabine/lapatinib for HER2 positive advanced breast cancer, all patients had baseline brain imaging, and 9/450 (2%) of patients with negative baseline imaging developed new brain disease during T-DM1.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
29440169-9	2018	Treatment with the ErbB2 kinase inhibitor lapatinib decreased PKM2-Y105 phosphorylation and cancer stem-like cells, impeding PKM2 tumor-promoting function.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-24
29440169-9	2018	Treatment with the ErbB2 kinase inhibitor lapatinib decreased PKM2-Y105 phosphorylation and cancer stem-like cells, impeding PKM2 tumor-promoting function.	Lapatinib	42-51	pyruvate kinase M1/2	Homo sapiens	62-66
29440169-9	2018	Treatment with the ErbB2 kinase inhibitor lapatinib decreased PKM2-Y105 phosphorylation and cancer stem-like cells, impeding PKM2 tumor-promoting function.	Lapatinib	42-51	pyruvate kinase M1/2	Homo sapiens	125-129
29872641-11	2018	Conclusion: This network meta-analysis suggests that dual anti-HER2 blockade with trastuzumab plus either lapatinib or pertuzumab are probably the best treatment options in the (neo)adjuvant setting for HER2-positive breast cancer patients in terms of OS gain.	Lapatinib	106-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	203-207
29712619-3	2018	Here, we show that lapatinib, an ATP-competitive inhibitor of HER2, is able to induce proliferation cooperatively with the HER3 ligand neuregulin.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 3	Homo sapiens	123-127
29712619-5	2018	By stabilising a particular HER2 conformer, lapatinib drives HER2-HER3 kinase domain heterocomplex formation.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
29712619-5	2018	By stabilising a particular HER2 conformer, lapatinib drives HER2-HER3 kinase domain heterocomplex formation.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
29712619-5	2018	By stabilising a particular HER2 conformer, lapatinib drives HER2-HER3 kinase domain heterocomplex formation.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 3	Homo sapiens	66-70
29409051-2	2018	Patients and methods: We prospectively evaluated the efficacy of combining lapatinib with capecitabine and oxaliplatin as first line neoadjuvant therapy in patients with previously untreated, HER2-overexpressing advanced gastric cancer.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	192-196
29329808-4	2018	Herein we combined structural data and molecular dynamics (MD) simulations coupled to an MMGBSA approach to provide insight into the binding mechanism between two dual synthetics (lapatinib and TAK-285) and one dual natural inhibitor (EGCG) which target EGFR/HER2.	Lapatinib	180-189	epidermal growth factor receptor	Homo sapiens	254-258
29329808-4	2018	Herein we combined structural data and molecular dynamics (MD) simulations coupled to an MMGBSA approach to provide insight into the binding mechanism between two dual synthetics (lapatinib and TAK-285) and one dual natural inhibitor (EGCG) which target EGFR/HER2.	Lapatinib	180-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	259-263
29329808-7	2018	Energetic analysis points out that lapatinib and TAK-285 have better affinity for inactive EGFR than the active EGFR state or HER2, whereas some EGCG derivatives seem to form binding affinities similar to those observed for lapatinib or TAK-285.	Lapatinib	35-44	epidermal growth factor receptor	Homo sapiens	91-95
29329808-7	2018	Energetic analysis points out that lapatinib and TAK-285 have better affinity for inactive EGFR than the active EGFR state or HER2, whereas some EGCG derivatives seem to form binding affinities similar to those observed for lapatinib or TAK-285.	Lapatinib	35-44	epidermal growth factor receptor	Homo sapiens	112-116
29543566-1	2018	Purpose The GeparQuinto phase III trial demonstrated a lower pathologic complete response (pCR; pT0 ypN0) rate when lapatinib was added to standard anthracycline-taxane chemotherapy compared with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer.	Lapatinib	116-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	231-265
29543566-1	2018	Purpose The GeparQuinto phase III trial demonstrated a lower pathologic complete response (pCR; pT0 ypN0) rate when lapatinib was added to standard anthracycline-taxane chemotherapy compared with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer.	Lapatinib	116-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	267-271
29543566-13	2018	In patients with hormone receptor-positive tumors, prolonged anti-HER2 treatment-neoadjuvant lapatinib for 6 months, followed by adjuvant trastuzumab for 12 months-significantly improved survival compared with anti-HER2 treatment with trastuzumab alone.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
29755619-6	2018	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-63
29755619-6	2018	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	65-69
29755619-6	2018	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-76
29755619-6	2018	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-148
29453318-8	2018	This bifurcation of signaling complexes from distinct ShcA pools transduces non-redundant signals that integrate the AKT/mTOR and SFK pathways to cooperatively increase breast tumor growth and resistance to tyrosine kinase inhibitors, including lapatinib and PP2.	Lapatinib	245-254	SHC adaptor protein 1	Homo sapiens	54-58
29453318-8	2018	This bifurcation of signaling complexes from distinct ShcA pools transduces non-redundant signals that integrate the AKT/mTOR and SFK pathways to cooperatively increase breast tumor growth and resistance to tyrosine kinase inhibitors, including lapatinib and PP2.	Lapatinib	245-254	AKT serine/threonine kinase 1	Homo sapiens	117-120
29453318-8	2018	This bifurcation of signaling complexes from distinct ShcA pools transduces non-redundant signals that integrate the AKT/mTOR and SFK pathways to cooperatively increase breast tumor growth and resistance to tyrosine kinase inhibitors, including lapatinib and PP2.	Lapatinib	245-254	mechanistic target of rapamycin kinase	Homo sapiens	121-125
29453318-8	2018	This bifurcation of signaling complexes from distinct ShcA pools transduces non-redundant signals that integrate the AKT/mTOR and SFK pathways to cooperatively increase breast tumor growth and resistance to tyrosine kinase inhibitors, including lapatinib and PP2.	Lapatinib	245-254	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	130-133
29740279-5	2018	The ErbB inhibitor lapatinib was administered to hens 4 h prior to and 4 days after TOCP exposure.	Lapatinib	19-28	epidermal growth factor receptor	Homo sapiens	4-8
29740279-12	2018	Lapatinib also prevented the TOCP-induced inhibition of neuropathy target esterase (NTE), a key enzyme during the development of OPIDN, and the disturbed metabolism of phosphatidylcholine in sciatic nerves.	Lapatinib	0-9	patatin like phospholipase domain containing 6	Homo sapiens	56-82
29740279-12	2018	Lapatinib also prevented the TOCP-induced inhibition of neuropathy target esterase (NTE), a key enzyme during the development of OPIDN, and the disturbed metabolism of phosphatidylcholine in sciatic nerves.	Lapatinib	0-9	patatin like phospholipase domain containing 6	Homo sapiens	84-87
29740279-13	2018	In addition, lapatinib was shown, in vitro, to protect sNF96.2 cells from TOCP-induced dedifferentiation through neuregulin 1/ErbB signaling.	Lapatinib	13-22	neuregulin 1	Homo sapiens	113-125
29740279-13	2018	In addition, lapatinib was shown, in vitro, to protect sNF96.2 cells from TOCP-induced dedifferentiation through neuregulin 1/ErbB signaling.	Lapatinib	13-22	epidermal growth factor receptor	Homo sapiens	126-130
29522716-5	2018	MTT assay was first performed to detect the effect of inhibitors of c-ABL (imatinib) and EGFR (lapatinib) on FRBC cells.	Lapatinib	95-104	epidermal growth factor receptor	Homo sapiens	89-93
29280043-0	2018	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	70-79	CREB regulated transcription coactivator 2	Mus musculus	196-202
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	70-79	CREB regulated transcription coactivator 2	Mus musculus	196-202
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	212-221	CREB regulated transcription coactivator 2	Mus musculus	10-16
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	212-221	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	212-221	CREB regulated transcription coactivator 2	Mus musculus	196-202
29358172-7	2018	Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition.	Lapatinib	212-221	CREB regulated transcription coactivator 2	Mus musculus	196-202
29471066-3	2018	Lapatinib is a tyrosine kinase inhibitor (TKI), approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-118
29330210-3	2018	Presented are three cases of HER2 amplified colorectal cancer that developed acquired refractoriness to trastuzumab pertuzumab with subsequent clinical benefit to lapatinib plus trastuzumab, highlighting the potential for HER2 tyrosine kinase inhibition plus trastuzumab in overcoming trastuzumab/pertuzumab resistance.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
29330210-3	2018	Presented are three cases of HER2 amplified colorectal cancer that developed acquired refractoriness to trastuzumab pertuzumab with subsequent clinical benefit to lapatinib plus trastuzumab, highlighting the potential for HER2 tyrosine kinase inhibition plus trastuzumab in overcoming trastuzumab/pertuzumab resistance.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	222-226
29333945-1	2018	In clinical practice, one subgroup patients of breast cancer might have developed resistance to multi-anti-HER2 targeted drugs(trastuzumab, lapatinib and/or T-DM1) and can not benefit from the anti-HER2 targeted therapy continuously.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
29471066-3	2018	Lapatinib is a tyrosine kinase inhibitor (TKI), approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
29662626-4	2018	In this project, we showed that disruption of the EGFR/ErbB2-dependent signalling by lapatinib and CP-724714, two inhibitors of the receptor tyrosine kinase (RTK), dramatically reduced the amplitude of the SOCE in breast cancer cells.	Lapatinib	85-94	ret proto-oncogene	Homo sapiens	158-161
29428415-7	2018	When searching for genes related to lapatinib resistance, CARE identified PRKD3 as the top candidate.	Lapatinib	36-45	protein kinase D3	Homo sapiens	74-79
29428415-8	2018	PRKD3 inhibition, by both small interfering RNA and compounds, significantly sensitized breast cancer cells to lapatinib.	Lapatinib	111-120	protein kinase D3	Homo sapiens	0-5
29662626-4	2018	In this project, we showed that disruption of the EGFR/ErbB2-dependent signalling by lapatinib and CP-724714, two inhibitors of the receptor tyrosine kinase (RTK), dramatically reduced the amplitude of the SOCE in breast cancer cells.	Lapatinib	85-94	epidermal growth factor receptor	Homo sapiens	50-54
29662626-4	2018	In this project, we showed that disruption of the EGFR/ErbB2-dependent signalling by lapatinib and CP-724714, two inhibitors of the receptor tyrosine kinase (RTK), dramatically reduced the amplitude of the SOCE in breast cancer cells.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-60
29596781-2	2018	use microenvironment microarrays to assess how extrinsic signals within the tumor microenvironment influence HER2++ breast cancer resistance to the HER2-targeted tyrosine kinase inhibitor lapatinib.	Lapatinib	188-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
29596781-2	2018	use microenvironment microarrays to assess how extrinsic signals within the tumor microenvironment influence HER2++ breast cancer resistance to the HER2-targeted tyrosine kinase inhibitor lapatinib.	Lapatinib	188-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
29476008-7	2018	Reduced ESR1 expression in turn prevents ERalpha-mediated transcription of NOXA, mitigating apoptosis following treatment with the HER2i lapatinib.	Lapatinib	137-146	estrogen receptor 1	Homo sapiens	8-12
29662626-4	2018	In this project, we showed that disruption of the EGFR/ErbB2-dependent signalling by lapatinib and CP-724714, two inhibitors of the receptor tyrosine kinase (RTK), dramatically reduced the amplitude of the SOCE in breast cancer cells.	Lapatinib	85-94	ret proto-oncogene	Homo sapiens	132-156
29476008-7	2018	Reduced ESR1 expression in turn prevents ERalpha-mediated transcription of NOXA, mitigating apoptosis following treatment with the HER2i lapatinib.	Lapatinib	137-146	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	75-79
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	126-135	ES cell expressed Ras	Homo sapiens	270-274
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	126-135	ES cell expressed Ras	Homo sapiens	26-30
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	356-360
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	137-143	ES cell expressed Ras	Homo sapiens	26-30
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	137-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	144-150	ES cell expressed Ras	Homo sapiens	26-30
29315394-0	2018	A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
29315394-1	2018	Background: The combination of lapatinib and oral vinorelbine for HER2 positive metastatic breast cancer (MBC) is convenient but with uncertain toxicity profiles.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
29344640-5	2018	EGFR inhibitor (lapatinib) suppressed EGFR protein expression, inhibited cell proliferation and LDH activity, and induced apoptosis and caspase-3 activity in cisplatin-induced A549 cells by over-regulation of microRNA-133b.	Lapatinib	16-25	epidermal growth factor receptor	Homo sapiens	0-4
29326437-8	2018	Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	Lapatinib	144-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
29344640-5	2018	EGFR inhibitor (lapatinib) suppressed EGFR protein expression, inhibited cell proliferation and LDH activity, and induced apoptosis and caspase-3 activity in cisplatin-induced A549 cells by over-regulation of microRNA-133b.	Lapatinib	16-25	epidermal growth factor receptor	Homo sapiens	38-42
29326440-6	2018	Importantly, combination of the BRAF inhibitors (BRAFi) vemurafenib (PLX4032), dabrafenib, or encorafenib with inhibitors dually targeting the EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC cells.	Lapatinib	166-175	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
29344640-5	2018	EGFR inhibitor (lapatinib) suppressed EGFR protein expression, inhibited cell proliferation and LDH activity, and induced apoptosis and caspase-3 activity in cisplatin-induced A549 cells by over-regulation of microRNA-133b.	Lapatinib	16-25	caspase 3	Homo sapiens	136-145
29231164-0	2018	Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review : .	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
29344640-5	2018	EGFR inhibitor (lapatinib) suppressed EGFR protein expression, inhibited cell proliferation and LDH activity, and induced apoptosis and caspase-3 activity in cisplatin-induced A549 cells by over-regulation of microRNA-133b.	Lapatinib	16-25	microRNA 133b	Homo sapiens	209-222
29223420-11	2018	The EAC OE33 cell line, with amplification and overexpression of both MET and HER2, demonstrated reduced sensitivity to foretinib or lapatinib and had a transient effect on downstream inhibition of phosphorylated AKT and ERK (p-AKT, p-ERK).	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
29223420-12	2018	The coadministration of foretinib and lapatinib effectively blocked both MET and HER2 signaling through the p-AKT and p-ERK pathways, dramatically inhibited growth, and induced apoptosis to overcome single-agent resistance in OE33 cells.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-85
29223420-12	2018	The coadministration of foretinib and lapatinib effectively blocked both MET and HER2 signaling through the p-AKT and p-ERK pathways, dramatically inhibited growth, and induced apoptosis to overcome single-agent resistance in OE33 cells.	Lapatinib	38-47	AKT serine/threonine kinase 1	Homo sapiens	110-113
29223420-12	2018	The coadministration of foretinib and lapatinib effectively blocked both MET and HER2 signaling through the p-AKT and p-ERK pathways, dramatically inhibited growth, and induced apoptosis to overcome single-agent resistance in OE33 cells.	Lapatinib	38-47	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	118-123
29315394-11	2018	The MTD was determined at lapatinib 1000 mg plus oral vinorelbine 50 mg/m2.	Lapatinib	26-35	metallothionein 1E	Homo sapiens	4-7
29110152-0	2018	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.	Lapatinib	71-80	phosphatase and tensin homolog	Homo sapiens	4-8
29110152-0	2018	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.	Lapatinib	71-80	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	20-26
29110152-0	2018	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-139
29231164-4	2018	The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
29389942-0	2018	Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
29309638-6	2018	Recommendations: Level 3: Lapatinib may be considered for use in reducing vestibular schwannoma size and improvement in hearing in NF2.	Lapatinib	26-35	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	131-134
29129754-0	2018	CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.	Lapatinib	38-47	CD44 antigen	Mus musculus	0-4
29389942-3	2018	Recently, it was reported that MCF10A, BT474, and MDA-MB-231 cells bearing the HER2 K753E mutation were resistant to lapatinib.	Lapatinib	117-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
29389942-4	2018	Present study revealed that HER-2 mutant K753E showed some contrasting behaviour as compared to wild, L768S and V773L HER-2 in complex with lapatinib while similar to previously known lapatinib resistant L755S HER-2 mutant.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
29389942-4	2018	Present study revealed that HER-2 mutant K753E showed some contrasting behaviour as compared to wild, L768S and V773L HER-2 in complex with lapatinib while similar to previously known lapatinib resistant L755S HER-2 mutant.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-123
29389942-4	2018	Present study revealed that HER-2 mutant K753E showed some contrasting behaviour as compared to wild, L768S and V773L HER-2 in complex with lapatinib while similar to previously known lapatinib resistant L755S HER-2 mutant.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-123
29389942-4	2018	Present study revealed that HER-2 mutant K753E showed some contrasting behaviour as compared to wild, L768S and V773L HER-2 in complex with lapatinib while similar to previously known lapatinib resistant L755S HER-2 mutant.	Lapatinib	184-193	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
29389942-5	2018	Lapatinib showed stable but reverse orientation in binding site of K753E and the highest binding energy among studied HER2-lapatinib complexes but slightly lesser than L755S mutant.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-122
28343375-0	2018	FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.	Lapatinib	47-56	forkhead box O1	Homo sapiens	0-5
29154981-4	2018	Of these, p38 MAPK phosphorylation was confirmed to occur in response to inhibition of either EGFR or HER2 signaling through multiple validation steps, including differing bladder cancer cell lines (RT112, UM-UC-3, and T24) and methods of receptor pathway inhibition (erlotinib, lapatinib, and siRNA depletion of EGFR or HER2).	Lapatinib	279-288	mitogen-activated protein kinase 14	Homo sapiens	10-13
29154981-4	2018	Of these, p38 MAPK phosphorylation was confirmed to occur in response to inhibition of either EGFR or HER2 signaling through multiple validation steps, including differing bladder cancer cell lines (RT112, UM-UC-3, and T24) and methods of receptor pathway inhibition (erlotinib, lapatinib, and siRNA depletion of EGFR or HER2).	Lapatinib	279-288	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
29275232-3	2018	Three derivatives bearing 5-carboxylic acid side chain, namely the 3-chloroanilino derivative (8c), the 3-bromoaniline (8d) and the lapatinib analogue (10) demonstrated the most significant submicromolar EGFR inhibition.	Lapatinib	132-141	epidermal growth factor receptor	Homo sapiens	204-208
29375317-7	2017	Our results show that addition of recombinant human NRG1 (rhNRG1) to the medium significantly increased MN survival through the activation of ErbB receptors which was ablated with lapatinib (LP), an ErbB inhibitor, and reduced microglial reactivity overcoming the excitotoxicity effects.	Lapatinib	180-189	neuregulin 1	Homo sapiens	52-56
29375317-7	2017	Our results show that addition of recombinant human NRG1 (rhNRG1) to the medium significantly increased MN survival through the activation of ErbB receptors which was ablated with lapatinib (LP), an ErbB inhibitor, and reduced microglial reactivity overcoming the excitotoxicity effects.	Lapatinib	180-189	epidermal growth factor receptor	Homo sapiens	142-146
29375317-7	2017	Our results show that addition of recombinant human NRG1 (rhNRG1) to the medium significantly increased MN survival through the activation of ErbB receptors which was ablated with lapatinib (LP), an ErbB inhibitor, and reduced microglial reactivity overcoming the excitotoxicity effects.	Lapatinib	191-193	neuregulin 1	Homo sapiens	52-56
29375317-7	2017	Our results show that addition of recombinant human NRG1 (rhNRG1) to the medium significantly increased MN survival through the activation of ErbB receptors which was ablated with lapatinib (LP), an ErbB inhibitor, and reduced microglial reactivity overcoming the excitotoxicity effects.	Lapatinib	191-193	epidermal growth factor receptor	Homo sapiens	142-146
29293494-2	2018	Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models.	Lapatinib	85-94	epidermal growth factor receptor	Homo sapiens	13-17
29293494-2	2018	Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models.	Lapatinib	85-94	epidermal growth factor receptor	Homo sapiens	49-53
29293494-2	2018	Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
29293494-4	2018	Here, we developed a computational approach to model the in vitro cellular dynamics of the EGFR-mutant cell line SF268 in response to different lapatinib concentrations and dosing schedules.	Lapatinib	144-153	epidermal growth factor receptor	Homo sapiens	91-95
28343375-0	2018	FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
28343375-1	2018	PURPOSE: Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-119
28343375-1	2018	PURPOSE: Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
28343375-3	2018	The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells.	Lapatinib	100-109	forkhead box O1	Homo sapiens	50-65
28343375-3	2018	The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells.	Lapatinib	100-109	forkhead box O1	Homo sapiens	67-72
28343375-3	2018	The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells.	Lapatinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	124-128
28343375-4	2018	MATERIALS AND METHODS: Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive SNU-216 cells to lapatinib.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-145
28343375-10	2018	FOXO1 overexpression in SNU-216 LR cells significantly suppressed resistance to lapatinib and/or cisplatin.	Lapatinib	80-89	forkhead box O1	Homo sapiens	0-5
28343375-12	2018	A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin.	Lapatinib	91-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-43
28343375-13	2018	CONCLUSION: FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells.	Lapatinib	155-164	forkhead box O1	Homo sapiens	12-17
28343375-13	2018	CONCLUSION: FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells.	Lapatinib	155-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
28343375-13	2018	CONCLUSION: FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells.	Lapatinib	155-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
29387217-10	2018	Furthermore, lapatinib induced apoptosis by decreasing Bcl-2 and PML-RARalpha levels, and by increasing the levels of Bax, cleaved PARP, cleaved caspase-3 and cleaved caspase-9.	Lapatinib	13-22	BCL2 apoptosis regulator	Homo sapiens	55-60
29387217-10	2018	Furthermore, lapatinib induced apoptosis by decreasing Bcl-2 and PML-RARalpha levels, and by increasing the levels of Bax, cleaved PARP, cleaved caspase-3 and cleaved caspase-9.	Lapatinib	13-22	PML nuclear body scaffold	Homo sapiens	65-68
29387217-10	2018	Furthermore, lapatinib induced apoptosis by decreasing Bcl-2 and PML-RARalpha levels, and by increasing the levels of Bax, cleaved PARP, cleaved caspase-3 and cleaved caspase-9.	Lapatinib	13-22	retinoic acid receptor alpha	Homo sapiens	69-77
29387217-10	2018	Furthermore, lapatinib induced apoptosis by decreasing Bcl-2 and PML-RARalpha levels, and by increasing the levels of Bax, cleaved PARP, cleaved caspase-3 and cleaved caspase-9.	Lapatinib	13-22	BCL2 associated X, apoptosis regulator	Homo sapiens	118-121
29387217-10	2018	Furthermore, lapatinib induced apoptosis by decreasing Bcl-2 and PML-RARalpha levels, and by increasing the levels of Bax, cleaved PARP, cleaved caspase-3 and cleaved caspase-9.	Lapatinib	13-22	collagen type XI alpha 2 chain	Homo sapiens	131-135
29387217-10	2018	Furthermore, lapatinib induced apoptosis by decreasing Bcl-2 and PML-RARalpha levels, and by increasing the levels of Bax, cleaved PARP, cleaved caspase-3 and cleaved caspase-9.	Lapatinib	13-22	caspase 9	Homo sapiens	167-176
29387217-11	2018	In addition, lapatinib increased the levels of phospho-p38 MAPK and phospho-JNK, and decreased the levels of phospho-Akt.	Lapatinib	13-22	mitogen-activated protein kinase 14	Homo sapiens	55-58
29387217-11	2018	In addition, lapatinib increased the levels of phospho-p38 MAPK and phospho-JNK, and decreased the levels of phospho-Akt.	Lapatinib	13-22	mitogen-activated protein kinase 8	Homo sapiens	76-79
29387217-12	2018	The p38 inhibitor PD169316 partially blocked lapatinib-induced proliferation inhibition and apoptosis, whereas the JNK inhibitor SP600125 had no such effects.	Lapatinib	45-54	mitogen-activated protein kinase 14	Homo sapiens	4-7
29098381-0	2017	The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.	Lapatinib	15-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-33
28800870-5	2017	Moreover, this may also aid in resolving the major issue of resistance-development towards HER2 targeted agents (trastuzumab and lapatinib), since epigenetic alterations are important therapeutic markers and modulate the response towards HER2 targeted therapy.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
28800870-5	2017	Moreover, this may also aid in resolving the major issue of resistance-development towards HER2 targeted agents (trastuzumab and lapatinib), since epigenetic alterations are important therapeutic markers and modulate the response towards HER2 targeted therapy.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	238-242
30069757-5	2018	Lapatinib, an oral dual tyrosine kinase inhibitor, blocks HER1 and HER2 tyrosine kinase activity by binding to the ATP-binding site of the receptor"s intracellular domain, resulting in inhibition of tumor cell growth.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	58-62
30069757-5	2018	Lapatinib, an oral dual tyrosine kinase inhibitor, blocks HER1 and HER2 tyrosine kinase activity by binding to the ATP-binding site of the receptor"s intracellular domain, resulting in inhibition of tumor cell growth.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
30069757-10	2018	Since 2010, lapatinib is approved in combination with letrozole in the treatment of postmenopausal women with advanced HER2- and hormone receptor-positive breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
30069757-16	2018	Also, lapatinib may have distinct advantages over antibodies in targeting truncated HER2 and crossing the blood-brain barrier.	Lapatinib	6-15	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
29343208-0	2018	Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression.	Lapatinib	0-9	pyruvate kinase M1/2	Homo sapiens	67-71
29343208-4	2018	Lapatinib is a small molecule epidermal growth factor receptor tyrosine kinase inhibitor that can inhibit epidermal growth factor receptor and human epidermal growth factor receptor 2, though its effect on pyruvate kinase type M2 remains elusive.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	30-62
29343208-4	2018	Lapatinib is a small molecule epidermal growth factor receptor tyrosine kinase inhibitor that can inhibit epidermal growth factor receptor and human epidermal growth factor receptor 2, though its effect on pyruvate kinase type M2 remains elusive.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	106-138
29343208-4	2018	Lapatinib is a small molecule epidermal growth factor receptor tyrosine kinase inhibitor that can inhibit epidermal growth factor receptor and human epidermal growth factor receptor 2, though its effect on pyruvate kinase type M2 remains elusive.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	106-138
29343208-9	2018	Together with previous reports, our findings show that lapatinib inhibits breast cancer cell proliferation by influencing pyruvate kinase type M2 expression, which results in a reduction in both Signal transducer and activator of transcription 3 and phosphorylated Signal transducer and activator of transcription 3.	Lapatinib	55-64	signal transducer and activator of transcription 3	Homo sapiens	195-245
29343208-9	2018	Together with previous reports, our findings show that lapatinib inhibits breast cancer cell proliferation by influencing pyruvate kinase type M2 expression, which results in a reduction in both Signal transducer and activator of transcription 3 and phosphorylated Signal transducer and activator of transcription 3.	Lapatinib	55-64	signal transducer and activator of transcription 3	Homo sapiens	265-315
28989055-7	2017	Furthermore, HER2 inhibitors, such as lapatinib, down-regulate HECTD3 expression and thus promote the chemosensitivity of ovarian cancer cells to carboplatin.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
28989055-7	2017	Furthermore, HER2 inhibitors, such as lapatinib, down-regulate HECTD3 expression and thus promote the chemosensitivity of ovarian cancer cells to carboplatin.	Lapatinib	38-47	HECT domain E3 ubiquitin protein ligase 3	Homo sapiens	63-69
28989055-10	2017	Through decreasing HECTD3, lapatinib possesses significantly increased anti-tumor activity when combined with carboplatin compared with each agent alone, which provides an optional therapeutic regimen for serous ovarian cancer.	Lapatinib	27-36	HECT domain E3 ubiquitin protein ligase 3	Homo sapiens	19-25
29159332-5	2017	This approach uncovered that cells on 2D hydrogels and spheroids encapsulated in 3D hydrogels were less responsive to receptor tyrosine kinase (RTK)-targeting drugs sorafenib and lapatinib, but not cytotoxic drugs, compared to single cells in hydrogels and cells on plastic.	Lapatinib	179-188	ret proto-oncogene	Homo sapiens	144-147
28825152-1	2017	PURPOSE: Lapatinib is a tyrosine kinase inhibitor that targets the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR/HER1), and there are concerns about its cardiac toxicity.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-107
28825152-1	2017	PURPOSE: Lapatinib is a tyrosine kinase inhibitor that targets the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR/HER1), and there are concerns about its cardiac toxicity.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
28825152-1	2017	PURPOSE: Lapatinib is a tyrosine kinase inhibitor that targets the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR/HER1), and there are concerns about its cardiac toxicity.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	73-105
28825152-1	2017	PURPOSE: Lapatinib is a tyrosine kinase inhibitor that targets the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR/HER1), and there are concerns about its cardiac toxicity.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	157-161
28825152-1	2017	PURPOSE: Lapatinib is a tyrosine kinase inhibitor that targets the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR/HER1), and there are concerns about its cardiac toxicity.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	162-166
29098381-1	2017	PURPOSE: The potential inhibition of CYP3A4 by lapatinib was studied using midazolam as a probe substrate in patients with cancer.	Lapatinib	47-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
29098381-8	2017	CONCLUSION: These data show that lapatinib caused weak inhibition of gastrointestinal CYP3A4 in vivo.	Lapatinib	33-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
29098381-9	2017	This suggests that oral CYP3A4 drug substrates with a narrow therapeutic index may need dose reduction if lapatinib is to be co-prescribed.	Lapatinib	106-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
28750133-13	2017	Univariate stratified analyses detected a significant predictive effect on risk for progression with lapatinib compared with trastuzumab among patients with low CD8+ sTIL counts (observed hazard ratio, 2.94; 95% CI, 1.40-6.17; P = .003) and among those with high CD8+ sTIL counts (observed hazard ratio, 1.36; 95% CI, 1.05-1.75; P = .02), confirmed in stepwise multivariate analysis (interaction P = .04).	Lapatinib	101-110	CD8a molecule	Homo sapiens	161-164
28745317-8	2017	Moreover, we demonstrated that RCN2 knockout sensitized HCC cells to tyrosine kinase inhibitors, including erlotinib, lapatinib and sunitinib.	Lapatinib	118-127	reticulocalbin 2	Homo sapiens	31-35
29109274-5	2017	Two breast cancer drugs, docetaxel and HER2-targeted lapatinib, were delivered to MDA-MB-231 and SKBR3 (overexpressing HER2) breast cancer cells and compared with release in noncancerous RAW 264.7 macrophage cells.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Mus musculus	39-43
28750133-13	2017	Univariate stratified analyses detected a significant predictive effect on risk for progression with lapatinib compared with trastuzumab among patients with low CD8+ sTIL counts (observed hazard ratio, 2.94; 95% CI, 1.40-6.17; P = .003) and among those with high CD8+ sTIL counts (observed hazard ratio, 1.36; 95% CI, 1.05-1.75; P = .02), confirmed in stepwise multivariate analysis (interaction P = .04).	Lapatinib	101-110	STIL centriolar assembly protein	Homo sapiens	166-170
28750133-13	2017	Univariate stratified analyses detected a significant predictive effect on risk for progression with lapatinib compared with trastuzumab among patients with low CD8+ sTIL counts (observed hazard ratio, 2.94; 95% CI, 1.40-6.17; P = .003) and among those with high CD8+ sTIL counts (observed hazard ratio, 1.36; 95% CI, 1.05-1.75; P = .02), confirmed in stepwise multivariate analysis (interaction P = .04).	Lapatinib	101-110	CD8a molecule	Homo sapiens	263-266
28750133-13	2017	Univariate stratified analyses detected a significant predictive effect on risk for progression with lapatinib compared with trastuzumab among patients with low CD8+ sTIL counts (observed hazard ratio, 2.94; 95% CI, 1.40-6.17; P = .003) and among those with high CD8+ sTIL counts (observed hazard ratio, 1.36; 95% CI, 1.05-1.75; P = .02), confirmed in stepwise multivariate analysis (interaction P = .04).	Lapatinib	101-110	STIL centriolar assembly protein	Homo sapiens	268-272
28873009-1	2017	Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kinase inhibitor lapatinib can induce a compensatory HER3 increase, which may attenuate antitumor efficacy.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-53
29109274-7	2017	Using a femtosecond pulsed laser, lapatinib release from a nanoshell-based human serum albumin protein host complex resulted in increased cancerous cell death while noncancerous control cells were unaffected.	Lapatinib	34-43	albumin	Mus musculus	81-94
28950146-13	2017	CONCLUSION: Combining buparlisib and lapatinib in HER2-positive trastuzumab-resistant advanced breast cancer was feasible.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
28873009-1	2017	Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kinase inhibitor lapatinib can induce a compensatory HER3 increase, which may attenuate antitumor efficacy.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
28873009-1	2017	Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kinase inhibitor lapatinib can induce a compensatory HER3 increase, which may attenuate antitumor efficacy.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 3	Homo sapiens	149-153
28873009-3	2017	Lapatinib effects on HER3 cell surface expression and mAb3481 internalization were evaluated in human breast (BT474, SKBR3) and gastric (N87) cancer cell lines using flow cytometry.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 3	Homo sapiens	21-25
28873009-7	2017	In vitro, lapatinib increased membranous HER3 in BT474, SKBR3 and N87 cells, and consequently mAb3481 internalization 1.7-fold (BT474), 1.4-fold (SKBR3) and 1.4-fold (N87).	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 3	Homo sapiens	41-45
28873009-10	2017	In conclusion, lapatinib increased in vitro HER3 tumor cell expression, but not when these cells were xenografted.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 3	Homo sapiens	44-48
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Lapatinib	172-181	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	93-100
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Lapatinib	172-181	nectin cell adhesion molecule 4	Homo sapiens	102-109
29262628-0	2017	Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.	Lapatinib	125-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Lapatinib	172-181	integrin subunit beta 6	Homo sapiens	111-116
29262628-0	2017	Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.	Lapatinib	125-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
29262628-1	2017	Lapatinib is a HER1 and HER2 tyrosine kinase inhibitor (TKI) approved in second line treatment of advanced or metastatic breast cancer following progression on trastuzumab-containing therapy.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	15-19
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Lapatinib	172-181	kelch domain containing 9	Homo sapiens	122-128
29262628-1	2017	Lapatinib is a HER1 and HER2 tyrosine kinase inhibitor (TKI) approved in second line treatment of advanced or metastatic breast cancer following progression on trastuzumab-containing therapy.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
29262628-11	2017	Patients with moderately overexpressed HER2 levels and high p95HER2 expression may have best outcomes while receiving lapatinib following progression on trastuzumab.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-43
28810186-0	2017	The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-51
29020637-8	2017	Fibronectin, type IV collagen, and matrix rigidity are significant regulators of lapatinib resistance in HER2-amplified breast cancer cells.	Lapatinib	81-90	fibronectin 1	Homo sapiens	0-11
29020637-8	2017	Fibronectin, type IV collagen, and matrix rigidity are significant regulators of lapatinib resistance in HER2-amplified breast cancer cells.	Lapatinib	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
28810186-2	2017	Among approved drugs for HER-2+ BC, lapatinib (L) is associated with single agent activity toward BMs.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-30
28959362-0	2017	Inhibition of Hes1 enhances lapatinib sensitivity in gastric cancer sphere-forming cells.	Lapatinib	28-37	hes family bHLH transcription factor 1	Homo sapiens	14-18
28735458-0	2017	The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.	Lapatinib	16-25	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	92-95
28735458-3	2017	In vitro dose response assays demonstrated potent activity of lapatinib and nilotinib against the mouse schwannoma SC4 (Nf2 -/-) cell line.	Lapatinib	62-71	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	120-123
27925186-4	2017	EGF-induced elevation of TRPM6 expression was inhibited by erlotinib, gefitinib, and lapatinib.	Lapatinib	85-94	transient receptor potential cation channel subfamily M member 6	Homo sapiens	25-30
28775148-5	2017	Molecular therapeutics against EGFR/HER2 or EGFR only, such as lapatinib and erlotinib, respectively, were developed to target these receptors, but resistance often occurs in relapsing cancers.	Lapatinib	63-72	epidermal growth factor receptor	Homo sapiens	31-35
28775148-5	2017	Molecular therapeutics against EGFR/HER2 or EGFR only, such as lapatinib and erlotinib, respectively, were developed to target these receptors, but resistance often occurs in relapsing cancers.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
28775148-5	2017	Molecular therapeutics against EGFR/HER2 or EGFR only, such as lapatinib and erlotinib, respectively, were developed to target these receptors, but resistance often occurs in relapsing cancers.	Lapatinib	63-72	epidermal growth factor receptor	Homo sapiens	44-48
28775148-6	2017	Here we show that, though OPCML interacts only with HER2 and not with EGFR, the interaction of OPCML with HER2 disrupts the formation of the HER2-EGFR heterodimer, and this translates into a better response to both lapatinib and erlotinib in HER2-expressing ovarian and breast cancer cell lines.	Lapatinib	215-224	opioid binding protein/cell adhesion molecule like	Homo sapiens	26-31
28775148-6	2017	Here we show that, though OPCML interacts only with HER2 and not with EGFR, the interaction of OPCML with HER2 disrupts the formation of the HER2-EGFR heterodimer, and this translates into a better response to both lapatinib and erlotinib in HER2-expressing ovarian and breast cancer cell lines.	Lapatinib	215-224	opioid binding protein/cell adhesion molecule like	Homo sapiens	95-100
28775148-6	2017	Here we show that, though OPCML interacts only with HER2 and not with EGFR, the interaction of OPCML with HER2 disrupts the formation of the HER2-EGFR heterodimer, and this translates into a better response to both lapatinib and erlotinib in HER2-expressing ovarian and breast cancer cell lines.	Lapatinib	215-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
28775148-6	2017	Here we show that, though OPCML interacts only with HER2 and not with EGFR, the interaction of OPCML with HER2 disrupts the formation of the HER2-EGFR heterodimer, and this translates into a better response to both lapatinib and erlotinib in HER2-expressing ovarian and breast cancer cell lines.	Lapatinib	215-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
28775148-6	2017	Here we show that, though OPCML interacts only with HER2 and not with EGFR, the interaction of OPCML with HER2 disrupts the formation of the HER2-EGFR heterodimer, and this translates into a better response to both lapatinib and erlotinib in HER2-expressing ovarian and breast cancer cell lines.	Lapatinib	215-224	epidermal growth factor receptor	Homo sapiens	146-150
28775148-6	2017	Here we show that, though OPCML interacts only with HER2 and not with EGFR, the interaction of OPCML with HER2 disrupts the formation of the HER2-EGFR heterodimer, and this translates into a better response to both lapatinib and erlotinib in HER2-expressing ovarian and breast cancer cell lines.	Lapatinib	215-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
28775148-7	2017	Also, we show that high OPCML expression is associated with better response to lapatinib therapy in breast cancer patients and better survival in HER2-overexpressing ovarian cancer patients, suggesting that OPCML co-therapy could be a valuable sensitizing approach to RTK inhibitors.	Lapatinib	79-88	opioid binding protein/cell adhesion molecule like	Homo sapiens	24-29
28959362-3	2017	The present study aimed to delineate the role of the Notch1 signaling pathway in GCSCs and lapatinib sensitivity.	Lapatinib	91-100	notch receptor 1	Homo sapiens	53-59
28959362-10	2017	Furthermore, the inhibition of Hes1 effectively enhanced lapatinib sensitivity in sphere-forming cells.	Lapatinib	57-66	hes family bHLH transcription factor 1	Homo sapiens	31-35
28959362-11	2017	These results suggest that sphere-forming gastric cancer cells possess the characteristics of CSCs, and that the Notch1 signaling pathway serves an essential role in the maintenance of CSCs and lapatinib sensitivity.	Lapatinib	194-203	notch receptor 1	Homo sapiens	113-119
28838691-3	2017	Comparing with reference compounds gefitinib and lapatinib, compounds 7d, 8d, 9b and 9d showed higher inhibitory activities against EGFR (IC50: 1.79-10.71nM).	Lapatinib	49-58	epidermal growth factor receptor	Homo sapiens	132-136
29169418-10	2017	Conclusion Lapatinib could inhibit cell proliferation and promote apoptosis in HL60 cells by inhibiting the CIP2A/AKT/c-MYC signal pathway.	Lapatinib	11-20	cellular inhibitor of PP2A	Homo sapiens	108-113
29169418-10	2017	Conclusion Lapatinib could inhibit cell proliferation and promote apoptosis in HL60 cells by inhibiting the CIP2A/AKT/c-MYC signal pathway.	Lapatinib	11-20	AKT serine/threonine kinase 1	Homo sapiens	114-117
29169418-10	2017	Conclusion Lapatinib could inhibit cell proliferation and promote apoptosis in HL60 cells by inhibiting the CIP2A/AKT/c-MYC signal pathway.	Lapatinib	11-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-123
28487443-8	2017	The HER1/2-irreversible inhibitors afatinib and neratinib substantially inhibited both resistant cell growth and the HER2 and downstream AKT/MAPK signaling driven by HER2L755S in vitro and in vivoConclusions: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to lapatinib-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.	Lapatinib	329-338	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
28887806-0	2017	Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
28735814-3	2017	The EGFR/HER2-targeting tyrosine kinase inhibitor (TKI) lapatinib and the next generation TKIs afatinib and neratinib, can alter HER2 levels, potentially modulating the ADCC response to trastuzumab.	Lapatinib	56-65	epidermal growth factor receptor	Homo sapiens	4-8
28735814-3	2017	The EGFR/HER2-targeting tyrosine kinase inhibitor (TKI) lapatinib and the next generation TKIs afatinib and neratinib, can alter HER2 levels, potentially modulating the ADCC response to trastuzumab.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
28735814-3	2017	The EGFR/HER2-targeting tyrosine kinase inhibitor (TKI) lapatinib and the next generation TKIs afatinib and neratinib, can alter HER2 levels, potentially modulating the ADCC response to trastuzumab.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
28735814-5	2017	METHODS: HER2 levels were determined in lapatinib, afatinib and neratinib-treated SKBR3 and MCF-7 using high content analysis (HCA).	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
28487443-8	2017	The HER1/2-irreversible inhibitors afatinib and neratinib substantially inhibited both resistant cell growth and the HER2 and downstream AKT/MAPK signaling driven by HER2L755S in vitro and in vivoConclusions: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to lapatinib-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.	Lapatinib	329-338	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
28487443-8	2017	The HER1/2-irreversible inhibitors afatinib and neratinib substantially inhibited both resistant cell growth and the HER2 and downstream AKT/MAPK signaling driven by HER2L755S in vitro and in vivoConclusions: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to lapatinib-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.	Lapatinib	329-338	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
28487443-8	2017	The HER1/2-irreversible inhibitors afatinib and neratinib substantially inhibited both resistant cell growth and the HER2 and downstream AKT/MAPK signaling driven by HER2L755S in vitro and in vivoConclusions: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to lapatinib-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.	Lapatinib	329-338	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
28487443-2	2017	Here we employed BT474 parental and treatment-resistant cell line models to investigate a mechanism by which HER2+ breast cancer can reactivate the HER network under potent HER2-targeted therapies.Experimental Design: Resistant derivatives to lapatinib (L), trastuzumab (T), or the combination (LR/TR/LTR) were developed independently from two independent estrogen receptor ER+/HER2+ BT474 cell lines (AZ/ATCC).	Lapatinib	243-252	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
28487443-8	2017	The HER1/2-irreversible inhibitors afatinib and neratinib substantially inhibited both resistant cell growth and the HER2 and downstream AKT/MAPK signaling driven by HER2L755S in vitro and in vivoConclusions: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to lapatinib-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.	Lapatinib	329-338	epidermal growth factor receptor	Homo sapiens	4-8
28669012-2	2017	Trials involving erlotinib have shown mixed results, likely owing to a mechanism of the mutation that may instead favor other EGFR inhibitors, such as lapatinib.	Lapatinib	151-160	epidermal growth factor receptor	Homo sapiens	126-130
29285221-0	2017	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib.	Lapatinib	97-106	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	2-7
28827805-8	2017	In contrast, the expression of transferrin, which is responsible for the transport of iron into cells, is increased following treatment with lapatinib alone or in combination with siramesine.	Lapatinib	141-150	transferrin	Homo sapiens	31-42
28759294-5	2017	Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels.	Lapatinib	77-86	epidermal growth factor receptor	Homo sapiens	57-61
28759294-5	2017	Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels.	Lapatinib	77-86	epidermal growth factor receptor	Homo sapiens	63-67
28759294-5	2017	Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
28759294-5	2017	Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels.	Lapatinib	77-86	AKT serine/threonine kinase 1	Homo sapiens	129-132
28759294-5	2017	Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels.	Lapatinib	77-86	E1A binding protein p300	Homo sapiens	161-165
28687923-2	2017	Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
28687923-2	2017	Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
28687923-2	2017	Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	29-38	epidermal growth factor receptor	Homo sapiens	9-13
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	29-38	mitogen-activated protein kinase 1	Homo sapiens	85-89
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-175
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	29-38	mitogen-activated protein kinase 1	Homo sapiens	190-194
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	40-43	epidermal growth factor receptor	Homo sapiens	9-13
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	40-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	40-43	mitogen-activated protein kinase 1	Homo sapiens	85-89
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	40-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-175
29113345-3	2017	The dual EGFR/HER2 inhibitor lapatinib (LPN) displayed greater cytotoxic potency and MAPK signaling inhibition than the EGFR inhibitor erlotinib, suggesting both EGFR and HER2 contribute to MAPK signaling in this TNBC model.	Lapatinib	40-43	mitogen-activated protein kinase 1	Homo sapiens	190-194
28759294-5	2017	Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels.	Lapatinib	77-86	transcriptional adaptor 3	Homo sapiens	186-190
28759294-7	2017	ADA3 knockdown led to cell cycle inhibitory effects, as well as apoptosis similar to those induced by lapatinib treatment of HER2+ breast cancer cells, as seen by accumulation of CDK inhibitor p27, reduction in mitotic marker pH3(S10), and a decrease in the S-phase marker PCNA, as well as the appearance of cleaved PARP.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
29285221-0	2017	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib.	Lapatinib	97-106	mitogen-activated protein kinase 8	Homo sapiens	37-40
29285221-4	2017	Herein, we report that treatment with the covalent JNK inhibitor, JNK-IN-8, synergizes with lapatinib to cause cell death, while these compounds as single agents have little effect.	Lapatinib	92-101	mitogen-activated protein kinase 8	Homo sapiens	51-54
29285221-4	2017	Herein, we report that treatment with the covalent JNK inhibitor, JNK-IN-8, synergizes with lapatinib to cause cell death, while these compounds as single agents have little effect.	Lapatinib	92-101	mitogen-activated protein kinase 8	Homo sapiens	66-69
29285221-6	2017	Our studies demonstrate that lapatinib treatment increases c-Jun and JNK phosphorylation indicating a mechanism of resistance.	Lapatinib	29-38	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	59-64
29285221-6	2017	Our studies demonstrate that lapatinib treatment increases c-Jun and JNK phosphorylation indicating a mechanism of resistance.	Lapatinib	29-38	mitogen-activated protein kinase 8	Homo sapiens	69-72
29285221-9	2017	Over expression of p65 or Nrf2 also significantly rescues viability during JNK-IN-8 and lapatinib treatment.	Lapatinib	88-97	RELA proto-oncogene, NF-kB subunit	Homo sapiens	19-22
29285221-9	2017	Over expression of p65 or Nrf2 also significantly rescues viability during JNK-IN-8 and lapatinib treatment.	Lapatinib	88-97	NFE2 like bZIP transcription factor 2	Homo sapiens	26-30
29069787-0	2017	Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
29069787-0	2017	Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.	Lapatinib	118-127	estrogen receptor 1	Homo sapiens	50-67
29069787-0	2017	Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
28768804-5	2017	S63845 displayed synergistic activity with docetaxel in triple-negative breast cancer and with trastuzumab or lapatinib in HER2-amplified breast cancer.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
28381415-7	2017	Stimulation of BT474 cells with FGF4 promoted resistance to lapatinib + trastuzumab in vitro Treatment with FGFR tyrosine kinase inhibitors reversed these changes and overcame resistance to lapatinib + trastuzumab.	Lapatinib	60-69	fibroblast growth factor 4	Homo sapiens	32-36
28484925-0	2017	Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
28484925-0	2017	Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).	Lapatinib	107-116	chaperonin containing TCP1 subunit 3	Homo sapiens	95-99
28381415-7	2017	Stimulation of BT474 cells with FGF4 promoted resistance to lapatinib + trastuzumab in vitro Treatment with FGFR tyrosine kinase inhibitors reversed these changes and overcame resistance to lapatinib + trastuzumab.	Lapatinib	190-199	fibroblast growth factor 4	Homo sapiens	32-36
28969039-5	2017	PD-L1 expression in HER2-amplified cell lines was evaluated by western blotting, fluorescence-activated cell sorting, reverse transcription, and real-time quantitative PCR analyses before and after afatinib, lapatinib, pictilisib and trametinib treatment.	Lapatinib	208-217	CD274 molecule	Homo sapiens	0-5
29156708-8	2017	In HCC1954, the most refametinib-sensitive cell line (IC50= 397 nM), lapatinib treatment inhibits phosphorylation of MEK and MAPK but activates AKT phosphorylation, in contrast to the other 2 parental cell lines tested (BT474-P, SKBR3-P), suggesting that HER2 may directly activate MEK/MAPK and not PI3K/AKT in HCC1954 cells but not in the other 2 cell lines, perhaps explaining the refametinib-sensitivity of this cell line.	Lapatinib	69-78	mitogen-activated protein kinase kinase 7	Homo sapiens	117-120
29156708-8	2017	In HCC1954, the most refametinib-sensitive cell line (IC50= 397 nM), lapatinib treatment inhibits phosphorylation of MEK and MAPK but activates AKT phosphorylation, in contrast to the other 2 parental cell lines tested (BT474-P, SKBR3-P), suggesting that HER2 may directly activate MEK/MAPK and not PI3K/AKT in HCC1954 cells but not in the other 2 cell lines, perhaps explaining the refametinib-sensitivity of this cell line.	Lapatinib	69-78	AKT serine/threonine kinase 1	Homo sapiens	144-147
28938602-10	2017	Importantly, lapatinib induced differential CIP2A downregulation between parental BT474 and BT474/LR cell lines.	Lapatinib	13-22	cellular inhibitor of PP2A	Homo sapiens	44-49
28938602-11	2017	Moreover, CIP2A shRNA knockdown significantly sensitized the BT474/LR cells to lapatinib.	Lapatinib	79-88	cellular inhibitor of PP2A	Homo sapiens	10-15
28938602-12	2017	Collectively, our results demonstrate that CIP2A is a molecular target and resistance factor of lapatinib with a critical role in lapatinib-induced cellular responses, including the inhibition of the CIP2A-Akt feedback loop.	Lapatinib	96-105	cellular inhibitor of PP2A	Homo sapiens	43-48
28938602-12	2017	Collectively, our results demonstrate that CIP2A is a molecular target and resistance factor of lapatinib with a critical role in lapatinib-induced cellular responses, including the inhibition of the CIP2A-Akt feedback loop.	Lapatinib	96-105	cellular inhibitor of PP2A	Homo sapiens	200-205
28938602-12	2017	Collectively, our results demonstrate that CIP2A is a molecular target and resistance factor of lapatinib with a critical role in lapatinib-induced cellular responses, including the inhibition of the CIP2A-Akt feedback loop.	Lapatinib	96-105	AKT serine/threonine kinase 1	Homo sapiens	206-209
28938602-12	2017	Collectively, our results demonstrate that CIP2A is a molecular target and resistance factor of lapatinib with a critical role in lapatinib-induced cellular responses, including the inhibition of the CIP2A-Akt feedback loop.	Lapatinib	130-139	cellular inhibitor of PP2A	Homo sapiens	43-48
28938602-12	2017	Collectively, our results demonstrate that CIP2A is a molecular target and resistance factor of lapatinib with a critical role in lapatinib-induced cellular responses, including the inhibition of the CIP2A-Akt feedback loop.	Lapatinib	130-139	cellular inhibitor of PP2A	Homo sapiens	200-205
28938602-12	2017	Collectively, our results demonstrate that CIP2A is a molecular target and resistance factor of lapatinib with a critical role in lapatinib-induced cellular responses, including the inhibition of the CIP2A-Akt feedback loop.	Lapatinib	130-139	AKT serine/threonine kinase 1	Homo sapiens	206-209
28938602-13	2017	Further investigation of lapatinib-mediated CIP2A regulation will advance our understanding of lapatinib-associated anti-tumor activities and drug resistance.	Lapatinib	25-34	cellular inhibitor of PP2A	Homo sapiens	44-49
28938602-13	2017	Further investigation of lapatinib-mediated CIP2A regulation will advance our understanding of lapatinib-associated anti-tumor activities and drug resistance.	Lapatinib	95-104	cellular inhibitor of PP2A	Homo sapiens	44-49
28520590-7	2017	Human prolactinomas have differential ErbB receptor expression associated with aggressive behaviour and data from an ongoing clinical trial suggest that resistant prolactinomas may respond to the EGFR TKI lapatinib.	Lapatinib	205-214	epidermal growth factor receptor	Homo sapiens	196-200
29156708-8	2017	In HCC1954, the most refametinib-sensitive cell line (IC50= 397 nM), lapatinib treatment inhibits phosphorylation of MEK and MAPK but activates AKT phosphorylation, in contrast to the other 2 parental cell lines tested (BT474-P, SKBR3-P), suggesting that HER2 may directly activate MEK/MAPK and not PI3K/AKT in HCC1954 cells but not in the other 2 cell lines, perhaps explaining the refametinib-sensitivity of this cell line.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	255-259
29156708-8	2017	In HCC1954, the most refametinib-sensitive cell line (IC50= 397 nM), lapatinib treatment inhibits phosphorylation of MEK and MAPK but activates AKT phosphorylation, in contrast to the other 2 parental cell lines tested (BT474-P, SKBR3-P), suggesting that HER2 may directly activate MEK/MAPK and not PI3K/AKT in HCC1954 cells but not in the other 2 cell lines, perhaps explaining the refametinib-sensitivity of this cell line.	Lapatinib	69-78	mitogen-activated protein kinase kinase 7	Homo sapiens	282-285
29156708-8	2017	In HCC1954, the most refametinib-sensitive cell line (IC50= 397 nM), lapatinib treatment inhibits phosphorylation of MEK and MAPK but activates AKT phosphorylation, in contrast to the other 2 parental cell lines tested (BT474-P, SKBR3-P), suggesting that HER2 may directly activate MEK/MAPK and not PI3K/AKT in HCC1954 cells but not in the other 2 cell lines, perhaps explaining the refametinib-sensitivity of this cell line.	Lapatinib	69-78	AKT serine/threonine kinase 1	Homo sapiens	304-307
29156708-10	2017	The combination of MEK inhibition (MEKi) with refametinib and copanlisib led to synergistic inhibition of growth in 4/6 cell lines tested (CI @ED75 = 0.39-0.75), whilst the combinations of lapatinib and refametinib led to synergistic inhibition of growth in 3/6 cell lines (CI @ED75 = 0.39-0.80).	Lapatinib	189-198	mitogen-activated protein kinase kinase 7	Homo sapiens	19-22
29156708-12	2017	The direct down-regulation of MEK/MAPK but not AKT signalling by HER2 inhibition (e.g. by lapatinib or trastuzumab), which we demonstrate occurs in 18% of HER2-positive breast cancers may serve as a potential biomarker of responsiveness to the MEK inhibitor refametinib.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-159
28938602-0	2017	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.	Lapatinib	65-74	cellular inhibitor of PP2A	Homo sapiens	14-41
28938602-0	2017	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.	Lapatinib	65-74	cellular inhibitor of PP2A	Homo sapiens	43-48
28938602-0	2017	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.	Lapatinib	65-74	cellular inhibitor of PP2A	Homo sapiens	107-112
28938602-0	2017	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.	Lapatinib	65-74	AKT serine/threonine kinase 1	Homo sapiens	113-116
28938602-0	2017	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-139
28938602-1	2017	Lapatinib, a small molecule ErbB2/EGFR inhibitor, is FDA-approved for the treatment of metastatic ErbB2-overexpressing breast cancer; however, lapatinib resistance is an emerging clinical challenge.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
28938602-1	2017	Lapatinib, a small molecule ErbB2/EGFR inhibitor, is FDA-approved for the treatment of metastatic ErbB2-overexpressing breast cancer; however, lapatinib resistance is an emerging clinical challenge.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	34-38
28938602-1	2017	Lapatinib, a small molecule ErbB2/EGFR inhibitor, is FDA-approved for the treatment of metastatic ErbB2-overexpressing breast cancer; however, lapatinib resistance is an emerging clinical challenge.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
28938602-4	2017	Our study investigated the role of CIP2A in the anti-cancer efficacy of lapatinib in ErbB2-overexpressing breast cancer cells.	Lapatinib	72-81	cellular inhibitor of PP2A	Homo sapiens	35-40
28938602-4	2017	Our study investigated the role of CIP2A in the anti-cancer efficacy of lapatinib in ErbB2-overexpressing breast cancer cells.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
28938602-5	2017	We found that lapatinib concurrently downregulated CIP2A and receptor tyrosine kinase signaling in ErbB2-overexpressing SKBR3 and 78617 cells; however, these effects were attenuated in lapatinib-resistant (LR) cells.	Lapatinib	14-23	cellular inhibitor of PP2A	Homo sapiens	51-56
28938602-5	2017	We found that lapatinib concurrently downregulated CIP2A and receptor tyrosine kinase signaling in ErbB2-overexpressing SKBR3 and 78617 cells; however, these effects were attenuated in lapatinib-resistant (LR) cells.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-104
28938602-6	2017	CIP2A overexpression rendered SKBR3 and 78617 cells resistant to lapatinib-induced apoptosis and growth inhibition.	Lapatinib	65-74	cellular inhibitor of PP2A	Homo sapiens	0-5
28938602-7	2017	Conversely, CIP2A knockdown via lentiviral shRNA enhanced cell sensitivity to lapatinib-induced growth inhibition and apoptosis.	Lapatinib	78-87	cellular inhibitor of PP2A	Homo sapiens	12-17
28938602-8	2017	Results also suggested that lapatinib downregulated CIP2A through regulation of protein stability.	Lapatinib	28-37	cellular inhibitor of PP2A	Homo sapiens	52-57
28938602-9	2017	We further demonstrated that lapatinib-induced CIP2A downregulation can be recapitulated by LY294002, suggesting that Akt mediates CIP2A upregulation.	Lapatinib	29-38	cellular inhibitor of PP2A	Homo sapiens	47-52
28938602-9	2017	We further demonstrated that lapatinib-induced CIP2A downregulation can be recapitulated by LY294002, suggesting that Akt mediates CIP2A upregulation.	Lapatinib	29-38	AKT serine/threonine kinase 1	Homo sapiens	118-121
28938602-9	2017	We further demonstrated that lapatinib-induced CIP2A downregulation can be recapitulated by LY294002, suggesting that Akt mediates CIP2A upregulation.	Lapatinib	29-38	cellular inhibitor of PP2A	Homo sapiens	131-136
28969039-10	2017	In HER2-overexpressing cell lines, PD-L1 expression was decreased in a dose- and time-dependent manner after afatinib and lapatinib treatment.	Lapatinib	122-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
28969039-10	2017	In HER2-overexpressing cell lines, PD-L1 expression was decreased in a dose- and time-dependent manner after afatinib and lapatinib treatment.	Lapatinib	122-131	CD274 molecule	Homo sapiens	35-40
28969039-12	2017	After lapatinib treatment, the release of CCL2, CCL21, VEGF and CXCL1 decreased in a dose-dependent manner.	Lapatinib	6-15	C-C motif chemokine ligand 2	Homo sapiens	42-46
28969039-12	2017	After lapatinib treatment, the release of CCL2, CCL21, VEGF and CXCL1 decreased in a dose-dependent manner.	Lapatinib	6-15	C-C motif chemokine ligand 21	Homo sapiens	48-53
28969039-12	2017	After lapatinib treatment, the release of CCL2, CCL21, VEGF and CXCL1 decreased in a dose-dependent manner.	Lapatinib	6-15	vascular endothelial growth factor A	Homo sapiens	55-59
28969039-12	2017	After lapatinib treatment, the release of CCL2, CCL21, VEGF and CXCL1 decreased in a dose-dependent manner.	Lapatinib	6-15	C-X-C motif chemokine ligand 1	Homo sapiens	64-69
28744398-5	2017	Lapatinib inhibits the kinase activity of both HER1 and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	47-51
28744399-3	2017	In this work, we have evaluated the effects and the mechanism of action of the combination of calcitriol or its analog EB1089 with lapatinib or neratinib on EGFR and/or HER2 positive breast cancer cell lines.	Lapatinib	131-140	epidermal growth factor receptor	Homo sapiens	157-161
28744398-5	2017	Lapatinib inhibits the kinase activity of both HER1 and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
28744399-3	2017	In this work, we have evaluated the effects and the mechanism of action of the combination of calcitriol or its analog EB1089 with lapatinib or neratinib on EGFR and/or HER2 positive breast cancer cell lines.	Lapatinib	131-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	epidermal growth factor receptor	Homo sapiens	89-95
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	zinc fingers and homeoboxes 2	Homo sapiens	152-155
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	mitogen-activated protein kinase kinase 7	Homo sapiens	157-160
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	mitogen-activated protein kinase 1	Homo sapiens	166-169
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	epidermal growth factor receptor	Homo sapiens	89-93
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	zinc fingers and homeoboxes 2	Homo sapiens	291-294
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	mitogen-activated protein kinase kinase 7	Homo sapiens	295-298
28744398-6	2017	In the current study, we found that repeated treatment of HER2+ breast cancer cells with HER1/2 inhibitor Lapatinib led to increased phosphorylation of RAF, MEK, and ERK, while suppressing HER1 phosphorylation and reduced the active form of Ras, indicating existence of factor(s) activating RAF/MEK/ERK by bypassing RAS activation.	Lapatinib	106-115	mitogen-activated protein kinase 1	Homo sapiens	299-302
28744398-7	2017	Notably, the Lapatinib treatment-induced phosphorylation of ERK was dependent on FOXO transcription factors, which are also activated by Lapatinib-mediated suppression of AKT.	Lapatinib	13-22	mitogen-activated protein kinase 1	Homo sapiens	60-63
28744398-7	2017	Notably, the Lapatinib treatment-induced phosphorylation of ERK was dependent on FOXO transcription factors, which are also activated by Lapatinib-mediated suppression of AKT.	Lapatinib	13-22	AKT serine/threonine kinase 1	Homo sapiens	171-174
28744398-7	2017	Notably, the Lapatinib treatment-induced phosphorylation of ERK was dependent on FOXO transcription factors, which are also activated by Lapatinib-mediated suppression of AKT.	Lapatinib	137-146	mitogen-activated protein kinase 1	Homo sapiens	60-63
28744398-7	2017	Notably, the Lapatinib treatment-induced phosphorylation of ERK was dependent on FOXO transcription factors, which are also activated by Lapatinib-mediated suppression of AKT.	Lapatinib	137-146	AKT serine/threonine kinase 1	Homo sapiens	171-174
28744398-8	2017	Moreover, the Lapatinib-induced phosphorylation of RAF and ERK is inhibited by a pan-PKC inhibitor.	Lapatinib	14-23	zinc fingers and homeoboxes 2	Homo sapiens	51-54
28744398-8	2017	Moreover, the Lapatinib-induced phosphorylation of RAF and ERK is inhibited by a pan-PKC inhibitor.	Lapatinib	14-23	mitogen-activated protein kinase 1	Homo sapiens	59-62
28744398-9	2017	Furthermore, the Lapatinib induced increased ERK phosphorylation is correlated with increased stability of c-Myc, which is known to be stabilized by ERK-mediated phosphorylation.	Lapatinib	17-26	mitogen-activated protein kinase 1	Homo sapiens	45-48
28744398-9	2017	Furthermore, the Lapatinib induced increased ERK phosphorylation is correlated with increased stability of c-Myc, which is known to be stabilized by ERK-mediated phosphorylation.	Lapatinib	17-26	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	107-112
28744398-9	2017	Furthermore, the Lapatinib induced increased ERK phosphorylation is correlated with increased stability of c-Myc, which is known to be stabilized by ERK-mediated phosphorylation.	Lapatinib	17-26	mitogen-activated protein kinase 1	Homo sapiens	149-152
28785185-8	2017	Up to now, most reported studies used lapatinib as treatment of HER2-positive breast cancer with BM, a treatment with only a modest effect and a high toxicity profile.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
28744398-10	2017	Together, these results suggest that chronic inhibition of the HER1/2 by Lapatinib triggers a feedback loop to activate RAF/MEK/ERK pathway, in a FOXO dependent but Ras-independent manner.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	63-67
28744398-10	2017	Together, these results suggest that chronic inhibition of the HER1/2 by Lapatinib triggers a feedback loop to activate RAF/MEK/ERK pathway, in a FOXO dependent but Ras-independent manner.	Lapatinib	73-82	zinc fingers and homeoboxes 2	Homo sapiens	120-123
28744398-10	2017	Together, these results suggest that chronic inhibition of the HER1/2 by Lapatinib triggers a feedback loop to activate RAF/MEK/ERK pathway, in a FOXO dependent but Ras-independent manner.	Lapatinib	73-82	mitogen-activated protein kinase kinase 7	Homo sapiens	124-127
28744398-10	2017	Together, these results suggest that chronic inhibition of the HER1/2 by Lapatinib triggers a feedback loop to activate RAF/MEK/ERK pathway, in a FOXO dependent but Ras-independent manner.	Lapatinib	73-82	mitogen-activated protein kinase 1	Homo sapiens	128-131
28415602-0	2017	ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.	Lapatinib	54-63	steroid receptor associated and regulated protein	Homo sapiens	0-4
28596528-0	2017	Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	84-89
28596528-4	2017	Applying a systematic pairwise drug combination screen we observed a highly potent synergy in neuroblastoma cells between the EGFR kinase inhibitor lapatinib and the anticancer compound YM155 that is preserved across several neuroblastoma variants.	Lapatinib	148-157	epidermal growth factor receptor	Homo sapiens	126-130
28596528-5	2017	Mechanistically, the synergy was based on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neuroblastoma cells, which allowed prolonged and elevated cytotoxicity of YM155.	Lapatinib	44-53	ATP binding cassette subfamily B member 1	Homo sapiens	120-125
28415602-0	2017	ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-21
28415602-0	2017	ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.	Lapatinib	54-63	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	96-100
28415602-0	2017	ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-110
28415602-2	2017	Here we report that ERRF also plays an important role in the response of ERBB2-positive breast cancer cells to lapatinib, a dual tyrosine kinase inhibitor that interrupts the ERBB2 and EGFR pathway.	Lapatinib	111-120	steroid receptor associated and regulated protein	Homo sapiens	20-24
28415602-2	2017	Here we report that ERRF also plays an important role in the response of ERBB2-positive breast cancer cells to lapatinib, a dual tyrosine kinase inhibitor that interrupts the ERBB2 and EGFR pathway.	Lapatinib	111-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
28415602-2	2017	Here we report that ERRF also plays an important role in the response of ERBB2-positive breast cancer cells to lapatinib, a dual tyrosine kinase inhibitor that interrupts the ERBB2 and EGFR pathway.	Lapatinib	111-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-180
28415602-2	2017	Here we report that ERRF also plays an important role in the response of ERBB2-positive breast cancer cells to lapatinib, a dual tyrosine kinase inhibitor that interrupts the ERBB2 and EGFR pathway.	Lapatinib	111-120	epidermal growth factor receptor	Homo sapiens	185-189
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	92-101	steroid receptor associated and regulated protein	Homo sapiens	60-64
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-3	2017	In ERBB2-positive breast cancer cell lines, lower levels of ERRF expression correlated with lapatinib resistance, restoration of ERRF expression in lapatinib-resistant cell lines JIMT-1 and MDA-MB-453 enhanced their lapatinib responses, and knockdown of ERRF in lapatinib sensitive cell lines BT-474 and SK-BR-3 caused lapatinib resistance.	Lapatinib	148-157	steroid receptor associated and regulated protein	Homo sapiens	129-133
28415602-4	2017	ERRF-enhanced lapatinib sensitivity was also confirmed in xenograft tumors of JIMT-1 cells.	Lapatinib	14-23	steroid receptor associated and regulated protein	Homo sapiens	0-4
28415602-5	2017	In patients with ERBB2-positive breast cancer, higher level of ERRF expression correlated with both pathologic complete response (pCR) to lapatinib and better survival.	Lapatinib	138-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-22
28415602-5	2017	In patients with ERBB2-positive breast cancer, higher level of ERRF expression correlated with both pathologic complete response (pCR) to lapatinib and better survival.	Lapatinib	138-147	steroid receptor associated and regulated protein	Homo sapiens	63-67
28415602-6	2017	Mechanistically, ERRF expression in resistant cells promoted lapatinib-induced apoptosis by attenuating MCL1 and ERBB2 expression.	Lapatinib	61-70	steroid receptor associated and regulated protein	Homo sapiens	17-21
28415602-6	2017	Mechanistically, ERRF expression in resistant cells promoted lapatinib-induced apoptosis by attenuating MCL1 and ERBB2 expression.	Lapatinib	61-70	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	104-108
28415602-6	2017	Mechanistically, ERRF expression in resistant cells promoted lapatinib-induced apoptosis by attenuating MCL1 and ERBB2 expression.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-118
28415602-7	2017	These results suggest that ERRF plays an important role in lapatinib response of ERBB2-positive breast cancer, and further study of ERRF could lead to improved prediction and sensitivity of lapatinib response.	Lapatinib	59-68	steroid receptor associated and regulated protein	Homo sapiens	27-31
28415602-7	2017	These results suggest that ERRF plays an important role in lapatinib response of ERBB2-positive breast cancer, and further study of ERRF could lead to improved prediction and sensitivity of lapatinib response.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-86
28415602-7	2017	These results suggest that ERRF plays an important role in lapatinib response of ERBB2-positive breast cancer, and further study of ERRF could lead to improved prediction and sensitivity of lapatinib response.	Lapatinib	190-199	steroid receptor associated and regulated protein	Homo sapiens	132-136
28481952-3	2017	Here, we take a systems biology approach to understand the molecular mechanisms that prevent breast cancer (BC) cells from responding to lapatinib, a dual kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-225
29069742-9	2017	p-EGFR inhibition by lapatinib reduced UBE2J2-promoted cell invasion, suggesting p-EGFR is important for UBE2J2-mediated HCCLM3 cell invasion.	Lapatinib	21-30	epidermal growth factor receptor	Homo sapiens	2-6
29069742-9	2017	p-EGFR inhibition by lapatinib reduced UBE2J2-promoted cell invasion, suggesting p-EGFR is important for UBE2J2-mediated HCCLM3 cell invasion.	Lapatinib	21-30	ubiquitin conjugating enzyme E2 J2	Homo sapiens	39-45
28464908-0	2017	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.	Lapatinib	19-28	AXL receptor tyrosine kinase	Homo sapiens	69-72
28464908-0	2017	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.	Lapatinib	19-28	vascular endothelial growth factor A	Homo sapiens	77-111
28464908-0	2017	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-175
28464908-0	2017	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-182
28481952-3	2017	Here, we take a systems biology approach to understand the molecular mechanisms that prevent breast cancer (BC) cells from responding to lapatinib, a dual kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	227-231
28481952-3	2017	Here, we take a systems biology approach to understand the molecular mechanisms that prevent breast cancer (BC) cells from responding to lapatinib, a dual kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).	Lapatinib	137-146	epidermal growth factor receptor	Homo sapiens	191-223
28481952-3	2017	Here, we take a systems biology approach to understand the molecular mechanisms that prevent breast cancer (BC) cells from responding to lapatinib, a dual kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).	Lapatinib	137-146	epidermal growth factor receptor	Homo sapiens	271-275
28481952-9	2017	Further bioinformatics analysis identified vitamin D receptor (VDR) as a potential target of interest for lapatinib non-responsive BC cells.	Lapatinib	106-115	vitamin D receptor	Homo sapiens	43-61
28481952-9	2017	Further bioinformatics analysis identified vitamin D receptor (VDR) as a potential target of interest for lapatinib non-responsive BC cells.	Lapatinib	106-115	vitamin D receptor	Homo sapiens	63-66
28481952-10	2017	Experimentally, calcitriol, a commonly used reagent for VDR targeted therapy, in combination with lapatinib additively inhibited proliferation in two HER2 positive cell lines, lapatinib insensitive MDA-MB-453 and lapatinib resistant HCC 1954-L cells.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
28730769-0	2017	Downregulation and subcellular distribution of HER2 involved in MDA-MB-453 breast cancer cell apoptosis induced by lapatinib/celastrol combination.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
28341957-0	2017	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
28341957-10	2017	CONCLUSIONS: Combination of pegylated liposomal doxorubicin and lapatinib is feasible and potentially active in pretreated HER2-positive advanced breast cancer patients.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
28730769-8	2017	RESULTS: Combination celastrol and lapatinib produced strong synergy in growth inhibition and apoptosis in comparison to single-agent treatment in HER2/neu-overexpressing MDA-MB-453 cells.	Lapatinib	35-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-155
28730769-1	2017	PURPOSE: To investigate the effect and related molecular mechanisms of lapatinib/celastrol combination or single-agent treatment in HER2/neu-overexpressing MDA-MB-453 breast cancer cells.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
28730769-9	2017	Interestingly, compared with celastrol treatment alone, lapatinib/celastrol combination induced more HER2 membrane protein downregulation and ectopic to cytoplasm and nucleus in MDA-MB-453 cells.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
28730769-10	2017	CONCLUSION: The combination of celastrol and lapatinib could be used as a novel combination regimen which provides a strong anticancer synergy in the treatment of HER2/neu-overexpressing cancer cells.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
28730769-10	2017	CONCLUSION: The combination of celastrol and lapatinib could be used as a novel combination regimen which provides a strong anticancer synergy in the treatment of HER2/neu-overexpressing cancer cells.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-171
28730769-1	2017	PURPOSE: To investigate the effect and related molecular mechanisms of lapatinib/celastrol combination or single-agent treatment in HER2/neu-overexpressing MDA-MB-453 breast cancer cells.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-140
28649658-3	2017	To evaluate whether differential intra-tumor responses to targeted therapy occur in vivo, we examined the sensitivity of human epidermal growth factor receptor 2-positive tumors to lapatinib using a previously described ductal carcinoma in situ-like model characterized by tumor cell confinement within ductal structures surrounded by an organized basement membrane.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-161
28393315-1	2017	Lapatinib, a novel oral dual tyrosine kinase inhibitor blocking HER1 and HER2 pathways, has presented beneficial effects on breast cancer with positive HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	64-68
28393315-1	2017	Lapatinib, a novel oral dual tyrosine kinase inhibitor blocking HER1 and HER2 pathways, has presented beneficial effects on breast cancer with positive HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
28393315-1	2017	Lapatinib, a novel oral dual tyrosine kinase inhibitor blocking HER1 and HER2 pathways, has presented beneficial effects on breast cancer with positive HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
28393315-11	2017	Protein-protein interaction network construction revealed that some hub genes, such as PPARG, TGFBI, TGFBR2, TIMP1, CTGF, UBA52 and JUN, might have an association with Lapatinib resistance.	Lapatinib	168-177	peroxisome proliferator activated receptor gamma	Homo sapiens	87-92
28393315-11	2017	Protein-protein interaction network construction revealed that some hub genes, such as PPARG, TGFBI, TGFBR2, TIMP1, CTGF, UBA52 and JUN, might have an association with Lapatinib resistance.	Lapatinib	168-177	transforming growth factor beta induced	Homo sapiens	94-99
28393315-11	2017	Protein-protein interaction network construction revealed that some hub genes, such as PPARG, TGFBI, TGFBR2, TIMP1, CTGF, UBA52 and JUN, might have an association with Lapatinib resistance.	Lapatinib	168-177	transforming growth factor beta receptor 2	Homo sapiens	101-107
28393315-11	2017	Protein-protein interaction network construction revealed that some hub genes, such as PPARG, TGFBI, TGFBR2, TIMP1, CTGF, UBA52 and JUN, might have an association with Lapatinib resistance.	Lapatinib	168-177	TIMP metallopeptidase inhibitor 1	Homo sapiens	109-114
28393315-11	2017	Protein-protein interaction network construction revealed that some hub genes, such as PPARG, TGFBI, TGFBR2, TIMP1, CTGF, UBA52 and JUN, might have an association with Lapatinib resistance.	Lapatinib	168-177	cellular communication network factor 2	Homo sapiens	116-120
28393315-11	2017	Protein-protein interaction network construction revealed that some hub genes, such as PPARG, TGFBI, TGFBR2, TIMP1, CTGF, UBA52 and JUN, might have an association with Lapatinib resistance.	Lapatinib	168-177	ubiquitin A-52 residue ribosomal protein fusion product 1	Homo sapiens	122-127
28649658-5	2017	We found that the pro-survival protein BCL2 is selectively induced in the niche-protected tumor cells following lapatinib treatment, and combined inhibition of HER2 and BCL-2/XL enhanced targeting of these residual tumor cells.	Lapatinib	112-121	BCL2 apoptosis regulator	Homo sapiens	39-43
28445439-7	2017	HER2 cleavage during EMT can explain why secondary metastatic tumors with high percentage of mesenchymal-like cancer stem cells are mostly resistant to trastuzumab but still sensitive to lapatinib.	Lapatinib	187-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
28238593-0	2017	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.	Lapatinib	97-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
28209619-1	2017	HER2/ERBB2-overexpressing breast cancers targeted effectively by the small-molecule kinase inhibitor lapatinib frequently acquire resistance to this drug.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
28209619-1	2017	HER2/ERBB2-overexpressing breast cancers targeted effectively by the small-molecule kinase inhibitor lapatinib frequently acquire resistance to this drug.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-10
28065859-0	2017	Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.	Lapatinib	59-68	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	20-47
28238614-4	2017	The result of docking with EGFR suggested the binding mode of 2a was similar to that of lapatinib.	Lapatinib	88-97	epidermal growth factor receptor	Homo sapiens	27-31
28153500-7	2017	The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger).	Lapatinib	102-111	epidermal growth factor receptor	Homo sapiens	16-20
28153500-7	2017	The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger).	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
28153500-7	2017	The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger).	Lapatinib	102-111	endothelin 1	Homo sapiens	56-60
28153500-7	2017	The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger).	Lapatinib	102-111	epidermal growth factor receptor	Homo sapiens	113-117
28153500-7	2017	The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger).	Lapatinib	102-111	epidermal growth factor receptor	Homo sapiens	113-117
28288164-7	2017	Using two lapatinib-treated ErbB2-positive breast cancer cell-lines: SKBR3 and BT474, our method identified similar dysregulated signaling pathways including EGFR-related pathways as well as other receptor-related pathways, many of which were reported previously as compensatory pathways of EGFR-inhibition via signaling cross-talk.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
28423638-4	2017	Herein, we showed that lapatinib prevented MAPK rebound and sensitized BRAFV600E-positive papillary thyroid cancer cells to BRAF/MEK inhibitors.	Lapatinib	23-32	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	71-75
28423638-4	2017	Herein, we showed that lapatinib prevented MAPK rebound and sensitized BRAFV600E-positive papillary thyroid cancer cells to BRAF/MEK inhibitors.	Lapatinib	23-32	mitogen-activated protein kinase kinase 7	Homo sapiens	129-132
28112728-4	2017	We also discovered amplifications in immune targets CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2), and the BCAR4 long non-coding RNA, which has been associated with response to lapatinib.	Lapatinib	194-203	CD274 molecule	Homo sapiens	52-57
28112728-4	2017	We also discovered amplifications in immune targets CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2), and the BCAR4 long non-coding RNA, which has been associated with response to lapatinib.	Lapatinib	194-203	CD274 molecule	Homo sapiens	73-78
28112728-4	2017	We also discovered amplifications in immune targets CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2), and the BCAR4 long non-coding RNA, which has been associated with response to lapatinib.	Lapatinib	194-203	programmed cell death 1 ligand 2	Homo sapiens	108-113
28112728-4	2017	We also discovered amplifications in immune targets CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2), and the BCAR4 long non-coding RNA, which has been associated with response to lapatinib.	Lapatinib	194-203	breast cancer anti-estrogen resistance 4	Homo sapiens	124-129
28288164-7	2017	Using two lapatinib-treated ErbB2-positive breast cancer cell-lines: SKBR3 and BT474, our method identified similar dysregulated signaling pathways including EGFR-related pathways as well as other receptor-related pathways, many of which were reported previously as compensatory pathways of EGFR-inhibition via signaling cross-talk.	Lapatinib	10-19	epidermal growth factor receptor	Homo sapiens	291-295
28288164-7	2017	Using two lapatinib-treated ErbB2-positive breast cancer cell-lines: SKBR3 and BT474, our method identified similar dysregulated signaling pathways including EGFR-related pathways as well as other receptor-related pathways, many of which were reported previously as compensatory pathways of EGFR-inhibition via signaling cross-talk.	Lapatinib	10-19	epidermal growth factor receptor	Homo sapiens	158-162
28349782-0	2017	HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.	Lapatinib	91-100	IL2 inducible T cell kinase	Homo sapiens	115-118
29063053-8	2017	Tyrosine kinase inhibitors are more capable of crossing into the brain and they have been shown to be beneficial for treating BM in HER2-positive patients, especially lapatinib combined with capecitabine.	Lapatinib	167-176	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
27154770-0	2017	Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
27154770-1	2017	BACKGROUND: Lapatinib is a commonly used drug that interrupts signaling from the epidermal growth factor receptors, EGFR and HER2/neu.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	116-120
27154770-1	2017	BACKGROUND: Lapatinib is a commonly used drug that interrupts signaling from the epidermal growth factor receptors, EGFR and HER2/neu.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-133
27154770-3	2017	The aim of this study was to verify whether combinations of lapatinib with one of isothiocyanates (sulforaphane, erucin or sulforaphene), targeting different levels of HER2 signaling pathway, exert stronger cytotoxic effect than therapy targeting the receptor only, using heterogeneous populations consisting of lapatinib-sensitive and lapatinib-resistant breast cancer cells.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-172
27154770-3	2017	The aim of this study was to verify whether combinations of lapatinib with one of isothiocyanates (sulforaphane, erucin or sulforaphene), targeting different levels of HER2 signaling pathway, exert stronger cytotoxic effect than therapy targeting the receptor only, using heterogeneous populations consisting of lapatinib-sensitive and lapatinib-resistant breast cancer cells.	Lapatinib	312-321	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-172
27154770-3	2017	The aim of this study was to verify whether combinations of lapatinib with one of isothiocyanates (sulforaphane, erucin or sulforaphene), targeting different levels of HER2 signaling pathway, exert stronger cytotoxic effect than therapy targeting the receptor only, using heterogeneous populations consisting of lapatinib-sensitive and lapatinib-resistant breast cancer cells.	Lapatinib	312-321	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-172
27154770-4	2017	METHODS: Lapatinib-sensitive HER2 overproducing SKBR-3 breast cancer cells and their lapatinib-resistant derivatives were combined at different proportions to simulate enrichment of cancer cell population in a drug-resistant fraction during lapatinib therapy.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
27154770-7	2017	In case of population entirely composed of lapatinib-resistant cells the most effective was combination of lapatinib with erucin which decreased cell viability and motility, phosphorylation of Akt, S6 and VEGF level more efficiently than each agent alone.	Lapatinib	43-52	vascular endothelial growth factor A	Homo sapiens	205-209
27154770-7	2017	In case of population entirely composed of lapatinib-resistant cells the most effective was combination of lapatinib with erucin which decreased cell viability and motility, phosphorylation of Akt, S6 and VEGF level more efficiently than each agent alone.	Lapatinib	107-116	AKT serine/threonine kinase 1	Homo sapiens	193-196
27154770-7	2017	In case of population entirely composed of lapatinib-resistant cells the most effective was combination of lapatinib with erucin which decreased cell viability and motility, phosphorylation of Akt, S6 and VEGF level more efficiently than each agent alone.	Lapatinib	107-116	vascular endothelial growth factor A	Homo sapiens	205-209
28289045-0	2017	Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
28289045-4	2017	METHODS: Randomised controlled trials (RCTs), published in PubMed, Embase and Web of Science, were systematically reviewed to assess the survival benefits and toxicity profile of HER2-positive patients with breast cancer who were treated with lapatinib and trastuzumab.	Lapatinib	243-252	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
28349782-8	2017	Treatment of these cells with the dual-specificity tyrosine-kinase inhibitor lapatinib led to downregulation of epithelial-to-mesenchymal transition as indicated by lower levels of SNAI1 and SNAI2 transcripts, integrin alphavbeta6, and matrix metalloproteinase 9 protein.	Lapatinib	77-86	matrix metallopeptidase 9	Homo sapiens	236-262
28349782-8	2017	Treatment of these cells with the dual-specificity tyrosine-kinase inhibitor lapatinib led to downregulation of epithelial-to-mesenchymal transition as indicated by lower levels of SNAI1 and SNAI2 transcripts, integrin alphavbeta6, and matrix metalloproteinase 9 protein.	Lapatinib	77-86	snail family transcriptional repressor 1	Homo sapiens	181-186
28349782-8	2017	Treatment of these cells with the dual-specificity tyrosine-kinase inhibitor lapatinib led to downregulation of epithelial-to-mesenchymal transition as indicated by lower levels of SNAI1 and SNAI2 transcripts, integrin alphavbeta6, and matrix metalloproteinase 9 protein.	Lapatinib	77-86	snail family transcriptional repressor 2	Homo sapiens	191-196
28222497-0	2017	Correction: Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.	Lapatinib	12-21	cellular inhibitor of PP2A	Homo sapiens	31-36
28250972-3	2017	Hormone receptor-positive and HER2-enriched cancers can be targeted using hormone and HER2-targeting therapies such as trastuzumab or lapatinib.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
28253087-5	2017	We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity.	Lapatinib	325-334	major histocompatibility complex, class II, DR beta 1	Homo sapiens	169-172
28253087-5	2017	We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity.	Lapatinib	325-334	major histocompatibility complex, class II, DQ beta 1	Homo sapiens	194-202
28253087-5	2017	We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity.	Lapatinib	325-334	major histocompatibility complex, class I, B	Homo sapiens	238-243
28253087-5	2017	We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity.	Lapatinib	325-334	major histocompatibility complex, class II, DR beta 1	Homo sapiens	270-278
28253087-5	2017	We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity.	Lapatinib	325-334	major histocompatibility complex, class II, DR beta 1	Homo sapiens	306-314
28222497-0	2017	Correction: Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.	Lapatinib	12-21	protein phosphatase 2 phosphatase activator	Homo sapiens	37-41
27872081-1	2017	Human African trypanosomiasis is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei Lapatinib, a human epidermal growth factor receptor (EGFR) inhibitor, can cure 25% of trypanosome-infected mice, although the parasite lacks EGFR-like tyrosine kinases.	Lapatinib	114-123	epidermal growth factor receptor	Homo sapiens	133-165
28158234-11	2017	Silencing of Yes1 by siRNA induced both BT-474-R and BT-474-RL2 to restore the sensitivity to trastuzumab and lapatinib.	Lapatinib	110-119	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	13-17
28158234-12	2017	Pharmaceutical inhibition of Yes1 by the Src inhibitor dasatinib was also effective to restore the sensitivity to trastuzumab and lapatinib in the two resistant cell lines.	Lapatinib	130-139	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	29-33
28158234-12	2017	Pharmaceutical inhibition of Yes1 by the Src inhibitor dasatinib was also effective to restore the sensitivity to trastuzumab and lapatinib in the two resistant cell lines.	Lapatinib	130-139	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	41-44
28158234-16	2017	CONCLUSION: Yes1 plays an important role in acquired resistance to trastuzumab and lapatinib in HER2-positive breast cancer.	Lapatinib	83-92	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	12-16
28158234-17	2017	Our data suggest that pharmacological inhibition of Yes1 may be an effective strategy to overcome resistance to trastuzumab and lapatinib.	Lapatinib	128-137	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	52-56
27872081-1	2017	Human African trypanosomiasis is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei Lapatinib, a human epidermal growth factor receptor (EGFR) inhibitor, can cure 25% of trypanosome-infected mice, although the parasite lacks EGFR-like tyrosine kinases.	Lapatinib	114-123	epidermal growth factor receptor	Homo sapiens	167-171
27872081-1	2017	Human African trypanosomiasis is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei Lapatinib, a human epidermal growth factor receptor (EGFR) inhibitor, can cure 25% of trypanosome-infected mice, although the parasite lacks EGFR-like tyrosine kinases.	Lapatinib	114-123	epidermal growth factor receptor	Homo sapiens	255-259
27872081-8	2017	In direct chemical biology tests of these speculations, lapatinib-treated trypanosomes (i) lost segments of the PFR inside the flagellum, (ii) were inhibited in the endocytosis of transferrin, and (iii) changed morphology from long and slender to rounded.	Lapatinib	56-65	transferrin	Homo sapiens	180-191
28032592-7	2017	Interestingly, lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, blocked the increase of cetuximab-induced HER3 phosphorylation.	Lapatinib	15-24	epidermal growth factor receptor	Homo sapiens	33-37
27791982-7	2017	Thus, our data suggest that mutant p53 sensitizes cancer cells to lapatinib via two complementary mechanisms: mutant p53 mediated amplification of ErbB2 signaling, and simultaneous annihilation of both potent oncogenic drivers, ErbB2 and mutant p53.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-152
27791982-7	2017	Thus, our data suggest that mutant p53 sensitizes cancer cells to lapatinib via two complementary mechanisms: mutant p53 mediated amplification of ErbB2 signaling, and simultaneous annihilation of both potent oncogenic drivers, ErbB2 and mutant p53.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	228-233
27791982-7	2017	Thus, our data suggest that mutant p53 sensitizes cancer cells to lapatinib via two complementary mechanisms: mutant p53 mediated amplification of ErbB2 signaling, and simultaneous annihilation of both potent oncogenic drivers, ErbB2 and mutant p53.	Lapatinib	66-75	tumor protein p53	Homo sapiens	117-120
27791982-0	2017	ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
27791982-0	2017	ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.	Lapatinib	20-29	tumor protein p53	Homo sapiens	61-64
27791982-5	2017	Here we report that pharmacological interception of this circuit by ErbB2 inhibitor lapatinib downregulates mutant p53 in vitro and in vivo.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73
27791982-5	2017	Here we report that pharmacological interception of this circuit by ErbB2 inhibitor lapatinib downregulates mutant p53 in vitro and in vivo.	Lapatinib	84-93	tumor protein p53	Homo sapiens	115-118
27791982-6	2017	We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-19
27791982-6	2017	We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner.	Lapatinib	34-43	heat shock transcription factor 1	Homo sapiens	74-78
27791982-6	2017	We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner.	Lapatinib	34-43	heat shock protein 90 alpha family class A member 1	Homo sapiens	95-100
27791982-6	2017	We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner.	Lapatinib	34-43	tumor protein p53	Homo sapiens	121-124
27791982-6	2017	We found that ErbB2 inhibition by lapatinib inhibits transcription factor HSF1, and its target Hsp90, followed by mutant p53 degradation in MDM2 dependent manner.	Lapatinib	34-43	MDM2 proto-oncogene	Homo sapiens	140-144
27791982-7	2017	Thus, our data suggest that mutant p53 sensitizes cancer cells to lapatinib via two complementary mechanisms: mutant p53 mediated amplification of ErbB2 signaling, and simultaneous annihilation of both potent oncogenic drivers, ErbB2 and mutant p53.	Lapatinib	66-75	tumor protein p53	Homo sapiens	35-38
27791982-7	2017	Thus, our data suggest that mutant p53 sensitizes cancer cells to lapatinib via two complementary mechanisms: mutant p53 mediated amplification of ErbB2 signaling, and simultaneous annihilation of both potent oncogenic drivers, ErbB2 and mutant p53.	Lapatinib	66-75	tumor protein p53	Homo sapiens	117-120
28032592-7	2017	Interestingly, lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, blocked the increase of cetuximab-induced HER3 phosphorylation.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
28032592-7	2017	Interestingly, lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, blocked the increase of cetuximab-induced HER3 phosphorylation.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 3	Homo sapiens	116-120
28032592-8	2017	Additionally, we showed that upon HER3 knockdown, cetuximab combined with lapatinib was able to decrease cell viability compared to HER3 expressing cells.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 3	Homo sapiens	34-38
28243326-0	2017	The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma.	Lapatinib	16-25	mitogen-activated protein kinase 1	Homo sapiens	107-110
28243326-0	2017	The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma.	Lapatinib	16-25	AKT serine/threonine kinase 1	Homo sapiens	116-119
28243326-3	2017	Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
28243326-3	2017	Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-44
28243326-3	2017	Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	49-53
28243326-6	2017	In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells.	Lapatinib	42-51	AKT serine/threonine kinase 1	Homo sapiens	69-72
28243326-6	2017	In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells.	Lapatinib	42-51	mechanistic target of rapamycin kinase	Homo sapiens	73-77
28243326-7	2017	Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.	Lapatinib	13-22	mitogen-activated protein kinase 1	Homo sapiens	89-92
28243326-7	2017	Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.	Lapatinib	13-22	AKT serine/threonine kinase 1	Homo sapiens	98-101
28061785-0	2017	Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Mus musculus	106-112
28059154-5	2017	Furthermore, lapatinib, the inhibitor of ABCG2, potently reversed mitoxantrone- and topotecan-resistance of xH460/MX20 cells.	Lapatinib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	41-46
27903634-1	2017	Targeted inhibitors of the human epidermal growth factor receptor 2 (HER2), such as trastuzumab and lapatinib, are among the first examples of molecularly targeted cancer therapy and have proven largely effective for the treatment of HER2-positive breast cancers.	Lapatinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-67
27903634-1	2017	Targeted inhibitors of the human epidermal growth factor receptor 2 (HER2), such as trastuzumab and lapatinib, are among the first examples of molecularly targeted cancer therapy and have proven largely effective for the treatment of HER2-positive breast cancers.	Lapatinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
28177460-9	2017	Mutations in the "Regulation of RhoA activity" pathway were associated with higher pCR rate to lapatinib (OR = 14.8, adjusted P = 0.001), lapatinib + trastuzumab (OR = 3.0, adjusted P = 0.09), and all arms combined (OR = 3.77, adjusted P = 0.02).	Lapatinib	95-104	ras homolog family member A	Homo sapiens	32-36
28061785-2	2017	Previous studies have demonstrated that administration of EGFR/erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development.	Lapatinib	80-89	epidermal growth factor receptor	Mus musculus	58-62
28061785-2	2017	Previous studies have demonstrated that administration of EGFR/erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Mus musculus	63-69
28061785-2	2017	Previous studies have demonstrated that administration of EGFR/erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Mus musculus	98-104
28061785-8	2017	Then, we tested the efficacy of brief exposure to lapatinib (100 mg/kg/day for 8 weeks), beginning at 16 weeks of age, in the prevention of mammary tumor development in MMTV-erbB-2 mice.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Mus musculus	174-180
28061785-12	2017	Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues.	Lapatinib	34-43	epidermal growth factor receptor	Mus musculus	88-92
28061785-12	2017	Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 3	Mus musculus	94-100
28061785-12	2017	Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Mus musculus	102-108
28061785-12	2017	Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues.	Lapatinib	34-43	thymoma viral proto-oncogene 1	Mus musculus	110-114
28061785-12	2017	Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues.	Lapatinib	34-43	mitogen-activated protein kinase 3	Mus musculus	120-126
28061785-13	2017	Also, lapatinib drastically inhibited the phosphorylation and expression of ERalpha and the transcription of ER target genes in premalignant mammary tissues.	Lapatinib	6-15	estrogen receptor 1 (alpha)	Mus musculus	76-83
28061785-16	2017	Our findings support further clinical testing to explore the benefit of shorter lapatinib exposure in the prevention of erbB-2-mediated carcinogenesis.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Mus musculus	120-126
28177460-9	2017	Mutations in the "Regulation of RhoA activity" pathway were associated with higher pCR rate to lapatinib (OR = 14.8, adjusted P = 0.001), lapatinib + trastuzumab (OR = 3.0, adjusted P = 0.09), and all arms combined (OR = 3.77, adjusted P = 0.02).	Lapatinib	138-147	ras homolog family member A	Homo sapiens	32-36
28177460-12	2017	Conclusions: Mutations in the RhoA pathway are associated with pCR to lapatinib and mutations in a PIK3CA-related network are associated with resistance to trastuzumab.	Lapatinib	70-79	ras homolog family member A	Homo sapiens	30-34
28034079-1	2017	Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2-positive metastatic urothelial bladder cancer (UBC).	Lapatinib	41-50	epidermal growth factor receptor	Homo sapiens	104-144
27942916-0	2017	Synergistic disruption of ERalpha/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.	Lapatinib	66-75	estrogen receptor 1	Homo sapiens	26-33
27942916-0	2017	Synergistic disruption of ERalpha/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
27942916-3	2017	Separately, disruption of the crosstalk using probe antagonists against ERalpha (tamoxifen) and HER2 (e.g., lapatinib) has been explored clinically.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
27942916-4	2017	However, the efficacy of this combination may be confounded by lapatinib, a potent inactivator of CYP3A4/5 which could negate the bioactivation of tamoxifen to the active metabolite endoxifen.	Lapatinib	63-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
27942916-6	2017	Simultaneous antagonism of ERalpha and HER2 using endoxifen and lapatinib could overcome these problems.	Lapatinib	64-73	estrogen receptor 1	Homo sapiens	27-34
27942916-6	2017	Simultaneous antagonism of ERalpha and HER2 using endoxifen and lapatinib could overcome these problems.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-43
27942916-10	2017	Synergistic activity was uncovered for lapatinib and endoxifen against BT474, TAM-R and MCF-7/HER2 models of ERalpha/HER2 crosstalk.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
27942916-10	2017	Synergistic activity was uncovered for lapatinib and endoxifen against BT474, TAM-R and MCF-7/HER2 models of ERalpha/HER2 crosstalk.	Lapatinib	39-48	estrogen receptor 1	Homo sapiens	109-116
27942916-10	2017	Synergistic activity was uncovered for lapatinib and endoxifen against BT474, TAM-R and MCF-7/HER2 models of ERalpha/HER2 crosstalk.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
27942916-12	2017	CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen.	Lapatinib	319-328	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185
28365969-0	2017	Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-82
28034079-1	2017	Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2-positive metastatic urothelial bladder cancer (UBC).	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
27811012-0	2017	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.	Lapatinib	135-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
27811012-12	2017	Lapatinib-treated Asian participants and those less than 60 years had significant improvement in progression-free survival (PFS), particularly among those whose cancers had 5.01-10.0 and >10.0-fold amplification of HER2 In conclusion, HER2 is commonly amplified in UGI adenocarcinomas with amplification highly correlated to overexpression, and HER2 amplification levels correlated with PFS.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	218-222
27811012-12	2017	Lapatinib-treated Asian participants and those less than 60 years had significant improvement in progression-free survival (PFS), particularly among those whose cancers had 5.01-10.0 and >10.0-fold amplification of HER2 In conclusion, HER2 is commonly amplified in UGI adenocarcinomas with amplification highly correlated to overexpression, and HER2 amplification levels correlated with PFS.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	238-242
27811012-12	2017	Lapatinib-treated Asian participants and those less than 60 years had significant improvement in progression-free survival (PFS), particularly among those whose cancers had 5.01-10.0 and >10.0-fold amplification of HER2 In conclusion, HER2 is commonly amplified in UGI adenocarcinomas with amplification highly correlated to overexpression, and HER2 amplification levels correlated with PFS.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	238-242
28478451-0	2017	Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.	Lapatinib	91-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	8-12
28478451-1	2017	OBJECTIVE: The aim of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2)-related biomarkers and the treatment outcomes using lapatinib plus capecitabine (LC) and to evaluate the influence of the estrogen receptor (ER) status in trastuzumab-refractory HER2-positive advanced breast cancer.	Lapatinib	176-185	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-122
28478451-0	2017	Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.	Lapatinib	91-100	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	64-70
28478451-1	2017	OBJECTIVE: The aim of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2)-related biomarkers and the treatment outcomes using lapatinib plus capecitabine (LC) and to evaluate the influence of the estrogen receptor (ER) status in trastuzumab-refractory HER2-positive advanced breast cancer.	Lapatinib	176-185	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-116
29410730-0	2017	NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.	Lapatinib	93-102	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
29410730-0	2017	NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.	Lapatinib	93-102	epidermal growth factor receptor	Homo sapiens	15-19
28000738-0	2016	Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.	Lapatinib	77-86	toll-like receptor 7	Mus musculus	50-54
28164759-8	2017	Therefore, chemotherapy schedules and new HER2-targeted agents such as lapatinib, pertuzumab, and T-DM1 have been introduced into the neoadjuvant setting.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
27989141-1	2016	It is hypothesized that lapatinib-induced liver injury is caused by HLA-mediated antigen presentation to CD4 positive T cells.	Lapatinib	24-33	major histocompatibility complex, class II, DR beta 1	Homo sapiens	68-71
27989141-1	2016	It is hypothesized that lapatinib-induced liver injury is caused by HLA-mediated antigen presentation to CD4 positive T cells.	Lapatinib	24-33	CD4 molecule	Homo sapiens	105-108
27989141-2	2016	However, analysis of PBMC and cloned T-cells from patients with HLA-DRB1*07:01-restricted lapatinib-induced liver injury revealed no evidence for drug-specific activation.	Lapatinib	90-99	major histocompatibility complex, class II, DR beta 1	Homo sapiens	64-72
27934102-2	2016	While EGFR/ERBB-targeted therapies, including monoclonal antibodies, e.g., trastuzumab, and small molecule kinase inhibitors, such as lapatinib, have been developed, rapid identification and classification of cancer cells is key to identifying the best treatment regime.	Lapatinib	134-143	epidermal growth factor receptor	Homo sapiens	6-10
27768588-0	2016	Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.	Lapatinib	124-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
27768588-0	2016	Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.	Lapatinib	124-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
27768588-1	2016	BACKGROUND: Overexpression of heregulin, a HER3 ligand, is one mechanism that confers resistance to the anti-HER2 agents trastuzumab and lapatinib.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 3	Homo sapiens	43-47
27768588-1	2016	BACKGROUND: Overexpression of heregulin, a HER3 ligand, is one mechanism that confers resistance to the anti-HER2 agents trastuzumab and lapatinib.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
27825137-5	2016	The mesenchymal population that remained following TGF-beta stimulation and withdrawal was quickly selected for during subsequent Lapatinib treatment, manifesting in inherent drug resistance.	Lapatinib	130-139	transforming growth factor beta 1	Homo sapiens	51-59
27934102-2	2016	While EGFR/ERBB-targeted therapies, including monoclonal antibodies, e.g., trastuzumab, and small molecule kinase inhibitors, such as lapatinib, have been developed, rapid identification and classification of cancer cells is key to identifying the best treatment regime.	Lapatinib	134-143	epidermal growth factor receptor	Homo sapiens	11-15
27435628-1	2016	The dual small molecule tyrosine kinase inhibitor lapatinib blocks both human epidermal growth factor receptor (HER-1) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinase activity by binding reversibly to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	78-110
28228709-3	2016	Despite the improvement of survival thanks to trastuzumab, unclear mechanisms of resistance occur, which has led to the development of new anti-HER2 therapies such as lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1).	Lapatinib	167-176	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
27882700-0	2016	Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-106
27882700-1	2016	This meta-analysis compared the efficiency and safety of lapatinib and trastuzumab, alone or in combination, administered with neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-209
27435628-1	2016	The dual small molecule tyrosine kinase inhibitor lapatinib blocks both human epidermal growth factor receptor (HER-1) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinase activity by binding reversibly to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	112-117
27435628-1	2016	The dual small molecule tyrosine kinase inhibitor lapatinib blocks both human epidermal growth factor receptor (HER-1) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinase activity by binding reversibly to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-163
27435628-1	2016	The dual small molecule tyrosine kinase inhibitor lapatinib blocks both human epidermal growth factor receptor (HER-1) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinase activity by binding reversibly to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-170
27435628-2	2016	Lapatinib, in combination with capecitabine, has been approved in 2007 for the treatment of patients with advanced HER-2+ breast cancer upon progressive disease following standard chemotherapy.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-120
27435628-5	2016	For example, in 2013 the European Medicines Agency approved the combination of lapatinib and trastuzumab in HER-2+/HR- patients.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-113
27435628-5	2016	For example, in 2013 the European Medicines Agency approved the combination of lapatinib and trastuzumab in HER-2+/HR- patients.	Lapatinib	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	115-117
27435628-8	2016	Finally, we examine the potential of molecularly subtyping HER-2+ tumors using the PAM50 test as a predictor of response to treatment with the combination of trastuzumab and lapatinib.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-64
27678331-5	2016	Among sensitive cell lines, breast cancer lines with HER2 overexpression were most potently inhibited by ibrutinib (<100 nmol/L); in addition, the IC50s were lower than that of lapatinib and dacomitinib.	Lapatinib	180-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
27696309-10	2016	In summary, Cetuximab and Lapatinib have been found to mediate cell-cell adhesion by restoration of E-cadherin expression and function.	Lapatinib	26-35	cadherin 1	Homo sapiens	100-110
27157613-0	2016	MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.	Lapatinib	32-41	glycerophosphodiester phosphodiesterase 1	Homo sapiens	0-6
27157613-0	2016	MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-60
27157613-0	2016	MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.	Lapatinib	32-41	cyclin J	Homo sapiens	118-122
27157613-0	2016	MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.	Lapatinib	32-41	far upstream element binding protein 1	Homo sapiens	127-132
27157613-3	2016	The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor, have proved highly beneficial.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-10
27157613-6	2016	TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16.	Lapatinib	7-16	mitogen-activated protein kinase 3	Homo sapiens	34-76
27157613-6	2016	TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16.	Lapatinib	7-16	AKT serine/threonine kinase 1	Homo sapiens	118-121
27157613-6	2016	TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16.	Lapatinib	7-16	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	150-155
27157613-6	2016	TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16.	Lapatinib	7-16	glycerophosphodiester phosphodiesterase 1	Homo sapiens	201-207
27157613-7	2016	Forced expression of miR-16 inhibited in vitro proliferation in BC and GC cells, both sensitive and resistant to TZ and lapatinib, as well as in a preclinical BC model resistant to these agents.	Lapatinib	120-129	glycerophosphodiester phosphodiesterase 1	Homo sapiens	21-27
27157613-12	2016	Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ- and lapatinib-resistant ErbB-2-positive BC and GC.	Lapatinib	79-88	glycerophosphodiester phosphodiesterase 1	Homo sapiens	25-31
27157613-12	2016	Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ- and lapatinib-resistant ErbB-2-positive BC and GC.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-105
27738326-0	2016	Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.	Lapatinib	27-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-80
27738326-3	2016	Lapatinib down-regulated phosphorylated (p)-HER2, p-epidermal growth factor receptor, p-AKT, and p-extracellular signal-regulated kinase.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
27738326-4	2016	Pretreatment of lapatinib increased the radiosensitivity of SKBR3 (sensitizer enhancement ratio [SER]: 1.21 at a surviving fraction of 0.5) and BT474 (SER: 1.26 at a surviving fraction of 0.5) cells and hindered the repair of DNA damage, as suggested by the prolongation of radiation-induced gammaH2AX foci and the down-regulation of phosphorylated DNA-dependent protein kinase, catalytic subunit (p-DNAPKcs).	Lapatinib	16-25	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	349-396
27738326-6	2016	Furthermore, lapatinib did not radiosensitize a HER2- negative breast cancer cell line or normal human astrocytes.These findings suggest that lapatinib can potentiate radiation-induced cell death in HER2-overexpressing breast cancer cells and may increase the efficacy of radiotherapy.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	199-203
27109096-9	2016	Furthermore, ErbB2-directed RNAi or treatment with lapatinib, an ErbB2/EGFR small-molecule inhibitor used for breast cancer therapy, upregulated Perp in ErbB2-positive human breast and ovarian carcinoma cells.	Lapatinib	51-60	p53 apoptosis effector related to PMP22	Homo sapiens	145-149
27671678-5	2016	Using synthetic lethality approaches, we identified molecular pathways whose inhibition sensitizes HER2+ breast cancer cells to lapatinib both in vitro and in vivo, including JAK2/STAT3 and hyaluronic acid.	Lapatinib	128-137	Janus kinase 2	Homo sapiens	175-179
27671678-5	2016	Using synthetic lethality approaches, we identified molecular pathways whose inhibition sensitizes HER2+ breast cancer cells to lapatinib both in vitro and in vivo, including JAK2/STAT3 and hyaluronic acid.	Lapatinib	128-137	signal transducer and activator of transcription 3	Homo sapiens	180-185
27671678-6	2016	Neoadjuvant lapatinib therapy in HER2+ breast tumors lead to a significant increase of phospho-STAT3+ cancer cells and a decrease in the spatial proximity of proliferating (Ki67+) cells to CAFs impacting therapeutic responses.	Lapatinib	12-21	signal transducer and activator of transcription 3	Homo sapiens	95-100
27671678-6	2016	Neoadjuvant lapatinib therapy in HER2+ breast tumors lead to a significant increase of phospho-STAT3+ cancer cells and a decrease in the spatial proximity of proliferating (Ki67+) cells to CAFs impacting therapeutic responses.	Lapatinib	12-21	T-box transcription factor 1	Homo sapiens	189-193
27109096-9	2016	Furthermore, ErbB2-directed RNAi or treatment with lapatinib, an ErbB2/EGFR small-molecule inhibitor used for breast cancer therapy, upregulated Perp in ErbB2-positive human breast and ovarian carcinoma cells.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-70
27109096-9	2016	Furthermore, ErbB2-directed RNAi or treatment with lapatinib, an ErbB2/EGFR small-molecule inhibitor used for breast cancer therapy, upregulated Perp in ErbB2-positive human breast and ovarian carcinoma cells.	Lapatinib	51-60	epidermal growth factor receptor	Homo sapiens	71-75
27597738-4	2016	In this study we report the effects of lapatinib and neratinib on the mRNA and protein levels of the ErbB2 receptor.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
27845365-8	2016	Lapatinib and indirubin-3"-monoxime showed moderate hCOX-1 activity (19.5% and 28% of enzyme inhibition at 25 muM respectively).	Lapatinib	0-9	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	52-58
27109096-9	2016	Furthermore, ErbB2-directed RNAi or treatment with lapatinib, an ErbB2/EGFR small-molecule inhibitor used for breast cancer therapy, upregulated Perp in ErbB2-positive human breast and ovarian carcinoma cells.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-70
27613609-9	2016	In addition, treatment with lapatinib, an FDA-approved HER2 inhibitor, decreased PFKFB3 expression and glucose metabolism in HER2+ cells.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
27613609-9	2016	In addition, treatment with lapatinib, an FDA-approved HER2 inhibitor, decreased PFKFB3 expression and glucose metabolism in HER2+ cells.	Lapatinib	28-37	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	81-87
27613609-9	2016	In addition, treatment with lapatinib, an FDA-approved HER2 inhibitor, decreased PFKFB3 expression and glucose metabolism in HER2+ cells.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
27474152-8	2016	By targeting ERBB2/ERBB3 as a functional unit, it is also effective in cases in which ERBB2-directed inhibitors, such as lapatinib, alone show reduced potency.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-18
27636304-7	2016	The Her2-targeted agents lapatinib and trastuzumab emtansine failed to improve outcome when either added to or compared with chemotherapy.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
28133221-1	2016	Lapatinib is an orally bioavailable dual inhibitor of the intracellular domain of both the HER2 protein and the epidermal growth factor receptor.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
28133221-1	2016	Lapatinib is an orally bioavailable dual inhibitor of the intracellular domain of both the HER2 protein and the epidermal growth factor receptor.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	112-144
28133221-3	2016	Lapatinib was demonstrated to be beneficial in patients with HER2-positive locally advanced and metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
27474152-8	2016	By targeting ERBB2/ERBB3 as a functional unit, it is also effective in cases in which ERBB2-directed inhibitors, such as lapatinib, alone show reduced potency.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 3	Homo sapiens	19-24
27474152-8	2016	By targeting ERBB2/ERBB3 as a functional unit, it is also effective in cases in which ERBB2-directed inhibitors, such as lapatinib, alone show reduced potency.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-91
27708243-0	2016	JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.	Lapatinib	57-66	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	0-3
27633099-0	2016	Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	153-156
27633099-0	2016	Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.	Lapatinib	0-9	cyclin D2	Homo sapiens	157-166
27633099-0	2016	Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	148-152
27611952-3	2016	TP53 status was correlated to response to neoadjuvant anthracycline/taxane-based chemotherapy with or without carboplatin and trastuzumab/lapatinib in HER2-positive and bevacizumab in TNBC.	Lapatinib	138-147	tumor protein p53	Homo sapiens	0-4
27708243-3	2016	The aim of this study was to identify JWA as a biomarker for lapatinib resistance in GC cells and elucidate the underlying mechanisms.	Lapatinib	61-70	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	38-41
27708243-5	2016	JWA activation conferred lapatinib unresponsiveness, but reversed cisplatin resistance in GC cells.	Lapatinib	25-34	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	0-3
27708243-6	2016	Whereas, deletion of JWA significantly restored lapatinib suppression on proliferation and lapatinib-induced apoptosis.	Lapatinib	48-57	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	21-24
27708243-6	2016	Whereas, deletion of JWA significantly restored lapatinib suppression on proliferation and lapatinib-induced apoptosis.	Lapatinib	91-100	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	21-24
27708243-7	2016	JWA-induced down-regulation of HER2 and activation of ERK phosphorylation led to lapatinib resistance.	Lapatinib	81-90	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	0-3
27708243-7	2016	JWA-induced down-regulation of HER2 and activation of ERK phosphorylation led to lapatinib resistance.	Lapatinib	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
27708243-7	2016	JWA-induced down-regulation of HER2 and activation of ERK phosphorylation led to lapatinib resistance.	Lapatinib	81-90	mitogen-activated protein kinase 1	Homo sapiens	54-57
27708243-9	2016	Taken together, JWA is a potential predictive marker for lapatinib resistance, targeting the patients that may benefit from lapatinib treatment in human GC.	Lapatinib	57-66	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	16-19
27708243-9	2016	Taken together, JWA is a potential predictive marker for lapatinib resistance, targeting the patients that may benefit from lapatinib treatment in human GC.	Lapatinib	124-133	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	16-19
27756261-0	2016	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.	Lapatinib	78-87	eukaryotic elongation factor 2 kinase	Homo sapiens	14-26
27756261-0	2016	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.	Lapatinib	78-87	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	118-121
27756261-0	2016	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.	Lapatinib	78-87	mitogen-activated protein kinase 1	Homo sapiens	126-129
27756261-2	2016	In the present study, we investigated the relationship between eEF-2 kinase and lapatinib, a dual inhibitor of EGFR and HER-2, in nasopharyngeal carcinoma (NPC) cells.	Lapatinib	80-89	eukaryotic elongation factor 2 kinase	Homo sapiens	63-75
27756261-2	2016	In the present study, we investigated the relationship between eEF-2 kinase and lapatinib, a dual inhibitor of EGFR and HER-2, in nasopharyngeal carcinoma (NPC) cells.	Lapatinib	80-89	epidermal growth factor receptor	Homo sapiens	111-115
27633099-1	2016	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-63
27633099-1	2016	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	65-69
27633099-1	2016	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-76
27633099-1	2016	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-148
27633099-3	2016	Oral squamous cell carcinoma (OSCC) cell lines HSC3, HSC4 and Ca9-22 were sensitive to the antiproliferative effects of lapatinib in anchorage-dependent culture, but the OSCC cell lines KB and SAS and the prostate cancer cell line DU145 were resistant to lapatinib.	Lapatinib	120-129	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	47-51
27633099-4	2016	Phosphorylation levels of EGFR in all cell lines decreased during lapatinib treatment in anchorage-dependent culture.	Lapatinib	66-75	epidermal growth factor receptor	Homo sapiens	26-30
27633099-5	2016	Furthermore, the phosphorylation levels of ErbB2, ErbB3 and Akt and the protein levels of cyclin D1 were decreased by lapatinib treatment of HSC3, HSC4 and Ca9-22 cells.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-48
27633099-5	2016	Furthermore, the phosphorylation levels of ErbB2, ErbB3 and Akt and the protein levels of cyclin D1 were decreased by lapatinib treatment of HSC3, HSC4 and Ca9-22 cells.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 3	Homo sapiens	50-55
27633099-5	2016	Furthermore, the phosphorylation levels of ErbB2, ErbB3 and Akt and the protein levels of cyclin D1 were decreased by lapatinib treatment of HSC3, HSC4 and Ca9-22 cells.	Lapatinib	118-127	AKT serine/threonine kinase 1	Homo sapiens	60-63
27633099-5	2016	Furthermore, the phosphorylation levels of ErbB2, ErbB3 and Akt and the protein levels of cyclin D1 were decreased by lapatinib treatment of HSC3, HSC4 and Ca9-22 cells.	Lapatinib	118-127	cyclin D1	Homo sapiens	90-99
27633099-5	2016	Furthermore, the phosphorylation levels of ErbB2, ErbB3 and Akt and the protein levels of cyclin D1 were decreased by lapatinib treatment of HSC3, HSC4 and Ca9-22 cells.	Lapatinib	118-127	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	141-145
27633099-9	2016	The phosphorylation levels of ErbB2 and AKT and protein levels of cyclin D2 increased during sphere formation of SAS cells and decreased with lapatinib treatment.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-35
27633099-9	2016	The phosphorylation levels of ErbB2 and AKT and protein levels of cyclin D2 increased during sphere formation of SAS cells and decreased with lapatinib treatment.	Lapatinib	142-151	AKT serine/threonine kinase 1	Homo sapiens	40-43
27633099-9	2016	The phosphorylation levels of ErbB2 and AKT and protein levels of cyclin D2 increased during sphere formation of SAS cells and decreased with lapatinib treatment.	Lapatinib	142-151	cyclin D2	Homo sapiens	66-75
27633099-14	2016	These results suggested that phosphorylation of EGFR and ErbB2 by cell detachment from the substratum induces the AKT pathway/cyclin D2-dependent sphere growth in SAS epithelial cancer stem-like cells, thereby rendering SAS spheres sensitive to lapatinib treatment.	Lapatinib	245-254	epidermal growth factor receptor	Homo sapiens	48-52
27633099-14	2016	These results suggested that phosphorylation of EGFR and ErbB2 by cell detachment from the substratum induces the AKT pathway/cyclin D2-dependent sphere growth in SAS epithelial cancer stem-like cells, thereby rendering SAS spheres sensitive to lapatinib treatment.	Lapatinib	245-254	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-62
27633099-14	2016	These results suggested that phosphorylation of EGFR and ErbB2 by cell detachment from the substratum induces the AKT pathway/cyclin D2-dependent sphere growth in SAS epithelial cancer stem-like cells, thereby rendering SAS spheres sensitive to lapatinib treatment.	Lapatinib	245-254	AKT serine/threonine kinase 1	Homo sapiens	114-117
27633099-14	2016	These results suggested that phosphorylation of EGFR and ErbB2 by cell detachment from the substratum induces the AKT pathway/cyclin D2-dependent sphere growth in SAS epithelial cancer stem-like cells, thereby rendering SAS spheres sensitive to lapatinib treatment.	Lapatinib	245-254	cyclin D2	Homo sapiens	126-135
27756261-2	2016	In the present study, we investigated the relationship between eEF-2 kinase and lapatinib, a dual inhibitor of EGFR and HER-2, in nasopharyngeal carcinoma (NPC) cells.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-125
27756261-6	2016	RESULTS: The expression of eEF-2 kinase was significantly associated with NPC cell sensitivity to lapatinib.	Lapatinib	98-107	eukaryotic elongation factor 2 kinase	Homo sapiens	27-39
27756261-8	2016	Furthermore, inhibition of eEF-2 kinase, by either RNA interference (eEF-2 kinase siRNA or shRNA) or pharmacological inhibition (NH125), enhanced lapatinib-induced apoptosis of NPC cells.	Lapatinib	146-155	eukaryotic elongation factor 2 kinase	Homo sapiens	27-39
27611952-3	2016	TP53 status was correlated to response to neoadjuvant anthracycline/taxane-based chemotherapy with or without carboplatin and trastuzumab/lapatinib in HER2-positive and bevacizumab in TNBC.	Lapatinib	138-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
27958595-6	2016	Data driven from in vitro and animal studies on the merlin pathway [e.g., post-translational and upstream/downstream regulation] allowed biologically targeted treatment strategies [e.g., Lapatinib, Erlotinib, Bevacizumab] aimed to multiple tumour shrinkage and/or regression and tumour arrest of progression with functional improvement.	Lapatinib	187-196	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	52-58
27756261-11	2016	CONCLUSIONS: The results of this study suggest that targeting eEF-2 kinase may improve the efficacy of therapeutic interventions such as lapatinib in NPC cells.	Lapatinib	137-146	eukaryotic elongation factor 2 kinase	Homo sapiens	62-74
27475932-4	2016	The present study provides preclinical evidence that Delta16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
27785067-0	2016	Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells.	Lapatinib	45-54	eukaryotic elongation factor 2 kinase	Homo sapiens	63-100
27785067-9	2016	This study further found that lapatinib induced both apoptosis and autophagy in NPC cells, and this autophagic activity was described as type II programmed cell death via an eEF-2 kinase-dependent pathway.	Lapatinib	30-39	eukaryotic elongation factor 2 kinase	Homo sapiens	174-186
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	29-38	mechanistic target of rapamycin kinase	Homo sapiens	60-89
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	29-38	mechanistic target of rapamycin kinase	Homo sapiens	91-95
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	29-38	mechanistic target of rapamycin kinase	Homo sapiens	182-186
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	29-38	eukaryotic elongation factor 2 kinase	Homo sapiens	197-209
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	151-160	mechanistic target of rapamycin kinase	Homo sapiens	60-89
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	151-160	mechanistic target of rapamycin kinase	Homo sapiens	91-95
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	151-160	mechanistic target of rapamycin kinase	Homo sapiens	182-186
27785067-10	2016	In addition, augmentation of lapatinib-induced autophagy by mammalian target of rapamycin (mTOR) inhibitor everolimus enhanced the cytocidal effect of lapatinib in NPC cells via the mTOR/S6 kinase/eEF-2 kinase pathway.	Lapatinib	151-160	eukaryotic elongation factor 2 kinase	Homo sapiens	197-209
27785067-11	2016	CONCLUSION: This study reveals that everolimus can sensitize NPC cells to lapatinib by the activation of eEF-2 kinase and provides a potential model of combination therapy.	Lapatinib	74-83	eukaryotic elongation factor 2 kinase	Homo sapiens	105-117
27726101-0	2016	Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
27726101-2	2016	Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor, has greatly improved breast cancer prognosis in recent years after the initial introduction of trastuzumab (Herceptin).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-50
27726101-2	2016	Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor, has greatly improved breast cancer prognosis in recent years after the initial introduction of trastuzumab (Herceptin).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	52-56
27726101-2	2016	Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor, has greatly improved breast cancer prognosis in recent years after the initial introduction of trastuzumab (Herceptin).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
27726101-3	2016	However, clinical evidence indicates the existence of both primary unresponsiveness and secondary lapatinib resistance, which leads to the failure of this agent in HER2+ cancer patients.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
27726101-8	2016	The present review, in the hope of providing further scientific support for molecular targeted therapies in HER2+ cancers, discusses about the latest findings and new concepts on molecular mechanisms underlying lapatinib resistance.	Lapatinib	211-220	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
27491481-0	2016	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.	Lapatinib	44-53	estrogen receptor 1	Homo sapiens	89-106
27491481-0	2016	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-156
27491481-13	2016	CONCLUSIONS: When this chemo-free, combination neoadjuvant therapy with letrozole and lapatinib is given for Asian postmenopausal ER+HER2+ breast cancer, TILs, change of ER expression following neoadjuvant treatment, and SUVmax in baseline FES-PET are to be considered potential biomarkers in these patients.	Lapatinib	86-95	estrogen receptor 1	Homo sapiens	130-132
27491481-13	2016	CONCLUSIONS: When this chemo-free, combination neoadjuvant therapy with letrozole and lapatinib is given for Asian postmenopausal ER+HER2+ breast cancer, TILs, change of ER expression following neoadjuvant treatment, and SUVmax in baseline FES-PET are to be considered potential biomarkers in these patients.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
27491481-13	2016	CONCLUSIONS: When this chemo-free, combination neoadjuvant therapy with letrozole and lapatinib is given for Asian postmenopausal ER+HER2+ breast cancer, TILs, change of ER expression following neoadjuvant treatment, and SUVmax in baseline FES-PET are to be considered potential biomarkers in these patients.	Lapatinib	86-95	estrogen receptor 1	Homo sapiens	134-136
27450182-2	2016	The objective of this study was to examine the roles of CYP3A4 and CYP3A5 in lapatinib bioactivation leading to a reactive, potentially toxic quinoneimine.	Lapatinib	77-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
27450182-2	2016	The objective of this study was to examine the roles of CYP3A4 and CYP3A5 in lapatinib bioactivation leading to a reactive, potentially toxic quinoneimine.	Lapatinib	77-86	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	67-73
27450182-5	2016	A screen of cDNA-expressed P450s confirmed that CYP3A4 and CYP3A5 are the primary enzymes responsible for quinoneimine-GSH adduct formation using lapatinib or O-dealkylated lapatinib as the substrate.	Lapatinib	146-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
27450182-0	2016	Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.	Lapatinib	58-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
27450182-5	2016	A screen of cDNA-expressed P450s confirmed that CYP3A4 and CYP3A5 are the primary enzymes responsible for quinoneimine-GSH adduct formation using lapatinib or O-dealkylated lapatinib as the substrate.	Lapatinib	146-155	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	59-65
27450182-5	2016	A screen of cDNA-expressed P450s confirmed that CYP3A4 and CYP3A5 are the primary enzymes responsible for quinoneimine-GSH adduct formation using lapatinib or O-dealkylated lapatinib as the substrate.	Lapatinib	173-182	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
27450182-0	2016	Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.	Lapatinib	58-67	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	24-30
27450182-5	2016	A screen of cDNA-expressed P450s confirmed that CYP3A4 and CYP3A5 are the primary enzymes responsible for quinoneimine-GSH adduct formation using lapatinib or O-dealkylated lapatinib as the substrate.	Lapatinib	173-182	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	59-65
27450182-1	2016	Metabolic activation of the dual-tyrosine kinase inhibitor lapatinib by cytochromes CYP3A4 and CYP3A5 has been implicated in lapatinib-induced idiosyncratic hepatotoxicity; however, the relative enzyme contributions have not been established.	Lapatinib	59-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
27450182-6	2016	The mean kinetic parameters (Km and kcat) of lapatinib O-dealkylation revealed that CYP3A4 was 5.2-fold more efficient than CYP3A5 at lapatinib O-dealkylation (CYP3A4 kcat/Km = 6.8 muM(-1) min(-1) versus CYP3A5 kcat/Km = 1.3 muM(-1) min(-1)).	Lapatinib	45-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
27450182-6	2016	The mean kinetic parameters (Km and kcat) of lapatinib O-dealkylation revealed that CYP3A4 was 5.2-fold more efficient than CYP3A5 at lapatinib O-dealkylation (CYP3A4 kcat/Km = 6.8 muM(-1) min(-1) versus CYP3A5 kcat/Km = 1.3 muM(-1) min(-1)).	Lapatinib	45-54	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	124-130
27450182-1	2016	Metabolic activation of the dual-tyrosine kinase inhibitor lapatinib by cytochromes CYP3A4 and CYP3A5 has been implicated in lapatinib-induced idiosyncratic hepatotoxicity; however, the relative enzyme contributions have not been established.	Lapatinib	59-68	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	95-101
27450182-6	2016	The mean kinetic parameters (Km and kcat) of lapatinib O-dealkylation revealed that CYP3A4 was 5.2-fold more efficient than CYP3A5 at lapatinib O-dealkylation (CYP3A4 kcat/Km = 6.8 muM(-1) min(-1) versus CYP3A5 kcat/Km = 1.3 muM(-1) min(-1)).	Lapatinib	45-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-166
27450182-1	2016	Metabolic activation of the dual-tyrosine kinase inhibitor lapatinib by cytochromes CYP3A4 and CYP3A5 has been implicated in lapatinib-induced idiosyncratic hepatotoxicity; however, the relative enzyme contributions have not been established.	Lapatinib	125-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
27450182-6	2016	The mean kinetic parameters (Km and kcat) of lapatinib O-dealkylation revealed that CYP3A4 was 5.2-fold more efficient than CYP3A5 at lapatinib O-dealkylation (CYP3A4 kcat/Km = 6.8 muM(-1) min(-1) versus CYP3A5 kcat/Km = 1.3 muM(-1) min(-1)).	Lapatinib	134-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
27450182-6	2016	The mean kinetic parameters (Km and kcat) of lapatinib O-dealkylation revealed that CYP3A4 was 5.2-fold more efficient than CYP3A5 at lapatinib O-dealkylation (CYP3A4 kcat/Km = 6.8 muM(-1) min(-1) versus CYP3A5 kcat/Km = 1.3 muM(-1) min(-1)).	Lapatinib	134-143	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	124-130
27450182-1	2016	Metabolic activation of the dual-tyrosine kinase inhibitor lapatinib by cytochromes CYP3A4 and CYP3A5 has been implicated in lapatinib-induced idiosyncratic hepatotoxicity; however, the relative enzyme contributions have not been established.	Lapatinib	125-134	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	95-101
27450182-6	2016	The mean kinetic parameters (Km and kcat) of lapatinib O-dealkylation revealed that CYP3A4 was 5.2-fold more efficient than CYP3A5 at lapatinib O-dealkylation (CYP3A4 kcat/Km = 6.8 muM(-1) min(-1) versus CYP3A5 kcat/Km = 1.3 muM(-1) min(-1)).	Lapatinib	134-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-166
27450182-9	2016	The 16%-22% difference between CYP3A- and CYP3A4-selective inhibition indicates the involvement of remaining CYP3A5 activity in generating reactive metabolites from lapatinib in pooled HLMs.	Lapatinib	165-174	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-36
27450182-9	2016	The 16%-22% difference between CYP3A- and CYP3A4-selective inhibition indicates the involvement of remaining CYP3A5 activity in generating reactive metabolites from lapatinib in pooled HLMs.	Lapatinib	165-174	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
27450182-9	2016	The 16%-22% difference between CYP3A- and CYP3A4-selective inhibition indicates the involvement of remaining CYP3A5 activity in generating reactive metabolites from lapatinib in pooled HLMs.	Lapatinib	165-174	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	109-115
27450182-10	2016	Collectively, these findings support the conclusion that both CYP3A4 and CYP3A5 are quantitatively important contributors to lapatinib bioactivation.	Lapatinib	125-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
27450182-10	2016	Collectively, these findings support the conclusion that both CYP3A4 and CYP3A5 are quantitatively important contributors to lapatinib bioactivation.	Lapatinib	125-134	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	73-79
27507850-7	2016	To further explore the relationship between EGFR and RB1-associated cell-cycle activity, we evaluated simultaneous inhibition of RB1 phosphorylation with the CDK4/6 inhibitor palbociclib and of EGFR activity with lapatinib or afatinib.	Lapatinib	213-222	epidermal growth factor receptor	Homo sapiens	194-198
27281556-0	2016	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.	Lapatinib	132-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	42-58
27281556-13	2016	Patients with HER2-negative/HER2-enriched disease benefited from lapatinib therapy (median PFS, 6.49 vs 2.60 months; progression-free survival hazard ratio, 0.238 [95% CI, 0.066-0.863]; interaction P = .02).	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
27281556-13	2016	Patients with HER2-negative/HER2-enriched disease benefited from lapatinib therapy (median PFS, 6.49 vs 2.60 months; progression-free survival hazard ratio, 0.238 [95% CI, 0.066-0.863]; interaction P = .02).	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
27281556-15	2016	Patients with HR-positive/HER2-negative disease with a HER2-enriched profile may benefit from lapatinib in combination with endocrine therapy.	Lapatinib	94-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-16
27281556-15	2016	Patients with HR-positive/HER2-negative disease with a HER2-enriched profile may benefit from lapatinib in combination with endocrine therapy.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
27281556-15	2016	Patients with HR-positive/HER2-negative disease with a HER2-enriched profile may benefit from lapatinib in combination with endocrine therapy.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
27590506-3	2016	Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells.	Lapatinib	94-103	AXL receptor tyrosine kinase	Homo sapiens	15-18
27378608-8	2016	Our study provides evidence for a FcgammaRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ BC.	Lapatinib	113-122	Fc gamma receptor IIIa	Homo sapiens	34-46
27378608-8	2016	Our study provides evidence for a FcgammaRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ BC.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
27590506-3	2016	Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells.	Lapatinib	94-103	epidermal growth factor receptor	Homo sapiens	59-63
27659302-5	2016	This high-throughput western blot approach allowed us to identify and characterize alterations in cellular signal transduction that occur during the development of resistance to the kinase inhibitor Lapatinib, revealing major changes in the activation state of Ephrin-mediated signalling and a central role for p53-controlled processes.	Lapatinib	199-208	tumor protein p53	Homo sapiens	311-314
27256378-6	2016	Importantly, inhibition of BTK prevents activation of the AKT signaling pathway by NRG or EGF that has been shown to promote growth factor-driven lapatinib resistance in HER2(+) breast cancer cells.	Lapatinib	146-155	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
27694691-0	2016	Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.	Lapatinib	40-49	interleukin 6	Homo sapiens	0-13
27694691-0	2016	Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
27694691-1	2016	Lapatinib is an inhibitor of human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-25% of breast cancers.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-69
27694691-1	2016	Lapatinib is an inhibitor of human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-25% of breast cancers.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
27694691-2	2016	Clinically, lapatinib has shown promising benefits for HER2-positive breast cancer patients; however, patients eventually acquire resistance, limiting its long-term use.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
27694691-3	2016	In a previous study, we found that interleukin-6 (IL-6) production was increased in acquired lapatinib-resistant HER2-positive breast cancer cells.	Lapatinib	93-102	interleukin 6	Homo sapiens	35-48
27694691-3	2016	In a previous study, we found that interleukin-6 (IL-6) production was increased in acquired lapatinib-resistant HER2-positive breast cancer cells.	Lapatinib	93-102	interleukin 6	Homo sapiens	50-54
27694691-3	2016	In a previous study, we found that interleukin-6 (IL-6) production was increased in acquired lapatinib-resistant HER2-positive breast cancer cells.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
27694691-4	2016	In the present study, we confirmed that lapatinib-resistant cells had elevated IL-6 expression and also maintained both stemness population and property.	Lapatinib	40-49	interleukin 6	Homo sapiens	79-83
27694691-6	2016	Blocking IL-6 activity reduced spheroid formation, cell viability and subsequently overcame lapatinib resistance, whereas stimulation of IL-6 rendered parental cells more resistant to lapatinib-induced cytotoxicity.	Lapatinib	92-101	interleukin 6	Homo sapiens	9-13
27694691-6	2016	Blocking IL-6 activity reduced spheroid formation, cell viability and subsequently overcame lapatinib resistance, whereas stimulation of IL-6 rendered parental cells more resistant to lapatinib-induced cytotoxicity.	Lapatinib	184-193	interleukin 6	Homo sapiens	137-141
27694691-7	2016	These results point to a novel mechanism underlying lapatinib resistance and provide a potential strategy to overcome resistance via IL-6 inhibition.	Lapatinib	52-61	interleukin 6	Homo sapiens	133-137
27140927-2	2016	Randomized trials assessed HER2 dual block by adding lapatinib to trastuzumab and chemotherapy in the neoadjuvant setting using pathologic complete response (pCR) as the outcome measure.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
27140927-8	2016	CONCLUSIONS: On the basis of DeltapCR data, the dual block with trastuzumab and lapatinib plus chemotherapy is a very active treatment only in HER2(+) and hormone receptor-negative breast cancer treated with taxane monochemotherapy.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
27416292-0	2016	Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
27416292-1	2016	Lapatinib, a novel tyrosine kinase inhibitor of HER2/EGFR, is used to treat HER2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
27416292-1	2016	Lapatinib, a novel tyrosine kinase inhibitor of HER2/EGFR, is used to treat HER2-positive breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	53-57
27416292-8	2016	Specially, lapatinib activated both the c-Myc/pro-Nrf2 pathway and GSK-3beta signaling to stabilize Nrf2 and maintain a low level of ROS in resistant cells.	Lapatinib	11-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	40-45
27416292-8	2016	Specially, lapatinib activated both the c-Myc/pro-Nrf2 pathway and GSK-3beta signaling to stabilize Nrf2 and maintain a low level of ROS in resistant cells.	Lapatinib	11-20	NFE2 like bZIP transcription factor 2	Homo sapiens	50-54
27416292-8	2016	Specially, lapatinib activated both the c-Myc/pro-Nrf2 pathway and GSK-3beta signaling to stabilize Nrf2 and maintain a low level of ROS in resistant cells.	Lapatinib	11-20	glycogen synthase kinase 3 beta	Homo sapiens	67-76
27416292-8	2016	Specially, lapatinib activated both the c-Myc/pro-Nrf2 pathway and GSK-3beta signaling to stabilize Nrf2 and maintain a low level of ROS in resistant cells.	Lapatinib	11-20	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
27416292-9	2016	However, berberine can upset the ROS balance by downregulating c-Myc to reverse the lapatinib resistance.	Lapatinib	84-93	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	63-68
27655166-5	2016	METHODS/DESIGN: This Bayesian phase II trial with adaptive randomization was designed to assess the efficacy of adding lapatinib, a dual inhibitor of EGFR and HER-2, to standard radiochemotherapy with capecitabine in stages II and III rectal cancer.	Lapatinib	119-128	epidermal growth factor receptor	Homo sapiens	150-154
27655166-5	2016	METHODS/DESIGN: This Bayesian phase II trial with adaptive randomization was designed to assess the efficacy of adding lapatinib, a dual inhibitor of EGFR and HER-2, to standard radiochemotherapy with capecitabine in stages II and III rectal cancer.	Lapatinib	119-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-164
27256378-6	2016	Importantly, inhibition of BTK prevents activation of the AKT signaling pathway by NRG or EGF that has been shown to promote growth factor-driven lapatinib resistance in HER2(+) breast cancer cells.	Lapatinib	146-155	Bruton tyrosine kinase	Homo sapiens	27-30
27256378-6	2016	Importantly, inhibition of BTK prevents activation of the AKT signaling pathway by NRG or EGF that has been shown to promote growth factor-driven lapatinib resistance in HER2(+) breast cancer cells.	Lapatinib	146-155	AKT serine/threonine kinase 1	Homo sapiens	58-61
27295361-2	2016	Poroelastic behavior within porous matrix may modulate the molecule events in cell-matrix and cell-cell interaction like the complex formation of human epidermal growth factor receptor-2 (HER2)-Src-alpha6beta4 integrin, influencing the targeted therapy with lapatinib.	Lapatinib	258-267	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-192
27155465-5	2016	A structure-function analysis revealed that most of the thiourea derivatives exhibited cooperative action with lapatinib in the BT474 cancer cell line and the BT/Lap(R)1.0 lapatinib-resistant cell line.	Lapatinib	172-181	LAP	Homo sapiens	162-165
27426262-9	2016	Her2 small molecular inhibitor, Lapatinib, dose-dependently suppressed cell proliferation while the levels of phospho-Ser81 AR and p27 protein were increased.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
27426262-9	2016	Her2 small molecular inhibitor, Lapatinib, dose-dependently suppressed cell proliferation while the levels of phospho-Ser81 AR and p27 protein were increased.	Lapatinib	32-41	interferon alpha inducible protein 27	Homo sapiens	131-134
27177864-0	2016	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.	Lapatinib	197-206	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-6
27197158-7	2016	In HER2-amplified cells, exposure to an mTORC1/2 dual kinase inhibitor decreased Akt-dependent cell survival, including in cells resistant to lapatinib, where cytotoxicity could be restored.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Mus musculus	3-7
27197158-7	2016	In HER2-amplified cells, exposure to an mTORC1/2 dual kinase inhibitor decreased Akt-dependent cell survival, including in cells resistant to lapatinib, where cytotoxicity could be restored.	Lapatinib	142-151	CREB regulated transcription coactivator 1	Mus musculus	40-46
27197158-7	2016	In HER2-amplified cells, exposure to an mTORC1/2 dual kinase inhibitor decreased Akt-dependent cell survival, including in cells resistant to lapatinib, where cytotoxicity could be restored.	Lapatinib	142-151	thymoma viral proto-oncogene 1	Mus musculus	81-84
26920887-8	2016	PIK3CA mutations were associated with shorter median PFS (mutant vs. wild type: 4.3 vs. 6.4 months) and OS (17.3 vs. 27.8 months) in capecitabine plus lapatinib-treated patients, but not in T-DM1-treated patients (PFS, 10.9 vs. 9.8 months; OS, not reached in mutant or wild type).	Lapatinib	151-160	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-6
27499639-1	2016	Lapatinib is an oral-form dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR or ErbB/Her) superfamily members with anticancer activity.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	60-92
27338847-6	2016	Additionally, newer HER2 therapies such as Lapatinib, Pertuzumab and Ado-trastuzumab (TDM1) are either approved or are being evaluated in clinical trials for cancer therapy.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
27441659-7	2016	We found that the expression of transferrin, which is responsible for the transport of iron into cells, is increased following treatment with lapatinib alone or in combination with siramesine.	Lapatinib	142-151	transferrin	Homo sapiens	32-43
27499639-1	2016	Lapatinib is an oral-form dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR or ErbB/Her) superfamily members with anticancer activity.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	94-98
27499639-1	2016	Lapatinib is an oral-form dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR or ErbB/Her) superfamily members with anticancer activity.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	102-106
27499639-5	2016	Moreover, lapatinib treatment caused autophagic cell death as shown by positive acridine orange staining, the massive formation of vacuoles as seen by electronic microscopy, and the upregulation of LC3-II, ATG5, and ATG7 in AML U937 cells.	Lapatinib	10-19	autophagy related 5	Homo sapiens	206-210
27499639-5	2016	Moreover, lapatinib treatment caused autophagic cell death as shown by positive acridine orange staining, the massive formation of vacuoles as seen by electronic microscopy, and the upregulation of LC3-II, ATG5, and ATG7 in AML U937 cells.	Lapatinib	10-19	autophagy related 7	Homo sapiens	216-220
27499639-6	2016	Furthermore, autophagy inhibitor 3-methyladenine and knockdown of ATG5, ATG7, and Beclin-1 using short hairpin RNA (shRNA) partially rescued lapatinib-induced cell death.	Lapatinib	141-150	autophagy related 5	Homo sapiens	66-70
27499639-6	2016	Furthermore, autophagy inhibitor 3-methyladenine and knockdown of ATG5, ATG7, and Beclin-1 using short hairpin RNA (shRNA) partially rescued lapatinib-induced cell death.	Lapatinib	141-150	autophagy related 7	Homo sapiens	72-76
27499639-6	2016	Furthermore, autophagy inhibitor 3-methyladenine and knockdown of ATG5, ATG7, and Beclin-1 using short hairpin RNA (shRNA) partially rescued lapatinib-induced cell death.	Lapatinib	141-150	beclin 1	Homo sapiens	82-90
27499639-7	2016	In addition, the induction of phagocytosis and ROS production as well as the upregulation of surface markers CD14 and CD68 was detected in lapatinib-treated U937 cells, suggesting the induction of macrophagic differentiation in AML U937 cells by lapatinib.	Lapatinib	139-148	CD14 molecule	Homo sapiens	109-113
27499639-7	2016	In addition, the induction of phagocytosis and ROS production as well as the upregulation of surface markers CD14 and CD68 was detected in lapatinib-treated U937 cells, suggesting the induction of macrophagic differentiation in AML U937 cells by lapatinib.	Lapatinib	139-148	CD68 molecule	Homo sapiens	118-122
27402251-0	2016	ERRalpha mediates metabolic adaptations driving lapatinib resistance in breast cancer.	Lapatinib	48-57	estrogen related receptor alpha	Homo sapiens	0-8
26936914-9	2016	Furthermore, concomitantly treating CRPC cells with abiraterone and an ErbB2 inhibitor, lapatinib, blocked AR reactivation and suppressed tumor progression.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-76
26936914-9	2016	Furthermore, concomitantly treating CRPC cells with abiraterone and an ErbB2 inhibitor, lapatinib, blocked AR reactivation and suppressed tumor progression.	Lapatinib	88-97	androgen receptor	Homo sapiens	107-109
27402251-1	2016	Despite the initial benefits of treating HER2-amplified breast cancer patients with the tyrosine kinase inhibitor lapatinib, resistance inevitably develops.	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
27402251-2	2016	Here we report that lapatinib induces the degradation of the nuclear receptor ERRalpha, a master regulator of cellular metabolism, and that the expression of ERRalpha is restored in lapatinib-resistant breast cancer cells through reactivation of mTOR signalling.	Lapatinib	20-29	estrogen related receptor alpha	Homo sapiens	78-86
27402251-2	2016	Here we report that lapatinib induces the degradation of the nuclear receptor ERRalpha, a master regulator of cellular metabolism, and that the expression of ERRalpha is restored in lapatinib-resistant breast cancer cells through reactivation of mTOR signalling.	Lapatinib	20-29	estrogen related receptor alpha	Homo sapiens	158-166
27402251-2	2016	Here we report that lapatinib induces the degradation of the nuclear receptor ERRalpha, a master regulator of cellular metabolism, and that the expression of ERRalpha is restored in lapatinib-resistant breast cancer cells through reactivation of mTOR signalling.	Lapatinib	20-29	mechanistic target of rapamycin kinase	Homo sapiens	246-250
27402251-2	2016	Here we report that lapatinib induces the degradation of the nuclear receptor ERRalpha, a master regulator of cellular metabolism, and that the expression of ERRalpha is restored in lapatinib-resistant breast cancer cells through reactivation of mTOR signalling.	Lapatinib	182-191	estrogen related receptor alpha	Homo sapiens	158-166
27402251-2	2016	Here we report that lapatinib induces the degradation of the nuclear receptor ERRalpha, a master regulator of cellular metabolism, and that the expression of ERRalpha is restored in lapatinib-resistant breast cancer cells through reactivation of mTOR signalling.	Lapatinib	182-191	mechanistic target of rapamycin kinase	Homo sapiens	246-250
27402251-4	2016	An ERRalpha inverse agonist counteracts these metabolic adaptations and overcomes lapatinib resistance in a HER2-induced mammary tumour mouse model.	Lapatinib	82-91	estrogen related receptor, alpha	Mus musculus	3-11
27402251-5	2016	This work reveals a molecular mechanism by which ERRalpha-induced metabolic reprogramming promotes survival of lapatinib-resistant cancer cells and demonstrates the potential of ERRalpha inhibition as an effective adjuvant therapy in poor outcome HER2-positive breast cancer.	Lapatinib	111-120	estrogen related receptor alpha	Homo sapiens	49-57
27402251-5	2016	This work reveals a molecular mechanism by which ERRalpha-induced metabolic reprogramming promotes survival of lapatinib-resistant cancer cells and demonstrates the potential of ERRalpha inhibition as an effective adjuvant therapy in poor outcome HER2-positive breast cancer.	Lapatinib	111-120	estrogen related receptor alpha	Homo sapiens	178-186
27402251-5	2016	This work reveals a molecular mechanism by which ERRalpha-induced metabolic reprogramming promotes survival of lapatinib-resistant cancer cells and demonstrates the potential of ERRalpha inhibition as an effective adjuvant therapy in poor outcome HER2-positive breast cancer.	Lapatinib	111-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	247-251
27172793-9	2016	In cell model, ESCC cells were more sensitive to AXL inhibitor foretinib than to the HER2 inhibitor lapatinib.	Lapatinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
27165728-1	2016	According to data from a phase II study, the anti-HER2 combination of trastuzumab and lapatinib is active in patients with KRAS-wild-type, HER2-positive metastatic colorectal cancer.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
27165728-1	2016	According to data from a phase II study, the anti-HER2 combination of trastuzumab and lapatinib is active in patients with KRAS-wild-type, HER2-positive metastatic colorectal cancer.	Lapatinib	86-95	KRAS proto-oncogene, GTPase	Homo sapiens	123-127
27165728-1	2016	According to data from a phase II study, the anti-HER2 combination of trastuzumab and lapatinib is active in patients with KRAS-wild-type, HER2-positive metastatic colorectal cancer.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
26753626-5	2016	A simulation was conducted to examine the impact of using different model structures on cost-effectiveness results in the context of a combination therapy of lapatinib and capecitabine for the treatment of HER2-positive ABC.	Lapatinib	158-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	206-210
28051000-0	2016	Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
27128364-0	2016	Characterization of the binding of an anticancer drug, lapatinib to human serum albumin.	Lapatinib	55-64	albumin	Homo sapiens	74-87
27128364-1	2016	Interaction of a promising anticancer drug, lapatinib (LAP) with the major transport protein in human blood circulation, human serum albumin (HSA) was investigated using fluorescence and circular dichroism (CD) spectroscopy as well as molecular docking analysis.	Lapatinib	44-53	albumin	Homo sapiens	127-140
27172793-10	2016	Meanwhile, the AXL inhibitor foretinib showed a synergistic effect with HER2 inhibitors and the potential to overcome drug resistance to lapatinib.	Lapatinib	137-146	AXL receptor tyrosine kinase	Homo sapiens	15-18
27086917-2	2016	However, the feature of epidermal growth factor receptor (EGFR) frequently overexpressed in TNBC offers the opportunity to employ lapatinib, a dual-tyrosine kinase inhibitor of human epidermal growth factor receptor-2 (HER2) and EGFR, in the treatment of brain metastasis of TNBC.	Lapatinib	130-139	epidermal growth factor receptor	Homo sapiens	24-56
27086917-2	2016	However, the feature of epidermal growth factor receptor (EGFR) frequently overexpressed in TNBC offers the opportunity to employ lapatinib, a dual-tyrosine kinase inhibitor of human epidermal growth factor receptor-2 (HER2) and EGFR, in the treatment of brain metastasis of TNBC.	Lapatinib	130-139	epidermal growth factor receptor	Homo sapiens	58-62
27086917-2	2016	However, the feature of epidermal growth factor receptor (EGFR) frequently overexpressed in TNBC offers the opportunity to employ lapatinib, a dual-tyrosine kinase inhibitor of human epidermal growth factor receptor-2 (HER2) and EGFR, in the treatment of brain metastasis of TNBC.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-217
27086917-2	2016	However, the feature of epidermal growth factor receptor (EGFR) frequently overexpressed in TNBC offers the opportunity to employ lapatinib, a dual-tyrosine kinase inhibitor of human epidermal growth factor receptor-2 (HER2) and EGFR, in the treatment of brain metastasis of TNBC.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	219-223
27086917-2	2016	However, the feature of epidermal growth factor receptor (EGFR) frequently overexpressed in TNBC offers the opportunity to employ lapatinib, a dual-tyrosine kinase inhibitor of human epidermal growth factor receptor-2 (HER2) and EGFR, in the treatment of brain metastasis of TNBC.	Lapatinib	130-139	epidermal growth factor receptor	Homo sapiens	229-233
27026198-2	2016	This phase I study combined the investigational AKT inhibitor, MK-2206, with lapatinib to determine the MTD.	Lapatinib	77-86	metallothionein 1E	Homo sapiens	104-107
27494978-4	2016	Recently, dual HER2 blockade strategies (lapatinib-trastuzumab or pertuzumab-trastuzumab) demonstrated a significant improvement in terms of pathological complete response over trastuzumab.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
27026198-9	2016	The MTD was reached at MK-2206 45 mg orally every other day and lapatinib 1,500 mg orally daily.	Lapatinib	64-73	metallothionein 1E	Homo sapiens	4-7
27092881-7	2016	MUC1 knockout cells were more sensitive to the EGFR inhibitor, lapatinib.	Lapatinib	63-72	mucin 1, cell surface associated	Homo sapiens	0-4
26850287-6	2016	The GPMBC model was tested and validated in a specific context, by assessing the cost-effectiveness of lapatinib plus letrozole compared with other widely used first-line therapies for post-menopausal women with hormone receptor-positive (HR+) and epidermal growth factor receptor 2-positive (HER2+) MBC.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	212-282
26850287-8	2016	Results of the model testing were quite similar to those obtained by Delea et al., who also assessed the cost-effectiveness of lapatinib in combination with letrozole in HR+/HER2 + MBC in Canada, thus suggesting that the GPMBC model can replicate results of well-conducted economic evaluations.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
27108243-0	2016	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.	Lapatinib	43-52	KRAS proto-oncogene, GTPase	Homo sapiens	78-82
27108243-0	2016	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
27108243-1	2016	BACKGROUND: We previously found that dual HER2 blockade with trastuzumab and lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic colorectal cancer.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
27108243-1	2016	BACKGROUND: We previously found that dual HER2 blockade with trastuzumab and lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic colorectal cancer.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-159
27108243-2	2016	In this study, we aimed to assess the antitumour activity of trastuzumab and lapatinib in patients with HER2-positive colorectal cancer.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
27108243-16	2016	INTERPRETATION: The combination of trastuzumab and lapatinib is active and well tolerated in treatment-refractory patients with HER2-positive metastatic colorectal cancer.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
27092881-7	2016	MUC1 knockout cells were more sensitive to the EGFR inhibitor, lapatinib.	Lapatinib	63-72	epidermal growth factor receptor	Homo sapiens	47-51
27313469-4	2016	OBJECTIVE: The main objective was to evaluate the efficiency and safety of trastuzumab and lapatinib added to NAC for treatment of Her2-positive breast cancer.	Lapatinib	91-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
27224517-0	2016	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.	Lapatinib	22-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
26958860-0	2016	P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2.	Lapatinib	36-45	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93
27218867-9	2016	In patients with HER2-positive disease, several retrospective or post hoc analyses showed a longer brain progression-free survival with trastuzumab in combination with or followed by other anti-HER2 drugs (such as pertuzumab, lapatinib, and T-DM1).	Lapatinib	226-235	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21
27034004-4	2016	Inhibition of GAS5 promoted SKBR-3 cell proliferation, and GAS5 knockdown partially reversed lapatinib-induced inhibition of SKBR-3/Tr cell proliferation.	Lapatinib	93-102	growth arrest specific 5	Homo sapiens	59-63
27106482-0	2016	Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73
27293993-0	2016	Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.	Lapatinib	154-163	solute carrier family 2 member 4	Homo sapiens	18-23
26921329-2	2016	To identify improved therapeutic possibilities, we combined the EGFR/HER2 inhibitor lapatinib with a novel small molecule, CBL0137, which inhibits FACT (facilitates chromatin transcription), a histone chaperone complex predominantly expressed in undifferentiated cells.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	64-68
27293993-0	2016	Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.	Lapatinib	154-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
27293993-3	2016	Here, we tested the feasibility of the HER2-targeting agent lapatinib in prevention and/or early intervention of an ER-/HER2+ early-stage breast disease model.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-43
27293993-3	2016	Here, we tested the feasibility of the HER2-targeting agent lapatinib in prevention and/or early intervention of an ER-/HER2+ early-stage breast disease model.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
27293993-4	2016	We found that lapatinib treatment forestalled the progression of atypical ductal hyperplasia (ADH)-like acini to ductal carcinoma in situ (DCIS)-like acini in ER-/HER2+ human mammary epithelial cells (HMECs) in 3D culture.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
27293993-5	2016	Mechanistically, we found that inhibition of HER2/Akt signaling by lapatinib led to downregulation of GLUT4 and a reduced glucose uptake in HER2-overexpressing cells, resulting in decreased proliferation and increased apoptosis of these cells in 3D culture.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
27293993-5	2016	Mechanistically, we found that inhibition of HER2/Akt signaling by lapatinib led to downregulation of GLUT4 and a reduced glucose uptake in HER2-overexpressing cells, resulting in decreased proliferation and increased apoptosis of these cells in 3D culture.	Lapatinib	67-76	AKT serine/threonine kinase 1	Homo sapiens	50-53
27293993-5	2016	Mechanistically, we found that inhibition of HER2/Akt signaling by lapatinib led to downregulation of GLUT4 and a reduced glucose uptake in HER2-overexpressing cells, resulting in decreased proliferation and increased apoptosis of these cells in 3D culture.	Lapatinib	67-76	solute carrier family 2 member 4	Homo sapiens	102-107
27293993-5	2016	Mechanistically, we found that inhibition of HER2/Akt signaling by lapatinib led to downregulation of GLUT4 and a reduced glucose uptake in HER2-overexpressing cells, resulting in decreased proliferation and increased apoptosis of these cells in 3D culture.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-144
27293993-6	2016	Additionally, our data suggest that HER2-driven glycolytic metabolic dysregulation in ER-/HER2+ HMECs might promote early-stage breast disease progression, which can be reversed by lapatinib treatment.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
27293993-6	2016	Additionally, our data suggest that HER2-driven glycolytic metabolic dysregulation in ER-/HER2+ HMECs might promote early-stage breast disease progression, which can be reversed by lapatinib treatment.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
27293993-7	2016	Furthermore, low-dose lapatinib treatment, starting at the early stages of mammary grand transformation in the MMTV-neu* mouse model, significantly delayed mammary tumor initiation and progression, extended tumor-free survival, which corresponded to effective inhibition of HER2/Akt signaling and downregulation of GLUT4 in vivo.	Lapatinib	22-31	erb-b2 receptor tyrosine kinase 2	Mus musculus	274-278
27293993-7	2016	Furthermore, low-dose lapatinib treatment, starting at the early stages of mammary grand transformation in the MMTV-neu* mouse model, significantly delayed mammary tumor initiation and progression, extended tumor-free survival, which corresponded to effective inhibition of HER2/Akt signaling and downregulation of GLUT4 in vivo.	Lapatinib	22-31	thymoma viral proto-oncogene 1	Mus musculus	279-282
27293993-7	2016	Furthermore, low-dose lapatinib treatment, starting at the early stages of mammary grand transformation in the MMTV-neu* mouse model, significantly delayed mammary tumor initiation and progression, extended tumor-free survival, which corresponded to effective inhibition of HER2/Akt signaling and downregulation of GLUT4 in vivo.	Lapatinib	22-31	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	315-320
27293993-8	2016	Taken together, our results indicate that lapatinib, through its inhibition of key signaling pathways and tumor-promoting metabolic events, is a promising agent for the prevention/early intervention of ER-/HER2+ breast cancer progression.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	206-210
26581908-9	2016	Lastly, lapatinib-induced HER3 upregulation was significantly inhibited by treatment of metformin in HER3 siRNA-transfected TR MCF-7 cells.	Lapatinib	8-17	erb-b2 receptor tyrosine kinase 3	Homo sapiens	26-30
26581908-9	2016	Lastly, lapatinib-induced HER3 upregulation was significantly inhibited by treatment of metformin in HER3 siRNA-transfected TR MCF-7 cells.	Lapatinib	8-17	erb-b2 receptor tyrosine kinase 3	Homo sapiens	101-105
26921329-2	2016	To identify improved therapeutic possibilities, we combined the EGFR/HER2 inhibitor lapatinib with a novel small molecule, CBL0137, which inhibits FACT (facilitates chromatin transcription), a histone chaperone complex predominantly expressed in undifferentiated cells.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
27045589-1	2016	Strategies for successful primary treatment of HER2-positive breast cancer include use of the HER2 inhibitors trastuzumab or lapatinib in combination with standard chemotherapy.	Lapatinib	125-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
26454612-0	2016	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
27239176-6	2016	For progression of metastasis in the brain after anti-HER2 therapy, lapatinib and chemotherapy appear to be a good alternative after best local treatment.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
26894975-3	2016	We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines.	Lapatinib	175-184	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
27220786-6	2016	The HERACLES trial further indicated that a combination of trastuzumab and lapatinib showed promising antitumor effects in patients with emerging HER2 amplification.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
25987243-0	2016	Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.	Lapatinib	40-49	major histocompatibility complex, class II, DR beta 1	Homo sapiens	132-140
25987243-2	2016	Previous investigations have identified and confirmed the Class II allele HLA-DRB1*07:01 to be strongly associated with lapatinib-induced liver injury; however, the moderate positive predictive value limits its clinical utility.	Lapatinib	120-129	major histocompatibility complex, class II, DR beta 1	Homo sapiens	74-82
26752332-9	2016	Lapatinib effectively inhibited the HER2 signaling pathway in our SNUC cell line.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
27073542-0	2016	Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of beta-catenin expression.	Lapatinib	0-9	catenin beta 1	Homo sapiens	126-138
27073542-9	2016	In addition, the protein expression levels of beta-catenin were altered in the epithelial- and mesenchymal-associated SCC cell lines following treatment with lapatinib and gefitinib.	Lapatinib	158-167	catenin beta 1	Homo sapiens	46-58
27073542-10	2016	Furthermore, lapatinib induced the downregulation of vimentin and upregulation of E-cadherin in HNSCC11A cells in a time-dependent manner.	Lapatinib	13-22	vimentin	Homo sapiens	53-61
27073542-10	2016	Furthermore, lapatinib induced the downregulation of vimentin and upregulation of E-cadherin in HNSCC11A cells in a time-dependent manner.	Lapatinib	13-22	cadherin 1	Homo sapiens	82-92
27073542-12	2016	In summary, the results of the present study demonstrated that lapatinib-induced MET led to an unexpected alteration of the protein expression levels of beta-catenin in SCC cells.	Lapatinib	63-72	catenin beta 1	Homo sapiens	153-165
26894975-3	2016	We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines.	Lapatinib	175-184	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-195
26833126-2	2016	Targeting HER2(+) tumors with trastuzumab or the receptor tyrosine kinase (RTK) inhibitor lapatinib significantly improves survival, yet tumor resistance and progression of metastatic disease still develop over time.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
26811533-1	2016	PURPOSE: We examined the prognostic and predictive value of serum human epidermal growth factor 2 (HER2) extracellular domain (sHER2) in patients with advanced breast cancer treated with lapatinib using data from three randomized trials.	Lapatinib	187-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
26833126-2	2016	Targeting HER2(+) tumors with trastuzumab or the receptor tyrosine kinase (RTK) inhibitor lapatinib significantly improves survival, yet tumor resistance and progression of metastatic disease still develop over time.	Lapatinib	90-99	ret proto-oncogene	Homo sapiens	49-73
26833126-2	2016	Targeting HER2(+) tumors with trastuzumab or the receptor tyrosine kinase (RTK) inhibitor lapatinib significantly improves survival, yet tumor resistance and progression of metastatic disease still develop over time.	Lapatinib	90-99	ret proto-oncogene	Homo sapiens	75-78
26833126-9	2016	Importantly, lapatinib and palbociclib strictly block de novo synthesis of DNA, mostly through disruption of E2F1 and its target genes.	Lapatinib	13-22	E2F transcription factor 1	Homo sapiens	109-113
26883193-2	2016	To identify pathways linked to resistance, we generated HER2-positive breast cancer cell lines which are resistant to either lapatinib or AZD8931, two pan-HER family kinase inhibitors.	Lapatinib	125-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
26829011-2	2016	For patients who might be able to receive the tyrosine kinase inhibitor (TKI) lapatinib (e.g. after patent expiration), it is important to identify subgroups of patients for whom anti-HER2 TKI therapy could be beneficial.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
26829011-3	2016	To do this, we used data from 2489 patients with centrally confirmed HER2+ disease enrolled in the adjuvant Tykerb Evaluation After Chemotherapy (TEACH) trial, investigating the effect of lapatinib in patients with HER2+ early breast cancer not treated with trastuzumab.	Lapatinib	188-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	215-219
26829011-5	2016	Hormone receptor negative (HR-) patients on lapatinib had a significantly prolonged disease-free survival (DFS) compared to HR- patients on placebo (hazard ratio 0.64, P=0.003).	Lapatinib	44-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-16
26998056-10	2016	miRNA levels increased with cancer progression, and lapatinib and 5-fluorouracil (5-FU; the active form of capecitabine) treatment increased the miRNA levels (specifically miR-210 and miR-221) in the treatment-resistant pancreatic cancer PANC-1 and MIA PaCa-2 cell lines.	Lapatinib	52-61	microRNA 210	Homo sapiens	172-179
26980172-0	2016	[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-26
26998056-10	2016	miRNA levels increased with cancer progression, and lapatinib and 5-fluorouracil (5-FU; the active form of capecitabine) treatment increased the miRNA levels (specifically miR-210 and miR-221) in the treatment-resistant pancreatic cancer PANC-1 and MIA PaCa-2 cell lines.	Lapatinib	52-61	microRNA 221	Homo sapiens	184-191
26875184-12	2016	In a cohort of patients with HER2-positive MBC treated primarily with trastuzumab and lapatinib, 7 % of patients were "exceptional responders."	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
27104161-8	2016	However, small tyrosine kinase inhibitors such as lapatinib, has been noted to be a promising agent that can be used as a radiosensitizer to affect HER2-positive breast cancer.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
26824320-0	2016	Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.	Lapatinib	0-9	cellular inhibitor of PP2A	Homo sapiens	19-24
26824320-0	2016	Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.	Lapatinib	0-9	protein phosphatase 2 phosphatase activator	Homo sapiens	25-29
26824320-1	2016	We tested the efficacy of lapatinib, a dual tyrosine kinase inhibitor which interrupts the HER2 and epidermal growth factor receptor (EGFR) pathways, in a panel of triple-negative breast cancer (TNBC) cells, and examined the drug mechanism.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
26824320-1	2016	We tested the efficacy of lapatinib, a dual tyrosine kinase inhibitor which interrupts the HER2 and epidermal growth factor receptor (EGFR) pathways, in a panel of triple-negative breast cancer (TNBC) cells, and examined the drug mechanism.	Lapatinib	26-35	epidermal growth factor receptor	Homo sapiens	100-132
26824320-1	2016	We tested the efficacy of lapatinib, a dual tyrosine kinase inhibitor which interrupts the HER2 and epidermal growth factor receptor (EGFR) pathways, in a panel of triple-negative breast cancer (TNBC) cells, and examined the drug mechanism.	Lapatinib	26-35	epidermal growth factor receptor	Homo sapiens	134-138
26824320-3	2016	Lapatinib induced significant apoptosis and inhibited CIP2A and p-Akt in a dose and time-dependent manner in the three TNBC cell lines.	Lapatinib	0-9	cellular inhibitor of PP2A	Homo sapiens	54-59
26824320-4	2016	Overexpression of CIP2A reduced lapatinib-induced apoptosis in MDA-MB-468 cells.	Lapatinib	32-41	cellular inhibitor of PP2A	Homo sapiens	18-23
26824320-5	2016	In addition, lapatinib increased PP2A activity (in relation to CIP2A inhibition).	Lapatinib	13-22	protein phosphatase 2 phosphatase activator	Homo sapiens	33-37
26824320-5	2016	In addition, lapatinib increased PP2A activity (in relation to CIP2A inhibition).	Lapatinib	13-22	cellular inhibitor of PP2A	Homo sapiens	63-68
26824320-6	2016	Moreover, lapatinib-induced apoptosis and p-Akt downregulation was attenuated by PP2A antagonist okadaic acid.	Lapatinib	10-19	protein phosphatase 2 phosphatase activator	Homo sapiens	81-85
26628478-0	2016	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-103
26628478-0	2016	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Lapatinib	0-9	trio Rho guanine nucleotide exchange factor	Homo sapiens	193-197
26692570-5	2016	Consistently, receptor binding assays and western blotting demonstrate that beta2ARs levels are markedly increased in ErbB2(tg) myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib.	Lapatinib	176-185	epidermal growth factor receptor	Mus musculus	154-158
26692570-5	2016	Consistently, receptor binding assays and western blotting demonstrate that beta2ARs levels are markedly increased in ErbB2(tg) myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib.	Lapatinib	176-185	erb-b2 receptor tyrosine kinase 2	Mus musculus	159-164
26824320-7	2016	Furthermore, lapatinib indirectly decreased CIP2A transcription by disturbing the binding of Elk1 to the CIP2A promoter.	Lapatinib	13-22	cellular inhibitor of PP2A	Homo sapiens	44-49
26824320-7	2016	Furthermore, lapatinib indirectly decreased CIP2A transcription by disturbing the binding of Elk1 to the CIP2A promoter.	Lapatinib	13-22	ETS transcription factor ELK1	Homo sapiens	93-97
26824320-7	2016	Furthermore, lapatinib indirectly decreased CIP2A transcription by disturbing the binding of Elk1 to the CIP2A promoter.	Lapatinib	13-22	cellular inhibitor of PP2A	Homo sapiens	105-110
26824320-8	2016	Importantly, lapatinib showed anti-tumor activity in mice bearing MDA-MB-468 xenograft tumors, and suppressed CIP2A as well as p-Akt in these xenografted tumors.	Lapatinib	13-22	cell proliferation regulating inhibitor of protein phosphatase 2A	Mus musculus	110-115
26824320-9	2016	In summary, inhibition of CIP2A determines the effects of lapatinib-induced apoptosis in TNBC cells.	Lapatinib	58-67	cellular inhibitor of PP2A	Homo sapiens	26-31
26824320-10	2016	In addition to being a dual tyrosine kinase inhibitor of HER2 and EGFR, lapatinib also inhibits CIP2A/PP2A/p-Akt signaling in TNBC cells.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
26824320-10	2016	In addition to being a dual tyrosine kinase inhibitor of HER2 and EGFR, lapatinib also inhibits CIP2A/PP2A/p-Akt signaling in TNBC cells.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	66-70
26824320-10	2016	In addition to being a dual tyrosine kinase inhibitor of HER2 and EGFR, lapatinib also inhibits CIP2A/PP2A/p-Akt signaling in TNBC cells.	Lapatinib	72-81	cellular inhibitor of PP2A	Homo sapiens	96-101
26824320-10	2016	In addition to being a dual tyrosine kinase inhibitor of HER2 and EGFR, lapatinib also inhibits CIP2A/PP2A/p-Akt signaling in TNBC cells.	Lapatinib	72-81	protein phosphatase 2 phosphatase activator	Homo sapiens	102-106
26887956-12	2016	Despite the low patient number, lapatinib plus vinorelbine may constitute a potential treatment option in heavily pretreated patients with HER-2/neu-positive MBC previously exposed to lapatinib.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-144
26887956-12	2016	Despite the low patient number, lapatinib plus vinorelbine may constitute a potential treatment option in heavily pretreated patients with HER-2/neu-positive MBC previously exposed to lapatinib.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-148
26628478-1	2016	PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-173
26628478-1	2016	PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
26369543-0	2016	Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
26643609-0	2016	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-135
26643609-1	2016	Acquired resistance to lapatinib, a human epidermal growth factor receptor 2 kinase inhibitor, remains a clinical problem for women with human epidermal growth factor receptor 2-positive advanced breast cancer, as metastasis is commonly observed in these patients.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-76
26643609-1	2016	Acquired resistance to lapatinib, a human epidermal growth factor receptor 2 kinase inhibitor, remains a clinical problem for women with human epidermal growth factor receptor 2-positive advanced breast cancer, as metastasis is commonly observed in these patients.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-177
26643609-5	2016	Lapatinib-resistant SKBR3 and BT474 cells exhibited up-regulation of the phenotypic epithelial-mesenchymal transition markers Snail, vimentin and alpha-smooth muscle actin, accompanied by activation of nuclear factor-kB and Src and a concomitant increase in stem cell marker expression (CD44(high)/CD24(low)), compared to naive lapatinib-sensitive SKBR3 and BT474 cells, respectively.	Lapatinib	0-9	snail family transcriptional repressor 1	Homo sapiens	126-131
26643609-5	2016	Lapatinib-resistant SKBR3 and BT474 cells exhibited up-regulation of the phenotypic epithelial-mesenchymal transition markers Snail, vimentin and alpha-smooth muscle actin, accompanied by activation of nuclear factor-kB and Src and a concomitant increase in stem cell marker expression (CD44(high)/CD24(low)), compared to naive lapatinib-sensitive SKBR3 and BT474 cells, respectively.	Lapatinib	0-9	vimentin	Homo sapiens	133-141
26643609-5	2016	Lapatinib-resistant SKBR3 and BT474 cells exhibited up-regulation of the phenotypic epithelial-mesenchymal transition markers Snail, vimentin and alpha-smooth muscle actin, accompanied by activation of nuclear factor-kB and Src and a concomitant increase in stem cell marker expression (CD44(high)/CD24(low)), compared to naive lapatinib-sensitive SKBR3 and BT474 cells, respectively.	Lapatinib	0-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	224-227
26643609-5	2016	Lapatinib-resistant SKBR3 and BT474 cells exhibited up-regulation of the phenotypic epithelial-mesenchymal transition markers Snail, vimentin and alpha-smooth muscle actin, accompanied by activation of nuclear factor-kB and Src and a concomitant increase in stem cell marker expression (CD44(high)/CD24(low)), compared to naive lapatinib-sensitive SKBR3 and BT474 cells, respectively.	Lapatinib	0-9	CD44 molecule (Indian blood group)	Homo sapiens	287-291
26643609-6	2016	Interestingly, niclosamide reversed epithelial-mesenchymal transition, induced apoptosis and inhibited cell growth by perturbing aberrant signaling pathway activation in lapatinib-resistant human epidermal growth factor receptor 2-positive cells.	Lapatinib	170-179	erb-b2 receptor tyrosine kinase 2	Homo sapiens	196-230
26647992-5	2016	Importantly, the regulation of N-cadherin on EMT and stemness was counteracted by lapatinib, a specific ErbB signaling pathway inhibitor.	Lapatinib	82-91	cadherin 2	Homo sapiens	31-41
26647992-5	2016	Importantly, the regulation of N-cadherin on EMT and stemness was counteracted by lapatinib, a specific ErbB signaling pathway inhibitor.	Lapatinib	82-91	epidermal growth factor receptor	Homo sapiens	104-108
26834107-1	2016	Since the approval of trastuzumab, a humanized monoclonal antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2), 3 other HER2-targeting agents have gained regulatory approval: lapatinib, pertuzumab, and trastuzumab-emtansine.	Lapatinib	215-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-164
26369543-1	2016	Lapatinib, a tyrosine kinase inhibitor of HER2/EGFR, can inhibit the proliferation of HER2-positive breast cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
26369543-1	2016	Lapatinib, a tyrosine kinase inhibitor of HER2/EGFR, can inhibit the proliferation of HER2-positive breast cancer cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	47-51
26369543-1	2016	Lapatinib, a tyrosine kinase inhibitor of HER2/EGFR, can inhibit the proliferation of HER2-positive breast cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
26369543-4	2016	We previously found that brief treatment with lapatinib induced both apoptosis and autophagy in HER2-positive breast cancer cells.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
26369543-8	2016	Thus, autophagy is a potential novel therapeutic target for reversing lapatinib resistance of HER2-positive breast cancer cells.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
26621843-0	2016	The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 3	Homo sapiens	4-9
26621843-4	2016	Knockdown of erbB3 inhibited Akt in SKBR3-pool2 and BT474-HR20 cells, significantly increased lapatinib efficacy, and dramatically re-sensitized the cells to lapatinib-induced apoptosis.	Lapatinib	158-167	erb-b2 receptor tyrosine kinase 3	Homo sapiens	13-18
26621843-7	2016	Furthermore, a specific inhibitor of Akt, but not Src, significantly enhanced lapatinib-mediated anti-proliferative/anti-survival effects on SKBR3-pool2 and BT474-HR20 cells.	Lapatinib	78-87	AKT serine/threonine kinase 1	Homo sapiens	37-40
26621843-8	2016	These data indicate that erbB3 signaling is critical for both trastuzumab and lapatinib resistances mainly through the PI-3K/Akt pathway, whereas IGF-1R-initiated Src activation results in trastuzumab resistance without affecting lapatinib sensitivity.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 3	Homo sapiens	25-30
26621843-8	2016	These data indicate that erbB3 signaling is critical for both trastuzumab and lapatinib resistances mainly through the PI-3K/Akt pathway, whereas IGF-1R-initiated Src activation results in trastuzumab resistance without affecting lapatinib sensitivity.	Lapatinib	78-87	AKT serine/threonine kinase 1	Homo sapiens	125-128
26621843-8	2016	These data indicate that erbB3 signaling is critical for both trastuzumab and lapatinib resistances mainly through the PI-3K/Akt pathway, whereas IGF-1R-initiated Src activation results in trastuzumab resistance without affecting lapatinib sensitivity.	Lapatinib	230-239	erb-b2 receptor tyrosine kinase 3	Homo sapiens	25-30
26621843-0	2016	The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.	Lapatinib	87-96	insulin like growth factor 1 receptor	Homo sapiens	15-29
26621843-8	2016	These data indicate that erbB3 signaling is critical for both trastuzumab and lapatinib resistances mainly through the PI-3K/Akt pathway, whereas IGF-1R-initiated Src activation results in trastuzumab resistance without affecting lapatinib sensitivity.	Lapatinib	230-239	insulin like growth factor 1 receptor	Homo sapiens	146-152
26621843-8	2016	These data indicate that erbB3 signaling is critical for both trastuzumab and lapatinib resistances mainly through the PI-3K/Akt pathway, whereas IGF-1R-initiated Src activation results in trastuzumab resistance without affecting lapatinib sensitivity.	Lapatinib	230-239	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	163-166
26621843-2	2016	However, it remains unclear whether erbB3- and IGF-1R-initiated signaling pathways possess distinct effects on the sensitivity of lapatinib, a dual tyrosine kinase inhibitor against both EGFR and erbB2, in trastuzumab-resistant breast cancer.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 3	Homo sapiens	36-41
26621843-2	2016	However, it remains unclear whether erbB3- and IGF-1R-initiated signaling pathways possess distinct effects on the sensitivity of lapatinib, a dual tyrosine kinase inhibitor against both EGFR and erbB2, in trastuzumab-resistant breast cancer.	Lapatinib	130-139	insulin like growth factor 1 receptor	Homo sapiens	47-53
26621843-2	2016	However, it remains unclear whether erbB3- and IGF-1R-initiated signaling pathways possess distinct effects on the sensitivity of lapatinib, a dual tyrosine kinase inhibitor against both EGFR and erbB2, in trastuzumab-resistant breast cancer.	Lapatinib	130-139	epidermal growth factor receptor	Homo sapiens	187-191
26621843-2	2016	However, it remains unclear whether erbB3- and IGF-1R-initiated signaling pathways possess distinct effects on the sensitivity of lapatinib, a dual tyrosine kinase inhibitor against both EGFR and erbB2, in trastuzumab-resistant breast cancer.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	196-201
26621843-4	2016	Knockdown of erbB3 inhibited Akt in SKBR3-pool2 and BT474-HR20 cells, significantly increased lapatinib efficacy, and dramatically re-sensitized the cells to lapatinib-induced apoptosis.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 3	Homo sapiens	13-18
26673621-5	2016	Although the 6 lines most resistant to BRAF inhibition showed synergistic benefit from combination with lapatinib, the signaling mechanisms by which this combination generated synergistic cytotoxicity differed between the cell lines.	Lapatinib	104-113	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	39-43
26595522-0	2016	HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.	Lapatinib	49-58	X protein	Hepatitis B virus	0-3
26623720-2	2016	The aim of this study was to correlate expression of selected proteins involved in ErbB family signaling pathways with clinical efficacy of lapatinib.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
26623720-3	2016	Study group included 270 HER2-positive advanced breast cancer patients treated with lapatinib and capecitabine.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
26595522-0	2016	HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 3	Homo sapiens	76-81
26623720-10	2016	IN CONCLUSION: the efficacy of lapatinib seems to be associated with the activity of downstream signaling pathways - AMPK/mTOR and Ras/Raf/MAPK.	Lapatinib	31-40	mechanistic target of rapamycin kinase	Homo sapiens	122-126
26623720-10	2016	IN CONCLUSION: the efficacy of lapatinib seems to be associated with the activity of downstream signaling pathways - AMPK/mTOR and Ras/Raf/MAPK.	Lapatinib	31-40	zinc fingers and homeoboxes 2	Homo sapiens	135-138
26595522-4	2016	In this study, our data showed that HBx overexpression did not alter the cellular sensitivity of HCC cell lines to sorafenib but unexpectedly enhanced the cell death induced by EGFR family inhibitors, including gefitinib, erlotinib, and lapatinib due to ErbB3 up-regulation.	Lapatinib	237-246	X protein	Hepatitis B virus	36-39
25715765-9	2016	Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metastasis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
26619359-3	2016	HER2-targeting agents, including trastuzumab, lapatinib, trastuzumab emtansine, and pertuzumab, have been approved for the treatment of HER2-positive breast cancer, with trastuzumab also approved for the treatment of HER2-positive gastric cancer.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
26934461-4	2016	An established protocol that integrated bioinformatics modeling and kinase inhibition assay was employed to examine the structural basis, energetic property, and biological implication underlying the intermolecular interaction between HER2 kinase domain and three representative TKIs, i.e. two FDA-approved drugs lapatinib and gefitinib as well as a pan-kinase inhibitor staurosporine.	Lapatinib	313-322	erb-b2 receptor tyrosine kinase 2	Homo sapiens	235-239
26350262-3	2016	ErbB-2-positive breast tumors are aggressive and frequently become resistant to trastuzumab or lapatinib.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-6
26350262-5	2016	EXPERIMENTAL DESIGN: Here, we sought to elucidate mechanisms by which ErbB-2 attenuates Notch signaling and how this is reversed by trastuzumab or lapatinib.	Lapatinib	147-156	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-76
27114895-3	2016	Lapatinib, the only brain permeable targeted agent for HER2-positive cancer, has demonstrated limited intracranial response rates and little improvement in progression free survival (PFS) for HER-2 positive patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	192-197
29375730-3	2016	We previously reported that MDM2 promotes degradation of another ubiquitin E3 ligase HUWE1 by ubiquitination, particularly, which confers HER2+ breast cancer cells resistance to the HER2 inhibitor lapatinib.	Lapatinib	197-206	MDM2 proto-oncogene	Homo sapiens	28-32
29375730-3	2016	We previously reported that MDM2 promotes degradation of another ubiquitin E3 ligase HUWE1 by ubiquitination, particularly, which confers HER2+ breast cancer cells resistance to the HER2 inhibitor lapatinib.	Lapatinib	197-206	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Homo sapiens	85-90
29375730-3	2016	We previously reported that MDM2 promotes degradation of another ubiquitin E3 ligase HUWE1 by ubiquitination, particularly, which confers HER2+ breast cancer cells resistance to the HER2 inhibitor lapatinib.	Lapatinib	197-206	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
29375730-3	2016	We previously reported that MDM2 promotes degradation of another ubiquitin E3 ligase HUWE1 by ubiquitination, particularly, which confers HER2+ breast cancer cells resistance to the HER2 inhibitor lapatinib.	Lapatinib	197-206	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-186
26468947-1	2016	BACKGROUND/OBJECTIVE: Lapatinib is a potent HER1 and HER2 inhibitor.	Lapatinib	22-31	epidermal growth factor receptor	Homo sapiens	44-48
26391018-8	2016	However, the cognate inhibitor lapatinib and the non-cognate inhibitor bosutinib were predicted to have low affinity for wild-type HER2 but high affinity for HER2(YVMA) mutant, which was confirmed by subsequent kinase assay experiments; the inhibitory potencies of bosutinib against wild-type and mutant HER2 were determined to be IC(50) > 1000 and =27 nM, respectively, suggesting that the bosutinib might be exploited as a selective inhibitor for mutant over wild-type HER2.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
26391018-8	2016	However, the cognate inhibitor lapatinib and the non-cognate inhibitor bosutinib were predicted to have low affinity for wild-type HER2 but high affinity for HER2(YVMA) mutant, which was confirmed by subsequent kinase assay experiments; the inhibitory potencies of bosutinib against wild-type and mutant HER2 were determined to be IC(50) > 1000 and =27 nM, respectively, suggesting that the bosutinib might be exploited as a selective inhibitor for mutant over wild-type HER2.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
26391018-8	2016	However, the cognate inhibitor lapatinib and the non-cognate inhibitor bosutinib were predicted to have low affinity for wild-type HER2 but high affinity for HER2(YVMA) mutant, which was confirmed by subsequent kinase assay experiments; the inhibitory potencies of bosutinib against wild-type and mutant HER2 were determined to be IC(50) > 1000 and =27 nM, respectively, suggesting that the bosutinib might be exploited as a selective inhibitor for mutant over wild-type HER2.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
26391018-8	2016	However, the cognate inhibitor lapatinib and the non-cognate inhibitor bosutinib were predicted to have low affinity for wild-type HER2 but high affinity for HER2(YVMA) mutant, which was confirmed by subsequent kinase assay experiments; the inhibitory potencies of bosutinib against wild-type and mutant HER2 were determined to be IC(50) > 1000 and =27 nM, respectively, suggesting that the bosutinib might be exploited as a selective inhibitor for mutant over wild-type HER2.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
26996617-5	2016	Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	170-174
26776172-8	2016	Using biophysical simulations and analysis of protein structure networks, we show that conformational-specific drug binding of Lapatinib may elicit resistant mutations in the EGFR kinase that are linked with the ligand-mediated changes in the residue interaction networks and global network properties of key residues that are responsible for structural stability of specific functional states.	Lapatinib	127-136	epidermal growth factor receptor	Homo sapiens	175-179
26776172-9	2016	A strong network dependency on high centrality residues in the conformation-specific Lapatinib-EGFR complex may explain vulnerability of drug binding to a broad spectrum of mutations and the emergence of drug resistance.	Lapatinib	85-94	epidermal growth factor receptor	Homo sapiens	95-99
26468947-1	2016	BACKGROUND/OBJECTIVE: Lapatinib is a potent HER1 and HER2 inhibitor.	Lapatinib	22-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
26296355-6	2015	Lapatinib alone acutely inhibited all HER receptors and effectors but led to delayed rephosphorylation of HER3 and EGFR and partial restoration of ERK and AKT activity.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 3	Homo sapiens	106-110
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Lapatinib	46-50	erb-b2 receptor tyrosine kinase 2	Mus musculus	96-100
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Lapatinib	46-50	phosphoglycolate phosphatase	Mus musculus	105-109
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Lapatinib	141-145	erb-b2 receptor tyrosine kinase 2	Mus musculus	96-100
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Lapatinib	141-145	phosphoglycolate phosphatase	Mus musculus	105-109
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Lapatinib	141-145	phosphoglycolate phosphatase	Mus musculus	168-172
26474677-9	2015	To summarize, this localized co-delivery system with good synergistic effects between LAPA and PTX might offer a potential strategy for HER2 and P-gp positive breast cancer.	Lapatinib	86-90	erb-b2 receptor tyrosine kinase 2	Mus musculus	136-140
26474677-1	2015	The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Mus musculus	57-61
26474677-1	2015	The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Mus musculus	195-199
26474677-1	2015	The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer.	Lapatinib	48-52	erb-b2 receptor tyrosine kinase 2	Mus musculus	195-199
26296355-6	2015	Lapatinib alone acutely inhibited all HER receptors and effectors but led to delayed rephosphorylation of HER3 and EGFR and partial restoration of ERK and AKT activity.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	115-119
26296355-6	2015	Lapatinib alone acutely inhibited all HER receptors and effectors but led to delayed rephosphorylation of HER3 and EGFR and partial restoration of ERK and AKT activity.	Lapatinib	0-9	mitogen-activated protein kinase 1	Homo sapiens	147-150
26296355-6	2015	Lapatinib alone acutely inhibited all HER receptors and effectors but led to delayed rephosphorylation of HER3 and EGFR and partial restoration of ERK and AKT activity.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	155-158
26296355-7	2015	When combined with lapatinib, trastuzumab prevented HER3/EGFR reactivation and caused prolonged inhibition of ERK/AKT.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 3	Homo sapiens	52-56
26296355-7	2015	When combined with lapatinib, trastuzumab prevented HER3/EGFR reactivation and caused prolonged inhibition of ERK/AKT.	Lapatinib	19-28	epidermal growth factor receptor	Homo sapiens	57-61
26296355-7	2015	When combined with lapatinib, trastuzumab prevented HER3/EGFR reactivation and caused prolonged inhibition of ERK/AKT.	Lapatinib	19-28	mitogen-activated protein kinase 1	Homo sapiens	110-113
26296355-7	2015	When combined with lapatinib, trastuzumab prevented HER3/EGFR reactivation and caused prolonged inhibition of ERK/AKT.	Lapatinib	19-28	AKT serine/threonine kinase 1	Homo sapiens	114-117
26296355-10	2015	CONCLUSIONS: Only prolonged inhibition of HER3 and EGFR, achievable by dual blockade with trastuzumab and lapatinib or irreversible HER2 inhibition by single-agent afatinib, led to regression of HER2-amplified gastrointestinal carcinomas.	Lapatinib	106-115	erb-b2 receptor tyrosine kinase 3	Homo sapiens	42-46
26296355-10	2015	CONCLUSIONS: Only prolonged inhibition of HER3 and EGFR, achievable by dual blockade with trastuzumab and lapatinib or irreversible HER2 inhibition by single-agent afatinib, led to regression of HER2-amplified gastrointestinal carcinomas.	Lapatinib	106-115	epidermal growth factor receptor	Homo sapiens	51-55
25967286-1	2015	BACKGROUND: Lapatinib is the human epidermal growth factor receptor 2 (HER2) targeting agent approved globally for HER2-positive metastatic breast cancer (MBC).	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-69
26527790-1	2015	PURPOSE: This multicenter phase III study evaluated the efficacy and safety of lapatinib, an epidermal growth factor receptor/ErbB2 inhibitor, administered concomitantly with chemoradiotherapy and as maintenance monotherapy in patients with high-risk surgically treated squamous cell carcinoma of the head and neck (SCCHN).	Lapatinib	79-88	epidermal growth factor receptor	Homo sapiens	93-125
26527790-1	2015	PURPOSE: This multicenter phase III study evaluated the efficacy and safety of lapatinib, an epidermal growth factor receptor/ErbB2 inhibitor, administered concomitantly with chemoradiotherapy and as maintenance monotherapy in patients with high-risk surgically treated squamous cell carcinoma of the head and neck (SCCHN).	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-131
26642944-3	2015	Inhibition kinetic profiles of a panel of UGT enzymes (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17) by four TKIs (axitinib, imatinib, lapatinib and vandetanib) were characterized by using hepatic microsomes and recombinant proteins.	Lapatinib	159-168	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	42-45
26384789-0	2015	Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108
26384789-1	2015	Lapatinib plus capecitabine (lap+cap) is approved as treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), who have progressed on prior trastuzumab in the metastatic setting.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-121
26384789-1	2015	Lapatinib plus capecitabine (lap+cap) is approved as treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), who have progressed on prior trastuzumab in the metastatic setting.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
26362459-1	2015	BACKGROUND: Lapatinib has proven efficacy as monotherapy and in combination with capecitabine in patients with metastatic breast cancer (MBC) overexpressing HER2 and/or EGFR.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
26362459-1	2015	BACKGROUND: Lapatinib has proven efficacy as monotherapy and in combination with capecitabine in patients with metastatic breast cancer (MBC) overexpressing HER2 and/or EGFR.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	169-173
26642944-4	2015	Lapatinib exhibited potent competitive inhibition against UGT1A1 activity with a Ki of 0.5 muM.	Lapatinib	0-9	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	58-64
26642944-7	2015	Results from modeling for the quantitative prediction of DDI risk indicated that the coadministration of lapatinib or imatinib at clinical doses could result in a significant increase in AUC of drugs primarily cleared by UGT1A1 or 2B17.	Lapatinib	105-114	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	221-227
26642944-8	2015	Lapatinib and imatinib may cause clinically significant DDIs when co-administered UGT1A1 or 2B17 substrates.	Lapatinib	0-9	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	82-88
26507197-4	2015	Lapatinib is a tyrosine kinase inhibitor that binds to both EGFR and HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	60-64
26507197-4	2015	Lapatinib is a tyrosine kinase inhibitor that binds to both EGFR and HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-74
26276735-0	2015	Mechanisms of lapatinib resistance in HER2-driven breast cancer.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
26276735-3	2015	HER2-targeting therapies (trastuzumab, pertuzumab, TDM1 and lapatinib) are available, but a significant fraction of HER2-positive breast cancers eventually relapse or progress.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
26539808-0	2015	Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.	Lapatinib	17-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
26539808-1	2015	Lapatinib, a selective small-molecule dual-tyrosine kinase inhibitor of HER2 and EGFR, is effective in HER2-positive patients with advanced metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
26539808-1	2015	Lapatinib, a selective small-molecule dual-tyrosine kinase inhibitor of HER2 and EGFR, is effective in HER2-positive patients with advanced metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	81-85
26539808-1	2015	Lapatinib, a selective small-molecule dual-tyrosine kinase inhibitor of HER2 and EGFR, is effective in HER2-positive patients with advanced metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
25967286-1	2015	BACKGROUND: Lapatinib is the human epidermal growth factor receptor 2 (HER2) targeting agent approved globally for HER2-positive metastatic breast cancer (MBC).	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
25967286-1	2015	BACKGROUND: Lapatinib is the human epidermal growth factor receptor 2 (HER2) targeting agent approved globally for HER2-positive metastatic breast cancer (MBC).	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
26516700-0	2015	Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.	Lapatinib	131-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
26555641-0	2015	Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA).	Lapatinib	81-90	albumin	Homo sapiens	117-130
26555641-1	2015	The binding interactions of three kinds of tyrosine kinase inhibitors (TKIs), such as gefitinib, lapatinib and sunitinib, with bovine serum albumin (BSA) were studied using ultraviolet spectrophotometry, fluorescence spectroscopy, circular dichroism (CD), Fourier transform infrared spectroscopy (FT-IR) and molecular docking methods.	Lapatinib	97-106	albumin	Homo sapiens	134-147
26503698-0	2015	Lapatinib enhances trastuzumab-mediated antibody-dependent  cellular cytotoxicity via upregulation of HER2  in malignant mesothelioma cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
26503698-2	2015	It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) in HER2-positive breast cancer, suggesting that this combination is a promising strategy for MPM treatment.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
26516700-0	2015	Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.	Lapatinib	131-140	CREB regulated transcription coactivator 2	Homo sapiens	59-64
26516700-6	2015	We conducted a comparative analysis of such secondary targets in combination with the HER2 inhibitor lapatinib and find that the inhibition of mTor affords the highest degree of synergy.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
26516700-6	2015	We conducted a comparative analysis of such secondary targets in combination with the HER2 inhibitor lapatinib and find that the inhibition of mTor affords the highest degree of synergy.	Lapatinib	101-110	mechanistic target of rapamycin kinase	Homo sapiens	143-147
26516700-7	2015	In further dissecting the individual roles of TORC1 and TORC2 complexes using pharmacologic and genetic tools, we find that it is specifically the inactivation of TORC2 that most synergistically enhances the efficacy of lapatinib.	Lapatinib	220-229	CREB regulated transcription coactivator 1	Homo sapiens	46-51
26516700-7	2015	In further dissecting the individual roles of TORC1 and TORC2 complexes using pharmacologic and genetic tools, we find that it is specifically the inactivation of TORC2 that most synergistically enhances the efficacy of lapatinib.	Lapatinib	220-229	CREB regulated transcription coactivator 2	Homo sapiens	56-61
26503698-7	2015	In MPM cell lines, HER2 expression was upregulated by lapatinib, downregulated by afatinib and unaffected by gefitinib.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
26516700-7	2015	In further dissecting the individual roles of TORC1 and TORC2 complexes using pharmacologic and genetic tools, we find that it is specifically the inactivation of TORC2 that most synergistically enhances the efficacy of lapatinib.	Lapatinib	220-229	CREB regulated transcription coactivator 2	Homo sapiens	163-168
26503698-9	2015	In patient-derived MPM cells, both HER2 and EGFR were upregulated by lapatinib, resulting in the enhancement of both trastuzumab- and cetuximab-mediated ADCC.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
26706012-6	2015	Data driven from in vitro and animal studies on the merlin pathway allowed biologically targeted treatment strategies (employing Lapatinib, Erlotinib, Everolimus, Picropodophyllin, OSU.03012, Imatinib, Sorafenib, and Bevacizumab) aimed at multiple tumor shrinkage or regression or both and tumor arrest of progression with functional improvement.	Lapatinib	129-138	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	52-58
26503698-9	2015	In patient-derived MPM cells, both HER2 and EGFR were upregulated by lapatinib, resulting in the enhancement of both trastuzumab- and cetuximab-mediated ADCC.	Lapatinib	69-78	epidermal growth factor receptor	Homo sapiens	44-48
26503698-10	2015	Of the three TKIs, only lapatinib enhanced trastuzumab-mediated ADCC via the upregulation of HER2 expression in MPM cells, suggesting that sequential combination of lapatinib and trastuzumab may be a promising strategy for MPM treatment.	Lapatinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
26615133-5	2015	Recent research has focused on dual blockade of HER2 (trastuzumab-lapatinib; trastuzumab-pertuzumab) and concomitant blockade of the endocrine driver and other pathways such as the PI3K/AKT/mTOR pathway (everolimus-exemestane), HER2 (trastuzumab/lapatinib-endocrine therapy) and the cell cycle through cyclin-dependent kinase inhibition (letrozole-palbociclib).	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
26484410-0	2015	Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
26337386-0	2015	Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Mus musculus	53-57
26337386-0	2015	Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.	Lapatinib	93-102	yes-associated protein 1	Mus musculus	107-110
26337386-0	2015	Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.	Lapatinib	93-102	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	115-118
26337386-3	2015	Tumor progression is accompanied by changes in the biophysical properties of the tissue, and we asked whether matrix rigidity modulated the sensitive versus resistant states in HER2-amplified breast cancer cell responses to the HER2-targeted kinase inhibitor lapatinib.	Lapatinib	259-268	erb-b2 receptor tyrosine kinase 2	Mus musculus	177-181
26337386-5	2015	Down-regulation of the mechanosensitive transcription coactivators YAP and TAZ, either by siRNA or with the small-molecule YAP/TEAD inhibitor verteporfin, eliminated modulus-dependent lapatinib resistance.	Lapatinib	184-193	yes-associated protein 1	Mus musculus	67-70
26337386-5	2015	Down-regulation of the mechanosensitive transcription coactivators YAP and TAZ, either by siRNA or with the small-molecule YAP/TEAD inhibitor verteporfin, eliminated modulus-dependent lapatinib resistance.	Lapatinib	184-193	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	75-78
26337386-5	2015	Down-regulation of the mechanosensitive transcription coactivators YAP and TAZ, either by siRNA or with the small-molecule YAP/TEAD inhibitor verteporfin, eliminated modulus-dependent lapatinib resistance.	Lapatinib	184-193	yes-associated protein 1	Mus musculus	123-126
26337386-6	2015	Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased.	Lapatinib	137-146	yes-associated protein 1	Mus musculus	13-16
26337386-6	2015	Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Mus musculus	69-73
26337386-6	2015	Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased.	Lapatinib	137-146	yes-associated protein 1	Mus musculus	150-153
26581390-11	2015	Activation of the epidermal growth factor receptor (EGFR) pathway was observed in recurrent tumors, and inhibition of EGFR with lapatinib in combination with BGJ398 resulted in a significant delay in tumor recurrence accompanied by reduced stroma, yet there was no difference observed in initial tumor regression between the groups treated with BGJ398 alone or in combination with lapatinib.	Lapatinib	128-137	epidermal growth factor receptor	Mus musculus	18-50
26581390-11	2015	Activation of the epidermal growth factor receptor (EGFR) pathway was observed in recurrent tumors, and inhibition of EGFR with lapatinib in combination with BGJ398 resulted in a significant delay in tumor recurrence accompanied by reduced stroma, yet there was no difference observed in initial tumor regression between the groups treated with BGJ398 alone or in combination with lapatinib.	Lapatinib	128-137	epidermal growth factor receptor	Mus musculus	52-56
26581390-11	2015	Activation of the epidermal growth factor receptor (EGFR) pathway was observed in recurrent tumors, and inhibition of EGFR with lapatinib in combination with BGJ398 resulted in a significant delay in tumor recurrence accompanied by reduced stroma, yet there was no difference observed in initial tumor regression between the groups treated with BGJ398 alone or in combination with lapatinib.	Lapatinib	128-137	epidermal growth factor receptor	Mus musculus	118-122
26581390-11	2015	Activation of the epidermal growth factor receptor (EGFR) pathway was observed in recurrent tumors, and inhibition of EGFR with lapatinib in combination with BGJ398 resulted in a significant delay in tumor recurrence accompanied by reduced stroma, yet there was no difference observed in initial tumor regression between the groups treated with BGJ398 alone or in combination with lapatinib.	Lapatinib	381-390	epidermal growth factor receptor	Mus musculus	18-50
26581390-11	2015	Activation of the epidermal growth factor receptor (EGFR) pathway was observed in recurrent tumors, and inhibition of EGFR with lapatinib in combination with BGJ398 resulted in a significant delay in tumor recurrence accompanied by reduced stroma, yet there was no difference observed in initial tumor regression between the groups treated with BGJ398 alone or in combination with lapatinib.	Lapatinib	381-390	epidermal growth factor receptor	Mus musculus	52-56
26581390-11	2015	Activation of the epidermal growth factor receptor (EGFR) pathway was observed in recurrent tumors, and inhibition of EGFR with lapatinib in combination with BGJ398 resulted in a significant delay in tumor recurrence accompanied by reduced stroma, yet there was no difference observed in initial tumor regression between the groups treated with BGJ398 alone or in combination with lapatinib.	Lapatinib	381-390	epidermal growth factor receptor	Mus musculus	118-122
26484410-1	2015	BACKGROUND: Lapatinib, a dual EGFR and HER2 inhibitor has shown disappointing results in clinical trials of metastatic oesophago-gastric adenocarcinomas (OGAs), and in vitro studies suggest that MET, IGFR, and HER3 confer resistance.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	30-34
26484410-1	2015	BACKGROUND: Lapatinib, a dual EGFR and HER2 inhibitor has shown disappointing results in clinical trials of metastatic oesophago-gastric adenocarcinomas (OGAs), and in vitro studies suggest that MET, IGFR, and HER3 confer resistance.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-43
26484410-1	2015	BACKGROUND: Lapatinib, a dual EGFR and HER2 inhibitor has shown disappointing results in clinical trials of metastatic oesophago-gastric adenocarcinomas (OGAs), and in vitro studies suggest that MET, IGFR, and HER3 confer resistance.	Lapatinib	12-21	insulin like growth factor 1 receptor	Homo sapiens	200-204
26513016-0	2015	Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.	Lapatinib	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	103-108
26484410-1	2015	BACKGROUND: Lapatinib, a dual EGFR and HER2 inhibitor has shown disappointing results in clinical trials of metastatic oesophago-gastric adenocarcinomas (OGAs), and in vitro studies suggest that MET, IGFR, and HER3 confer resistance.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 3	Homo sapiens	210-214
26513016-0	2015	Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.	Lapatinib	0-9	interleukin 6	Homo sapiens	124-137
26513016-1	2015	Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor (TKI), has been approved for HER2-positive breast cancer patients.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-50
26435481-7	2015	Co-administration of trastuzumab and lapatinib in the HER2-overexpressed PDX significantly inhibited tumor growth compared to the control.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
26484410-3	2015	METHODS: Patients with HER2 overexpressing OGA were treated for 10 days with Lapatinib monotherapy, and then in combination with three cycles of Oxaliplatin and Capecitabine before surgery.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
26513016-1	2015	Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor (TKI), has been approved for HER2-positive breast cancer patients.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	52-56
26513016-1	2015	Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor (TKI), has been approved for HER2-positive breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
26484410-3	2015	METHODS: Patients with HER2 overexpressing OGA were treated for 10 days with Lapatinib monotherapy, and then in combination with three cycles of Oxaliplatin and Capecitabine before surgery.	Lapatinib	77-86	O-GlcNAcase	Homo sapiens	43-46
26513016-1	2015	Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor (TKI), has been approved for HER2-positive breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
26513016-4	2015	In this study, we explored that the level of interleukin-6 (IL-6) was elevated in lapatinib-treated TNBC cells.	Lapatinib	82-91	interleukin 6	Homo sapiens	45-58
26513016-4	2015	In this study, we explored that the level of interleukin-6 (IL-6) was elevated in lapatinib-treated TNBC cells.	Lapatinib	82-91	interleukin 6	Homo sapiens	60-64
26484410-8	2015	Proteomic analysis pre and post-Lapatinib demonstrated target inhibition (P-ERBB2, P-EGFR, P-PI3K, P-AKT, and P-ERK) that persisted until surgery.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	85-89
26484410-8	2015	Proteomic analysis pre and post-Lapatinib demonstrated target inhibition (P-ERBB2, P-EGFR, P-PI3K, P-AKT, and P-ERK) that persisted until surgery.	Lapatinib	32-41	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	110-115
26513016-5	2015	Treatment with IL-6 antibody abolished the lapatinib-induced migration.	Lapatinib	43-52	interleukin 6	Homo sapiens	15-19
26204261-4	2015	However, the functionally relevant HER2-HER3 complex has proven much more difficult to inhibit than had been anticipated, and because of its modest efficacy, the HER2 inhibitor lapatinib is currently used predominantly in combinations and in very advanced stages of disease.	Lapatinib	177-186	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
26513016-6	2015	Mechanistically, the signaling axis of Raf-1/mitogen-activated protein kinases (MAPKs), c-Jun N-terminal kinases (JNKs), p38 MAPK, and activator protein 1 (AP-1) was activated in response to lapatinib treatment to induce IL-6 expression.	Lapatinib	191-200	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	39-44
26513016-6	2015	Mechanistically, the signaling axis of Raf-1/mitogen-activated protein kinases (MAPKs), c-Jun N-terminal kinases (JNKs), p38 MAPK, and activator protein 1 (AP-1) was activated in response to lapatinib treatment to induce IL-6 expression.	Lapatinib	191-200	interleukin 6	Homo sapiens	221-225
26513016-8	2015	Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression.	Lapatinib	57-66	interleukin 6	Homo sapiens	30-34
26513016-8	2015	Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression.	Lapatinib	153-162	leukocyte immunoglobulin like receptor B1	Homo sapiens	124-128
26513016-8	2015	Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression.	Lapatinib	153-162	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	129-134
26513016-8	2015	Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression.	Lapatinib	153-162	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	140-144
26513016-8	2015	Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression.	Lapatinib	153-162	interleukin 6	Homo sapiens	171-175
26535009-6	2015	Pharmacological inhibition of the activity of SREBP site 1 protease or of all EGFR family members (with lapatinib), but not EGFR alone (with erlotinib), impaired NRG1-induced expression of cholesterol biosynthesis genes.	Lapatinib	104-113	epidermal growth factor receptor	Homo sapiens	78-82
26535009-6	2015	Pharmacological inhibition of the activity of SREBP site 1 protease or of all EGFR family members (with lapatinib), but not EGFR alone (with erlotinib), impaired NRG1-induced expression of cholesterol biosynthesis genes.	Lapatinib	104-113	neuregulin 1	Homo sapiens	162-166
26486732-2	2015	Reliable HER2 evaluation is central to determine the eligibility of patients with breast cancer to targeted anti-HER2 therapies such as trastuzumab and lapatinib.	Lapatinib	152-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
26486732-2	2015	Reliable HER2 evaluation is central to determine the eligibility of patients with breast cancer to targeted anti-HER2 therapies such as trastuzumab and lapatinib.	Lapatinib	152-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
27137717-1	2015	The potential for an interaction between lapatinib and absorption of the P-glycoprotein (ABCB1) substrate digoxin at a therapeutic dose in breast cancer patients was characterized.	Lapatinib	41-50	ATP binding cassette subfamily B member 1	Homo sapiens	89-94
27137717-5	2015	Lapatinib 1500 mg/day increased digoxin absorption approximately 80%, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	117-122
27137717-5	2015	Lapatinib 1500 mg/day increased digoxin absorption approximately 80%, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux.	Lapatinib	82-91	ATP binding cassette subfamily B member 1	Homo sapiens	117-122
27137717-6	2015	In summary, coadministration of lapatinib with narrow therapeutic index drugs that are substrates of ABCB1 should be undertaken with caution and dose adjustment should be considered.	Lapatinib	32-41	ATP binding cassette subfamily B member 1	Homo sapiens	101-106
26204261-4	2015	However, the functionally relevant HER2-HER3 complex has proven much more difficult to inhibit than had been anticipated, and because of its modest efficacy, the HER2 inhibitor lapatinib is currently used predominantly in combinations and in very advanced stages of disease.	Lapatinib	177-186	erb-b2 receptor tyrosine kinase 3	Homo sapiens	40-44
26204261-4	2015	However, the functionally relevant HER2-HER3 complex has proven much more difficult to inhibit than had been anticipated, and because of its modest efficacy, the HER2 inhibitor lapatinib is currently used predominantly in combinations and in very advanced stages of disease.	Lapatinib	177-186	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
26449765-11	2015	In a phase II trial of trastuzumab and lapatinib in a cetuximab-resistant population, HERACLES Diagnostic Criteria shaped the selection of patients and defined ERBB2 as a predictive marker for response to ERBB2-targeted therapy in metastatic colorectal cancer.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-165
26557900-3	2015	Recently, a number of novel HER2 targeted agents have become available, including lapatinib (a small molecule tyrosine kinase inhibitor of both HER2 and the epidermal growth factor receptor), pertuzumab (a new anti-HER2 monoclonal antibody) and ado-trastuzumab emtansine (T-DM1, a novel antibody-drug conjugate), which provide additional treatment options for patients with HER2+ MBC.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
26557906-0	2015	Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib.	Lapatinib	103-112	estrogen receptor 1	Homo sapiens	10-27
26557900-3	2015	Recently, a number of novel HER2 targeted agents have become available, including lapatinib (a small molecule tyrosine kinase inhibitor of both HER2 and the epidermal growth factor receptor), pertuzumab (a new anti-HER2 monoclonal antibody) and ado-trastuzumab emtansine (T-DM1, a novel antibody-drug conjugate), which provide additional treatment options for patients with HER2+ MBC.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
26557906-2	2015	The aim of this study was to investigate the role of estrogen receptor (ER) signaling compensatory activation in acquired resistance to lapatinib in breast cancer cells BT474 and the related mechanism.	Lapatinib	136-145	estrogen receptor 1	Homo sapiens	53-70
26557906-2	2015	The aim of this study was to investigate the role of estrogen receptor (ER) signaling compensatory activation in acquired resistance to lapatinib in breast cancer cells BT474 and the related mechanism.	Lapatinib	136-145	estrogen receptor 1	Homo sapiens	72-74
26557900-3	2015	Recently, a number of novel HER2 targeted agents have become available, including lapatinib (a small molecule tyrosine kinase inhibitor of both HER2 and the epidermal growth factor receptor), pertuzumab (a new anti-HER2 monoclonal antibody) and ado-trastuzumab emtansine (T-DM1, a novel antibody-drug conjugate), which provide additional treatment options for patients with HER2+ MBC.	Lapatinib	82-91	epidermal growth factor receptor	Homo sapiens	157-189
26557906-4	2015	Real-time polymerase chain reaction and Western blotting were used to determine the changes of human epidermal growth factor receptor (HER)2 and ER pathways in breast cancer cell BT474 after treatment with lapatinib and the distinction between BT474 and rBT474.	Lapatinib	206-215	epidermal growth factor receptor	Homo sapiens	101-133
26557900-3	2015	Recently, a number of novel HER2 targeted agents have become available, including lapatinib (a small molecule tyrosine kinase inhibitor of both HER2 and the epidermal growth factor receptor), pertuzumab (a new anti-HER2 monoclonal antibody) and ado-trastuzumab emtansine (T-DM1, a novel antibody-drug conjugate), which provide additional treatment options for patients with HER2+ MBC.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
26557906-4	2015	Real-time polymerase chain reaction and Western blotting were used to determine the changes of human epidermal growth factor receptor (HER)2 and ER pathways in breast cancer cell BT474 after treatment with lapatinib and the distinction between BT474 and rBT474.	Lapatinib	206-215	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-140
26557906-4	2015	Real-time polymerase chain reaction and Western blotting were used to determine the changes of human epidermal growth factor receptor (HER)2 and ER pathways in breast cancer cell BT474 after treatment with lapatinib and the distinction between BT474 and rBT474.	Lapatinib	206-215	estrogen receptor 1	Homo sapiens	136-138
26557906-6	2015	RESULTS: Lapatinib could inhibit phosphorylation of HER2 and induce expression of forkhead-box protein O3a and progesterone receptor.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
26557906-11	2015	CONCLUSION: ER signaling compensatory activation may partly contribute to lapatinib acquired resistance in HER2-overexpressing/ERalpha-positive breast cancer cells, which might be related to PI3K/AKT inhibition and MAPK pathway activation.	Lapatinib	74-83	estrogen receptor 1	Homo sapiens	12-14
26557906-11	2015	CONCLUSION: ER signaling compensatory activation may partly contribute to lapatinib acquired resistance in HER2-overexpressing/ERalpha-positive breast cancer cells, which might be related to PI3K/AKT inhibition and MAPK pathway activation.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
26557906-11	2015	CONCLUSION: ER signaling compensatory activation may partly contribute to lapatinib acquired resistance in HER2-overexpressing/ERalpha-positive breast cancer cells, which might be related to PI3K/AKT inhibition and MAPK pathway activation.	Lapatinib	74-83	estrogen receptor 1	Homo sapiens	127-134
26557900-3	2015	Recently, a number of novel HER2 targeted agents have become available, including lapatinib (a small molecule tyrosine kinase inhibitor of both HER2 and the epidermal growth factor receptor), pertuzumab (a new anti-HER2 monoclonal antibody) and ado-trastuzumab emtansine (T-DM1, a novel antibody-drug conjugate), which provide additional treatment options for patients with HER2+ MBC.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
26557906-11	2015	CONCLUSION: ER signaling compensatory activation may partly contribute to lapatinib acquired resistance in HER2-overexpressing/ERalpha-positive breast cancer cells, which might be related to PI3K/AKT inhibition and MAPK pathway activation.	Lapatinib	74-83	AKT serine/threonine kinase 1	Homo sapiens	196-199
26430732-0	2015	t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
26430732-7	2015	Lapatinib-resistant SKBR3 cells (SK/LapR) showed a marked change in the Darpp-32:t-Darpp ratio toward a predominance of t-Darpp.	Lapatinib	0-9	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	72-80
25619841-6	2015	CT8 treatment suppresses the induction of HER3 that accompanies lapatinib treatment of HER2-amplified cancers and synergistically enhances the apoptotic effects of lapatinib.	Lapatinib	64-73	leucine zipper protein 4	Homo sapiens	0-3
26461093-3	2015	We found that an epigenetic pathway involving MLL2 is crucial for growth of HER2(+) cells and MLL2 reduces sensitivity of the cancer cells to a HER2 inhibitor, lapatinib.	Lapatinib	160-169	lysine methyltransferase 2D	Homo sapiens	46-50
26461093-3	2015	We found that an epigenetic pathway involving MLL2 is crucial for growth of HER2(+) cells and MLL2 reduces sensitivity of the cancer cells to a HER2 inhibitor, lapatinib.	Lapatinib	160-169	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
26461093-3	2015	We found that an epigenetic pathway involving MLL2 is crucial for growth of HER2(+) cells and MLL2 reduces sensitivity of the cancer cells to a HER2 inhibitor, lapatinib.	Lapatinib	160-169	lysine methyltransferase 2D	Homo sapiens	94-98
26461093-3	2015	We found that an epigenetic pathway involving MLL2 is crucial for growth of HER2(+) cells and MLL2 reduces sensitivity of the cancer cells to a HER2 inhibitor, lapatinib.	Lapatinib	160-169	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
26461093-4	2015	Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib.	Lapatinib	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104
26461093-4	2015	Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib.	Lapatinib	0-9	lysine methyltransferase 2D	Homo sapiens	149-153
26461093-4	2015	Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib.	Lapatinib	233-242	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104
26461093-4	2015	Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib.	Lapatinib	233-242	lysine methyltransferase 2D	Homo sapiens	149-153
26461093-5	2015	An epigenetic inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.	Lapatinib	58-67	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	36-41
26461093-5	2015	An epigenetic inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.	Lapatinib	58-67	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	133-138
26461093-5	2015	An epigenetic inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.	Lapatinib	58-67	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	133-138
25619841-6	2015	CT8 treatment suppresses the induction of HER3 that accompanies lapatinib treatment of HER2-amplified cancers and synergistically enhances the apoptotic effects of lapatinib.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 3	Homo sapiens	42-46
25619841-6	2015	CT8 treatment suppresses the induction of HER3 that accompanies lapatinib treatment of HER2-amplified cancers and synergistically enhances the apoptotic effects of lapatinib.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
25619841-6	2015	CT8 treatment suppresses the induction of HER3 that accompanies lapatinib treatment of HER2-amplified cancers and synergistically enhances the apoptotic effects of lapatinib.	Lapatinib	164-173	leucine zipper protein 4	Homo sapiens	0-3
26442201-3	2015	Currently, the therapeutic drugs trastuzumab and lapatinib are the most commonly used to combat HER2+ breast cancer.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
26960462-0	2015	Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-46
26320173-9	2015	RUNX2 expression also increased HER2-mediated tumorsphere size, which was reduced after treatment with the HER2-targeting agents Herceptin and lapatinib.	Lapatinib	143-152	RUNX family transcription factor 2	Homo sapiens	0-5
26320173-9	2015	RUNX2 expression also increased HER2-mediated tumorsphere size, which was reduced after treatment with the HER2-targeting agents Herceptin and lapatinib.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
26227488-10	2015	Furthermore, recapitulation of EGFR in miR-124-overexpressing SCC15 cells was sufficient to completely block the antiproliferative effects of lapatinib and afatinib.	Lapatinib	142-151	epidermal growth factor receptor	Homo sapiens	31-35
26227488-10	2015	Furthermore, recapitulation of EGFR in miR-124-overexpressing SCC15 cells was sufficient to completely block the antiproliferative effects of lapatinib and afatinib.	Lapatinib	142-151	membrane associated ring-CH-type finger 8	Homo sapiens	39-42
26320173-9	2015	RUNX2 expression also increased HER2-mediated tumorsphere size, which was reduced after treatment with the HER2-targeting agents Herceptin and lapatinib.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
26210681-1	2015	PURPOSE: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine kinases including c-Met through, plausibly, network inhibition effects.	Lapatinib	34-43	fms related receptor tyrosine kinase 1	Homo sapiens	143-156
26405815-6	2015	Layered over base-line resistance was substantial upregulation of many ErbB pathway genes in response to BRaf inhibition, thus generating the vulnerability to combination with lapatinib.	Lapatinib	176-185	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	105-109
26210681-1	2015	PURPOSE: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine kinases including c-Met through, plausibly, network inhibition effects.	Lapatinib	34-43	platelet derived growth factor receptor beta	Homo sapiens	158-163
26210681-1	2015	PURPOSE: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine kinases including c-Met through, plausibly, network inhibition effects.	Lapatinib	34-43	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	168-173
26210681-1	2015	PURPOSE: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine kinases including c-Met through, plausibly, network inhibition effects.	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	187-191
26210681-1	2015	PURPOSE: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine kinases including c-Met through, plausibly, network inhibition effects.	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	144-148
25700774-0	2015	Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.	Lapatinib	17-26	thymidylate synthetase	Homo sapiens	165-185
26210681-1	2015	PURPOSE: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine kinases including c-Met through, plausibly, network inhibition effects.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	201-205
25700774-1	2015	INTRODUCTION: Lapatinib is a dual tyrosine kinase inhibitor that targets epidermal growth factor receptor and HER2.	Lapatinib	14-23	epidermal growth factor receptor	Homo sapiens	73-105
26210681-1	2015	PURPOSE: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine kinases including c-Met through, plausibly, network inhibition effects.	Lapatinib	34-43	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	264-269
25700774-1	2015	INTRODUCTION: Lapatinib is a dual tyrosine kinase inhibitor that targets epidermal growth factor receptor and HER2.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
26099744-5	2015	In breast cancer, this potent signature has directed women to anti-HER2-targeted therapies such as trastuzumab and lapatinib.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
26015514-6	2015	In the neoadjuvant clinical study, lapatinib treatment for 2 weeks was associated with parallel upregulation of ER and Bcl2 (Spearman coefficient: 0.70; P = 0.0002).	Lapatinib	35-44	estrogen receptor 1	Homo sapiens	112-114
26015514-6	2015	In the neoadjuvant clinical study, lapatinib treatment for 2 weeks was associated with parallel upregulation of ER and Bcl2 (Spearman coefficient: 0.70; P = 0.0002).	Lapatinib	35-44	BCL2 apoptosis regulator	Homo sapiens	119-123
26169615-0	2015	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).	Lapatinib	18-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-117
26245675-8	2015	For patients receiving trastuzumab plus lapatinib, the probability of pCR was higher in PIK3CA wild-type tumors (48.4% vs. 12.5%; p = .06).	Lapatinib	40-49	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	88-94
26152725-5	2015	Moreover, HER2-directed drugs such as trastuzumab and lapatinib as well as depletion of HER2 or HER3 stimulated MLK3 kinase activity in HER2+ breast cancer cell lines.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
26152725-5	2015	Moreover, HER2-directed drugs such as trastuzumab and lapatinib as well as depletion of HER2 or HER3 stimulated MLK3 kinase activity in HER2+ breast cancer cell lines.	Lapatinib	54-63	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	112-116
26317614-14	2015	A similar effect was observed upon knockdown of ERBB2/3 and exposure to lapatinib, implying that BCAR4 acts in an ERBB2/3-dependent manner.	Lapatinib	72-81	breast cancer anti-estrogen resistance 4	Homo sapiens	97-102
26317614-14	2015	A similar effect was observed upon knockdown of ERBB2/3 and exposure to lapatinib, implying that BCAR4 acts in an ERBB2/3-dependent manner.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
26317614-16	2015	Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts BCAR4-driven tumor cell growth, a clinical relevant observation.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	33-37
26317614-16	2015	Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts BCAR4-driven tumor cell growth, a clinical relevant observation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-43
26317614-16	2015	Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts BCAR4-driven tumor cell growth, a clinical relevant observation.	Lapatinib	0-9	breast cancer anti-estrogen resistance 4	Homo sapiens	67-72
26713522-7	2015	RESULTS: The combination of lapatinib and chlorogenic acid inhibited the expression of CD206 induced by IL-13[(42.17%+-2.59%) vs (61.15%+-7.58%), P<0.05].	Lapatinib	28-37	mannose receptor, C type 1	Mus musculus	87-92
26713522-7	2015	RESULTS: The combination of lapatinib and chlorogenic acid inhibited the expression of CD206 induced by IL-13[(42.17%+-2.59%) vs (61.15%+-7.58%), P<0.05].	Lapatinib	28-37	interleukin 13	Mus musculus	104-109
26713522-9	2015	The combination of lapatinib and chlorogenic acid significantly reduced metastatic nodes in lung[P<0.05], and also significantly decreased the percentage of CD206(+) cells in breast cancer compared to controls[(6.08%+-2.60%) vs(29.04%+-5.86%), P<0.05].	Lapatinib	19-28	mannose receptor, C type 1	Mus musculus	160-165
26152725-6	2015	In addition, the noted inhibitory effect of HER2 on MLK3 kinase activity was mediated via its phosphorylation on Ser(674) by AKT and that pharmacological inhibitors of PI3K/AKT prevented trastuzumab- and lapatinib-induced stimulation of MLK3 activity.	Lapatinib	204-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
26152725-6	2015	In addition, the noted inhibitory effect of HER2 on MLK3 kinase activity was mediated via its phosphorylation on Ser(674) by AKT and that pharmacological inhibitors of PI3K/AKT prevented trastuzumab- and lapatinib-induced stimulation of MLK3 activity.	Lapatinib	204-213	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	52-56
26152725-6	2015	In addition, the noted inhibitory effect of HER2 on MLK3 kinase activity was mediated via its phosphorylation on Ser(674) by AKT and that pharmacological inhibitors of PI3K/AKT prevented trastuzumab- and lapatinib-induced stimulation of MLK3 activity.	Lapatinib	204-213	AKT serine/threonine kinase 1	Homo sapiens	125-128
26152725-6	2015	In addition, the noted inhibitory effect of HER2 on MLK3 kinase activity was mediated via its phosphorylation on Ser(674) by AKT and that pharmacological inhibitors of PI3K/AKT prevented trastuzumab- and lapatinib-induced stimulation of MLK3 activity.	Lapatinib	204-213	AKT serine/threonine kinase 1	Homo sapiens	173-176
26152725-7	2015	Consistent with the pro-apoptotic function of MLK3, stable knockdown of MLK3 in the HER2+ cell line blunted the pro-apoptotic effects of trastuzumab and lapatinib.	Lapatinib	153-162	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	72-76
26152725-7	2015	Consistent with the pro-apoptotic function of MLK3, stable knockdown of MLK3 in the HER2+ cell line blunted the pro-apoptotic effects of trastuzumab and lapatinib.	Lapatinib	153-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
26169615-1	2015	PURPOSE: Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-145
26169615-12	2015	CONCLUSION: Early use of lapatinib and trastuzumab is active in human epidermal growth factor receptor 2-positive MBC.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-104
26270481-6	2015	For drug repurposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progression-free survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed HER2.	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	25-29
26270481-6	2015	For drug repurposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progression-free survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed HER2.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
26270481-6	2015	For drug repurposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progression-free survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed HER2.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	276-280
26086099-10	2015	Furthermore, lapatinib, an inhibitor of both ErbB1 and ErbB2, effectively masked the effect of TSA on the inhibition of A549 cell proliferation and migration, suggesting TSA does work, at least in part, by downregulating ErbB receptors.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Mus musculus	55-60
26063481-0	2015	Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1.	Lapatinib	0-9	ATP binding cassette subfamily C member 1	Homo sapiens	109-150
26238995-5	2015	METHODS: In order to further understand the molecular mechanisms of treatment-response with HER2-inhibitors, we used a highly-optimised and reproducible quantitative label-free LC-MS strategy to characterize the proteomes of HER2-overexpressing breast-cancer cell-lines (SKBR3, BT474 and HCC1954) in response to drug-treatment with HER2-inhibitors (lapatinib, neratinib or afatinib).	Lapatinib	349-358	erb-b2 receptor tyrosine kinase 2	Homo sapiens	225-229
26238995-5	2015	METHODS: In order to further understand the molecular mechanisms of treatment-response with HER2-inhibitors, we used a highly-optimised and reproducible quantitative label-free LC-MS strategy to characterize the proteomes of HER2-overexpressing breast-cancer cell-lines (SKBR3, BT474 and HCC1954) in response to drug-treatment with HER2-inhibitors (lapatinib, neratinib or afatinib).	Lapatinib	349-358	erb-b2 receptor tyrosine kinase 2	Homo sapiens	225-229
26238995-6	2015	RESULTS: Following 12 ours treatment with different HER2-inhibitors in the BT474 cell-line; compared to the untreated cells, 16 proteins changed significantly in abundance following lapatinib treatment (1 muM), 21 proteins changed significantly following neratinib treatment (150 nM) and 38 proteins changed significantly following afatinib treatment (150 nM).	Lapatinib	182-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
26238995-6	2015	RESULTS: Following 12 ours treatment with different HER2-inhibitors in the BT474 cell-line; compared to the untreated cells, 16 proteins changed significantly in abundance following lapatinib treatment (1 muM), 21 proteins changed significantly following neratinib treatment (150 nM) and 38 proteins changed significantly following afatinib treatment (150 nM).	Lapatinib	182-191	latexin	Homo sapiens	205-208
26081723-5	2015	Lapatinib, an EGFR and an HER2 inhibitor, reversed the activation of ERK1/2 by inhibiting the phosphorylation of EGFR and HER2 and cancelled the resistance.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	14-18
26081723-5	2015	Lapatinib, an EGFR and an HER2 inhibitor, reversed the activation of ERK1/2 by inhibiting the phosphorylation of EGFR and HER2 and cancelled the resistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
26081723-5	2015	Lapatinib, an EGFR and an HER2 inhibitor, reversed the activation of ERK1/2 by inhibiting the phosphorylation of EGFR and HER2 and cancelled the resistance.	Lapatinib	0-9	mitogen-activated protein kinase 3	Homo sapiens	69-75
26081723-5	2015	Lapatinib, an EGFR and an HER2 inhibitor, reversed the activation of ERK1/2 by inhibiting the phosphorylation of EGFR and HER2 and cancelled the resistance.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	113-117
26081723-5	2015	Lapatinib, an EGFR and an HER2 inhibitor, reversed the activation of ERK1/2 by inhibiting the phosphorylation of EGFR and HER2 and cancelled the resistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
26081723-6	2015	The combination of trametinib and lapatinib synergistically inhibited the cell growth of the OCUM-1 cell line and strongly induced apoptosis by inhibiting the activated EGFR and HER2 signals.	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	169-173
26081723-6	2015	The combination of trametinib and lapatinib synergistically inhibited the cell growth of the OCUM-1 cell line and strongly induced apoptosis by inhibiting the activated EGFR and HER2 signals.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	178-182
26081723-8	2015	Moreover, combination therapy with trametinib and lapatinib can exhibit a synergistic effect and may contribute to overcoming the resistance to MEK inhibitors.	Lapatinib	50-59	mitogen-activated protein kinase kinase 7	Homo sapiens	144-147
26281684-2	2015	PIK3CA mutations are the predictive markers for anti-EGFR antibodies, trastuzumab, and lapatinib.	Lapatinib	87-96	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-6
25981168-4	2015	We found that combined treatment with EGFR TKIs (erlotinib, gefitinib, or lapatinib) and vATPase inhibitors (bafilomycin A1 or concanamycin A) enhanced synergistic cell death compared to treatments with each drug alone.	Lapatinib	74-83	epidermal growth factor receptor	Homo sapiens	38-42
25953157-3	2015	RESULTS: HER2 dual blockade with trastuzumab and lapatinib as third-line therapy led to complete metabolic response in 2 weeks and confirmed radiological partial response after 8 weeks.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
26063481-7	2015	Western blot analysis revealed that lapatinib inhibited the phosphorylation of EGFR, AKT and p38 in doxorubicin-treated tumorspheres.	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	79-83
26063481-7	2015	Western blot analysis revealed that lapatinib inhibited the phosphorylation of EGFR, AKT and p38 in doxorubicin-treated tumorspheres.	Lapatinib	36-45	AKT serine/threonine kinase 1	Homo sapiens	85-88
26063481-7	2015	Western blot analysis revealed that lapatinib inhibited the phosphorylation of EGFR, AKT and p38 in doxorubicin-treated tumorspheres.	Lapatinib	36-45	mitogen-activated protein kinase 14	Homo sapiens	93-96
26063481-8	2015	The inhibition of EGFR signaling by the treatment with lapatinib suppressed the expression of multidrug resistance-associated protein-1 (MRP-1), leading to increased cytotoxicity of doxorubicin to tumorspheres.	Lapatinib	55-64	epidermal growth factor receptor	Homo sapiens	18-22
26063481-8	2015	The inhibition of EGFR signaling by the treatment with lapatinib suppressed the expression of multidrug resistance-associated protein-1 (MRP-1), leading to increased cytotoxicity of doxorubicin to tumorspheres.	Lapatinib	55-64	ATP binding cassette subfamily C member 1	Homo sapiens	94-135
26063481-8	2015	The inhibition of EGFR signaling by the treatment with lapatinib suppressed the expression of multidrug resistance-associated protein-1 (MRP-1), leading to increased cytotoxicity of doxorubicin to tumorspheres.	Lapatinib	55-64	ATP binding cassette subfamily C member 1	Homo sapiens	137-142
26063481-10	2015	These results demonstrate that lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting doxorubicin-induced MRP-1 expression via PI3K/AKT and p38 MAPK signaling pathways.	Lapatinib	31-40	ATP binding cassette subfamily C member 1	Homo sapiens	142-147
26063481-10	2015	These results demonstrate that lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting doxorubicin-induced MRP-1 expression via PI3K/AKT and p38 MAPK signaling pathways.	Lapatinib	31-40	AKT serine/threonine kinase 1	Homo sapiens	168-171
26063481-10	2015	These results demonstrate that lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting doxorubicin-induced MRP-1 expression via PI3K/AKT and p38 MAPK signaling pathways.	Lapatinib	31-40	mitogen-activated protein kinase 14	Homo sapiens	176-179
26181325-3	2015	We observed that combinations of lapatinib plus AKTi were synergistic in HER2(+)/PIK3CA(mut) cell lines but not in HER2(+)/PIK3CA(wt) cell lines.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
26710948-0	2015	[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance].	Lapatinib	51-60	phosphatase and tensin homolog	Homo sapiens	1-5
25347743-5	2015	Thus, Ras-MAPK cytostatic signaling delays HER2 tumor initiation and increases LPN cytotoxicity in Fer-deficient model systems.	Lapatinib	79-82	fer (fms/fps related) protein kinase	Mus musculus	99-102
25347743-6	2015	Taken together, these data suggest that targeting Fer alone, or in combination with LPN, may be of therapeutic benefit in HER2(+) breast cancer.	Lapatinib	84-87	erb-b2 receptor tyrosine kinase 2	Mus musculus	122-126
26181325-3	2015	We observed that combinations of lapatinib plus AKTi were synergistic in HER2(+)/PIK3CA(mut) cell lines but not in HER2(+)/PIK3CA(wt) cell lines.	Lapatinib	33-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	81-87
25398453-11	2015	Whereas Ki67 reduction with lapatinib was greatest in HER2(+) breast cancer (-46%; P = 0.003), there was a significant Ki67 decrease in HER2(-) breast cancer (-27%; P = 0.017) with 14% of HER2(-) breast cancer demonstrating >=50% Ki67 reduction with lapatinib.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
26181325-5	2015	This revealed that p-S6RP levels were less well attenuated by lapatinib in HER2(+)/PIK3CA(mut) cells compared to HER2(+)/PIK3CAwt cells and that lapatinib + AKTi reduced p-S6RP levels to those achieved in HER2(+)/PIK3CA(wt) cells with lapatinib alone.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
26181325-5	2015	This revealed that p-S6RP levels were less well attenuated by lapatinib in HER2(+)/PIK3CA(mut) cells compared to HER2(+)/PIK3CAwt cells and that lapatinib + AKTi reduced p-S6RP levels to those achieved in HER2(+)/PIK3CA(wt) cells with lapatinib alone.	Lapatinib	62-71	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	83-89
26181325-6	2015	We also found that that compensatory up-regulation of p-HER3 and p-HER2 is blunted in PIK3CA(mut) cells following lapatinib + AKTi treatment.	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 3	Homo sapiens	56-60
26181325-6	2015	We also found that that compensatory up-regulation of p-HER3 and p-HER2 is blunted in PIK3CA(mut) cells following lapatinib + AKTi treatment.	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
26181325-6	2015	We also found that that compensatory up-regulation of p-HER3 and p-HER2 is blunted in PIK3CA(mut) cells following lapatinib + AKTi treatment.	Lapatinib	114-123	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	86-92
26181325-8	2015	We used a nonlinear ordinary differential equation model to support the idea that PIK3CA mutations act as downstream activators of AKT that blunt lapatinib inhibition of downstream AKT signaling and that the effects of PIK3CA mutations can be countered by combining lapatinib with an AKTi.	Lapatinib	146-155	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	82-88
26181325-8	2015	We used a nonlinear ordinary differential equation model to support the idea that PIK3CA mutations act as downstream activators of AKT that blunt lapatinib inhibition of downstream AKT signaling and that the effects of PIK3CA mutations can be countered by combining lapatinib with an AKTi.	Lapatinib	146-155	AKT serine/threonine kinase 1	Homo sapiens	131-134
26181325-8	2015	We used a nonlinear ordinary differential equation model to support the idea that PIK3CA mutations act as downstream activators of AKT that blunt lapatinib inhibition of downstream AKT signaling and that the effects of PIK3CA mutations can be countered by combining lapatinib with an AKTi.	Lapatinib	146-155	AKT serine/threonine kinase 1	Homo sapiens	181-184
26181325-8	2015	We used a nonlinear ordinary differential equation model to support the idea that PIK3CA mutations act as downstream activators of AKT that blunt lapatinib inhibition of downstream AKT signaling and that the effects of PIK3CA mutations can be countered by combining lapatinib with an AKTi.	Lapatinib	266-275	AKT serine/threonine kinase 1	Homo sapiens	131-134
26036634-1	2015	Lapatinib has been used in combination with capecitabine or paclitaxel to treat patients with progressive HER2-overexpressing metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
26036634-5	2015	Lapatinib was shown to increase the accumulation of doxorubicin in ABCB1-overexpressing hepatocellular cancer cells and normal liver tissues without altering the protein level of ABCB1.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	67-72
26036634-8	2015	Our study thus revealed for the first time that the higher incidence of hepatotoxicity during this combinational treatment was due to the increased drug accumulation in hepatocytes mediated by the inhibition of ABCB1 by lapatinib.	Lapatinib	220-229	ATP binding cassette subfamily B member 1	Homo sapiens	211-216
26036637-3	2015	Our results showed that pre-treatment of MCF-7 and MDA-MB-468 cells with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib or lapatinib significantly enhanced the cytotoxic effects of DNA-damaging agents compared to coadministration of the EGFR inhibitor and DNA-damaging agent.	Lapatinib	152-161	epidermal growth factor receptor	Homo sapiens	266-270
26124325-7	2015	The aim of the study was to investigate the expression pattern of specific markers in p16-positive SCC cells after stimulation with lapatinib and gefitinib.	Lapatinib	132-141	cyclin dependent kinase inhibitor 2A	Homo sapiens	86-89
26124325-8	2015	MATERIALS AND METHODS: We incubated p16-positive CERV196 cells with lapatinib and gefitinib (2 mug/ml) and after 5, 24 and 96 h determined E-cadherin, vimentin, matrix metalloproteinase-9 (MMP9), cyclin D1 and beta-catenin by immunocytochemistry, enzyme-linked immunosorbent assay and quantitative polymerase chain reaction (PCR).	Lapatinib	68-77	cyclin dependent kinase inhibitor 2A	Homo sapiens	36-39
26124325-10	2015	We detected an alteration of expression of vimentin and E-cadherin level after treatment with lapatinib and gefitinib.	Lapatinib	94-103	vimentin	Homo sapiens	43-51
26124325-10	2015	We detected an alteration of expression of vimentin and E-cadherin level after treatment with lapatinib and gefitinib.	Lapatinib	94-103	cadherin 1	Homo sapiens	56-66
26124325-11	2015	We demonstrated a statistically significant lapatinib- and gefitinib-induced repression of cyclin D1, MMP9 and beta-catenin in CERV196 cells dependent on incubation time.	Lapatinib	44-53	cyclin D1	Homo sapiens	91-100
26124325-11	2015	We demonstrated a statistically significant lapatinib- and gefitinib-induced repression of cyclin D1, MMP9 and beta-catenin in CERV196 cells dependent on incubation time.	Lapatinib	44-53	matrix metallopeptidase 9	Homo sapiens	102-106
26124325-11	2015	We demonstrated a statistically significant lapatinib- and gefitinib-induced repression of cyclin D1, MMP9 and beta-catenin in CERV196 cells dependent on incubation time.	Lapatinib	44-53	catenin beta 1	Homo sapiens	111-123
26124325-12	2015	CONCLUSION: Cyclin D1 and MMP9 expression profiles may represent an early measure of sensitivity and level of response to lapatinib and gefitinib.	Lapatinib	122-131	cyclin D1	Homo sapiens	12-21
26124325-12	2015	CONCLUSION: Cyclin D1 and MMP9 expression profiles may represent an early measure of sensitivity and level of response to lapatinib and gefitinib.	Lapatinib	122-131	matrix metallopeptidase 9	Homo sapiens	26-30
25711535-4	2015	FMC lines K12 and K248 expressing HER1, HER2, and HER3 were sensitive to receptor tyrosine kinase (RTK) inhibitors gefitinib and lapatinib.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Felis catus	40-44
25711535-4	2015	FMC lines K12 and K248 expressing HER1, HER2, and HER3 were sensitive to receptor tyrosine kinase (RTK) inhibitors gefitinib and lapatinib.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 3	Mus musculus	50-54
26710948-0	2015	[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance].	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
26710948-1	2015	OBJECTIVE: To discuss the indexes related to the efficacy of lapatinib after failure in trastuzumab in HER2-positive metastatic breast cancer (MBC) such as the status of PTEN, p-4EBP1 and clinical features.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
26710948-1	2015	OBJECTIVE: To discuss the indexes related to the efficacy of lapatinib after failure in trastuzumab in HER2-positive metastatic breast cancer (MBC) such as the status of PTEN, p-4EBP1 and clinical features.	Lapatinib	61-70	phosphatase and tensin homolog	Homo sapiens	170-174
26710948-5	2015	RESULTS: In all patients, themedian progression free survival (PFS), ORR and CBR was 4.6 months, 36.7% and 50.0% respectively.Univariate analysis revealed that lapatinib-treated patients with PTEN loss (P = 0.015) and liver metastasis (P = 0.02) had significantly shorter median PFS.	Lapatinib	160-169	phosphatase and tensin homolog	Homo sapiens	192-196
26710948-7	2015	CONCLUSION: HER2-positive MBC with trastuzumab-resistance could benefit from lapatinib regimen.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
26710948-8	2015	PTEN statusand liver metastasis couldpredict theclinical efficacyof subsequent lapatinib therapy.	Lapatinib	79-88	phosphatase and tensin homolog	Homo sapiens	0-4
25825476-1	2015	PURPOSE: Dual anti-HER2 blockade with trastuzumab/pertuzumab or trastuzumab/lapatinib in combination with anthracycline/taxane-based chemotherapy can reach pathologic complete response (pCR) rates of up to 60% in HER2-positive breast cancer.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	213-217
25398453-15	2015	CONCLUSIONS: Lapatinib has antiproliferative effects in a subgroup of HER2(-) nonamplified tumors characterized by high HER3 expression.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
25398453-15	2015	CONCLUSIONS: Lapatinib has antiproliferative effects in a subgroup of HER2(-) nonamplified tumors characterized by high HER3 expression.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 3	Homo sapiens	120-124
25398453-16	2015	The possible role of high HER2:HER3 heterodimers in predicting response to lapatinib merits investigation in HER2(-) tumors.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
25398453-16	2015	The possible role of high HER2:HER3 heterodimers in predicting response to lapatinib merits investigation in HER2(-) tumors.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 3	Homo sapiens	31-35
25398453-16	2015	The possible role of high HER2:HER3 heterodimers in predicting response to lapatinib merits investigation in HER2(-) tumors.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
25748080-5	2015	Metastatic "de novo" HER2 Luminal (co-expression of HER2 and hormone receptors) Patients are eligible for anastrozole and trastuzumab but if pretreated with trastuzumab they are also eligible for lapatinib and letrozole.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
25545366-0	2015	miR-1470 mediates lapatinib induced p27 upregulation by targeting c-jun.	Lapatinib	18-27	microRNA 1470	Homo sapiens	0-8
25545366-0	2015	miR-1470 mediates lapatinib induced p27 upregulation by targeting c-jun.	Lapatinib	18-27	interferon alpha inducible protein 27	Homo sapiens	36-39
25545366-0	2015	miR-1470 mediates lapatinib induced p27 upregulation by targeting c-jun.	Lapatinib	18-27	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-71
25545366-1	2015	Our previous study indicated that lapatinib induces p27-dependent G(1) arrest through both transcriptional and post-translational mechanisms.	Lapatinib	34-43	interferon alpha inducible protein 27	Homo sapiens	52-55
25545366-2	2015	Using miRNA microarray technology and quantitative RT-PCR, we further investigated the potential miRNAs that involved in p27 upregulation and Her-2 signaling pathway alteration with lapatinib treatment.	Lapatinib	182-191	interferon alpha inducible protein 27	Homo sapiens	121-124
25545366-2	2015	Using miRNA microarray technology and quantitative RT-PCR, we further investigated the potential miRNAs that involved in p27 upregulation and Her-2 signaling pathway alteration with lapatinib treatment.	Lapatinib	182-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-147
25545366-7	2015	Taken together, the present study provided the first evidences that miR-1470 mediated lapatinib induced p27 upregulation by targeting c-jun.	Lapatinib	86-95	microRNA 1470	Homo sapiens	68-76
25545366-7	2015	Taken together, the present study provided the first evidences that miR-1470 mediated lapatinib induced p27 upregulation by targeting c-jun.	Lapatinib	86-95	interferon alpha inducible protein 27	Homo sapiens	104-107
25545366-7	2015	Taken together, the present study provided the first evidences that miR-1470 mediated lapatinib induced p27 upregulation by targeting c-jun.	Lapatinib	86-95	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	134-139
26181252-0	2015	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.	Lapatinib	164-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
25876877-0	2015	The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 3	Homo sapiens	4-9
26181274-1	2015	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.	Lapatinib	164-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
25876877-0	2015	The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.	Lapatinib	41-50	proliferation-associated 2G4	Homo sapiens	26-30
25876877-3	2015	We therefore examined the effects of EBP1 expression on the response to the ErbB1/2 tyrosine kinase inhibitor lapatinib.	Lapatinib	110-119	proliferation-associated 2G4	Homo sapiens	37-41
25876877-4	2015	We found a negative correlation between endogenous EBP1 levels and lapatinib sensitivity in prostate cancer cell lines.	Lapatinib	67-76	proliferation-associated 2G4	Homo sapiens	51-55
25876877-6	2015	Silencing EBP1 expression increased lapatinib sensitivity and overexpression of EBP1 increased resistance in androgen-containing media.	Lapatinib	36-45	proliferation-associated 2G4	Homo sapiens	10-14
25876877-7	2015	Androgen depletion resulted in an increased sensitivity of androgen-dependent EBP1 expressing cells to lapatinib, but did not affect the lapatinib sensitivity of hormone resistant cells.	Lapatinib	103-112	proliferation-associated 2G4	Homo sapiens	78-82
25876877-8	2015	However, EBP1 silenced cells were still more sensitive to lapatinib than EBP1-expressing cells in the absence of androgens.	Lapatinib	58-67	proliferation-associated 2G4	Homo sapiens	9-13
25876877-9	2015	The increase in sensitivity to lapatinib following EBP1 silencing was associated with increased ErbB2 levels.	Lapatinib	31-40	proliferation-associated 2G4	Homo sapiens	51-55
25876877-9	2015	The increase in sensitivity to lapatinib following EBP1 silencing was associated with increased ErbB2 levels.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-101
25876877-10	2015	In addition, lapatinib treatment increased ErbB2 levels in sensitive cells that express low levels of EBP1, but decreased ErbB2 levels in resistant EBP1-expressing cells.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-48
25876877-10	2015	In addition, lapatinib treatment increased ErbB2 levels in sensitive cells that express low levels of EBP1, but decreased ErbB2 levels in resistant EBP1-expressing cells.	Lapatinib	13-22	proliferation-associated 2G4	Homo sapiens	102-106
25876877-10	2015	In addition, lapatinib treatment increased ErbB2 levels in sensitive cells that express low levels of EBP1, but decreased ErbB2 levels in resistant EBP1-expressing cells.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-127
25876877-10	2015	In addition, lapatinib treatment increased ErbB2 levels in sensitive cells that express low levels of EBP1, but decreased ErbB2 levels in resistant EBP1-expressing cells.	Lapatinib	13-22	proliferation-associated 2G4	Homo sapiens	148-152
25876877-14	2015	These studies suggest that the ability of EBP1 to activate ErbB2 signaling pathways results in increased lapatinib sensitivity.	Lapatinib	105-114	proliferation-associated 2G4	Homo sapiens	42-46
25876877-14	2015	These studies suggest that the ability of EBP1 to activate ErbB2 signaling pathways results in increased lapatinib sensitivity.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-64
26107737-2	2015	The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical HER2+ breast cancer models of trastuzumab and lapatinib resistance.	Lapatinib	188-197	fatty acid synthase	Homo sapiens	32-36
26107737-3	2015	We developed and molecularly characterized in vitro HER2+ models of resistance to trastuzumab (SKTR), lapatinib (SKLR) and both (SKLTR).	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
26107737-9	2015	In vitro, anti-FASN compounds plus pertuzumab showed synergistic interactions in lapatinib- and dual- resistant cells and improved the results of pertuzumab plus trastuzumab co-treatment.	Lapatinib	81-90	fatty acid synthase	Homo sapiens	15-19
26098642-1	2015	Idiosyncratic lapatinib-induced liver injury has been reported to be associated with human leukocyte antigen (HLA)-DRB1*07:01.	Lapatinib	14-23	major histocompatibility complex, class II, DR beta 1	Homo sapiens	91-119
26084280-0	2015	PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.	Lapatinib	38-47	protein tyrosine kinase 6	Homo sapiens	0-4
26084280-0	2015	PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
26084280-0	2015	PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.	Lapatinib	38-47	BCL2 like 11	Homo sapiens	98-101
26084280-3	2015	We hypothesized that PTK6 inhibition is an effective strategy to inhibit growth and survival of Her2(+) breast cancer cells, including those that are relatively resistant to Lapatinib, a targeted therapy for Her2(+) breast cancer, either intrinsically or acquired after continuous drug exposure.	Lapatinib	174-183	protein tyrosine kinase 6	Homo sapiens	21-25
26084280-3	2015	We hypothesized that PTK6 inhibition is an effective strategy to inhibit growth and survival of Her2(+) breast cancer cells, including those that are relatively resistant to Lapatinib, a targeted therapy for Her2(+) breast cancer, either intrinsically or acquired after continuous drug exposure.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	208-212
26084280-4	2015	METHODS: To determine the effects of PTK6 inhibition on Lapatinib-resistant Her2(+) breast cancer cell lines (UACC893R1 and MDA-MB-453), we used short hairpin ribonucleic acid (shRNA) vectors to downregulate PTK6 expression.	Lapatinib	56-65	protein tyrosine kinase 6	Homo sapiens	37-41
26084280-4	2015	METHODS: To determine the effects of PTK6 inhibition on Lapatinib-resistant Her2(+) breast cancer cell lines (UACC893R1 and MDA-MB-453), we used short hairpin ribonucleic acid (shRNA) vectors to downregulate PTK6 expression.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
26084280-6	2015	RESULTS: Lapatinib treatment of "sensitive" Her2(+) cells induces apoptotic cell death and enhances transcript and protein levels of Bim, a pro-apoptotic Bcl2 family member.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
26084280-6	2015	RESULTS: Lapatinib treatment of "sensitive" Her2(+) cells induces apoptotic cell death and enhances transcript and protein levels of Bim, a pro-apoptotic Bcl2 family member.	Lapatinib	9-18	BCL2 like 11	Homo sapiens	133-136
26084280-6	2015	RESULTS: Lapatinib treatment of "sensitive" Her2(+) cells induces apoptotic cell death and enhances transcript and protein levels of Bim, a pro-apoptotic Bcl2 family member.	Lapatinib	9-18	BCL2 apoptosis regulator	Homo sapiens	154-158
26084280-13	2015	CONCLUSIONS: PTK6 downregulation induces apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by enhancing Bim expression via p38 activation.	Lapatinib	54-63	protein tyrosine kinase 6	Homo sapiens	13-17
26084280-13	2015	CONCLUSIONS: PTK6 downregulation induces apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by enhancing Bim expression via p38 activation.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
26084280-13	2015	CONCLUSIONS: PTK6 downregulation induces apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by enhancing Bim expression via p38 activation.	Lapatinib	54-63	BCL2 like 11	Homo sapiens	115-118
26084280-13	2015	CONCLUSIONS: PTK6 downregulation induces apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by enhancing Bim expression via p38 activation.	Lapatinib	54-63	mitogen-activated protein kinase 14	Homo sapiens	134-137
26083256-0	2015	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
26083256-1	2015	BACKGROUND: To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC).	Lapatinib	40-49	epidermal growth factor receptor	Homo sapiens	58-62
26070816-9	2015	In the melanoma xenograft model, serum phospho-CSE1L level declined 5 days after vemurafenib/sunitinib treatment and 3 days after sorafenib/lapatinib treatment in the HT-29 colon cancer xenograft model.	Lapatinib	140-149	chromosome segregation 1-like (S. cerevisiae)	Mus musculus	47-52
26083256-1	2015	BACKGROUND: To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC).	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
26083256-1	2015	BACKGROUND: To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC).	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
26083256-9	2015	CONCLUSIONS: The above results indicate that lapatinib is effective in decreasing HER2-positive CTCs in patients with MBC irrespectively of the HER2 status of the primary tumor and imply the feasibility of monitoring the molecular changes on CTCs during treatment with targeted agents.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
26070816-0	2015	Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.	Lapatinib	100-109	chromosome segregation 1-like (S. cerevisiae)	Mus musculus	31-36
26098642-2	2015	In order to investigate its mechanism, interaction of lapatinib with HLA-DRB1*07:01 and its ligand peptide derived from tetanus toxoid, has been evaluated in vitro.	Lapatinib	54-63	major histocompatibility complex, class II, DR beta 1	Homo sapiens	69-77
26098642-3	2015	Here we show that lapatinib enhances binding of the ligand peptide to HLA-DRB1*07:01.	Lapatinib	18-27	major histocompatibility complex, class II, DR beta 1	Homo sapiens	70-78
26098642-4	2015	Furthermore in silico molecular dynamics analysis revealed that lapatinib could change the beta chain helix in the HLA-DRB1*07:01 specifically to form a tightly closed binding groove structure and modify a large part of the binding groove.	Lapatinib	64-73	major histocompatibility complex, class II, DR beta 1	Homo sapiens	115-123
26098642-5	2015	These results indicate that lapatinib affects the ligand binding to HLA-DRB1*07:01 and idiosyncratic lapatinib-induced liver injury might be triggered by this mechanism.	Lapatinib	28-37	major histocompatibility complex, class II, DR beta 1	Homo sapiens	68-76
26199252-4	2015	Whole-brain irradiation(33.6 Gy) was performed, and the chemotherapy regimen was changed to lapatinib (LAP: orally at 1,250 mg/day, every day) and capecitabine (CAP: orally at 2,000 mg/m2, every day for 2 weeks, followed by a 1-week rest interval, as 1 cycle).	Lapatinib	92-101	LAP	Homo sapiens	103-106
26112944-0	2015	Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
26112944-1	2015	BACKGROUND: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2(+)BC) after progression on trastuzumab based therapy.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
26112944-1	2015	BACKGROUND: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2(+)BC) after progression on trastuzumab based therapy.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-164
26112944-9	2015	CONCLUSION: Lapatinib based therapy is an effective treatment for women with advanced/metastatic HER2(+)BC after prior exposure to trastuzumab.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
26102468-0	2015	Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
26261492-6	2015	Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism.	Lapatinib	170-179	erb-b2 receptor tyrosine kinase 2	Mus musculus	51-56
26261492-6	2015	Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism.	Lapatinib	170-179	erb-b2 receptor tyrosine kinase 2	Mus musculus	146-151
26261492-6	2015	Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism.	Lapatinib	170-179	erb-b2 receptor tyrosine kinase 2	Mus musculus	146-151
26102468-3	2015	In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-131
26102468-3	2015	In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	269-274
26102468-3	2015	In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer.	Lapatinib	15-24	nuclear receptor subfamily 4 group A member 1	Homo sapiens	279-295
26102468-4	2015	In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-65
26102468-4	2015	In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-138
25641763-3	2015	Cetuximab targets EGFR, whereas lapatinib inhibits both EGFR and ErbB2.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	56-60
25961594-1	2015	SKBR3-cells, characterized by ERBB2/RARA co-amplification, represent a subgroup of HER2+ breast-cancers sensitive to all-trans retinoic acid (ATRA) and Lapatinib.	Lapatinib	152-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
25641763-3	2015	Cetuximab targets EGFR, whereas lapatinib inhibits both EGFR and ErbB2.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-70
25641763-16	2015	CONCLUSIONS: The combination of cetuximab and lapatinib was well tolerated, had the expected toxicities, and exhibited notable clinical activity, including in patients who had received previous anti-EGFR therapy.	Lapatinib	46-55	epidermal growth factor receptor	Homo sapiens	199-203
25779558-0	2015	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-89
25779558-11	2015	In patients with centrally confirmed HER2-positive tumors, median PFS was 9.1 months with lapatinib and 13.6 months with trastuzumab (HR, 1.48; 95% CI, 1.20 to 1.83; P < .001).	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
25779558-14	2015	CONCLUSION: As first-line therapy for HER2-positive metastatic BC, lapatinib combined with taxane was associated with shorter PFS and more toxicity compared with trastuzumab combined with taxane.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
25820099-0	2015	Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	45-49
25883211-3	2015	Here we show that co-treatment with clinically validated inhibitors of c-ABL (imatinib) and EGFR (lapatinib) results in synergistic growth inhibition in TNBC cells.	Lapatinib	98-107	epidermal growth factor receptor	Homo sapiens	92-96
25883211-3	2015	Here we show that co-treatment with clinically validated inhibitors of c-ABL (imatinib) and EGFR (lapatinib) results in synergistic growth inhibition in TNBC cells.	Lapatinib	98-107	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	71-76
25820099-0	2015	Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	50-54
25820099-1	2015	We report the photophysical properties, binding-induced turn-on emission, and fluorescence imaging of the cellular uptake and distribution of lapatinib, an EGFR/ERBB inhibitor.	Lapatinib	142-151	epidermal growth factor receptor	Homo sapiens	156-160
25820099-1	2015	We report the photophysical properties, binding-induced turn-on emission, and fluorescence imaging of the cellular uptake and distribution of lapatinib, an EGFR/ERBB inhibitor.	Lapatinib	142-151	epidermal growth factor receptor	Homo sapiens	161-165
25820099-2	2015	Lapatinib, a type II, i.e. inactive state, inhibitor that targets the ATP binding pocket of the EGFR family of receptor tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	96-100
25820099-5	2015	The hydrophobicity of lapatinib leads to fluorescent aggregates in solution, however, binding to the lipid-carrier protein, BSA or to the kinase domain of ERBB2, produces spectroscopically distinct photoemission.	Lapatinib	22-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-160
25820099-6	2015	Confocal fluorescence microscopy imaging of lapatinib uptake in ERBB2-overexpressing MCF7 and BT474 cells reveals pools of intracellular inhibitor with emission profiles consistent with aggregated lapatinib.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-69
25820099-6	2015	Confocal fluorescence microscopy imaging of lapatinib uptake in ERBB2-overexpressing MCF7 and BT474 cells reveals pools of intracellular inhibitor with emission profiles consistent with aggregated lapatinib.	Lapatinib	197-206	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-69
25859842-2	2015	Lapatinib, a selective ERBB1 and ERBB2 inhibitor has produced prolonged disease stabilization in patients with ependymoma in a phase I study.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	23-28
26054673-5	2015	The results showed that inhibition of EGFR/HER2 signaling by lapatinib sensitized MCF-7 tumorspheres to doxorubicin by inhibiting the expression of the ABC transporters, MDR-1 and BCRP, and thus, enhancing the intracellular accumulation of doxorubicin.	Lapatinib	61-70	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	152-155
26054673-5	2015	The results showed that inhibition of EGFR/HER2 signaling by lapatinib sensitized MCF-7 tumorspheres to doxorubicin by inhibiting the expression of the ABC transporters, MDR-1 and BCRP, and thus, enhancing the intracellular accumulation of doxorubicin.	Lapatinib	61-70	ATP binding cassette subfamily B member 1	Homo sapiens	170-175
26054673-5	2015	The results showed that inhibition of EGFR/HER2 signaling by lapatinib sensitized MCF-7 tumorspheres to doxorubicin by inhibiting the expression of the ABC transporters, MDR-1 and BCRP, and thus, enhancing the intracellular accumulation of doxorubicin.	Lapatinib	61-70	BCR pseudogene 1	Homo sapiens	180-184
27140800-1	2015	Lapatinib is approved for use in various therapeutic combinations for treating metastatic breast cancers that over-express HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
26054673-0	2015	Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters.	Lapatinib	0-9	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	120-123
26054673-5	2015	The results showed that inhibition of EGFR/HER2 signaling by lapatinib sensitized MCF-7 tumorspheres to doxorubicin by inhibiting the expression of the ABC transporters, MDR-1 and BCRP, and thus, enhancing the intracellular accumulation of doxorubicin.	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	38-42
26054673-5	2015	The results showed that inhibition of EGFR/HER2 signaling by lapatinib sensitized MCF-7 tumorspheres to doxorubicin by inhibiting the expression of the ABC transporters, MDR-1 and BCRP, and thus, enhancing the intracellular accumulation of doxorubicin.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
25859842-2	2015	Lapatinib, a selective ERBB1 and ERBB2 inhibitor has produced prolonged disease stabilization in patients with ependymoma in a phase I study.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
25977884-0	2015	Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
25700543-0	2015	The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.	Lapatinib	21-30	albumin	Mus musculus	44-57
25700543-3	2015	Previous studies have indicated that lapatinib, a selective small-molecular dual-tyrosine kinase inhibitor of HER2 and EGFR, is effective in reducing cancer progression and metastasis, indicating that it might be a candidate for TNBC treatment.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Mus musculus	110-114
25700543-3	2015	Previous studies have indicated that lapatinib, a selective small-molecular dual-tyrosine kinase inhibitor of HER2 and EGFR, is effective in reducing cancer progression and metastasis, indicating that it might be a candidate for TNBC treatment.	Lapatinib	37-46	epidermal growth factor receptor	Mus musculus	119-123
25700543-5	2015	In this study, we developed human serum albumin (HSA) nanoparticles loaded with lapatinib for intravenous administration to overcome these disadvantages and enhance its efficacy against TNBC.	Lapatinib	80-89	albumin	Mus musculus	34-47
26063888-6	2015	The prospective testing of HER2-targeted therapies (eg, trastuzumab and lapatinib) demonstrated the validity of this concept and the potential to change the outcome of this aggressive disease.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
25987214-5	2015	Activation of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in AhR overexpressing breast cancer cells effectively suppressed the apoptotic response induced by UV-irradiation, doxorubicin, lapatinib and paclitaxel.	Lapatinib	192-201	aryl hydrocarbon receptor	Homo sapiens	14-17
25987214-5	2015	Activation of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in AhR overexpressing breast cancer cells effectively suppressed the apoptotic response induced by UV-irradiation, doxorubicin, lapatinib and paclitaxel.	Lapatinib	192-201	aryl hydrocarbon receptor	Homo sapiens	67-70
24909179-6	2015	Pharmacological blockade of BCL-XL/BCL-2 partially abrogated the rescue effects conferred by PRKACA and PIM1, and sensitized cells to lapatinib treatment.	Lapatinib	134-143	BCL2 like 1	Homo sapiens	28-34
25559818-5	2015	Patients treated with a combination of trastuzumab and lapatinib who had wild-type PIK3CA obtained a total pathologic complete response (pCR) rate of 53.1%, which decreased to 28.6% in patients with tumors that carried PIK3CA activating mutations (P = .012).	Lapatinib	55-64	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	83-89
25559818-5	2015	Patients treated with a combination of trastuzumab and lapatinib who had wild-type PIK3CA obtained a total pathologic complete response (pCR) rate of 53.1%, which decreased to 28.6% in patients with tumors that carried PIK3CA activating mutations (P = .012).	Lapatinib	55-64	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	219-225
25871401-0	2015	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-22
25871401-0	2015	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.	Lapatinib	40-49	Y-box binding protein 1	Homo sapiens	23-26
25871401-0	2015	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.	Lapatinib	40-49	androgen receptor	Homo sapiens	27-29
25871401-6	2015	HER2 dependent AR activation in LNCaP and ENZR cells was effectively blocked by treatment with the EGFR/HER2 inhibitor Lapatinib, which reduced cell viability and increased apoptosis.	Lapatinib	119-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
25871401-6	2015	HER2 dependent AR activation in LNCaP and ENZR cells was effectively blocked by treatment with the EGFR/HER2 inhibitor Lapatinib, which reduced cell viability and increased apoptosis.	Lapatinib	119-128	androgen receptor	Homo sapiens	15-17
25871401-6	2015	HER2 dependent AR activation in LNCaP and ENZR cells was effectively blocked by treatment with the EGFR/HER2 inhibitor Lapatinib, which reduced cell viability and increased apoptosis.	Lapatinib	119-128	epidermal growth factor receptor	Homo sapiens	99-103
25871401-6	2015	HER2 dependent AR activation in LNCaP and ENZR cells was effectively blocked by treatment with the EGFR/HER2 inhibitor Lapatinib, which reduced cell viability and increased apoptosis.	Lapatinib	119-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
25865888-0	2015	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
25865888-0	2015	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.	Lapatinib	14-23	delta/notch like EGF repeat containing	Homo sapiens	98-101
25865888-1	2015	Therapeutics that target ERBB2, such as lapatinib, often provide initial clinical benefit, but resistance frequently develops.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-30
25865888-2	2015	Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and activation of multiple tyrosine kinases.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-116
25865888-2	2015	Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and activation of multiple tyrosine kinases.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 3	Homo sapiens	117-122
25865888-5	2015	Genetic and chemical inhibition of BET bromodomain chromatin readers suppresses transcription of many lapatinib-induced kinases involved in resistance, including ERBB3, IGF1R, DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation.	Lapatinib	102-111	delta/notch like EGF repeat containing	Homo sapiens	35-38
25865888-5	2015	Genetic and chemical inhibition of BET bromodomain chromatin readers suppresses transcription of many lapatinib-induced kinases involved in resistance, including ERBB3, IGF1R, DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 3	Homo sapiens	162-167
25865888-5	2015	Genetic and chemical inhibition of BET bromodomain chromatin readers suppresses transcription of many lapatinib-induced kinases involved in resistance, including ERBB3, IGF1R, DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation.	Lapatinib	102-111	insulin like growth factor 1 receptor	Homo sapiens	169-174
25865888-5	2015	Genetic and chemical inhibition of BET bromodomain chromatin readers suppresses transcription of many lapatinib-induced kinases involved in resistance, including ERBB3, IGF1R, DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation.	Lapatinib	102-111	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	220-223
25865888-5	2015	Genetic and chemical inhibition of BET bromodomain chromatin readers suppresses transcription of many lapatinib-induced kinases involved in resistance, including ERBB3, IGF1R, DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation.	Lapatinib	102-111	protein tyrosine kinase 2	Homo sapiens	224-227
25886138-8	2015	RESULTS: We found that combined treatment with the IGF-IR and EGFR/Her-2 inhibitors NVP-AEW541 and lapatinib, respectively, synergistically inhibited pancreatic cancer cell growth.	Lapatinib	99-108	insulin like growth factor 1 receptor	Homo sapiens	51-57
25886138-8	2015	RESULTS: We found that combined treatment with the IGF-IR and EGFR/Her-2 inhibitors NVP-AEW541 and lapatinib, respectively, synergistically inhibited pancreatic cancer cell growth.	Lapatinib	99-108	epidermal growth factor receptor	Homo sapiens	62-66
25886138-8	2015	RESULTS: We found that combined treatment with the IGF-IR and EGFR/Her-2 inhibitors NVP-AEW541 and lapatinib, respectively, synergistically inhibited pancreatic cancer cell growth.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-72
25886138-11	2015	CONCLUSIONS: Taken together, these data indicate that simultaneous blockade of IGF-IR and EGFR/Her-2 using NVP-AEW541 and lapatinib may overcome resistance in pancreatic cancer.	Lapatinib	122-131	insulin like growth factor 1 receptor	Homo sapiens	79-85
25886138-11	2015	CONCLUSIONS: Taken together, these data indicate that simultaneous blockade of IGF-IR and EGFR/Her-2 using NVP-AEW541 and lapatinib may overcome resistance in pancreatic cancer.	Lapatinib	122-131	epidermal growth factor receptor	Homo sapiens	90-94
25157953-10	2015	Using patient-derived tumor cell models isolated from pericardial effusion of HER2(+) and MET(+) GC cases, we demonstrated that the combination of HER2-inhibitor (lapatinib) and MET-inhibitor offered a more profound inhibition in the ERK/AKT pathway and cell proliferation than lapatinib alone.	Lapatinib	163-172	EPH receptor B2	Homo sapiens	234-237
25881004-7	2015	METHODS: We evaluated whether direct modulation of Cx43 using a Cx43-directed therapeutic peptide, called ACT1, enhances Cx43 gap junctional activity in breast cancer cells, impairs breast cancer cell proliferation or survival, and enhances the activity of the targeted inhibitors tamoxifen and lapatinib.	Lapatinib	295-304	gap junction protein alpha 1	Homo sapiens	64-68
25881004-7	2015	METHODS: We evaluated whether direct modulation of Cx43 using a Cx43-directed therapeutic peptide, called ACT1, enhances Cx43 gap junctional activity in breast cancer cells, impairs breast cancer cell proliferation or survival, and enhances the activity of the targeted inhibitors tamoxifen and lapatinib.	Lapatinib	295-304	TRAF3 interacting protein 2	Homo sapiens	106-110
25881004-7	2015	METHODS: We evaluated whether direct modulation of Cx43 using a Cx43-directed therapeutic peptide, called ACT1, enhances Cx43 gap junctional activity in breast cancer cells, impairs breast cancer cell proliferation or survival, and enhances the activity of the targeted inhibitors tamoxifen and lapatinib.	Lapatinib	295-304	gap junction protein alpha 1	Homo sapiens	64-68
25881004-10	2015	Furthermore, treating ER+ breast cancer cells with a combination of ACT1 and tamoxifen or HER2+ breast cancer cells with ACT1 and lapatinib augments the activity of these targeted inhibitors.	Lapatinib	130-139	TRAF3 interacting protein 2	Homo sapiens	68-72
25881004-10	2015	Furthermore, treating ER+ breast cancer cells with a combination of ACT1 and tamoxifen or HER2+ breast cancer cells with ACT1 and lapatinib augments the activity of these targeted inhibitors.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
25881004-11	2015	CONCLUSIONS: Based on our findings, we conclude that modulation of Cx43 activity in breast cancer can be effectively achieved with the agent ACT1 to sustain Cx43-mediated gap junctional activity resulting in impaired malignant progression and enhanced activity of lapatinib and tamoxifen, implicating ACT1 as part of a combination regimen in breast cancer.	Lapatinib	264-273	gap junction protein alpha 1	Homo sapiens	67-71
25881004-11	2015	CONCLUSIONS: Based on our findings, we conclude that modulation of Cx43 activity in breast cancer can be effectively achieved with the agent ACT1 to sustain Cx43-mediated gap junctional activity resulting in impaired malignant progression and enhanced activity of lapatinib and tamoxifen, implicating ACT1 as part of a combination regimen in breast cancer.	Lapatinib	264-273	TRAF3 interacting protein 2	Homo sapiens	141-145
25881004-11	2015	CONCLUSIONS: Based on our findings, we conclude that modulation of Cx43 activity in breast cancer can be effectively achieved with the agent ACT1 to sustain Cx43-mediated gap junctional activity resulting in impaired malignant progression and enhanced activity of lapatinib and tamoxifen, implicating ACT1 as part of a combination regimen in breast cancer.	Lapatinib	264-273	gap junction protein alpha 1	Homo sapiens	157-161
25587128-7	2015	Oral curcumin (2000 mg) and lapatinib (250 mg) are the best available clinical BCRP inhibitors.	Lapatinib	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-83
25752740-0	2015	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.	Lapatinib	100-109	epidermal growth factor receptor	Homo sapiens	131-163
25752740-0	2015	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.	Lapatinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
25752740-13	2015	These placebo-controlled results may also help to inform physicians and patients using lapatinib in metastatic HER2 positive breast cancer.	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
25881004-0	2015	Targeting connexin 43 with alpha-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.	Lapatinib	139-148	gap junction protein alpha 1	Homo sapiens	10-21
25881004-0	2015	Targeting connexin 43 with alpha-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.	Lapatinib	139-148	TRAF3 interacting protein 2	Homo sapiens	61-65
25881004-0	2015	Targeting connexin 43 with alpha-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.	Lapatinib	139-148	TRAF3 interacting protein 2	Homo sapiens	193-197
25881004-7	2015	METHODS: We evaluated whether direct modulation of Cx43 using a Cx43-directed therapeutic peptide, called ACT1, enhances Cx43 gap junctional activity in breast cancer cells, impairs breast cancer cell proliferation or survival, and enhances the activity of the targeted inhibitors tamoxifen and lapatinib.	Lapatinib	295-304	gap junction protein alpha 1	Homo sapiens	51-55
25157953-10	2015	Using patient-derived tumor cell models isolated from pericardial effusion of HER2(+) and MET(+) GC cases, we demonstrated that the combination of HER2-inhibitor (lapatinib) and MET-inhibitor offered a more profound inhibition in the ERK/AKT pathway and cell proliferation than lapatinib alone.	Lapatinib	163-172	AKT serine/threonine kinase 1	Homo sapiens	238-241
25157953-10	2015	Using patient-derived tumor cell models isolated from pericardial effusion of HER2(+) and MET(+) GC cases, we demonstrated that the combination of HER2-inhibitor (lapatinib) and MET-inhibitor offered a more profound inhibition in the ERK/AKT pathway and cell proliferation than lapatinib alone.	Lapatinib	278-287	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
25529010-4	2015	However, CNS penetrable HER2 receptor antagonists such as lapatinib and intrathecal administration of trastuzumab might benefit patients, and are worthy of further investigation.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
25732265-0	2015	Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21
25732265-0	2015	Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
25732265-1	2015	BACKGROUND: Randomized clinical trials (RCT) that evaluated the addition of lapatinib to trastuzumab plus neoadjuvant chemotherapy (NAC) in patients with HER2-positive, operable breast cancer revealed a questionable improvement in pathologic complete response (pCR) rate.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
25789974-4	2015	Furthermore, KLF4/5 protein was rapidly upregulated in human breast cancer cells following treatment with the HER2/epidermal growth factor receptor inhibitor, lapatinib.	Lapatinib	159-168	Kruppel like factor 4	Homo sapiens	13-19
25691057-0	2015	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.	Lapatinib	10-19	neuregulin 1	Homo sapiens	75-79
25691057-0	2015	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
25691057-0	2015	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.	Lapatinib	47-56	neuregulin 1	Homo sapiens	75-79
25691057-0	2015	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
25691057-1	2015	Acquired resistance to lapatinib, an inhibitor of EGFR and HER2 kinases, is common.	Lapatinib	23-32	epidermal growth factor receptor	Homo sapiens	50-54
25691057-1	2015	Acquired resistance to lapatinib, an inhibitor of EGFR and HER2 kinases, is common.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
25691057-2	2015	We found that reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment after their initial dephosphorylation.	Lapatinib	78-87	epidermal growth factor receptor	Homo sapiens	30-34
25691057-2	2015	We found that reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment after their initial dephosphorylation.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
25691057-2	2015	We found that reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment after their initial dephosphorylation.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 3	Homo sapiens	45-49
25691057-3	2015	This was associated with increased expression of NRG1 in cells treated with lapatinib.	Lapatinib	76-85	neuregulin 1	Homo sapiens	49-53
25789974-4	2015	Furthermore, KLF4/5 protein was rapidly upregulated in human breast cancer cells following treatment with the HER2/epidermal growth factor receptor inhibitor, lapatinib.	Lapatinib	159-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
25691057-4	2015	Exogenous NRG1 partially rescued breast cancer cells from growth inhibition by lapatinib.	Lapatinib	79-88	neuregulin 1	Homo sapiens	10-14
25789974-4	2015	Furthermore, KLF4/5 protein was rapidly upregulated in human breast cancer cells following treatment with the HER2/epidermal growth factor receptor inhibitor, lapatinib.	Lapatinib	159-168	epidermal growth factor receptor	Homo sapiens	115-147
25691057-5	2015	In addition, both parental and lapatinib-resistant breast cancer cells were sensitive to SGP1, which inhibits binding of NRG1 and other HER3 ligands.	Lapatinib	31-40	neuregulin 1	Homo sapiens	121-125
25789974-7	2015	Using tumor cells derived from this model as well as human breast cancer cells, suppression of KLF4 and/or KLF5 sensitized HER2-overexpressing cells to lapatinib.	Lapatinib	152-161	Kruppel like factor 4	Homo sapiens	95-99
25691057-5	2015	In addition, both parental and lapatinib-resistant breast cancer cells were sensitive to SGP1, which inhibits binding of NRG1 and other HER3 ligands.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 3	Homo sapiens	136-140
25789974-7	2015	Using tumor cells derived from this model as well as human breast cancer cells, suppression of KLF4 and/or KLF5 sensitized HER2-overexpressing cells to lapatinib.	Lapatinib	152-161	Kruppel like factor 5	Homo sapiens	107-111
25691057-6	2015	Addition of pertuzumab to lapatinib further inhibited NRG1-induced signalling, which was not fully inhibited by either drug alone.	Lapatinib	26-35	neuregulin 1	Homo sapiens	54-58
25789974-7	2015	Using tumor cells derived from this model as well as human breast cancer cells, suppression of KLF4 and/or KLF5 sensitized HER2-overexpressing cells to lapatinib.	Lapatinib	152-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
25789974-10	2015	Moreover, MCL1 was upregulated by lapatinib in a KLF4/5-dependent manner, and enforced expression of MCL1 in KLF4/5-deficient cells restored drug resistance.	Lapatinib	34-43	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	10-14
25789974-10	2015	Moreover, MCL1 was upregulated by lapatinib in a KLF4/5-dependent manner, and enforced expression of MCL1 in KLF4/5-deficient cells restored drug resistance.	Lapatinib	34-43	Kruppel like factor 4	Homo sapiens	49-53
25789974-10	2015	Moreover, MCL1 was upregulated by lapatinib in a KLF4/5-dependent manner, and enforced expression of MCL1 in KLF4/5-deficient cells restored drug resistance.	Lapatinib	34-43	Kruppel like factor 4	Homo sapiens	109-113
25789974-13	2015	These results identify KLF4 and KLF5 as cooperating protumorigenic factors and critical participants in resistance to lapatinib, furthering the rationale for combining anti-MCL1/BCL-XL inhibitors with conventional HER2-targeted therapies.	Lapatinib	118-127	Kruppel like factor 4	Homo sapiens	23-27
25789974-13	2015	These results identify KLF4 and KLF5 as cooperating protumorigenic factors and critical participants in resistance to lapatinib, furthering the rationale for combining anti-MCL1/BCL-XL inhibitors with conventional HER2-targeted therapies.	Lapatinib	118-127	Kruppel like factor 5	Homo sapiens	32-36
25789974-13	2015	These results identify KLF4 and KLF5 as cooperating protumorigenic factors and critical participants in resistance to lapatinib, furthering the rationale for combining anti-MCL1/BCL-XL inhibitors with conventional HER2-targeted therapies.	Lapatinib	118-127	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	173-177
25663912-0	2015	Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-135
25538175-5	2015	Using the CCLE dataset, selected genes (ERBB2, EGFR) were better or equally correlated to the IC50 of their companion drug (lapatinib, erlotinib), when applying the alternative centralization.	Lapatinib	124-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-45
25538175-5	2015	Using the CCLE dataset, selected genes (ERBB2, EGFR) were better or equally correlated to the IC50 of their companion drug (lapatinib, erlotinib), when applying the alternative centralization.	Lapatinib	124-133	epidermal growth factor receptor	Homo sapiens	47-51
25848335-8	2015	Newer her2-targeted agents (lapatinib, pertuzumab, T-DM1, neratinib) have been or are still being evaluated in both adjuvant and neoadjuvant trials, either by direct comparison with trastuzumab alone or combined with trastuzumab.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
26225238-4	2015	Activating mutations in the PI3K and MAPK pathways (PIK3CA and KRAS), and expression of the HER3 ligand heregulin determined sensitivity to combinations of inhibitors against HER2 (lapatinib), HER3 (MM-111), AKT (MK-2206), and MEK (GSK-1120212; trametinib), in addition to the standard of care trastuzumab (Herceptin).	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 3	Homo sapiens	92-96
26225238-4	2015	Activating mutations in the PI3K and MAPK pathways (PIK3CA and KRAS), and expression of the HER3 ligand heregulin determined sensitivity to combinations of inhibitors against HER2 (lapatinib), HER3 (MM-111), AKT (MK-2206), and MEK (GSK-1120212; trametinib), in addition to the standard of care trastuzumab (Herceptin).	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	0-20	epidermal growth factor receptor	Homo sapiens	35-72
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	0-20	epidermal growth factor receptor	Homo sapiens	74-78
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	0-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	0-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	22-25	epidermal growth factor receptor	Homo sapiens	35-72
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	22-25	epidermal growth factor receptor	Homo sapiens	74-78
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	22-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
25694417-3	2015	Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in HER2-positive breast cancer.	Lapatinib	22-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
25435280-8	2015	We also functionally studied all HER2 mutants and showed that they conferred an aggressive phenotype and altered effects of the TKI lapatinib.	Lapatinib	132-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
25660155-2	2015	Lapatinib inhibits the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	67-99
25660155-2	2015	Lapatinib inhibits the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	101-105
25660155-2	2015	Lapatinib inhibits the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
25663912-1	2015	The purpose of the present study was to quantify the cumulative randomized evidence for the efficacy and safety of lapatinib combined with neoadjuvant therapy in human epidermal growth factor receptor (HER) 2-positive breast cancer.	Lapatinib	115-124	epidermal growth factor receptor	Homo sapiens	168-200
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	47-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	47-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-109
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	273-282	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-105
25663912-6	2015	Compared with the patients who did not receive lapatinib, the pCR rate was higher in the hormone receptor (HR)-positive [risk ratio (RR), 1.39; 95% confidence interval (CI), 1.12-1.72; P=0.002) and HR-negative (RR, 1.38; 95% CI, 1.14-1.68; P=0.0009) patients that received lapatinib.	Lapatinib	273-282	nuclear receptor subfamily 4 group A member 1	Homo sapiens	107-109
25596742-6	2015	HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions.	Lapatinib	48-57	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-5
25596742-6	2015	HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions.	Lapatinib	48-57	hypoxia inducible factor 1 subunit alpha	Homo sapiens	97-102
25596742-0	2015	Hypoxia/HIF1alpha induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.	Lapatinib	26-35	hypoxia inducible factor 1 subunit alpha	Homo sapiens	8-17
25596742-6	2015	HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111
25596742-0	2015	Hypoxia/HIF1alpha induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-55
25596742-6	2015	HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-182
25596742-0	2015	Hypoxia/HIF1alpha induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.	Lapatinib	26-35	dual specificity phosphatase 2	Homo sapiens	103-108
25596742-6	2015	HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions.	Lapatinib	136-145	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-5
25596742-2	2015	Breast cancer patients with ERBB2 amplifications are currently treated with lapatinib, a small-molecule kinase inhibitor that specifically blocks EGFR/ERBB2 signaling.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
25596742-2	2015	Breast cancer patients with ERBB2 amplifications are currently treated with lapatinib, a small-molecule kinase inhibitor that specifically blocks EGFR/ERBB2 signaling.	Lapatinib	76-85	epidermal growth factor receptor	Homo sapiens	146-150
25596742-2	2015	Breast cancer patients with ERBB2 amplifications are currently treated with lapatinib, a small-molecule kinase inhibitor that specifically blocks EGFR/ERBB2 signaling.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-156
25596742-3	2015	Here, we show that hypoxia, via HIF-1, induces resistance to lapatinib-mediated effects in ERBB2-expressing mammary epithelial and ERBB2-positive breast cancer cells.	Lapatinib	61-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	32-37
25596742-6	2015	HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions.	Lapatinib	136-145	hypoxia inducible factor 1 subunit alpha	Homo sapiens	97-102
25596742-3	2015	Here, we show that hypoxia, via HIF-1, induces resistance to lapatinib-mediated effects in ERBB2-expressing mammary epithelial and ERBB2-positive breast cancer cells.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-96
25596742-3	2015	Here, we show that hypoxia, via HIF-1, induces resistance to lapatinib-mediated effects in ERBB2-expressing mammary epithelial and ERBB2-positive breast cancer cells.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-136
25596742-6	2015	HIF-1 is both required and sufficient to induce lapatinib resistance as overexpression of stable HIF-1 in ERBB2-expressing cells blocks lapatinib-mediated effects and maintains ERBB2-downstream signaling under normoxic conditions.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111
25596742-5	2015	Hypoxia can maintain activation of signaling pathways downstream from ERBB2 including AKT and ERK in the presence of lapatinib.	Lapatinib	117-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-75
25596742-7	2015	Under hypoxia, activation of ERK signaling is required for lapatinib resistance as treatment with MEK inhibitor trametinib reverses hypoxia-mediated lapatinib resistance.	Lapatinib	59-68	mitogen-activated protein kinase 1	Homo sapiens	29-32
25596742-7	2015	Under hypoxia, activation of ERK signaling is required for lapatinib resistance as treatment with MEK inhibitor trametinib reverses hypoxia-mediated lapatinib resistance.	Lapatinib	59-68	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
25596742-7	2015	Under hypoxia, activation of ERK signaling is required for lapatinib resistance as treatment with MEK inhibitor trametinib reverses hypoxia-mediated lapatinib resistance.	Lapatinib	149-158	mitogen-activated protein kinase 1	Homo sapiens	29-32
25596742-7	2015	Under hypoxia, activation of ERK signaling is required for lapatinib resistance as treatment with MEK inhibitor trametinib reverses hypoxia-mediated lapatinib resistance.	Lapatinib	149-158	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
25596742-8	2015	HIF-1 can bypass the lapatinib-treated inhibition of the ERK pathway via inhibition of the dual-specificity phosphatase 2 (DUSP2).	Lapatinib	21-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-5
25596742-8	2015	HIF-1 can bypass the lapatinib-treated inhibition of the ERK pathway via inhibition of the dual-specificity phosphatase 2 (DUSP2).	Lapatinib	21-30	mitogen-activated protein kinase 1	Homo sapiens	57-60
25596742-8	2015	HIF-1 can bypass the lapatinib-treated inhibition of the ERK pathway via inhibition of the dual-specificity phosphatase 2 (DUSP2).	Lapatinib	21-30	dual specificity phosphatase 2	Homo sapiens	91-121
25596742-8	2015	HIF-1 can bypass the lapatinib-treated inhibition of the ERK pathway via inhibition of the dual-specificity phosphatase 2 (DUSP2).	Lapatinib	21-30	dual specificity phosphatase 2	Homo sapiens	123-128
25596742-9	2015	Indeed, overexpression of DUSP2 in ErbB2-positve breast cancer cells reverses hypoxia-mediated lapatinib resistance.	Lapatinib	95-104	dual specificity phosphatase 2	Homo sapiens	26-31
25596742-9	2015	Indeed, overexpression of DUSP2 in ErbB2-positve breast cancer cells reverses hypoxia-mediated lapatinib resistance.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-40
25596742-10	2015	Thus, our results provide rationale for therapeutic evaluation of the treatment of hypoxic ERBB2 expressing breast tumors with a combination of lapatinib and MEK inhibitors.	Lapatinib	144-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-96
25678800-1	2015	BACKGROUND: Lapatinib is a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	32-64
25678800-1	2015	BACKGROUND: Lapatinib is a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	66-70
25678800-1	2015	BACKGROUND: Lapatinib is a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
25678800-8	2015	RESULTS: Lapatinib reduced E6 and E7 expression and Akt phosphorylation, inhibited cell proliferation and induced cell death in HPV-positive cell lines.	Lapatinib	9-18	AKT serine/threonine kinase 1	Homo sapiens	52-55
25467016-1	2015	BACKGROUND: Neoadjuvant trials conducted using a double HER2 blockade with lapatinib and trastuzumab, combined with different paclitaxel-containing chemotherapy regimens, have shown high pathological complete response (pCR) rates, but at the cost of important toxicity.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
25620423-0	2015	Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
25467182-0	2015	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
25467182-10	2015	CONCLUSIONS: Increasing HER2 protein expression correlated with increased benefit of adding lapatinib to trastuzumab.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
25467182-11	2015	HER2 expression is a stronger predictor of pCR and PFS than p95HER2 for response to lapatinib, trastuzumab and, more significantly, L+T.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
25639891-5	2015	Lapatinib exhibits both covalent binding to the apoprotein and formation of a metabolite-intermediate complex in an enzyme-selective manner (CYP3A4 versus CYP3A5), each with different reactive metabolites.	Lapatinib	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
25639891-5	2015	Lapatinib exhibits both covalent binding to the apoprotein and formation of a metabolite-intermediate complex in an enzyme-selective manner (CYP3A4 versus CYP3A5), each with different reactive metabolites.	Lapatinib	0-9	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	155-161
25283886-2	2015	The aim of the present study was to detect the potential effect of lapatinib an inhibitor of EGFR tyrosine kinases on collagen-induced arthritis.	Lapatinib	67-76	epidermal growth factor receptor	Rattus norvegicus	93-97
25283886-7	2015	TNF-alpha, IL-17 and MDA levels, and Nrf2 and HO-1 expressions were lower in lapatinib-treated (30 mg/kg/day) group compared to sham group, while SOD, catalase, and GPx activities were higher (p < 0.05).	Lapatinib	77-86	tumor necrosis factor	Rattus norvegicus	0-9
25283886-7	2015	TNF-alpha, IL-17 and MDA levels, and Nrf2 and HO-1 expressions were lower in lapatinib-treated (30 mg/kg/day) group compared to sham group, while SOD, catalase, and GPx activities were higher (p < 0.05).	Lapatinib	77-86	interleukin 17A	Rattus norvegicus	11-16
25283886-7	2015	TNF-alpha, IL-17 and MDA levels, and Nrf2 and HO-1 expressions were lower in lapatinib-treated (30 mg/kg/day) group compared to sham group, while SOD, catalase, and GPx activities were higher (p < 0.05).	Lapatinib	77-86	NFE2 like bZIP transcription factor 2	Rattus norvegicus	37-41
25283886-7	2015	TNF-alpha, IL-17 and MDA levels, and Nrf2 and HO-1 expressions were lower in lapatinib-treated (30 mg/kg/day) group compared to sham group, while SOD, catalase, and GPx activities were higher (p < 0.05).	Lapatinib	77-86	heme oxygenase 1	Rattus norvegicus	46-50
25620423-5	2015	MD simulations revealed that the L755P mutation caused structural changes in the regions of helix alphaC, the glycine-rich loop, and the activation loop, thereby leading to the loss of interactions between the solubilizing group of lapatinib and HER2.	Lapatinib	232-241	erb-b2 receptor tyrosine kinase 2	Homo sapiens	246-250
25620423-6	2015	Moreover, MM-GBSA calculations suggested that hydrophobic interactions between lapatinib and HER2 contribute most to the binding affinity, and that the L755P mutation could result in a less energetically favorable HER2/lapatinib complex.	Lapatinib	219-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	214-218
25620423-7	2015	This may weaken the binding of lapatinib to the mutated HER2, thereby leading to the emergence of drug resistance.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
25620423-8	2015	This study offers a structural explanation for the effect of the L755P mutation on the HER2/lapatinib complex.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
25620423-2	2015	A missense mutation, L755P, in the HER2 kinase domain has been involved in lung cancer in humans and exhibits reduced response to lapatinib therapy.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
25620423-3	2015	However, the detailed mechanism of how the HER2 L755P mutation causes drug resistance to lapatinib remains elusive.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
25482142-2	2015	Gefitinib (Iressa ) is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor).	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	103-107
25482142-2	2015	Gefitinib (Iressa ) is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor).	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	103-107
25987098-0	2015	Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
25449780-0	2015	Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.	Lapatinib	144-153	heat shock protein 90 alpha family class A member 1	Homo sapiens	6-11
25449780-4	2015	We found that FW-04-806 alone or with laptinib inhibits cell proliferation, induces cell apoptosis and reduces the total and activated HER3 levels in these cells, while lapatinib has been reported to increase HER3 expression followed HER2 inhibition.	Lapatinib	169-178	erb-b2 receptor tyrosine kinase 3	Homo sapiens	209-213
25449780-4	2015	We found that FW-04-806 alone or with laptinib inhibits cell proliferation, induces cell apoptosis and reduces the total and activated HER3 levels in these cells, while lapatinib has been reported to increase HER3 expression followed HER2 inhibition.	Lapatinib	169-178	erb-b2 receptor tyrosine kinase 2	Homo sapiens	234-238
25449780-5	2015	The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
25449780-5	2015	The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.	Lapatinib	33-42	AKT serine/threonine kinase 1	Homo sapiens	115-118
25449780-5	2015	The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.	Lapatinib	33-42	mitogen-activated protein kinase kinase 7	Homo sapiens	127-130
25449780-5	2015	The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.	Lapatinib	33-42	EPH receptor B2	Homo sapiens	131-134
25449780-5	2015	The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.	Lapatinib	33-42	AKT serine/threonine kinase 1	Homo sapiens	169-172
25449780-5	2015	The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.	Lapatinib	33-42	forkhead box O3	Homo sapiens	182-188
25449780-5	2015	The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	364-368
25599599-5	2015	We employed a fully Bayesian approach known as the p 1-model to infer posterior probabilities of gene-pairs in networks derived from the gene expression datasets of ErbB2-positive breast cancer cell-lines (parental, lapatinib-sensitive cell-line SKBR3 and the lapatinib-resistant cell-line SKBR3-R, derived from SKBR3).	Lapatinib	216-225	beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)	Homo sapiens	51-54
25599599-5	2015	We employed a fully Bayesian approach known as the p 1-model to infer posterior probabilities of gene-pairs in networks derived from the gene expression datasets of ErbB2-positive breast cancer cell-lines (parental, lapatinib-sensitive cell-line SKBR3 and the lapatinib-resistant cell-line SKBR3-R, derived from SKBR3).	Lapatinib	216-225	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-170
25599599-6	2015	Using this computational framework, we searched for cross-talks between EGFR/ErbB and other signaling pathways from Reactome, KEGG and WikiPathway databases that contribute to lapatinib resistance.	Lapatinib	176-185	epidermal growth factor receptor	Homo sapiens	72-76
25599599-6	2015	Using this computational framework, we searched for cross-talks between EGFR/ErbB and other signaling pathways from Reactome, KEGG and WikiPathway databases that contribute to lapatinib resistance.	Lapatinib	176-185	epidermal growth factor receptor	Homo sapiens	77-81
25599599-12	2015	We also analyzed an independent study of lapatinib resistance in the BT474 breast cancer cell-line and found the same signaling pathways making cross-talks with the EGFR/ErbB signaling pathway as in the primary dataset.	Lapatinib	41-50	epidermal growth factor receptor	Homo sapiens	165-169
25599599-12	2015	We also analyzed an independent study of lapatinib resistance in the BT474 breast cancer cell-line and found the same signaling pathways making cross-talks with the EGFR/ErbB signaling pathway as in the primary dataset.	Lapatinib	41-50	epidermal growth factor receptor	Homo sapiens	170-174
25599599-13	2015	CONCLUSIONS: Our results indicate that the activation of compensatory pathways can potentially cause up-regulation of EGFR/ErbB pathway genes (counteracting the inhibiting effect of lapatinib) via signaling cross-talk.	Lapatinib	182-191	epidermal growth factor receptor	Homo sapiens	118-122
25599599-13	2015	CONCLUSIONS: Our results indicate that the activation of compensatory pathways can potentially cause up-regulation of EGFR/ErbB pathway genes (counteracting the inhibiting effect of lapatinib) via signaling cross-talk.	Lapatinib	182-191	epidermal growth factor receptor	Homo sapiens	123-127
25973295-6	2015	Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops with the dual tyrosine kinase inhibitor Lapatinib or ER-alpha36 down-regulator Broussoflavonol B in tamoxifen resistant MCF7 cells restored tamoxifen sensitivity.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
25326580-5	2015	All effects were blocked with the HER2 inhibitor lapatinib.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
25550597-0	2015	Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
25550597-11	2015	CONCLUSION: Lapatinib-plus-PLD is active and safe in HER2-positive MBC, especially suitable for patients with cardiological risk or brain metastases.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
25987098-3	2015	We retrospectively analyzed the efficacy of trastuzumab-based chemotherapy in HER2+ metastatic breast cancer patients whose disease progressed after lapatinib.	Lapatinib	149-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
25528021-11	2015	For HER2-positive patients with brain metastases, regardless of the use of trastuzumab before developing brain metastasis, treatment with both trastuzumab and lapatinib might improve survival.	Lapatinib	159-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
25528022-8	2015	The combination of HER2-targeted therapies and BAY 80-6946 inhibited growth more effectively than either therapy used alone (with clear synergism in many cases), and can restore sensitivity to trastuzumab and lapatinib in cells with acquired resistance to either trastuzumab and/or lapatinib.	Lapatinib	209-218	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
25515931-1	2015	Breast cancer patients who are HER2-positive receive targeted inhibitors to HER2, including trastuzumab and lapatinib.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
25528022-8	2015	The combination of HER2-targeted therapies and BAY 80-6946 inhibited growth more effectively than either therapy used alone (with clear synergism in many cases), and can restore sensitivity to trastuzumab and lapatinib in cells with acquired resistance to either trastuzumab and/or lapatinib.	Lapatinib	282-291	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
25692408-0	2015	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.	Lapatinib	42-51	mechanistic target of rapamycin kinase	Homo sapiens	17-21
25692408-0	2015	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.	Lapatinib	42-51	mechanistic target of rapamycin kinase	Homo sapiens	118-122
25692408-5	2015	Intriguingly, LapR cells had constitutive cytosolic cytochrome C, indicating that LapR cells suppress lapatinib-induced apoptosis downstream of cytochrome C release from mitochondria into the cytosol rather than by preventing its release into the cytosol.	Lapatinib	102-111	cytochrome c, somatic	Homo sapiens	52-64
25692408-0	2015	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.	Lapatinib	42-51	heat shock protein 90 alpha family class A member 1	Homo sapiens	127-132
25692408-5	2015	Intriguingly, LapR cells had constitutive cytosolic cytochrome C, indicating that LapR cells suppress lapatinib-induced apoptosis downstream of cytochrome C release from mitochondria into the cytosol rather than by preventing its release into the cytosol.	Lapatinib	102-111	cytochrome c, somatic	Homo sapiens	144-156
25692408-7	2015	Further, treatment with the mTOR kinase inhibitor AZD8055 or the Hsp90 inhibitor 17-AAG reversed expression of IAPs and overcame lapatinib resistance in LapR cells.	Lapatinib	129-138	mechanistic target of rapamycin kinase	Homo sapiens	28-32
25692408-4	2015	Lapatinib resistance could be reversed by mTOR kinase inhibition.	Lapatinib	0-9	mechanistic target of rapamycin kinase	Homo sapiens	42-46
25692408-7	2015	Further, treatment with the mTOR kinase inhibitor AZD8055 or the Hsp90 inhibitor 17-AAG reversed expression of IAPs and overcame lapatinib resistance in LapR cells.	Lapatinib	129-138	heat shock protein 90 alpha family class A member 1	Homo sapiens	65-70
25590338-7	2015	Importantly, ERBB4 knockdown triggered apoptosis not only in lapatinib-resistant cells but also in trastuzumab-resistant cells.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 4	Homo sapiens	13-18
25692408-8	2015	Together, these data suggest that suppression of apoptosis downstream of cytosolic cytochrome C release, possibly through increased expression of IAPs or other caspase-suppressing proteins, may promote lapatinib resistance.	Lapatinib	202-211	cytochrome c, somatic	Homo sapiens	83-95
25722902-0	2015	Metastatic, her-2 amplified lacrimal gland carcinoma with response to lapatinib treatment.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-17
25722902-5	2015	This case report describes treatment of a patient with metastatic lacrimal gland carcinoma with lapatinib, an oral agent with activity against Her-2/neu amplified malignancies.	Lapatinib	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-148
25722902-5	2015	This case report describes treatment of a patient with metastatic lacrimal gland carcinoma with lapatinib, an oral agent with activity against Her-2/neu amplified malignancies.	Lapatinib	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-152
25590338-4	2015	We demonstrate that genetic ablation of ERBB4, but not ERBB1-3, led to apoptosis in lapatinib-resistant cells, suggesting that the efficacy of pan-ERBB inhibitors was, at least in part, mediated by the inhibition of ERBB4.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 4	Homo sapiens	40-45
25590338-8	2015	Our results suggest that although ERBB4 is dispensable for naive ERBB2+ breast cancer cells, it may play a key role in the survival of ERBB2+ cancer cells after they develop resistance to ERBB2 inhibitors, lapatinib and trastuzumab.	Lapatinib	206-215	erb-b2 receptor tyrosine kinase 4	Homo sapiens	34-39
25590338-4	2015	We demonstrate that genetic ablation of ERBB4, but not ERBB1-3, led to apoptosis in lapatinib-resistant cells, suggesting that the efficacy of pan-ERBB inhibitors was, at least in part, mediated by the inhibition of ERBB4.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	40-44
25590338-4	2015	We demonstrate that genetic ablation of ERBB4, but not ERBB1-3, led to apoptosis in lapatinib-resistant cells, suggesting that the efficacy of pan-ERBB inhibitors was, at least in part, mediated by the inhibition of ERBB4.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 4	Homo sapiens	216-221
25590338-5	2015	Moreover, ERBB4 was upregulated at the protein level in ERBB2+ breast cancer cell lines selected for acquired lapatinib resistance in vitro and in MMTV-Neu mice following prolonged lapatinib treatment.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 4	Homo sapiens	10-15
25590338-5	2015	Moreover, ERBB4 was upregulated at the protein level in ERBB2+ breast cancer cell lines selected for acquired lapatinib resistance in vitro and in MMTV-Neu mice following prolonged lapatinib treatment.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
25590338-5	2015	Moreover, ERBB4 was upregulated at the protein level in ERBB2+ breast cancer cell lines selected for acquired lapatinib resistance in vitro and in MMTV-Neu mice following prolonged lapatinib treatment.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 4	Homo sapiens	10-15
25590338-5	2015	Moreover, ERBB4 was upregulated at the protein level in ERBB2+ breast cancer cell lines selected for acquired lapatinib resistance in vitro and in MMTV-Neu mice following prolonged lapatinib treatment.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
25421492-0	2015	A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-145
25590338-6	2015	Knockdown of ERBB4 caused a decrease in AKT phosphorylation in resistant cells but not in sensitive cells, suggesting that ERBB4 activated the PI3K/AKT pathway in lapatinib-resistant cells.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 4	Homo sapiens	13-18
25590338-6	2015	Knockdown of ERBB4 caused a decrease in AKT phosphorylation in resistant cells but not in sensitive cells, suggesting that ERBB4 activated the PI3K/AKT pathway in lapatinib-resistant cells.	Lapatinib	163-172	AKT serine/threonine kinase 1	Homo sapiens	40-43
25590338-6	2015	Knockdown of ERBB4 caused a decrease in AKT phosphorylation in resistant cells but not in sensitive cells, suggesting that ERBB4 activated the PI3K/AKT pathway in lapatinib-resistant cells.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 4	Homo sapiens	123-128
25590338-6	2015	Knockdown of ERBB4 caused a decrease in AKT phosphorylation in resistant cells but not in sensitive cells, suggesting that ERBB4 activated the PI3K/AKT pathway in lapatinib-resistant cells.	Lapatinib	163-172	AKT serine/threonine kinase 1	Homo sapiens	148-151
26624928-1	2015	BACKGROUND/AIMS: The human epidermal growth factor receptors tyrosine kinase inhibitor lapatinib has been shown to trigger suicidal death or apoptosis of tumor cells and is thus used for the treatment of malignancy.	Lapatinib	87-96	epidermal growth factor	Homo sapiens	27-50
26624928-6	2015	RESULTS: A 48 hours exposure of human erythrocytes to lapatinib (>= 1 microg/ml) significantly increased the percentage of annexin-V-binding cells, and significantly decreased forward scatter.	Lapatinib	54-63	annexin A5	Homo sapiens	126-135
26624928-9	2015	Lapatinib (7.5 microg/ml) enhanced the annexin-V-binding in the presence of the Ca2+ ionophore ionomycin (1 microM) without significantly modifying Fluo3 fluorescence in the presence of ionomycin.	Lapatinib	0-9	annexin A5	Homo sapiens	39-48
24911215-1	2015	The present studies were to determine whether the multi-kinase inhibitor sorafenib or its derivative regorafenib interacted with the ERBB1/ERBB2 inhibitor lapatinib to kill CNS tumor cells.	Lapatinib	155-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-144
26114862-0	2015	The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.	Lapatinib	56-65	epidermal growth factor receptor	Homo sapiens	22-26
26114862-0	2015	The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-36
26114862-4	2015	Chronic in vivo or acute ex vivo Lapatinib treatment also significantly attenuated diabetes-induced increases in phosphorylation of EGFR, ErbB2, ERK1/2, AKT, ROCK2 and IkB-alpha as well as normalized the reduced levels of phosphorylated FOXO3A, and eNOS (Ser1177) in the diabetic MVB.	Lapatinib	33-42	epidermal growth factor receptor	Homo sapiens	132-136
26114862-4	2015	Chronic in vivo or acute ex vivo Lapatinib treatment also significantly attenuated diabetes-induced increases in phosphorylation of EGFR, ErbB2, ERK1/2, AKT, ROCK2 and IkB-alpha as well as normalized the reduced levels of phosphorylated FOXO3A, and eNOS (Ser1177) in the diabetic MVB.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-143
26114862-4	2015	Chronic in vivo or acute ex vivo Lapatinib treatment also significantly attenuated diabetes-induced increases in phosphorylation of EGFR, ErbB2, ERK1/2, AKT, ROCK2 and IkB-alpha as well as normalized the reduced levels of phosphorylated FOXO3A, and eNOS (Ser1177) in the diabetic MVB.	Lapatinib	33-42	mitogen-activated protein kinase 3	Homo sapiens	145-151
26114862-4	2015	Chronic in vivo or acute ex vivo Lapatinib treatment also significantly attenuated diabetes-induced increases in phosphorylation of EGFR, ErbB2, ERK1/2, AKT, ROCK2 and IkB-alpha as well as normalized the reduced levels of phosphorylated FOXO3A, and eNOS (Ser1177) in the diabetic MVB.	Lapatinib	33-42	AKT serine/threonine kinase 1	Homo sapiens	153-156
26114862-4	2015	Chronic in vivo or acute ex vivo Lapatinib treatment also significantly attenuated diabetes-induced increases in phosphorylation of EGFR, ErbB2, ERK1/2, AKT, ROCK2 and IkB-alpha as well as normalized the reduced levels of phosphorylated FOXO3A, and eNOS (Ser1177) in the diabetic MVB.	Lapatinib	33-42	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	158-163
26114862-4	2015	Chronic in vivo or acute ex vivo Lapatinib treatment also significantly attenuated diabetes-induced increases in phosphorylation of EGFR, ErbB2, ERK1/2, AKT, ROCK2 and IkB-alpha as well as normalized the reduced levels of phosphorylated FOXO3A, and eNOS (Ser1177) in the diabetic MVB.	Lapatinib	33-42	NFKB inhibitor alpha	Homo sapiens	168-177
26114862-4	2015	Chronic in vivo or acute ex vivo Lapatinib treatment also significantly attenuated diabetes-induced increases in phosphorylation of EGFR, ErbB2, ERK1/2, AKT, ROCK2 and IkB-alpha as well as normalized the reduced levels of phosphorylated FOXO3A, and eNOS (Ser1177) in the diabetic MVB.	Lapatinib	33-42	forkhead box O3	Homo sapiens	237-243
26114862-5	2015	Similar results were observed in vascular smooth muscle cells (VSMCs) cultured in high glucose (25 mM) treated with Lapatinib or small interfering RNA (siRNA) targeting the ErbB2 receptor.	Lapatinib	116-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-178
26114862-7	2015	Thus, Lapatinib corrects hyperglycemia-induced apoptosis and vascular dysfunction with concomitant reversal of diabetes or high glucose-induced signaling changes in EGFR/ErbB2 and downstream signaling pathways implying that targeted dual inhibition of EGFR/ErbB2 might be an effective vasculoprotective treatment strategy in diabetic patients.	Lapatinib	6-15	epidermal growth factor receptor	Homo sapiens	165-169
26114862-7	2015	Thus, Lapatinib corrects hyperglycemia-induced apoptosis and vascular dysfunction with concomitant reversal of diabetes or high glucose-induced signaling changes in EGFR/ErbB2 and downstream signaling pathways implying that targeted dual inhibition of EGFR/ErbB2 might be an effective vasculoprotective treatment strategy in diabetic patients.	Lapatinib	6-15	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-175
26114862-7	2015	Thus, Lapatinib corrects hyperglycemia-induced apoptosis and vascular dysfunction with concomitant reversal of diabetes or high glucose-induced signaling changes in EGFR/ErbB2 and downstream signaling pathways implying that targeted dual inhibition of EGFR/ErbB2 might be an effective vasculoprotective treatment strategy in diabetic patients.	Lapatinib	6-15	epidermal growth factor receptor	Homo sapiens	252-256
26114862-7	2015	Thus, Lapatinib corrects hyperglycemia-induced apoptosis and vascular dysfunction with concomitant reversal of diabetes or high glucose-induced signaling changes in EGFR/ErbB2 and downstream signaling pathways implying that targeted dual inhibition of EGFR/ErbB2 might be an effective vasculoprotective treatment strategy in diabetic patients.	Lapatinib	6-15	erb-b2 receptor tyrosine kinase 2	Homo sapiens	257-262
26516301-4	2015	Lasso and elastic net regression identified HER2 as a predictor protein for lapatinib, afatinib, gefitinib and erlotinib, which target HER2 or the EGF receptor, thus providing an internal control for the approach.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
26516301-4	2015	Lasso and elastic net regression identified HER2 as a predictor protein for lapatinib, afatinib, gefitinib and erlotinib, which target HER2 or the EGF receptor, thus providing an internal control for the approach.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-139
25435079-4	2015	Lapatinib is a dual TKI that targets both EGFR and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	42-46
25435079-4	2015	Lapatinib is a dual TKI that targets both EGFR and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	epidermal growth factor receptor	Mus musculus	11-15
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Mus musculus	19-23
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	epidermal growth factor receptor	Mus musculus	109-113
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Mus musculus	118-122
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	prolactin	Mus musculus	147-150
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	prolactin	Mus musculus	179-182
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	epidermal growth factor receptor	Mus musculus	109-113
25375038-4	2015	Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Mus musculus	118-122
25421492-1	2015	Lapatinib (LPT) could sensitize human epidermal growth factor receptor-2 (HER-2) positive breast cancer to paclitaxel (PTX) and induce synergetic action with PTX in preclinical test and phase II/III trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-72
25421492-1	2015	Lapatinib (LPT) could sensitize human epidermal growth factor receptor-2 (HER-2) positive breast cancer to paclitaxel (PTX) and induce synergetic action with PTX in preclinical test and phase II/III trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
25421492-1	2015	Lapatinib (LPT) could sensitize human epidermal growth factor receptor-2 (HER-2) positive breast cancer to paclitaxel (PTX) and induce synergetic action with PTX in preclinical test and phase II/III trial.	Lapatinib	11-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-72
25421492-1	2015	Lapatinib (LPT) could sensitize human epidermal growth factor receptor-2 (HER-2) positive breast cancer to paclitaxel (PTX) and induce synergetic action with PTX in preclinical test and phase II/III trial.	Lapatinib	11-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
26134366-0	2015	Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21
25622903-0	2015	Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.	Lapatinib	41-50	heparanase	Homo sapiens	0-10
25622903-3	2015	Lapatinib (Tykerb) is a small-molecule and dual inhibitor of human epidermal growth factor receptor1 and 2 (EGFR and HER2, respectively) which are both high-risk predictors of BMBC.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-106
25622903-3	2015	Lapatinib (Tykerb) is a small-molecule and dual inhibitor of human epidermal growth factor receptor1 and 2 (EGFR and HER2, respectively) which are both high-risk predictors of BMBC.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	108-112
25622903-3	2015	Lapatinib (Tykerb) is a small-molecule and dual inhibitor of human epidermal growth factor receptor1 and 2 (EGFR and HER2, respectively) which are both high-risk predictors of BMBC.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
25622903-3	2015	Lapatinib (Tykerb) is a small-molecule and dual inhibitor of human epidermal growth factor receptor1 and 2 (EGFR and HER2, respectively) which are both high-risk predictors of BMBC.	Lapatinib	11-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-106
25622903-3	2015	Lapatinib (Tykerb) is a small-molecule and dual inhibitor of human epidermal growth factor receptor1 and 2 (EGFR and HER2, respectively) which are both high-risk predictors of BMBC.	Lapatinib	11-17	epidermal growth factor receptor	Homo sapiens	108-112
25622903-3	2015	Lapatinib (Tykerb) is a small-molecule and dual inhibitor of human epidermal growth factor receptor1 and 2 (EGFR and HER2, respectively) which are both high-risk predictors of BMBC.	Lapatinib	11-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
26241555-5	2015	OOS reduced the proliferation of these cells, and augmented the action of lapatinib, a HER2 inhibitor used in the breast cancer clinic.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
25622903-8	2015	Roneparstat overcame lapatinib resistance by inhibiting pathways associated with EGFR tyrosine residues that are not targeted by lapatinib.	Lapatinib	21-30	epidermal growth factor receptor	Homo sapiens	81-85
25622903-10	2015	A molecular mechanism was identified by which HPSE mediates an alternative survival pathway in lapatinib-resistant clones and is modulated by Roneparstat.	Lapatinib	95-104	heparanase	Homo sapiens	46-50
25622903-11	2015	These results demonstrate that the inhibition of HPSE-mediated signaling plays important roles in lapatinib resistance, and provide mechanistic insights to validate the use of Roneparstat for novel BMBC therapeutic strategies.	Lapatinib	98-107	heparanase	Homo sapiens	49-53
26134366-4	2015	In our in vitro research we used a commercially available drug, lapatinib, acting at the level of the receptor in combination with 1 of the plant-derived isothiocyanates: sulforaphane, erucin, or sulforaphene, as it has been shown previously that sulforaphane inhibits Akt-mTOR-S6K1 pathway in breast cancer cells.	Lapatinib	64-73	mechanistic target of rapamycin kinase	Homo sapiens	273-277
26134366-4	2015	In our in vitro research we used a commercially available drug, lapatinib, acting at the level of the receptor in combination with 1 of the plant-derived isothiocyanates: sulforaphane, erucin, or sulforaphene, as it has been shown previously that sulforaphane inhibits Akt-mTOR-S6K1 pathway in breast cancer cells.	Lapatinib	64-73	AKT serine/threonine kinase 1	Homo sapiens	269-272
25587029-7	2014	To address the significance of p27 mislocalization in Her2+ breast cancer cells we interrogated the cellular response to the dual-Her2/EGFR kinase inhibitor, lapatinib.	Lapatinib	158-167	interferon alpha inducible protein 27	Homo sapiens	31-34
25623322-11	2014	Lapatinib plus trastuzumab achieves better pCR than trastuzumab so that it and may become a first-choice of neoadjuvant therapy for HER-2 positive breast cancer regardless of economic affordability for patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-137
26265235-2	2015	Since human leukocyte antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous reactions, this study investigated the association of HLA alleles with lapatinib-induced rash.	Lapatinib	171-180	major histocompatibility complex, class II, DR beta 1	Homo sapiens	31-34
26265235-2	2015	Since human leukocyte antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous reactions, this study investigated the association of HLA alleles with lapatinib-induced rash.	Lapatinib	171-180	major histocompatibility complex, class II, DR beta 1	Homo sapiens	154-157
25587029-7	2014	To address the significance of p27 mislocalization in Her2+ breast cancer cells we interrogated the cellular response to the dual-Her2/EGFR kinase inhibitor, lapatinib.	Lapatinib	158-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
25587029-7	2014	To address the significance of p27 mislocalization in Her2+ breast cancer cells we interrogated the cellular response to the dual-Her2/EGFR kinase inhibitor, lapatinib.	Lapatinib	158-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
25587029-7	2014	To address the significance of p27 mislocalization in Her2+ breast cancer cells we interrogated the cellular response to the dual-Her2/EGFR kinase inhibitor, lapatinib.	Lapatinib	158-167	epidermal growth factor receptor	Homo sapiens	135-139
25348000-9	2014	For HER2-positive tumors, lapatinib was associated with longer median PFS (5.9 v 3.3 months), but the differential treatment effect by HER2 status was not significant (P = .53).	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
25587029-8	2014	Knockdown of p27 using shRNA sensitized Her2+ cells to lapatinib-induced apoptosis.	Lapatinib	55-64	interferon alpha inducible protein 27	Homo sapiens	13-16
25587029-8	2014	Knockdown of p27 using shRNA sensitized Her2+ cells to lapatinib-induced apoptosis.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
25587029-9	2014	Moreover, expression of a constitutively cytoplasmic form of p27 (p27DeltaNLS) reversed the lapatinib-induced apoptosis, suggesting that cytoplasmic p27 contributed to lapatinib resistance in Her2+ breast cancer cells by suppressing apoptosis.	Lapatinib	92-101	interferon alpha inducible protein 27	Homo sapiens	61-64
25587029-9	2014	Moreover, expression of a constitutively cytoplasmic form of p27 (p27DeltaNLS) reversed the lapatinib-induced apoptosis, suggesting that cytoplasmic p27 contributed to lapatinib resistance in Her2+ breast cancer cells by suppressing apoptosis.	Lapatinib	92-101	interferon alpha inducible protein 27	Homo sapiens	66-69
25587029-9	2014	Moreover, expression of a constitutively cytoplasmic form of p27 (p27DeltaNLS) reversed the lapatinib-induced apoptosis, suggesting that cytoplasmic p27 contributed to lapatinib resistance in Her2+ breast cancer cells by suppressing apoptosis.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	192-196
25587029-9	2014	Moreover, expression of a constitutively cytoplasmic form of p27 (p27DeltaNLS) reversed the lapatinib-induced apoptosis, suggesting that cytoplasmic p27 contributed to lapatinib resistance in Her2+ breast cancer cells by suppressing apoptosis.	Lapatinib	168-177	interferon alpha inducible protein 27	Homo sapiens	61-64
25587029-9	2014	Moreover, expression of a constitutively cytoplasmic form of p27 (p27DeltaNLS) reversed the lapatinib-induced apoptosis, suggesting that cytoplasmic p27 contributed to lapatinib resistance in Her2+ breast cancer cells by suppressing apoptosis.	Lapatinib	168-177	interferon alpha inducible protein 27	Homo sapiens	66-69
25587029-9	2014	Moreover, expression of a constitutively cytoplasmic form of p27 (p27DeltaNLS) reversed the lapatinib-induced apoptosis, suggesting that cytoplasmic p27 contributed to lapatinib resistance in Her2+ breast cancer cells by suppressing apoptosis.	Lapatinib	168-177	erb-b2 receptor tyrosine kinase 2	Homo sapiens	192-196
25623322-0	2014	[Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73
25623322-1	2014	OBJECTIVE: To compare the efficacy of lapatinib or lapatinib plus trastuzumab versus trastuzumab in the neoadjuvant therapy of human epidermal growth factor receptor 2 (HER-2) positive breast cancer.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-174
25294905-2	2014	We investigated the effectiveness of HER2 inhibition using lapatinib and trastuzumab in vitro and in xenografts derived from USC cell lines and USC patient-derived xenografts.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
25294905-4	2014	ARK1, ARK2, and SPEC2 cell lines were treated with trastuzumab or lapatinib.	Lapatinib	66-75	aurora kinase A	Homo sapiens	0-4
25294905-4	2014	ARK1, ARK2, and SPEC2 cell lines were treated with trastuzumab or lapatinib.	Lapatinib	66-75	CDC42 small effector 2	Homo sapiens	16-21
25294905-9	2014	Lapatinib decreased in vitro proliferation of all cell lines and in vivo growth of HER2-amplified xenografts (ARK2, EnCa1).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
25294905-9	2014	Lapatinib decreased in vitro proliferation of all cell lines and in vivo growth of HER2-amplified xenografts (ARK2, EnCa1).	Lapatinib	0-9	aurora kinase B	Homo sapiens	110-114
25294905-10	2014	In addition, dual therapy with trastuzumab and lapatinib resulted in significant antitumor activity only in ARK2 and EnCa1 tumors.	Lapatinib	47-56	aurora kinase B	Homo sapiens	108-112
25294905-12	2014	CONCLUSIONS: Although trastuzumab alone did not impact USC growth, dual anti-HER2 therapy with lapatinib led to improved inhibition of tumor growth in HER2-amplified USC and may be a promising avenue for future investigation.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
25294905-12	2014	CONCLUSIONS: Although trastuzumab alone did not impact USC growth, dual anti-HER2 therapy with lapatinib led to improved inhibition of tumor growth in HER2-amplified USC and may be a promising avenue for future investigation.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
25351929-0	2014	Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
25492965-4	2014	Knocking down YAP or ERBB4 prevented the induction of CTGF expression by NRG1, as did treating cells with the ERBB inhibitors lapatinib or erlotinib, which reduced ERBB4 cleavage.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 4	Homo sapiens	164-169
25475708-8	2014	Lapatinib, a dual tyrosine kinase inhibitor anti-HER2 and EGFR, has shown significant activity in two phase II studies dedicated to HER2-positive IBC.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-53
25475708-8	2014	Lapatinib, a dual tyrosine kinase inhibitor anti-HER2 and EGFR, has shown significant activity in two phase II studies dedicated to HER2-positive IBC.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	58-62
25475708-8	2014	Lapatinib, a dual tyrosine kinase inhibitor anti-HER2 and EGFR, has shown significant activity in two phase II studies dedicated to HER2-positive IBC.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	197-206	ETS transcription factor ELK1	Homo sapiens	111-116
25674245-4	2014	Furthermore, the human OS cell lines MG-63 and U2-OS were treated with FASN-specific RNAi Plasmid or Lapatinib (an inhibitor of HER2).	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	197-206	E2F transcription factor 1	Homo sapiens	121-125
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	197-206	GATA binding protein 1	Homo sapiens	216-222
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	197-206	erb-b2 receptor tyrosine kinase 2	Homo sapiens	254-259
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	197-206	erb-b2 receptor tyrosine kinase 2	Homo sapiens	302-307
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	385-394	ETS transcription factor ELK1	Homo sapiens	111-116
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	385-394	E2F transcription factor 1	Homo sapiens	121-125
25303361-4	2014	We identified major hubs at various stages of culture associated with normal and abnormal tissue growth (i.e., ELK-1 and E2F1, respectively) and the mechanism of action for a targeted therapeutic, lapatinib, through GATA-1, which were confirmed in human ErbB2 positive breast cancer patients and human ErbB2 positive breast cancer cell lines that were either sensitive or resistant to lapatinib.	Lapatinib	385-394	GATA binding protein 1	Homo sapiens	216-222
25195596-5	2014	By applying this genome-wide approach to cell lines representing two subtypes of HER2(+) breast cancer, we identified 62 candidate lapatinib resistance genes.	Lapatinib	131-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-85
25294797-2	2014	The aim of this study is to investigate efficacy and tolerability of the combination of lapatinib and capecitabine (LC) in HER2+ve BC patients with brain metastases (BCBM).	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
25070180-6	2014	We found one of them, JAK3 inhibitor VI, capable of inhibiting invasion of highly invasive ErbB2-positive ovarian cancer cells as efficiently as lapatinib, whereas Go6979 and Roscovitine displayed more modest inhibition.	Lapatinib	145-154	Janus kinase 3	Homo sapiens	22-26
25070180-11	2014	Additionally, we introduce a novel function for lapatinib in controlling malignant lysosomal distribution, that may also be involved in its capability to inhibit ErbB2-induced invasion in vivo.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-167
25436131-3	2014	Her treatment was then switched to dual HER2 blockade with both trastuzumab and lapatinib in combination with capecitabine.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
25436131-6	2014	Discordant negative expression of HER2 and subclonal mutations in brain lesions were discovered, which, at least in part, explained her brain metastases in the presence of capecitabine and lapatinib, as both agents are known to be able to cross the blood brain barrier.	Lapatinib	189-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
25195596-6	2014	We validated the top ranking genes, i.e., PIK3CA and PIK3CB, by showing that their forced expression confers resistance to lapatinib in vitro and found that their mutation/overexpression is associated to poor prognosis in human breast tumors.	Lapatinib	123-132	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	42-48
25195596-6	2014	We validated the top ranking genes, i.e., PIK3CA and PIK3CB, by showing that their forced expression confers resistance to lapatinib in vitro and found that their mutation/overexpression is associated to poor prognosis in human breast tumors.	Lapatinib	123-132	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	53-59
25440878-0	2014	Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-138
25275302-2	2014	Lapatinib (Lap)-based LDT reagents not only labeled a receptor tyrosine kinase, HER2, target protein, but also the protein disulfide isomerase (PDI) that should be an off-target protein for Lap.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
25275302-2	2014	Lapatinib (Lap)-based LDT reagents not only labeled a receptor tyrosine kinase, HER2, target protein, but also the protein disulfide isomerase (PDI) that should be an off-target protein for Lap.	Lapatinib	0-9	prolyl 4-hydroxylase subunit beta	Homo sapiens	115-142
25275302-2	2014	Lapatinib (Lap)-based LDT reagents not only labeled a receptor tyrosine kinase, HER2, target protein, but also the protein disulfide isomerase (PDI) that should be an off-target protein for Lap.	Lapatinib	0-9	prolyl 4-hydroxylase subunit beta	Homo sapiens	144-147
25440878-2	2014	Overexpression of Her-2 can be a predictive biomarker for stratification of patients for therapy with Herceptin (containing humanized IgG1 monoclonal antibody trastuzumab) or Tykerb (containing lapatinib di-p-toluenesulfonate) drug.	Lapatinib	175-181	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-23
25440878-4	2014	The objective of the present work was to standardize the conjugation of anti-cancer drug lapatinib (which recognizes selectively the Her-2 extracellular domain) with technetium-99m complex, of type "4+1", to obtain (99m)Tc(NS3)(CN-lapatinib) conjugate for use as in vivo tracer of the Her-2 expression in breast cancer.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-138
25440878-4	2014	The objective of the present work was to standardize the conjugation of anti-cancer drug lapatinib (which recognizes selectively the Her-2 extracellular domain) with technetium-99m complex, of type "4+1", to obtain (99m)Tc(NS3)(CN-lapatinib) conjugate for use as in vivo tracer of the Her-2 expression in breast cancer.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	285-290
25270122-0	2014	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	131-163
23335064-0	2014	Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
25305330-0	2014	Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates.	Lapatinib	24-33	epidermal growth factor receptor	Homo sapiens	82-86
25305330-0	2014	Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates.	Lapatinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
25082874-10	2014	CONCLUSION: Ado-trastuzumab emtansine is a novel ADC effective for HER2-positive MBC in patients previously treated with trastuzumab, lapatinib, and a taxane.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
25270122-0	2014	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
25270122-1	2014	This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC).	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
24692179-6	2014	To test if ErbB2 kinase activity was required for the HRG-induced downregulation, we treated cells with the ErbB2/EGFR inhibitor lapatinib.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-16
24692179-6	2014	To test if ErbB2 kinase activity was required for the HRG-induced downregulation, we treated cells with the ErbB2/EGFR inhibitor lapatinib.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-113
24692179-6	2014	To test if ErbB2 kinase activity was required for the HRG-induced downregulation, we treated cells with the ErbB2/EGFR inhibitor lapatinib.	Lapatinib	129-138	epidermal growth factor receptor	Homo sapiens	114-118
24692179-7	2014	Lapatinib diminished the HRG-induced decrease in ErbB2 and ErbB3 mRNA and protein, suggesting that the kinase activity of EGFR/ErbB2 is involved in the HRG-induced receptor downregulation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-54
24692179-7	2014	Lapatinib diminished the HRG-induced decrease in ErbB2 and ErbB3 mRNA and protein, suggesting that the kinase activity of EGFR/ErbB2 is involved in the HRG-induced receptor downregulation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 3	Homo sapiens	59-64
24692179-7	2014	Lapatinib diminished the HRG-induced decrease in ErbB2 and ErbB3 mRNA and protein, suggesting that the kinase activity of EGFR/ErbB2 is involved in the HRG-induced receptor downregulation.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	122-126
24692179-7	2014	Lapatinib diminished the HRG-induced decrease in ErbB2 and ErbB3 mRNA and protein, suggesting that the kinase activity of EGFR/ErbB2 is involved in the HRG-induced receptor downregulation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-132
25489176-0	2014	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.	Lapatinib	46-55	EMAP like 4	Homo sapiens	83-87
25688493-1	2014	AIMS: The study aimed to determine if retreatment with trastuzumab after progression on treatment with lapatinib is feasible in a previously heavily pretreated population of HER2-positive metastatic breast cancer patients and if some range of activity and an acceptable toxicity profile could be shown.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
25688493-5	2014	RESULTS: Between April 2007 and February 2013, a total of 77 patients with HER2-positive metastatic breast cancer were identified who had been treated with lapatinib plus capecitabine at our institution.	Lapatinib	156-165	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
25091467-4	2014	In OE21 cells, the TKIs erlotinib, gefitinib, and lapatinib slightly affected epidermal growth factor receptor EGFR/EGFR, but not EGFR/HER2 dimerization as detected by in situ proximity ligation assay (in situ PLA).	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	111-115
25091467-4	2014	In OE21 cells, the TKIs erlotinib, gefitinib, and lapatinib slightly affected epidermal growth factor receptor EGFR/EGFR, but not EGFR/HER2 dimerization as detected by in situ proximity ligation assay (in situ PLA).	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	116-120
25091467-4	2014	In OE21 cells, the TKIs erlotinib, gefitinib, and lapatinib slightly affected epidermal growth factor receptor EGFR/EGFR, but not EGFR/HER2 dimerization as detected by in situ proximity ligation assay (in situ PLA).	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	116-120
25091467-7	2014	In contrast, in OE33 cells, only lapatinib decreased STAT5, Src family kinase (SFK), and FAK activity as well as beta-catenin expression.	Lapatinib	33-42	signal transducer and activator of transcription 5A	Homo sapiens	53-58
25091467-7	2014	In contrast, in OE33 cells, only lapatinib decreased STAT5, Src family kinase (SFK), and FAK activity as well as beta-catenin expression.	Lapatinib	33-42	protein tyrosine kinase 2	Homo sapiens	89-92
25225290-10	2014	PMA-induced Erk phosphorylation was reduced by ErbB2 inhibitor lapatinib, as well as by knockdown of PKC-delta but not that of PKC-alpha.	Lapatinib	63-72	mitogen-activated protein kinase 1	Homo sapiens	12-15
25225290-10	2014	PMA-induced Erk phosphorylation was reduced by ErbB2 inhibitor lapatinib, as well as by knockdown of PKC-delta but not that of PKC-alpha.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
25350844-0	2014	Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.	Lapatinib	30-39	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
25350844-0	2014	Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
25350844-4	2014	We generated lapatinib-resistant (LR) subclones from an initially lapatinib-sensitive ERBB2-amplified esophageal adenocarcinoma cell line, OE19.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-91
25350844-8	2014	Genetic and pharmacologic inhibition of Src resensitized these subclones to lapatinib.	Lapatinib	76-85	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	40-43
25350844-9	2014	Biochemically, Src mutations could activate both the phosphatidylinositol 3-kinase and mitogen activated protein kinase pathways in the lapatinib-treated LR OE19 cells.	Lapatinib	136-145	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	15-18
25489176-0	2014	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.	Lapatinib	46-55	ALK receptor tyrosine kinase	Homo sapiens	88-91
25489176-6	2014	Computer aided molecular docking data show Tivozanib and Lapatinib bind EML4-ALK with high score.	Lapatinib	57-66	EMAP like 4	Homo sapiens	72-76
25489176-6	2014	Computer aided molecular docking data show Tivozanib and Lapatinib bind EML4-ALK with high score.	Lapatinib	57-66	ALK receptor tyrosine kinase	Homo sapiens	77-80
25489176-7	2014	Tivozanib is in clinical trials for renal cell cancer and Lapatinib is a known dual tyrosine kinase inhibitor effective in breast cancer patients with HER2 over-expression.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
25053627-1	2014	Lapatinib, a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2), is prescribed for the treatment of patients with metastatic breast cancer overexpressing HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	58-90
25442282-4	2014	Synergism between (+)-PA and lapatinib, a HER2 active drug, was also evaluated.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
25199759-4	2014	All HER2-positive patients received either trastuzumab or lapatinib or the combination plus anthracycline-taxane chemotherapy.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
25199759-11	2014	In patients with PIK3CA mutation, the pCR rates were 16%, 24.3%, and 17.4% with lapatinib, trastuzumab, and the combination, respectively (P = .654) and in the wild-type group, they were 18.2%, 33.%, and 37.1%, respectively (P = .017).	Lapatinib	80-89	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	17-23
25216762-1	2014	Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-56
25053627-1	2014	Lapatinib, a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2), is prescribed for the treatment of patients with metastatic breast cancer overexpressing HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	92-96
25053627-1	2014	Lapatinib, a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2), is prescribed for the treatment of patients with metastatic breast cancer overexpressing HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-142
25053627-1	2014	Lapatinib, a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2), is prescribed for the treatment of patients with metastatic breast cancer overexpressing HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-149
25053627-1	2014	Lapatinib, a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2), is prescribed for the treatment of patients with metastatic breast cancer overexpressing HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	241-246
24112786-1	2014	Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	63-95
24510732-7	2014	In EAC cells (OE19, OE33 and SK-GT-4), lapatinib was similarly effective in strongly HER2-positive (mainly HER2 homodimers and some HER2/EGFR heterodimers) OE19 and OE33 cells.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
24112786-0	2014	Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
24510732-7	2014	In EAC cells (OE19, OE33 and SK-GT-4), lapatinib was similarly effective in strongly HER2-positive (mainly HER2 homodimers and some HER2/EGFR heterodimers) OE19 and OE33 cells.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
24510732-7	2014	In EAC cells (OE19, OE33 and SK-GT-4), lapatinib was similarly effective in strongly HER2-positive (mainly HER2 homodimers and some HER2/EGFR heterodimers) OE19 and OE33 cells.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
24510732-7	2014	In EAC cells (OE19, OE33 and SK-GT-4), lapatinib was similarly effective in strongly HER2-positive (mainly HER2 homodimers and some HER2/EGFR heterodimers) OE19 and OE33 cells.	Lapatinib	39-48	epidermal growth factor receptor	Homo sapiens	137-141
24112786-1	2014	Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-112
24112786-1	2014	Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	118-150
24112786-1	2014	Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	152-156
25249538-0	2014	Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.	Lapatinib	130-139	epidermal growth factor receptor	Mus musculus	14-18
25579538-0	2014	Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-81
25579538-2	2014	PATIENTS AND METHODS: This is a descriptive retrospective study of trastuzumab plus lapatinib activity in patients with HER2-overexpressing mBC from two centers.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
25579538-5	2014	RESULTS: A total of 23 HER2-positive mBC patients previously treated with trastuzumab received a trastuzumab plus lapatinib based therapy.	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
25055963-7	2014	Activation of ErbB signaling by neuregulin-1beta (NRG, a natural ligand for ErbB4) and its modulation by trastuzumab (a monoclonal anti-ErbB2 antibody) and lapatinib (a small molecule ErbB2 tyrosine kinase inhibitor) were evaluated through assessing phosphorylation of AKT and Erk1/2, two major downstream kinases of ErbB signaling, using nanofluidic proteomic immunoassay.	Lapatinib	156-165	epidermal growth factor receptor	Homo sapiens	14-18
25249538-0	2014	Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 3	Mus musculus	29-33
25249538-0	2014	Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.	Lapatinib	130-139	neurotensin	Mus musculus	37-48
25249538-0	2014	Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.	Lapatinib	130-139	neurotensin receptor 1	Mus musculus	49-71
25249538-8	2014	Accordingly, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, as well as metformin, reduced the tumor growth of cells overexpressing NTS and NTSR1.	Lapatinib	13-22	epidermal growth factor receptor	Mus musculus	27-31
25249538-8	2014	Accordingly, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, as well as metformin, reduced the tumor growth of cells overexpressing NTS and NTSR1.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Mus musculus	32-36
25249538-8	2014	Accordingly, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, as well as metformin, reduced the tumor growth of cells overexpressing NTS and NTSR1.	Lapatinib	13-22	neurotensin	Mus musculus	135-138
25249538-8	2014	Accordingly, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, as well as metformin, reduced the tumor growth of cells overexpressing NTS and NTSR1.	Lapatinib	13-22	neurotensin receptor 1	Mus musculus	143-148
25105301-0	2014	Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.	Lapatinib	0-9	ATP binding cassette subfamily C member 1	Homo sapiens	22-63
24615495-8	2014	The cytotoxicity of expanded NK cells against HER2-positive gastric cancer cells could be increased by Herceptin and further augmented by Lapatinib.	Lapatinib	138-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50
25203051-6	2014	Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops with the dual tyrosine kinase inhibitor Lapatinib or ER-alpha36 down-regulator Broussoflavonol B in tamoxifen resistant MCF7 cells restored tamoxifen sensitivity.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
25105301-1	2014	Lapatinib, a tyrosine kinase inhibitor, is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
25105301-4	2014	We demonstrated that lapatinib could enhance the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells in vitro and in vivo, but no effect in MRP2-, MPR4- and LRP-overexpressing cells.	Lapatinib	21-30	ATP binding cassette subfamily C member 1	Homo sapiens	101-105
25105301-2	2014	Lapatinib can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and ABCG2), which are the major mechanism responsible for multidrug resistance (MDR) in cancer.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	80-85
25105301-5	2014	Furthermore, lapatinib significantly increased the accumulation of rhodamine 123 (Rho123) and doxorubicin (DOX) in MRP1-overexpressing cells.	Lapatinib	13-22	ATP binding cassette subfamily C member 1	Homo sapiens	115-119
25105301-8	2014	In conclusion, lapatinib enhanced the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells by inhibiting MRP1 transport function without altering the level of AKT or ERK1/2 phosphorylation.	Lapatinib	15-24	ATP binding cassette subfamily C member 1	Homo sapiens	90-94
25105301-8	2014	In conclusion, lapatinib enhanced the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells by inhibiting MRP1 transport function without altering the level of AKT or ERK1/2 phosphorylation.	Lapatinib	15-24	ATP binding cassette subfamily C member 1	Homo sapiens	130-134
25105301-2	2014	Lapatinib can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and ABCG2), which are the major mechanism responsible for multidrug resistance (MDR) in cancer.	Lapatinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	90-95
25105301-9	2014	These findings will encourage the clinical research of lapatinib combined with conventional chemotherapeutic drugs in MRP1-overexpressing cancer patients.	Lapatinib	55-64	ATP binding cassette subfamily C member 1	Homo sapiens	118-122
25105301-3	2014	In this study, we investigated the effect of lapatinib on multidrug resistance-associated protein 1 (MRP1 [ABCC1]), MRP2 (ABCC2), MRP4 (ABCC4) and lung relative resistance protein (LRP) drug efflux pumps.	Lapatinib	45-54	ATP binding cassette subfamily C member 1	Homo sapiens	101-105
25055934-2	2014	This study aimed to identify histological and molecular changes within the intestine following lapatinib to elucidate mechanisms of diarrhoea related to treatment with this dual EGFR TKI.	Lapatinib	95-104	epidermal growth factor receptor	Rattus norvegicus	178-182
25186428-10	2014	CONCLUSIONS: Four weeks of neoadjuvant lapatinib in patients with HER2-positive DCIS resulted in inhibition of HER2 and RAS/MAPK signaling pathway.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
25186428-10	2014	CONCLUSIONS: Four weeks of neoadjuvant lapatinib in patients with HER2-positive DCIS resulted in inhibition of HER2 and RAS/MAPK signaling pathway.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
24971884-0	2014	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-15
24971884-1	2014	Lapatinib, a dual tyrosine kinase inhibitor of ErbB1 and ErbB2, shows a clinical benefit in a subset of patients with advanced urothelial bladder cancer (UBC).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	47-52
24971884-1	2014	Lapatinib, a dual tyrosine kinase inhibitor of ErbB1 and ErbB2, shows a clinical benefit in a subset of patients with advanced urothelial bladder cancer (UBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-62
25186428-0	2014	Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
25186428-2	2014	This study aimed to determine the molecular effects of the HER2 inhibitor lapatinib in patients with HER2 positive DCIS.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
25186428-2	2014	This study aimed to determine the molecular effects of the HER2 inhibitor lapatinib in patients with HER2 positive DCIS.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
25186428-3	2014	METHODS: Patients with HER2 positive DCIS received 1,500 mg daily of lapatinib for four consecutive weeks prior to surgical resection.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
25186428-5	2014	The molecular effects of lapatinib on HER2 signaling (PI3K/AKT and RAS/MAPK pathways), cell proliferation (Ki67 and p27) and apoptosis (TUNEL) were determined in pre and post-lapatinib treatment samples.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
24953979-6	2014	Several molecules which target multiple ErbB receptors are being investigated in NSCLC and other indications including afatinib, an ErbB Family Blocker, as well as dacomitinib and lapatinib.	Lapatinib	180-189	epidermal growth factor receptor	Homo sapiens	40-44
24971884-2	2014	We hypothesized that the corresponding gene, ERBB2, is affected by mutations in a subset of UBC and that these mutations impact ErbB2 function, signaling, UBC proliferation, gene expression, and predict response to lapatinib.	Lapatinib	215-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-50
24971884-2	2014	We hypothesized that the corresponding gene, ERBB2, is affected by mutations in a subset of UBC and that these mutations impact ErbB2 function, signaling, UBC proliferation, gene expression, and predict response to lapatinib.	Lapatinib	215-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-133
24971884-8	2014	The sensitivity to lapatinib was greatest among cell lines with ERBB2 mutations.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-69
24971884-9	2014	In conclusion, ERBB2 mutations occur in a subset of UBC and impact proliferation, signaling, gene expression and predict a greater response to lapatinib.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
25055934-10	2014	Markers of apoptosis (caspase-3) and proliferation (Ki-67) were only significantly altered in rats treated with both lapatinib and paclitaxel.	Lapatinib	117-126	caspase 3	Rattus norvegicus	22-31
25055934-11	2014	CONCLUSIONS: In our novel rat model of lapatinib-induced diarrhoea we have shown that changes in small intestinal morphometry and expression of EGFR are associated with diarrhoea.	Lapatinib	39-48	epidermal growth factor receptor	Rattus norvegicus	144-148
25285186-6	2014	There has been progress, with the approval of three additional HER2-targeted agents in the last six years: lapatinib, pertuzumab, and ado-trastuzumab emtansine (T-DM1).	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
24973425-0	2014	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 3	Homo sapiens	44-48
24973425-0	2014	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.	Lapatinib	90-99	insulin like growth factor 1 receptor	Homo sapiens	50-55
24973425-0	2014	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.	Lapatinib	90-99	insulin receptor	Homo sapiens	57-61
24973425-0	2014	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
24973425-2	2014	However, as seen in recent clinical trials, most of HER2+ gastric cancer are actually unresponsive to HER2-targeted agents, including lapatinib.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
24973425-3	2014	The aim of this study is to identify the responsible receptor tyrosine kinases (RTK) potentially conferring lapatinib unresponsiveness in HER2+ gastric cancer and elucidate the molecular mechanism underlying this RTKs-induced resistance.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
24973425-4	2014	EXPERIMENTAL DESIGN: A functional RNAi screen targeting human RTKs and related growth factors was used to identify candidate RTKs conferring lapatinib unresponsiveness in HER2+ gastric cancer cells.	Lapatinib	141-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-175
24973425-9	2014	RESULTS: MET, HER3, insulin-like growth factor (IGF)-1R, and INSR were identified to mediate lapatinib unresponsiveness in HER2+ gastric cancer cells.	Lapatinib	93-102	insulin like growth factor 1 receptor	Homo sapiens	20-55
24973425-9	2014	RESULTS: MET, HER3, insulin-like growth factor (IGF)-1R, and INSR were identified to mediate lapatinib unresponsiveness in HER2+ gastric cancer cells.	Lapatinib	93-102	insulin receptor	Homo sapiens	61-65
24973425-10	2014	Activation of these bypass RTKs attenuated lapatinib-induced apoptosis and suppression of cell motility, mechanistically because of restimulating the shared downstream AKT or ERK signaling, as well as restimulating WNT signaling and epithelial-to-mesenchymal transition (EMT)-like process.	Lapatinib	43-52	AKT serine/threonine kinase 1	Homo sapiens	168-171
24973425-12	2014	CONCLUSIONS: MET, HER3, IGF1R, and INSR pathways activation represent novel mechanism underlying lapatinib unresponsiveness in HER2+ gastric cancer.	Lapatinib	97-106	insulin receptor	Homo sapiens	35-39
24973425-12	2014	CONCLUSIONS: MET, HER3, IGF1R, and INSR pathways activation represent novel mechanism underlying lapatinib unresponsiveness in HER2+ gastric cancer.	Lapatinib	97-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
24820961-5	2014	We identified one of the final molecular targets of lapatinib to be interstitial collagenase, matrix metallopeptidase 1 (MMP1).	Lapatinib	52-61	matrix metallopeptidase 1	Homo sapiens	68-92
25350800-4	2014	Patients were required to receive HER-2-targeted therapy (trastuzumab or lapatinib) during follow-up.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-39
24820961-0	2014	A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.	Lapatinib	33-42	matrix metallopeptidase 1	Homo sapiens	72-97
24820961-0	2014	A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.	Lapatinib	33-42	matrix metallopeptidase 1	Homo sapiens	99-103
24820961-5	2014	We identified one of the final molecular targets of lapatinib to be interstitial collagenase, matrix metallopeptidase 1 (MMP1).	Lapatinib	52-61	matrix metallopeptidase 1	Homo sapiens	94-119
24820961-2	2014	These new findings about endometrial cancer suggest a potential for targeted therapy with lapatinib, a dual inhibitor of epidermal growth factor receptor and HER2 tyrosine kinases.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
24820961-5	2014	We identified one of the final molecular targets of lapatinib to be interstitial collagenase, matrix metallopeptidase 1 (MMP1).	Lapatinib	52-61	matrix metallopeptidase 1	Homo sapiens	121-125
24820961-6	2014	Lapatinib suppresses MMP1 through EGFR and HER2, and their downstream ERK and AKT signaling pathways.	Lapatinib	0-9	matrix metallopeptidase 1	Homo sapiens	21-25
24820961-6	2014	Lapatinib suppresses MMP1 through EGFR and HER2, and their downstream ERK and AKT signaling pathways.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	34-38
24820961-6	2014	Lapatinib suppresses MMP1 through EGFR and HER2, and their downstream ERK and AKT signaling pathways.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
24820961-6	2014	Lapatinib suppresses MMP1 through EGFR and HER2, and their downstream ERK and AKT signaling pathways.	Lapatinib	0-9	EPH receptor B2	Homo sapiens	70-73
24820961-6	2014	Lapatinib suppresses MMP1 through EGFR and HER2, and their downstream ERK and AKT signaling pathways.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	78-81
24820961-8	2014	Our results also showed that forced expression of active ERK or active AKT mutants rescued MMP1 expression from lapatinib suppression, further suggesting the importance of molecular selection to find appropriate patients with endometrial cancer for future clinical trials with any targeted therapies.	Lapatinib	112-121	EPH receptor B2	Homo sapiens	57-60
24820961-8	2014	Our results also showed that forced expression of active ERK or active AKT mutants rescued MMP1 expression from lapatinib suppression, further suggesting the importance of molecular selection to find appropriate patients with endometrial cancer for future clinical trials with any targeted therapies.	Lapatinib	112-121	AKT serine/threonine kinase 1	Homo sapiens	71-74
24820961-8	2014	Our results also showed that forced expression of active ERK or active AKT mutants rescued MMP1 expression from lapatinib suppression, further suggesting the importance of molecular selection to find appropriate patients with endometrial cancer for future clinical trials with any targeted therapies.	Lapatinib	112-121	matrix metallopeptidase 1	Homo sapiens	91-95
24820961-10	2014	Lapatinib inhibited MMP1 via both HER2 and EGFR signaling pathways.	Lapatinib	0-9	matrix metallopeptidase 1	Homo sapiens	20-24
24820961-10	2014	Lapatinib inhibited MMP1 via both HER2 and EGFR signaling pathways.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
24820961-10	2014	Lapatinib inhibited MMP1 via both HER2 and EGFR signaling pathways.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	43-47
24820961-11	2014	Both AKT and ERK need to be inhibited for efficient MMP1 suppression by lapatinib.	Lapatinib	72-81	AKT serine/threonine kinase 1	Homo sapiens	5-8
24820961-11	2014	Both AKT and ERK need to be inhibited for efficient MMP1 suppression by lapatinib.	Lapatinib	72-81	EPH receptor B2	Homo sapiens	13-16
24820961-11	2014	Both AKT and ERK need to be inhibited for efficient MMP1 suppression by lapatinib.	Lapatinib	72-81	matrix metallopeptidase 1	Homo sapiens	52-56
24820961-13	2014	Suppression of both c-fos and c-Jun bound to AP1 binding site is required for lapatinib inhibition.	Lapatinib	78-87	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	20-25
24820961-13	2014	Suppression of both c-fos and c-Jun bound to AP1 binding site is required for lapatinib inhibition.	Lapatinib	78-87	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
25056500-2	2014	We studied the prognostic and predictive value of PIK3CA mutations and PTEN low in patients receiving paclitaxel alone or in combination with lapatinib.	Lapatinib	142-151	phosphatase and tensin homolog	Homo sapiens	71-75
24928736-9	2014	Gefitinib, erlotinib, and afatinib are orally effective protein-kinase targeted quinazoline derivatives that are used in the treatment of ERBB1-mutant lung cancer and lapatinib is an orally effective quinazoline derivative used in the treatment of ErbB2-overexpressing breast cancer.	Lapatinib	167-176	epidermal growth factor receptor	Homo sapiens	138-143
24928736-9	2014	Gefitinib, erlotinib, and afatinib are orally effective protein-kinase targeted quinazoline derivatives that are used in the treatment of ERBB1-mutant lung cancer and lapatinib is an orally effective quinazoline derivative used in the treatment of ErbB2-overexpressing breast cancer.	Lapatinib	167-176	erb-b2 receptor tyrosine kinase 2	Homo sapiens	248-253
25114858-2	2014	Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved for the treatment of breast cancer patients with HER-2 over-expressed.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-177
25232326-0	2014	Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months" Remission with Lapatinib plus Capecitabine.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
25109964-3	2014	The outlook for patients with HER2-positive breast cancer has been revolutionized by the introduction of HER2-targeted agents, such as trastuzumab and lapatinib, yet resistance is frequently encountered and multiple different resistance mechanisms have been identified.	Lapatinib	151-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
25130997-0	2014	Dual targeting of HER2 with lapatinib and trastuzumab.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-22
25130998-0	2014	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
25130998-1	2014	BACKGROUND: Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab significantly improved rates of pathological complete response compared with either drug alone.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
25342988-6	2014	Combined administration of two different HER2-targeted agents, that is, trastuzumab with lapatinib or pertuzumab, and primary chemotherapy shows enhanced antitumour activity, with an increase in pCR to values never reached in the past.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
24967516-3	2014	Initial clinical evaluation led to a phase III trial in advanced HER2-positive breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine.	Lapatinib	282-291	immunoglobulin heavy diversity 1-7	Homo sapiens	192-195
25086636-1	2014	Trastuzumab and lapatinib are established treatments for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer with different mechanisms of action.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
25086636-1	2014	Trastuzumab and lapatinib are established treatments for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer with different mechanisms of action.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-117
24877986-3	2014	Initial studies of agents such as bevacizumab (angiogenesis inhibitor) and lapatinib (epidermal growth factor and ErbB2 inhibitor) have indicated benefit for selected patients.	Lapatinib	75-84	epidermal growth factor	Homo sapiens	86-109
24877986-3	2014	Initial studies of agents such as bevacizumab (angiogenesis inhibitor) and lapatinib (epidermal growth factor and ErbB2 inhibitor) have indicated benefit for selected patients.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
24687830-0	2014	Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.	Lapatinib	89-98	major histocompatibility complex, class II, DR beta 1	Homo sapiens	26-34
24687830-5	2014	RESULTS: In lapatinib-treated patients, there was a significant difference in ALT case incidence between HLA carriers and noncarriers.	Lapatinib	12-21	major histocompatibility complex, class II, DR beta 1	Homo sapiens	105-108
24687830-8	2014	In lapatinib-treated patients, the overall risk for National Cancer Institute-Common Terminology Criteria for Adverse Events grade 3 ALT elevation (> 5x upper limit of normal) was 2.1%; HLA allele carriers had an increased risk of 7.7%; in noncarriers, risk was reduced to 0.5%, comparable to ALT elevation for all patients receiving placebo.	Lapatinib	3-12	major histocompatibility complex, class II, DR beta 1	Homo sapiens	189-192
24687830-10	2014	CONCLUSION: These results validate HLA-DRB1*07:01 allele carriage as a predictor of increased risk of lapatinib-induced liver injury and implicate an immune pathology.	Lapatinib	102-111	major histocompatibility complex, class II, DR beta 1	Homo sapiens	35-43
24687830-11	2014	The HLA association could support clinical management of patients experiencing hepatotoxicity during lapatinib treatment.	Lapatinib	101-110	major histocompatibility complex, class II, DR beta 1	Homo sapiens	4-7
25114575-1	2014	Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor-2 (HER2) tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	67-99
25114575-1	2014	Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor-2 (HER2) tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-144
25114575-1	2014	Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor-2 (HER2) tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
25114575-2	2014	In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine for the treatment of women with HER2-overexpressing, advanced or metastatic breast cancer.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
25114575-4	2014	In pivotal phase III trials, a combination of lapatinib and capecitabine significantly decreased the risk of disease progression compared to capecitabine alone in women with HER2-positive advanced or metastatic breast cancer.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
25114575-9	2014	Thus, lapatinib warrants further evaluation in HER2-positive metastatic and early-stage breast cancer patients.	Lapatinib	6-15	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
25056500-7	2014	In the PIK3CA wild-type subgroup, lapatinib plus paclitaxel reduced risk of progression compared with paclitaxel alone (HR = 0.44; 95% CI: 0.28, 0.69; P <0.0001); progression-free survival (PFS) was not significantly improved within the PIK3CA mutation subgroup (P = 0.179).	Lapatinib	34-43	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	7-13
25056500-7	2014	In the PIK3CA wild-type subgroup, lapatinib plus paclitaxel reduced risk of progression compared with paclitaxel alone (HR = 0.44; 95% CI: 0.28, 0.69; P <0.0001); progression-free survival (PFS) was not significantly improved within the PIK3CA mutation subgroup (P = 0.179).	Lapatinib	34-43	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	240-246
25056500-8	2014	In the PTEN low group, OS was improved with addition of lapatinib (P = 0.039).	Lapatinib	56-65	phosphatase and tensin homolog	Homo sapiens	7-11
25056500-9	2014	In both PTEN subgroups, addition of lapatinib was associated with improvements in PFS (P <0.050).	Lapatinib	36-45	phosphatase and tensin homolog	Homo sapiens	8-12
24916181-0	2014	A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
25114718-1	2014	BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Mus musculus	12-16
25114718-1	2014	BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Mus musculus	35-39
25114718-1	2014	BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Mus musculus	35-39
24876102-4	2014	NmU overexpression occurred in cells with acquired or innate resistance to lapatinib, trastuzumab, neratinib, and afatinib, all of which displayed a similar trend upon short-term exposure, suggesting NmU induction may be an early response.	Lapatinib	75-84	neuromedin U	Homo sapiens	0-3
24754246-1	2014	Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-40
24947784-1	2014	Lapatinib, an orally administered small-molecule tyrosine kinase inhibitor targeting epidermal growth factor receptors (EGFR) and Her2/Neu, has been widely accepted in the treatment of breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	85-118
24947784-1	2014	Lapatinib, an orally administered small-molecule tyrosine kinase inhibitor targeting epidermal growth factor receptors (EGFR) and Her2/Neu, has been widely accepted in the treatment of breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	120-124
24947784-1	2014	Lapatinib, an orally administered small-molecule tyrosine kinase inhibitor targeting epidermal growth factor receptors (EGFR) and Her2/Neu, has been widely accepted in the treatment of breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-138
24947784-2	2014	In this study, we found that lapatinib induced cytotoxicity in human hepatoma Huh7, HepG2 and HA22T cells.	Lapatinib	29-38	MIR7-3 host gene	Homo sapiens	78-82
24947784-4	2014	Moreover, lapatinib-induced autophagy in hepatoma cells was confirmed by the detection of autophagic LC3-II conversion, the up-regulation of autophagy-related proteins, and the down-regulation of p62 by immunoblotting.	Lapatinib	10-19	nucleoporin 62	Homo sapiens	196-199
24754246-1	2014	Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
24754246-1	2014	Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
24916181-0	2014	A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.	Lapatinib	62-71	forkhead box O3	Homo sapiens	132-137
24754246-1	2014	Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.	Lapatinib	133-142	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	171-200
24754246-1	2014	Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.	Lapatinib	133-142	AKT serine/threonine kinase 1	Homo sapiens	202-211
24754246-10	2014	Moreover, knockdown of CD24 increased the sensitivity of HER2-positive breast cancer cells to lapatinib treatment.	Lapatinib	94-103	CD24 molecule	Homo sapiens	23-27
24754246-10	2014	Moreover, knockdown of CD24 increased the sensitivity of HER2-positive breast cancer cells to lapatinib treatment.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
24916181-5	2014	The synergistic anti-tumor activity of the entinostat/lapatinib combination was due to downregulation of phosphorylated Akt, which activated transcriptional activity of FOXO3, resulting in induction of Bim1 (a BH3 domain-containing pro-apoptotic protein).	Lapatinib	54-63	AKT serine/threonine kinase 1	Homo sapiens	120-123
24916181-5	2014	The synergistic anti-tumor activity of the entinostat/lapatinib combination was due to downregulation of phosphorylated Akt, which activated transcriptional activity of FOXO3, resulting in induction of Bim1 (a BH3 domain-containing pro-apoptotic protein).	Lapatinib	54-63	forkhead box O3	Homo sapiens	169-174
24916181-6	2014	Furthermore, entinostat sensitized trastuzumab/lapatinib-resistance-HER2-overexpressing cells to the trastuzumab/lapatinib combination and enhanced the anti-proliferation effect compare with single or double combination treatment.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
24916181-6	2014	Furthermore, entinostat sensitized trastuzumab/lapatinib-resistance-HER2-overexpressing cells to the trastuzumab/lapatinib combination and enhanced the anti-proliferation effect compare with single or double combination treatment.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
24916181-8	2014	Our finding justifies for conducting a clinical trial of combinational treatment with entinostat, lapatinib, and trastuzumab in patients with HER2-overexpressing breast cancer resistant to trastuzumab-based treatment.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-146
24628946-4	2014	Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a novel activating mutation of BRAF.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 4	Homo sapiens	161-166
24868024-0	2014	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
24868024-12	2014	CONCLUSION: Lapatinib plus paclitaxel demonstrated activity in the second-line treatment of patients with HER2 FISH-positive IHC3+ advanced gastric cancer but did not significantly improve OS in the intent-to-treat population.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
24861025-7	2014	This approach, propelled by the development of novel anti-ERBB2 therapeutics, has led to the recent approval of Lapatinib, Pertuzumab and T-DM1 as additional anti-ERBB2 therapeutics in BC.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-63
24861025-7	2014	This approach, propelled by the development of novel anti-ERBB2 therapeutics, has led to the recent approval of Lapatinib, Pertuzumab and T-DM1 as additional anti-ERBB2 therapeutics in BC.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-168
24628946-4	2014	Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a novel activating mutation of BRAF.	Lapatinib	136-145	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	227-231
25669042-4	2014	The overexpression/amplification of human epidermal growth factor receptor 2 (HER2) is predictive of a favorable response to anti-HER2 agents such as trastuzumab, lapatinib, and pertuzumab.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-76
25669042-4	2014	The overexpression/amplification of human epidermal growth factor receptor 2 (HER2) is predictive of a favorable response to anti-HER2 agents such as trastuzumab, lapatinib, and pertuzumab.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
24643685-2	2014	Resistance has been reported to human epidermal growth factor receptor 2 (HER2)-targeted therapy with the tyrosine kinase inhibitor lapatinib and the antibody trastuzumab in metastatic gastric cancer.	Lapatinib	132-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-72
24643685-2	2014	Resistance has been reported to human epidermal growth factor receptor 2 (HER2)-targeted therapy with the tyrosine kinase inhibitor lapatinib and the antibody trastuzumab in metastatic gastric cancer.	Lapatinib	132-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
24709886-8	2014	Multi-erbB targeting with the irreversible tyrosine kinase inhibitor canertinib exerted a more effective growth inhibitory effect in both BRAF wildtype and mutant melanoma cells compared with the single-erbB or dual-erbB targeting inhibitors, gefitinib, erlotinib, and lapatinib.	Lapatinib	269-278	epidermal growth factor receptor	Homo sapiens	6-10
24902791-1	2014	AIM: Lapatinib is a dual inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2), and used to treat advanced breast cancer.	Lapatinib	5-14	epidermal growth factor receptor	Homo sapiens	38-42
24902791-1	2014	AIM: Lapatinib is a dual inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2), and used to treat advanced breast cancer.	Lapatinib	5-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-87
24902791-1	2014	AIM: Lapatinib is a dual inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2), and used to treat advanced breast cancer.	Lapatinib	5-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
24958351-1	2014	BACKGROUND: HER2 targeted therapies including trastuzumab and more recently lapatinib have significantly improved the prognosis for HER2 positive breast cancer patients.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
24958351-1	2014	BACKGROUND: HER2 targeted therapies including trastuzumab and more recently lapatinib have significantly improved the prognosis for HER2 positive breast cancer patients.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
24958351-10	2014	PP2A inhibition significantly enhanced response to lapatinib in both the SKBR3 and SKBR3-L cells.	Lapatinib	51-60	protein phosphatase 2 phosphatase activator	Homo sapiens	0-4
24958351-11	2014	Furthermore, treatment of SKBR3 parental cells with the PP2A activator, FTY720, decreased sensitivity to lapatinib.	Lapatinib	105-114	protein phosphatase 2 phosphatase activator	Homo sapiens	56-60
24958351-12	2014	The alteration in eEF2 phosphorylation, PP2A activity and sensitivity to okadaic acid were also observed in a second HER2 positive cell line model of acquired lapatinib resistance, HCC1954-L.	Lapatinib	159-168	eukaryotic translation elongation factor 2	Homo sapiens	18-22
24958351-12	2014	The alteration in eEF2 phosphorylation, PP2A activity and sensitivity to okadaic acid were also observed in a second HER2 positive cell line model of acquired lapatinib resistance, HCC1954-L.	Lapatinib	159-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
23873022-0	2014	Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.	Lapatinib	95-104	SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1	Homo sapiens	0-10
23873022-2	2014	Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway.	Lapatinib	22-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
23873022-4	2014	In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
23873022-4	2014	In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	213-217
23873022-8	2014	We showed that the inhibition of Testican-1 by small interfering RNA decreased Testican-1-induced, MET-dependent, downstream signaling, and restored sensitivity to lapatinib in these cells.	Lapatinib	164-173	SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1	Homo sapiens	33-43
23438846-1	2014	Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer).	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-148
23438846-1	2014	Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer).	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
24711549-0	2014	Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-132
24800949-11	2014	Coadministration of pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4, had an inhibitory effect on paclitaxel clearance.	Lapatinib	34-43	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	64-70
24800949-11	2014	Coadministration of pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4, had an inhibitory effect on paclitaxel clearance.	Lapatinib	34-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
24711549-2	2014	HER2-HER3 signaling can be inactivated by doses of lapatinib that fully inactivate the HER2 kinase.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
24711549-2	2014	HER2-HER3 signaling can be inactivated by doses of lapatinib that fully inactivate the HER2 kinase.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 3	Homo sapiens	5-9
24711549-2	2014	HER2-HER3 signaling can be inactivated by doses of lapatinib that fully inactivate the HER2 kinase.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
24667724-0	2014	Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
24103790-5	2014	In recent years, ABCC10 inhibitors, including cepharanthine, lapatinib, erlotinib, nilotinib, imatinib, sildenafil, and vardenafil, have been reported to overcome ABCC10-mediated MDR.	Lapatinib	61-70	ATP binding cassette subfamily C member 10	Homo sapiens	17-23
24103790-5	2014	In recent years, ABCC10 inhibitors, including cepharanthine, lapatinib, erlotinib, nilotinib, imatinib, sildenafil, and vardenafil, have been reported to overcome ABCC10-mediated MDR.	Lapatinib	61-70	ATP binding cassette subfamily C member 10	Homo sapiens	163-169
24936383-9	2014	After adjustment for potential confounders, when compared to trastuzumab patients, lapatinib patients had a higher rate of treatment discontinuation (hazard ratio [HR] = 1.57; P < 0.001), a higher rate of outpatient visits (not treatment administration related) (IRR = 1.19; P < 0.004), and a lower rate of medical visits associated with treatment administration (IRR = 0.34; P < 0.001).	Lapatinib	83-92	insulin receptor related receptor	Homo sapiens	266-269
24936383-9	2014	After adjustment for potential confounders, when compared to trastuzumab patients, lapatinib patients had a higher rate of treatment discontinuation (hazard ratio [HR] = 1.57; P < 0.001), a higher rate of outpatient visits (not treatment administration related) (IRR = 1.19; P < 0.004), and a lower rate of medical visits associated with treatment administration (IRR = 0.34; P < 0.001).	Lapatinib	83-92	insulin receptor related receptor	Homo sapiens	370-373
24887236-0	2014	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.	Lapatinib	82-91	epidermal growth factor receptor	Homo sapiens	0-32
24887236-0	2014	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.	Lapatinib	82-91	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	54-57
24887236-2	2014	To identify the mechanism by which Src overexpression sustains this resistance, we tested a panel of breast cancer cell lines either sensitive or resistant to lapatinib.	Lapatinib	159-168	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	35-38
24887236-5	2014	We used artificial metastasis assays to evaluate the effect of Src inhibition on the invasiveness of lapatinib-resistant cells.	Lapatinib	101-110	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	63-66
24887236-7	2014	RESULTS: Src activation was higher in lapatinib-resistant than in lapatinib-sensitive cells.	Lapatinib	38-47	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	9-12
24887236-7	2014	RESULTS: Src activation was higher in lapatinib-resistant than in lapatinib-sensitive cells.	Lapatinib	66-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	9-12
24887236-8	2014	The selective small-molecule Src inhibitor saracatinib combined with lapatinib synergistically inhibited the proliferation, migration, and invasion of lapatinib-resistant cells.	Lapatinib	151-160	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	29-32
24887236-10	2014	Unexpectedly, in lapatinib-resistant cells, Src preferentially interacted with epidermal growth factor receptor (EGFR) rather than with HER2.	Lapatinib	17-26	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	44-47
24887236-10	2014	Unexpectedly, in lapatinib-resistant cells, Src preferentially interacted with epidermal growth factor receptor (EGFR) rather than with HER2.	Lapatinib	17-26	epidermal growth factor receptor	Homo sapiens	79-111
24887236-10	2014	Unexpectedly, in lapatinib-resistant cells, Src preferentially interacted with epidermal growth factor receptor (EGFR) rather than with HER2.	Lapatinib	17-26	epidermal growth factor receptor	Homo sapiens	113-117
24887236-11	2014	Moreover, EGFR targeting and lapatinib synergistically inhibited survival, migration, and invasion of resistant cells, thereby counteracting Src-mediated resistance.	Lapatinib	29-38	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	141-144
24887236-12	2014	These findings demonstrate that Src activation in lapatinib-resistant cells depends on EGFR-dependent rather than on HER2-dependent signaling.	Lapatinib	50-59	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	32-35
24887236-12	2014	These findings demonstrate that Src activation in lapatinib-resistant cells depends on EGFR-dependent rather than on HER2-dependent signaling.	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	87-91
24887236-13	2014	CONCLUSIONS: Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent resistance to lapatinib in breast cancer.	Lapatinib	108-117	epidermal growth factor receptor	Homo sapiens	36-40
24887236-13	2014	CONCLUSIONS: Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent resistance to lapatinib in breast cancer.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
24887236-13	2014	CONCLUSIONS: Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent resistance to lapatinib in breast cancer.	Lapatinib	108-117	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	80-83
24675532-5	2014	Although lapatinib initially inhibited trastuzumab-resistant mouse tumors, tumors by-passed the inhibition by activating the PI3K/mTOR signaling network as shown by the quantitative protein arrays.	Lapatinib	9-18	mechanistic target of rapamycin kinase	Mus musculus	130-134
24675532-6	2014	Interestingly, activation of the mTOR pathway was also observed in neoadjuvant lapatinib-treated patients manifesting lapatinib resistance.	Lapatinib	79-88	mechanistic target of rapamycin kinase	Homo sapiens	33-37
24675532-6	2014	Interestingly, activation of the mTOR pathway was also observed in neoadjuvant lapatinib-treated patients manifesting lapatinib resistance.	Lapatinib	118-127	mechanistic target of rapamycin kinase	Homo sapiens	33-37
24675532-7	2014	Trastuzumab + lapatinib resistance was effectively overcome by sequential application of a PI3K/mTOR dual kinase inhibitor (BEZ235) with no significant toxicity.	Lapatinib	14-23	mechanistic target of rapamycin kinase	Mus musculus	96-100
24675532-9	2014	Mechanistically, we identified ErbB2 protein stabilization and activation as a novel mechanism of BEZ235 resistance, which was reversed by subsequent treatment with lapatinib + BEZ235 combination.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Mus musculus	31-36
24833915-1	2014	Anti-HER2 agents, such as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer overexpressing the human epidermal growth factor receptor 2 (HER2).	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
24424115-0	2014	Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
24554387-2	2014	AZD8931, a dual tyrosine kinase inhibitor (TKI) of epithelial growth factor receptor (EGFR)/HER2, has been shown to more effectively block ligand-dependent HER signaling than the HER TKIs lapatinib or gefitinib.	Lapatinib	188-197	epidermal growth factor receptor	Homo sapiens	86-90
24360619-4	2014	Second-generation studies in metastatic disease led to the approval of several new HER2-targeted therapies using small molecule tyrosine kinase inhibitors such as lapatinib, new HER2/HER3 antibodies such as pertuzumab, and the new antibody chemotherapy conjugate ado-trastuzumab emtansine.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
24487029-9	2014	In addition, TBK1/IKKepsilon inhibition cooperated with lapatinib, a HER2/EGFR1-targeted drug, to accelerate apoptosis and kill HER2(+) breast cancer cells both in culture and in xenografts.	Lapatinib	56-65	TANK binding kinase 1	Homo sapiens	13-17
24487029-9	2014	In addition, TBK1/IKKepsilon inhibition cooperated with lapatinib, a HER2/EGFR1-targeted drug, to accelerate apoptosis and kill HER2(+) breast cancer cells both in culture and in xenografts.	Lapatinib	56-65	inhibitor of nuclear factor kappa B kinase subunit epsilon	Homo sapiens	18-28
24424115-2	2014	Treatment with lapatinib plus capecitabine for HER2-positive metastatic breast cancer (MBC) with primary or acquired resistance to trastuzumab was analyzed retrospectively.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
24487029-9	2014	In addition, TBK1/IKKepsilon inhibition cooperated with lapatinib, a HER2/EGFR1-targeted drug, to accelerate apoptosis and kill HER2(+) breast cancer cells both in culture and in xenografts.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
24487029-9	2014	In addition, TBK1/IKKepsilon inhibition cooperated with lapatinib, a HER2/EGFR1-targeted drug, to accelerate apoptosis and kill HER2(+) breast cancer cells both in culture and in xenografts.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
24520092-8	2014	In the absence of a strong enzymatic activity to target, the focus has been on strategies to prevent HER3 activation including blocking its most relevant dimerization partner"s kinase activity (erlotinib, gefitinib, and lapatinib), blocking its most relevant dimerization partner"s ability to dimerize with HER3 (trastuzumab and pertuzumab), and directly targeting the HER3 ECD (MM-121, U3-1287, and LJM716).	Lapatinib	220-229	erb-b2 receptor tyrosine kinase 3	Homo sapiens	101-105
24711706-7	2014	Lapatinib, a small-molecule dual inhibitor (TKI) of both HER2 and EGFR (epidermal growth factor receptor) pathways, has an antitumor activity translated into progression-free survival benefit in HER2-positive metastatic patients previously treated with a taxane, an anthracycline, and trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
24711706-7	2014	Lapatinib, a small-molecule dual inhibitor (TKI) of both HER2 and EGFR (epidermal growth factor receptor) pathways, has an antitumor activity translated into progression-free survival benefit in HER2-positive metastatic patients previously treated with a taxane, an anthracycline, and trastuzumab.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	66-70
24711706-7	2014	Lapatinib, a small-molecule dual inhibitor (TKI) of both HER2 and EGFR (epidermal growth factor receptor) pathways, has an antitumor activity translated into progression-free survival benefit in HER2-positive metastatic patients previously treated with a taxane, an anthracycline, and trastuzumab.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	72-104
24711706-7	2014	Lapatinib, a small-molecule dual inhibitor (TKI) of both HER2 and EGFR (epidermal growth factor receptor) pathways, has an antitumor activity translated into progression-free survival benefit in HER2-positive metastatic patients previously treated with a taxane, an anthracycline, and trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	195-199
24669898-1	2014	OBJECTIVE: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
24669898-9	2014	CONCLUSIONS: The treatment with HER2-receptor inhibitors in our patients resulted in progression-free survival rates similar to those published in clinical trials with patients receiving Lapatinib + Trastuzumab not combined with any other anti-cancer therapy, with good treatment tolerability.	Lapatinib	187-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
24965400-8	2014	Moreover, celastrol enhanced the ability of lapatinib to down regulate EGFR protein expression in HepG2 cells.	Lapatinib	44-53	epidermal growth factor receptor	Homo sapiens	71-75
24590635-13	2014	In unselected estrogen receptor-positive/HER2-negative patients, letrozole-lapatinib and letrozole-placebo resulted in a similar overall clinical response rate and similar effect on Ki-67 and pAKT.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
24590635-14	2014	Our secondary end point findings of a significant correlation between PIK3CA mutation and response to letrozole-lapatinib in HR-positive/HER2-negative early breast cancer must now be independently confirmed.	Lapatinib	112-121	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	70-76
24590635-14	2014	Our secondary end point findings of a significant correlation between PIK3CA mutation and response to letrozole-lapatinib in HR-positive/HER2-negative early breast cancer must now be independently confirmed.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
24862757-10	2014	Furthermore, dual inhibition of Axl and HER2/3 using BMS777607 and lapatinib led to a significant inhibition of cell viability in Axl-expressing MDA-MB231 and Ovcar8 cells.	Lapatinib	67-76	AXL receptor tyrosine kinase	Homo sapiens	32-35
24862757-10	2014	Furthermore, dual inhibition of Axl and HER2/3 using BMS777607 and lapatinib led to a significant inhibition of cell viability in Axl-expressing MDA-MB231 and Ovcar8 cells.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
24862757-10	2014	Furthermore, dual inhibition of Axl and HER2/3 using BMS777607 and lapatinib led to a significant inhibition of cell viability in Axl-expressing MDA-MB231 and Ovcar8 cells.	Lapatinib	67-76	AXL receptor tyrosine kinase	Homo sapiens	130-133
24054871-0	2014	The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.	Lapatinib	50-59	CREB regulated transcription coactivator 1	Mus musculus	22-28
24054871-0	2014	The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.	Lapatinib	50-59	CREB regulated transcription coactivator 2	Homo sapiens	29-34
24655723-4	2014	METHODS: We investigated the levels of intra- and extracellular miR-630 in cells and conditioned media from breast cancer cell lines with either innate- or acquired- resistance to HER-targeting lapatinib and neratinib, compared to their corresponding drug sensitive cell lines, using qPCR.	Lapatinib	194-203	microRNA 630	Homo sapiens	64-71
24655723-9	2014	RESULTS: We established that introducing miR-630 into cells with innate- or acquired- resistance to HER-drugs significantly restored the efficacy of lapatinib, neratinib and afatinib; through a mechanism which we have determined to, at least partly, involve miR-630"s regulation of IGF1R.	Lapatinib	149-158	microRNA 630	Homo sapiens	41-48
24655723-9	2014	RESULTS: We established that introducing miR-630 into cells with innate- or acquired- resistance to HER-drugs significantly restored the efficacy of lapatinib, neratinib and afatinib; through a mechanism which we have determined to, at least partly, involve miR-630"s regulation of IGF1R.	Lapatinib	149-158	microRNA 630	Homo sapiens	258-265
24655723-9	2014	RESULTS: We established that introducing miR-630 into cells with innate- or acquired- resistance to HER-drugs significantly restored the efficacy of lapatinib, neratinib and afatinib; through a mechanism which we have determined to, at least partly, involve miR-630"s regulation of IGF1R.	Lapatinib	149-158	insulin like growth factor 1 receptor	Homo sapiens	282-287
24462377-2	2014	Two compounds have been registered for HER-2-positive tumour treatment: trastuzumab, a humanised antibody directed against the HER-2 extracellular domain, and lapatinib, a small molecule acting as a dual EGF-R and HER-2 tyrosine kinase inhibitor.	Lapatinib	159-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44
25594009-8	2014	In addition, TBK1-II cooperated with lapatinib, a EGFR/HER2 inhibitor, to accelerate apoptosis in vitro and suppress tumor growth in a xenograft model of HER2(+) BC.	Lapatinib	37-46	epidermal growth factor receptor	Homo sapiens	50-54
25594009-8	2014	In addition, TBK1-II cooperated with lapatinib, a EGFR/HER2 inhibitor, to accelerate apoptosis in vitro and suppress tumor growth in a xenograft model of HER2(+) BC.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
25594009-8	2014	In addition, TBK1-II cooperated with lapatinib, a EGFR/HER2 inhibitor, to accelerate apoptosis in vitro and suppress tumor growth in a xenograft model of HER2(+) BC.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
24457911-1	2014	BACKGROUND: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-203
24457911-1	2014	BACKGROUND: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
24222194-0	2014	Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.	Lapatinib	123-132	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-176
24462377-2	2014	Two compounds have been registered for HER-2-positive tumour treatment: trastuzumab, a humanised antibody directed against the HER-2 extracellular domain, and lapatinib, a small molecule acting as a dual EGF-R and HER-2 tyrosine kinase inhibitor.	Lapatinib	159-168	epidermal growth factor receptor	Homo sapiens	204-209
24799970-1	2014	BACKGROUND: The HER2/neu gene is a proto-oncogene that can predict the response to treatment with trastuzumab, pertuzumab, and lapatinib.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-24
24492289-7	2014	In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
24080257-7	2014	The very slow off-rate of lapatinib from the epidermal growth factor receptor and dasatinib from Bruton"s tyrosine kinase and colony stimulating factor 1 receptor (CSF1R) were confirmed.	Lapatinib	26-35	colony stimulating factor 1 receptor	Homo sapiens	126-162
24080257-7	2014	The very slow off-rate of lapatinib from the epidermal growth factor receptor and dasatinib from Bruton"s tyrosine kinase and colony stimulating factor 1 receptor (CSF1R) were confirmed.	Lapatinib	26-35	colony stimulating factor 1 receptor	Homo sapiens	164-169
23852769-6	2014	CONCLUSION: The combination of trastuzumab, lapatinib, and bevacizumab may warrant investigation as a non-cytotoxic alternative for treatment of HER2-amplified or overexpressed salivary duct carcinoma and other HER2-amplified or overexpressed salivary gland tumors, particularly those not responsive to trastuzumab monotherapy.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
24492289-7	2014	In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 3	Homo sapiens	59-63
24492289-7	2014	In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 3	Homo sapiens	134-138
24319068-4	2014	In this study, we report that constitutively active NF-kappaB rendered HER2-positive cancer cells resistant to anti-HER2 drugs and cells selected for lapatinib resistance upregulated NF-kappaB.	Lapatinib	150-159	nuclear factor kappa B subunit 1	Homo sapiens	52-61
24319068-4	2014	In this study, we report that constitutively active NF-kappaB rendered HER2-positive cancer cells resistant to anti-HER2 drugs and cells selected for lapatinib resistance upregulated NF-kappaB.	Lapatinib	150-159	nuclear factor kappa B subunit 1	Homo sapiens	183-192
24492289-7	2014	In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
24319068-6	2014	Lapatinib-resistant cells were refractory to HER2 and NF-kappaB inhibitors alone but were sensitive to their combination, suggesting a novel therapeutic strategy.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
24319068-6	2014	Lapatinib-resistant cells were refractory to HER2 and NF-kappaB inhibitors alone but were sensitive to their combination, suggesting a novel therapeutic strategy.	Lapatinib	0-9	nuclear factor kappa B subunit 1	Homo sapiens	54-63
24379439-4	2014	Enhanced erbB3 kinase activity is linked to heterointeractions with catalytically active erbB2, since it is largely blocked in cells pretreated with lapatinib or pertuzumab.	Lapatinib	149-158	receptor tyrosine-protein kinase erbB-3	Cricetulus griseus	9-14
24492289-7	2014	In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 3	Homo sapiens	134-138
24379439-4	2014	Enhanced erbB3 kinase activity is linked to heterointeractions with catalytically active erbB2, since it is largely blocked in cells pretreated with lapatinib or pertuzumab.	Lapatinib	149-158	receptor tyrosine-protein kinase erbB-2	Cricetulus griseus	89-94
24492289-7	2014	In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 3	Homo sapiens	134-138
26034656-1	2014	BACKGROUND: Lapatinib in combination with capecitabine is approved for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-208
26034656-1	2014	BACKGROUND: Lapatinib in combination with capecitabine is approved for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	210-214
26034656-0	2014	Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer.	Lapatinib	18-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
26034656-13	2014	CONCLUSION: The combination of lapatinib and vinorelbine was active, feasible and well tolerated in patients with HER2-positive advanced breast cancer.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
23474757-0	2014	Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-72
23474757-4	2014	Using a high-throughput functional screen we assessed whether genes found to be recurrently amplified and overexpressed in ERBB2+ve breast cancers mediate resistance to the ERBB2-targeted agent lapatinib.	Lapatinib	194-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
23474757-4	2014	Using a high-throughput functional screen we assessed whether genes found to be recurrently amplified and overexpressed in ERBB2+ve breast cancers mediate resistance to the ERBB2-targeted agent lapatinib.	Lapatinib	194-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-178
23474757-5	2014	Lapatinib-resistant ERBB2-amplified breast cancer cell lines were screened, in the presence or absence of lapatinib, with an RNA interference library targeting 369 genes recurrently amplified and overexpressed in both ERBB2-amplified breast cancer tumours and cell lines.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-25
23474757-5	2014	Lapatinib-resistant ERBB2-amplified breast cancer cell lines were screened, in the presence or absence of lapatinib, with an RNA interference library targeting 369 genes recurrently amplified and overexpressed in both ERBB2-amplified breast cancer tumours and cell lines.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	218-223
23474757-7	2014	The mechanisms of resistance conferred by the identified genes were further investigated and in the case of NIBP (TRAPPC9), lapatinib resistance was found to be mediated through NF-kappaB signalling.	Lapatinib	124-133	trafficking protein particle complex subunit 9	Homo sapiens	108-112
23474757-7	2014	The mechanisms of resistance conferred by the identified genes were further investigated and in the case of NIBP (TRAPPC9), lapatinib resistance was found to be mediated through NF-kappaB signalling.	Lapatinib	124-133	trafficking protein particle complex subunit 9	Homo sapiens	114-121
24611017-6	2014	Lapatinib is an oral agent that targets multiple transmembrane receptors within the epidermal growth factor receptor family, and offers a promising new approach to treatment.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	84-116
24551203-6	2014	Furthermore, PUVA can reverse therapeutic resistance to lapatinib and other ErbB2 targeted therapies, including resistance mediated via expression of a phosphorylated, truncated form of ErbB2 (p85(ErbB2)) that is preferentially expressed in tumor cell nuclei.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	186-191
24551203-6	2014	Furthermore, PUVA can reverse therapeutic resistance to lapatinib and other ErbB2 targeted therapies, including resistance mediated via expression of a phosphorylated, truncated form of ErbB2 (p85(ErbB2)) that is preferentially expressed in tumor cell nuclei.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	186-191
24496495-2	2014	Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
24402830-0	2014	A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-117
24402830-1	2014	Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-126
24402830-1	2014	Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
24402830-12	2014	Lapatinib plus vinorelbine offers an effective treatment option for patients with HER2-overexpressing MBC, having displayed comparable efficacy and tolerability rates to lapatinib plus capecitabine.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
24352641-2	2014	Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
24352641-2	2014	Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer.	Lapatinib	127-136	estrogen receptor 1	Homo sapiens	33-35
24352641-2	2014	Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	208-212
25083500-3	2014	It has demonstrated activity in trastuzumab-resistant patients, and neoadjuvant studies in HER2+ patients have demonstrated higher pathologic complete response (pCR) rates with the addition of lapatinib to trastuzumab and chemotherapy.	Lapatinib	193-202	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
24125103-2	2014	In light of these results, we modelled the potential cost-effectiveness of adjuvant lapatinib for patients with HER2-positive early-stage breast cancer.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
24125103-13	2014	Adjuvant lapatinib becomes cost-effective at the 0.879 hazard ratio where the ICER is $44 825/QALY.	Lapatinib	9-18	cAMP responsive element modulator	Homo sapiens	78-82
24125103-14	2014	CONCLUSION: In the Irish setting, an adjuvant lapatinib regimen would be considered cost-effective for patients with HER2-positive early-stage breast cancer for four of the five hypothesised hazard ratios.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
24176518-6	2014	Still, the only dually targeted strategy approved by some regulatory agencies is the combination of hormonal therapy using aromatase inhibition and the HER2 kinase inhibitor lapatinib.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
24198242-0	2014	Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.	Lapatinib	65-74	progesterone receptor	Homo sapiens	20-23
24198242-0	2014	Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
24198242-1	2014	PURPOSE: Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor, remains unproven in non-HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	27-59
24198242-1	2014	PURPOSE: Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor, remains unproven in non-HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	61-65
24198242-1	2014	PURPOSE: Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor, remains unproven in non-HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
24198242-2	2014	EGF30008, a phase III trial of letrozole and lapatinib versus letrozole and placebo, demonstrated that lapatinib significantly improves outcome for postmenopausal women with HER2-amplified, but not HER2-negative, MBC.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
24496495-2	2014	Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
24384723-5	2014	Inhibiting HER2 pharmacologically by Lapatinib (a dual HER2/epidermal growth factor receptor inhibitor) or CP724.714 (a specific HER2 inhibitor), or by knockdown via siRNA leads to inhibition of phosphoactivated Ser326 HSF1, and subsequently blocks the activity of the HSP90 chaperone machinery in HER2-overexpressing breast cancer lines.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
24075779-0	2014	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
24451154-9	2014	RESULTS: Here we describe the acquisition of a hotspot PIK3CA mutation in cells selected for resistance to the HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	142-151	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	55-61
24451154-9	2014	RESULTS: Here we describe the acquisition of a hotspot PIK3CA mutation in cells selected for resistance to the HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Mus musculus	111-115
24451154-12	2014	In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Mus musculus	16-20
24451154-12	2014	In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression.	Lapatinib	101-110	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	41-47
24451154-12	2014	In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Mus musculus	65-69
24451154-14	2014	In a PIK3CA-mutant HER2+ xenograft, PI3K inhibition with BKM120 in combination with lapatinib and trastuzumab was required to achieve tumor regression.	Lapatinib	84-93	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	5-11
24368101-1	2014	PURPOSE: Lapatinib is a dual EGFR and HER2 inhibitor that is used to treat HER2-overexpressing cancers.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	29-33
24368101-1	2014	PURPOSE: Lapatinib is a dual EGFR and HER2 inhibitor that is used to treat HER2-overexpressing cancers.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
24368101-1	2014	PURPOSE: Lapatinib is a dual EGFR and HER2 inhibitor that is used to treat HER2-overexpressing cancers.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
24384723-5	2014	Inhibiting HER2 pharmacologically by Lapatinib (a dual HER2/epidermal growth factor receptor inhibitor) or CP724.714 (a specific HER2 inhibitor), or by knockdown via siRNA leads to inhibition of phosphoactivated Ser326 HSF1, and subsequently blocks the activity of the HSP90 chaperone machinery in HER2-overexpressing breast cancer lines.	Lapatinib	37-46	epidermal growth factor receptor	Homo sapiens	60-92
24384723-10	2014	In the mouse model of HER2-driven breast cancer, ErbB2 inhibition by Lapatinib strongly suppresses tumor progression, and this is associated with inactivation of the HSF1 pathway.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Mus musculus	22-26
24384723-10	2014	In the mouse model of HER2-driven breast cancer, ErbB2 inhibition by Lapatinib strongly suppresses tumor progression, and this is associated with inactivation of the HSF1 pathway.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Mus musculus	49-54
24707474-0	2014	Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.	Lapatinib	107-116	epidermal growth factor receptor	Homo sapiens	26-30
24468788-8	2014	Lapatinib, CI-1033, erlotinib, axitinib, sunitinib, PKI-166, and AEE788 inhibited the replication of bloodstream T. brucei, with a 50% growth inhibitory concentration (GI50) between 1.3 muM and 2.5 muM.	Lapatinib	0-9	latexin	Homo sapiens	186-189
24468788-8	2014	Lapatinib, CI-1033, erlotinib, axitinib, sunitinib, PKI-166, and AEE788 inhibited the replication of bloodstream T. brucei, with a 50% growth inhibitory concentration (GI50) between 1.3 muM and 2.5 muM.	Lapatinib	0-9	latexin	Homo sapiens	198-201
25605188-1	2014	BACKGROUND: Lapatinib, a dual tyrosine kinase inhibitor that interrupts the epidermal growth factor receptor (EGFR) and HER2/neu pathways, has been indicated to have significant efficacy in treating HER2-positive breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	76-108
25605188-1	2014	BACKGROUND: Lapatinib, a dual tyrosine kinase inhibitor that interrupts the epidermal growth factor receptor (EGFR) and HER2/neu pathways, has been indicated to have significant efficacy in treating HER2-positive breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	110-114
25605188-1	2014	BACKGROUND: Lapatinib, a dual tyrosine kinase inhibitor that interrupts the epidermal growth factor receptor (EGFR) and HER2/neu pathways, has been indicated to have significant efficacy in treating HER2-positive breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-128
24468788-3	2014	In human proliferative diseases, protein tyrosine kinase (PTK) inhibitors (PTKIs) have been developed into drugs (e.g., lapatinib and erlotinib) by optimization of a 4-anilinoquinazoline scaffold.	Lapatinib	120-129	protein tyrosine kinase 2 beta	Homo sapiens	58-61
24355130-3	2014	The HER2/EGFR dual kinase inhibitor lapatinib was shown to inhibit some trastuzumab resistant breast cancer cell lines and is currently in clinical trials.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
24355130-3	2014	The HER2/EGFR dual kinase inhibitor lapatinib was shown to inhibit some trastuzumab resistant breast cancer cell lines and is currently in clinical trials.	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	9-13
24707474-1	2014	Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, has been shown to improve the survival rate of patients with advanced HER2-positive breast cancers.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
24707474-1	2014	Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, has been shown to improve the survival rate of patients with advanced HER2-positive breast cancers.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
24707474-2	2014	However, the off-target activity of lapatinib in inducing EGFR expression without tyrosine kinase activity was demonstrated to render HER2-negative breast cancer cells more metastatic, suggesting a limitation to the therapeutic effectiveness of this dual inhibitor in HER2-heterogeneous tumors.	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	58-62
24707474-2	2014	However, the off-target activity of lapatinib in inducing EGFR expression without tyrosine kinase activity was demonstrated to render HER2-negative breast cancer cells more metastatic, suggesting a limitation to the therapeutic effectiveness of this dual inhibitor in HER2-heterogeneous tumors.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
24707474-2	2014	However, the off-target activity of lapatinib in inducing EGFR expression without tyrosine kinase activity was demonstrated to render HER2-negative breast cancer cells more metastatic, suggesting a limitation to the therapeutic effectiveness of this dual inhibitor in HER2-heterogeneous tumors.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	268-272
24707474-3	2014	Therefore, targeting EGFR expression may be a feasible approach to improve the anticancer efficiency of lapatinib-based therapy.	Lapatinib	104-113	epidermal growth factor receptor	Homo sapiens	21-25
24707474-5	2014	In this study, however, our data indicated that treatment with HDAC inhibitors trichostatin A (TSA), but not suberoylanilide hydroxamic acid (SAHA) or HDAC siRNA, can attenuate both protein and mRNA expressions of EGFR in lapatinib-treated triple-negative breast cancer cells, suggesting that TSA may suppress EGFR expression independently of HDAC inhibition.	Lapatinib	222-231	histone deacetylase 9	Homo sapiens	63-67
25598845-6	2014	In addition, overexpression of FOXM1 reduces the sensitivity of HER2-positive breast cancer cells to trastuzumab or lapatinib.	Lapatinib	116-125	forkhead box M1	Homo sapiens	31-36
25598845-6	2014	In addition, overexpression of FOXM1 reduces the sensitivity of HER2-positive breast cancer cells to trastuzumab or lapatinib.	Lapatinib	116-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
24200972-0	2014	Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.	Lapatinib	98-107	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	Lapatinib	65-74	mitogen-activated protein kinase 3	Homo sapiens	91-97
24200972-0	2014	Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.	Lapatinib	98-107	C-X-C motif chemokine receptor 4	Homo sapiens	8-13
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	Lapatinib	165-174	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	19-22
24200972-1	2014	Lapatinib is a dual EGFR and ErbB-2 tyrosine kinase inhibitor that has significantly improved the clinical outcome of ErbB-2-overexpressing breast cancer patients.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	20-24
24200972-10	2014	Taken together, our results demonstrate that breast cancer cells with acquired resistance to lapatinib have a more aggressive phenotype compared with their parental counterpart, and that Src signaling and CXCR4 play an important role in this phenomenon, thus representing potential targets for therapeutic intervention in lapatinib-resistant breast cancer patients.	Lapatinib	93-102	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	187-190
24200972-1	2014	Lapatinib is a dual EGFR and ErbB-2 tyrosine kinase inhibitor that has significantly improved the clinical outcome of ErbB-2-overexpressing breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-35
24200972-10	2014	Taken together, our results demonstrate that breast cancer cells with acquired resistance to lapatinib have a more aggressive phenotype compared with their parental counterpart, and that Src signaling and CXCR4 play an important role in this phenomenon, thus representing potential targets for therapeutic intervention in lapatinib-resistant breast cancer patients.	Lapatinib	93-102	C-X-C motif chemokine receptor 4	Homo sapiens	205-210
24200972-1	2014	Lapatinib is a dual EGFR and ErbB-2 tyrosine kinase inhibitor that has significantly improved the clinical outcome of ErbB-2-overexpressing breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-124
24200972-10	2014	Taken together, our results demonstrate that breast cancer cells with acquired resistance to lapatinib have a more aggressive phenotype compared with their parental counterpart, and that Src signaling and CXCR4 play an important role in this phenomenon, thus representing potential targets for therapeutic intervention in lapatinib-resistant breast cancer patients.	Lapatinib	322-331	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	187-190
24200972-5	2014	Lapatinib-resistant cells have an increased Src kinase activity and persistent levels of activation of ERK1/2 and AKT compared with parental cells.	Lapatinib	0-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	44-47
24200972-5	2014	Lapatinib-resistant cells have an increased Src kinase activity and persistent levels of activation of ERK1/2 and AKT compared with parental cells.	Lapatinib	0-9	mitogen-activated protein kinase 3	Homo sapiens	103-109
24200972-5	2014	Lapatinib-resistant cells have an increased Src kinase activity and persistent levels of activation of ERK1/2 and AKT compared with parental cells.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	114-117
24247151-6	2014	When grown as differentiated DCIS acini in 3D-matrigel culture, Lapatinib only reduced acini size in the HER2-positive samples via decreased proliferation.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	Lapatinib	65-74	AKT serine/threonine kinase 1	Homo sapiens	83-86
24442625-4	2014	Several newer anti-HER2 agents have been developed, including lapatinib, pertuzumab, and trastuzumab emtansine.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
24036211-4	2014	Activated HER3 association with MTK1 is dependent on HER2 activation and is decreased by pre-treatment with the HER2 inhibitor, lapatinib.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 3	Homo sapiens	10-14
24036211-4	2014	Activated HER3 association with MTK1 is dependent on HER2 activation and is decreased by pre-treatment with the HER2 inhibitor, lapatinib.	Lapatinib	128-137	mitogen-activated protein kinase kinase kinase 4	Homo sapiens	32-36
24036211-4	2014	Activated HER3 association with MTK1 is dependent on HER2 activation and is decreased by pre-treatment with the HER2 inhibitor, lapatinib.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
24036211-4	2014	Activated HER3 association with MTK1 is dependent on HER2 activation and is decreased by pre-treatment with the HER2 inhibitor, lapatinib.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
24135146-4	2014	In phase II studies, T-DM1 was active in patients with trastuzumab- and lapatinib-refractory metastatic breast cancer and led to improved progression-free survival compared with the combination of trastuzumab and docetaxel in the first-line setting.	Lapatinib	72-81	immunoglobulin heavy diversity 1-7	Homo sapiens	23-26
24587811-3	2014	Thus, we examined the sensitivity of DF in combination with the EGFR/ERBB2-targeting reagent lapatinib on cancer cells.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-74
24279293-3	2014	Using a neonatal PV mouse model, we demonstrate that epidermal blistering can be prevented in a dose-dependent manner by clinically approved EGFR inhibitors erlotinib and lapatinib, but only up to approximately 50% of normal EGFR activity.	Lapatinib	171-180	epidermal growth factor receptor	Mus musculus	225-229
24279293-6	2014	Moreover, lapatinib (a dual EGFR/ErbB2 inhibitor) but not erlotinib significantly reduced blistering in the oral cavity, suggesting that signalling mechanisms differ between PV predilection sites.	Lapatinib	10-19	epidermal growth factor receptor	Homo sapiens	28-32
24279293-6	2014	Moreover, lapatinib (a dual EGFR/ErbB2 inhibitor) but not erlotinib significantly reduced blistering in the oral cavity, suggesting that signalling mechanisms differ between PV predilection sites.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
24898245-7	2014	In addition to Trastuzumab, new drugs targeting the HER2 receptor, such as Lapatinib, Pertuzumab and Afatinib, are either approved or being evaluated in clinical trials for cancer therapy.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
24191259-0	2014	Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.	Lapatinib	148-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
24191259-2	2014	Lapatinib is extensively metabolized by cytochrome P450 3A4/5 to yield an O-debenzylated metabolite, which can undergo further oxidation to a reactive quinone imine.	Lapatinib	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-59
24191259-3	2014	A recent clinical study reported that concomitant use of lapatinib with dexamethasone increased the incidence of hepatotoxicity in metastatic breast cancer patients treated with lapatinib, and so we hypothesized that induction of CYP3A enhances the bioactivation of lapatinib to reactive intermediates that contribute to hepatotoxicity.	Lapatinib	57-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	230-235
24191259-3	2014	A recent clinical study reported that concomitant use of lapatinib with dexamethasone increased the incidence of hepatotoxicity in metastatic breast cancer patients treated with lapatinib, and so we hypothesized that induction of CYP3A enhances the bioactivation of lapatinib to reactive intermediates that contribute to hepatotoxicity.	Lapatinib	178-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	230-235
24191259-3	2014	A recent clinical study reported that concomitant use of lapatinib with dexamethasone increased the incidence of hepatotoxicity in metastatic breast cancer patients treated with lapatinib, and so we hypothesized that induction of CYP3A enhances the bioactivation of lapatinib to reactive intermediates that contribute to hepatotoxicity.	Lapatinib	178-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	230-235
24191259-4	2014	Therefore, we examined the effect of CYP3A4 induction on the cytotoxicity and metabolism of lapatinib in the HepaRG human hepatic cell line.	Lapatinib	92-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
24191259-7	2014	Induction of CYP3A4 by dexamethasone or rifampicin enhanced lapatinib-induced cytotoxicity, compared with treatment with lapatinib alone.	Lapatinib	60-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
24191259-7	2014	Induction of CYP3A4 by dexamethasone or rifampicin enhanced lapatinib-induced cytotoxicity, compared with treatment with lapatinib alone.	Lapatinib	121-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
24191259-9	2014	Furthermore, pretreatment with 25 muM l-buthionine sulfoximine to deplete intracellular glutathione markedly enhanced lapatinib cytotoxicity.	Lapatinib	118-127	latexin	Homo sapiens	34-37
24191259-11	2014	Collectively, these data suggest that CYP3A4 induction potentiates lapatinib-induced hepatotoxicity via increased reactive metabolite formation.	Lapatinib	67-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
24279293-3	2014	Using a neonatal PV mouse model, we demonstrate that epidermal blistering can be prevented in a dose-dependent manner by clinically approved EGFR inhibitors erlotinib and lapatinib, but only up to approximately 50% of normal EGFR activity.	Lapatinib	171-180	epidermal growth factor receptor	Mus musculus	141-145
25015148-1	2014	The use of human epidermal growth factor receptor type 2 (HER2) gene amplification and overexpression as a molecular predictive marker has become critically important for proper selection of breast cancer patients for treatment with targeted therapeutic agents such as trastuzumab, lapatinib, pertuzumab, and T-DM1.	Lapatinib	282-291	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
23948998-0	2014	Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
23948998-9	2014	This growth inhibition of the Tmab-resistant cells by lapatinib was due to both G1 cell-cycle arrest and apoptosis induction via effective blockade of the PI3K/Akt and MAPK pathways.	Lapatinib	54-63	AKT serine/threonine kinase 1	Homo sapiens	160-163
23948998-11	2014	CONCLUSION: These results suggest that lapatinib has antitumor activity against the Tmab-resistant gastric cancer cell lines, and that these cell lines are useful for understanding the mechanism of Tmab resistance and for developing a new molecular therapy for Tmab-resistant HER2-positive gastric cancers.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	276-280
24258993-4	2014	Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 4	Homo sapiens	8-13
24258993-4	2014	Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 4	Homo sapiens	48-53
24258993-8	2014	This sequencing technique has successfully been applied within a clinical trial selecting patients with ERBB4-mutant melanoma for lapatinib treatment.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 4	Homo sapiens	104-109
24366975-9	2014	In one epidermal growth factor receptor(EGFR)-positive xenograft, responsiveness to lapatinib was evaluated by comparing the pre- and post treatment findings.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	7-39
24249715-0	2014	Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alpha-selective PI3K inhibitor.	Lapatinib	51-60	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	14-23
24249715-0	2014	Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alpha-selective PI3K inhibitor.	Lapatinib	51-60	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	110-119
24249715-3	2014	Genomic and proteomic analyses revealed that lapatinib-resistant breast cancer cells gained additional phosphoinositide 3-kinase (PI3K) activation through activating mutation in PI3K p110alpha and/or increasing protein expression of existing mutant p110alpha.	Lapatinib	45-54	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	183-192
24249715-3	2014	Genomic and proteomic analyses revealed that lapatinib-resistant breast cancer cells gained additional phosphoinositide 3-kinase (PI3K) activation through activating mutation in PI3K p110alpha and/or increasing protein expression of existing mutant p110alpha.	Lapatinib	45-54	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	249-258
24249715-4	2014	p110alpha protein upregulation in lapatinib-resistant cells occurred through gene amplification or posttranscriptional upregulation.	Lapatinib	34-43	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-9
24249715-5	2014	Knockdown of p110alpha, but not p110beta, the other PI3K catalytic subunit present in epithelial cells, inhibited proliferation of lapatinib-resistant cells, especially when combined with lapatinib.	Lapatinib	131-140	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	13-22
24249715-5	2014	Knockdown of p110alpha, but not p110beta, the other PI3K catalytic subunit present in epithelial cells, inhibited proliferation of lapatinib-resistant cells, especially when combined with lapatinib.	Lapatinib	188-197	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	13-22
24249715-6	2014	Lapatinib-resistant xenograft growth was inhibited persistently by combination treatment with the p110alpha-selective PI3K inhibitor BYL719 and lapatinib; the drug combination was also well tolerated in mice.	Lapatinib	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	98-107
24249715-6	2014	Lapatinib-resistant xenograft growth was inhibited persistently by combination treatment with the p110alpha-selective PI3K inhibitor BYL719 and lapatinib; the drug combination was also well tolerated in mice.	Lapatinib	144-153	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	98-107
24249715-7	2014	Mechanistically, the combination of lapatinib plus BYL719 more effectively inhibited Akt phosphorylation and, surprisingly, Erk phosphorylation, than either drug alone in the resistance model.	Lapatinib	36-45	mitogen-activated protein kinase 1	Homo sapiens	124-127
24249715-8	2014	These findings indicate that lapatinib resistance can occur through p110alpha protein upregulation-mediated, and/or mutation-induced, PI3K activation.	Lapatinib	29-38	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	68-77
24172910-0	2014	Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
24172910-0	2014	Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	115-118
24172910-0	2014	Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.	Lapatinib	0-9	fatty acid synthase	Homo sapiens	119-123
24172910-1	2014	Lapatinib, an inhibitor of human epidermal growth factor receptor 2 (HER2) phosphorylation, has been reported to inhibit several types of tumors such as HER2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-67
24172910-1	2014	Lapatinib, an inhibitor of human epidermal growth factor receptor 2 (HER2) phosphorylation, has been reported to inhibit several types of tumors such as HER2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
24172910-1	2014	Lapatinib, an inhibitor of human epidermal growth factor receptor 2 (HER2) phosphorylation, has been reported to inhibit several types of tumors such as HER2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
24172910-12	2014	Western blotting showed that lapatinib suppressed the activity of HER2-PI3K/AKT-FASN in U2-OS and MG-63 cells in vitro.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
24172910-12	2014	Western blotting showed that lapatinib suppressed the activity of HER2-PI3K/AKT-FASN in U2-OS and MG-63 cells in vitro.	Lapatinib	29-38	AKT serine/threonine kinase 1	Homo sapiens	76-79
24172910-12	2014	Western blotting showed that lapatinib suppressed the activity of HER2-PI3K/AKT-FASN in U2-OS and MG-63 cells in vitro.	Lapatinib	29-38	fatty acid synthase	Homo sapiens	80-84
24172910-13	2014	These results suggest that lapatinib may alter the malignant phenotype of OS cells via downregulation of the activity of the HER2-PI3K/AKT-FASN signaling pathway in vitro.	Lapatinib	27-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
24172910-13	2014	These results suggest that lapatinib may alter the malignant phenotype of OS cells via downregulation of the activity of the HER2-PI3K/AKT-FASN signaling pathway in vitro.	Lapatinib	27-36	AKT serine/threonine kinase 1	Homo sapiens	135-138
24172910-13	2014	These results suggest that lapatinib may alter the malignant phenotype of OS cells via downregulation of the activity of the HER2-PI3K/AKT-FASN signaling pathway in vitro.	Lapatinib	27-36	fatty acid synthase	Homo sapiens	139-143
24366975-9	2014	In one epidermal growth factor receptor(EGFR)-positive xenograft, responsiveness to lapatinib was evaluated by comparing the pre- and post treatment findings.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	40-44
24756789-4	2014	Lapatinib is a dual tyrosine kinase inhibitor (TKI), blocking HER1 and HER2 tyrosine kinase activity by binding to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	62-66
24269963-13	2014	Lapatinib is an orally effective quinazoline derivative used in the treatment of ErbB2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-86
24756789-4	2014	Lapatinib is a dual tyrosine kinase inhibitor (TKI), blocking HER1 and HER2 tyrosine kinase activity by binding to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
24354805-6	2013	Besides inhibition of cell motility and invasiveness, AnxA6-depleted cells were also more sensitive to the EGFR-targeted TKIs lapatinib and PD153035.	Lapatinib	126-135	annexin A6	Homo sapiens	54-59
25441944-1	2014	Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-107
24694813-4	2014	Here, we employed these technologies to quantify the temporal response of phosphorylation dynamics in SKBR3 breast cancer cells to lapatinib, a kinase inhibitor for epidermal growth factor receptor (EGFR) and EGFR2 (also known as HER2).	Lapatinib	131-140	epidermal growth factor receptor	Homo sapiens	165-197
24694813-4	2014	Here, we employed these technologies to quantify the temporal response of phosphorylation dynamics in SKBR3 breast cancer cells to lapatinib, a kinase inhibitor for epidermal growth factor receptor (EGFR) and EGFR2 (also known as HER2).	Lapatinib	131-140	epidermal growth factor receptor	Homo sapiens	199-203
24694813-4	2014	Here, we employed these technologies to quantify the temporal response of phosphorylation dynamics in SKBR3 breast cancer cells to lapatinib, a kinase inhibitor for epidermal growth factor receptor (EGFR) and EGFR2 (also known as HER2).	Lapatinib	131-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	230-234
24694813-6	2014	The results provide new insights into EGFR/HER2 regulation through region-specific phosphorylation, as well as a global view of the cellular signaling networks associated with the anti-breast cancer action of lapatinib.	Lapatinib	209-218	epidermal growth factor receptor	Homo sapiens	38-42
24694813-6	2014	The results provide new insights into EGFR/HER2 regulation through region-specific phosphorylation, as well as a global view of the cellular signaling networks associated with the anti-breast cancer action of lapatinib.	Lapatinib	209-218	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
24354805-6	2013	Besides inhibition of cell motility and invasiveness, AnxA6-depleted cells were also more sensitive to the EGFR-targeted TKIs lapatinib and PD153035.	Lapatinib	126-135	epidermal growth factor receptor	Homo sapiens	107-111
24304724-8	2013	Tumor cells of patients with pCR in the trastuzumab or lapatinib treatment arms showed nonphosphorylated FOXO, phosphorylated Stat5, and sparse signal-transduction protein network crosstalk representing different patterns of connections with PI3K and autophagy proteins compared with no pCR.	Lapatinib	55-64	signal transducer and activator of transcription 5A	Homo sapiens	126-131
24013510-3	2013	METHODS: HER2-positive MBC with brain metastasis not previously treated with whole-brain radiotherapy received first-line combination of lapatinib and capecitabine in a phase II study.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
24550751-0	2013	Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.	Lapatinib	22-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-93
24068620-4	2013	The lapatinib-sensitive HCC827 and PC9 and lapatinib-resistant H1650 and H1975 cell lines showed poor responses to CZ0775 and AZD6244 monotherapy with an IC50 > 10 muM.	Lapatinib	4-13	proprotein convertase subtilisin/kexin type 9	Homo sapiens	35-38
24112719-5	2013	Here, we investigated whether and how HRG1 causes resistance to lapatinib in gastric and gastroesophageal junction cancers in vitro.	Lapatinib	64-73	neuregulin 1	Homo sapiens	38-42
24112719-6	2013	HER2-amplified gastric and gastroesophageal junction cancer cell lines were highly sensitive to lapatinib.	Lapatinib	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
24112719-7	2013	Exposure to HRG1 together with lapatinib rescued cells from lapatinib-induced cell cycle arrest and apoptosis.	Lapatinib	60-69	neuregulin 1	Homo sapiens	12-16
24112719-8	2013	Downregulation of HER3 with siRNA in the presence of HRG1 re-sensitized HER2-amplified cancer cells to lapatinib.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 3	Homo sapiens	18-22
24112719-8	2013	Downregulation of HER3 with siRNA in the presence of HRG1 re-sensitized HER2-amplified cancer cells to lapatinib.	Lapatinib	103-112	neuregulin 1	Homo sapiens	53-57
24112719-8	2013	Downregulation of HER3 with siRNA in the presence of HRG1 re-sensitized HER2-amplified cancer cells to lapatinib.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
24112719-9	2013	Immunoblotting analysis indicated that HRG1 re-activated HER3 and AKT in the presence of lapatinib, which persisted for at least 72 h. Activation of HER3 and downstream AKT was mediated by residual activity of HER2.	Lapatinib	89-98	neuregulin 1	Homo sapiens	39-43
24112719-9	2013	Immunoblotting analysis indicated that HRG1 re-activated HER3 and AKT in the presence of lapatinib, which persisted for at least 72 h. Activation of HER3 and downstream AKT was mediated by residual activity of HER2.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 3	Homo sapiens	57-61
24112719-11	2013	Thus, we conclude that HRG1 mediates resistance to lapatinib through HER3 and AKT activation, and that this depends on residual HER2 activity.	Lapatinib	51-60	neuregulin 1	Homo sapiens	23-27
24112719-11	2013	Thus, we conclude that HRG1 mediates resistance to lapatinib through HER3 and AKT activation, and that this depends on residual HER2 activity.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 3	Homo sapiens	69-73
24112719-11	2013	Thus, we conclude that HRG1 mediates resistance to lapatinib through HER3 and AKT activation, and that this depends on residual HER2 activity.	Lapatinib	51-60	AKT serine/threonine kinase 1	Homo sapiens	78-81
24112719-0	2013	Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
24112719-2	2013	Lapatinib, a dual HER2 and epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated clinical efficacy in HER2-amplified cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-22
24112719-2	2013	Lapatinib, a dual HER2 and epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated clinical efficacy in HER2-amplified cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
24112719-4	2013	One of these, Heregulin1 (HRG1), can confer resistance to lapatinib-mediated growth inhibition in HER2-amplified breast cancer cells, but the underlying mechanisms remain unknown.	Lapatinib	58-67	neuregulin 1	Homo sapiens	14-24
24112719-4	2013	One of these, Heregulin1 (HRG1), can confer resistance to lapatinib-mediated growth inhibition in HER2-amplified breast cancer cells, but the underlying mechanisms remain unknown.	Lapatinib	58-67	neuregulin 1	Homo sapiens	26-30
24112719-4	2013	One of these, Heregulin1 (HRG1), can confer resistance to lapatinib-mediated growth inhibition in HER2-amplified breast cancer cells, but the underlying mechanisms remain unknown.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
23907440-5	2013	Randomized, phase III clinical trials indicate targeted HER2 treatment with lapatinib and capecitabine in brain metastases from breast cancer increases the time to progression and decreases the frequency of CNS involvement at progression.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
24068620-5	2013	By contrast, combination treatment with lapatinib and CZ0775 inhibited cell proliferation and produced a 2-fold higher number of annexin V-labeled cells than lapatinib alone in H1975 cells.	Lapatinib	40-49	annexin A5	Homo sapiens	129-138
24068620-7	2013	siRNA-mediated BIM depletion reduced caspase-3 activity (~40%) in lapatinib and CZ0775 treated H1975 cells.	Lapatinib	66-75	caspase 3	Homo sapiens	37-46
24068620-8	2013	An in vitro ERK activity assay showed that p-ERK levels were approximately a 3-fold lower in H1975 cells treated with CZ0775 and lapatinib combination than in cells treated with lapatinib alone.	Lapatinib	129-138	EPH receptor B2	Homo sapiens	12-15
24068620-8	2013	An in vitro ERK activity assay showed that p-ERK levels were approximately a 3-fold lower in H1975 cells treated with CZ0775 and lapatinib combination than in cells treated with lapatinib alone.	Lapatinib	129-138	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	43-48
23794518-0	2013	Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
24068620-8	2013	An in vitro ERK activity assay showed that p-ERK levels were approximately a 3-fold lower in H1975 cells treated with CZ0775 and lapatinib combination than in cells treated with lapatinib alone.	Lapatinib	178-187	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	43-48
23794518-2	2013	Lapatinib is an oral dual tyrosine kinase inhibitor (TKI) that targets both EGFR and HER2 to inhibit the proliferation of breast cancer cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	76-80
24527364-0	2013	Impact of STAT1 and CD8+ T cells on the antineoplastic activity of lapatinib and doxorubicin against spontaneous mammary tumors.	Lapatinib	67-76	signal transducer and activator of transcription 1	Mus musculus	10-15
23794518-2	2013	Lapatinib is an oral dual tyrosine kinase inhibitor (TKI) that targets both EGFR and HER2 to inhibit the proliferation of breast cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
23794518-4	2013	In this study, we investigated the apoptosis and the autophagy in the HER2-overexpressing breast cancer cells BT474 and AU565 treated with lapatinib, and further examined their relationship.	Lapatinib	139-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
23794518-5	2013	Lapatinib inhibited the proliferation and the rate of DNA synthesis in HER2-positive cells, as observed by MTT, colony formation and EDU assays.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
23794518-6	2013	Lapatinib not only induced apoptosis accompanied by an increased expression of cleaved Caspase-3 and cleaved PARP, but it also induced autophagy in vitro, as confirmed by electron microscopy (EM), acridine orange (AO) staining and LC3-II expression.	Lapatinib	0-9	caspase 3	Homo sapiens	87-96
23794518-6	2013	Lapatinib not only induced apoptosis accompanied by an increased expression of cleaved Caspase-3 and cleaved PARP, but it also induced autophagy in vitro, as confirmed by electron microscopy (EM), acridine orange (AO) staining and LC3-II expression.	Lapatinib	0-9	collagen type XI alpha 2 chain	Homo sapiens	109-113
23794518-7	2013	Meanwhile, lapatinib inhibited the phosphorylation of HER2, AKT, mTOR, and p70S6K, whereas that of AMPK was activated.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
23794518-7	2013	Meanwhile, lapatinib inhibited the phosphorylation of HER2, AKT, mTOR, and p70S6K, whereas that of AMPK was activated.	Lapatinib	11-20	AKT serine/threonine kinase 1	Homo sapiens	60-63
23794518-7	2013	Meanwhile, lapatinib inhibited the phosphorylation of HER2, AKT, mTOR, and p70S6K, whereas that of AMPK was activated.	Lapatinib	11-20	mechanistic target of rapamycin kinase	Homo sapiens	65-69
23794518-7	2013	Meanwhile, lapatinib inhibited the phosphorylation of HER2, AKT, mTOR, and p70S6K, whereas that of AMPK was activated.	Lapatinib	11-20	ribosomal protein S6 kinase B1	Homo sapiens	75-81
23794518-10	2013	The addition of 3-MA could attenuate the inhibitory role on HER2/AKT/mTOR pathway and the active role on AMPK that was raised by lapatinib.	Lapatinib	129-138	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	105-109
24263233-0	2013	Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.	Lapatinib	81-90	AKT serine/threonine kinase 1	Homo sapiens	61-64
24263233-0	2013	Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.	Lapatinib	81-90	mitogen-activated protein kinase 1	Homo sapiens	74-77
24263233-1	2013	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-63
24263233-1	2013	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	65-69
24263233-1	2013	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-115
24263233-1	2013	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
24263233-1	2013	Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
24263233-2	2013	However, similar to other EGFR-targeting drugs, acquired resistance to lapatinib by HER2-positive cancer cells remains a major clinical challenge.	Lapatinib	71-80	epidermal growth factor receptor	Homo sapiens	26-30
24263233-2	2013	However, similar to other EGFR-targeting drugs, acquired resistance to lapatinib by HER2-positive cancer cells remains a major clinical challenge.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
24263233-3	2013	To elucidate resistance mechanisms to EGFR/HER2-targeting agents, we performed a systematic quantitative comparison of the phosphoproteome of lapatinib-resistant (LR) human gastric cancer cells (SNU216-LR) versus parental cells (SNU216) using a titanium dioxide (TiO2) phosphopeptide enrichment method and analysis with a Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer.	Lapatinib	142-151	epidermal growth factor receptor	Homo sapiens	38-42
24263233-3	2013	To elucidate resistance mechanisms to EGFR/HER2-targeting agents, we performed a systematic quantitative comparison of the phosphoproteome of lapatinib-resistant (LR) human gastric cancer cells (SNU216-LR) versus parental cells (SNU216) using a titanium dioxide (TiO2) phosphopeptide enrichment method and analysis with a Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
24197661-0	2013	A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-116
24127451-0	2013	Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-99
24216290-3	2013	METHODS: Triple-negative breast cancer cell lines were treated with proteasome inhibitors in combination with lapatinib (a dual epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor).	Lapatinib	110-119	epidermal growth factor receptor	Homo sapiens	128-160
24216290-3	2013	METHODS: Triple-negative breast cancer cell lines were treated with proteasome inhibitors in combination with lapatinib (a dual epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor).	Lapatinib	110-119	epidermal growth factor receptor	Homo sapiens	162-166
24216290-3	2013	METHODS: Triple-negative breast cancer cell lines were treated with proteasome inhibitors in combination with lapatinib (a dual epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor).	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-172
24216290-6	2013	RESULTS: Our data showed that nuclear factor (NF)-kappaB activation was elicited by lapatinib, independent of EGFR/HER2 inhibition, in TNBCs.	Lapatinib	84-93	nuclear factor kappa B subunit 1	Homo sapiens	30-56
24216290-7	2013	Lapatinib-induced constitutive activation of NF-kappaB involved Src family kinase (SFK)-dependent p65 and IkappaBalpha phosphorylations, and rendered these cells more vulnerable to NF-kappaB inhibition by p65 small hairpin RNA.	Lapatinib	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	98-101
24216290-7	2013	Lapatinib-induced constitutive activation of NF-kappaB involved Src family kinase (SFK)-dependent p65 and IkappaBalpha phosphorylations, and rendered these cells more vulnerable to NF-kappaB inhibition by p65 small hairpin RNA.	Lapatinib	0-9	NFKB inhibitor alpha	Homo sapiens	106-118
24216290-7	2013	Lapatinib-induced constitutive activation of NF-kappaB involved Src family kinase (SFK)-dependent p65 and IkappaBalpha phosphorylations, and rendered these cells more vulnerable to NF-kappaB inhibition by p65 small hairpin RNA.	Lapatinib	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	205-208
24197661-0	2013	A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-122
23950206-6	2013	Here, we report the molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR genomic alterations.	Lapatinib	74-83	epidermal growth factor receptor	Homo sapiens	169-173
24156325-5	2013	Lapatinib demonstrated activity against BM from HER-2-positive breast cancer in small Phase II and retrospective studies, mainly in combination with capecitabine, and cases of dramatic responses to such treatment are present in literature.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-53
24057042-0	2013	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-65
24057042-2	2013	This study was conducted to determine the safety and pharmacokinetics (PK) of the combination of lapatinib, a Her1 and 2 inhibitor, and everolimus and to describe its anti-tumor activity in the Phase I setting.	Lapatinib	97-106	epidermal growth factor receptor	Homo sapiens	110-120
24121234-1	2013	To develop potent dual EGFR/HER-2 inhibitors with improved druggability, a series of new lapatinib analogs were designed and synthesized.	Lapatinib	89-98	epidermal growth factor receptor	Homo sapiens	23-27
24121234-1	2013	To develop potent dual EGFR/HER-2 inhibitors with improved druggability, a series of new lapatinib analogs were designed and synthesized.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
23950206-2	2013	Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
23950206-6	2013	Here, we report the molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR genomic alterations.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-164
23913859-7	2013	Moreover, using a murine treatment model of bleomycin-induced pulmonary fibrosis we found that inhibition of TGFbeta/PDGF and ErbB pathways with imatinib plus lapatinib, respectively, not only prevented myofibroblast gene expression to a greater extent than either drug alone, but also essentially stabilized gas exchange (oxygen saturation) as an overall measure of lung function.	Lapatinib	159-168	transforming growth factor, beta 1	Mus musculus	109-116
23913859-7	2013	Moreover, using a murine treatment model of bleomycin-induced pulmonary fibrosis we found that inhibition of TGFbeta/PDGF and ErbB pathways with imatinib plus lapatinib, respectively, not only prevented myofibroblast gene expression to a greater extent than either drug alone, but also essentially stabilized gas exchange (oxygen saturation) as an overall measure of lung function.	Lapatinib	159-168	epidermal growth factor receptor	Mus musculus	126-130
24155918-10	2013	Similarly, when HER2-positive, ACSL4-negative, SKBr3 breast cancer cells were induced to express ACSL4, the proliferation rate increased and the apoptotic effect of lapatinib was reduced.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20
24095300-0	2013	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
23811285-0	2013	RON confers lapatinib resistance in HER2-positive breast cancer cells.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
23811285-2	2013	SK-BR-3-LR, a lapatinib-resistant cell clone, was established from HER2-positive SK-BR-3 breast cancer cells following chronic exposure to lapatinib.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
23811285-4	2013	However, both small-molecular Recepteur d"Origine Nantais (RON) inhibitors and RON-targeted small interfering RNA (siRNA) effectively restored lapatinib sensitivity in these cells by inhibiting PI3K/AKT activation.	Lapatinib	143-152	AKT serine/threonine kinase 1	Homo sapiens	199-202
24025972-6	2013	CREB downregulation in HER-2/neu-transformed cells by shRNA and by the inhibitors KG-501 and lapatinib caused morphologic changes, reduced cell proliferation with G0-G1 cell-cycle arrest, which was rescued by CREB expression.	Lapatinib	93-102	cAMP responsive element binding protein 1	Homo sapiens	0-4
24025972-6	2013	CREB downregulation in HER-2/neu-transformed cells by shRNA and by the inhibitors KG-501 and lapatinib caused morphologic changes, reduced cell proliferation with G0-G1 cell-cycle arrest, which was rescued by CREB expression.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-28
24025972-6	2013	CREB downregulation in HER-2/neu-transformed cells by shRNA and by the inhibitors KG-501 and lapatinib caused morphologic changes, reduced cell proliferation with G0-G1 cell-cycle arrest, which was rescued by CREB expression.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-32
24025972-6	2013	CREB downregulation in HER-2/neu-transformed cells by shRNA and by the inhibitors KG-501 and lapatinib caused morphologic changes, reduced cell proliferation with G0-G1 cell-cycle arrest, which was rescued by CREB expression.	Lapatinib	93-102	cAMP responsive element binding protein 1	Homo sapiens	209-213
24223926-6	2013	Additional modules from the HER2 transcriptome model, including ubiquitin-mediated proteolysis, TGF-beta signaling, RHO-family GTPase signaling, and M-phase progression, were linked to response to lapatinib and paclitaxel in vitro and/or risk of relapse in the N9831 dataset.	Lapatinib	197-206	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
24194858-6	2013	The present computational approach aims to model this emergence in EGFR and ErbB2 after treatment with the drug lapatinib, by investigating the structural, dynamic and energetic effects on these kinases when bound to the natural substrate ATP and to lapatinib.	Lapatinib	112-121	epidermal growth factor receptor	Homo sapiens	67-71
24194858-6	2013	The present computational approach aims to model this emergence in EGFR and ErbB2 after treatment with the drug lapatinib, by investigating the structural, dynamic and energetic effects on these kinases when bound to the natural substrate ATP and to lapatinib.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-81
24194858-6	2013	The present computational approach aims to model this emergence in EGFR and ErbB2 after treatment with the drug lapatinib, by investigating the structural, dynamic and energetic effects on these kinases when bound to the natural substrate ATP and to lapatinib.	Lapatinib	250-259	epidermal growth factor receptor	Homo sapiens	67-71
24194858-6	2013	The present computational approach aims to model this emergence in EGFR and ErbB2 after treatment with the drug lapatinib, by investigating the structural, dynamic and energetic effects on these kinases when bound to the natural substrate ATP and to lapatinib.	Lapatinib	250-259	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-81
24014028-7	2013	The small-molecule tyrosine kinase inhibitors erlotinib and lapatinib differentially enhance the dimerization of the various ErbB receptor pairings, with the EGFR/ErbB3 heterodimer being particularly sensitive to the effects of erlotinib.	Lapatinib	60-69	epidermal growth factor receptor	Homo sapiens	158-162
24014028-7	2013	The small-molecule tyrosine kinase inhibitors erlotinib and lapatinib differentially enhance the dimerization of the various ErbB receptor pairings, with the EGFR/ErbB3 heterodimer being particularly sensitive to the effects of erlotinib.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 3	Homo sapiens	163-168
24155918-10	2013	Similarly, when HER2-positive, ACSL4-negative, SKBr3 breast cancer cells were induced to express ACSL4, the proliferation rate increased and the apoptotic effect of lapatinib was reduced.	Lapatinib	165-174	acyl-CoA synthetase long chain family member 4	Homo sapiens	31-36
24155918-10	2013	Similarly, when HER2-positive, ACSL4-negative, SKBr3 breast cancer cells were induced to express ACSL4, the proliferation rate increased and the apoptotic effect of lapatinib was reduced.	Lapatinib	165-174	acyl-CoA synthetase long chain family member 4	Homo sapiens	97-102
23434074-7	2013	Four of these studies assessed dual HER2-targeting approaches, which universally increased pCR at the expense of increased non-cardiac toxicity when lapatinib, but not pertuzumab, was added to trastuzumab.	Lapatinib	149-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
23827380-3	2013	Trastuzumab and pertuzumab (anti-HER2 monoclonal antibodies), lapatinib (a small molecule inhibitor of HER2 and the epidermal growth factor receptor [EGFR]) are approved for treating HER2-positive MBC in the United States.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
23827380-3	2013	Trastuzumab and pertuzumab (anti-HER2 monoclonal antibodies), lapatinib (a small molecule inhibitor of HER2 and the epidermal growth factor receptor [EGFR]) are approved for treating HER2-positive MBC in the United States.	Lapatinib	62-71	epidermal growth factor receptor	Homo sapiens	116-148
23827380-3	2013	Trastuzumab and pertuzumab (anti-HER2 monoclonal antibodies), lapatinib (a small molecule inhibitor of HER2 and the epidermal growth factor receptor [EGFR]) are approved for treating HER2-positive MBC in the United States.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
23928571-8	2013	The significant lapatinib-docetaxel interaction is likely CYP3A4-mediated, suggesting that caution should be exercised when this combination is administered, particularly to patients with compromised CYP3A activity, and recipients should be monitored closely for enhanced toxicity, particularly for adverse effects on the intestine.	Lapatinib	16-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
23954396-0	2013	Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.	Lapatinib	18-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
23954396-1	2013	BACKGROUND: The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine in women with HER2 positive metastatic or recurrent breast cancer.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
23948973-2	2013	A T798M mutation in the HER2 oncogene has been shown to confer resistance to the tyrosine kinase inhibitor (TKI) lapatinib.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
23948973-13	2013	Addition of the EGFR neutralizing antibody cetuximab or lapatinib restored trastuzumab sensitivity of BT474-T798M cells and xenografts, suggesting that increased EGFR ligand production was causally associated with drug resistance.	Lapatinib	56-65	epidermal growth factor receptor	Homo sapiens	162-166
24155635-0	2013	Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.	Lapatinib	22-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	65-81
24155635-1	2013	BACKGROUND: The cost-effectiveness of first-line treatment with lapatinib plus letrozole for postmenopausal women with hormone receptor-positive (hr+), human epidermal growth factor receptor 2-positive (her2+) metastatic breast cancer (mbc) has not been assessed from the Canadian health care system and societal perspectives.	Lapatinib	64-73	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-135
24155635-1	2013	BACKGROUND: The cost-effectiveness of first-line treatment with lapatinib plus letrozole for postmenopausal women with hormone receptor-positive (hr+), human epidermal growth factor receptor 2-positive (her2+) metastatic breast cancer (mbc) has not been assessed from the Canadian health care system and societal perspectives.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-192
24122755-8	2013	43: 2718-2729] demonstrates a crucial role for the IFN signaling molecule STAT1 during doxorubicin and Lapatinib treatment of HER2/Neu-driven mammary carcinomas.	Lapatinib	103-112	signal transducer and activator of transcription 1	Homo sapiens	74-79
23843024-2	2013	Using MMTV-neu mice as an animal model for HER2-positive breast cancer, we observed enhanced tumor infiltration by IFN-gamma-secreting T cells after treatment with doxorubicin and/or lapatinib.	Lapatinib	183-192	erb-b2 receptor tyrosine kinase 2	Mus musculus	43-47
23843024-8	2013	Taken together, the results point to an important contribution toward enhancing T-cell and IFN-gamma-based immunity by lapatinib as well as doxorubicin and emphasize the role of Stat1 in building an effective antitumor immune response.	Lapatinib	119-128	interferon gamma	Mus musculus	91-100
23843024-0	2013	Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.	Lapatinib	0-9	signal transducer and activator of transcription 1	Mus musculus	38-43
23843024-1	2013	The dual erbB1/2 tyrosine kinase inhibitor lapatinib as well as the anthracycline doxorubicin are both used in the therapy of HER2-positive breast cancer.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Mus musculus	126-130
23187882-2	2013	Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	56-60
23187882-2	2013	Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
23187882-4	2013	METHODS: Nine gastric cancer cell lines were evaluated for the effects of lapatinib on the cell-surface accumulation of HER2 and analyzed for their additional effects on trastuzumab-mediated ADCC.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
23187882-6	2013	RESULTS: Lapatinib inhibited HER2 signaling and cell proliferation in the panel of gastric cancer cell lines.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
23187882-7	2013	Lapatinib also induced the accumulation of HER2 on the cell surface, resulting in the enhancement of trastuzumab-mediated ADCC of gastric cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
24105053-10	2013	Lapatinib should also be considered for the treatment of patients with brain metastases from human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	99-131
24122755-8	2013	43: 2718-2729] demonstrates a crucial role for the IFN signaling molecule STAT1 during doxorubicin and Lapatinib treatment of HER2/Neu-driven mammary carcinomas.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
24122755-8	2013	43: 2718-2729] demonstrates a crucial role for the IFN signaling molecule STAT1 during doxorubicin and Lapatinib treatment of HER2/Neu-driven mammary carcinomas.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-134
24122755-9	2013	The genotoxic anthracycline doxorubicin causes immunogenic cancer cell death and is expected to depend on the immune system, but the dual ErbB2/HER2/Neu and ErbB1/EGFR inhibitor Lapatinib also turns out to cause immune reactivity.	Lapatinib	178-187	epidermal growth factor receptor	Homo sapiens	163-167
24518715-2	2013	Gefitinib is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor).	Lapatinib	51-60	epidermal growth factor receptor	Homo sapiens	93-97
24518715-2	2013	Gefitinib is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor).	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
24518715-2	2013	Gefitinib is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor).	Lapatinib	51-60	epidermal growth factor receptor	Homo sapiens	93-97
23933942-5	2013	The mRNA amounts of human equilibrative nucleoside transporter (hENT1), deoxycytidine kinase (dCK) and ribonucleotide reductase subunit M1 (RRM1) genes were measured by quantitative real-time polymerase chain reaction in cells exposed to lapatinib for 48 h, as compared with untreated cells.	Lapatinib	238-247	ribonucleotide reductase catalytic subunit M1	Homo sapiens	140-144
24069582-6	2013	HER2-positive breast cancers are currently treated with anti-HER2 therapies including trastuzumab and lapatinib, and preclinical and clinical studies are now being conducted to test these drugs for the prevention of HER2-positive breast cancers.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
24069582-6	2013	HER2-positive breast cancers are currently treated with anti-HER2 therapies including trastuzumab and lapatinib, and preclinical and clinical studies are now being conducted to test these drugs for the prevention of HER2-positive breast cancers.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
24069582-6	2013	HER2-positive breast cancers are currently treated with anti-HER2 therapies including trastuzumab and lapatinib, and preclinical and clinical studies are now being conducted to test these drugs for the prevention of HER2-positive breast cancers.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
23913825-6	2013	When combined with the EGFR/HER2 dual-targeting drug lapatinib, an Src-targeting combinatorial regimen prevented outgrowth of disseminated breast cancer cells through the induction of cell-cycle arrest.	Lapatinib	53-62	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	67-70
23878115-9	2013	CONCLUSIONS: Lapatinib/docetaxel/trastuzumab is a feasible and well-tolerated treatment of untreated HER2-positive stage IV MBC.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
23451915-2	2013	Lapatinib is a dual inhibitor of the EGF receptor and EGF receptor 2 approved by the US FDA to treat advanced breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	37-68
23991019-9	2013	Using this model we provide the first clear evidence that resistance to trastuzumab (and lapatinib) can occur spontaneously as HER-2+ cells shift from a luminal to a basal/mesenchymal phenotype following EMT.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-132
23983820-1	2013	Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib.	Lapatinib	247-256	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-172
23983820-1	2013	Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib.	Lapatinib	247-256	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
23983820-1	2013	Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib.	Lapatinib	247-256	epidermal growth factor receptor	Homo sapiens	138-170
23983820-1	2013	Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib.	Lapatinib	247-256	epidermal growth factor receptor	Homo sapiens	217-221
23907131-0	2013	Lapatinib induces p27(Kip1)-dependent G1 arrest through both transcriptional and post-translational mechanisms.	Lapatinib	0-9	cyclin dependent kinase inhibitor 1B	Homo sapiens	22-26
23907131-1	2013	Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, has been shown to have potent antitumor effects against human breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
23907131-1	2013	Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, has been shown to have potent antitumor effects against human breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
23907131-2	2013	Recent studies have shown that lapatinib upregulates p27(Kip1) (here after referred to as p27) expression and induces G1 cell cycle arrest in various types of cancer cells.	Lapatinib	31-40	interferon alpha inducible protein 27	Homo sapiens	53-56
23907131-2	2013	Recent studies have shown that lapatinib upregulates p27(Kip1) (here after referred to as p27) expression and induces G1 cell cycle arrest in various types of cancer cells.	Lapatinib	31-40	cyclin dependent kinase inhibitor 1B	Homo sapiens	57-61
23907131-2	2013	Recent studies have shown that lapatinib upregulates p27(Kip1) (here after referred to as p27) expression and induces G1 cell cycle arrest in various types of cancer cells.	Lapatinib	31-40	interferon alpha inducible protein 27	Homo sapiens	90-93
23907131-3	2013	However, the regulation of p27 in lapatinib-induced cell cycle arrest is not well studied.	Lapatinib	34-43	interferon alpha inducible protein 27	Homo sapiens	27-30
23907131-4	2013	Here we demonstrate that lapatinib-induced cell growth inhibition and G1 cell cycle arrest in HER2-overexpressing human breast cancer cells were dependent on p27.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
23907131-4	2013	Here we demonstrate that lapatinib-induced cell growth inhibition and G1 cell cycle arrest in HER2-overexpressing human breast cancer cells were dependent on p27.	Lapatinib	25-34	interferon alpha inducible protein 27	Homo sapiens	158-161
23907131-5	2013	We also show that lapatinib-induced upregulation of p27 expression was mediated through both transcriptional and post-translational mechanisms.	Lapatinib	18-27	interferon alpha inducible protein 27	Homo sapiens	52-55
23907131-6	2013	On the one hand, lapatinib treatment led to increased FOXO3a expression and enhanced p27 transcription.	Lapatinib	17-26	forkhead box O3	Homo sapiens	54-60
23907131-6	2013	On the one hand, lapatinib treatment led to increased FOXO3a expression and enhanced p27 transcription.	Lapatinib	17-26	interferon alpha inducible protein 27	Homo sapiens	85-88
23907131-7	2013	On the other hand, lapatinib treatment resulted in increased DYRK1B expression, which correlated with increased p27 phosphorylation at Ser10 and decreased p27 degradation.	Lapatinib	19-28	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	61-67
23907131-7	2013	On the other hand, lapatinib treatment resulted in increased DYRK1B expression, which correlated with increased p27 phosphorylation at Ser10 and decreased p27 degradation.	Lapatinib	19-28	interferon alpha inducible protein 27	Homo sapiens	112-115
23907131-7	2013	On the other hand, lapatinib treatment resulted in increased DYRK1B expression, which correlated with increased p27 phosphorylation at Ser10 and decreased p27 degradation.	Lapatinib	19-28	interferon alpha inducible protein 27	Homo sapiens	155-158
23907131-8	2013	Interestingly, we found that ERbeta1 but not ERbeta2 expression also upregulated p27 and enhanced lapatinib-induced cell proliferation inhibition and G1 cell cycle arrest in HER2-overexpressing breast cancer cells.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
23907131-9	2013	Taken together, our results suggest that lapatinib induces p27 expression via both transcriptional and post-translational upregulations, leading to cell cycle arrest and cell proliferation inhibition, and that its effect on breast cancer cells may be modified by ER expression status.	Lapatinib	41-50	interferon alpha inducible protein 27	Homo sapiens	59-62
23940356-9	2013	Finally, HER2(+)/PIK3CA tumors were resistant to trastuzumab alone and in combination with lapatinib or pertuzumab.	Lapatinib	91-100	erb-b2 receptor tyrosine kinase 2	Mus musculus	9-13
23940356-9	2013	Finally, HER2(+)/PIK3CA tumors were resistant to trastuzumab alone and in combination with lapatinib or pertuzumab.	Lapatinib	91-100	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	17-23
23907131-0	2013	Lapatinib induces p27(Kip1)-dependent G1 arrest through both transcriptional and post-translational mechanisms.	Lapatinib	0-9	interferon alpha inducible protein 27	Homo sapiens	18-21
23943608-6	2013	In particular, ERBB2-amplified breast cancer cells stimulated with the ErbB3 ligand heregulin were resistant to growth arrest induced by inhibitors of AKT and MEK or coapplication of two inhibitors of the receptor ErbB2 [Herceptin (trastuzumab) and Tykerb (lapatinib)].	Lapatinib	249-255	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
23943608-6	2013	In particular, ERBB2-amplified breast cancer cells stimulated with the ErbB3 ligand heregulin were resistant to growth arrest induced by inhibitors of AKT and MEK or coapplication of two inhibitors of the receptor ErbB2 [Herceptin (trastuzumab) and Tykerb (lapatinib)].	Lapatinib	249-255	erb-b2 receptor tyrosine kinase 3	Homo sapiens	71-76
23943608-6	2013	In particular, ERBB2-amplified breast cancer cells stimulated with the ErbB3 ligand heregulin were resistant to growth arrest induced by inhibitors of AKT and MEK or coapplication of two inhibitors of the receptor ErbB2 [Herceptin (trastuzumab) and Tykerb (lapatinib)].	Lapatinib	257-266	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
23943608-6	2013	In particular, ERBB2-amplified breast cancer cells stimulated with the ErbB3 ligand heregulin were resistant to growth arrest induced by inhibitors of AKT and MEK or coapplication of two inhibitors of the receptor ErbB2 [Herceptin (trastuzumab) and Tykerb (lapatinib)].	Lapatinib	257-266	erb-b2 receptor tyrosine kinase 3	Homo sapiens	71-76
23943608-8	2013	Treatment with trastuzumab, lapatinib, and the ErbB3 inhibitor MM-111 was more effective in inhibiting tumor growth than the combination of AKT and MEK inhibitors and even induced tumor regression, indicating that targeting both ErbB3 and ErbB2 may be an improved therapeutic approach for ErbB2-positive breast cancer patients.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 3	Homo sapiens	229-234
23878115-0	2013	Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
23648830-8	2013	Compared to susceptible flies, P-gp levels in the resistant strain were markedly suppressed by the dEGFR and dAkt inhibitors lapatinib and wortmannin.	Lapatinib	125-134	Multi drug resistance 65	Drosophila melanogaster	31-35
23648830-8	2013	Compared to susceptible flies, P-gp levels in the resistant strain were markedly suppressed by the dEGFR and dAkt inhibitors lapatinib and wortmannin.	Lapatinib	125-134	Epidermal growth factor receptor	Drosophila melanogaster	99-104
23648830-8	2013	Compared to susceptible flies, P-gp levels in the resistant strain were markedly suppressed by the dEGFR and dAkt inhibitors lapatinib and wortmannin.	Lapatinib	125-134	Akt1	Drosophila melanogaster	109-113
23011099-0	2013	A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
23011099-4	2013	The international clinical study in which six Japanese patients participated indicated the antitumor activity of lapatinib against brain metastases of HER2-overexpressing breast cancer.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
23011099-5	2013	METHODS: The efficacy, safety, and pharmacokinetics of lapatinib 750 mg given twice daily to Japanese HER2-overexpressing MBC patients with brain metastases were assessed as part of the international clinical study.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
23011099-10	2013	CONCLUSION: These results suggest that lapatinib monotherapy 750 mg given twice daily can exert some efficacy and has potential as a clinically meaningful treatment option for Japanese HER2-overexpressing breast cancer patients with brain metastases after cranial radiation.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
23723125-7	2013	Genetic ablation of ESX decreased EGFR and Her2 levels and enhanced the antiproliferative effects of EGFR/Her2 tyrosine kinase inhibitors (TKI), lapatinib and afatinib.	Lapatinib	145-154	E74 like ETS transcription factor 3	Homo sapiens	20-23
22458846-0	2013	Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.	Lapatinib	41-50	KRAS proto-oncogene, GTPase	Homo sapiens	105-109
23844917-7	2013	The addition of anti-HER2 agents such as trastuzumab and lapatinib to hormonal therapies has improved outcomes but it is unclear whether these approaches are additive or synergistic.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
22458846-6	2013	From a previous study in mice, we know that everolimus is a P-glycoprotein (P-gp) substrate and that a lapatinib pretreatment increases significantly (2.6-fold) everolimus AUC by inhibiting its intestinal P-gp efflux.	Lapatinib	103-112	phosphoglycolate phosphatase	Mus musculus	205-209
23703612-8	2013	These findings shed new light on mechanisms involved in lapatinib-mediated autophagy in Her2-expressing breast carcinoma cell lines and in Beclin-1 signaling in these cells.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23896512-10	2013	Anti-ErbB3 mAbs strongly synergize also with the dual EGFR and HER2 inhibitor lapatinib.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 3	Homo sapiens	5-10
23896512-10	2013	Anti-ErbB3 mAbs strongly synergize also with the dual EGFR and HER2 inhibitor lapatinib.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
23936456-10	2013	Both canertinib and the FDA-approved ErbB1/2-directed TKI lapatinib abrogated proliferation and increased sensitivity to BCR/ABL-directed TKIs at clinically relevant doses.	Lapatinib	58-67	epidermal growth factor receptor	Homo sapiens	37-42
23936456-10	2013	Both canertinib and the FDA-approved ErbB1/2-directed TKI lapatinib abrogated proliferation and increased sensitivity to BCR/ABL-directed TKIs at clinically relevant doses.	Lapatinib	58-67	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	121-128
23708506-1	2013	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	49-81
23708506-1	2013	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	83-87
23708506-1	2013	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	99-103
23708506-1	2013	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
23708506-8	2013	Lapatinib in combination with 5-FU had more potent antitumor effects in the primary ESCC xenograft model, and markedly reduced the phosphorylation of EGFR and HER2, compared with lapatinib alone or in combination with oxaliplatin.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	150-154
23708506-8	2013	Lapatinib in combination with 5-FU had more potent antitumor effects in the primary ESCC xenograft model, and markedly reduced the phosphorylation of EGFR and HER2, compared with lapatinib alone or in combination with oxaliplatin.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
23708506-9	2013	These data indicate that lapatinib has activity in EGFR- and/or HER2-expressing ESCC primary cells, and that lapatinib in combination with 5-FU may be a promising treatment strategy for patients with ESCC.	Lapatinib	25-34	epidermal growth factor receptor	Homo sapiens	51-55
23708506-9	2013	These data indicate that lapatinib has activity in EGFR- and/or HER2-expressing ESCC primary cells, and that lapatinib in combination with 5-FU may be a promising treatment strategy for patients with ESCC.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
23816254-11	2013	CONCLUSIONS: In these HER2-expressing cell line models, lapatinib, neratinib, afatinib and trastuzumab treatment generated a characteristic and specific gene expression response, proportionate to the sensitivity of the cell lines to the HER2 inhibitor.Characterisation of the induced changes in expression levels of these genes may therefore give a valuable, very early predictor of the likely extent and specificity of tumour HER2 inhibitor response in patients, potentially guiding more specific use of these agents.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
22458639-0	2013	Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-63
22458639-0	2013	Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-108
23292912-7	2013	To confirm the importance of ErbB2 activation, animals were treated with lapatinib, a dual ErbB1 and ErbB2 inhibitor.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-34
23292912-7	2013	To confirm the importance of ErbB2 activation, animals were treated with lapatinib, a dual ErbB1 and ErbB2 inhibitor.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
23292912-8	2013	Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signaling pathways (Akt, ERKs and Stat3).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	106-111
23292912-8	2013	Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signaling pathways (Akt, ERKs and Stat3).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-121
23292912-8	2013	Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signaling pathways (Akt, ERKs and Stat3).	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	184-187
23292912-8	2013	Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signaling pathways (Akt, ERKs and Stat3).	Lapatinib	0-9	signal transducer and activator of transcription 3	Homo sapiens	198-203
23911931-3	2013	The binding mechanisms and dynamics are detailed with respect to two approved inhibitors against EGFR (lapatinib) and HER2 (SYR127063).	Lapatinib	103-112	epidermal growth factor receptor	Homo sapiens	97-101
23559153-0	2013	Phase II study on lapatinib in advanced EGFR-positive chordoma.	Lapatinib	18-27	epidermal growth factor receptor	Homo sapiens	40-44
23559153-1	2013	BACKGROUND: To report on a prospective, investigator-driven, phase II study on lapatinib in epidermal growth factor receptor (EGFR)-positive advanced chordoma patients.	Lapatinib	79-88	epidermal growth factor receptor	Homo sapiens	92-124
23559153-1	2013	BACKGROUND: To report on a prospective, investigator-driven, phase II study on lapatinib in epidermal growth factor receptor (EGFR)-positive advanced chordoma patients.	Lapatinib	79-88	epidermal growth factor receptor	Homo sapiens	126-130
23633485-6	2013	Similarly, inhibition of ErbB RTKs with lapatinib did not affect PI3K signaling in PIK3CA(H1047R)-expressing tumors.	Lapatinib	40-49	epidermal growth factor receptor	Homo sapiens	25-29
23633485-7	2013	However, the p110alpha-specific inhibitor BYL719 in combination with lapatinib impaired mammary tumor growth and PI3K signaling more potently than BYL719 alone.	Lapatinib	69-78	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	13-22
22458639-9	2013	Our findings indicated that the combination of lapatinib and cisplatin is one of the promising treatment strategies for esophageal carcinomas with EGFR and HER2 overexpression.	Lapatinib	47-56	epidermal growth factor receptor	Homo sapiens	147-151
22458639-9	2013	Our findings indicated that the combination of lapatinib and cisplatin is one of the promising treatment strategies for esophageal carcinomas with EGFR and HER2 overexpression.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
23292912-9	2013	ErbB2 activation could still occur due to the formation of ErbB2/ErbB3 heterodimers, and ErbB3 activation was completely inhibited by lapatinib.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
23292912-9	2013	ErbB2 activation could still occur due to the formation of ErbB2/ErbB3 heterodimers, and ErbB3 activation was completely inhibited by lapatinib.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 3	Homo sapiens	89-94
23292912-10	2013	Finally, combined inhibition of ErbB1 (gefitinib) and ErbB3 activities (knockdown expression by shRNA) inhibited tumoral testicular cells proliferation in a similar way to lapatinib.	Lapatinib	172-181	erb-b2 receptor tyrosine kinase 3	Homo sapiens	54-59
23816254-2	2013	Lapatinib, afatinib and neratinib are tyrosine kinase inhibitors (TKIs) of HER2 and EGFR growth factor receptors.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
23816254-4	2013	RESULTS: Treatment of HER2 TKI-sensitive SKBR3 and BT474 cell lines with lapatinib, afatinib and neratinib induced an increase in the expression of RB1CC1, ERBB3, FOXO3a and NR3C1.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
23816254-4	2013	RESULTS: Treatment of HER2 TKI-sensitive SKBR3 and BT474 cell lines with lapatinib, afatinib and neratinib induced an increase in the expression of RB1CC1, ERBB3, FOXO3a and NR3C1.	Lapatinib	73-82	RB1 inducible coiled-coil 1	Homo sapiens	148-154
23816254-4	2013	RESULTS: Treatment of HER2 TKI-sensitive SKBR3 and BT474 cell lines with lapatinib, afatinib and neratinib induced an increase in the expression of RB1CC1, ERBB3, FOXO3a and NR3C1.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 3	Homo sapiens	156-161
23816254-4	2013	RESULTS: Treatment of HER2 TKI-sensitive SKBR3 and BT474 cell lines with lapatinib, afatinib and neratinib induced an increase in the expression of RB1CC1, ERBB3, FOXO3a and NR3C1.	Lapatinib	73-82	forkhead box O3	Homo sapiens	163-169
23816254-11	2013	CONCLUSIONS: In these HER2-expressing cell line models, lapatinib, neratinib, afatinib and trastuzumab treatment generated a characteristic and specific gene expression response, proportionate to the sensitivity of the cell lines to the HER2 inhibitor.Characterisation of the induced changes in expression levels of these genes may therefore give a valuable, very early predictor of the likely extent and specificity of tumour HER2 inhibitor response in patients, potentially guiding more specific use of these agents.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	237-241
23816254-11	2013	CONCLUSIONS: In these HER2-expressing cell line models, lapatinib, neratinib, afatinib and trastuzumab treatment generated a characteristic and specific gene expression response, proportionate to the sensitivity of the cell lines to the HER2 inhibitor.Characterisation of the induced changes in expression levels of these genes may therefore give a valuable, very early predictor of the likely extent and specificity of tumour HER2 inhibitor response in patients, potentially guiding more specific use of these agents.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	237-241
24124748-0	2013	[Effects of mammalian-target-of-rapamycin pathway on lapatinib resistance in breast cancer MDA-MB-231 cells].	Lapatinib	53-62	mechanistic target of rapamycin kinase	Homo sapiens	12-41
23816254-4	2013	RESULTS: Treatment of HER2 TKI-sensitive SKBR3 and BT474 cell lines with lapatinib, afatinib and neratinib induced an increase in the expression of RB1CC1, ERBB3, FOXO3a and NR3C1.	Lapatinib	73-82	nuclear receptor subfamily 3 group C member 1	Homo sapiens	174-179
24124748-13	2013	CONCLUSIONS: The up-regulation of mTOR plays an important role in the lapatinib-resistant phenotype of human breast cancer rMDA-MB-231 cells.	Lapatinib	70-79	mechanistic target of rapamycin kinase	Homo sapiens	34-38
24124748-14	2013	And the down-regulation of mTOR increases the apoptotic death of lapatinib against rMDA-MB-231 cells.	Lapatinib	65-74	mechanistic target of rapamycin kinase	Homo sapiens	27-31
23686416-13	2013	Combination of fulv and EGFR family tyrosine kinase inhibitors (erlotinib and lapatinib) significantly decreased EGFR signaling and cell survival.	Lapatinib	78-87	epidermal growth factor receptor	Homo sapiens	24-28
24257305-0	2013	[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
24257305-3	2013	The aim of the present study was to evaluate retrospectively the clinical value of trastuzumab in patients with lapatinib-resistant HER2-positive advanced breast cancer treated in our center.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
24257305-14	2013	CONCLUSIONS: Trastuzumab plus conventional treatment is superior to conventional treatment in women with lapatinib-resistant HER2-positive metastatic breast cancer.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
23686416-13	2013	Combination of fulv and EGFR family tyrosine kinase inhibitors (erlotinib and lapatinib) significantly decreased EGFR signaling and cell survival.	Lapatinib	78-87	epidermal growth factor receptor	Homo sapiens	113-117
23725567-7	2013	The only Food and Drug Administration-approved targeted therapy in EGC is trastuzumab, an anti-Her2 antibody, and the results of a Phase III evaluation of lapatinib, an anti-Her2 TKI, are awaited.	Lapatinib	155-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
23635947-8	2013	Several HLA alleles also demonstrate drug-specific associations with DILI, such as HLA-A*33:03 for ticlopidine, HLA-B*57:01 for flucloxacillin and HLA-DQA1*02:01 for lapatinib.	Lapatinib	166-175	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	8-11
23076814-1	2013	The aim of this study was to investigate the effect of lapatinib, a selective inhibitor of EGFR/HER2 tyrosine kinases, on pancreatic cancer cell lines both alone and in combination with chemotherapy.	Lapatinib	55-64	epidermal growth factor receptor	Homo sapiens	91-95
23076814-1	2013	The aim of this study was to investigate the effect of lapatinib, a selective inhibitor of EGFR/HER2 tyrosine kinases, on pancreatic cancer cell lines both alone and in combination with chemotherapy.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
23076814-3	2013	Lapatinib also demonstrated some activity in three K-Ras mutated pancreatic cancer cell lines which displayed resistance to erlotinib.	Lapatinib	0-9	KRAS proto-oncogene, GTPase	Homo sapiens	51-56
23076814-8	2013	Based on our in vitro results, lapatinib may provide clinical benefit in EGFR positive pancreatic ductal adenocarcinoma.	Lapatinib	31-40	epidermal growth factor receptor	Homo sapiens	73-77
23509322-0	2013	Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-125
23509322-1	2013	PURPOSE: Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	79-111
23509322-1	2013	PURPOSE: Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-156
23509322-1	2013	PURPOSE: Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
23509322-2	2013	This study is designed to test whether the addition of lapatinib to paclitaxel improves overall survival (OS) compared with placebo plus paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
23509322-3	2013	PATIENTS AND METHODS: This phase III, randomized, double-blind study assessed the efficacy and safety of lapatinib plus paclitaxel compared with placebo plus paclitaxel in patients with newly diagnosed HER2-positive MBC.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
23509322-14	2013	CONCLUSION: This trial demonstrated that lapatinib combined with paclitaxel offers a significant and clinically meaningful survival advantage over paclitaxel alone in patients with HER2-positive MBC.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185
23635947-8	2013	Several HLA alleles also demonstrate drug-specific associations with DILI, such as HLA-A*33:03 for ticlopidine, HLA-B*57:01 for flucloxacillin and HLA-DQA1*02:01 for lapatinib.	Lapatinib	166-175	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	147-155
23375777-0	2013	Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.	Lapatinib	204-213	epidermal growth factor receptor	Homo sapiens	177-181
23375777-0	2013	Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.	Lapatinib	204-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	183-188
23375777-11	2013	The first target selected for further analysis, the inhibition of ErbB2-EGFR pathway by the small molecule inhibitor lapatinib, indicated inhibition of cell migration properties and the initiation of apoptosis.	Lapatinib	117-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71
23375777-11	2013	The first target selected for further analysis, the inhibition of ErbB2-EGFR pathway by the small molecule inhibitor lapatinib, indicated inhibition of cell migration properties and the initiation of apoptosis.	Lapatinib	117-126	epidermal growth factor receptor	Homo sapiens	72-76
23700641-8	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for BC patients who can probably benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small molecule drug that inhibits the TK activity of the HER2 signaling pathway) (8, 9).	Lapatinib	319-328	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
23697602-0	2013	An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
23697602-1	2013	BACKGROUND: Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-203
23697602-1	2013	BACKGROUND: Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
23697602-11	2013	CONCLUSIONS: The dose-limiting toxicity of paclitaxel, trastuzumab, and lapatinib in first-line HER2-positive MBC was diarrhea.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
23609057-15	2013	These preliminary results suggest that the addition of lapatinib to letrozole has a favorable safety profile and could overcome tumoral resistance to letrozole among HER2-negative tumors.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
23700641-8	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for BC patients who can probably benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small molecule drug that inhibits the TK activity of the HER2 signaling pathway) (8, 9).	Lapatinib	319-328	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23700641-8	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for BC patients who can probably benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small molecule drug that inhibits the TK activity of the HER2 signaling pathway) (8, 9).	Lapatinib	319-328	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23700641-8	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for BC patients who can probably benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small molecule drug that inhibits the TK activity of the HER2 signaling pathway) (8, 9).	Lapatinib	319-328	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23706161-0	2013	OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.	Lapatinib	39-48	NCK adaptor protein 1	Homo sapiens	82-86
23667487-0	2013	The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
23706161-1	2013	BACKGROUND: Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	45-50
23706161-1	2013	BACKGROUND: Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-56
23706161-3	2013	METHODS: In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays.	Lapatinib	229-238	estrogen receptor 1	Homo sapiens	33-50
23706161-3	2013	METHODS: In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays.	Lapatinib	229-238	estrogen receptor 1	Homo sapiens	52-54
23706161-4	2013	RESULTS: Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects.	Lapatinib	52-61	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	112-117
23706161-9	2013	Finally, co-immunoprecipitation assays indicated that eIF2-alpha dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment.	Lapatinib	123-132	eukaryotic translation initiation factor 2A	Homo sapiens	54-64
23706161-9	2013	Finally, co-immunoprecipitation assays indicated that eIF2-alpha dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment.	Lapatinib	123-132	NCK adaptor protein 1	Homo sapiens	86-90
23706161-9	2013	Finally, co-immunoprecipitation assays indicated that eIF2-alpha dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment.	Lapatinib	123-132	neuropeptide Y receptor Y4	Homo sapiens	91-94
23706161-10	2013	CONCLUSIONS: These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy, which functions to enhance cell killing through the Nck1/eIF2 complex.	Lapatinib	52-61	NCK adaptor protein 1	Homo sapiens	164-168
23706161-10	2013	CONCLUSIONS: These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy, which functions to enhance cell killing through the Nck1/eIF2 complex.	Lapatinib	52-61	eukaryotic translation initiation factor 2 subunit alpha	Homo sapiens	169-173
23569315-0	2013	Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-172
23569315-1	2013	PURPOSE: We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when expressed.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-91
23569315-1	2013	PURPOSE: We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when expressed.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
23569315-1	2013	PURPOSE: We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when expressed.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Mus musculus	156-160
23652204-6	2013	In HER2-positive breast cancer cells treated with the HER2 tyrosine kinase inhibitor lapatinib, MDM2 was degraded and HUWE1 was stabilized.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
23652204-6	2013	In HER2-positive breast cancer cells treated with the HER2 tyrosine kinase inhibitor lapatinib, MDM2 was degraded and HUWE1 was stabilized.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
23652204-6	2013	In HER2-positive breast cancer cells treated with the HER2 tyrosine kinase inhibitor lapatinib, MDM2 was degraded and HUWE1 was stabilized.	Lapatinib	85-94	MDM2 proto-oncogene	Homo sapiens	96-100
23652204-6	2013	In HER2-positive breast cancer cells treated with the HER2 tyrosine kinase inhibitor lapatinib, MDM2 was degraded and HUWE1 was stabilized.	Lapatinib	85-94	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Homo sapiens	118-123
23652204-7	2013	In contrast, in breast cancer cells that acquired resistance to lapatinib, the abundance of MDM2 was not decreased and HUWE1 was degraded, which inhibited apoptosis, regardless of p53 status.	Lapatinib	64-73	MDM2 proto-oncogene	Homo sapiens	92-96
23652204-7	2013	In contrast, in breast cancer cells that acquired resistance to lapatinib, the abundance of MDM2 was not decreased and HUWE1 was degraded, which inhibited apoptosis, regardless of p53 status.	Lapatinib	64-73	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Homo sapiens	119-124
23652204-8	2013	MDM2 inhibition overcame lapatinib resistance in cells with either wild-type or mutant p53 and in xenograft models.	Lapatinib	25-34	MDM2 proto-oncogene	Homo sapiens	0-4
23652204-8	2013	MDM2 inhibition overcame lapatinib resistance in cells with either wild-type or mutant p53 and in xenograft models.	Lapatinib	25-34	tumor protein p53	Homo sapiens	87-90
23652204-9	2013	These findings demonstrate broader, p53-independent roles for MDM2 and HUWE1 in apoptosis and specifically suggest the potential for therapy directed against MDM2 to overcome lapatinib resistance.	Lapatinib	175-184	MDM2 proto-oncogene	Homo sapiens	158-162
23638490-7	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for breast cancer patients who are likely to benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small-molecule drug that inhibits the TK activity of the HER2 signaling pathway) (6, 7).	Lapatinib	331-340	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
23638490-7	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for breast cancer patients who are likely to benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small-molecule drug that inhibits the TK activity of the HER2 signaling pathway) (6, 7).	Lapatinib	331-340	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23638490-7	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for breast cancer patients who are likely to benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small-molecule drug that inhibits the TK activity of the HER2 signaling pathway) (6, 7).	Lapatinib	331-340	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23638490-7	2004	The radionuclide-labeled Affibody ZHER2:342 (and its derivatives), directed against the HER2 (ZHER2:342Kd = 22 pM for HER2), has been used successfully with molecular imaging techniques to screen for breast cancer patients who are likely to benefit most from treatment with trastuzumab (a monoclonal antibody that targets HER2) or lapatinib (a small-molecule drug that inhibits the TK activity of the HER2 signaling pathway) (6, 7).	Lapatinib	331-340	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23667487-0	2013	The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.	Lapatinib	16-25	epidermal growth factor receptor	Homo sapiens	97-101
23667487-2	2013	We examined whether lapatinib which binds both HER2 and EGFR could induce depletion of the EGFR-positive pool of CTCs, which may in turn lead to clinical benefits.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
23667487-2	2013	We examined whether lapatinib which binds both HER2 and EGFR could induce depletion of the EGFR-positive pool of CTCs, which may in turn lead to clinical benefits.	Lapatinib	20-29	epidermal growth factor receptor	Homo sapiens	56-60
23667487-2	2013	We examined whether lapatinib which binds both HER2 and EGFR could induce depletion of the EGFR-positive pool of CTCs, which may in turn lead to clinical benefits.	Lapatinib	20-29	epidermal growth factor receptor	Homo sapiens	91-95
22658319-3	2013	Two HER2-directed therapies have been approved by the United States Food and Drug Administration for the treatment of HER2-overexpressing breast cancer: trastuzumab, a humanized monoclonal antibody against the extracellular portion of HER2; and lapatinib, a dual HER2- and epidermal growth factor receptor-specific tyrosine kinase inhibitor.	Lapatinib	245-254	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
22727691-2	2013	A literature search was conducted to obtain data on the clinical efficacy of trastuzumab and lapatinib in patients with HER2-positive MBC and brain metastasis, as well as the transport of therapeutic molecules across the BBB.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
23411345-9	2013	Rac1 activation by EGF was inhibited by gefitinib, lapatinib or SB203580 but amplified by PD98059.	Lapatinib	51-60	Rac family small GTPase 1	Homo sapiens	0-4
23365119-5	2013	The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors.	Lapatinib	25-34	mitogen-activated protein kinase 1	Homo sapiens	44-48
23365119-5	2013	The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors.	Lapatinib	25-34	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	72-76
23365119-5	2013	The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors.	Lapatinib	25-34	zinc fingers and homeoboxes 2	Homo sapiens	73-76
23365119-5	2013	The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors.	Lapatinib	25-34	mitogen-activated protein kinase 1	Homo sapiens	119-122
23411345-7	2013	EGF-induced relocalization of T-cad to cell-cell contacts could be abrogated by specific inhibitors of EGFR tyrosine kinase activity (gefitinib or lapatinib), lipid raft integrity (filipin), actin microfilament polymerization (cytochalasin D or cytochalasin B), p38MAPK (SB203580) or Rac1 (compound4).	Lapatinib	147-156	cadherin 13	Homo sapiens	30-35
23258611-4	2013	Silencing of NPM expression significantly sensitized HCC cells-particularly those bearing inactivated p53 gene (Huh7, Hep3B, and Mahlavu)-to ultraviolet irradiation, mitomycin C, doxorubicin, cisplatin, sorafenib, and lapatinib.	Lapatinib	218-227	nucleophosmin 1	Homo sapiens	13-16
23404373-0	2013	Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.	Lapatinib	45-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
23404373-4	2013	We describe an approach combining heme iron oxidation with potassium ferricyanide and metabolite profiling to probe the mechanism of MI complex-based CYP3A4 inactivation by the secondary alkylamine drug lapatinib.	Lapatinib	203-212	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
23404373-5	2013	Ten metabolites formed from lapatinib by CYP3A4-mediated heteroatom dealkylation, C-hydroxylation, N-oxygenation with or without further oxidation, or a combination thereof, were detected by accurate mass spectrometry.	Lapatinib	28-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
23404373-9	2013	Our findings support the mechanism of lapatinib CYP3A4 inactivation as MI complex formation with the nitroso metabolite formed through the secondary hydroxylamine and nitrone pathway, rather than by N-dealkylation to the primary amine followed by N-hydroxylation and dehydrogenation as is usually assumed.	Lapatinib	38-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
23375200-1	2013	OBJECTIVE: To determine whether inhibition of epidermal growth factor (EGF) receptor tyrosine kinase with lapatinib affects oocyte maturation, expression of the cumulus expansion-associated genes such as tumor necrosis factor alpha-induced protein 6 (TNFAIP6) and prostaglandin-endoperoxide synthase 2 (PTGS2), and synthesis of hyaluronan (HA) and progesterone (P) by porcine oocyte cumulus complexes (OCC).	Lapatinib	106-115	epidermal growth factor receptor	Homo sapiens	46-84
23375200-2	2013	DESIGN: Our work focuses on lapatinib, an orally active small molecule that selectively inhibits the tyrosine kinase domain of both EGF receptor and human EGF receptor 2, and downstream signaling.	Lapatinib	28-37	epidermal growth factor receptor	Homo sapiens	132-144
23375200-2	2013	DESIGN: Our work focuses on lapatinib, an orally active small molecule that selectively inhibits the tyrosine kinase domain of both EGF receptor and human EGF receptor 2, and downstream signaling.	Lapatinib	28-37	epidermal growth factor receptor	Homo sapiens	155-167
23375200-8	2013	However, weaker HA- and weaker cytoplasmic TNFAIP6 were detected were detected in lapatinib-pretreated OCC.	Lapatinib	82-91	TNF alpha induced protein 6	Homo sapiens	43-50
23375200-10	2013	Lapatinib (10 muM) inhibited FSH/LH-induced oocyte meiotic maturation.	Lapatinib	0-9	latexin	Homo sapiens	14-17
23375200-11	2013	Progesterone production increased after OCC stimulation with FSH/LH and was significantly decreased by lapatinib (10 muM).	Lapatinib	103-112	latexin	Homo sapiens	117-120
23445612-0	2013	Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.	Lapatinib	70-79	Y-box binding protein 1	Homo sapiens	0-23
23543055-4	2013	ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 3	Mus musculus	0-5
23543055-4	2013	ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Mus musculus	33-38
23543055-4	2013	ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Mus musculus	50-55
23445612-5	2013	YB-1 knockdown induced drug resistance to lapatinib, a dual EGFR and HER2 kinase inhibitor, and also to erlotinib, an EGFR kinase inhibitor.	Lapatinib	42-51	Y-box binding protein 1	Homo sapiens	0-4
23502424-4	2013	Unexpectedly, we find that Cdc37 binding to protein kinases is itself antagonized by ATP-competitive kinase inhibitors, including vemurafenib and lapatinib.	Lapatinib	146-155	cell division cycle 37, HSP90 cochaperone	Homo sapiens	27-32
23401075-8	2013	97-1 cells showed constitutive EGFR activation, and were highly sensitive to combined treatment with the mTOR inhibitor Torin1 and EGFR inhibitors Lapatinib or Afatinib.	Lapatinib	147-156	epidermal growth factor receptor	Homo sapiens	131-135
23571701-1	2013	The importance of human epidermal growth factor-2 (HER2) in terms of prognosis and aggressiveness of growth has long been known in breast cancer, and interruption of its growth cascade by agents such as trastuzumab and lapatinib has markedly improved outcomes for these patients with HER2 overexpression.	Lapatinib	219-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	284-288
24158082-0	2013	Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.	Lapatinib	52-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
24158082-1	2013	Lapatinib, in combination with capecitabine, has shown clinical activity in both first-line and refractory disease in patients with HER2-positive advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
24158082-5	2013	In advanced breast cancer patients with skin metastases overexpressing HER2, previously treated with anthracyclines, taxanes and trastuzumab, lapatinib and capecitabine may represent a very active, safe and well-tolerated treatment option.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
24158083-0	2013	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
24158084-1	2013	This clinical report describes durable control of disease in a postmenopausal patient receiving hemodialysis and letrozole plus lapatinib since the diagnosis of HER2-positive, estrogen receptor-positive liver metastasis from breast cancer after anastrozole plus trastuzumab failure.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	161-165
23233650-0	2013	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
23233650-1	2013	BACKGROUND: This phase II, open-label, multicentre study aimed to evaluate changes in cell proliferation and biomarkers, as well as efficacy of lapatinib in treatment-naive patients with HER-2-negative primary breast cancer.	Lapatinib	144-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	187-192
23233650-9	2013	CONCLUSIONS: Overall, a pre-surgical course of lapatinib monotherapy had little effect on this group of patients; however, in subsets of patients, especially those with HER-3-positive tumors, we observed either reduction in proliferation (Ki67) or tumor size; EGFR/ER status had no impact.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 3	Homo sapiens	169-174
23233650-9	2013	CONCLUSIONS: Overall, a pre-surgical course of lapatinib monotherapy had little effect on this group of patients; however, in subsets of patients, especially those with HER-3-positive tumors, we observed either reduction in proliferation (Ki67) or tumor size; EGFR/ER status had no impact.	Lapatinib	47-56	epidermal growth factor receptor	Homo sapiens	260-264
23233650-9	2013	CONCLUSIONS: Overall, a pre-surgical course of lapatinib monotherapy had little effect on this group of patients; however, in subsets of patients, especially those with HER-3-positive tumors, we observed either reduction in proliferation (Ki67) or tumor size; EGFR/ER status had no impact.	Lapatinib	47-56	estrogen receptor 1	Homo sapiens	170-172
23377763-3	2013	Besides trastuzumab, two other anti-HER2 agents-lapatinib and pertuzumab-have been approved for the treatment of HER2-positive advanced breast cancer.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
23377763-3	2013	Besides trastuzumab, two other anti-HER2 agents-lapatinib and pertuzumab-have been approved for the treatment of HER2-positive advanced breast cancer.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
23479422-2	2013	This study assesses the safety and feasibility of adding lapatinib to paclitaxel and trastuzumab (THL) as part of the adjuvant therapy for HER2-positive breast cancer (HER2+ BC).	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
23395887-7	2013	The effect was associated with a blockade of induced HER3 mRNA expression caused by lapatinib or gefitinib treatment.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 3	Homo sapiens	53-57
23296546-13	2013	In sub-analysis of patients with HER2-overexpression, lapatinib-based chemotherapy was also associated with better local tumor control (P = 0.002).	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	neuregulin 1	Homo sapiens	19-23
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	TNF receptor superfamily member 12A	Homo sapiens	50-54
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	TNF receptor superfamily member 12A	Homo sapiens	97-101
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
23472669-0	2013	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.	Lapatinib	62-71	epidermal growth factor receptor	Homo sapiens	0-32
23472669-0	2013	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
23472669-1	2013	OBJECTIVE: Lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor (TKI), associated to capecitabine represents the treatment of choice in HER2-positive metastatic breast cancer (BC) patients in progression after trastuzumab-based therapy.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
23472669-1	2013	OBJECTIVE: Lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor (TKI), associated to capecitabine represents the treatment of choice in HER2-positive metastatic breast cancer (BC) patients in progression after trastuzumab-based therapy.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	34-38
23472669-1	2013	OBJECTIVE: Lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor (TKI), associated to capecitabine represents the treatment of choice in HER2-positive metastatic breast cancer (BC) patients in progression after trastuzumab-based therapy.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
23472669-7	2013	RESULTS: A statistical significant correlation between EGFR GCN value > 3.36 and response to lapatinib (p = 0.01) was found.	Lapatinib	96-105	epidermal growth factor receptor	Homo sapiens	55-59
23472669-8	2013	Cox regression analysis further supported these findings evidencing that HER2 score 3+ and EGFR GCN increase are positive predictor factors of lapatinib response.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
23472669-8	2013	Cox regression analysis further supported these findings evidencing that HER2 score 3+ and EGFR GCN increase are positive predictor factors of lapatinib response.	Lapatinib	143-152	epidermal growth factor receptor	Homo sapiens	91-95
23472669-9	2013	CONCLUSIONS: Though further investigations are needed to confirm these findings, EGFR GCN could be a suitable screening to identify the subset of BC patients particularly responsive to the dual TKI lapatinib.	Lapatinib	198-207	epidermal growth factor receptor	Homo sapiens	81-85
23315145-1	2013	Lapatinib is an oral 4-anilinoquinazoline derivative that dually inhibits epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	74-106
23315145-1	2013	Lapatinib is an oral 4-anilinoquinazoline derivative that dually inhibits epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-151
23315145-1	2013	Lapatinib is an oral 4-anilinoquinazoline derivative that dually inhibits epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
23355539-0	2013	Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.	Lapatinib	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	19-35
23355539-0	2013	Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	51-83
23355539-0	2013	Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.	Lapatinib	0-9	ELAV like RNA binding protein 1	Homo sapiens	84-87
23355539-1	2013	Lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) kinase inhibitor, showed clinical benefits in advanced HER2-positive breast cancer patients.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-50
23355539-1	2013	Lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) kinase inhibitor, showed clinical benefits in advanced HER2-positive breast cancer patients.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	52-56
23355539-1	2013	Lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) kinase inhibitor, showed clinical benefits in advanced HER2-positive breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-98
23355539-1	2013	Lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) kinase inhibitor, showed clinical benefits in advanced HER2-positive breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
23355539-1	2013	Lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) kinase inhibitor, showed clinical benefits in advanced HER2-positive breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	161-165
23355539-6	2013	The lapatinib-increased motility was attributed by the elevation of EGFR through the downregulation of microRNA-7 and by the subsequent overexpression of cyclooxygenase-2 (COX-2).	Lapatinib	4-13	epidermal growth factor receptor	Homo sapiens	68-72
23355539-6	2013	The lapatinib-increased motility was attributed by the elevation of EGFR through the downregulation of microRNA-7 and by the subsequent overexpression of cyclooxygenase-2 (COX-2).	Lapatinib	4-13	prostaglandin-endoperoxide synthase 2	Homo sapiens	154-170
23355539-6	2013	The lapatinib-increased motility was attributed by the elevation of EGFR through the downregulation of microRNA-7 and by the subsequent overexpression of cyclooxygenase-2 (COX-2).	Lapatinib	4-13	prostaglandin-endoperoxide synthase 2	Homo sapiens	172-177
23355539-8	2013	Our results suggest that lapatinib may increase the migration and invasion of MDA-MB-231 cells by upregulating EGFR and COX-2 through the downregulation of microRNA-7, providing a potential explanation for the worse clinical outcome of TNBC patients who receive lapatinib-based treatment.	Lapatinib	25-34	epidermal growth factor receptor	Homo sapiens	111-115
23355539-8	2013	Our results suggest that lapatinib may increase the migration and invasion of MDA-MB-231 cells by upregulating EGFR and COX-2 through the downregulation of microRNA-7, providing a potential explanation for the worse clinical outcome of TNBC patients who receive lapatinib-based treatment.	Lapatinib	25-34	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-125
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
23378579-8	2013	Both the HER2- and HRG1-beta1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 3	Homo sapiens	227-231
23334956-2	2013	In vitro, TIMP-1 can regulate shedding of the extracellular domain of HER2 and signalling via the Akt pathway, and we hypothesize that TIMP-1 therefore can affect sensitivity to the HER2-targeting drugs trastuzumab and lapatinib.	Lapatinib	219-228	TIMP metallopeptidase inhibitor 1	Homo sapiens	10-16
23358664-4	2013	The HER2-lytic hybrid peptide showed high cytotoxic activity against all ovarian and breast cancer cell lines, even trastuzumab- and/or lapatinib-resistant cells, but not against normal cells.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
23358664-8	2013	The HER2-lytic hybrid peptide was effective even in breast cancer cell lines that are resistant to trastuzumab and/or lapatinib in vitro and in vivo.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
23334956-2	2013	In vitro, TIMP-1 can regulate shedding of the extracellular domain of HER2 and signalling via the Akt pathway, and we hypothesize that TIMP-1 therefore can affect sensitivity to the HER2-targeting drugs trastuzumab and lapatinib.	Lapatinib	219-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
23334956-2	2013	In vitro, TIMP-1 can regulate shedding of the extracellular domain of HER2 and signalling via the Akt pathway, and we hypothesize that TIMP-1 therefore can affect sensitivity to the HER2-targeting drugs trastuzumab and lapatinib.	Lapatinib	219-228	TIMP metallopeptidase inhibitor 1	Homo sapiens	135-141
23334956-2	2013	In vitro, TIMP-1 can regulate shedding of the extracellular domain of HER2 and signalling via the Akt pathway, and we hypothesize that TIMP-1 therefore can affect sensitivity to the HER2-targeting drugs trastuzumab and lapatinib.	Lapatinib	219-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-186
23334956-3	2013	SK-BR-3 human breast cancer cells were stably transfected with TIMP-1, characterized with regard to TIMP-1 protein expression, proliferation, and functionality of the secreted TIMP-1, and the sensitivity to trastuzumab and lapatinib was studied in five selected single-cell subclones expressing TIMP-1 protein at various levels plus the parental SK-BR-3 cell line.	Lapatinib	223-232	TIMP metallopeptidase inhibitor 1	Homo sapiens	63-69
22948710-1	2013	The anticancer drug lapatinib (Tykerb) is a dual tyrosine kinase inhibitor targeting the HER2 (ERBB2) and EGFR (ERBB1, HER1) pathways that have been shown in clinical trials to display some cardiotoxicity.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	95-100
23302228-9	2013	In contrast, lapatinib radiosensitized RAD51KD and RT112 cells but not Ku80KD cells.	Lapatinib	13-22	RAD51 recombinase	Homo sapiens	39-44
23350584-1	2013	Upon disease progression on trastuzumab-based therapy, patients with HER-2 positive metastatic breast cancer (MBC) may switch to lapatinib or continue on trastuzumab.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-74
22948710-1	2013	The anticancer drug lapatinib (Tykerb) is a dual tyrosine kinase inhibitor targeting the HER2 (ERBB2) and EGFR (ERBB1, HER1) pathways that have been shown in clinical trials to display some cardiotoxicity.	Lapatinib	20-29	epidermal growth factor receptor	Rattus norvegicus	106-110
22948710-1	2013	The anticancer drug lapatinib (Tykerb) is a dual tyrosine kinase inhibitor targeting the HER2 (ERBB2) and EGFR (ERBB1, HER1) pathways that have been shown in clinical trials to display some cardiotoxicity.	Lapatinib	20-29	epidermal growth factor receptor	Rattus norvegicus	112-117
22948710-1	2013	The anticancer drug lapatinib (Tykerb) is a dual tyrosine kinase inhibitor targeting the HER2 (ERBB2) and EGFR (ERBB1, HER1) pathways that have been shown in clinical trials to display some cardiotoxicity.	Lapatinib	31-37	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	95-100
22948710-1	2013	The anticancer drug lapatinib (Tykerb) is a dual tyrosine kinase inhibitor targeting the HER2 (ERBB2) and EGFR (ERBB1, HER1) pathways that have been shown in clinical trials to display some cardiotoxicity.	Lapatinib	31-37	epidermal growth factor receptor	Rattus norvegicus	106-110
22948710-1	2013	The anticancer drug lapatinib (Tykerb) is a dual tyrosine kinase inhibitor targeting the HER2 (ERBB2) and EGFR (ERBB1, HER1) pathways that have been shown in clinical trials to display some cardiotoxicity.	Lapatinib	31-37	epidermal growth factor receptor	Rattus norvegicus	112-117
22948710-6	2013	Lapatinib alone treatment decreased phosphorylated ERK (MAPK), which may have, in part, contributed to the increased myocyte damage.	Lapatinib	0-9	Eph receptor B1	Rattus norvegicus	51-54
23224399-1	2013	PURPOSE: Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors.	Lapatinib	52-61	erb-b2 receptor tyrosine kinase 2	Mus musculus	26-30
22711713-6	2013	Other agents targeting the HER2 pathway (lapatinib) or other domains of epidermal growth factor receptor family (cetuximab) are currently being investigated for the treatment of an advanced gastric cancer.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
24649173-5	2013	The kinetic analysis of the binding curves further demonstrated TKI-dependent balances of EGFR monomer and dimer populations, where lapatinib promoted the monomeric form, while the other TKIs induced dimers.	Lapatinib	132-141	epidermal growth factor receptor	Homo sapiens	90-94
23363814-2	2013	We hypothesized that patients with recurrent glioblastoma would exhibit differential antitumor benefit based on tumor PTEN/EGFRvIII status when treated with the antiangiogenic agent pazopanib and the ErbB inhibitor lapatinib.	Lapatinib	215-224	epidermal growth factor receptor	Homo sapiens	200-204
23149820-9	2013	Furthermore, lapatinib, which targets EGFR/HER2, inhibited the mammosphere-promoting effect of IL-8 in both HER2-positive and negative patient-derived cancers.	Lapatinib	13-22	epidermal growth factor receptor	Homo sapiens	38-42
23149820-9	2013	Furthermore, lapatinib, which targets EGFR/HER2, inhibited the mammosphere-promoting effect of IL-8 in both HER2-positive and negative patient-derived cancers.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
23149820-9	2013	Furthermore, lapatinib, which targets EGFR/HER2, inhibited the mammosphere-promoting effect of IL-8 in both HER2-positive and negative patient-derived cancers.	Lapatinib	13-22	C-X-C motif chemokine ligand 8	Homo sapiens	95-99
23224399-8	2013	RESULTS: Treatment with U3-1287 blocked the upregulation of total and phosphorylated HER3 that followed treatment with lapatinib and trastuzumab and, in turn, enhanced the antitumor action of the combination against trastuzumab-sensitive and -resistant cells.	Lapatinib	119-128	erb-b2 receptor tyrosine kinase 3	Mus musculus	85-89
23149820-9	2013	Furthermore, lapatinib, which targets EGFR/HER2, inhibited the mammosphere-promoting effect of IL-8 in both HER2-positive and negative patient-derived cancers.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
23224399-9	2013	Mice bearing HER2(+) xenografts treated with lapatinib, trastuzumab, and U3-1287 exhibited fewer recurrences and better survival than mice treated with lapatinib and trastuzumab.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Mus musculus	13-17
23149820-10	2013	CXCR1/2 inhibition also blocked the effect of IL-8 on mammosphere formation and added to the efficacy of lapatinib in HER2-positive cancers.	Lapatinib	105-114	C-X-C motif chemokine receptor 1	Homo sapiens	0-5
23441129-0	2013	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.	Lapatinib	199-208	mitogen-activated protein kinase kinase 7	Homo sapiens	82-85
23241641-1	2013	PURPOSE OF REVIEW: To review the recently published trials to help us refine and optimize the use of approved HER2-targeted agents (trastuzumab and lapatinib) and highlight future combination strategies for the treatment of HER2-positive breast cancer.	Lapatinib	148-157	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
23241641-3	2013	Dual anti-HER2 regimens combining trastuzumab with lapatinib or pertuzumab show remarkable synergy and improved outcomes in patients previously thought to have refractory disease.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
22955422-4	2013	Our goal is to better understand the origin of the two distinct EGFR protein conformations, their dynamic differences, and their relative preference for Type-I inhibitors such as gefitinib and Type-II inhibitors such as lapatinib.	Lapatinib	220-229	epidermal growth factor receptor	Homo sapiens	64-68
23441129-6	2013	Acute treatment of established tumors with trametinib resulted in an increase in AKT2 phosphorylation that was blunted in mice treated with both trametinib and lapatinib.	Lapatinib	160-169	thymoma viral proto-oncogene 2	Mus musculus	81-85
22086611-1	2013	Lapatinib, an oral, small-molecule, reversible inhibitor of both EGFR and HER2, is highly active in HER2 positive breast cancer as a single agent and in combination with other therapeutics.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	65-69
22086611-1	2013	Lapatinib, an oral, small-molecule, reversible inhibitor of both EGFR and HER2, is highly active in HER2 positive breast cancer as a single agent and in combination with other therapeutics.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
22086611-1	2013	Lapatinib, an oral, small-molecule, reversible inhibitor of both EGFR and HER2, is highly active in HER2 positive breast cancer as a single agent and in combination with other therapeutics.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
22086611-7	2013	However, quercetin-3-methyl ether caused a pronounced G(2)/M block mainly through the Chk1-Cdc25c-cyclin B1/Cdk1 pathway in lapatinib-sensitive and -resistant cells.	Lapatinib	124-133	checkpoint kinase 1	Homo sapiens	86-90
22086611-7	2013	However, quercetin-3-methyl ether caused a pronounced G(2)/M block mainly through the Chk1-Cdc25c-cyclin B1/Cdk1 pathway in lapatinib-sensitive and -resistant cells.	Lapatinib	124-133	cell division cycle 25C	Homo sapiens	91-97
22086611-7	2013	However, quercetin-3-methyl ether caused a pronounced G(2)/M block mainly through the Chk1-Cdc25c-cyclin B1/Cdk1 pathway in lapatinib-sensitive and -resistant cells.	Lapatinib	124-133	cyclin B1	Homo sapiens	98-107
22086611-7	2013	However, quercetin-3-methyl ether caused a pronounced G(2)/M block mainly through the Chk1-Cdc25c-cyclin B1/Cdk1 pathway in lapatinib-sensitive and -resistant cells.	Lapatinib	124-133	cyclin dependent kinase 1	Homo sapiens	108-112
22086611-8	2013	In contrast, lapatinib produced an accumulation of cells in the G(1) phase mediated through cyclin D1, but only in lapatinib-sensitive cells.	Lapatinib	13-22	cyclin D1	Homo sapiens	92-101
23441129-0	2013	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.	Lapatinib	199-208	epidermal growth factor receptor	Homo sapiens	151-183
23441129-0	2013	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.	Lapatinib	199-208	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
23441129-4	2013	Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.	Lapatinib	189-198	mitogen-activated protein kinase kinase 1	Homo sapiens	83-89
23441129-4	2013	Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.	Lapatinib	189-198	epidermal growth factor receptor	Homo sapiens	169-173
23441129-4	2013	Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.	Lapatinib	189-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
23229346-0	2013	Lapatinib inhibits the activation of NF-kappaB through reducing phosphorylation             of IkappaB-alpha in breast cancer cells.	Lapatinib	0-9	nuclear factor kappa B subunit 1	Homo sapiens	37-46
23229346-0	2013	Lapatinib inhibits the activation of NF-kappaB through reducing phosphorylation             of IkappaB-alpha in breast cancer cells.	Lapatinib	0-9	NFKB inhibitor alpha	Homo sapiens	95-108
23229346-1	2013	Lapatinib is highly active against breast cancer with HER2 overexpression             in preclinical and clinical settings.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
23229346-4	2013	However, the effect of lapatinib on NF-kappaB activity             is not completely clear.	Lapatinib	23-32	nuclear factor kappa B subunit 1	Homo sapiens	36-45
23229346-5	2013	In this study, we showed that lapatinib potently inhibited             activation of NF-kappaB in HER2-overexpressing breast cancer cells, including SKBR3             and MDA-MB-453; but not in non-HER2-overexpressing breast cancer cells, MDA-MB-231,             MDA-MB-468 and MDA-MB-435.	Lapatinib	30-39	nuclear factor kappa B subunit 1	Homo sapiens	85-94
23229346-5	2013	In this study, we showed that lapatinib potently inhibited             activation of NF-kappaB in HER2-overexpressing breast cancer cells, including SKBR3             and MDA-MB-453; but not in non-HER2-overexpressing breast cancer cells, MDA-MB-231,             MDA-MB-468 and MDA-MB-435.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
23229346-8	2013	Western blot analysis showed that lapatinib reduced             the phosphorylation of IkappaB-alpha in a time- and dose-dependent manner in SKBR3 cells.	Lapatinib	34-43	NFKB inhibitor alpha	Homo sapiens	87-100
23229346-12	2013	Our results suggest that lapatinib potently inhibits             the activation of NF-kappaB in HER2-overexpressing breast cancer cells.	Lapatinib	25-34	nuclear factor kappa B subunit 1	Homo sapiens	83-92
23229346-12	2013	Our results suggest that lapatinib potently inhibits             the activation of NF-kappaB in HER2-overexpressing breast cancer cells.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
23229346-13	2013	Lapatinib             appears to inactivate NF-kappaB through reducing phosphorylation of IkappaB-alpha via blocking             the PI3K/Akt cascade.	Lapatinib	0-9	nuclear factor kappa B subunit 1	Homo sapiens	44-53
23229346-13	2013	Lapatinib             appears to inactivate NF-kappaB through reducing phosphorylation of IkappaB-alpha via blocking             the PI3K/Akt cascade.	Lapatinib	0-9	NFKB inhibitor alpha	Homo sapiens	90-103
23229346-13	2013	Lapatinib             appears to inactivate NF-kappaB through reducing phosphorylation of IkappaB-alpha via blocking             the PI3K/Akt cascade.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	138-141
23224144-0	2013	Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
25841741-0	2013	Lapatinib as a therapeutic option in brain metastases from HER2+ breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
23224144-1	2013	Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven antitumor activity in HER2-positive metastatic breast cancer (MBC).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	44-76
23305997-4	2013	In HER2-positive metastatic breast cancer with brain metastases not previously treated with whole brain radiotherapy, capecitabine and lapatinib combination obtains a volumetric reponse in two thirds of patients (LANDSCAPE study).	Lapatinib	135-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
23224144-1	2013	Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven antitumor activity in HER2-positive metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-121
23224144-1	2013	Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven antitumor activity in HER2-positive metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
23971878-11	2013	We noted that LOXL2 induced ErbB2 activation through reactive oxygen species (ROS) production, and ErbB2 inhibition by using Herceptin or lapatinib abrogated the effects of LOXL2 on MCF10A cells.	Lapatinib	138-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-104
23224144-1	2013	Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven antitumor activity in HER2-positive metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
23224144-3	2013	This was an open-label, single-arm, multicenter, Phase II study to evaluate the efficacy and safety of nab-paclitaxel plus lapatinib in women with HER2 over-expressing MBC who had received no more than one prior chemotherapeutic regimen.	Lapatinib	123-132	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
23971878-11	2013	We noted that LOXL2 induced ErbB2 activation through reactive oxygen species (ROS) production, and ErbB2 inhibition by using Herceptin or lapatinib abrogated the effects of LOXL2 on MCF10A cells.	Lapatinib	138-147	lysyl oxidase like 2	Homo sapiens	173-178
24044505-0	2013	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.	Lapatinib	69-78	epidermal growth factor receptor	Homo sapiens	13-17
24044505-0	2013	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 3	Homo sapiens	18-22
24044505-0	2013	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
24044505-6	2013	Using a targeted molecular knockdown approach to interrogate the causal molecular underpinnings of EGFR-persistent activation, we found that lapatinib-resistant cells were no longer oncogene addicted to HER2-HER3-PI3K signaling, as seen in the parental lapatinib-sensitive cell lines, but instead were dependent on a heregulin (HRG)-driven HER3-EGFR-PI3K-PDK1 signaling axis.	Lapatinib	141-150	epidermal growth factor receptor	Homo sapiens	99-103
24044505-6	2013	Using a targeted molecular knockdown approach to interrogate the causal molecular underpinnings of EGFR-persistent activation, we found that lapatinib-resistant cells were no longer oncogene addicted to HER2-HER3-PI3K signaling, as seen in the parental lapatinib-sensitive cell lines, but instead were dependent on a heregulin (HRG)-driven HER3-EGFR-PI3K-PDK1 signaling axis.	Lapatinib	141-150	erb-b2 receptor tyrosine kinase 3	Homo sapiens	340-344
24044505-6	2013	Using a targeted molecular knockdown approach to interrogate the causal molecular underpinnings of EGFR-persistent activation, we found that lapatinib-resistant cells were no longer oncogene addicted to HER2-HER3-PI3K signaling, as seen in the parental lapatinib-sensitive cell lines, but instead were dependent on a heregulin (HRG)-driven HER3-EGFR-PI3K-PDK1 signaling axis.	Lapatinib	141-150	epidermal growth factor receptor	Homo sapiens	345-349
24044505-2	2013	Although lapatinib, an FDA-approved small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), represents a significant therapeutic advancement in the treatment of HER2+ breast cancers, responses to lapatinib have not been durable.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
23224144-10	2013	Lapatinib 1,000 mg with nab-paclitaxel 100 mg/m(2) IV is feasible with manageable and predictable toxicity and an ORR of 53 % comparing favorably with other HER2-based combinations in this setting.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
24044505-2	2013	Although lapatinib, an FDA-approved small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), represents a significant therapeutic advancement in the treatment of HER2+ breast cancers, responses to lapatinib have not been durable.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	60-92
24044505-2	2013	Although lapatinib, an FDA-approved small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), represents a significant therapeutic advancement in the treatment of HER2+ breast cancers, responses to lapatinib have not been durable.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	94-98
29046878-3	2013	HER2-overexpressing SKBR3 breast cancer cells were treated with lapatinib for 12 hours and the resultant proteome analyzed by a comprehensive ion-current-based LC-MS strategy.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
24044505-2	2013	Although lapatinib, an FDA-approved small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), represents a significant therapeutic advancement in the treatment of HER2+ breast cancers, responses to lapatinib have not been durable.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
24044505-5	2013	RESULTS: The signaling analysis revealed that whereas HER2 was appropriately inhibited in lapatinib-resistant cells, EGFR tyrosine phosphorylation was incompletely inhibited.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
24191208-3	2013	We report a patient with breast cancer overexpressing HER-2 where brain metastases were successfully treated with radiation and a combination of lapatinib and capecitabine.	Lapatinib	145-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
24115917-0	2013	Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-97
24115917-1	2013	BACKGROUND: This paper reports a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy of lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in human epidermal growth factor receptor 2-overexpressing (HER-2+) locally advanced or metastatic breast cancer.	Lapatinib	131-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	263-268
24115917-13	2013	CONCLUSION: The combination of CET plus lapatinib increased the overall response rate, progression-free survival, and overall survival in patients with HER-2+ locally advanced or metastatic breast cancer.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-157
22999386-0	2013	An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-172
22999386-0	2013	An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
22999386-1	2013	BACKGROUND: Lapatinib is an effective anti-HER2 therapy in advanced breast cancer and docetaxel is one of the most active agents in breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
24044505-6	2013	Using a targeted molecular knockdown approach to interrogate the causal molecular underpinnings of EGFR-persistent activation, we found that lapatinib-resistant cells were no longer oncogene addicted to HER2-HER3-PI3K signaling, as seen in the parental lapatinib-sensitive cell lines, but instead were dependent on a heregulin (HRG)-driven HER3-EGFR-PI3K-PDK1 signaling axis.	Lapatinib	141-150	pyruvate dehydrogenase kinase 1	Homo sapiens	355-359
24044505-6	2013	Using a targeted molecular knockdown approach to interrogate the causal molecular underpinnings of EGFR-persistent activation, we found that lapatinib-resistant cells were no longer oncogene addicted to HER2-HER3-PI3K signaling, as seen in the parental lapatinib-sensitive cell lines, but instead were dependent on a heregulin (HRG)-driven HER3-EGFR-PI3K-PDK1 signaling axis.	Lapatinib	253-262	epidermal growth factor receptor	Homo sapiens	99-103
24044505-8	2013	The ability to overcome EGFR-mediated acquired therapeutic resistance to lapatinib was demonstrated through molecular knockdown of EGFR and treatment with the irreversible pan-HER TKI neratinib, which blocked HRG-dependent phosphorylation of HER3 and EGFR, resulting in apoptosis of resistant cells.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	24-28
24044505-8	2013	The ability to overcome EGFR-mediated acquired therapeutic resistance to lapatinib was demonstrated through molecular knockdown of EGFR and treatment with the irreversible pan-HER TKI neratinib, which blocked HRG-dependent phosphorylation of HER3 and EGFR, resulting in apoptosis of resistant cells.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	131-135
24044505-8	2013	The ability to overcome EGFR-mediated acquired therapeutic resistance to lapatinib was demonstrated through molecular knockdown of EGFR and treatment with the irreversible pan-HER TKI neratinib, which blocked HRG-dependent phosphorylation of HER3 and EGFR, resulting in apoptosis of resistant cells.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 3	Homo sapiens	242-246
24044505-8	2013	The ability to overcome EGFR-mediated acquired therapeutic resistance to lapatinib was demonstrated through molecular knockdown of EGFR and treatment with the irreversible pan-HER TKI neratinib, which blocked HRG-dependent phosphorylation of HER3 and EGFR, resulting in apoptosis of resistant cells.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	131-135
24044505-9	2013	In addition, whereas HRG reversed lapatinib-mediated antitumor effects in parental HER2+ breast cancer cells, neratinib was comparatively resistant to the effects of HRG in parental cells.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
24044505-11	2013	CONCLUSIONS: Molecular analysis of acquired therapeutic resistance to lapatinib identified a new resistance mechanism based on incomplete and "leaky" inhibition of EGFR by lapatinib.	Lapatinib	70-79	epidermal growth factor receptor	Homo sapiens	164-168
24044505-11	2013	CONCLUSIONS: Molecular analysis of acquired therapeutic resistance to lapatinib identified a new resistance mechanism based on incomplete and "leaky" inhibition of EGFR by lapatinib.	Lapatinib	172-181	epidermal growth factor receptor	Homo sapiens	164-168
23531216-0	2013	MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.	Lapatinib	25-34	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
23531216-0	2013	MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.	Lapatinib	25-34	forkhead box M1	Homo sapiens	65-70
23531216-3	2013	The dual EGFR/HER2 small molecule tyrosine kinase inhibitor lapatinib is approved for use in trastuzumab-refractory metastatic HER2-positive breast cancer.	Lapatinib	60-69	epidermal growth factor receptor	Homo sapiens	9-13
23531216-3	2013	The dual EGFR/HER2 small molecule tyrosine kinase inhibitor lapatinib is approved for use in trastuzumab-refractory metastatic HER2-positive breast cancer.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
23531216-3	2013	The dual EGFR/HER2 small molecule tyrosine kinase inhibitor lapatinib is approved for use in trastuzumab-refractory metastatic HER2-positive breast cancer.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
23531216-5	2013	Understanding the mechanisms underlying lapatinib resistance may ultimately facilitate development of new therapeutic strategies for HER2-overexpressing breast cancer.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
23531216-6	2013	Our current results indicate that MEK inhibition increases lapatinib-mediated cytotoxicity in resistant HER2-overexpressing breast cancer cells.	Lapatinib	59-68	mitogen-activated protein kinase kinase 7	Homo sapiens	34-37
23531216-6	2013	Our current results indicate that MEK inhibition increases lapatinib-mediated cytotoxicity in resistant HER2-overexpressing breast cancer cells.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
23531216-8	2013	Combined MEK inhibition and lapatinib treatment reduced phosphorylated ERK more than single agent treatment.	Lapatinib	28-37	EPH receptor B2	Homo sapiens	71-74
23531216-9	2013	In addition, Western blots, immunofluorescence, and immunohistochemistry demonstrated that the combination of MEK inhibitor plus lapatinib reduced nuclear expression of the MEK/ERK downstream proto-oncogene FOXM1.	Lapatinib	129-138	mitogen-activated protein kinase kinase 7	Homo sapiens	173-176
23531216-9	2013	In addition, Western blots, immunofluorescence, and immunohistochemistry demonstrated that the combination of MEK inhibitor plus lapatinib reduced nuclear expression of the MEK/ERK downstream proto-oncogene FOXM1.	Lapatinib	129-138	EPH receptor B2	Homo sapiens	177-180
23531216-9	2013	In addition, Western blots, immunofluorescence, and immunohistochemistry demonstrated that the combination of MEK inhibitor plus lapatinib reduced nuclear expression of the MEK/ERK downstream proto-oncogene FOXM1.	Lapatinib	129-138	forkhead box M1	Homo sapiens	207-212
23531216-11	2013	Finally, xenograft studies demonstrated that combined pharmacological inhibition of MEK plus lapatinib suppressed tumor growth and reduced expression of FOXM1 in HER2-overexpressing breast cancers that are resistant to trastuzumab and lapatinib.	Lapatinib	93-102	forkhead box M1	Homo sapiens	153-158
23531216-11	2013	Finally, xenograft studies demonstrated that combined pharmacological inhibition of MEK plus lapatinib suppressed tumor growth and reduced expression of FOXM1 in HER2-overexpressing breast cancers that are resistant to trastuzumab and lapatinib.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
23531216-11	2013	Finally, xenograft studies demonstrated that combined pharmacological inhibition of MEK plus lapatinib suppressed tumor growth and reduced expression of FOXM1 in HER2-overexpressing breast cancers that are resistant to trastuzumab and lapatinib.	Lapatinib	235-244	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
23531216-12	2013	Our results suggest that FoxM1 contributes to lapatinib resistance downstream of MEK signaling, and supports further study of pharmacological MEK inhibition to improve response to lapatinib in HER2-overexpressing trastuzumab-resistant breast cancer.	Lapatinib	46-55	forkhead box M1	Homo sapiens	25-30
23531216-12	2013	Our results suggest that FoxM1 contributes to lapatinib resistance downstream of MEK signaling, and supports further study of pharmacological MEK inhibition to improve response to lapatinib in HER2-overexpressing trastuzumab-resistant breast cancer.	Lapatinib	180-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-197
29046878-6	2013	Knockdown and inhibition of CENPE demonstrated that CENPE enhances SKBR3 cell survival in the presence of lapatinib.	Lapatinib	106-115	centromere protein E	Homo sapiens	28-33
29046878-6	2013	Knockdown and inhibition of CENPE demonstrated that CENPE enhances SKBR3 cell survival in the presence of lapatinib.	Lapatinib	106-115	centromere protein E	Homo sapiens	52-57
29046878-7	2013	Based on this study, CENPE inhibitors may warrant further investigation for use in combination with lapatinib.	Lapatinib	100-109	centromere protein E	Homo sapiens	21-26
23122784-0	2013	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
21396844-0	2013	A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.	Lapatinib	20-29	epidermal growth factor receptor	Homo sapiens	38-42
23234763-0	2013	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50
23144237-9	2013	Saracatinib enhanced the effects of lapatinib, an EGFR/HER2 dual inhibitor, in SNU216 and NCI-N87 cells.	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	50-54
23144237-9	2013	Saracatinib enhanced the effects of lapatinib, an EGFR/HER2 dual inhibitor, in SNU216 and NCI-N87 cells.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
23234763-2	2013	We investigated the efficacy and safety of adjuvant lapatinib for patients with trastuzumab-naive HER2-positive early-stage breast cancer, started at any time after diagnosis.	Lapatinib	52-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
23234763-12	2013	157 (13%) of 1230 confirmed HER2-positive patients in the lapatinib group and in 208 (17%) of 1260 in the placebo group had a disease-free survival event (HR 0 82, 95% 0 67-1 00; p=0 04).	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
23909036-1	2013	Targeted therapy (lapatinib and/or trastuzumab) in combination with chemotherapy (capecitabine) is highly effective in metastatic lesions of the brain in breast cancer patients with overexpress HER-2/neu.	Lapatinib	18-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-203
21396844-0	2013	A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
21396844-3	2013	Lapatinib is an oral inhibitor of EGFR and HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	34-38
21396844-3	2013	Lapatinib is an oral inhibitor of EGFR and HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-48
22203214-6	2012	Lapatinib, a reversible inhibitor of EGFR and Her2, was included for comparison.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	37-41
23213241-5	2012	Most cell lines were resistant to the direct effects of anti-ERBB2 Mabs, suggesting that the effects of lapatinib might mainly be through ERBB1.	Lapatinib	104-113	epidermal growth factor receptor	Homo sapiens	138-143
23089982-0	2012	PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.	Lapatinib	53-62	CREB regulated transcription coactivator 1	Mus musculus	31-37
23089982-0	2012	PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
23089982-1	2012	Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-29
23089982-1	2012	Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-159
23089982-1	2012	Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer.	Lapatinib	82-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-29
23089982-1	2012	Therapies targeting the ERBB2 receptor, including the kinase inhibitor lapatinib (Tykerb, GlaxoSmithKline), have improved clinical outcome for women with ERBB2-amplified breast cancer.	Lapatinib	82-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-159
23089982-3	2012	We sought to define molecular alterations that confer an acquired lapatinib resistance phenotype in ER-/ERBB2+ human breast cancer cells.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-109
23089982-4	2012	ERBB2-amplified SKBR3 breast cancer cells were rendered resistant to lapatinib via culture in increasing concentrations of the drug, and molecular changes associated with a resistant phenotype were interrogated using a collaborative enzyme-enhanced immunoassay platform and immunoblotting techniques for detection of phosphorylated signaling cascade proteins.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
23089982-6	2012	These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib.	Lapatinib	170-179	CREB regulated transcription coactivator 1	Mus musculus	59-65
23089982-6	2012	These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib.	Lapatinib	170-179	erb-b2 receptor tyrosine kinase 2	Homo sapiens	208-213
23089982-6	2012	These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib.	Lapatinib	170-179	erb-b2 receptor tyrosine kinase 2	Homo sapiens	298-303
23089982-6	2012	These data demonstrate a role for downstream activation of mTORC1 in the absence of molecular alterations leading to PI3K/AKT hyperactivation as a potential mechanism of lapatinib resistance in this model of ERBB2+ breast cancer and support the rationale of combination or sequential therapy using ERBB2 and mTOR-targeting molecules to prevent or target resistance to lapatinib.	Lapatinib	170-179	mechanistic target of rapamycin kinase	Homo sapiens	59-63
23089982-7	2012	Moreover, our data suggest that assessment of mTOR substrate phosphorylation (i.e., S6) may serve as a more robust biomarker to predict sensitivity to mTOR inhibitors in the context of lapatinib resistance than PI3K mutations, loss of PTEN and p-AKT levels.	Lapatinib	185-194	mechanistic target of rapamycin kinase	Homo sapiens	46-50
23089982-7	2012	Moreover, our data suggest that assessment of mTOR substrate phosphorylation (i.e., S6) may serve as a more robust biomarker to predict sensitivity to mTOR inhibitors in the context of lapatinib resistance than PI3K mutations, loss of PTEN and p-AKT levels.	Lapatinib	185-194	mechanistic target of rapamycin kinase	Homo sapiens	151-155
23108247-5	2012	In breast cancer, current studies on drug treatment of brain metastases are mainly focusing on human epidermal growth factor receptor 2 targeting agents such as lapatinib.	Lapatinib	161-170	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-135
22203214-6	2012	Lapatinib, a reversible inhibitor of EGFR and Her2, was included for comparison.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50
22989520-3	2012	Lapatinib and obatoclax killed multiple tumor cell types, and cells lacking phosphatase and tensin homolog (PTEN) function were relatively resistant to drug combination lethality; expression of PTEN in PTEN-null breast cancer cells restored drug sensitivity.	Lapatinib	0-9	phosphatase and tensin homolog	Homo sapiens	194-198
22729366-0	2012	Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
22729366-1	2012	Lapatinib is a dual tyrosine kinase inhibitor (TKI) that has a considerable efficacy in ErbB2-positive metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-93
22729366-3	2012	This study assessed the cardiac safety of lapatinib in women with ErbB2-positive MBC.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71
22989520-3	2012	Lapatinib and obatoclax killed multiple tumor cell types, and cells lacking phosphatase and tensin homolog (PTEN) function were relatively resistant to drug combination lethality; expression of PTEN in PTEN-null breast cancer cells restored drug sensitivity.	Lapatinib	0-9	phosphatase and tensin homolog	Homo sapiens	194-198
22964224-0	2012	Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.	Lapatinib	22-31	epidermal growth factor receptor	Homo sapiens	70-74
22964224-0	2012	Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.	Lapatinib	22-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
23307622-6	2012	A lentiviral-delivered small hairpin RNA stable knockdown of the ATG12 gene fully suppressed the refractoriness of JIMT1 cells to trastuzumab, erlotinib, gefitinib, and lapatinib in vitro.	Lapatinib	169-178	autophagy related 12	Homo sapiens	65-70
22964224-1	2012	Lapatinib is a clinically potent kinase inhibitor for breast cancer patients because of its outstanding selectivity for epidermal growth factor receptor (EGFR) and EGFR2 (also known as HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	120-152
23007710-2	2012	The target specific molecular agent lapatinib, a dual ErbB1 and ErbB2             receptor tyrosine kinase inhibitor, has shown significant activity against ErbB1             and ErbB2-expressing tumors.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-69
23007710-2	2012	The target specific molecular agent lapatinib, a dual ErbB1 and ErbB2             receptor tyrosine kinase inhibitor, has shown significant activity against ErbB1             and ErbB2-expressing tumors.	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	157-162
23007710-2	2012	The target specific molecular agent lapatinib, a dual ErbB1 and ErbB2             receptor tyrosine kinase inhibitor, has shown significant activity against ErbB1             and ErbB2-expressing tumors.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-184
23007710-9	2012	The lapatinib-treated             cells showed a dose-dependent inhibition of cell proliferation and induction of             apoptosis at the same concentrations that blocked ErbB1/ErbB2 phosphorylation.	Lapatinib	4-13	epidermal growth factor receptor	Homo sapiens	176-181
23007710-9	2012	The lapatinib-treated             cells showed a dose-dependent inhibition of cell proliferation and induction of             apoptosis at the same concentrations that blocked ErbB1/ErbB2 phosphorylation.	Lapatinib	4-13	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-187
22964224-1	2012	Lapatinib is a clinically potent kinase inhibitor for breast cancer patients because of its outstanding selectivity for epidermal growth factor receptor (EGFR) and EGFR2 (also known as HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	154-158
22964224-1	2012	Lapatinib is a clinically potent kinase inhibitor for breast cancer patients because of its outstanding selectivity for epidermal growth factor receptor (EGFR) and EGFR2 (also known as HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
22964224-2	2012	However, there is only limited information about the in vivo effects of lapatinib on EGFR/HER2 and downstream signaling targets.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	85-89
22964224-2	2012	However, there is only limited information about the in vivo effects of lapatinib on EGFR/HER2 and downstream signaling targets.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
22964224-10	2012	The results provide new insights into EGFR/HER2 regulation through region-specific phosphorylation, as well as a global view of the cellular signaling networks associated with the anti-breast cancer action of lapatinib.	Lapatinib	209-218	epidermal growth factor receptor	Homo sapiens	38-42
22964224-10	2012	The results provide new insights into EGFR/HER2 regulation through region-specific phosphorylation, as well as a global view of the cellular signaling networks associated with the anti-breast cancer action of lapatinib.	Lapatinib	209-218	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
23007710-2	2012	The target specific molecular agent lapatinib, a dual ErbB1 and ErbB2             receptor tyrosine kinase inhibitor, has shown significant activity against ErbB1             and ErbB2-expressing tumors.	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	54-59
23007710-12	2012	Simultaneous             dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition with lapatinib results             in significant reduction of pancreatic cancer cell growth and proliferation.	Lapatinib	87-96	epidermal growth factor receptor	Homo sapiens	30-35
23003202-2	2012	This study evaluates the effects of the EGFR/HER2 tyrosine kinase inhibitor lapatinib, the heat shock protein-90 inhibitor 17AAG, and their combination, on HER2 expression with in vivo HER2-PET imaging.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
23007710-12	2012	Simultaneous             dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition with lapatinib results             in significant reduction of pancreatic cancer cell growth and proliferation.	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-45
23071298-5	2012	As seen in patients, the HER2 inhibitors trastuzumab and lapatinib controlled tumor progression in the breast but failed to contain tumor growth in the brain.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
23003202-2	2012	This study evaluates the effects of the EGFR/HER2 tyrosine kinase inhibitor lapatinib, the heat shock protein-90 inhibitor 17AAG, and their combination, on HER2 expression with in vivo HER2-PET imaging.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
23003202-3	2012	Lapatinib and 17AAG effects on EGFR and HER2 membrane expression were determined in vitro using flow cytometry of human SKBR3 tumor cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
23003202-3	2012	Lapatinib and 17AAG effects on EGFR and HER2 membrane expression were determined in vitro using flow cytometry of human SKBR3 tumor cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
23003202-10	2012	EGFR/HER2 downregulation by 17AAG was inhibited by lapatinib pretreatment.	Lapatinib	51-60	epidermal growth factor receptor	Homo sapiens	0-4
23003202-10	2012	EGFR/HER2 downregulation by 17AAG was inhibited by lapatinib pretreatment.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
23003202-13	2012	Lapatinib inhibits HER2 internalization and 17AAG lowers HER2 membrane expression.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
22876762-2	2012	AREAS COVERED: This review reports the background on the potential implication of the EGF/EGFR pathway in RCC, the different data on EGFR positivity in RCC and results from prospective Phase II and III trials on lapatinib in RCC, along with other EGF/EGFR inhibitors.	Lapatinib	212-221	epidermal growth factor receptor	Homo sapiens	90-94
22504780-0	2012	Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-29
22820413-9	2012	Regarding HER2-positive breast cancer patients with established brain metastases, lapatinib (small molecule TKI) seems particularly active in association with capecitabine.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
22885469-11	2012	CONCLUSION: While lapatinib has limited activity in unselected cases, the identification of a previously unreported mutation in EGFR (E690K) with a response suggests that lapatinib may be beneficial in some cases of EC.	Lapatinib	171-180	epidermal growth factor receptor	Homo sapiens	128-132
22821509-6	2012	Increased proliferation due to strong activation of extracellular-signal-regulated kinase 1/2 (ERK1/2) is caused by overexpression/activation of platelet-derived growth factor receptor-beta (PDGFR-beta) and ErbB2/3 which we successfully blocked with AZD6244, sorafenib, or lapatinib.	Lapatinib	273-282	mitogen-activated protein kinase 1	Homo sapiens	52-93
22821509-6	2012	Increased proliferation due to strong activation of extracellular-signal-regulated kinase 1/2 (ERK1/2) is caused by overexpression/activation of platelet-derived growth factor receptor-beta (PDGFR-beta) and ErbB2/3 which we successfully blocked with AZD6244, sorafenib, or lapatinib.	Lapatinib	273-282	mitogen-activated protein kinase 3	Homo sapiens	95-101
22821509-6	2012	Increased proliferation due to strong activation of extracellular-signal-regulated kinase 1/2 (ERK1/2) is caused by overexpression/activation of platelet-derived growth factor receptor-beta (PDGFR-beta) and ErbB2/3 which we successfully blocked with AZD6244, sorafenib, or lapatinib.	Lapatinib	273-282	platelet derived growth factor receptor beta	Homo sapiens	145-189
22821509-6	2012	Increased proliferation due to strong activation of extracellular-signal-regulated kinase 1/2 (ERK1/2) is caused by overexpression/activation of platelet-derived growth factor receptor-beta (PDGFR-beta) and ErbB2/3 which we successfully blocked with AZD6244, sorafenib, or lapatinib.	Lapatinib	273-282	platelet derived growth factor receptor alpha	Homo sapiens	191-201
22821509-6	2012	Increased proliferation due to strong activation of extracellular-signal-regulated kinase 1/2 (ERK1/2) is caused by overexpression/activation of platelet-derived growth factor receptor-beta (PDGFR-beta) and ErbB2/3 which we successfully blocked with AZD6244, sorafenib, or lapatinib.	Lapatinib	273-282	erb-b2 receptor tyrosine kinase 2	Homo sapiens	207-214
23152018-0	2012	[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
23152018-1	2012	We retrospectively investigated the efficacy and toxicity of lapatinib plus capecitabine in 45 HER2-positive breast cancer patients.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
23152022-0	2012	[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
22872574-9	2012	This regimen even exhibited activity in lapatinib-resistant HER2(+) tumors.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Mus musculus	60-64
22989664-0	2012	EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.	Lapatinib	118-127	epidermal growth factor receptor	Homo sapiens	136-140
22989664-0	2012	EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-146
23042933-11	2012	Moreover, nelfinavir inhibited the growth of trastuzumab- and/or lapatinib-resistant, HER2-positive breast cancer cells in vitro at clinically achievable concentrations.	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
23027040-1	2012	OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	60-92
23027040-1	2012	OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	94-98
23027040-1	2012	OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-144
23027040-1	2012	OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
23027040-1	2012	OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.	Lapatinib	11-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	167-199
23027040-1	2012	OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.	Lapatinib	11-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	201-205
21701940-0	2012	Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.	Lapatinib	22-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
21701940-1	2012	BACKGROUND: In a phase III trial of women with HER2+ metastatic breast cancer (MBC) previously treated with trastuzumab, an anthracycline, and taxanes (EGF100151), lapatinib plus capecitabine (L+C) improved time to progression (TTP) versus capecitabine monotherapy (C-only).	Lapatinib	164-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
22918394-11	2012	Anti-HER2 treatment after BM was associated with a survival benefit, especially when both trastuzumab and lapatinib were utilised.	Lapatinib	106-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
22006161-0	2012	A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
22006161-1	2012	We conducted a phase I trial to determine the feasible dose for lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor, with paclitaxel and gemcitabine as a neoadjuvant treatment in HER2 positive patients.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
22006161-1	2012	We conducted a phase I trial to determine the feasible dose for lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor, with paclitaxel and gemcitabine as a neoadjuvant treatment in HER2 positive patients.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185
22843892-1	2012	BACKGROUND: Lapatinib targets human epidermal growth factor-receptor (EGFR) and Her2/neu receptor tyrosine-kinases and hence is under investigation in multimodal therapy concepts of advanced head and neck squamous cell carcinoma (HNSCC).	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-88
22987969-3	2012	Benefits were also seen for the combination of trastuzumab with lapatinib or pertuzumab, suggesting that dual blockage of the HER-2 will probably emerge as the new standard.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-131
22824822-4	2012	The small molecule tyrosine kinase inhibitor lapatinib has demonstrated activity in HER2-positive metastatic breast cancer (MBC) and in the preoperative setting.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
22761403-2	2012	Trastuzumab and lapatinib are standard treatments for HER2-amplified breast cancer, but a significant number of patients do not respond or develop resistance to these drugs.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
22761403-11	2012	This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clinical testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib.	Lapatinib	241-250	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
22942906-1	2012	The treatment of breast cancer that is driven by amplification and overexpression of human epidermal growth factor receptor 2 (HER2) has been drastically improved by the development of HER2-targeted therapies including trastuzumab and lapatinib.	Lapatinib	235-244	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
22942906-5	2012	Several phase I studies have shown T-DM1 is safe, tolerable and has activity in trastuzumab- and lapatinib-pretreated breast cancer.	Lapatinib	97-106	immunoglobulin heavy diversity 1-7	Homo sapiens	37-40
22705569-5	2012	Pain-related behavior was retested after intraperitoneal injection of the ErbB2 inhibitor Lapatinib, an agent shown by others to reduce breast cancer pain.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	74-79
22892392-0	2012	BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.	Lapatinib	71-80	breast cancer anti-estrogen resistance 4	Homo sapiens	0-5
22892392-2	2012	We determined whether BCAR4 expression sensitises breast cancer cells to lapatinib, and identifies a subgroup of patients who possibly may benefit from ERBB2-targeted therapies despite having tumours with low ERBB2 expression.	Lapatinib	73-82	breast cancer anti-estrogen resistance 4	Homo sapiens	22-27
22892392-3	2012	METHODS: Proliferation assays were applied to determine the effect of BCAR4 expression on lapatinib treatment.	Lapatinib	90-99	breast cancer anti-estrogen resistance 4	Homo sapiens	70-75
22892392-7	2012	RESULTS: BCAR4 expression strongly sensitised ZR-75-1 and MCF7 breast cancer cells to the combination of lapatinib and antioestrogens.	Lapatinib	105-114	breast cancer anti-estrogen resistance 4	Homo sapiens	9-14
22892392-8	2012	Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and STAT6.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-50
22892392-8	2012	Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and STAT6.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	80-83
22892392-8	2012	Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and STAT6.	Lapatinib	0-9	protein tyrosine kinase 2	Homo sapiens	85-88
22892392-8	2012	Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and STAT6.	Lapatinib	0-9	SHC adaptor protein 1	Homo sapiens	90-93
22892392-8	2012	Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and STAT6.	Lapatinib	0-9	signal transducer and activator of transcription 5A	Homo sapiens	95-100
22892392-8	2012	Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and STAT6.	Lapatinib	0-9	signal transducer and activator of transcription 6	Homo sapiens	106-111
22892393-0	2012	Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
22844108-0	2012	Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.	Lapatinib	18-27	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	65-89
22844108-1	2012	This single-institution phase II study was performed to estimate the response rate to lapatinib in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS).	Lapatinib	86-95	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	99-123
22844108-1	2012	This single-institution phase II study was performed to estimate the response rate to lapatinib in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS).	Lapatinib	86-95	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	125-128
22844108-13	2012	Lapatinib carries minor toxicity and has objective activity in NF2 patients with progressive VS, including volumetric and hearing responses.	Lapatinib	0-9	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	63-66
22942906-1	2012	The treatment of breast cancer that is driven by amplification and overexpression of human epidermal growth factor receptor 2 (HER2) has been drastically improved by the development of HER2-targeted therapies including trastuzumab and lapatinib.	Lapatinib	235-244	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-125
22942906-1	2012	The treatment of breast cancer that is driven by amplification and overexpression of human epidermal growth factor receptor 2 (HER2) has been drastically improved by the development of HER2-targeted therapies including trastuzumab and lapatinib.	Lapatinib	235-244	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
22627808-10	2012	HRG-induced MMP-1 and -9 expressions were significantly decreased by lapatinib, which inhibits HER1 and HER2 activity, in both vector alone and HER2 overexpressed MCF7 cells.	Lapatinib	69-78	matrix metallopeptidase 1	Homo sapiens	12-24
22627808-10	2012	HRG-induced MMP-1 and -9 expressions were significantly decreased by lapatinib, which inhibits HER1 and HER2 activity, in both vector alone and HER2 overexpressed MCF7 cells.	Lapatinib	69-78	epidermal growth factor receptor	Homo sapiens	95-99
22627808-10	2012	HRG-induced MMP-1 and -9 expressions were significantly decreased by lapatinib, which inhibits HER1 and HER2 activity, in both vector alone and HER2 overexpressed MCF7 cells.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
22627808-10	2012	HRG-induced MMP-1 and -9 expressions were significantly decreased by lapatinib, which inhibits HER1 and HER2 activity, in both vector alone and HER2 overexpressed MCF7 cells.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
22843892-1	2012	BACKGROUND: Lapatinib targets human epidermal growth factor-receptor (EGFR) and Her2/neu receptor tyrosine-kinases and hence is under investigation in multimodal therapy concepts of advanced head and neck squamous cell carcinoma (HNSCC).	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	36-68
22843892-1	2012	BACKGROUND: Lapatinib targets human epidermal growth factor-receptor (EGFR) and Her2/neu receptor tyrosine-kinases and hence is under investigation in multimodal therapy concepts of advanced head and neck squamous cell carcinoma (HNSCC).	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	70-74
22305205-2	2012	While the introduction of HER2-targeted therapies, such as the monoclonal antibody trastuzumab and the small-molecule tyrosine kinase inhibitor lapatinib, has significantly improved outcomes in HER2+ breast cancer compared with previously available therapies, use of these targeted therapies is often limited by the development of drug resistance and tolerability issues.	Lapatinib	144-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
22305205-2	2012	While the introduction of HER2-targeted therapies, such as the monoclonal antibody trastuzumab and the small-molecule tyrosine kinase inhibitor lapatinib, has significantly improved outcomes in HER2+ breast cancer compared with previously available therapies, use of these targeted therapies is often limited by the development of drug resistance and tolerability issues.	Lapatinib	144-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
22687601-9	2012	CONCLUSIONS: In metastatic breast cancer, metabolomics may play a role in sub selecting patients with HER2 positive disease with greater sensitivity to paclitaxel plus lapatinib.	Lapatinib	168-177	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
22738819-2	2012	For HR+, HER2+ MBC, combination of an AI with an anti-HER2 agent (lapatinib or trastuzumab) has shown clinical benefit.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
21623901-1	2012	The combination of lapatinib and capecitabine is approved in Her2+ metastatic breast cancer.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
21623901-5	2012	Lapatinib proved to markedly downregulate TS activity, thus suggesting a subsequent better efficacy of capecitabine.	Lapatinib	0-9	thymidylate synthetase	Homo sapiens	42-44
21623901-6	2012	Capecitabine optimized the downregulation of p-AKT and p-P42/44 expression by lapatinib.	Lapatinib	78-87	erythrocyte membrane protein band 4.2	Homo sapiens	57-60
21623901-12	2012	Besides, modulation of TS expression by lapatinib makes its association with capecitabine a promising way to overcome breast cancers resistant in relation with TS overexpression.	Lapatinib	40-49	thymidylate synthetase	Homo sapiens	23-25
21623901-12	2012	Besides, modulation of TS expression by lapatinib makes its association with capecitabine a promising way to overcome breast cancers resistant in relation with TS overexpression.	Lapatinib	40-49	thymidylate synthetase	Homo sapiens	160-162
23024989-0	2012	Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
22056878-0	2012	Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-123
22839200-0	2012	Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
22689807-0	2012	Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-130
22689807-1	2012	PURPOSE: Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC).	Lapatinib	52-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	269-303
22689807-1	2012	PURPOSE: Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC).	Lapatinib	52-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	305-309
22056878-0	2012	Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.	Lapatinib	34-43	retinoic acid receptor alpha	Homo sapiens	128-132
22689807-10	2012	CONCLUSION: These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
22056878-5	2012	In estrogen-receptor-negative cellular models showing coamplification of ERBB2 and RARA, simultaneous targeting of the corresponding gene products with combinations of lapatinib and ATRA causes synergistic growth inhibition, cyto-differentiation and apoptosis.	Lapatinib	168-177	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
22056878-5	2012	In estrogen-receptor-negative cellular models showing coamplification of ERBB2 and RARA, simultaneous targeting of the corresponding gene products with combinations of lapatinib and ATRA causes synergistic growth inhibition, cyto-differentiation and apoptosis.	Lapatinib	168-177	retinoic acid receptor alpha	Homo sapiens	83-87
22056878-9	2012	Induction of the retinoid-dependent RARRES3 protein by ATRA stabilizes the effect of lapatinib inhibiting ERBB2 phosphorylation.	Lapatinib	85-94	phospholipase A and acyltransferase 4	Homo sapiens	36-43
22056878-9	2012	Induction of the retinoid-dependent RARRES3 protein by ATRA stabilizes the effect of lapatinib inhibiting ERBB2 phosphorylation.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111
22056878-10	2012	Upregulation and activation of the transcription factor FOXO3A integrates ATRA-dependent transcriptional and lapatinib-dependent posttranscriptional signals, controlling the levels of effector proteins like the antiapoptotic factor, BIRC5.	Lapatinib	109-118	forkhead box O3	Homo sapiens	56-62
22056878-10	2012	Upregulation and activation of the transcription factor FOXO3A integrates ATRA-dependent transcriptional and lapatinib-dependent posttranscriptional signals, controlling the levels of effector proteins like the antiapoptotic factor, BIRC5.	Lapatinib	109-118	baculoviral IAP repeat containing 5	Homo sapiens	233-238
21526426-4	2012	Anti-HER2 treatments, trastuzumab or lapatinib, have demonstrated clinically significant efficacy.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
22511346-7	2012	The reduced CO difference spectrum further suggested that a large fraction of the reactive metabolite of lapatinib is covalently adducted to the apoprotein of CYP3A5.	Lapatinib	105-114	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	159-165
22198412-0	2012	A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
22198412-12	2012	Lapatinib plus bevacizumab was active in patients with HER2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
22511346-0	2012	Interaction of lapatinib with cytochrome P450 3A5.	Lapatinib	15-24	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	30-49
22476856-0	2012	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
22476856-0	2012	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
22476856-2	2012	This multicenter phase II trial was designed to evaluate the activity of lapatinib in metastatic breast cancer patients with HER2-negative primary tumors and HER2-positive circulating tumor cells (CTCs).	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
22511346-8	2012	GSH trapping of a reactive metabolite of lapatinib formed by CYP3A5 confirmed the formation of a quinoneimine-GSH adduct derived from the O-dealkylated metabolite of lapatinib.	Lapatinib	41-50	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	61-67
22511346-2	2012	Recently, it has been found that lapatinib forms a metabolite-inhibitor complex (MIC) with CYP3A4 via the formation of an alkylnitroso intermediate.	Lapatinib	33-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
22511346-3	2012	Because CYP3A5 is highly polymorphic compared with CYP3A4 and also oxidizes lapatinib, we investigated the interactions of lapatinib with CYP3A5.	Lapatinib	76-85	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	8-14
22511346-3	2012	Because CYP3A5 is highly polymorphic compared with CYP3A4 and also oxidizes lapatinib, we investigated the interactions of lapatinib with CYP3A5.	Lapatinib	123-132	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	8-14
22511346-4	2012	Lapatinib inactivated CYP3A5 in a time-, concentration-, and NADPH-dependent manner using testosterone as a probe substrate with K(I) and k(inact) values of 0.0376 mM and 0.0226 min(-1), respectively.	Lapatinib	0-9	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	22-28
22511346-8	2012	GSH trapping of a reactive metabolite of lapatinib formed by CYP3A5 confirmed the formation of a quinoneimine-GSH adduct derived from the O-dealkylated metabolite of lapatinib.	Lapatinib	166-175	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	61-67
22511346-9	2012	In silico docking studies supported the preferential formation of an O-dealkylated metabolite of lapatinib by CYP3A5 compared with an N-hydroxylation reaction that is predominantly catalyzed by CYP3A4.	Lapatinib	97-106	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	110-116
22511346-9	2012	In silico docking studies supported the preferential formation of an O-dealkylated metabolite of lapatinib by CYP3A5 compared with an N-hydroxylation reaction that is predominantly catalyzed by CYP3A4.	Lapatinib	97-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	194-200
22511346-10	2012	In conclusion, lapatinib appears to be a mechanism-based inactivator of CYP3A5 via adduction of a quinoneimine metabolite.	Lapatinib	15-24	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	72-78
22511346-5	2012	However, similar results were not obtained when midazolam was used as the probe substrate, suggesting that inactivation of CYP3A5 by lapatinib is site-specific.	Lapatinib	133-142	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	123-129
22709873-1	2012	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
22790050-2	2012	We encountered a case of HER2-positive breast cancer with cerebral metastasis presenting with hydrocephalus, in which VP shunting was successful, enabling continued treatment with lapatinib+capecitabine and improvement of the patient"s QOL.	Lapatinib	180-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
22853752-1	2012	Passive immunotherapy with the monoclonal antibody trastuzumab and tyrosine kinase activity inhibition with lapatinib are HER2-targeted therapies used in the clinic for the treatment of HER2-overexpressing breast cancers.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
22853752-1	2012	Passive immunotherapy with the monoclonal antibody trastuzumab and tyrosine kinase activity inhibition with lapatinib are HER2-targeted therapies used in the clinic for the treatment of HER2-overexpressing breast cancers.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	186-190
22853752-4	2012	This Phase I study of HER2 immunotherapy with concomitant lapatinib treatment in 12 patients with metastatic breast cancer resistant to trastuzumab demonstrates the feasibility and safety of concurrent vaccination against HER2 and inhibition of HER1 and HER2 kinases.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	222-226
22853752-4	2012	This Phase I study of HER2 immunotherapy with concomitant lapatinib treatment in 12 patients with metastatic breast cancer resistant to trastuzumab demonstrates the feasibility and safety of concurrent vaccination against HER2 and inhibition of HER1 and HER2 kinases.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	222-226
22553357-6	2012	In ErbB2-overexpressing cells, both of the anti-ErbB3 surrobodies significantly augmented the activities of trastuzumab, lapatinib, and GDC-0941, agents that inhibit cell proliferation by different mechanisms.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-8
22553357-6	2012	In ErbB2-overexpressing cells, both of the anti-ErbB3 surrobodies significantly augmented the activities of trastuzumab, lapatinib, and GDC-0941, agents that inhibit cell proliferation by different mechanisms.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 3	Homo sapiens	48-53
22686613-6	2012	Proposed mechanisms of resistance to lapatinib involve derepression and/or activation of compensatory survival pathways through increased PI3K/AKT or estrogen receptor (ER) signalling.	Lapatinib	37-46	AKT serine/threonine kinase 1	Homo sapiens	143-146
22686613-6	2012	Proposed mechanisms of resistance to lapatinib involve derepression and/or activation of compensatory survival pathways through increased PI3K/AKT or estrogen receptor (ER) signalling.	Lapatinib	37-46	estrogen receptor 1	Homo sapiens	150-167
22686613-6	2012	Proposed mechanisms of resistance to lapatinib involve derepression and/or activation of compensatory survival pathways through increased PI3K/AKT or estrogen receptor (ER) signalling.	Lapatinib	37-46	estrogen receptor 1	Homo sapiens	169-171
22006669-1	2012	The success of endocrine therapies for hormone receptor-positive breast cancer and trastuzumab and lapatinib for targeting human epidermal growth factor receptor 2 (HER2)-positive tumors has paved the way for the clinical development of several other metastatic breast cancer (MBC)-targeted therapies.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-163
22006669-1	2012	The success of endocrine therapies for hormone receptor-positive breast cancer and trastuzumab and lapatinib for targeting human epidermal growth factor receptor 2 (HER2)-positive tumors has paved the way for the clinical development of several other metastatic breast cancer (MBC)-targeted therapies.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
22127954-6	2012	The EGFR/HER2 dual inhibitor Lapatinib and the NF-kB inhibitor Bortezomib inhibited sPLA2-IIa expression induced by Heregulin-alpha.	Lapatinib	29-38	epidermal growth factor receptor	Homo sapiens	4-8
22127954-6	2012	The EGFR/HER2 dual inhibitor Lapatinib and the NF-kB inhibitor Bortezomib inhibited sPLA2-IIa expression induced by Heregulin-alpha.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
22127954-6	2012	The EGFR/HER2 dual inhibitor Lapatinib and the NF-kB inhibitor Bortezomib inhibited sPLA2-IIa expression induced by Heregulin-alpha.	Lapatinib	29-38	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	84-93
22713170-3	2012	The anti-HER2 agents trastuzumab and lapatinib may cause left ventricular dysfunction or even congestive heart failure.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	157-166	RB1 inducible coiled-coil 1	Homo sapiens	49-55
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	157-166	forkhead box O3	Homo sapiens	57-63
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	157-166	nuclear receptor subfamily 3 group C member 1	Homo sapiens	65-70
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	157-166	erb-b2 receptor tyrosine kinase 3	Homo sapiens	75-80
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	288-297	RB1 inducible coiled-coil 1	Homo sapiens	49-55
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	288-297	forkhead box O3	Homo sapiens	57-63
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	288-297	nuclear receptor subfamily 3 group C member 1	Homo sapiens	65-70
22709873-9	2012	Furthermore, the expression of 4 of these genes (RB1CC1, FOXO3A, NR3C1 and ERBB3) was directly correlated with the degree of sensitivity of the cell line to lapatinib and their expression was observed to "switch" from up-regulated to down-regulated when the cell lines were arranged in a lapatinib-sensitive to insensitive order.	Lapatinib	288-297	erb-b2 receptor tyrosine kinase 3	Homo sapiens	75-80
22709873-1	2012	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	63-67
22709873-10	2012	These included the novel lapatinib response-associated genes RB1CC1 and NR3C1.	Lapatinib	25-34	RB1 inducible coiled-coil 1	Homo sapiens	61-67
22709873-10	2012	These included the novel lapatinib response-associated genes RB1CC1 and NR3C1.	Lapatinib	25-34	nuclear receptor subfamily 3 group C member 1	Homo sapiens	72-77
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Lapatinib	70-79	cyclin D1	Homo sapiens	4-13
22709873-11	2012	Additionally, Cyclin D1 (CCND1), a common regulator of the other four proteins, was also demonstrated to observe a proportional response to lapatinib exposure.	Lapatinib	140-149	cyclin D1	Homo sapiens	14-23
22709873-11	2012	Additionally, Cyclin D1 (CCND1), a common regulator of the other four proteins, was also demonstrated to observe a proportional response to lapatinib exposure.	Lapatinib	140-149	cyclin D1	Homo sapiens	25-30
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	29-38	epidermal growth factor receptor	Homo sapiens	59-91
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	29-38	epidermal growth factor receptor	Homo sapiens	93-97
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	29-38	ATP binding cassette subfamily B member 1	Homo sapiens	220-244
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	29-38	ATP binding cassette subfamily B member 1	Homo sapiens	246-251
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	29-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	257-281
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	29-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	283-288
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	40-48	epidermal growth factor receptor	Homo sapiens	59-91
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	40-48	epidermal growth factor receptor	Homo sapiens	93-97
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	40-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	40-48	ATP binding cassette subfamily B member 1	Homo sapiens	220-244
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	40-48	ATP binding cassette subfamily B member 1	Homo sapiens	246-251
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	40-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	257-281
22414725-2	2012	Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2).	Lapatinib	40-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	283-288
22414725-3	2012	In the present study, we conducted in vitro experiments to evaluate if GW583340 and GW2974, structural analogues of lapatinib, could reverse ABCB1- and ABCG2-mediated MDR.	Lapatinib	116-125	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
22414725-3	2012	In the present study, we conducted in vitro experiments to evaluate if GW583340 and GW2974, structural analogues of lapatinib, could reverse ABCB1- and ABCG2-mediated MDR.	Lapatinib	116-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	152-157
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Lapatinib	70-79	cyclin D1	Homo sapiens	15-20
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
21989330-9	2012	CONCLUSION: Our findings suggest that CCND1A870G may be useful in predicting clinical outcome in HER2-positive mBC patients treated with lapatinib plus capecitabine.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
22039084-0	2012	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
22039084-1	2012	BACKGROUND: Preclinical data suggest that treatment with lapatinib reinduces sensitivity to trastuzumab in human epidermal growth factor receptor 2(HER2)-positive breast cancer cells.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-147
22039084-1	2012	BACKGROUND: Preclinical data suggest that treatment with lapatinib reinduces sensitivity to trastuzumab in human epidermal growth factor receptor 2(HER2)-positive breast cancer cells.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
22370628-0	2012	Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence.	Lapatinib	60-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
22370628-1	2012	Concomitant usage of lapatinib, a cytochrome P450 (CYP) 3A4 substrate and dexamethasone, a CYP3A4 inducer, is a pharmacokinetic drug-drug interaction.	Lapatinib	21-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
22370628-8	2012	At 5 muM lapatinib, the introduction of dexamethasone 20 muM produced a 59% decline in viability.	Lapatinib	9-18	latexin	Homo sapiens	57-60
23869176-4	2012	Lapatinib is a small molecule dual inhibitor of epidermal growth factor receptor and HER2 tyrosine kinases, and is approved for trastuzumab-refractory disease.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
22614782-2	2012	To date, trastuzumab and lapatinib are the two anti-HER2 targeted therapies commonly used, demonstrating therapeutic effects.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
22461506-7	2012	In addition, loss of ErbB3 impaired Akt and p44/42 phosphorylation in preneoplastic HER2-overexpressing mammary glands and in tumors, decreased growth of preexisting HER2-overexpressing tumors, and improved tumor response to the HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	260-269	erb-b2 receptor tyrosine kinase 3	Homo sapiens	21-26
22811876-2	2012	Lapatinib is an oral EGFR and HER-2 dual tyrosine kinase inhibitor that has not shown significant activity in metastatic colorectal cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	21-25
22811876-2	2012	Lapatinib is an oral EGFR and HER-2 dual tyrosine kinase inhibitor that has not shown significant activity in metastatic colorectal cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-35
22745588-6	2012	Dual inhibition of EGFR and ERBB2 with lapatinib significantly reduced GBM proliferation in colony formation assays compared to cetuximab-mediated EGFR-specific inhibition.	Lapatinib	39-48	epidermal growth factor receptor	Homo sapiens	19-23
22407832-7	2012	RESULTS: The addition of lapatinib to INK-128 prevented both HER2 and HER3 phosphorylation induced by INK-128, resulting in inhibition of both PI3K/Akt/mTOR and ERK pathways.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
22407832-7	2012	RESULTS: The addition of lapatinib to INK-128 prevented both HER2 and HER3 phosphorylation induced by INK-128, resulting in inhibition of both PI3K/Akt/mTOR and ERK pathways.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 3	Homo sapiens	70-74
22407832-7	2012	RESULTS: The addition of lapatinib to INK-128 prevented both HER2 and HER3 phosphorylation induced by INK-128, resulting in inhibition of both PI3K/Akt/mTOR and ERK pathways.	Lapatinib	25-34	AKT serine/threonine kinase 1	Homo sapiens	148-151
22407832-7	2012	RESULTS: The addition of lapatinib to INK-128 prevented both HER2 and HER3 phosphorylation induced by INK-128, resulting in inhibition of both PI3K/Akt/mTOR and ERK pathways.	Lapatinib	25-34	mechanistic target of rapamycin kinase	Homo sapiens	152-156
22407832-7	2012	RESULTS: The addition of lapatinib to INK-128 prevented both HER2 and HER3 phosphorylation induced by INK-128, resulting in inhibition of both PI3K/Akt/mTOR and ERK pathways.	Lapatinib	25-34	mitogen-activated protein kinase 1	Homo sapiens	161-164
22407832-8	2012	This dual blockade produced synergistic induction of cell death in five different HER2-positive cell lines resistant to trastuzumab and lapatinib.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
22407832-10	2012	CONCLUSIONS: The simultaneous blockade of both PI3K/Akt/mTOR and ERK pathways obtained by combining lapatinib with INK-128 acts synergistically in inducing cell death and tumor regression in breast cancer models refractory to anti-HER2 therapy.	Lapatinib	100-109	AKT serine/threonine kinase 1	Homo sapiens	52-55
22407832-10	2012	CONCLUSIONS: The simultaneous blockade of both PI3K/Akt/mTOR and ERK pathways obtained by combining lapatinib with INK-128 acts synergistically in inducing cell death and tumor regression in breast cancer models refractory to anti-HER2 therapy.	Lapatinib	100-109	mechanistic target of rapamycin kinase	Homo sapiens	56-60
22407832-10	2012	CONCLUSIONS: The simultaneous blockade of both PI3K/Akt/mTOR and ERK pathways obtained by combining lapatinib with INK-128 acts synergistically in inducing cell death and tumor regression in breast cancer models refractory to anti-HER2 therapy.	Lapatinib	100-109	mitogen-activated protein kinase 1	Homo sapiens	65-68
22407832-10	2012	CONCLUSIONS: The simultaneous blockade of both PI3K/Akt/mTOR and ERK pathways obtained by combining lapatinib with INK-128 acts synergistically in inducing cell death and tumor regression in breast cancer models refractory to anti-HER2 therapy.	Lapatinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	231-235
22745588-7	2012	Phosphorylation of downstream ERBB signaling components (AKT, ERK1/2) and GBM CSC proliferation were inhibited by lapatinib.	Lapatinib	114-123	AKT serine/threonine kinase 1	Homo sapiens	57-60
22745588-7	2012	Phosphorylation of downstream ERBB signaling components (AKT, ERK1/2) and GBM CSC proliferation were inhibited by lapatinib.	Lapatinib	114-123	mitogen-activated protein kinase 3	Homo sapiens	62-68
22745588-6	2012	Dual inhibition of EGFR and ERBB2 with lapatinib significantly reduced GBM proliferation in colony formation assays compared to cetuximab-mediated EGFR-specific inhibition.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
22745588-7	2012	Phosphorylation of downstream ERBB signaling components (AKT, ERK1/2) and GBM CSC proliferation were inhibited by lapatinib.	Lapatinib	114-123	epidermal growth factor receptor	Homo sapiens	30-34
22293713-0	2012	Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects             with 5-fluorouracil on esophageal carcinoma.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
22293713-0	2012	Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects             with 5-fluorouracil on esophageal carcinoma.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
22293713-3	2012	We evaluated the antitumor             effects of lapatinib, a dual tyrosine kinase inhibitor which simultaneously inhibits             EGFR and HER2, 5-fluorouracil (5-Fu) alone and in combination on esophageal cancer             cells.	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	136-140
22293713-3	2012	We evaluated the antitumor             effects of lapatinib, a dual tyrosine kinase inhibitor which simultaneously inhibits             EGFR and HER2, 5-fluorouracil (5-Fu) alone and in combination on esophageal cancer             cells.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
22293713-9	2012	The potentiation effect of combined treatment was associated             with downregulation of EGFR and HER2 signaling pathways because data from western             blot analysis showed that lapatinib in combination with 5-Fu markedly reduced             the phosphorylation of EGFR and HER2, and inhibited the activation of downstream             signaling molecules, such as AKT and ERK.	Lapatinib	193-202	epidermal growth factor receptor	Homo sapiens	96-100
22293713-9	2012	The potentiation effect of combined treatment was associated             with downregulation of EGFR and HER2 signaling pathways because data from western             blot analysis showed that lapatinib in combination with 5-Fu markedly reduced             the phosphorylation of EGFR and HER2, and inhibited the activation of downstream             signaling molecules, such as AKT and ERK.	Lapatinib	193-202	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
22293713-9	2012	The potentiation effect of combined treatment was associated             with downregulation of EGFR and HER2 signaling pathways because data from western             blot analysis showed that lapatinib in combination with 5-Fu markedly reduced             the phosphorylation of EGFR and HER2, and inhibited the activation of downstream             signaling molecules, such as AKT and ERK.	Lapatinib	193-202	epidermal growth factor receptor	Homo sapiens	280-284
22293713-9	2012	The potentiation effect of combined treatment was associated             with downregulation of EGFR and HER2 signaling pathways because data from western             blot analysis showed that lapatinib in combination with 5-Fu markedly reduced             the phosphorylation of EGFR and HER2, and inhibited the activation of downstream             signaling molecules, such as AKT and ERK.	Lapatinib	193-202	erb-b2 receptor tyrosine kinase 2	Homo sapiens	289-293
22293713-9	2012	The potentiation effect of combined treatment was associated             with downregulation of EGFR and HER2 signaling pathways because data from western             blot analysis showed that lapatinib in combination with 5-Fu markedly reduced             the phosphorylation of EGFR and HER2, and inhibited the activation of downstream             signaling molecules, such as AKT and ERK.	Lapatinib	193-202	AKT serine/threonine kinase 1	Homo sapiens	379-382
22293713-11	2012	These results indicate that the combination             of the lapatinib and 5-Fu is a promising treatment option for esophageal carcinoma             with HER2 amplification.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
21359953-0	2012	Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
21860419-7	2012	Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF.	Lapatinib	5-14	forkhead box O3	Homo sapiens	38-44
21860419-7	2012	Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF.	Lapatinib	5-14	forkhead box M1	Homo sapiens	55-60
21860419-7	2012	Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF.	Lapatinib	5-14	histone deacetylase 2	Homo sapiens	97-118
21860419-7	2012	Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF.	Lapatinib	5-14	histone deacetylase 2	Homo sapiens	120-125
21860419-7	2012	Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF.	Lapatinib	5-14	vascular endothelial growth factor A	Homo sapiens	243-247
22357666-0	2012	Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	61-70
22357666-0	2012	Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.	Lapatinib	0-9	BCL2 like 1	Homo sapiens	97-103
22357666-0	2012	Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.	Lapatinib	0-9	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	108-113
22357666-6	2012	In parallel, we noted in CNS tumor cells that knockdown of BCL-xL (B-cell lymphoma-extra large)and MCL-1 (myeloid cell leukemia-1) interacted in an additive fashion to facilitate lapatinib lethality.	Lapatinib	179-188	BCL2 like 1	Homo sapiens	59-65
21860419-3	2012	Using the lapatinib-sensitive breast cancer cell lines BT474 and SKBR3 as model systems, we tested the possibility that VEGF expression is negatively regulated by FOXO3a.	Lapatinib	10-19	vascular endothelial growth factor A	Homo sapiens	120-124
21860419-4	2012	Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and activation of FOXO3a, followed by a reduction in VEGF expression.	Lapatinib	0-9	forkhead box O3	Homo sapiens	96-102
21860419-4	2012	Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and activation of FOXO3a, followed by a reduction in VEGF expression.	Lapatinib	0-9	vascular endothelial growth factor A	Homo sapiens	131-135
24367193-1	2012	PURPOSE: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	183-217
24367193-1	2012	PURPOSE: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	219-223
24367193-6	2012	Lapatinib is a novel, orally bioavailable epidermal growth factor receptor/HER2+ targeted agent.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	42-74
24367193-6	2012	Lapatinib is a novel, orally bioavailable epidermal growth factor receptor/HER2+ targeted agent.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
24367193-7	2012	Many trials have investigated the efficacy and safety of lapatinib alone and in conjunction with other agents in the treatment of HER2+ breast cancer.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
24367193-8	2012	METHODS AND RESULTS: Preclinical and clinical trials of lapatinib have shown that it is effective in the treatment on HER2+ breast cancer.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-122
24367193-13	2012	CONCLUSION: Lapatinib is effective alone and in conjunction with other agents in the treatment of HER2+ breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
21359953-1	2012	Lapatinib, a dual kinase inhibitor against epidermal growth factor receptor (EGFR) and human epidermal receptor two (HER2) has shown efficacy in treating HER2 positive breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	43-75
21359953-1	2012	Lapatinib, a dual kinase inhibitor against epidermal growth factor receptor (EGFR) and human epidermal receptor two (HER2) has shown efficacy in treating HER2 positive breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	77-81
21359953-1	2012	Lapatinib, a dual kinase inhibitor against epidermal growth factor receptor (EGFR) and human epidermal receptor two (HER2) has shown efficacy in treating HER2 positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
21359953-1	2012	Lapatinib, a dual kinase inhibitor against epidermal growth factor receptor (EGFR) and human epidermal receptor two (HER2) has shown efficacy in treating HER2 positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
21359953-10	2012	The combination of lapatinib and nab-paclitaxel was well tolerated and provided good efficacy in women with HER2 positive breast cancer.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
22357454-1	2012	Lapatinib is a clinically important component of the treatment for HER2-positive metastatic breast cancer and has an acceptable safety profile.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
22357454-2	2012	Lapatinib-associated Hy"s Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB1*07:01 and Gilbert"s syndrome UGT1A1*28/*28 genotypes.	Lapatinib	0-9	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	72-100
22357454-2	2012	Lapatinib-associated Hy"s Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB1*07:01 and Gilbert"s syndrome UGT1A1*28/*28 genotypes.	Lapatinib	0-9	major histocompatibility complex, class II, DR beta 1	Homo sapiens	107-111
22357454-2	2012	Lapatinib-associated Hy"s Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB1*07:01 and Gilbert"s syndrome UGT1A1*28/*28 genotypes.	Lapatinib	0-9	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	141-147
20857170-0	2012	Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
22389470-5	2012	Lapatinib, a tyrosine kinase inhibitor of HER2, could not suppress proliferation of these HER2-positive SCLC cells alone but successfully restored chemosensitivity to etoposide and SN-38 with a clinically applicable concentration.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
21161326-3	2012	Gene expression analyses using real-time (kinetic) RT-PCR were performed to monitor the transcriptional evolution of EGFR ligands EGF, TGFalpha, AR, BTC, EPI, NRG and HB-EGF in experimental modes induced to exhibit acquired resistance to the mono-HER1 inhibitor CTX, the mono-HER2 inhibitor trastuzumab (Tzb) or the dual HER1/HER2 inhibitor lapatinib (LPT).	Lapatinib	341-350	epidermal growth factor receptor	Homo sapiens	117-121
21161326-3	2012	Gene expression analyses using real-time (kinetic) RT-PCR were performed to monitor the transcriptional evolution of EGFR ligands EGF, TGFalpha, AR, BTC, EPI, NRG and HB-EGF in experimental modes induced to exhibit acquired resistance to the mono-HER1 inhibitor CTX, the mono-HER2 inhibitor trastuzumab (Tzb) or the dual HER1/HER2 inhibitor lapatinib (LPT).	Lapatinib	352-355	epidermal growth factor receptor	Homo sapiens	117-121
21161326-4	2012	Gene expression signatures for EGFR ligands distinctively related to the occurrence of unresponsiveness to CTX, Tzb or LPT, with minimal overlap between them.	Lapatinib	119-122	epidermal growth factor receptor	Homo sapiens	31-35
21604273-8	2012	SP inhibition also induced cell death in cell lines resistant to Lapatinib and Trastuzumab that have increased levels of active Her2, suggesting that this therapeutic approach could be also effective for those cancers resistant to current anti-ErbB therapies.	Lapatinib	65-74	tachykinin precursor 1	Homo sapiens	0-2
22178589-9	2012	Lapatinib, an inhibitor of HER2 and EGFR, was more effective in inhibiting growth of cholangiocarcinoma cell lines than trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
22178589-9	2012	Lapatinib, an inhibitor of HER2 and EGFR, was more effective in inhibiting growth of cholangiocarcinoma cell lines than trastuzumab.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	36-40
22219388-0	2012	Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.	Lapatinib	14-23	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	67-71
22219388-1	2012	Prior studies demonstrated that resistance to the ERBB1/2 inhibitor lapatinib could be overcome by the B cell CLL/lymphoma-2 (BCL-2) family antagonist obatoclax (GX15-070).	Lapatinib	68-77	epidermal growth factor receptor	Homo sapiens	50-57
22219388-1	2012	Prior studies demonstrated that resistance to the ERBB1/2 inhibitor lapatinib could be overcome by the B cell CLL/lymphoma-2 (BCL-2) family antagonist obatoclax (GX15-070).	Lapatinib	68-77	BCL2 apoptosis regulator	Homo sapiens	103-124
22219388-1	2012	Prior studies demonstrated that resistance to the ERBB1/2 inhibitor lapatinib could be overcome by the B cell CLL/lymphoma-2 (BCL-2) family antagonist obatoclax (GX15-070).	Lapatinib	68-77	BCL2 apoptosis regulator	Homo sapiens	126-131
22219388-2	2012	Coadministration of lapatinib with obatoclax caused synergistic cell killing by eliciting autophagic cell death that was dependent upstream on mitochondrial reactive oxygen species generation and increased p62 levels and downstream on activation of p38 mitogen-activated protein kinase and inactivation of mammalian target of rapamycin.	Lapatinib	20-29	nucleoporin 62	Homo sapiens	206-209
22219388-2	2012	Coadministration of lapatinib with obatoclax caused synergistic cell killing by eliciting autophagic cell death that was dependent upstream on mitochondrial reactive oxygen species generation and increased p62 levels and downstream on activation of p38 mitogen-activated protein kinase and inactivation of mammalian target of rapamycin.	Lapatinib	20-29	mitogen-activated protein kinase 14	Homo sapiens	249-252
22219388-2	2012	Coadministration of lapatinib with obatoclax caused synergistic cell killing by eliciting autophagic cell death that was dependent upstream on mitochondrial reactive oxygen species generation and increased p62 levels and downstream on activation of p38 mitogen-activated protein kinase and inactivation of mammalian target of rapamycin.	Lapatinib	20-29	mechanistic target of rapamycin kinase	Homo sapiens	306-335
22219388-6	2012	Lapatinib and obatoclax-initiated autophagy depended on NOXA-mediated displacement of the prosurvival BCL-2 family member, MCL-1, from beclin 1, which was essential for the initiation of autophagy.	Lapatinib	0-9	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	56-60
22219388-6	2012	Lapatinib and obatoclax-initiated autophagy depended on NOXA-mediated displacement of the prosurvival BCL-2 family member, MCL-1, from beclin 1, which was essential for the initiation of autophagy.	Lapatinib	0-9	BCL2 apoptosis regulator	Homo sapiens	102-107
22219388-6	2012	Lapatinib and obatoclax-initiated autophagy depended on NOXA-mediated displacement of the prosurvival BCL-2 family member, MCL-1, from beclin 1, which was essential for the initiation of autophagy.	Lapatinib	0-9	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	123-128
22219388-6	2012	Lapatinib and obatoclax-initiated autophagy depended on NOXA-mediated displacement of the prosurvival BCL-2 family member, MCL-1, from beclin 1, which was essential for the initiation of autophagy.	Lapatinib	0-9	beclin 1	Homo sapiens	135-143
22389470-7	2012	Moreover, knocking down of HER2 by an short interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
22389470-7	2012	Moreover, knocking down of HER2 by an short interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms.	Lapatinib	83-92	ATP binding cassette subfamily B member 1	Homo sapiens	96-101
22389470-7	2012	Moreover, knocking down of HER2 by an short interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
22389470-9	2012	In SBC-3/ETP cells, dephosphorylation of HER2 by lapatinib activates Src and successively leads to increased caveolin-1 phosphorylation.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
22389470-9	2012	In SBC-3/ETP cells, dephosphorylation of HER2 by lapatinib activates Src and successively leads to increased caveolin-1 phosphorylation.	Lapatinib	49-58	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	69-72
22389470-9	2012	In SBC-3/ETP cells, dephosphorylation of HER2 by lapatinib activates Src and successively leads to increased caveolin-1 phosphorylation.	Lapatinib	49-58	caveolin 1	Homo sapiens	109-119
22389470-12	2012	Collectively, these results indicate that combination therapy with lapatinib and cytotoxic agents could conquer ABC transporter-mediated chemoresistance especially in HER2-positive SCLC.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
22541101-1	2012	This study was aimed to investigate the therapeutic effect of two molecular targeted therapeutic drugs, tyrosine kinase inhibitors gefitinib and lapatinib, on JAK2 V617F positive myeloproliferative disorders (MPD).	Lapatinib	145-154	Janus kinase 2	Homo sapiens	159-163
22352796-1	2012	The dual kinase inhibitor lapatinib has a high affinity for EGFR and HER2 but a weak affinity for ErbB4, although the factors driving specificity for these highly homologous members of the ErbB family of receptor tyrosine kinases are not well understood.	Lapatinib	26-35	epidermal growth factor receptor	Homo sapiens	60-64
22352796-1	2012	The dual kinase inhibitor lapatinib has a high affinity for EGFR and HER2 but a weak affinity for ErbB4, although the factors driving specificity for these highly homologous members of the ErbB family of receptor tyrosine kinases are not well understood.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
22352796-1	2012	The dual kinase inhibitor lapatinib has a high affinity for EGFR and HER2 but a weak affinity for ErbB4, although the factors driving specificity for these highly homologous members of the ErbB family of receptor tyrosine kinases are not well understood.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 4	Homo sapiens	98-103
22352796-1	2012	The dual kinase inhibitor lapatinib has a high affinity for EGFR and HER2 but a weak affinity for ErbB4, although the factors driving specificity for these highly homologous members of the ErbB family of receptor tyrosine kinases are not well understood.	Lapatinib	26-35	epidermal growth factor receptor	Homo sapiens	98-102
22248472-2	2012	Although both the ErbB2 monoclonal antibody trastuzumab and ErbB1/ErbB2 dual kinase inhibitor lapatinib have met with success in the clinic, many patients fail to benefit.	Lapatinib	94-103	epidermal growth factor receptor	Homo sapiens	60-65
22238368-0	2012	MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
22238368-2	2012	Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating HER2(+) cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-22
22372864-2	2012	In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-43
22372864-2	2012	In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance.	Lapatinib	60-69	epidermal growth factor receptor	Homo sapiens	92-97
22372864-2	2012	In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
22238368-2	2012	Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating HER2(+) cancer cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	27-59
22238368-2	2012	Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating HER2(+) cancer cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	61-65
22248472-2	2012	Although both the ErbB2 monoclonal antibody trastuzumab and ErbB1/ErbB2 dual kinase inhibitor lapatinib have met with success in the clinic, many patients fail to benefit.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71
22238368-2	2012	Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating HER2(+) cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
22238368-5	2012	A panel of gastric cancer cell lines was treated with lapatinib, and we observed that cell proliferation was reduced by 70% and that the degree of HER2 amplification corresponds to sensitivity to lapatinib.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
22238368-5	2012	A panel of gastric cancer cell lines was treated with lapatinib, and we observed that cell proliferation was reduced by 70% and that the degree of HER2 amplification corresponds to sensitivity to lapatinib.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
22238368-6	2012	Immunoblotting analysis indicated that phosphorylation of HER2, EGFR, MET, AKT, and extracellular signal-regulated kinase was inhibited by lapatinib and presumably led to cell-cycle arrest as observed with flow cytometry.	Lapatinib	139-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
22238368-6	2012	Immunoblotting analysis indicated that phosphorylation of HER2, EGFR, MET, AKT, and extracellular signal-regulated kinase was inhibited by lapatinib and presumably led to cell-cycle arrest as observed with flow cytometry.	Lapatinib	139-148	epidermal growth factor receptor	Homo sapiens	64-68
22238368-6	2012	Immunoblotting analysis indicated that phosphorylation of HER2, EGFR, MET, AKT, and extracellular signal-regulated kinase was inhibited by lapatinib and presumably led to cell-cycle arrest as observed with flow cytometry.	Lapatinib	139-148	AKT serine/threonine kinase 1	Homo sapiens	75-78
22240778-0	2012	Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.	Lapatinib	17-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
22238368-7	2012	Hepatocyte growth factor (HGF) activation of MET receptors rescued cells from lapatinib-induced growth inhibition by restimulating the downstream pathways and restoring normal cell-cycle progression.	Lapatinib	78-87	hepatocyte growth factor	Homo sapiens	0-24
22238368-7	2012	Hepatocyte growth factor (HGF) activation of MET receptors rescued cells from lapatinib-induced growth inhibition by restimulating the downstream pathways and restoring normal cell-cycle progression.	Lapatinib	78-87	hepatocyte growth factor	Homo sapiens	26-29
22238368-11	2012	In conclusion, HGF/MET-mediated resistance to lapatinib is a novel mechanism of resistance to HER2-targeted agents in gastric cancer cells.	Lapatinib	46-55	hepatocyte growth factor	Homo sapiens	15-18
22238368-11	2012	In conclusion, HGF/MET-mediated resistance to lapatinib is a novel mechanism of resistance to HER2-targeted agents in gastric cancer cells.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
22011930-0	2012	Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	26-30
22011930-1	2012	PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer.	Lapatinib	9-18	epidermal growth factor receptor	Mus musculus	37-41
22011930-1	2012	PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Mus musculus	42-46
22011930-1	2012	PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Mus musculus	94-98
22011930-1	2012	PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Mus musculus	94-98
21368164-5	2012	In HER2(+) cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
21368164-5	2012	In HER2(+) cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
21368164-5	2012	In HER2(+) cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6.	Lapatinib	102-111	taste 2 receptor member 63 pseudogene	Homo sapiens	173-176
22257673-0	2012	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
22257673-1	2012	BACKGROUND: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-195
22240778-1	2012	BACKGROUND: To determine the recommended doses of lapatinib (LPT) combined with vinorelbine (VNR) in women with human epidermal growth factor receptor 2-overexpressing advanced breast cancer pretreated with trastuzumab.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-152
21559822-2	2012	Treatment with ErbB1/2-targeting agents (lapatinib) mediates tumor apoptosis by downregulating ErbB1/2 phosphorylation and downstream survival signaling.	Lapatinib	41-50	epidermal growth factor receptor	Homo sapiens	15-20
22325452-1	2012	BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease.	Lapatinib	186-195	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
22325452-1	2012	BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease.	Lapatinib	186-195	epidermal growth factor receptor	Homo sapiens	150-154
22325452-1	2012	BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease.	Lapatinib	186-195	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-159
22325452-2	2012	HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate enhanced anti-tumor activity when combined with lapatinib in murine models.	Lapatinib	135-144	erb-b2 receptor tyrosine kinase 2	Mus musculus	0-4
22043997-0	2012	Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.	Lapatinib	42-51	mechanistic target of rapamycin kinase	Homo sapiens	28-32
22043997-0	2012	Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
22043997-1	2012	Lapatinib, a dual EGFR/HER2 kinase inhibitor, is approved for use in patients with trastuzumab-refractory HER2- overexpressing breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
22043997-1	2012	Lapatinib, a dual EGFR/HER2 kinase inhibitor, is approved for use in patients with trastuzumab-refractory HER2- overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
22043997-1	2012	Lapatinib, a dual EGFR/HER2 kinase inhibitor, is approved for use in patients with trastuzumab-refractory HER2- overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
22043997-3	2012	The purpose of the current study was to determine if PI3K/mTOR activity affects lapatinib sensitivity.	Lapatinib	80-89	mechanistic target of rapamycin kinase	Homo sapiens	58-62
22043997-5	2012	Transfection of constitutively active Akt reduced lapatinib sensitivity, while kinase-dead Akt increased sensitivity.	Lapatinib	50-59	AKT serine/threonine kinase 1	Homo sapiens	38-41
22043997-6	2012	Knockdown of 4EBP1 also increased lapatinib sensitivity, in contrast to p70S6K knockdown, which did not affect response to lapatinib.	Lapatinib	34-43	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	13-18
22043997-7	2012	Pharmacologic inhibition of mTOR using rapamycin or ridaforolimus increased lapatinib sensitivity and reduced phospho-Akt levels in cells that showed poor response to single-agent lapatinib, including those transfected with hyperactive Akt.	Lapatinib	76-85	mechanistic target of rapamycin kinase	Homo sapiens	28-32
22043997-7	2012	Pharmacologic inhibition of mTOR using rapamycin or ridaforolimus increased lapatinib sensitivity and reduced phospho-Akt levels in cells that showed poor response to single-agent lapatinib, including those transfected with hyperactive Akt.	Lapatinib	180-189	mechanistic target of rapamycin kinase	Homo sapiens	28-32
22043997-8	2012	Finally, combination mTOR inhibition plus lapatinib resulted in synergistic inhibition of proliferation, reduced anchorage-independent growth, and reduced in vivo tumor growth of HER2- overexpressing breast cancer cells that have primary trastuzumab resistance.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
22043997-9	2012	Our data suggest that PI3K/mTOR inhibition is critical for achieving optimal response to lapatinib.	Lapatinib	89-98	mechanistic target of rapamycin kinase	Homo sapiens	27-31
22043997-10	2012	Collectively, these experiments support evaluation of lapatinib in combination with pharmacologic mTOR inhibition as a potential strategy for inhibiting growth of HER2-overexpressing breast cancers that show resistance to trastuzumab and poor response to lapatinib.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
21559822-2	2012	Treatment with ErbB1/2-targeting agents (lapatinib) mediates tumor apoptosis by downregulating ErbB1/2 phosphorylation and downstream survival signaling.	Lapatinib	41-50	epidermal growth factor receptor	Homo sapiens	95-100
21559822-9	2012	Taken together, these data demonstrate a novel mechanism of lapatinib-analog-induced apoptosis and indicate that resistant cells have increased antioxidant potential, which can be overcome by treatment with SOD modulators.	Lapatinib	60-69	superoxide dismutase 1	Homo sapiens	207-210
21964064-2	2012	Extending this work, here we present several lines of evidence for the potency of PKCepsilon to differently modulate the efficacy of EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and lapatinib.	Lapatinib	194-203	protein kinase C epsilon	Homo sapiens	82-92
21964064-2	2012	Extending this work, here we present several lines of evidence for the potency of PKCepsilon to differently modulate the efficacy of EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and lapatinib.	Lapatinib	194-203	epidermal growth factor receptor	Homo sapiens	133-137
22135232-2	2012	On the basis of recent studies about epidermal growth factor receptor (EGFR) or HER2-targeting agents (including gefitinib, lapatinib, and trastuzumab) in gastric cancer, the potent effects of pan-HER inhibitors targeting the HER family are anticipated.	Lapatinib	124-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
21964064-4	2012	Cell cycle and Western blot analysis revealed that the gefitinib-induced apoptosis was enhanced whereas the pro-apoptotic effect of lapatinib that requires another EGFR conformation was reduced by PKCepsilon.	Lapatinib	132-141	epidermal growth factor receptor	Homo sapiens	164-168
21964064-4	2012	Cell cycle and Western blot analysis revealed that the gefitinib-induced apoptosis was enhanced whereas the pro-apoptotic effect of lapatinib that requires another EGFR conformation was reduced by PKCepsilon.	Lapatinib	132-141	protein kinase C epsilon	Homo sapiens	197-207
22438669-5	2012	Lapatinib is an oral, small molecule tyrosine kinase inhibitor, that inhibits both the HER1 ahd HER2 receptors and may be able to overcome trastuzumab resistance.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	87-91
22127284-11	2012	INTERPRETATION: This retrospective single-centre study suggests that the introduction of lapatinib improved survival in patients with BM from HER2-positive breast cancer.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-146
21898114-3	2012	Lapatinib inhibits the tyrosine kinase of HER2 and has activity when added to conventionally scheduled capecitabine for the treatment of patients with trastuzumab-refractory, HER2-positive, metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
21898114-3	2012	Lapatinib inhibits the tyrosine kinase of HER2 and has activity when added to conventionally scheduled capecitabine for the treatment of patients with trastuzumab-refractory, HER2-positive, metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
22182581-1	2012	A series of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidine derivatives were elaborately designed based on the skeleton of Lapatinib, and evaluated for their potential to inhibit epidermal growth factor receptor (EGFR) and ErbB-2 tyrosine kinase activities and antiproliferative activities against A431 and SKOV-3 cell lines.	Lapatinib	153-162	epidermal growth factor receptor	Homo sapiens	209-241
22182581-1	2012	A series of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidine derivatives were elaborately designed based on the skeleton of Lapatinib, and evaluated for their potential to inhibit epidermal growth factor receptor (EGFR) and ErbB-2 tyrosine kinase activities and antiproliferative activities against A431 and SKOV-3 cell lines.	Lapatinib	153-162	epidermal growth factor receptor	Homo sapiens	243-247
22182581-1	2012	A series of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidine derivatives were elaborately designed based on the skeleton of Lapatinib, and evaluated for their potential to inhibit epidermal growth factor receptor (EGFR) and ErbB-2 tyrosine kinase activities and antiproliferative activities against A431 and SKOV-3 cell lines.	Lapatinib	153-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	253-259
21956210-2	2012	Presently, two HER2-targeted therapies are approved by the Food and Drug Administration for treatment of HER2-positive breast cancer: the HER2-targeted humanized monoclonal antibody trastuzumab and the small-molecule tyrosine kinase inhibitor lapatinib.	Lapatinib	243-252	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
22438669-5	2012	Lapatinib is an oral, small molecule tyrosine kinase inhibitor, that inhibits both the HER1 ahd HER2 receptors and may be able to overcome trastuzumab resistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
22204331-3	2012	The success of three EGFR inhibitors (Gefitnib, Erlotinib, Lapatinib) suggests that 4-anilinoquinazoline scaffold is still worth developing in the future.	Lapatinib	59-68	epidermal growth factor receptor	Homo sapiens	21-25
22471661-2	2012	Two approved therapies targeting HER2, the monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib, are clinically active against this type of breast cancer.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
22864381-0	2012	The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-89
22536237-4	2012	These data suggest that in over expressing HER2 metastatic breast cancer patients, sequential trastuzumab based chemotherapeutic regimens can achieve good response rate with prolonged TTP in responding patients, even after other target therapy such as lapatinib based combinations.	Lapatinib	252-261	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
23095788-5	2012	Trastuzumab and lapatinib target the HER2 receptor and are approved drugs for the treatment of metastatic breast cancer.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
22649737-2	2012	While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer, intrinsic and secondary resistance pose a significant challenge, underscoring the need to develop novel anti-HER2 therapies.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
22649737-2	2012	While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer, intrinsic and secondary resistance pose a significant challenge, underscoring the need to develop novel anti-HER2 therapies.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
22864381-3	2012	A network-based computational analysis of global gene expression data from matched sensitive and acquired drug-resistant cells to lapatinib, an EGFR/ErbB2 inhibitor, revealed an increased expression of the glucose deprivation response network, including glucagon signaling, glucose uptake, gluconeogenesis and unfolded protein response in the resistant cells.	Lapatinib	130-139	epidermal growth factor receptor	Homo sapiens	144-148
22864381-3	2012	A network-based computational analysis of global gene expression data from matched sensitive and acquired drug-resistant cells to lapatinib, an EGFR/ErbB2 inhibitor, revealed an increased expression of the glucose deprivation response network, including glucagon signaling, glucose uptake, gluconeogenesis and unfolded protein response in the resistant cells.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-154
23006498-5	2012	Endpoints included determination of toxicity, maximum tolerated dose, and analysis of the effect of lapatinib with or without radiation on EGFR and HER2 signaling pathways by immunohistochemistry.	Lapatinib	100-109	epidermal growth factor receptor	Homo sapiens	139-143
22477724-1	2012	Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human epidermal growth factor receptor (HER)-2 that exerts its action by competitive binding to the intracellular ATP-binding site of the receptor.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	91-123
22477724-1	2012	Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human epidermal growth factor receptor (HER)-2 that exerts its action by competitive binding to the intracellular ATP-binding site of the receptor.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-174
23006498-5	2012	Endpoints included determination of toxicity, maximum tolerated dose, and analysis of the effect of lapatinib with or without radiation on EGFR and HER2 signaling pathways by immunohistochemistry.	Lapatinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
23006498-10	2012	Total Her2 was relatively unchanged while phospho-Her2, phospho-Akt, and phospho-ERK showed variable responses to both lapatinib alone and dual therapy with lapatinib and radiation.	Lapatinib	119-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
23071597-2	2012	In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively.	Lapatinib	149-158	epidermal growth factor receptor	Homo sapiens	119-123
22433475-2	2012	Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	33-65
22433475-2	2012	Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	67-71
22433475-2	2012	Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-85
23071597-5	2012	Interestingly, lapatinib also increases cytosolic BRCA1 and EGFR, away from their nuclear DNA repair substrates.	Lapatinib	15-24	epidermal growth factor receptor	Homo sapiens	60-64
23207619-0	2012	Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-106
23071597-2	2012	In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively.	Lapatinib	149-158	poly(ADP-ribose) polymerase 1	Homo sapiens	128-132
23071597-4	2012	Further dissection of the mechanism reveals that EGFR and BRCA1 can be found in the same protein complex, which is reduced by lapatinib.	Lapatinib	126-135	epidermal growth factor receptor	Homo sapiens	49-53
23071597-4	2012	Further dissection of the mechanism reveals that EGFR and BRCA1 can be found in the same protein complex, which is reduced by lapatinib.	Lapatinib	126-135	BRCA1 DNA repair associated	Homo sapiens	58-63
23071597-5	2012	Interestingly, lapatinib also increases cytosolic BRCA1 and EGFR, away from their nuclear DNA repair substrates.	Lapatinib	15-24	BRCA1 DNA repair associated	Homo sapiens	50-55
22848366-0	2012	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
22912742-11	2012	The dependence of this hypertrophic phenotype on ErbB family signaling is confirmed by reduction in heart mass and cardiomyocyte size, and inactivation of pro-hypertrophic signaling in transgenic animals treated with the ErbB1/2 inhibitor, lapatinib.	Lapatinib	240-249	epidermal growth factor receptor	Mus musculus	49-53
22848366-0	2012	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 3	Homo sapiens	33-37
22848366-0	2012	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
22848366-1	2012	BACKGROUND: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
22848366-2	2012	We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine.	Lapatinib	123-132	erb-b2 receptor tyrosine kinase 3	Homo sapiens	89-93
22003817-1	2011	Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer.	Lapatinib	195-204	epidermal growth factor receptor	Homo sapiens	25-57
22761868-8	2012	Moreover, inhibition of both EGFR and HER2 by lapatinib or of src by SSKI-606, PP2, or dasatinib, blocked the sTbetaRII-mediated antagonism of colony formation in T3M4 cells.	Lapatinib	46-55	epidermal growth factor receptor	Homo sapiens	29-33
22761868-8	2012	Moreover, inhibition of both EGFR and HER2 by lapatinib or of src by SSKI-606, PP2, or dasatinib, blocked the sTbetaRII-mediated antagonism of colony formation in T3M4 cells.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
22236672-3	2012	Recently, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) (gefitinib and erlotinib) or human epidermal growth factor receptor 2 (HER2) (lapatinib) have a promising activity to brain metastasis of lung cancer with activating EGFR mutations or breast cancer with HER2 over expression.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-156
22236672-3	2012	Recently, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) (gefitinib and erlotinib) or human epidermal growth factor receptor 2 (HER2) (lapatinib) have a promising activity to brain metastasis of lung cancer with activating EGFR mutations or breast cancer with HER2 over expression.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
22236672-3	2012	Recently, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) (gefitinib and erlotinib) or human epidermal growth factor receptor 2 (HER2) (lapatinib) have a promising activity to brain metastasis of lung cancer with activating EGFR mutations or breast cancer with HER2 over expression.	Lapatinib	165-174	epidermal growth factor receptor	Homo sapiens	253-257
22236672-3	2012	Recently, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) (gefitinib and erlotinib) or human epidermal growth factor receptor 2 (HER2) (lapatinib) have a promising activity to brain metastasis of lung cancer with activating EGFR mutations or breast cancer with HER2 over expression.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	290-294
22815900-7	2012	In the erlotinib-resistant cells from PC9, constitutive PI3K/Akt activation was effectively inhibited by lapatinib (a dual TKI of EGFR and HER2) or BIBW2992 (pan-TKI of EGFR family proteins).	Lapatinib	105-114	proprotein convertase subtilisin/kexin type 9	Homo sapiens	38-41
22815900-7	2012	In the erlotinib-resistant cells from PC9, constitutive PI3K/Akt activation was effectively inhibited by lapatinib (a dual TKI of EGFR and HER2) or BIBW2992 (pan-TKI of EGFR family proteins).	Lapatinib	105-114	AKT serine/threonine kinase 1	Homo sapiens	61-64
22815900-7	2012	In the erlotinib-resistant cells from PC9, constitutive PI3K/Akt activation was effectively inhibited by lapatinib (a dual TKI of EGFR and HER2) or BIBW2992 (pan-TKI of EGFR family proteins).	Lapatinib	105-114	epidermal growth factor receptor	Homo sapiens	130-134
22815900-7	2012	In the erlotinib-resistant cells from PC9, constitutive PI3K/Akt activation was effectively inhibited by lapatinib (a dual TKI of EGFR and HER2) or BIBW2992 (pan-TKI of EGFR family proteins).	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
22815900-7	2012	In the erlotinib-resistant cells from PC9, constitutive PI3K/Akt activation was effectively inhibited by lapatinib (a dual TKI of EGFR and HER2) or BIBW2992 (pan-TKI of EGFR family proteins).	Lapatinib	105-114	epidermal growth factor receptor	Homo sapiens	169-173
22690483-9	2012	Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2 is approved with capecitabine in trastuzumab resistant patients and in combination with letrozole in first line.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	47-51
22690483-9	2012	Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2 is approved with capecitabine in trastuzumab resistant patients and in combination with letrozole in first line.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
22495699-0	2012	Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50
22495699-1	2012	AIMS AND BACKGROUND: Lapatinib in combination with capecitabine is feasible in patients with HER2-positive metastatic breast cancer pretreated with anthracyclines, taxanes and trastuzumab, but inferior results were reported in the global lapatinib expanded access program in comparison with the phase III registration trial.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
22495718-1	2012	AIMS AND BACKGROUND: Lapatinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptors 1 (EGFR/HER1) and 2 (HER2) used in the treatment of patients with HER2-positive breast cancer.	Lapatinib	21-30	epidermal growth factor receptor	Homo sapiens	109-113
22495718-1	2012	AIMS AND BACKGROUND: Lapatinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptors 1 (EGFR/HER1) and 2 (HER2) used in the treatment of patients with HER2-positive breast cancer.	Lapatinib	21-30	epidermal growth factor receptor	Homo sapiens	114-118
22495718-1	2012	AIMS AND BACKGROUND: Lapatinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptors 1 (EGFR/HER1) and 2 (HER2) used in the treatment of patients with HER2-positive breast cancer.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
22419895-10	2011	Novel Her2-targeted agents such as lapatinib and pertuzumab are currently under investigation in several clinical trials, while the role of bevacizumab, a monoclonal antibody inhibiting angiogenesis, awaits future clarification.	Lapatinib	35-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
22014215-11	2011	In addition, Zt/c9-Dox-IL in combination with small molecule inhibitors lapatinib, sunitinib, or dasatinib further reduced the viability of CSCs(+24/44/ESA).	Lapatinib	72-81	paraoxonase 1	Homo sapiens	140-156
21406472-1	2011	BACKGROUND: Progression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label study of women with human epidermal growth factor receptor 2 positive metastatic breast cancer who had documented progression on at least one T-containing regimen in the metastatic setting.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	196-230
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	72-104
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	106-110
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-156
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-168
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	23-31	epidermal growth factor receptor	Homo sapiens	72-104
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	23-31	epidermal growth factor receptor	Homo sapiens	106-110
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	23-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-156
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	23-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
21415234-1	2011	BACKGROUND: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets.	Lapatinib	23-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-168
21330148-7	2011	Better understanding of pathophysiology has paved the way for the introduction of newer anti-ErbB2 agents such as lapatinib, pertuzumab, T-DM1 and neratinib.	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-98
20571878-4	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) against both EGFR and HER-2, has been known to exert potent antitumor activity against several cancer models.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	63-67
21273092-2	2011	HER-2/neu predicts the sensitivity of breast tumors to trastuzumab and lapatinib.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-9
25786362-3	2011	Since lapatinib interacts with and inhibits P-gp activity, our objective was to determine whether the combination therapy of these two drugs can synergistically treat resistant prostate cancer.	Lapatinib	6-15	phosphoglycolate phosphatase	Mus musculus	44-48
21327450-0	2011	Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.	Lapatinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
21327450-0	2011	Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.	Lapatinib	24-33	epidermal growth factor receptor	Homo sapiens	94-98
21327450-8	2011	Immunohistochemical staining of the lapatinib-sensitive metastatic skin tumor showed it to be HER2(2+), FISH(-)/HER1(-).	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
21327450-8	2011	Immunohistochemical staining of the lapatinib-sensitive metastatic skin tumor showed it to be HER2(2+), FISH(-)/HER1(-).	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	112-116
21327450-9	2011	This result suggested that the lapatinib-sensitive lesions in the brain and meninges were also HER2-positive.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
21327450-11	2011	Here, we report the first case in which lapatinib has been used to effectively treat meningitis carcinomatosa in HER2(-)/HER1(-) relapsed breast cancer.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
21327450-11	2011	Here, we report the first case in which lapatinib has been used to effectively treat meningitis carcinomatosa in HER2(-)/HER1(-) relapsed breast cancer.	Lapatinib	40-49	epidermal growth factor receptor	Homo sapiens	121-125
25786362-5	2011	Lapatinib inhibited P-gp function but not its expression.	Lapatinib	0-9	phosphoglycolate phosphatase	Mus musculus	20-24
20571878-11	2011	Furthermore, our data demonstrated for the first time that lapatinib harbored potent anoikis-sensitization activity (i.e. sensitizing cancer cells to detachment-induced apoptosis) in human cancer cells overexpressing both EGFR and HER-2 (HK1-LMP1 and HK1).	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	231-236
20571878-11	2011	Furthermore, our data demonstrated for the first time that lapatinib harbored potent anoikis-sensitization activity (i.e. sensitizing cancer cells to detachment-induced apoptosis) in human cancer cells overexpressing both EGFR and HER-2 (HK1-LMP1 and HK1).	Lapatinib	59-68	hexokinase 1	Homo sapiens	238-241
20571878-4	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) against both EGFR and HER-2, has been known to exert potent antitumor activity against several cancer models.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
20571878-11	2011	Furthermore, our data demonstrated for the first time that lapatinib harbored potent anoikis-sensitization activity (i.e. sensitizing cancer cells to detachment-induced apoptosis) in human cancer cells overexpressing both EGFR and HER-2 (HK1-LMP1 and HK1).	Lapatinib	59-68	PDZ and LIM domain 7	Homo sapiens	242-246
20571878-6	2011	Using in vitro models of NPC, we demonstrated that lapatinib was able to efficiently inhibit the phosphorylation of both EGFR and HER-2.	Lapatinib	51-60	epidermal growth factor receptor	Homo sapiens	121-125
20571878-11	2011	Furthermore, our data demonstrated for the first time that lapatinib harbored potent anoikis-sensitization activity (i.e. sensitizing cancer cells to detachment-induced apoptosis) in human cancer cells overexpressing both EGFR and HER-2 (HK1-LMP1 and HK1).	Lapatinib	59-68	hexokinase 1	Homo sapiens	251-254
20571878-6	2011	Using in vitro models of NPC, we demonstrated that lapatinib was able to efficiently inhibit the phosphorylation of both EGFR and HER-2.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-135
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	hexokinase 1	Homo sapiens	44-47
20607587-0	2011	Modulation of P-gp expression by lapatinib.	Lapatinib	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	PDZ and LIM domain 7	Homo sapiens	48-52
20607587-4	2011	We examined the impact of co-incubation of chemotherapy drugs in combination with lapatinib in P-gp over-expressing drug resistant cells.	Lapatinib	82-91	ATP binding cassette subfamily B member 1	Homo sapiens	95-99
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	epidermal growth factor receptor	Homo sapiens	119-123
20607587-5	2011	Unexpectedly, lapatinib treatment, at clinically relevant concentrations, increased levels of the P-gp drug transporter in a dose- and time-responsive manner.	Lapatinib	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
20607587-7	2011	Despite the lapatinib-induced alteration in P-gp expression, use of accumulation, efflux and toxicity assays demonstrated that the induced alteration in P-gp expression by lapatinib had little direct impact on drug resistance.	Lapatinib	12-21	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
20607587-7	2011	Despite the lapatinib-induced alteration in P-gp expression, use of accumulation, efflux and toxicity assays demonstrated that the induced alteration in P-gp expression by lapatinib had little direct impact on drug resistance.	Lapatinib	172-181	ATP binding cassette subfamily B member 1	Homo sapiens	153-157
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-133
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	collagen type XI alpha 2 chain	Homo sapiens	212-216
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	caspase 3	Homo sapiens	227-236
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	340-345
20571878-8	2011	For the most lapatinib-sensitive cell line (HK1-LMP1, with IC(50) ~ 600 nM), which harbored the highest levels of both EGFR and HER-2, inhibition of cell growth was associated G(0)/G(1) cell cycle arrest, marked PARP cleavage, caspase-3 cleavage, as well as significant downregulation of several important survival proteins (e.g. survivin, Mcl-1 and cyclin D1).	Lapatinib	13-22	cyclin D1	Homo sapiens	350-359
20571878-10	2011	We found that lapatinib was able to inhibit cellular invasion of both HK1-LMP1 and HONE-1 cells.	Lapatinib	14-23	hexokinase 1	Homo sapiens	70-73
20571878-10	2011	We found that lapatinib was able to inhibit cellular invasion of both HK1-LMP1 and HONE-1 cells.	Lapatinib	14-23	PDZ and LIM domain 7	Homo sapiens	74-78
20571878-11	2011	Furthermore, our data demonstrated for the first time that lapatinib harbored potent anoikis-sensitization activity (i.e. sensitizing cancer cells to detachment-induced apoptosis) in human cancer cells overexpressing both EGFR and HER-2 (HK1-LMP1 and HK1).	Lapatinib	59-68	epidermal growth factor receptor	Homo sapiens	222-226
21706359-4	2011	This study evaluated the toxicity and efficacy of lapatinib in combination with chemotherapy among patients with HER2-positive, progressive brain metastases.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
22101934-4	2011	Here we show, using purified, near full-length human EGFR proteins (tEGFRs), that two oncogenic mutants are fully active independently of EGF and highly resistant to the therapeutic and endogenous inhibitors cetuximab, lapatinib and MIG6.	Lapatinib	219-228	epidermal growth factor receptor	Homo sapiens	53-57
22124364-3	2011	Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
22124364-3	2011	Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
21955398-4	2011	EGFR inhibition by the small molecule inhibitors lapatinib, gefitinib, and erlotinib as well as siRNA led to strong reduction of viability in high but not low expressing lines, confirming EGFR as a drug target in 10-20% of HNSCC cell lines.	Lapatinib	49-58	epidermal growth factor receptor	Homo sapiens	0-4
21955398-4	2011	EGFR inhibition by the small molecule inhibitors lapatinib, gefitinib, and erlotinib as well as siRNA led to strong reduction of viability in high but not low expressing lines, confirming EGFR as a drug target in 10-20% of HNSCC cell lines.	Lapatinib	49-58	epidermal growth factor receptor	Homo sapiens	188-192
21945930-0	2011	Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.	Lapatinib	40-49	CUB domain containing protein 1	Homo sapiens	84-89
21207425-6	2011	Lapatinib inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification positive ESCC cell line.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
21207425-7	2011	Lapatinib also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of HER2 and EGFR in ESCC cell lines.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
21207425-7	2011	Lapatinib also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of HER2 and EGFR in ESCC cell lines.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	111-115
21207425-10	2011	Cumulatively, the data indicate that Lapatinib has activity in EGFR- and/or HER2-expressing ESCC cells, and the combination therapy of Lapatinib and Cetuximab/Herceptin is a promising strategy in ESCC.	Lapatinib	37-46	epidermal growth factor receptor	Homo sapiens	63-67
21207425-10	2011	Cumulatively, the data indicate that Lapatinib has activity in EGFR- and/or HER2-expressing ESCC cells, and the combination therapy of Lapatinib and Cetuximab/Herceptin is a promising strategy in ESCC.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
21153051-0	2011	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
21153051-0	2011	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
21153051-3	2011	Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show significant antitumor activity, indicating that HER2 can be still exploited as a target after trastuzumab failure.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
21153051-3	2011	Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show significant antitumor activity, indicating that HER2 can be still exploited as a target after trastuzumab failure.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
21153051-6	2011	We characterized two human HER2 overexpressing breast cancer cell lines resistant to trastuzumab and lapatinib (T100 and JIMT-1) from a molecular and biological point of view.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
21456017-0	2011	Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.	Lapatinib	188-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-40
21456017-0	2011	Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.	Lapatinib	188-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
21456017-0	2011	Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.	Lapatinib	188-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
21456017-3	2011	METHODS: The EGF20009 study investigated lapatinib monotherapy in 138 HER2-positive patients with MBC previously untreated for their metastatic disease.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
21456017-11	2011	CONCLUSION: Significant decreases in serum HER2 levels during the first 16 weeks of lapatinib monotherapy were associated with better clinical outcome (longer PFS and increased ORR) in HER2-positive MBC patients.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
21456017-11	2011	CONCLUSION: Significant decreases in serum HER2 levels during the first 16 weeks of lapatinib monotherapy were associated with better clinical outcome (longer PFS and increased ORR) in HER2-positive MBC patients.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
22127113-4	2011	Thus intense efforts have been made to inhibit the activity of EGFR by designing antibodies against the ligand binding domains (cetuximab and panitumumab) or small molecules against the tyrosine kinase domain (erlotinib, gefitinib, and lapatinib).	Lapatinib	236-245	epidermal growth factor receptor	Homo sapiens	63-67
21967344-8	2011	The activity of lapatinib, an active agent in advanced HER2-positive breast cancer, is now being tested in HER2-overexpressing esophageal and gastric adenocarcinomas.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
21967344-8	2011	The activity of lapatinib, an active agent in advanced HER2-positive breast cancer, is now being tested in HER2-overexpressing esophageal and gastric adenocarcinomas.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
22202238-6	2011	Furthermore, the combination therapy of Herceptin and lapatinib is a new promising strategy for HER2 positive ESCC patients (29.4%).	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
24367183-0	2011	Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.	Lapatinib	39-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
24367183-0	2011	Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
24367183-4	2011	Lapatinib is a tyrosine kinase inhibitor which binds reversibly to the intracellular domains of the epidermal growth factor receptor and HER2, interfering with their ability to initiate signal transduction cascades that promote cancer cell proliferation, survival, and metastasis.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	100-132
24367183-4	2011	Lapatinib is a tyrosine kinase inhibitor which binds reversibly to the intracellular domains of the epidermal growth factor receptor and HER2, interfering with their ability to initiate signal transduction cascades that promote cancer cell proliferation, survival, and metastasis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
24367183-5	2011	In a recently published randomized, placebo-controlled Phase III study in postmenopausal HR+ metastatic breast cancer, the addition of lapatinib to the aromatase inhibitor letrozole significantly improved progression-free survival solely in women who were also HER2+.	Lapatinib	135-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	261-265
21207425-0	2011	Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	117-121
21207425-0	2011	Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
21207425-1	2011	Lapatinib is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	53-57
21207425-1	2011	Lapatinib is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
21207425-4	2011	EGFR and HER2 expression by the cell lines was established, and the effects of Lapatinib on inhibition of the phosphorylation of HER2, antiproliferative effect, apoptosis-inducing activity and accumulation of HER2 and EGFR on cell surface were evaluated.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
21207425-4	2011	EGFR and HER2 expression by the cell lines was established, and the effects of Lapatinib on inhibition of the phosphorylation of HER2, antiproliferative effect, apoptosis-inducing activity and accumulation of HER2 and EGFR on cell surface were evaluated.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
21207425-6	2011	Lapatinib inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification positive ESCC cell line.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
21207425-6	2011	Lapatinib inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification positive ESCC cell line.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
22110198-5	2011	In contrast, EGFR ligand-induced CD44 expression was reduced by EGFR inhibitors, AG1478 and lapatinib, respectively.	Lapatinib	92-101	epidermal growth factor receptor	Homo sapiens	13-17
22110198-5	2011	In contrast, EGFR ligand-induced CD44 expression was reduced by EGFR inhibitors, AG1478 and lapatinib, respectively.	Lapatinib	92-101	CD44 molecule (Indian blood group)	Homo sapiens	33-37
22110198-5	2011	In contrast, EGFR ligand-induced CD44 expression was reduced by EGFR inhibitors, AG1478 and lapatinib, respectively.	Lapatinib	92-101	epidermal growth factor receptor	Homo sapiens	64-68
21153051-13	2011	We provide preclinical evidence that tumor cells resistant to trastuzumab and lapatinib may rely on HER2 independent pathways that can be efficiently inhibited by sorafenib.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
21945930-3	2011	Lapatinib, a tyrosine kinase inhibitor (TKI), is approved for treatment of HER-2/neu overexpressing metastatic breast cancer and functions by preventing autophosphorylation following HER-2/neu receptor activation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-80
21945930-3	2011	Lapatinib, a tyrosine kinase inhibitor (TKI), is approved for treatment of HER-2/neu overexpressing metastatic breast cancer and functions by preventing autophosphorylation following HER-2/neu receptor activation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	183-188
21945930-5	2011	Moreover, studies were performed to examine if lapatinib provided any beneficial effect on HER-2/neu((+)/-)/CDCP1(+) breast cancer cell lines.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-96
21945930-5	2011	Moreover, studies were performed to examine if lapatinib provided any beneficial effect on HER-2/neu((+)/-)/CDCP1(+) breast cancer cell lines.	Lapatinib	47-56	CUB domain containing protein 1	Homo sapiens	108-113
21945930-7	2011	However, only HER-2/neu(+), but not HER-2/neu((+)/-) cells showed decreased proliferation and invasion and an enhanced level of apoptosis towards loss of anchorage when treated with lapatinib.	Lapatinib	182-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-19
21499296-1	2011	Despite the initial effectiveness of the tyrosine kinase inhibitor lapatinib against HER2 gene-amplified breast cancers, most patients eventually relapse after treatment, implying that tumors acquire mechanisms of drug resistance.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
21499296-2	2011	To discover these mechanisms, we generated six lapatinib-resistant HER2-overexpressing human breast cancer cell lines.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
21499296-3	2011	In cells that grew in the presence of lapatinib, HER2 autophosphorylation was undetectable, whereas active phosphoinositide-3 kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK) were maintained.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-53
21499296-6	2011	Treatment of these resistant cells with Src kinase inhibitors partially blocked PI3K-Akt signaling and restored lapatinib sensitivity.	Lapatinib	112-121	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	40-43
21499296-7	2011	Further, SFK mRNA expression was upregulated in primary HER2+ tumors treated with lapatinib.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
21499296-8	2011	Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Mus musculus	153-157
21499296-9	2011	These data suggest that increased Src kinase activity is a mechanism of lapatinib resistance and support the combination of HER2 antagonists with Src inhibitors early in the treatment of HER2+ breast cancers in order to prevent or overcome resistance to HER2 inhibitors.	Lapatinib	72-81	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	34-37
21868551-0	2011	Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
22015286-5	2011	Anti-HER2 therapy including both trastuzumab and lapatinib alone has established clinical efficacy in metastatic disease, with response rates of up to 35% and with some long term remissions.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
22015286-6	2011	Combination anti-HER2 therapy with trastuzumab/lapatinib and with trastuzumab/pertuzumab have also been shown to have efficacy as second line treatment inpatients after trastuzumab.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21
22015286-7	2011	Trastuzumab and Lapatinib have each been shown to improve time to progression and response rate when given with anastrazole and letrozole respectively as first line treatment for metastatic ER-positive HER2-positive disease.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
22059152-4	2011	In our investigation, studies of GBM cell lines, xenograft models, and GBM clinical samples, including those from patients treated with the EGFR tyrosine kinase inhibitor lapatinib, uncovered an EGFRvIII-activated, PI3K/SREBP-1-dependent tumor survival pathway through the low-density lipoprotein receptor (LDLR).	Lapatinib	171-180	epidermal growth factor receptor	Homo sapiens	140-144
22059152-4	2011	In our investigation, studies of GBM cell lines, xenograft models, and GBM clinical samples, including those from patients treated with the EGFR tyrosine kinase inhibitor lapatinib, uncovered an EGFRvIII-activated, PI3K/SREBP-1-dependent tumor survival pathway through the low-density lipoprotein receptor (LDLR).	Lapatinib	171-180	sterol regulatory element binding transcription factor 1	Homo sapiens	220-227
22059152-4	2011	In our investigation, studies of GBM cell lines, xenograft models, and GBM clinical samples, including those from patients treated with the EGFR tyrosine kinase inhibitor lapatinib, uncovered an EGFRvIII-activated, PI3K/SREBP-1-dependent tumor survival pathway through the low-density lipoprotein receptor (LDLR).	Lapatinib	171-180	low density lipoprotein receptor	Homo sapiens	273-305
22059152-4	2011	In our investigation, studies of GBM cell lines, xenograft models, and GBM clinical samples, including those from patients treated with the EGFR tyrosine kinase inhibitor lapatinib, uncovered an EGFRvIII-activated, PI3K/SREBP-1-dependent tumor survival pathway through the low-density lipoprotein receptor (LDLR).	Lapatinib	171-180	low density lipoprotein receptor	Homo sapiens	307-311
21741829-10	2011	Patients who continued/restarted anti-HER2 treatment (trastuzumab or lapatinib) after 2nd progression (N=52) had a post-progression survival of 18.8 compared with 13.3months for those who did not receive 3rd line treatment with anti-HER2 agents (N=88) (HR 0.63; p=0.02).	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
21847123-3	2011	We also studied if the combination therapy of lapatinib plus GSI can induce tumour regression of ErbB-2-positive breast cancer.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-103
21499301-0	2011	Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
21499301-1	2011	Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	51-83
21499301-1	2011	Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-128
21499301-1	2011	Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
21499301-1	2011	Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
21499301-4	2011	Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification.	Lapatinib	0-9	BCL2 apoptosis regulator	Homo sapiens	90-95
21499301-4	2011	Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification.	Lapatinib	0-9	BCL2 like 11	Homo sapiens	132-135
21499301-4	2011	Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification.	Lapatinib	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	163-166
21499301-4	2011	Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification.	Lapatinib	0-9	EPH receptor B2	Homo sapiens	167-170
21499301-4	2011	Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	217-221
21499301-5	2011	RNA interference (RNAi)-mediated depletion of BIM inhibited lapatinib-induced apoptosis, implicating BIM induction in this process.	Lapatinib	60-69	BCL2 like 11	Homo sapiens	46-49
21499301-6	2011	The pro-apoptotic effect of lapatinib was less pronounced in cells with a PIK3CA mutation than in those without one.	Lapatinib	28-37	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	74-80
21499301-8	2011	Depletion of PIK3CA (a catalytic subunit of PI3K) revealed that survivin expression is regulated by the PI3K pathway in these cells, suggesting that insufficient inhibition of PI3K-survivin signaling is responsible for the limited pro-apoptotic effect of lapatinib in HER2 amplification-positive cells with a PIK3CA mutation.	Lapatinib	255-264	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	13-19
21499301-9	2011	Consistent with this notion, depletion of survivin by RNAi or treatment with a PI3K inhibitor markedly increased the level of apoptosis in PIK3CA mutant cells treated with lapatinib.	Lapatinib	172-181	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	139-145
21907925-2	2011	Here, we show that BIKDD, a constitutively active mutant form of proapoptotic gene, BIK, effectively induces apoptosis of breast cancer cells and synergizes with lapatinib.	Lapatinib	162-171	BCL2 interacting killer	Homo sapiens	19-22
21868551-1	2011	BACKGROUND: Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	200-204
21868551-1	2011	BACKGROUND: Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Lapatinib	145-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	200-204
21868551-3	2011	RESULTS: In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-53
21868551-5	2011	CONCLUSION: Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
21929348-2	2011	Trastuzumab, a humanized monoclonal antibody and lapatinib, a tyrosine kinase inhibitor, are drugs that target HER2, which is highly expressed in 20-30% of breast cancers.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
22162984-3	2011	To this end, up-regulation of anti-apoptotic proteins has been associated with resistance to the HER2-targeted drug lapatinib, but has not yet been linked to Herceptin resistance.	Lapatinib	116-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
21786419-14	2011	Apparently, multiple anti-EGFR/Her2 targeting by using Trastuzumab, Pertuzumab, and Lapatinib more efficiently affects receptor function (interaction and activation) and consequently enhances their antiproliferative capacity.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	26-30
21786419-14	2011	Apparently, multiple anti-EGFR/Her2 targeting by using Trastuzumab, Pertuzumab, and Lapatinib more efficiently affects receptor function (interaction and activation) and consequently enhances their antiproliferative capacity.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
21829197-1	2011	BACKGROUND: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	45-77
21674127-3	2011	In this study, we describe a novel compound (NRC-AN-019), which has better antitumor activity than Lapatinib.	Lapatinib	99-108	nuclear receptor coactivator 6	Homo sapiens	45-48
21674127-7	2011	From our animal studies using SCID mice implanted with BT474 cells, we observed dose-dependent inhibition of tumor growth in NRC-AN-019-treated animals compared to controls or Lapatinib-treated mice at comparable concentrations.	Lapatinib	176-185	nuclear receptor coactivator 6	Homo sapiens	125-128
21884573-0	2011	beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.	Lapatinib	92-101	integrin subunit beta 1	Homo sapiens	0-14
21884573-1	2011	INTRODUCTION: The overexpression of human epidermal growth factor receptor (HER)-2 in 20% of human breast cancers and its association with aggressive growth has led to widespread use of HER2-targeted therapies, such as trastuzumab (T) and lapatinib (L).	Lapatinib	239-248	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-82
21884573-1	2011	INTRODUCTION: The overexpression of human epidermal growth factor receptor (HER)-2 in 20% of human breast cancers and its association with aggressive growth has led to widespread use of HER2-targeted therapies, such as trastuzumab (T) and lapatinib (L).	Lapatinib	239-248	erb-b2 receptor tyrosine kinase 2	Homo sapiens	186-190
21829197-1	2011	BACKGROUND: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	79-83
21829197-1	2011	BACKGROUND: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	95-99
21829197-1	2011	BACKGROUND: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108
21829197-8	2011	In the lapatinib single-agent responders, all had EGFR overexpression, 50% had EGFR amplification, and 50% had HER2 expression by immunohistochemistry (including one patient with HER2 amplification).	Lapatinib	7-16	epidermal growth factor receptor	Homo sapiens	50-54
21829197-8	2011	In the lapatinib single-agent responders, all had EGFR overexpression, 50% had EGFR amplification, and 50% had HER2 expression by immunohistochemistry (including one patient with HER2 amplification).	Lapatinib	7-16	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
21840482-1	2011	HER2 kinase inhibitors, such as lapatinib, have demonstrated clinical efficacy in HER2-amplified breast cancers.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
21840482-1	2011	HER2 kinase inhibitors, such as lapatinib, have demonstrated clinical efficacy in HER2-amplified breast cancers.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
21840482-3	2011	These cells were found to depend on a neuregulin-1 (NRG1)-mediated autocrine loop driving HER3 activation, which can be disrupted by lapatinib.	Lapatinib	133-142	neuregulin 1	Homo sapiens	52-56
21840482-4	2011	Elevated NRG1 expression and activated HER3 are strongly associated with lapatinib sensitivity in vitro, and these biomarkers were enriched in a subset of primary head and neck cancer samples.	Lapatinib	73-82	neuregulin 1	Homo sapiens	9-13
21840482-4	2011	Elevated NRG1 expression and activated HER3 are strongly associated with lapatinib sensitivity in vitro, and these biomarkers were enriched in a subset of primary head and neck cancer samples.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 3	Homo sapiens	39-43
21840482-3	2011	These cells were found to depend on a neuregulin-1 (NRG1)-mediated autocrine loop driving HER3 activation, which can be disrupted by lapatinib.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 3	Homo sapiens	90-94
21685235-1	2011	Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models.	Lapatinib	99-108	epidermal growth factor receptor	Mus musculus	5-37
21685235-1	2011	Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models.	Lapatinib	99-108	epidermal growth factor receptor	Mus musculus	39-43
21685235-1	2011	Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Mus musculus	49-53
21685235-1	2011	Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models.	Lapatinib	99-108	estrogen receptor 1 (alpha)	Mus musculus	187-204
21791570-2	2011	Lapatinib is a small molecule dual RTK inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	62-94
21816844-5	2011	Clinical trials include a recent placebo-controlled phase IIb presurgical trial of the dual EGFR HER2 inhibitor lapatinib that suppressed growth of breast premalignancy [including atypical ductal hyperplasia (ADH) and DCIS] and invasive cancer in patients with early-stage, HER2-overexpressing or -amplified breast cancer.	Lapatinib	112-121	epidermal growth factor receptor	Homo sapiens	92-96
21816844-5	2011	Clinical trials include a recent placebo-controlled phase IIb presurgical trial of the dual EGFR HER2 inhibitor lapatinib that suppressed growth of breast premalignancy [including atypical ductal hyperplasia (ADH) and DCIS] and invasive cancer in patients with early-stage, HER2-overexpressing or -amplified breast cancer.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Mus musculus	97-101
21685235-1	2011	Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models.	Lapatinib	99-108	estrogen receptor 1 (alpha)	Mus musculus	50-52
21816844-5	2011	Clinical trials include a recent placebo-controlled phase IIb presurgical trial of the dual EGFR HER2 inhibitor lapatinib that suppressed growth of breast premalignancy [including atypical ductal hyperplasia (ADH) and DCIS] and invasive cancer in patients with early-stage, HER2-overexpressing or -amplified breast cancer.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	274-278
21791570-2	2011	Lapatinib is a small molecule dual RTK inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	96-100
21791570-2	2011	Lapatinib is a small molecule dual RTK inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-146
21816844-6	2011	These results suggest that lapatinib can clinically suppress the progression of ADH and DCIS to invasive breast cancer, an effect previously observed in a mouse model of HER2-overexpressing, ER-negative mammary cancer.	Lapatinib	27-36	erb-b2 receptor tyrosine kinase 2	Mus musculus	170-174
21685235-1	2011	Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Mus musculus	143-147
21791570-2	2011	Lapatinib is a small molecule dual RTK inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
21791570-9	2011	Lapatinib effectively suppressed the abundance of HER2, phosphorylated HER2 (Tyr1221/1222), and phosphorylated EGFR (Tyr1173, Tyr1110) compared with tumors from untreated rats.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
21685235-6	2011	Compared with placebo, lapatinib reduced Ki-67 significantly more in ER-negative tumors (by 34.8%; P = 0.01) but not significantly more in ER-positive tumors (by 12.3%; P = 0.2) and reduced Ki-67 more (nonsignificantly) in cytosol PTEN-overexpressing tumors (P = 0.057).	Lapatinib	23-32	phosphatase and tensin homolog	Homo sapiens	231-235
21791570-9	2011	Lapatinib effectively suppressed the abundance of HER2, phosphorylated HER2 (Tyr1221/1222), and phosphorylated EGFR (Tyr1173, Tyr1110) compared with tumors from untreated rats.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
21685235-10	2011	In conclusion, short-term lapatinib decreased cell proliferation in DIN, DH, and invasive HER-2-positive (especially ER-negative) breast cancer, thus providing the rationale for further clinical development of lapatinib for breast cancer prevention in high-risk patients, including those with HER-2-positive DIN.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
21791570-9	2011	Lapatinib effectively suppressed the abundance of HER2, phosphorylated HER2 (Tyr1221/1222), and phosphorylated EGFR (Tyr1173, Tyr1110) compared with tumors from untreated rats.	Lapatinib	0-9	epidermal growth factor receptor	Rattus norvegicus	111-115
21685235-10	2011	In conclusion, short-term lapatinib decreased cell proliferation in DIN, DH, and invasive HER-2-positive (especially ER-negative) breast cancer, thus providing the rationale for further clinical development of lapatinib for breast cancer prevention in high-risk patients, including those with HER-2-positive DIN.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	293-298
21791570-11	2011	These results combined with immunoreactivity data indicated that, in addition to EGFR and HER2, lapatinib treatment was associated with changes in a number of other signaling molecules, including IGF-1R, Akt, and downstream targets such as GSK3, p27, p53, and cyclin D1 presumably leading to impaired proliferation, apoptosis, or cell-cycle arrest.	Lapatinib	96-105	AKT serine/threonine kinase 1	Rattus norvegicus	204-207
21791570-11	2011	These results combined with immunoreactivity data indicated that, in addition to EGFR and HER2, lapatinib treatment was associated with changes in a number of other signaling molecules, including IGF-1R, Akt, and downstream targets such as GSK3, p27, p53, and cyclin D1 presumably leading to impaired proliferation, apoptosis, or cell-cycle arrest.	Lapatinib	96-105	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	246-249
21791570-11	2011	These results combined with immunoreactivity data indicated that, in addition to EGFR and HER2, lapatinib treatment was associated with changes in a number of other signaling molecules, including IGF-1R, Akt, and downstream targets such as GSK3, p27, p53, and cyclin D1 presumably leading to impaired proliferation, apoptosis, or cell-cycle arrest.	Lapatinib	96-105	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	251-254
21570197-0	2011	Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
21791570-11	2011	These results combined with immunoreactivity data indicated that, in addition to EGFR and HER2, lapatinib treatment was associated with changes in a number of other signaling molecules, including IGF-1R, Akt, and downstream targets such as GSK3, p27, p53, and cyclin D1 presumably leading to impaired proliferation, apoptosis, or cell-cycle arrest.	Lapatinib	96-105	cyclin D1	Rattus norvegicus	260-269
21570197-2	2011	Lapatinib, an oral, reversible inhibitor of both ErbB2 and EGFR tyrosine kinases, was approved in combination with capecitabine for treating advanced stage ErbB2 positive breast cancers.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-54
21570197-6	2011	According to our preliminary data and related reference, we hypothesized that autophagy could facilitate the ErbB2 positive breast cancer cells to be Lapatinib resistant and promoted the survival of the resistant cells.	Lapatinib	150-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-114
21570197-2	2011	Lapatinib, an oral, reversible inhibitor of both ErbB2 and EGFR tyrosine kinases, was approved in combination with capecitabine for treating advanced stage ErbB2 positive breast cancers.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-161
21690228-6	2011	The combination of EGFR inhibition by using lapatinib and mTOR inhibition with rapamycin resulted in significantly greater cytotoxicity than the single agents alone and these effects were synergistic in vitro.	Lapatinib	44-53	epidermal growth factor receptor	Homo sapiens	19-23
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
21339742-0	2011	Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.	Lapatinib	121-130	BTG anti-proliferation factor 2	Homo sapiens	44-48
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	109-118	nibrin	Homo sapiens	103-106
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-154
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-154
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	210-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	210-219	nibrin	Homo sapiens	103-106
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	210-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-154
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	Lapatinib	210-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-154
21673090-6	2011	Furthermore, the expression of p95L was increased in ErbB2(+) breast cancer models of acquired therapeutic resistance to lapatinib that mimic the clinical setting.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-58
21673090-9	2011	When expressed in the nuclei of lapatinib-sensitive ErbB2(+) breast cancer cells, truncated ErbB2 rendered cells resistant to lapatinib-induced apoptosis.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-57
21673090-9	2011	When expressed in the nuclei of lapatinib-sensitive ErbB2(+) breast cancer cells, truncated ErbB2 rendered cells resistant to lapatinib-induced apoptosis.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-97
21673090-9	2011	When expressed in the nuclei of lapatinib-sensitive ErbB2(+) breast cancer cells, truncated ErbB2 rendered cells resistant to lapatinib-induced apoptosis.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-97
21339742-0	2011	Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	102-106
21339742-6	2011	Suppression of HER activation using the tyrosine kinase inhibitor lapatinib abrogates the effects of BTG2 knockdown, including the increased cell migration observed in vitro and the enhancement of tumorigenesis and metastasis in vivo.	Lapatinib	66-75	BTG anti-proliferation factor 2	Homo sapiens	101-105
20730488-0	2011	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.	Lapatinib	111-120	immunoglobulin heavy diversity 1-7	Homo sapiens	12-15
20730488-0	2011	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.	Lapatinib	111-120	immunoglobulin heavy diversity 1-7	Homo sapiens	19-22
20730488-5	2011	Here we report that T-DM1 retains the mechanisms of action of unconjugated trastuzumab and is active against lapatinib resistant cell lines and tumors.	Lapatinib	109-118	immunoglobulin heavy diversity 1-7	Homo sapiens	22-25
21659924-0	2011	ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.	Lapatinib	49-58	epidermal growth factor receptor	Homo sapiens	0-4
21599629-7	2011	Inhibitors of the epidermal growth factor receptor (EGFR) family, such as erlotinib and lapatinib were recently investigated.	Lapatinib	88-97	epidermal growth factor receptor	Homo sapiens	18-50
21599629-7	2011	Inhibitors of the epidermal growth factor receptor (EGFR) family, such as erlotinib and lapatinib were recently investigated.	Lapatinib	88-97	epidermal growth factor receptor	Homo sapiens	52-56
21514634-3	2011	We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan.	Lapatinib	117-126	epidermal growth factor receptor	Homo sapiens	149-153
21514634-3	2011	We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan.	Lapatinib	117-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	179-183
21514634-3	2011	We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan.	Lapatinib	117-126	ATP binding cassette subfamily B member 1	Homo sapiens	184-187
21514634-15	2011	Disruption of erbB signaling and BCRP/Pgp efflux with lapatinib was insufficient for overcoming topotecan resistance, suggesting alternative mechanisms of resistance are involved.	Lapatinib	54-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	33-37
21514634-15	2011	Disruption of erbB signaling and BCRP/Pgp efflux with lapatinib was insufficient for overcoming topotecan resistance, suggesting alternative mechanisms of resistance are involved.	Lapatinib	54-63	ATP binding cassette subfamily B member 1	Homo sapiens	38-41
22006739-0	2011	Lapatinib in the treatment of HER-2 overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-35
22006739-1	2011	Lapatinib is the only clinically available agent for the treatment of patients with human epidermal growth factor receptor-2 (HER-2) positive tumors that have progressed on treatment with trastuzumab, taxanes and anthracyclines.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-124
22006739-1	2011	Lapatinib is the only clinically available agent for the treatment of patients with human epidermal growth factor receptor-2 (HER-2) positive tumors that have progressed on treatment with trastuzumab, taxanes and anthracyclines.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-131
22006739-3	2011	Recently presented neoadjuvant data suggests an important place for the combination of trastuzumab and lapatinib in the therapy of early HER-2 positive breast cancer.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-142
21659924-6	2011	A robust, dose-dependent inhibition of VS growth and proliferation with the dual EGFR/ErbB2 inhibitor, lapatinib, was demonstrated.	Lapatinib	103-112	epidermal growth factor receptor	Homo sapiens	81-85
21659924-6	2011	A robust, dose-dependent inhibition of VS growth and proliferation with the dual EGFR/ErbB2 inhibitor, lapatinib, was demonstrated.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-91
21659924-10	2011	CONCLUSION: Dual EGFR and ErbB2 inhibition with lapatinib or combination therapy may provide therapeutic benefit in VS treatment, but further studies are necessary.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-31
21553932-1	2011	The 4-anilinoquinazolines (gefitinib, erlotinib and lapatinib) are members of a class of potent and selective inhibitors of the human epidermal growth factor receptor (HER) family of tyrosine kinases that have been developed to treat patients with tumours with defined genetic alterations of the HER tyrosine kinase domain.	Lapatinib	52-61	epidermal growth factor receptor	Homo sapiens	134-166
21676217-2	2011	HER2-related target drugs trastuzumab and lapatinib have been the foundation of treatment of HER2--positive breast cancer.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
21676217-3	2011	This study was designed to explore the relationship between PI3K pathway activation and the sensitivity to lapatinib in HER2--positive metastatic breast cancer patients pretreated with anthracyclins, taxanes and trastuzumab.	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
21676217-12	2011	PI3K pathway activation resulting from PTEN loss or PIK3CA mutations may lead to drug resistance to lapatinib and trastuzumab.	Lapatinib	100-109	phosphatase and tensin homolog	Homo sapiens	39-43
21676217-12	2011	PI3K pathway activation resulting from PTEN loss or PIK3CA mutations may lead to drug resistance to lapatinib and trastuzumab.	Lapatinib	100-109	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	52-58
21653830-4	2011	Tumors from mice treated with a combination of lapatinib and TRAIL exhibited more immunostaining for cleaved caspase-8, a marker of the extrinsic cell death pathway, than did tumors from mice treated with lapatinib or TRAIL alone.	Lapatinib	47-56	caspase 8	Mus musculus	109-118
21653830-4	2011	Tumors from mice treated with a combination of lapatinib and TRAIL exhibited more immunostaining for cleaved caspase-8, a marker of the extrinsic cell death pathway, than did tumors from mice treated with lapatinib or TRAIL alone.	Lapatinib	47-56	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	218-223
21653830-4	2011	Tumors from mice treated with a combination of lapatinib and TRAIL exhibited more immunostaining for cleaved caspase-8, a marker of the extrinsic cell death pathway, than did tumors from mice treated with lapatinib or TRAIL alone.	Lapatinib	205-214	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	61-66
21653830-6	2011	Lapatinib up-regulated the proapoptotic TRAIL death receptors DR4 and DR5, leading to more efficient induction of apoptosis in the presence of TRAIL receptor agonists.	Lapatinib	0-9	TNF superfamily member 10	Homo sapiens	40-45
21653830-6	2011	Lapatinib up-regulated the proapoptotic TRAIL death receptors DR4 and DR5, leading to more efficient induction of apoptosis in the presence of TRAIL receptor agonists.	Lapatinib	0-9	TNF receptor superfamily member 10a	Homo sapiens	62-65
21653830-6	2011	Lapatinib up-regulated the proapoptotic TRAIL death receptors DR4 and DR5, leading to more efficient induction of apoptosis in the presence of TRAIL receptor agonists.	Lapatinib	0-9	TNF receptor superfamily member 10b	Homo sapiens	70-73
21653830-6	2011	Lapatinib up-regulated the proapoptotic TRAIL death receptors DR4 and DR5, leading to more efficient induction of apoptosis in the presence of TRAIL receptor agonists.	Lapatinib	0-9	TNF superfamily member 10	Homo sapiens	143-148
21653830-8	2011	The off-target induction of DR5 by lapatinib resulted from activation of the c-Jun amino-terminal kinase (JNK)/c-Jun signaling axis.	Lapatinib	35-44	TNF receptor superfamily member 10b	Homo sapiens	28-31
21653830-8	2011	The off-target induction of DR5 by lapatinib resulted from activation of the c-Jun amino-terminal kinase (JNK)/c-Jun signaling axis.	Lapatinib	35-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	77-82
21653830-8	2011	The off-target induction of DR5 by lapatinib resulted from activation of the c-Jun amino-terminal kinase (JNK)/c-Jun signaling axis.	Lapatinib	35-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	111-116
21653830-9	2011	This activity of lapatinib on TRAIL death receptor expression and signaling may confer therapeutic benefit when increased doses of lapatinib are used in combination with TRAIL receptor-activating agents.	Lapatinib	17-26	TNF superfamily member 10	Homo sapiens	30-35
21653830-9	2011	This activity of lapatinib on TRAIL death receptor expression and signaling may confer therapeutic benefit when increased doses of lapatinib are used in combination with TRAIL receptor-activating agents.	Lapatinib	17-26	TNF superfamily member 10	Homo sapiens	170-175
21653830-9	2011	This activity of lapatinib on TRAIL death receptor expression and signaling may confer therapeutic benefit when increased doses of lapatinib are used in combination with TRAIL receptor-activating agents.	Lapatinib	131-140	TNF superfamily member 10	Homo sapiens	30-35
21482676-2	2011	In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 2	Mus musculus	96-101
21482676-2	2011	In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 3	Mus musculus	164-169
21482676-2	2011	In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth.	Lapatinib	128-137	thymoma viral proto-oncogene 1	Mus musculus	174-177
21482676-3	2011	In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib.	Lapatinib	172-181	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	8-37
21482676-3	2011	In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib.	Lapatinib	172-181	erb-b2 receptor tyrosine kinase 2	Mus musculus	68-73
20684884-3	2011	To date, trastuzumab and lapatinib are the two anti-HER2 targeted therapies commonly used, demonstrating therapeutic effects.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
21439954-6	2011	Other small-molecule EGFR tyrosine kinase inhibitors employed in the clinic, such as gefitinib, erlotinib and lapatinib, were able to abrogate proliferation of glioblastoma cell lines, which underwent a G(1) arrest.	Lapatinib	110-119	epidermal growth factor receptor	Homo sapiens	21-25
21653830-0	2011	Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.	Lapatinib	11-20	TNF superfamily member 10	Homo sapiens	68-73
21653830-1	2011	Lapatinib, a dual HER2/EGFR (human epidermal growth factor receptor 2/epidermal growth factor receptor) inhibitor, is a recently approved targeted therapy for metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-22
21653830-1	2011	Lapatinib, a dual HER2/EGFR (human epidermal growth factor receptor 2/epidermal growth factor receptor) inhibitor, is a recently approved targeted therapy for metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	23-27
21653830-1	2011	Lapatinib, a dual HER2/EGFR (human epidermal growth factor receptor 2/epidermal growth factor receptor) inhibitor, is a recently approved targeted therapy for metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-69
21653830-1	2011	Lapatinib, a dual HER2/EGFR (human epidermal growth factor receptor 2/epidermal growth factor receptor) inhibitor, is a recently approved targeted therapy for metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	35-67
21653830-3	2011	We found that lapatinib improved the proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two TRAIL receptor agonists, the antibodies mapatumumab and lexatumumab.	Lapatinib	14-23	TNF superfamily member 10	Homo sapiens	61-116
21653830-3	2011	We found that lapatinib improved the proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two TRAIL receptor agonists, the antibodies mapatumumab and lexatumumab.	Lapatinib	14-23	TNF superfamily member 10	Homo sapiens	118-123
21653830-3	2011	We found that lapatinib improved the proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two TRAIL receptor agonists, the antibodies mapatumumab and lexatumumab.	Lapatinib	14-23	TNF superfamily member 10	Homo sapiens	133-138
21553932-7	2011	Gefitinib, erlotinib and the absorbed fraction of lapatinib undergo extensive metabolism - mainly via hepatic and intestinal cytochrome P450 (CYP) 3A4 and also via CYP2D6 (gefitinib) and CYP1A2 (erlotinib) - and are primarily eliminated by biotransformation.	Lapatinib	50-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-150
21553932-7	2011	Gefitinib, erlotinib and the absorbed fraction of lapatinib undergo extensive metabolism - mainly via hepatic and intestinal cytochrome P450 (CYP) 3A4 and also via CYP2D6 (gefitinib) and CYP1A2 (erlotinib) - and are primarily eliminated by biotransformation.	Lapatinib	50-59	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	164-170
21553932-7	2011	Gefitinib, erlotinib and the absorbed fraction of lapatinib undergo extensive metabolism - mainly via hepatic and intestinal cytochrome P450 (CYP) 3A4 and also via CYP2D6 (gefitinib) and CYP1A2 (erlotinib) - and are primarily eliminated by biotransformation.	Lapatinib	50-59	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	187-193
21506905-7	2011	EXPERT OPINION: T-DM1 has significant antitumor potency in vitro and in vivo, which is maintained in tumors resistant to trastuzumab or lapatinib.	Lapatinib	136-145	immunoglobulin heavy diversity 1-7	Homo sapiens	18-21
21363997-0	2011	Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.	Lapatinib	73-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-69
21372222-0	2011	Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.	Lapatinib	154-163	C-reactive protein	Homo sapiens	15-33
21677477-11	2011	Lapatinib is an orally administered small-molecule, reversible inhibitor of both EGFR and HER2 tyrosine kinase, and its activities include subsequent inhibition of its down- stream MAPK-ERK1/2, and the AKT signaling pathway.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	81-85
21677477-11	2011	Lapatinib is an orally administered small-molecule, reversible inhibitor of both EGFR and HER2 tyrosine kinase, and its activities include subsequent inhibition of its down- stream MAPK-ERK1/2, and the AKT signaling pathway.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
21677477-11	2011	Lapatinib is an orally administered small-molecule, reversible inhibitor of both EGFR and HER2 tyrosine kinase, and its activities include subsequent inhibition of its down- stream MAPK-ERK1/2, and the AKT signaling pathway.	Lapatinib	0-9	mitogen-activated protein kinase 3	Homo sapiens	181-185
21677477-11	2011	Lapatinib is an orally administered small-molecule, reversible inhibitor of both EGFR and HER2 tyrosine kinase, and its activities include subsequent inhibition of its down- stream MAPK-ERK1/2, and the AKT signaling pathway.	Lapatinib	0-9	mitogen-activated protein kinase 3	Homo sapiens	186-192
21677477-13	2011	For women with trastuzumab pre-treated HER2-positive breast cancer, Here, I will review the basics of EGFR and HER, and the treatment strategy for HER2-positive breast cancer with lapatinib.	Lapatinib	180-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
21307659-1	2011	The antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are approved by the FDA for the treatment of HER2-overexpressing breast cancer.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
21633602-1	2011	Lapatinib is an inhibitor of the tyrosine kinases of human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor type 1, with clinical activity in HER2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
21633602-1	2011	Lapatinib is an inhibitor of the tyrosine kinases of human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor type 1, with clinical activity in HER2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
21464044-0	2011	The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.	Lapatinib	29-38	epidermal growth factor receptor	Homo sapiens	9-13
21464044-0	2011	The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
21464044-2	2011	Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	16-20
21464044-2	2011	Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
21464044-2	2011	Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.	Lapatinib	0-9	zinc fingers and homeoboxes 2	Homo sapiens	81-84
21464044-2	2011	Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.	Lapatinib	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	85-88
21464044-2	2011	Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.	Lapatinib	0-9	mitogen-activated protein kinase 1	Homo sapiens	94-97
21464044-2	2011	Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	183-186
21510863-15	2011	T-DM1 was found effective even on breast cancer cell lines with moderate HER2 expression levels and cross-resistance to trastuzumab and lapatinib (MDA-453 and JIMT-1).	Lapatinib	136-145	immunoglobulin heavy diversity 1-7	Homo sapiens	2-5
21527065-0	2011	Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
21527065-2	2011	This single-arm open-label trial (EGF109491; NCT00508274) was designed to confirm the efficacy and safety of lapatinib in combination with capecitabine in 52 heavily pretreated Chinese patients with HER2-positive MBC.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	199-203
22013564-0	2011	Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.	Lapatinib	0-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-95
22013564-4	2011	Lapatinib ditosylate is an orally available, small molecule targeting the tyrosine activity of the HER2 receptor.	Lapatinib	0-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
21440529-8	2011	Tyrosine kinase inhibitors of HER family, erlotinib, lapatinib and canertinib suppressed EGF-ligands mediated MMP1 overexpression.	Lapatinib	53-62	epidermal growth factor	Homo sapiens	89-92
21440529-8	2011	Tyrosine kinase inhibitors of HER family, erlotinib, lapatinib and canertinib suppressed EGF-ligands mediated MMP1 overexpression.	Lapatinib	53-62	matrix metallopeptidase 1	Homo sapiens	110-114
21496232-3	2011	We demonstrated the ability of the assays to quantitatively measure changes in activated HER1 and HER2 receptor levels in cell lines following treatment with 2C4, erlotinib, and lapatinib.	Lapatinib	178-187	epidermal growth factor receptor	Homo sapiens	89-93
21496232-3	2011	We demonstrated the ability of the assays to quantitatively measure changes in activated HER1 and HER2 receptor levels in cell lines following treatment with 2C4, erlotinib, and lapatinib.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
21496232-8	2011	EGF-dependent HER1 and HER2 phosphorylation was inhibited by lapatinib and erlotinib.	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	14-18
21496232-8	2011	EGF-dependent HER1 and HER2 phosphorylation was inhibited by lapatinib and erlotinib.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
21468131-6	2011	Cetuximab and panitumumab, two monoclonal antibodies against EGFR, and the dual EGFR and HER2 tyrosine kinase inhibitor lapatinib are currently undergoing phase III evaluation in esophagogastric cancer.	Lapatinib	120-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
21447712-6	2011	The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
21377448-0	2011	Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.	Lapatinib	127-136	fibroblast growth factor receptor 2	Homo sapiens	81-86
21377448-3	2011	We have established a line of lapatinib-resistant breast cancer cells (UACC812/LR) by chronic exposure of HER2-amplified and lapatinib-sensitive UACC812 cells to the drug.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
21447712-6	2011	The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth.	Lapatinib	19-28	insulin like growth factor 1 receptor	Homo sapiens	66-71
21447712-6	2011	The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
21271222-0	2011	KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.	Lapatinib	172-181	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
21271222-8	2011	Our study suggests that both HDACi/EGFR inhibitor-combination treatment and lapatinib-single treatment may be effective options for the therapy of NSCLC with KRAS mutations.	Lapatinib	76-85	KRAS proto-oncogene, GTPase	Homo sapiens	158-162
21498698-0	2011	Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).	Lapatinib	103-112	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	14-19
21138857-0	2011	Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
21138857-0	2011	Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-121
21186272-5	2011	NRG1/ErbB signaling was inhibited by oral treatment of animals with the dual ErbB1/ErbB2 tyrosine kinase inhibitor lapatinib.	Lapatinib	115-124	neuregulin 1	Rattus norvegicus	0-4
21186272-5	2011	NRG1/ErbB signaling was inhibited by oral treatment of animals with the dual ErbB1/ErbB2 tyrosine kinase inhibitor lapatinib.	Lapatinib	115-124	epidermal growth factor receptor	Rattus norvegicus	77-82
21186272-5	2011	NRG1/ErbB signaling was inhibited by oral treatment of animals with the dual ErbB1/ErbB2 tyrosine kinase inhibitor lapatinib.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	83-88
21186272-7	2011	Lapatinib prevented phosphorylation of ErbB2 and ERK1/2, but not of ErbB4 and protein kinase B (Akt), revealing that lapatinib only partially inhibited NRG1/ErbB signaling in the LV.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	39-44
21186272-7	2011	Lapatinib prevented phosphorylation of ErbB2 and ERK1/2, but not of ErbB4 and protein kinase B (Akt), revealing that lapatinib only partially inhibited NRG1/ErbB signaling in the LV.	Lapatinib	0-9	mitogen activated protein kinase 3	Rattus norvegicus	49-55
21186272-7	2011	Lapatinib prevented phosphorylation of ErbB2 and ERK1/2, but not of ErbB4 and protein kinase B (Akt), revealing that lapatinib only partially inhibited NRG1/ErbB signaling in the LV.	Lapatinib	117-126	neuregulin 1	Rattus norvegicus	152-156
20724575-1	2011	BACKGROUND: In the present study, we investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) treated with lapatinib and capecitabine (LC).	Lapatinib	206-215	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-156
20724575-1	2011	BACKGROUND: In the present study, we investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) treated with lapatinib and capecitabine (LC).	Lapatinib	206-215	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
21385943-2	2011	Here, we show that, after inhibition of the HER2 tyrosine kinase with lapatinib, there is PI3K/Akt and FoxO3a-dependent up-regulation of HER3 mRNA and protein.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
21385943-2	2011	Here, we show that, after inhibition of the HER2 tyrosine kinase with lapatinib, there is PI3K/Akt and FoxO3a-dependent up-regulation of HER3 mRNA and protein.	Lapatinib	70-79	AKT serine/threonine kinase 1	Homo sapiens	95-98
21385943-2	2011	Here, we show that, after inhibition of the HER2 tyrosine kinase with lapatinib, there is PI3K/Akt and FoxO3a-dependent up-regulation of HER3 mRNA and protein.	Lapatinib	70-79	forkhead box O3	Homo sapiens	103-109
21385943-2	2011	Here, we show that, after inhibition of the HER2 tyrosine kinase with lapatinib, there is PI3K/Akt and FoxO3a-dependent up-regulation of HER3 mRNA and protein.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 3	Homo sapiens	137-141
21385943-3	2011	Up-regulated HER3 was then phosphorylated by residual HER2 activity, thus partially maintaining P-Akt and limiting the antitumor action of lapatinib.	Lapatinib	139-148	erb-b2 receptor tyrosine kinase 3	Homo sapiens	13-17
21385943-3	2011	Up-regulated HER3 was then phosphorylated by residual HER2 activity, thus partially maintaining P-Akt and limiting the antitumor action of lapatinib.	Lapatinib	139-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
21385943-4	2011	Inhibition of HER3 with siRNA or a neutralizing HER3 antibody sensitized HER2+ breast cancer cells and xenografts to lapatinib both in vitro and in vivo.	Lapatinib	117-126	erb-b2 receptor tyrosine kinase 3	Homo sapiens	14-18
21385943-4	2011	Inhibition of HER3 with siRNA or a neutralizing HER3 antibody sensitized HER2+ breast cancer cells and xenografts to lapatinib both in vitro and in vivo.	Lapatinib	117-126	erb-b2 receptor tyrosine kinase 3	Homo sapiens	48-52
21385943-4	2011	Inhibition of HER3 with siRNA or a neutralizing HER3 antibody sensitized HER2+ breast cancer cells and xenografts to lapatinib both in vitro and in vivo.	Lapatinib	117-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
21498698-0	2011	Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).	Lapatinib	103-112	epidermal growth factor receptor	Homo sapiens	63-67
21498698-0	2011	Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).	Lapatinib	114-122	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	14-19
21498698-0	2011	Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).	Lapatinib	114-122	epidermal growth factor receptor	Homo sapiens	63-67
21498698-3	2011	In this study, we test whether the non-receptor tyrosine kinase c-Abl regulates the responsiveness of breast cancer cells to lapatinib and, if so, whether the combination treatment with lapatinib plus the c-ABL kinase inhibitor imatinib (STI571; Gleevec) can sensitize breast cancer cells to the treatment.	Lapatinib	125-134	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	64-69
21498698-4	2011	MATERIALS AND METHODS: The endogenous c-ABL kinase was silenced by RNA interference or inhibited by imatinib to test whether the co-treatment improves the responsiveness of the lapatinib-resistant breast cancer cell lines MDA-MB-468 and T47D, by measuring cell growth and cell-cycle progression.	Lapatinib	177-186	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	38-43
21498698-5	2011	CONCLUSION: The responsiveness to lapatinib can be improved by targeting the function of c-ABL, suggesting that combination treatment of lapatinib plus imatinib can lead to significant gains in therapeutic benefit.	Lapatinib	34-43	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	89-94
21498698-5	2011	CONCLUSION: The responsiveness to lapatinib can be improved by targeting the function of c-ABL, suggesting that combination treatment of lapatinib plus imatinib can lead to significant gains in therapeutic benefit.	Lapatinib	137-146	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	89-94
21324925-8	2011	Lastly, the HER2/EGFR tyrosine kinase inhibitor lapatinib blocked both homodimer- and heterodimer-induced growth.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
21324925-8	2011	Lastly, the HER2/EGFR tyrosine kinase inhibitor lapatinib blocked both homodimer- and heterodimer-induced growth.	Lapatinib	48-57	epidermal growth factor receptor	Homo sapiens	17-21
21245432-0	2011	HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.	Lapatinib	42-51	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	0-8
21252284-4	2011	Interestingly, MET-overexpressing tumor cell lines with HER1 or HER2 amplification also exhibited reduced sensitivity to lapatinib or erlotinib in the presence of hepatocyte growth factor (HGF), indicating MET activation can decrease the effectiveness of HER1/2 inhibitors in some cell lines.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	56-60
21252284-4	2011	Interestingly, MET-overexpressing tumor cell lines with HER1 or HER2 amplification also exhibited reduced sensitivity to lapatinib or erlotinib in the presence of hepatocyte growth factor (HGF), indicating MET activation can decrease the effectiveness of HER1/2 inhibitors in some cell lines.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
21252284-4	2011	Interestingly, MET-overexpressing tumor cell lines with HER1 or HER2 amplification also exhibited reduced sensitivity to lapatinib or erlotinib in the presence of hepatocyte growth factor (HGF), indicating MET activation can decrease the effectiveness of HER1/2 inhibitors in some cell lines.	Lapatinib	121-130	hepatocyte growth factor	Homo sapiens	163-187
21252284-4	2011	Interestingly, MET-overexpressing tumor cell lines with HER1 or HER2 amplification also exhibited reduced sensitivity to lapatinib or erlotinib in the presence of hepatocyte growth factor (HGF), indicating MET activation can decrease the effectiveness of HER1/2 inhibitors in some cell lines.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	255-261
21252284-5	2011	Consistent with this observation, the effect of HGF on lapatinib or erlotinib sensitivity in these cells was reversed by foretinib, other MET inhibitors, or siRNA to MET.	Lapatinib	55-64	hepatocyte growth factor	Homo sapiens	48-51
21252284-6	2011	Western blot analyses showed that combining foretinib with erlotinib or lapatinib effectively decreased the phosphorylation of MET, HER1, HER2, HER3, AKT, and ERK in these cells.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	132-136
21252284-6	2011	Western blot analyses showed that combining foretinib with erlotinib or lapatinib effectively decreased the phosphorylation of MET, HER1, HER2, HER3, AKT, and ERK in these cells.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
21252284-6	2011	Western blot analyses showed that combining foretinib with erlotinib or lapatinib effectively decreased the phosphorylation of MET, HER1, HER2, HER3, AKT, and ERK in these cells.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 3	Homo sapiens	144-148
21252284-6	2011	Western blot analyses showed that combining foretinib with erlotinib or lapatinib effectively decreased the phosphorylation of MET, HER1, HER2, HER3, AKT, and ERK in these cells.	Lapatinib	72-81	AKT serine/threonine kinase 1	Homo sapiens	150-153
21252284-6	2011	Western blot analyses showed that combining foretinib with erlotinib or lapatinib effectively decreased the phosphorylation of MET, HER1, HER2, HER3, AKT, and ERK in these cells.	Lapatinib	72-81	mitogen-activated protein kinase 1	Homo sapiens	159-162
21252284-7	2011	Furthermore, HER2-positive advanced or metastatic breast cancer patients treated with lapatinib who had higher tumor MET expression showed shorter progression-free survival (19.29 weeks in MET-high patients vs. 28.14 weeks in MET-low patients, P < 0.0225).	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
21248299-1	2011	The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
21248299-1	2011	The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
21245432-11	2011	Further work is required to determine whether testing for DQA1*02:01 allele carriage is clinically useful in managing liver safety risk during lapatinib treatment.	Lapatinib	143-152	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	58-62
21222496-0	2011	Lapatinib in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer: profile report.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
21222496-0	2011	Lapatinib in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer: profile report.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
21591301-2	2011	Trastuzumab and lapatinib are currently the two therapies targeting HER2, which have demonstrated their effectiveness in clinical practice.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
21349137-0	2011	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	126-135	fatty acid synthase	Homo sapiens	12-31
21349137-0	2011	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	126-135	epidermal growth factor receptor	Homo sapiens	90-94
21349137-0	2011	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
21135276-0	2011	Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-162
21526002-18	2011	This gives the clinician the opportunity to include drugs like trastuzumab and lapatinib in the treatment of patients with a transformation to HER-2/neu-positive cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-148
21526002-18	2011	This gives the clinician the opportunity to include drugs like trastuzumab and lapatinib in the treatment of patients with a transformation to HER-2/neu-positive cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-152
21088503-5	2011	Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab and Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-40
21135276-8	2011	RESULTS: Under low PTEN conditions, in vitro data indicate that lapatinib alone and in combination with trastuzumab was effective in decreasing p-MAPK and p-AKT levels, whereas trastuzumab was ineffective.	Lapatinib	64-73	phosphatase and tensin homolog	Homo sapiens	19-23
21135276-10	2011	CONCLUSION: Activation of PI3 kinase pathway is associated with trastuzumab resistance, whereas low PTEN predicted for response to lapatinib.	Lapatinib	131-140	phosphatase and tensin homolog	Homo sapiens	100-104
22123186-0	2011	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
20936340-0	2011	High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.	Lapatinib	47-56	transforming growth factor alpha	Homo sapiens	11-20
20936340-1	2011	Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-125
20936340-1	2011	Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
20936340-5	2011	The effect of TGF-alpha on in vitro sensitivity of SK-BR-3 cells to lapatinib was investigated.	Lapatinib	68-77	transforming growth factor alpha	Homo sapiens	14-23
20936340-10	2011	We confirmed that TGF-alpha diminished the sensitivity of SK-BR3-cells to lapatinib in vitro.	Lapatinib	74-83	transforming growth factor alpha	Homo sapiens	18-27
20936340-11	2011	The in vitro antiproliferative effect of cetuximab in combination with lapatinib was higher than that of lapatinib alone in SK-BR3-cells exposed to TGF-alpha.	Lapatinib	71-80	transforming growth factor alpha	Homo sapiens	148-157
20936340-12	2011	These data suggest that TGF-alpha plays a role in resistance to lapatinib and capecitabine therapy among HER2-positive breast cancer.	Lapatinib	64-73	transforming growth factor alpha	Homo sapiens	24-33
21847344-8	2011	Two such studies were recently reported, both showing a significant advantage of dual anti-HER2 therapy using lapatinib or pertuzumab in addition to trastuzumab and chemotherapy.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
20354831-2	2011	The HER-2-positive tumor was refractory to several agents, including anti-HER-2 therapy, trastuzumab, and lapatinib.	Lapatinib	106-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-9
22123186-1	2011	INTRODUCTION: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-58
22123186-1	2011	INTRODUCTION: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
20658522-5	2011	Lapatinib treatment significantly augments the concentration of the inactive (unphosphorylated) form of HER2 protein at the tumor cell membrane and promotes an exacerbated HER2 ECD shedding to the extracellular milieu of HER2-overexpressing cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
21827413-11	2011	The two major classes of anti-ErbB therapeutics are monoclonal antibodies (e.g. cetuximab, panitumumab) and small molecule Tyrosine kinase inhibitors (TKI, e.g. gefitinib, erlotinib, lapatinib).	Lapatinib	183-192	epidermal growth factor receptor	Homo sapiens	30-34
20825420-7	2011	Specifically, the epidermal growth factor receptor/HER2 tyrosine kinase inhibitor lapatinib partially overcame trastuzumab resistance in a clinical setting, so its efficacy results and limited data regarding potential mechanisms of resistance to the drug are also discussed.	Lapatinib	82-91	epidermal growth factor receptor	Homo sapiens	18-50
20825420-7	2011	Specifically, the epidermal growth factor receptor/HER2 tyrosine kinase inhibitor lapatinib partially overcame trastuzumab resistance in a clinical setting, so its efficacy results and limited data regarding potential mechanisms of resistance to the drug are also discussed.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
21254978-7	2011	Lapatinib (Tykerb ), a potent dual EGFR/ErbB-2 inhibitor, was approved for the treatment of ErbB-2-positive breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	35-39
21254978-7	2011	Lapatinib (Tykerb ), a potent dual EGFR/ErbB-2 inhibitor, was approved for the treatment of ErbB-2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-46
21254978-7	2011	Lapatinib (Tykerb ), a potent dual EGFR/ErbB-2 inhibitor, was approved for the treatment of ErbB-2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-98
21254978-7	2011	Lapatinib (Tykerb ), a potent dual EGFR/ErbB-2 inhibitor, was approved for the treatment of ErbB-2-positive breast cancer.	Lapatinib	11-17	epidermal growth factor receptor	Homo sapiens	35-39
21254978-7	2011	Lapatinib (Tykerb ), a potent dual EGFR/ErbB-2 inhibitor, was approved for the treatment of ErbB-2-positive breast cancer.	Lapatinib	11-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-46
21254978-7	2011	Lapatinib (Tykerb ), a potent dual EGFR/ErbB-2 inhibitor, was approved for the treatment of ErbB-2-positive breast cancer.	Lapatinib	11-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-98
21091041-4	2011	Lapatinib is an oral tyrosine kinase inhibitor which has both HER-1 and -2 activities and has been licensed for use in recurrent breast cancer that overexpresses HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	62-74
21091041-4	2011	Lapatinib is an oral tyrosine kinase inhibitor which has both HER-1 and -2 activities and has been licensed for use in recurrent breast cancer that overexpresses HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-167
21091041-11	2011	TAKE HOME MESSAGE: Lapatinib has provided an alternative for the treatment of advanced HER-2 overexpressing breast cancer and is currently being assessed in early disease.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-92
22152751-0	2011	Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	206-210
22152751-4	2011	OBJECTIVES: To review the clinical effectiveness and cost-effectiveness evidence base for lapatinib (LAP) in combination with an aromatase inhibitor (AI) and trastuzumab (TRA) in combination with an AI for the first-line treatment of patients who have hormone receptor-positive (HR+)/human epidermal growth factor 2-positive (HER2+) mBC.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	326-330
20658522-0	2011	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
20658522-0	2011	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
20658522-0	2011	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
20658522-0	2011	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
20658522-4	2011	The dual HER1/HER2 Tyrosine Kinase inhibitor lapatinib, which works intracellularly and directly targets the TK domain of HER2, drastically augments basal shedding of HER2 ECD to inhibit HER2-driven cancer cell growth.	Lapatinib	45-54	epidermal growth factor receptor	Homo sapiens	9-13
20658522-4	2011	The dual HER1/HER2 Tyrosine Kinase inhibitor lapatinib, which works intracellularly and directly targets the TK domain of HER2, drastically augments basal shedding of HER2 ECD to inhibit HER2-driven cancer cell growth.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
20658522-5	2011	Lapatinib treatment significantly augments the concentration of the inactive (unphosphorylated) form of HER2 protein at the tumor cell membrane and promotes an exacerbated HER2 ECD shedding to the extracellular milieu of HER2-overexpressing cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-176
20658522-4	2011	The dual HER1/HER2 Tyrosine Kinase inhibitor lapatinib, which works intracellularly and directly targets the TK domain of HER2, drastically augments basal shedding of HER2 ECD to inhibit HER2-driven cancer cell growth.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
20658522-4	2011	The dual HER1/HER2 Tyrosine Kinase inhibitor lapatinib, which works intracellularly and directly targets the TK domain of HER2, drastically augments basal shedding of HER2 ECD to inhibit HER2-driven cancer cell growth.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
20658522-5	2011	Lapatinib treatment significantly augments the concentration of the inactive (unphosphorylated) form of HER2 protein at the tumor cell membrane and promotes an exacerbated HER2 ECD shedding to the extracellular milieu of HER2-overexpressing cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-176
20658522-4	2011	The dual HER1/HER2 Tyrosine Kinase inhibitor lapatinib, which works intracellularly and directly targets the TK domain of HER2, drastically augments basal shedding of HER2 ECD to inhibit HER2-driven cancer cell growth.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
22190871-6	2011	MPPS1 cells maintain high ErbB2 overexpression when propagated in DFCI-1 or related media, and their growth is ErbB2-dependent, as demonstrated by concentration-dependent inhibition of proliferation with the ErbB kinase inhibitor Lapatinib.	Lapatinib	230-239	erb-b2 receptor tyrosine kinase 2	Mus musculus	111-116
22190871-9	2011	Immunofluorescence staining of control vs. Lapatinib-treated acini for markers of epithelial polarity revealed that inhibition of ErbB2 signaling led to rapid resumption of normal mammary epithelium-like cell polarity.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Mus musculus	130-135
20658522-6	2011	Exacerbated sensitivity of trastuzumab-resistant cancer cells, which contain nearly undetectable levels of soluble HER2 ECD when compared with trastuzumab-sensitive parental cells to lapatinib-induced cell growth inhibition, takes place when lapatinib treatment fully restores high levels of basal HER2 ECD shedding.	Lapatinib	183-192	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
20658522-6	2011	Exacerbated sensitivity of trastuzumab-resistant cancer cells, which contain nearly undetectable levels of soluble HER2 ECD when compared with trastuzumab-sensitive parental cells to lapatinib-induced cell growth inhibition, takes place when lapatinib treatment fully restores high levels of basal HER2 ECD shedding.	Lapatinib	183-192	erb-b2 receptor tyrosine kinase 2	Homo sapiens	298-302
20658522-6	2011	Exacerbated sensitivity of trastuzumab-resistant cancer cells, which contain nearly undetectable levels of soluble HER2 ECD when compared with trastuzumab-sensitive parental cells to lapatinib-induced cell growth inhibition, takes place when lapatinib treatment fully restores high levels of basal HER2 ECD shedding.	Lapatinib	242-251	erb-b2 receptor tyrosine kinase 2	Homo sapiens	298-302
20658522-7	2011	The dramatic augmentation of HER2 ECD shedding that occurs upon treatment of with lapatinib is fully suppressed in lapatinib-refractory HER2-positive cells.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
20658522-7	2011	The dramatic augmentation of HER2 ECD shedding that occurs upon treatment of with lapatinib is fully suppressed in lapatinib-refractory HER2-positive cells.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
20658522-7	2011	The dramatic augmentation of HER2 ECD shedding that occurs upon treatment of with lapatinib is fully suppressed in lapatinib-refractory HER2-positive cells.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
20658522-7	2011	The dramatic augmentation of HER2 ECD shedding that occurs upon treatment of with lapatinib is fully suppressed in lapatinib-refractory HER2-positive cells.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
20658522-8	2011	These findings, altogether, may provide crucial insights concerning clinical studies aimed to accurately describe HER2 ECD as a potential predictor of response or resistance to the HER2-targeted drugs trastuzumab and lapatinib.	Lapatinib	217-226	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
20658522-8	2011	These findings, altogether, may provide crucial insights concerning clinical studies aimed to accurately describe HER2 ECD as a potential predictor of response or resistance to the HER2-targeted drugs trastuzumab and lapatinib.	Lapatinib	217-226	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185
21106881-5	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	58-90
21106881-5	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	92-96
21106881-5	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	98-103
21106881-5	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
21106881-5	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1.	Lapatinib	0-9	prolactin	Homo sapiens	157-160
21106881-5	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	202-206
21106881-5	2011	Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	207-212
21106881-7	2011	Oral lapatinib treatment caused tumor shrinkage and serum PRL suppression both in HER2CA transfectant-inoculated Wistar-Furth rats and in estrogen-induced Fischer344 rat prolactinomas.	Lapatinib	5-14	prolactin	Rattus norvegicus	58-61
21106881-8	2011	In cultured human cells derived from resected prolactinoma tissue, lapatinib suppressed both PRL mRNA expression and secretion.	Lapatinib	67-76	prolactin	Homo sapiens	93-96
21577028-0	2011	Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
21577028-1	2011	BACKGROUND: The Lapatinib Expanded Access Program (LEAP) was initiated in 45 countries to provide lapatinib in combination with capecitabine to patients with ErbB2 (HER2)-positive breast cancer already treated with anthracyclines, taxanes and trastuzumab.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-163
21577028-1	2011	BACKGROUND: The Lapatinib Expanded Access Program (LEAP) was initiated in 45 countries to provide lapatinib in combination with capecitabine to patients with ErbB2 (HER2)-positive breast cancer already treated with anthracyclines, taxanes and trastuzumab.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
21577028-12	2011	CONCLUSIONS: Heavily pretreated patients with ErbB2-positive locally advanced or metastatic breast cancer may benefit from treatment with lapatinib and capecitabine, with a low risk of cardiac toxicity.	Lapatinib	138-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-51
22216158-1	2011	Lapatinib is an oral, small-molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptors (EGFR, or ErbB/Her) in solid tumors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	72-105
22216158-1	2011	Lapatinib is an oral, small-molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptors (EGFR, or ErbB/Her) in solid tumors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	107-111
22216158-1	2011	Lapatinib is an oral, small-molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptors (EGFR, or ErbB/Her) in solid tumors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	116-120
22216158-5	2011	Lapatinib-induced autophagic cell death was verified by LC3-II conversion, and upregulation of Beclin-1.	Lapatinib	0-9	beclin 1	Homo sapiens	95-103
22216158-6	2011	Further, autophagy inhibitor 3-methyladenine as well as autophagy-related proteins Beclin-1 (ATG6), ATG7, and ATG5 shRNA knockdown rescued the cells from lapatinib-induced growth inhibition.	Lapatinib	154-163	beclin 1	Homo sapiens	83-91
22216158-6	2011	Further, autophagy inhibitor 3-methyladenine as well as autophagy-related proteins Beclin-1 (ATG6), ATG7, and ATG5 shRNA knockdown rescued the cells from lapatinib-induced growth inhibition.	Lapatinib	154-163	beclin 1	Homo sapiens	93-97
22216158-6	2011	Further, autophagy inhibitor 3-methyladenine as well as autophagy-related proteins Beclin-1 (ATG6), ATG7, and ATG5 shRNA knockdown rescued the cells from lapatinib-induced growth inhibition.	Lapatinib	154-163	autophagy related 7	Homo sapiens	100-104
22216158-6	2011	Further, autophagy inhibitor 3-methyladenine as well as autophagy-related proteins Beclin-1 (ATG6), ATG7, and ATG5 shRNA knockdown rescued the cells from lapatinib-induced growth inhibition.	Lapatinib	154-163	autophagy related 5	Homo sapiens	110-114
21187479-8	2010	The time course study of the effect of lapatinib on EGFR-integrin beta(1) complex revealed an inhibition in complex formation up to 30 min after the application of the agent.	Lapatinib	39-48	epidermal growth factor receptor	Homo sapiens	52-56
21319046-0	2010	Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
21319046-4	2010	The patient failed to respond to lapatinib, a HER1 (EGFR)/HER2 tyrosine kinase inhibitor, received during the course of her treatment but then again responded to subsequently administered trastuzumab.	Lapatinib	33-42	epidermal growth factor receptor	Homo sapiens	46-50
22046346-0	2011	Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
22046346-1	2011	BACKGROUND: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer.	Lapatinib	146-155	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-39
22046346-1	2011	BACKGROUND: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer.	Lapatinib	146-155	epidermal growth factor receptor	Homo sapiens	117-122
22046346-1	2011	BACKGROUND: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer.	Lapatinib	146-155	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
22046346-1	2011	BACKGROUND: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer.	Lapatinib	146-155	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
22046346-4	2011	However, the sensitivity of lapatinib towards clinically observed ERBB2 mutations is not known.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71
22046346-6	2011	Both lapatinib-sensitive and lapatinib-resistant ERBB2 mutations were observed.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-54
22046346-7	2011	Interestingly, we were able to generate lapatinib resistance mutations in wt-ERBB2 cells incubated with lapatinib for prolonged periods of time.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-82
22046346-7	2011	Interestingly, we were able to generate lapatinib resistance mutations in wt-ERBB2 cells incubated with lapatinib for prolonged periods of time.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-82
22046346-9	2011	Lapatinib-resistant ERBB2 mutations were found to be highly resistant towards AEE788 treatment but remained sensitive towards the dual irreversible inhibitors CL-387785 and WZ-4002.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-25
22046346-12	2011	Irreversible ERBB2 inhibitors may offer alternative treatment options for breast cancer and other solid tumor patients harbouring lapatinib resistance mutations.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-18
21080629-0	2010	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.	Lapatinib	59-68	epidermal growth factor receptor	Homo sapiens	102-134
21080629-0	2010	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.	Lapatinib	59-68	epidermal growth factor receptor	Homo sapiens	136-140
21080629-0	2010	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-183
21187479-11	2010	CONCLUSION: The preliminary results of this study are the first to support the implication of a dual anti-EGFR/HER-2 agent, lapatinib and a multi-targeted agent, sunitinib in glioma cell migration, through a mechanism implying interruption of growth factor receptor integrin complexes formation.	Lapatinib	124-133	epidermal growth factor receptor	Homo sapiens	106-110
21293538-2	2010	Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	41-45
21293538-2	2010	Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	47-51
21293538-2	2010	Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	53-58
21293538-2	2010	Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
21293538-6	2010	CONCLUSION: Lapatinib (Tykerb/Tyverb) was Food and Drug Administration (FDA) approved in 2007 for use in combination with capecitabine for the treatment of HER2-positive advanced or metastatic breast cancer in patients who had received previous treatment (including anthracycline, taxane and trastuzumab containing regimens) and in 2010 for use in combination with letrozole for postmenopausal women with hormonal receptor positive and HER2- positive metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	436-440
21293538-2	2010	Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-75
21293538-7	2010	In contrast to trastuzumab (Herceptin), lapatinib is orally administered and it targets both HER2 and HER1 receptors.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
21293538-7	2010	In contrast to trastuzumab (Herceptin), lapatinib is orally administered and it targets both HER2 and HER1 receptors.	Lapatinib	40-49	epidermal growth factor receptor	Homo sapiens	102-106
21293538-12	2010	At this time, only HER2 amplification/overexpression is used to choose lapatinib therapy candidates.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
21293538-14	2010	PTEN loss and PIK3CA gene mutations are other markers that may predict lapatinib poor response.	Lapatinib	71-80	phosphatase and tensin homolog	Homo sapiens	0-4
21293538-14	2010	PTEN loss and PIK3CA gene mutations are other markers that may predict lapatinib poor response.	Lapatinib	71-80	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	14-20
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	97-122
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	124-128
21293538-2	2010	Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1) and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-80
21293538-6	2010	CONCLUSION: Lapatinib (Tykerb/Tyverb) was Food and Drug Administration (FDA) approved in 2007 for use in combination with capecitabine for the treatment of HER2-positive advanced or metastatic breast cancer in patients who had received previous treatment (including anthracycline, taxane and trastuzumab containing regimens) and in 2010 for use in combination with letrozole for postmenopausal women with hormonal receptor positive and HER2- positive metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
20889729-0	2010	A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.	Lapatinib	34-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	137-141
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-177
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	23-31	epidermal growth factor receptor	Homo sapiens	97-122
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	23-31	epidermal growth factor receptor	Homo sapiens	124-128
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	23-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
20042973-1	2010	OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.	Lapatinib	23-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-177
20042973-2	2010	Since EGFR and HER2 overexpression has also been seen in prostate cancer and appears to correlate with a worse clinical outcome, Lapatinib may represent a novel therapeutic strategy in prostate cancer.	Lapatinib	129-138	epidermal growth factor receptor	Homo sapiens	6-10
20042973-2	2010	Since EGFR and HER2 overexpression has also been seen in prostate cancer and appears to correlate with a worse clinical outcome, Lapatinib may represent a novel therapeutic strategy in prostate cancer.	Lapatinib	129-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
20213094-6	2010	Anti-Her-2 drugs, such as trastuzumab or lapatinib, are under investigation in urothelial neoplasms, but there is no phase III trial that has evaluated their use in bladder cancer.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-10
20889729-1	2010	Lapatinib is a specific HER1 and 2 targeted tyrosine kinase inhibitor now widely used in combination with chemotherapy in the clinical setting.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	24-34
20889729-9	2010	Flow cytometry analysis showed that lapatinib (10 mumol/L) inhibited the efflux of mitoxantrone, a specific substrate of the BCRP pump, in a manner similar to fumitremorgin C, a known BCRP inhibitor, confirming lapatinib as a BCRP inhibitor.	Lapatinib	36-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	125-129
20889729-10	2010	This work shows that lapatinib has a direct inhibitory effect on BCRP accounting for the synergistic findings.	Lapatinib	21-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	65-69
20855957-7	2010	Although a proof for the clinical significance of EGFR-positive circulating tumor cells is currently lacking, expression of EGFR may predict response to lapatinib-based treatments as in the case presented.	Lapatinib	153-162	epidermal growth factor receptor	Homo sapiens	124-128
24367169-3	2010	Lapatinib is a potent, orally bioavailable small molecule that reversibly and selectively inhibits epidermal growth factor receptor (EGFR1 or ERBB1) and ERBB2 tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	99-131
24367169-3	2010	Lapatinib is a potent, orally bioavailable small molecule that reversibly and selectively inhibits epidermal growth factor receptor (EGFR1 or ERBB1) and ERBB2 tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	142-147
24367169-3	2010	Lapatinib is a potent, orally bioavailable small molecule that reversibly and selectively inhibits epidermal growth factor receptor (EGFR1 or ERBB1) and ERBB2 tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-158
24367169-8	2010	Lapatinib has substantial activity for advanced ERBB2-positive breast cancer, particularly in combination with capecitabine, following progression after anthracyclines, taxanes, and trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-53
20855960-4	2010	Lapatinib-mediated inhibition of ERK1/2 and to a lesser extent AKT facilitated CDK inhibitor -induced suppression of MCL-1 levels.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	63-66
20855960-4	2010	Lapatinib-mediated inhibition of ERK1/2 and to a lesser extent AKT facilitated CDK inhibitor -induced suppression of MCL-1 levels.	Lapatinib	0-9	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	117-122
20855960-5	2010	Treatment of cells with the BH3 domain / MCL-1 inhibitor obatoclax enhanced the lethality of lapatinib in a synergistic fashion.	Lapatinib	93-102	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	41-46
20855960-6	2010	Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality.	Lapatinib	39-48	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-18
20855960-6	2010	Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality.	Lapatinib	39-48	BCL2 like 1	Homo sapiens	23-29
20855960-6	2010	Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality.	Lapatinib	142-151	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-18
20855960-6	2010	Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality.	Lapatinib	142-151	BCL2 like 1	Homo sapiens	23-29
20855960-4	2010	Lapatinib-mediated inhibition of ERK1/2 and to a lesser extent AKT facilitated CDK inhibitor -induced suppression of MCL-1 levels.	Lapatinib	0-9	mitogen-activated protein kinase 3	Homo sapiens	33-39
20855960-7	2010	Pre-treatment of cells with lapatinib or with obatoclax enhanced basal levels of BAX and BAK activity and further enhanced drug combination toxicity.	Lapatinib	28-37	BCL2 associated X, apoptosis regulator	Homo sapiens	81-84
20855960-2	2010	Treatment of breast cancer cells with CDK inhibitors (flavopiridol; roscovitine) enhanced the lethality of the ERBB1 inhibitor lapatinib in a synergistic fashion.	Lapatinib	127-136	epidermal growth factor receptor	Homo sapiens	111-116
20855960-7	2010	Pre-treatment of cells with lapatinib or with obatoclax enhanced basal levels of BAX and BAK activity and further enhanced drug combination toxicity.	Lapatinib	28-37	BCL2 antagonist/killer 1	Homo sapiens	89-92
20855960-3	2010	CDK inhibitors interacted with lapatinib to reduce MCL-1 expression and over-expression of MCL-1 or knock down of BAX and BAK suppressed drug combination lethality.	Lapatinib	31-40	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	51-56
20855960-3	2010	CDK inhibitors interacted with lapatinib to reduce MCL-1 expression and over-expression of MCL-1 or knock down of BAX and BAK suppressed drug combination lethality.	Lapatinib	31-40	BCL2 antagonist/killer 1	Homo sapiens	122-125
20578981-8	2010	We transduced the ErbB2 over-expressing BC line, BT474, with the HRAS (V12) mutant, then treated it with ErbB-family and phosphorylated MEK (MEKPP) inhibitors, Lapatinib and U0126, respectively.	Lapatinib	160-169	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-23
21129615-1	2010	Lapatinib, an orally available dual inhibitor targeting the tyrosine-kinase domain of both epidermal growth factor receptor-1 and 2, has been introduced for the treatment of advanced/metastatic HER2+ breast cancer in combination with capacitabine after chemotherapy regimens containing anthracycline, taxanes and trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-131
21129615-1	2010	Lapatinib, an orally available dual inhibitor targeting the tyrosine-kinase domain of both epidermal growth factor receptor-1 and 2, has been introduced for the treatment of advanced/metastatic HER2+ breast cancer in combination with capacitabine after chemotherapy regimens containing anthracycline, taxanes and trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
21070441-0	2010	Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-81
21070441-3	2010	Here we report the case of a patient with brain metastases from breast cancer overexpressing HER-2 who achieved a complete radiologic response after treatment by radiation and concurrent Lapatinib and Capecitabine.	Lapatinib	187-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-98
20542996-5	2010	Lapatinib, in combination with chemotherapeutic agents, such as capecitabine, provides clinical benefits to patients with ErbB2+ breast cancer, including patients who develop progressive disease on trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-127
21084819-0	2010	[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
20542996-6	2010	Lapatinib, in combination with non-chemotherapeutic agents, such as letrozole, may also provide a chemotherapy-free treatment option for postmenopausal patients with estrogen receptor-positive/ErbB2+ metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-198
20624855-1	2010	Fatalities stemming from hepatotoxicity associated with the clinical use of lapatinib (Tykerb), an oral dual tyrosine kinase inhibitor (ErbB-1 and ErbB-2) used in the treatment of metastatic breast cancer, have been reported.	Lapatinib	76-85	epidermal growth factor receptor	Homo sapiens	136-142
20542996-7	2010	Encouraging results have also emerged regarding the synergistic effects of lapatinib in combination with other agents for the treatment of ErbB2+ breast cancer.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-144
20542996-9	2010	Collectively, these results indicate that the judicious use of lapatinib, an effective oral therapy with a manageable toxicity profile, can enhance the management of patients with ErbB2+ breast cancer.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-185
20231058-6	2010	Lapatinib can selectively target HER-2 positive breast CSCs and improves disease-free survival in these patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
19603143-11	2010	However, MMP-9 and MMP-2 levels were decreased 48 h after treatment of M059K cells with sunitinib either alone or in combination with lapatinib.	Lapatinib	134-143	matrix metallopeptidase 9	Homo sapiens	9-14
19603143-11	2010	However, MMP-9 and MMP-2 levels were decreased 48 h after treatment of M059K cells with sunitinib either alone or in combination with lapatinib.	Lapatinib	134-143	matrix metallopeptidase 2	Homo sapiens	19-24
20542996-0	2010	Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.	Lapatinib	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-19
20542996-3	2010	In this review, we summarize the preclinical and clinical evidence that indicates how lapatinib, a novel inhibitor that targets the human epidermal growth factor receptor (ErbB1) and ErbB2 may help clinicians address four particularly challenging issues in the management of ErbB2+ breast cancer.	Lapatinib	86-95	epidermal growth factor receptor	Homo sapiens	138-170
20542996-3	2010	In this review, we summarize the preclinical and clinical evidence that indicates how lapatinib, a novel inhibitor that targets the human epidermal growth factor receptor (ErbB1) and ErbB2 may help clinicians address four particularly challenging issues in the management of ErbB2+ breast cancer.	Lapatinib	86-95	epidermal growth factor receptor	Homo sapiens	172-177
20542996-3	2010	In this review, we summarize the preclinical and clinical evidence that indicates how lapatinib, a novel inhibitor that targets the human epidermal growth factor receptor (ErbB1) and ErbB2 may help clinicians address four particularly challenging issues in the management of ErbB2+ breast cancer.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	183-188
20542996-3	2010	In this review, we summarize the preclinical and clinical evidence that indicates how lapatinib, a novel inhibitor that targets the human epidermal growth factor receptor (ErbB1) and ErbB2 may help clinicians address four particularly challenging issues in the management of ErbB2+ breast cancer.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	275-280
24367166-6	2010	HER2 represents a very interesting molecular target and a number of compounds (trastuzumab [Herceptin ; F. Hoffmann-La Roche, Basel, Switzerland] and lapatinib [Tykerb , GlaxoSmithKline, London, UK]) are currently under clinical evaluation.	Lapatinib	150-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
24367166-6	2010	HER2 represents a very interesting molecular target and a number of compounds (trastuzumab [Herceptin ; F. Hoffmann-La Roche, Basel, Switzerland] and lapatinib [Tykerb , GlaxoSmithKline, London, UK]) are currently under clinical evaluation.	Lapatinib	161-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
24367166-14	2010	On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
24367166-14	2010	On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.	Lapatinib	19-28	epidermal growth factor receptor	Homo sapiens	110-142
24367166-14	2010	On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.	Lapatinib	30-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
24367166-14	2010	On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.	Lapatinib	30-36	epidermal growth factor receptor	Homo sapiens	110-142
20701607-4	2010	In the current study, we show that the combination of lapatinib and bortezomib results in a synergistic growth inhibition in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and that the combination enhances apoptosis of SK-BR-3 cells.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
20701607-5	2010	Importantly, we found that the combination of lapatinib plus bortezomib more effectively blocked activation of the HER2 pathway in SK-BR-3 cells, compared with monotherapy.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
20701607-8	2010	Taken together, the current data indicate a synergistic interaction between lapatinib and bortezomib in HER2-overexpressing breast cancer cells and provide the rationale for the clinical evaluation of these two noncross-resistant targeted therapies.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
20701607-9	2010	The combination of lapatinib and bortezomib may be a potentially novel approach to prevent or delay the onset of acquired resistance to lapatinib in HER2-overxpressing/estrogen receptor (ER)-negative breast cancers.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
20701607-9	2010	The combination of lapatinib and bortezomib may be a potentially novel approach to prevent or delay the onset of acquired resistance to lapatinib in HER2-overxpressing/estrogen receptor (ER)-negative breast cancers.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
20624855-1	2010	Fatalities stemming from hepatotoxicity associated with the clinical use of lapatinib (Tykerb), an oral dual tyrosine kinase inhibitor (ErbB-1 and ErbB-2) used in the treatment of metastatic breast cancer, have been reported.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-153
20624855-1	2010	Fatalities stemming from hepatotoxicity associated with the clinical use of lapatinib (Tykerb), an oral dual tyrosine kinase inhibitor (ErbB-1 and ErbB-2) used in the treatment of metastatic breast cancer, have been reported.	Lapatinib	87-93	epidermal growth factor receptor	Homo sapiens	136-142
20624855-1	2010	Fatalities stemming from hepatotoxicity associated with the clinical use of lapatinib (Tykerb), an oral dual tyrosine kinase inhibitor (ErbB-1 and ErbB-2) used in the treatment of metastatic breast cancer, have been reported.	Lapatinib	87-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-153
20624855-2	2010	We investigated the inhibition of CYP3A4 by lapatinib as a possible cause of its idiosyncratic toxicity.	Lapatinib	44-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
20624855-6	2010	Testosterone protected CYP3A4 from inactivation by lapatinib.	Lapatinib	51-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
20624855-8	2010	However, reduced carbon monoxide (CO)-difference spectroscopy did reveal a 43% loss of the spectrally detectable CYP3A4-CO complex in the presence of lapatinib.	Lapatinib	150-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
20624855-11	2010	In conclusion, we demonstrated for the first time that lapatinib is a mechanism-based inactivator of CYP3A4, most likely via the formation and further oxidation of its O-dealkylated metabolite to a quinoneimine that covalently modifies the CYP3A4 apoprotein and/or heme moiety.	Lapatinib	55-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
20624855-11	2010	In conclusion, we demonstrated for the first time that lapatinib is a mechanism-based inactivator of CYP3A4, most likely via the formation and further oxidation of its O-dealkylated metabolite to a quinoneimine that covalently modifies the CYP3A4 apoprotein and/or heme moiety.	Lapatinib	55-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	240-246
19499189-3	2010	However, more detailed analysis revealed that the interaction of lapatinib with P-gp was distinct from that of gefitinib and erlotinib, and was characterised by direct inhibition of the stimulated P-gp ATPase activity.	Lapatinib	65-74	phosphoglycolate phosphatase	Homo sapiens	80-84
19946741-5	2010	Similar findings were observed with the EGFR/ErbB-2 inhibitor lapatinib.	Lapatinib	62-71	epidermal growth factor receptor	Homo sapiens	40-44
19946741-5	2010	Similar findings were observed with the EGFR/ErbB-2 inhibitor lapatinib.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-51
19946741-7	2010	Blockade of both receptors with gefitinib/trastuzumab or lapatinib induced a significant increase in the levels of p27(kip1) mRNA and in the nuclear levels of the p27(kip1) transcription factor FKHRL-1.	Lapatinib	57-66	interferon alpha inducible protein 27	Homo sapiens	115-118
19946741-7	2010	Blockade of both receptors with gefitinib/trastuzumab or lapatinib induced a significant increase in the levels of p27(kip1) mRNA and in the nuclear levels of the p27(kip1) transcription factor FKHRL-1.	Lapatinib	57-66	cyclin dependent kinase inhibitor 1B	Homo sapiens	119-123
19946741-7	2010	Blockade of both receptors with gefitinib/trastuzumab or lapatinib induced a significant increase in the levels of p27(kip1) mRNA and in the nuclear levels of the p27(kip1) transcription factor FKHRL-1.	Lapatinib	57-66	cyclin dependent kinase inhibitor 1B	Homo sapiens	115-123
19946741-7	2010	Blockade of both receptors with gefitinib/trastuzumab or lapatinib induced a significant increase in the levels of p27(kip1) mRNA and in the nuclear levels of the p27(kip1) transcription factor FKHRL-1.	Lapatinib	57-66	forkhead box O3	Homo sapiens	194-201
19946741-9	2010	Finally, down-modulation of FKHRL-1 with siRNAs prevented the lapatinib-induced increase of p27(kip1) mRNA.	Lapatinib	62-71	forkhead box O3	Homo sapiens	28-35
19946741-9	2010	Finally, down-modulation of FKHRL-1 with siRNAs prevented the lapatinib-induced increase of p27(kip1) mRNA.	Lapatinib	62-71	interferon alpha inducible protein 27	Homo sapiens	92-95
19946741-9	2010	Finally, down-modulation of FKHRL-1 with siRNAs prevented the lapatinib-induced increase of p27(kip1) mRNA.	Lapatinib	62-71	cyclin dependent kinase inhibitor 1B	Homo sapiens	96-100
20732960-10	2010	These findings underscore differences in skin toxicity as related to specificity of HER blockade, concordant with clinical tolerability and decreased severity of skin toxicity seen with the HER1/2i lapatinib compared with the HER1 inhibitors cetuximab, erlotinib, and panitumumab.	Lapatinib	198-207	epidermal growth factor receptor	Homo sapiens	190-194
20876920-0	2010	Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-50
20876920-1	2010	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-94
20876920-1	2010	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
20876920-1	2010	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-176
20876920-14	2010	CONCLUSION: In a patient population with heavily pretreated HER2-positive advanced breast cancer lapatinib plus capecitabine was well tolerated and offered clinical benefit.	Lapatinib	97-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
20100635-1	2010	BACKGROUND: In vitro studies have shown that lapatinib is most active in HER2 over-expressing tumors, but also has activity in cell lines over-expressing HER1.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
20100635-1	2010	BACKGROUND: In vitro studies have shown that lapatinib is most active in HER2 over-expressing tumors, but also has activity in cell lines over-expressing HER1.	Lapatinib	45-54	epidermal growth factor receptor	Homo sapiens	154-158
20100635-2	2010	Consequently, clinical testing of lapatinib has been carried out in both HER2-positive and HER2-negative patients.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
20100635-2	2010	Consequently, clinical testing of lapatinib has been carried out in both HER2-positive and HER2-negative patients.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
20100635-3	2010	Here we evaluate the clinical efficacy of lapatinib in HER2-positive and HER2-negative patients.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
20100635-3	2010	Here we evaluate the clinical efficacy of lapatinib in HER2-positive and HER2-negative patients.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
20100635-8	2010	Meta-analysis demonstrated the HR for PFS with lapatinib was 0.69 in patients with HER2-positive disease, while there was no improvement in PFS (HR=0.98, 95% CI 0.80-1.19) for treatment of HER2-negative breast cancer.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
20735304-1	2010	Lapatinib is an oral dual erbB 1/2 tyrosine kinase inhibitor that inhibits human EGF receptor 2 (HER2) and blocks the EGF receptor.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
20735304-2	2010	Studies have shown that in patients with metastatic HER2-positive breast cancer that is resistant to trastuzumab, the addition of lapatinib to capecitabine improves progression-free survival and appears to lengthen overall survival.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
20735304-6	2010	Current indications in the USA for the use of lapatinib are for the treatment of metastatic HER2-positive breast cancer, both in combination with capecitabine in patients who have received taxane, anthracycline and traztuzumab, and in combination with letrozole for postmenopausal patients with hormone receptor- and HER2-overexpressing breast cancer.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
20735304-6	2010	Current indications in the USA for the use of lapatinib are for the treatment of metastatic HER2-positive breast cancer, both in combination with capecitabine in patients who have received taxane, anthracycline and traztuzumab, and in combination with letrozole for postmenopausal patients with hormone receptor- and HER2-overexpressing breast cancer.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	317-321
20713864-1	2010	PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.	Lapatinib	116-125	epidermal growth factor receptor	Homo sapiens	139-171
20713864-9	2010	Frequent, high-level expression of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were observed in tumors, particularly in ependymomas that displayed prolonged stable disease on lapatinib therapy.	Lapatinib	219-228	epidermal growth factor receptor	Homo sapiens	62-66
20713864-9	2010	Frequent, high-level expression of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were observed in tumors, particularly in ependymomas that displayed prolonged stable disease on lapatinib therapy.	Lapatinib	219-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-76
20581867-7	2010	HRG siRNA inhibited growth of H1047R but not E545K-expressing cells and synergized with the HER2 inhibitors trastuzumab and lapatinib.	Lapatinib	124-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
20607690-6	2010	Lapatinib was an even more potent inhibitor of cholangiocarcinoma cell growth and inducer of apoptosis than either tryphostin when tested in vitro against these respective cholangiocarcinoma cell lines, regardless of differences in their levels of ErbB1 or ErbB2 protein expression and/or mechanism of activation.	Lapatinib	0-9	epidermal growth factor receptor	Rattus norvegicus	248-253
20607690-6	2010	Lapatinib was an even more potent inhibitor of cholangiocarcinoma cell growth and inducer of apoptosis than either tryphostin when tested in vitro against these respective cholangiocarcinoma cell lines, regardless of differences in their levels of ErbB1 or ErbB2 protein expression and/or mechanism of activation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	257-262
19859802-11	2010	However, the SKBR3/EGFR (clone 5) cell line remained sensitive to lapatinib, an EGFR/HER2 inhibitor.	Lapatinib	66-75	epidermal growth factor receptor	Homo sapiens	19-23
19859802-11	2010	However, the SKBR3/EGFR (clone 5) cell line remained sensitive to lapatinib, an EGFR/HER2 inhibitor.	Lapatinib	66-75	epidermal growth factor receptor	Homo sapiens	80-84
19859802-11	2010	However, the SKBR3/EGFR (clone 5) cell line remained sensitive to lapatinib, an EGFR/HER2 inhibitor.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
20735208-1	2010	Certain small-molecule inhibitors that target epidermal growth factor receptor (EGFR), such as Gefitinib, Erlotinib, and Lapatinib, provide a new approach for cancer treatment.	Lapatinib	121-130	epidermal growth factor receptor	Mus musculus	46-78
20735208-1	2010	Certain small-molecule inhibitors that target epidermal growth factor receptor (EGFR), such as Gefitinib, Erlotinib, and Lapatinib, provide a new approach for cancer treatment.	Lapatinib	121-130	epidermal growth factor receptor	Mus musculus	80-84
19499189-3	2010	However, more detailed analysis revealed that the interaction of lapatinib with P-gp was distinct from that of gefitinib and erlotinib, and was characterised by direct inhibition of the stimulated P-gp ATPase activity.	Lapatinib	65-74	phosphoglycolate phosphatase	Homo sapiens	197-201
19499189-4	2010	Lapatinib proved the most potent P-gp modulator of the TKIs examined.	Lapatinib	0-9	phosphoglycolate phosphatase	Homo sapiens	33-37
19499189-5	2010	Drug transport studies in the P-gp-over-expressing A549-Taxol cell line showed that lapatinib and erlotinib are capable of increasing docetaxel accumulation at clinically achievable concentrations.	Lapatinib	84-93	phosphoglycolate phosphatase	Homo sapiens	30-34
20511180-8	2010	Based on the findings, the small-molecule EGFR/ErbB2 kinase inhibitor lapatinib was selected for evaluation of target inhibition and treatment efficacy in our in vitro human schwannoma model.	Lapatinib	70-79	epidermal growth factor receptor	Homo sapiens	42-46
20606083-1	2010	PURPOSE: Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively.	Lapatinib	23-32	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	166-171
20606083-1	2010	PURPOSE: Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively.	Lapatinib	23-32	epidermal growth factor receptor	Homo sapiens	175-207
20606083-1	2010	PURPOSE: Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively.	Lapatinib	23-32	epidermal growth factor receptor	Homo sapiens	209-213
20606083-1	2010	PURPOSE: Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	225-259
20606083-1	2010	PURPOSE: Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	261-269
20511180-9	2010	EGFR/ErbB2 targeted therapy with lapatinib inhibited ErbB2 phosphorylation and survivin upregulation, as well as downstream ERK1/2 and AKT activation, resulting in decreased proliferation.	Lapatinib	33-42	epidermal growth factor receptor	Homo sapiens	0-4
20511180-9	2010	EGFR/ErbB2 targeted therapy with lapatinib inhibited ErbB2 phosphorylation and survivin upregulation, as well as downstream ERK1/2 and AKT activation, resulting in decreased proliferation.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-10
20511180-9	2010	EGFR/ErbB2 targeted therapy with lapatinib inhibited ErbB2 phosphorylation and survivin upregulation, as well as downstream ERK1/2 and AKT activation, resulting in decreased proliferation.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-58
20511180-8	2010	Based on the findings, the small-molecule EGFR/ErbB2 kinase inhibitor lapatinib was selected for evaluation of target inhibition and treatment efficacy in our in vitro human schwannoma model.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
20511180-9	2010	EGFR/ErbB2 targeted therapy with lapatinib inhibited ErbB2 phosphorylation and survivin upregulation, as well as downstream ERK1/2 and AKT activation, resulting in decreased proliferation.	Lapatinib	33-42	AKT serine/threonine kinase 1	Homo sapiens	135-138
20670419-1	2010	BACKGROUND: Accurate assessment of the human epidermal growth factor receptor 2 (HER2) of invasive breast cancer is essential to treatment decisions since the advent of targeted therapy with the humanized monoclonal antibody trastuzumab and the dual tyrosine kinase inhibitor lapatinib.	Lapatinib	276-285	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-79
20511180-10	2010	We conclude that EGFR family receptor activation is a consistent feature of both sporadic and NF2-related VS. Molecular targeted therapy with lapatinib downregulates survivin and has antiproliferative activity in a preclinical VS model.	Lapatinib	142-151	epidermal growth factor receptor	Homo sapiens	17-21
20511180-10	2010	We conclude that EGFR family receptor activation is a consistent feature of both sporadic and NF2-related VS. Molecular targeted therapy with lapatinib downregulates survivin and has antiproliferative activity in a preclinical VS model.	Lapatinib	142-151	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	94-97
20614948-0	2010	Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-56
20614948-0	2010	Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
20614948-1	2010	Lapatinib is an orally active, low molecular weight, reversible inhibitor of the intracellular tyrosine kinase domains of both human epidermal growth factor receptor (HER) type 1 (HER1) and type 2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	133-165
20614948-1	2010	Lapatinib is an orally active, low molecular weight, reversible inhibitor of the intracellular tyrosine kinase domains of both human epidermal growth factor receptor (HER) type 1 (HER1) and type 2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	180-184
20614948-1	2010	Lapatinib is an orally active, low molecular weight, reversible inhibitor of the intracellular tyrosine kinase domains of both human epidermal growth factor receptor (HER) type 1 (HER1) and type 2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	198-202
20670419-1	2010	BACKGROUND: Accurate assessment of the human epidermal growth factor receptor 2 (HER2) of invasive breast cancer is essential to treatment decisions since the advent of targeted therapy with the humanized monoclonal antibody trastuzumab and the dual tyrosine kinase inhibitor lapatinib.	Lapatinib	276-285	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-85
20664065-6	2010	Furthermore, we found that lapatinib, an EGFR inhibitor used as an anticancer drug, converted strong, transient Akt phosphorylation into weak, sustained Akt phosphorylation, and, because of the low-pass filter characteristics of the Akt pathway, this led to stronger S6 phosphorylation than occurred in the absence of the inhibitor.	Lapatinib	27-36	AKT serine/threonine kinase 1	Rattus norvegicus	153-156
20664065-6	2010	Furthermore, we found that lapatinib, an EGFR inhibitor used as an anticancer drug, converted strong, transient Akt phosphorylation into weak, sustained Akt phosphorylation, and, because of the low-pass filter characteristics of the Akt pathway, this led to stronger S6 phosphorylation than occurred in the absence of the inhibitor.	Lapatinib	27-36	epidermal growth factor receptor	Rattus norvegicus	41-45
20664065-6	2010	Furthermore, we found that lapatinib, an EGFR inhibitor used as an anticancer drug, converted strong, transient Akt phosphorylation into weak, sustained Akt phosphorylation, and, because of the low-pass filter characteristics of the Akt pathway, this led to stronger S6 phosphorylation than occurred in the absence of the inhibitor.	Lapatinib	27-36	AKT serine/threonine kinase 1	Rattus norvegicus	112-115
20664065-6	2010	Furthermore, we found that lapatinib, an EGFR inhibitor used as an anticancer drug, converted strong, transient Akt phosphorylation into weak, sustained Akt phosphorylation, and, because of the low-pass filter characteristics of the Akt pathway, this led to stronger S6 phosphorylation than occurred in the absence of the inhibitor.	Lapatinib	27-36	AKT serine/threonine kinase 1	Rattus norvegicus	153-156
20388063-7	2010	Inhibitors of the epidermal growth factor receptor (EGFR) family, such as erlotinib, cetuximab, and lapatinib were recently investigated.	Lapatinib	100-109	epidermal growth factor receptor	Homo sapiens	18-50
20530274-13	2010	CONCLUSION: Lapatinib monotherapy for 14 days followed by lapatinib plus paclitaxel for 12 weeks provided clinical benefit in IBC patients with HER2-overexpressing tumors without unexpected toxicity.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
20530283-3	2010	In breast cancer, two new targeted agents have recently been approved: lapatinib, directed against the human epidermal growth factor receptor 2 (HER2); and bevacizumab, directed against vascular endothelial growth factor (VEGF).	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-143
20530283-3	2010	In breast cancer, two new targeted agents have recently been approved: lapatinib, directed against the human epidermal growth factor receptor 2 (HER2); and bevacizumab, directed against vascular endothelial growth factor (VEGF).	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
20406211-5	2010	In ion channel studies, lapatinib inhibited the hERG current in a concentration-dependent manner, with a half-maximum inhibition concentration (IC(50)) of 0.8 +/- 0.09 microm.	Lapatinib	24-33	ETS transcription factor ERG	Homo sapiens	48-52
20406211-8	2010	These results suggest that the APD(90)-prolonging effect of lapatinib on rabbit Purkinje fibres is primarily a result of inhibition of the hERG current and I(Ks), but not I(Na), I(K1) or I(Ca).	Lapatinib	60-69	ETS transcription factor ERG	Homo sapiens	139-143
20388063-7	2010	Inhibitors of the epidermal growth factor receptor (EGFR) family, such as erlotinib, cetuximab, and lapatinib were recently investigated.	Lapatinib	100-109	epidermal growth factor receptor	Homo sapiens	52-56
23130185-5	2010	This case could represent the first case report of AGEP to the EGFR inhibitor, lapatinib.	Lapatinib	79-88	epidermal growth factor receptor	Homo sapiens	63-67
20479410-2	2010	Lapatinib is effective in the treatment of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
20614563-0	2010	Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
19856307-1	2010	The monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib improve the clinical outcome of patients with HER2-overexpressing breast cancer.	Lapatinib	80-89	epidermal growth factor receptor	Homo sapiens	44-48
20479410-0	2010	Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
20479410-0	2010	Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-116
20479410-2	2010	Lapatinib is effective in the treatment of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-83
19856307-8	2010	Our in vitro studies demonstrated that HER2 vaccine-induced antibodies effectively caused a decrease in HER2 expression, but when combined with lapatinib caused significant inhibition of HER2 signaling, decreased pERK and pAKT levels and reduced breast tumor cell proliferation.	Lapatinib	144-153	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	213-217
19856307-11	2010	Based on these results, we feel clinical studies using this approach to target HER2-overexpressing breast cancer, including trastuzumab- and lapatinib-resistant tumors is warranted.	Lapatinib	141-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
19856307-1	2010	The monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib improve the clinical outcome of patients with HER2-overexpressing breast cancer.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-53
19856307-1	2010	The monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib improve the clinical outcome of patients with HER2-overexpressing breast cancer.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
19856307-3	2010	Because HER2 overexpression persists, we hypothesized that the anti-HER2 immune response induced by cancer vaccines would be an effective strategy for treating trastuzumab- and lapatinib-refractory tumors.	Lapatinib	177-186	erb-b2 receptor tyrosine kinase 2	Homo sapiens	8-12
19856307-3	2010	Because HER2 overexpression persists, we hypothesized that the anti-HER2 immune response induced by cancer vaccines would be an effective strategy for treating trastuzumab- and lapatinib-refractory tumors.	Lapatinib	177-186	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
20503416-5	2010	Another chemotherapeutic drug, lapatinib, a dual tyrosine inhibitor of epidermal growth factor (EGFR) and HER2 signaling, in combination with capecitabine demonstrated encouraging results, with a 51% decrease in disease progression.	Lapatinib	31-40	epidermal growth factor	Homo sapiens	71-94
20220514-0	2010	Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
20220514-2	2010	Lapatinib is a novel tyrosine kinase inhibitor for treatment of breast cancer with human epidermal growth factor receptor 2 (HER2) amplification.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-123
20220514-2	2010	Lapatinib is a novel tyrosine kinase inhibitor for treatment of breast cancer with human epidermal growth factor receptor 2 (HER2) amplification.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
20220514-3	2010	Given promising results in clinical studies, we investigated the survival benefits of lapatinib use in patients with HER2-overexpressing advanced or metastatic breast cancer.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
20220514-11	2010	In conclusion, addition of lapatinib to conventional anticancer treatment might offer superior survival benefit to patients with advanced metastatic HER2-overexpressing breast cancer.	Lapatinib	27-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
20503407-4	2010	Trastuzumab and lapatinib, which target human epidermal growth factor receptor 2 (HER-2), have demonstrated benefit in clinical trials for HER-2-positive breast cancers.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-80
20503416-5	2010	Another chemotherapeutic drug, lapatinib, a dual tyrosine inhibitor of epidermal growth factor (EGFR) and HER2 signaling, in combination with capecitabine demonstrated encouraging results, with a 51% decrease in disease progression.	Lapatinib	31-40	epidermal growth factor	Homo sapiens	96-100
20503407-4	2010	Trastuzumab and lapatinib, which target human epidermal growth factor receptor 2 (HER-2), have demonstrated benefit in clinical trials for HER-2-positive breast cancers.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-87
20503407-4	2010	Trastuzumab and lapatinib, which target human epidermal growth factor receptor 2 (HER-2), have demonstrated benefit in clinical trials for HER-2-positive breast cancers.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-144
20503416-5	2010	Another chemotherapeutic drug, lapatinib, a dual tyrosine inhibitor of epidermal growth factor (EGFR) and HER2 signaling, in combination with capecitabine demonstrated encouraging results, with a 51% decrease in disease progression.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
20457354-0	2010	Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
20457354-0	2010	Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	90-94
20457354-6	2010	Immunohistochemical analyses demonstrated that radiosensitization by lapatinib correlated with ERK1/2 inhibition in the EGFR+ SUM149 model and with AKT inhibition in the HER2+ SUM225 model.	Lapatinib	69-78	mitogen-activated protein kinase 3	Homo sapiens	95-101
20457354-6	2010	Immunohistochemical analyses demonstrated that radiosensitization by lapatinib correlated with ERK1/2 inhibition in the EGFR+ SUM149 model and with AKT inhibition in the HER2+ SUM225 model.	Lapatinib	69-78	epidermal growth factor receptor	Homo sapiens	120-124
20457354-1	2010	PURPOSE: To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.	Lapatinib	30-39	epidermal growth factor receptor	Homo sapiens	48-80
20457354-6	2010	Immunohistochemical analyses demonstrated that radiosensitization by lapatinib correlated with ERK1/2 inhibition in the EGFR+ SUM149 model and with AKT inhibition in the HER2+ SUM225 model.	Lapatinib	69-78	AKT serine/threonine kinase 1	Homo sapiens	148-151
20457354-1	2010	PURPOSE: To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.	Lapatinib	30-39	epidermal growth factor receptor	Homo sapiens	82-86
20457354-6	2010	Immunohistochemical analyses demonstrated that radiosensitization by lapatinib correlated with ERK1/2 inhibition in the EGFR+ SUM149 model and with AKT inhibition in the HER2+ SUM225 model.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
20457354-1	2010	PURPOSE: To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
20457354-7	2010	CONCLUSION: Our data suggest that lapatinib combined with fractionated radiotherapy may be useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	106-110
20457354-7	2010	CONCLUSION: Our data suggest that lapatinib combined with fractionated radiotherapy may be useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
20457354-1	2010	PURPOSE: To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.	Lapatinib	30-39	epidermal growth factor receptor	Homo sapiens	130-134
20457354-7	2010	CONCLUSION: Our data suggest that lapatinib combined with fractionated radiotherapy may be useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.	Lapatinib	34-43	mitogen-activated protein kinase 3	Homo sapiens	184-190
20457354-1	2010	PURPOSE: To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
20457354-7	2010	CONCLUSION: Our data suggest that lapatinib combined with fractionated radiotherapy may be useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.	Lapatinib	34-43	AKT serine/threonine kinase 1	Homo sapiens	195-198
20457354-7	2010	CONCLUSION: Our data suggest that lapatinib combined with fractionated radiotherapy may be useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	232-236
20457354-3	2010	RESULTS: Basal-like/EGFR+ SUM149 breast cancer tumors were completely resistant to treatment with lapatinib alone but highly growth impaired with lapatinib plus radiotherapy, exhibiting an enhancement ratio average of 2.75 and a fractional tumor product ratio average of 2.20 during the study period.	Lapatinib	98-107	epidermal growth factor receptor	Homo sapiens	20-24
20457354-7	2010	CONCLUSION: Our data suggest that lapatinib combined with fractionated radiotherapy may be useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	242-246
20457354-3	2010	RESULTS: Basal-like/EGFR+ SUM149 breast cancer tumors were completely resistant to treatment with lapatinib alone but highly growth impaired with lapatinib plus radiotherapy, exhibiting an enhancement ratio average of 2.75 and a fractional tumor product ratio average of 2.20 during the study period.	Lapatinib	146-155	epidermal growth factor receptor	Homo sapiens	20-24
20457354-4	2010	In contrast, HER2+ SUM225 breast cancer tumors were highly responsive to treatment with lapatinib alone and yielded a relatively lower enhancement ratio average of 1.25 during the study period with lapatinib plus radiotherapy.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
20457354-4	2010	In contrast, HER2+ SUM225 breast cancer tumors were highly responsive to treatment with lapatinib alone and yielded a relatively lower enhancement ratio average of 1.25 during the study period with lapatinib plus radiotherapy.	Lapatinib	198-207	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
20457354-5	2010	Durable tumor control in the HER2+ SUM225 model was more effective with the combination treatment than either lapatinib or radiotherapy alone.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
20501798-11	2010	Thus, increased activation of the PI3K/AKT pathway correlates with resistance to trastuzumab, which can be overcome by lapatinib.	Lapatinib	119-128	AKT serine/threonine kinase 1	Homo sapiens	39-42
20501798-1	2010	Trastuzumab and lapatinib provide clinical benefit to women with human epidermal growth factor receptor 2 (HER)-positive breast cancer.	Lapatinib	16-25	epidermal growth factor receptor	Homo sapiens	71-103
20501798-4	2010	The aim of this study was to investigate the role of receptor tyrosine kinase signaling and phosphoinositide 3-kinase (PI3K)/AKT pathway activation in conferring resistance to trastuzumab and lapatinib.	Lapatinib	192-201	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	92-117
20501798-8	2010	In these cells, trastuzumab had little effect on AKT phosphorylation, whereas lapatinib retained activity through the dephosphorylation of AKT.	Lapatinib	78-87	AKT serine/threonine kinase 1	Homo sapiens	139-142
20406840-0	2010	Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-101
20501798-9	2010	Increased phosphorylation of HER2, epidermal growth factor receptor, HER3, and insulin-like growth factor IR correlated with response to lapatinib but not trastuzumab.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
20501798-9	2010	Increased phosphorylation of HER2, epidermal growth factor receptor, HER3, and insulin-like growth factor IR correlated with response to lapatinib but not trastuzumab.	Lapatinib	137-146	epidermal growth factor receptor	Homo sapiens	35-67
20501798-9	2010	Increased phosphorylation of HER2, epidermal growth factor receptor, HER3, and insulin-like growth factor IR correlated with response to lapatinib but not trastuzumab.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 3	Homo sapiens	69-73
20406840-11	2010	CONCLUSIONS: Lapatinib as a monotherapy or in combination with capecitabine seems to be equally effective in patients with p95HER2-positive and p95HER2-negative HER2-positive breast tumors.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
20549373-7	2010	One of these treatment options is lapatinib, an orally active small molecule that inhibits the tyrosine kinases of HER-2 and the epidermal growth factor receptor type 1 (EGFR).	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-120
20549373-7	2010	One of these treatment options is lapatinib, an orally active small molecule that inhibits the tyrosine kinases of HER-2 and the epidermal growth factor receptor type 1 (EGFR).	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	129-161
20549373-7	2010	One of these treatment options is lapatinib, an orally active small molecule that inhibits the tyrosine kinases of HER-2 and the epidermal growth factor receptor type 1 (EGFR).	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	170-174
20459769-0	2010	Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Mus musculus	57-62
20459769-3	2010	Recent studies demonstrate that lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast cancer.	Lapatinib	32-41	epidermal growth factor receptor	Mus musculus	79-83
20459769-3	2010	Recent studies demonstrate that lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast cancer.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Mus musculus	88-93
20459769-3	2010	Recent studies demonstrate that lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast cancer.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Mus musculus	137-142
20459769-9	2010	Furthermore, lapatinib induced G1 cell cycle arrest (P < 0.0001) and apoptotic cell death (P < 0.0006) and reduced cyclin A and B1 levels, which are regulators of S and G2/M cell cycle stages, respectively.	Lapatinib	13-22	cyclin A2	Mus musculus	121-136
20459769-10	2010	Stimulation of apoptosis in lapatinib-treated A549 cells was correlated with increased cleaved PARP, active caspase-3, and proapoptotic Bak-1 levels, and reduction in the antiapoptotic IAP-2 and Bcl-xL protein levels.	Lapatinib	28-37	poly (ADP-ribose) polymerase family, member 1	Mus musculus	95-99
20459769-10	2010	Stimulation of apoptosis in lapatinib-treated A549 cells was correlated with increased cleaved PARP, active caspase-3, and proapoptotic Bak-1 levels, and reduction in the antiapoptotic IAP-2 and Bcl-xL protein levels.	Lapatinib	28-37	caspase 3	Mus musculus	108-117
20459769-10	2010	Stimulation of apoptosis in lapatinib-treated A549 cells was correlated with increased cleaved PARP, active caspase-3, and proapoptotic Bak-1 levels, and reduction in the antiapoptotic IAP-2 and Bcl-xL protein levels.	Lapatinib	28-37	BCL2-antagonist/killer 1	Mus musculus	136-141
20459769-10	2010	Stimulation of apoptosis in lapatinib-treated A549 cells was correlated with increased cleaved PARP, active caspase-3, and proapoptotic Bak-1 levels, and reduction in the antiapoptotic IAP-2 and Bcl-xL protein levels.	Lapatinib	28-37	intracisternal A particle 2	Mus musculus	185-190
20459769-10	2010	Stimulation of apoptosis in lapatinib-treated A549 cells was correlated with increased cleaved PARP, active caspase-3, and proapoptotic Bak-1 levels, and reduction in the antiapoptotic IAP-2 and Bcl-xL protein levels.	Lapatinib	28-37	BCL2-like 1	Mus musculus	195-201
20459769-11	2010	We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels.	Lapatinib	25-34	epidermal growth factor receptor	Mus musculus	43-47
20459769-11	2010	We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Mus musculus	48-53
20459769-11	2010	We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels.	Lapatinib	25-34	epidermal growth factor receptor	Mus musculus	84-88
20459769-11	2010	We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Mus musculus	92-97
20459769-11	2010	We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels.	Lapatinib	25-34	proliferating cell nuclear antigen	Mus musculus	126-130
20406840-2	2010	We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
20064507-4	2010	With this, intense efforts have been made to inhibit the activity of the EGFR and HER2 by designing antibodies against the ligand binding domains (cetuximab, panitumumab and trastuzumab) or small molecules against the tyrosine kinase domains (erlotinib, gefitinib, and lapatinib).	Lapatinib	269-278	epidermal growth factor receptor	Homo sapiens	73-77
20214527-0	2010	Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
20214527-1	2010	OBJECTIVE: EGF103009 (ClinicalTrials.gov identifier: NCT00105950) was a phase 2, open-label, multicenter study that showed lapatinib monotherapy to be clinically active in women with relapsed or refractory HER2+ (ErbB2+) inflammatory breast cancer that progressed following prior therapy with anthracyclines, taxanes, and trastuzumab.	Lapatinib	123-132	erb-b2 receptor tyrosine kinase 2	Homo sapiens	206-210
20214497-2	2010	AREAS COVERED IN THIS REVIEW: This review considers the clinical value of trastuzumab and lapatinib, the two HER2-targeted therapies approved for clinical practice.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
20406946-2	2010	ErbB2 targeting is clinically relevant using trastuzumab (anti-ErbB2 antibody) and lapatinib (small-molecule ErbB1/2 inhibitor).	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
20406946-2	2010	ErbB2 targeting is clinically relevant using trastuzumab (anti-ErbB2 antibody) and lapatinib (small-molecule ErbB1/2 inhibitor).	Lapatinib	83-92	epidermal growth factor receptor	Homo sapiens	109-116
20406946-4	2010	In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors.	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	81-88
20406946-4	2010	In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors.	Lapatinib	61-70	X-linked inhibitor of apoptosis	Homo sapiens	183-222
20406946-4	2010	In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors.	Lapatinib	61-70	X-linked inhibitor of apoptosis	Homo sapiens	224-228
20406946-4	2010	In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	274-279
20406946-4	2010	In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors.	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	81-86
20424000-3	2010	We have now investigated the effects of combination treatment with the oral fluoropyrimidine S-1 and the HER2-targeting agents lapatinib or trastuzumab in gastric cancer cells with or without HER2 amplification.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
20424000-6	2010	Lapatinib or trastuzumab also induced downregulation of thymidylate synthase (TS) expression and activity only in cells with HER2 amplification.	Lapatinib	0-9	thymidylate synthetase	Homo sapiens	56-76
20424000-6	2010	Lapatinib or trastuzumab also induced downregulation of thymidylate synthase (TS) expression and activity only in cells with HER2 amplification.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
20424000-8	2010	These observations thus suggest that lapatinib-induced or trastuzumab-induced downregulation of TS is responsible, at least in part, for the synergistic antitumor effect of combined treatment with 5FU and HER2-targeting agents.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
20064507-4	2010	With this, intense efforts have been made to inhibit the activity of the EGFR and HER2 by designing antibodies against the ligand binding domains (cetuximab, panitumumab and trastuzumab) or small molecules against the tyrosine kinase domains (erlotinib, gefitinib, and lapatinib).	Lapatinib	269-278	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
20350896-1	2010	Lapatinib is an oral dual tyrosine kinase inhibitor targeting epidermal growth factor receptor and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	62-94
20095796-0	2010	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.	Lapatinib	78-87	twist family bHLH transcription factor 1	Homo sapiens	49-54
20095796-1	2010	BACKGROUND: In a phase 3 randomized, multicenter, double-blind, placebo-controlled study, first-line therapy with lapatinib plus paclitaxel significantly improved clinical outcomes based on a pre-planned analysis of ErbB2+ metastatic breast cancer patients (GSK Study #EGF30001; ClinicalTrials.gov identifier: NCT00075270).	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	216-221
20095796-9	2010	In the ErbB2+ subgroup, the lapatinib plus paclitaxel (L + P) arm demonstrated stable FACT-B scores over the first year, while average scores for patients on P + placebo (P + pla) monotherapy decreased (change from baseline: L + P, p = 0.99; P + pla, p = 0.01).	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	7-12
20350896-1	2010	Lapatinib is an oral dual tyrosine kinase inhibitor targeting epidermal growth factor receptor and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
20300520-6	2010	We further showed that suppression of eEF-2 kinase-regulated autophagy impeded cell growth in serum/nutrient-deprived cultures and handicapped cell survival, and enhanced the efficacy of the growth factor inhibitors such as trastuzumab, gefitinib, and lapatinib.	Lapatinib	252-261	eukaryotic elongation factor 2 kinase	Homo sapiens	38-50
20179708-0	2010	Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
20179708-0	2010	Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.	Lapatinib	91-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
19262991-3	2010	RESULTS: We are currently evaluating the activity of lapatinib in patients with HER-2 amplified solid tumors using the target-specific, histology-independent, randomized discontinuation design.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-85
20204279-0	2010	Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.	Lapatinib	21-30	epidermal growth factor receptor	Homo sapiens	63-67
20204279-0	2010	Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
20204279-0	2010	Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.	Lapatinib	32-40	epidermal growth factor receptor	Homo sapiens	63-67
20204279-0	2010	Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.	Lapatinib	32-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
20204279-3	2010	Lapatinib (GW572016) is a small molecule that is administrated orally and functions as a reversible inhibitor of both EGFR and HER-2 tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	118-122
20204279-3	2010	Lapatinib (GW572016) is a small molecule that is administrated orally and functions as a reversible inhibitor of both EGFR and HER-2 tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-132
20204279-3	2010	Lapatinib (GW572016) is a small molecule that is administrated orally and functions as a reversible inhibitor of both EGFR and HER-2 tyrosine kinases.	Lapatinib	11-19	epidermal growth factor receptor	Homo sapiens	118-122
20204279-3	2010	Lapatinib (GW572016) is a small molecule that is administrated orally and functions as a reversible inhibitor of both EGFR and HER-2 tyrosine kinases.	Lapatinib	11-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-132
20179708-9	2010	CONCLUSIONS: Lapatinib combined with capecitabine is an active treatment option for women with refractory HER2-positive MBC, including those with progressive CNS disease.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
20215545-1	2010	PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.	Lapatinib	109-118	epidermal growth factor receptor	Homo sapiens	187-219
20197472-2	2010	We show here that adhesion of human ErbB2+ breast cancer cells to basement membrane laminin-5 provides substantial resistance to trastuzumab and lapatinib, agents that respectively target the extracellular and kinase domains of ErbB2.	Lapatinib	145-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-41
20197472-2	2010	We show here that adhesion of human ErbB2+ breast cancer cells to basement membrane laminin-5 provides substantial resistance to trastuzumab and lapatinib, agents that respectively target the extracellular and kinase domains of ErbB2.	Lapatinib	145-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	228-233
20215545-1	2010	PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.	Lapatinib	109-118	epidermal growth factor receptor	Homo sapiens	221-225
20215545-1	2010	PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.	Lapatinib	109-118	epidermal growth factor receptor	Homo sapiens	237-241
20215545-1	2010	PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	245-249
20215545-1	2010	PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	250-253
20215545-1	2010	PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	255-259
20032127-0	2010	Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
20179226-6	2010	The effect of lapatinib on ERalpha signaling varied markedly depending on the nature of the HER2/ERalpha cross-talk.	Lapatinib	14-23	estrogen receptor 1	Homo sapiens	97-104
19455431-1	2010	In this work, we identified the detrimental missense mutations (point mutations) in epidermal growth factor receptor (EGFR) and its binding efficiency with the inhibitors namely Erlotinib, Gefitinib, and Lapatinib.	Lapatinib	204-213	epidermal growth factor receptor	Homo sapiens	84-116
19455431-1	2010	In this work, we identified the detrimental missense mutations (point mutations) in epidermal growth factor receptor (EGFR) and its binding efficiency with the inhibitors namely Erlotinib, Gefitinib, and Lapatinib.	Lapatinib	204-213	epidermal growth factor receptor	Homo sapiens	118-122
19815649-0	2010	An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
19815649-1	2010	BACKGROUND: The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, and a trastuzumab and had no other treatment options.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
20179222-0	2010	Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
20179222-0	2010	Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
20179226-7	2010	In long-term estrogen-deprived cells characterized by enhanced ERalpha function, lapatinib suppressed ERalpha genomic activity (as measured by pERSer118, ERalpha transcriptional activity, and PGR gene expression).	Lapatinib	81-90	estrogen receptor 1	Homo sapiens	63-70
20179222-0	2010	Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
20179222-2	2010	Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both EGFR and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	75-79
20179222-2	2010	Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both EGFR and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
20179222-6	2010	In HER2-amplified cells, the combination of trastuzumab and lapatinib was evaluated using the median effects principal.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
20179222-8	2010	RESULTS: Lapatinib had concentration-dependent antiproliferative activity across the panel with the greatest effects in HER2-amplified cells.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
20179222-10	2010	Cell cycle analysis revealed that lapatinib induced G(1) arrest in sensitive lines and phosphorylated AKT and phosphorylated ERK were decreased in response to lapatinib as well.	Lapatinib	34-43	AKT serine/threonine kinase 1	Homo sapiens	102-105
20179222-10	2010	Cell cycle analysis revealed that lapatinib induced G(1) arrest in sensitive lines and phosphorylated AKT and phosphorylated ERK were decreased in response to lapatinib as well.	Lapatinib	34-43	mitogen-activated protein kinase 1	Homo sapiens	125-128
20179222-10	2010	Cell cycle analysis revealed that lapatinib induced G(1) arrest in sensitive lines and phosphorylated AKT and phosphorylated ERK were decreased in response to lapatinib as well.	Lapatinib	159-168	AKT serine/threonine kinase 1	Homo sapiens	102-105
20179222-10	2010	Cell cycle analysis revealed that lapatinib induced G(1) arrest in sensitive lines and phosphorylated AKT and phosphorylated ERK were decreased in response to lapatinib as well.	Lapatinib	159-168	mitogen-activated protein kinase 1	Homo sapiens	125-128
20179222-14	2010	CONCLUSION: Together, these data suggest that lapatinib has activity in HER2-amplified upper gastrointestinal cancer and supports the ongoing clinical investigation of lapatinib in patients with HER2-amplified disease.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
20179226-0	2010	Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-154
20179226-2	2010	We investigated (a) whether the epidermal growth factor receptor/HER2 inhibitor lapatinib could restore endocrine responsiveness in cell models of acquired endocrine resistance with modest increases in HER2, and (b) the nature of ERalpha-HER2 cross-talk in this process.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
20179226-6	2010	The effect of lapatinib on ERalpha signaling varied markedly depending on the nature of the HER2/ERalpha cross-talk.	Lapatinib	14-23	estrogen receptor 1	Homo sapiens	27-34
20179226-6	2010	The effect of lapatinib on ERalpha signaling varied markedly depending on the nature of the HER2/ERalpha cross-talk.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
20088787-0	2010	Ras-induced resistance to lapatinib is overcome by MEK inhibition.	Lapatinib	26-35	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
20088787-1	2010	Lapatinib, a dual HER2 and EGFR tyrosine kinase inhibitor is highly active in HER2+ breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-22
20088787-1	2010	Lapatinib, a dual HER2 and EGFR tyrosine kinase inhibitor is highly active in HER2+ breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
20088787-5	2010	Using SKBR3 cells, a HER2+ breast cancer cell line that is naturally devoid of mutations in PI3KCA, PTEN, BRAF, and ras we show that both H-ras overexpression and expression of an oncogenic ras allele (ras V12) reduce susceptibility to lapatinib in analogy to what observed with activating PI3KCA mutations and with a constitutively active form of Akt.	Lapatinib	236-245	Harvey rat sarcoma virus oncogene	Mus musculus	138-143
20088787-6	2010	Importantly, we found that resistance to lapatinib due to ras overexpression or to ras V12 is overcome by MEK inhibition with U0126, suggesting a key role for the MEK-Erk pathway in ras-induced resistance.	Lapatinib	41-50	mitogen-activated protein kinase kinase 7	Homo sapiens	106-109
20088787-6	2010	Importantly, we found that resistance to lapatinib due to ras overexpression or to ras V12 is overcome by MEK inhibition with U0126, suggesting a key role for the MEK-Erk pathway in ras-induced resistance.	Lapatinib	41-50	mitogen-activated protein kinase kinase 7	Homo sapiens	163-166
20088787-6	2010	Importantly, we found that resistance to lapatinib due to ras overexpression or to ras V12 is overcome by MEK inhibition with U0126, suggesting a key role for the MEK-Erk pathway in ras-induced resistance.	Lapatinib	41-50	EPH receptor B2	Homo sapiens	167-170
20088787-9	2010	Combining MEK inhibitors with lapatinib may help overcome this form of resistance and increase the efficacy of lapatinib in these tumors.	Lapatinib	111-120	mitogen-activated protein kinase kinase 7	Homo sapiens	10-13
20179241-2	2010	Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.	Lapatinib	40-49	estrogen receptor 1	Homo sapiens	21-23
20179241-2	2010	Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
20179226-7	2010	In long-term estrogen-deprived cells characterized by enhanced ERalpha function, lapatinib suppressed ERalpha genomic activity (as measured by pERSer118, ERalpha transcriptional activity, and PGR gene expression).	Lapatinib	81-90	estrogen receptor 1	Homo sapiens	102-109
20179226-7	2010	In long-term estrogen-deprived cells characterized by enhanced ERalpha function, lapatinib suppressed ERalpha genomic activity (as measured by pERSer118, ERalpha transcriptional activity, and PGR gene expression).	Lapatinib	81-90	estrogen receptor 1	Homo sapiens	102-109
20179226-7	2010	In long-term estrogen-deprived cells characterized by enhanced ERalpha function, lapatinib suppressed ERalpha genomic activity (as measured by pERSer118, ERalpha transcriptional activity, and PGR gene expression).	Lapatinib	81-90	progesterone receptor	Homo sapiens	192-195
20179226-8	2010	In contrast, in long-term tamoxifen-treated cells with reduced ERalpha activation, lapatinib reactivated ERalpha genomic function.	Lapatinib	83-92	estrogen receptor 1	Homo sapiens	105-112
20179226-11	2010	Regardless, interrupting the HER2/ERalpha cross-talk with lapatinib can restore endocrine sensitivity and should be investigated as a therapeutic strategy in combination with endocrine therapy in ERalpha+/HER2- patients with acquired endocrine resistance.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
20179226-11	2010	Regardless, interrupting the HER2/ERalpha cross-talk with lapatinib can restore endocrine sensitivity and should be investigated as a therapeutic strategy in combination with endocrine therapy in ERalpha+/HER2- patients with acquired endocrine resistance.	Lapatinib	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
20124187-0	2010	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
20124187-1	2010	PURPOSE: Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-37
20124187-11	2010	CONCLUSION: Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.	Lapatinib	76-85	carbonyl reductase 1	Homo sapiens	149-152
20124187-11	2010	CONCLUSION: Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastuzumab significantly improved PFS and CBR versus lapatinib alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	269-274
20126311-1	2010	The efficacy of anti-HER2 therapeutics, such as lapatinib and trastuzumab, is limited by primary and acquired resistance.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
20174688-6	2010	Using our SILAC approach with non-dialyzed serum, we successfully quantified the phosphoproteome of MCF-7 cells induced by lapatinib, an EGFR1/Her2 dual kinase inhibitor.	Lapatinib	123-132	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
20126311-3	2010	Here, we used low-density arrays, quantitative PCR, and western blotting to determine how HER2 signaling inhibition with lapatinib or PI3K inhibitors affects the expression of genes involved in breast cancer metastatic spread and overall prognosis.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
20126311-7	2010	We found that lapatinib induces upregulation of Grb7, an adaptor protein involved in receptor tyrosine kinase signaling and promoting cell survival and cell migration.	Lapatinib	14-23	growth factor receptor bound protein 7	Homo sapiens	48-52
20126311-8	2010	Grb7 upregulation induced by lapatinib was found to occur in cancer cells in vitro and in vivo.	Lapatinib	29-38	growth factor receptor bound protein 7	Homo sapiens	0-4
20126311-10	2010	Thus, Grb7 is repressed by PI3K signaling and lapatinib-mediated Akt inhibition is responsible for Grb7 de-repression.	Lapatinib	46-55	AKT serine/threonine kinase 1	Homo sapiens	65-68
20126311-10	2010	Thus, Grb7 is repressed by PI3K signaling and lapatinib-mediated Akt inhibition is responsible for Grb7 de-repression.	Lapatinib	46-55	growth factor receptor bound protein 7	Homo sapiens	99-103
20126311-11	2010	Finally, we show that Grb7 removal by RNA-interference reduces breast cancer cell viability and increases the activity of lapatinib.	Lapatinib	122-131	growth factor receptor bound protein 7	Homo sapiens	22-26
20124457-5	2010	In addition, analysis of changes in phospho-RelA expression in sequential clinical biopsies from ErbB2(+) breast cancers treated with lapatinib monotherapy revealed marginally statistically significant differences between responders and nonresponders, which was consistent with our preclinical findings.	Lapatinib	134-143	RELA proto-oncogene, NF-kB subunit	Homo sapiens	44-48
19925494-1	2010	Lapatinib is a small molecule inhibitor of both HER2 and the epidermal growth factor receptor (EGFR).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
19925494-1	2010	Lapatinib is a small molecule inhibitor of both HER2 and the epidermal growth factor receptor (EGFR).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	61-93
19925494-1	2010	Lapatinib is a small molecule inhibitor of both HER2 and the epidermal growth factor receptor (EGFR).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	95-99
19925494-8	2010	A strong correlation was observed between HER2 expression and the anti-tumor effect of lapatinib in vivo.	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
20103665-7	2010	RESULTS: Lapatinib inhibited cell growth in four pancreatic cancer cell lines, but radiosensitized only wild-type K-ras-expressing T3M4 cells.	Lapatinib	9-18	KRAS proto-oncogene, GTPase	Homo sapiens	114-119
20103665-9	2010	Overexpression of constitutively active K-ras (G12V) abrogated lapatinib-mediated inhibition of both Akt phosphorylation and radiosensitization.	Lapatinib	63-72	KRAS proto-oncogene, GTPase	Homo sapiens	40-45
20103665-9	2010	Overexpression of constitutively active K-ras (G12V) abrogated lapatinib-mediated inhibition of both Akt phosphorylation and radiosensitization.	Lapatinib	63-72	AKT serine/threonine kinase 1	Homo sapiens	101-104
20124457-5	2010	In addition, analysis of changes in phospho-RelA expression in sequential clinical biopsies from ErbB2(+) breast cancers treated with lapatinib monotherapy revealed marginally statistically significant differences between responders and nonresponders, which was consistent with our preclinical findings.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-102
20124457-6	2010	Elucidating the regulation of RelA by lapatinib in ErbB2(+) breast cancers, and showing its role in the development of therapeutic resistance to lapatinib, identifies another therapeutic target to overcome or prevent the onset of resistance to lapatinib in some women with ErbB2(+) breast cancers.	Lapatinib	38-47	RELA proto-oncogene, NF-kB subunit	Homo sapiens	30-34
20124457-6	2010	Elucidating the regulation of RelA by lapatinib in ErbB2(+) breast cancers, and showing its role in the development of therapeutic resistance to lapatinib, identifies another therapeutic target to overcome or prevent the onset of resistance to lapatinib in some women with ErbB2(+) breast cancers.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-56
21779217-0	2010	Long-Term Disease Control with Lapatinib and Capecitabine in a Heavily Pretreated Patient with ErbB2-Positive Metastatic Breast Cancer.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-100
20027191-2	2010	Lapatinib is an oral small-molecule tyrosine kinase inhibitor directed against EGFR and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	79-83
20027191-2	2010	Lapatinib is an oral small-molecule tyrosine kinase inhibitor directed against EGFR and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
20027191-4	2010	HER2 status, either gene copy number or the protein expression level, is the best predictive marker available for assessing response to trastuzumab and lapatinib.	Lapatinib	152-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
19850946-4	2010	MEASUREMENTS AND MAIN RESULTS: The EGFR inhibitors gefitinib, erlotinib, and lapatinib inhibited the EGF-induced proliferation of pulmonary arterial smooth muscle cells.	Lapatinib	77-86	epidermal growth factor receptor	Rattus norvegicus	35-39
19850946-4	2010	MEASUREMENTS AND MAIN RESULTS: The EGFR inhibitors gefitinib, erlotinib, and lapatinib inhibited the EGF-induced proliferation of pulmonary arterial smooth muscle cells.	Lapatinib	77-86	epidermal growth factor like 1	Rattus norvegicus	35-38
19720054-0	2010	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.	Lapatinib	0-9	ATP binding cassette subfamily C member 10	Homo sapiens	55-59
19720054-0	2010	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.	Lapatinib	0-9	ATP binding cassette subfamily C member 10	Homo sapiens	61-67
19720054-2	2010	We recently reported a new pharmacological action of the 4-anilinoquinazoline derived EGFR TKIs, such as lapatinib (Tykerb) and erlotinib (Tarceva), which significantly affect the drug resistance patterns in cells expressing the multidrug resistance (MDR) phenotype.	Lapatinib	105-114	epidermal growth factor receptor	Homo sapiens	86-90
19720054-2	2010	We recently reported a new pharmacological action of the 4-anilinoquinazoline derived EGFR TKIs, such as lapatinib (Tykerb) and erlotinib (Tarceva), which significantly affect the drug resistance patterns in cells expressing the multidrug resistance (MDR) phenotype.	Lapatinib	116-122	epidermal growth factor receptor	Homo sapiens	86-90
19720054-3	2010	Previously, we showed that lapatinib and erlotinib could inhibit the drug efflux function of P-glycoprotein (P-gp, ABCB1) and ABCG2 transporters.	Lapatinib	27-36	ATP binding cassette subfamily B member 1	Homo sapiens	93-107
19720054-3	2010	Previously, we showed that lapatinib and erlotinib could inhibit the drug efflux function of P-glycoprotein (P-gp, ABCB1) and ABCG2 transporters.	Lapatinib	27-36	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
19720054-3	2010	Previously, we showed that lapatinib and erlotinib could inhibit the drug efflux function of P-glycoprotein (P-gp, ABCB1) and ABCG2 transporters.	Lapatinib	27-36	ATP binding cassette subfamily B member 1	Homo sapiens	115-120
19720054-3	2010	Previously, we showed that lapatinib and erlotinib could inhibit the drug efflux function of P-glycoprotein (P-gp, ABCB1) and ABCG2 transporters.	Lapatinib	27-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	126-131
19720054-5	2010	Our results showed that lapatinib and erlotinib dose-dependently enhanced the sensitivity of MRP7-transfected HEK293 cells to several established MRP7 substrates, specifically docetaxel, paclitaxel, vinblastine and vinorelbine, whereas there was no or a less effect on the control vector transfected HEK293 cells.	Lapatinib	24-33	ATP binding cassette subfamily C member 10	Homo sapiens	93-97
19720054-5	2010	Our results showed that lapatinib and erlotinib dose-dependently enhanced the sensitivity of MRP7-transfected HEK293 cells to several established MRP7 substrates, specifically docetaxel, paclitaxel, vinblastine and vinorelbine, whereas there was no or a less effect on the control vector transfected HEK293 cells.	Lapatinib	24-33	ATP binding cassette subfamily C member 10	Homo sapiens	146-150
19720054-6	2010	[(3)H]-paclitaxel accumulation and efflux studies demonstrated that lapatinib and erlotinib increased the intracellular accumulation of [(3)H]-paclitaxel and inhibited the efflux of [(3)H]-paclitaxel from MRP7-transfected cells but not in the control cell line.	Lapatinib	68-77	ATP binding cassette subfamily C member 10	Homo sapiens	205-209
19720054-7	2010	Lapatinib is a more potent inhibitor of MRP7 than erlotinib.	Lapatinib	0-9	ATP binding cassette subfamily C member 10	Homo sapiens	40-44
19720054-9	2010	We conclude that the EGFR TKIs, lapatinib and erlotinib reverse MRP7-mediated MDR through inhibition of the drug efflux function, suggesting that an EGFR TKI based combinational therapy may be applicable for chemotherapeutic practice clinically.	Lapatinib	32-41	ATP binding cassette subfamily C member 10	Homo sapiens	64-68
19720054-9	2010	We conclude that the EGFR TKIs, lapatinib and erlotinib reverse MRP7-mediated MDR through inhibition of the drug efflux function, suggesting that an EGFR TKI based combinational therapy may be applicable for chemotherapeutic practice clinically.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	149-153
21188093-1	2010	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	49-81
21188093-1	2010	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	83-87
21188093-1	2010	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	88-93
21188093-1	2010	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-139
21188093-1	2010	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-145
21188093-1	2010	Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-151
21188093-3	2010	Although lapatinib targets both EGFR and HER2, its effects on HER2 appear to be more critical.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	32-36
21188093-3	2010	Although lapatinib targets both EGFR and HER2, its effects on HER2 appear to be more critical.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
21188093-3	2010	Although lapatinib targets both EGFR and HER2, its effects on HER2 appear to be more critical.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
21188093-5	2010	A phase II first-line monotherapy lapatinib trial in HER2-therapy-naive metastatic breast cancer (MBC) patients confirms efficacy in HER2-positive tumors.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
21188093-6	2010	Retrospective analysis of a phase III, first-line MBC study confirmed incremental benefit from lapatinib and paclitaxel over paclitaxel alone in HER2-positive disease.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
21188093-7	2010	A prospective phase III study confirms superiority of letrozole and lapatinib over letrozole alone in HER2-positive MBC.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
21080941-5	2010	Lapatinib is a small-molecule tyrosine kinase inhibitor that blocks phosphorylation of the epidermal growth factor receptor and HER2 in breast cancer cells, resulting in apoptosis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
21080941-7	2010	METHODS: Using mass spectrometry, we identified FASN as one of the proteins that is dephosphorylated by lapatinib in SKBR3 breast cancer cells.	Lapatinib	104-113	fatty acid synthase	Homo sapiens	48-52
21080941-12	2010	Heregulin-induced FASN phosphorylation resulted in increased FASN enzymatic activity, which was inhibited by lapatinib.	Lapatinib	109-118	fatty acid synthase	Homo sapiens	18-22
21080941-12	2010	Heregulin-induced FASN phosphorylation resulted in increased FASN enzymatic activity, which was inhibited by lapatinib.	Lapatinib	109-118	fatty acid synthase	Homo sapiens	61-65
19499221-1	2010	PURPOSE: We undertook a phase I/II study of the EGFR/erbB2 inhibitor lapatinib in patients with recurrent glioblastoma multiforme (GBM) to determine response rate, pharmacokinetics (PK) and recommended dose in patients taking enzyme-inducing anti-epileptic drugs (EIAEDs) and to explore relationships of molecular genetics to outcome.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-58
20156908-0	2010	Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-56
21080941-14	2010	Blocking FASN phosphorylation and activity by lapatinib or C75 suppressed the activity of matrix metallopeptidase 9 and inhibited invasion of SKBR3 and BT474 cells.	Lapatinib	46-55	fatty acid synthase	Homo sapiens	9-13
21080941-14	2010	Blocking FASN phosphorylation and activity by lapatinib or C75 suppressed the activity of matrix metallopeptidase 9 and inhibited invasion of SKBR3 and BT474 cells.	Lapatinib	46-55	matrix metallopeptidase 9	Homo sapiens	90-115
21088439-0	2010	A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
21088439-1	2010	INTRODUCTION: Lapatinib, an orally active tyrosine kinase inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and ErbB2 (HER2), has activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC).	Lapatinib	14-23	epidermal growth factor receptor	Homo sapiens	71-109
21088439-1	2010	INTRODUCTION: Lapatinib, an orally active tyrosine kinase inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and ErbB2 (HER2), has activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC).	Lapatinib	14-23	epidermal growth factor receptor	Homo sapiens	111-115
21088439-1	2010	INTRODUCTION: Lapatinib, an orally active tyrosine kinase inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and ErbB2 (HER2), has activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC).	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-126
21088439-1	2010	INTRODUCTION: Lapatinib, an orally active tyrosine kinase inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and ErbB2 (HER2), has activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC).	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
21088439-1	2010	INTRODUCTION: Lapatinib, an orally active tyrosine kinase inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and ErbB2 (HER2), has activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC).	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	203-207
21088439-2	2010	METHODS: This phase II single-arm trial assessed the safety and efficacy of first-line lapatinib in combination with paclitaxel in previously untreated patients with HER2-overexpressing MBC.	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
20847826-4	2010	As a next step, tyrosine kinase inhibitors (TKIs) have been integrated into daily routine as an alternative approach for targeting HER2: The dual HER1/2 inhibitor lapatinib demonstrated activity in trastuzumab-pretreated mBC patients in combination with capecitabine.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
20847826-4	2010	As a next step, tyrosine kinase inhibitors (TKIs) have been integrated into daily routine as an alternative approach for targeting HER2: The dual HER1/2 inhibitor lapatinib demonstrated activity in trastuzumab-pretreated mBC patients in combination with capecitabine.	Lapatinib	163-172	epidermal growth factor receptor	Homo sapiens	146-152
20847826-5	2010	Furthermore, chemotherapy-free regimens (trastuzumab or lapatinib plus aromatase inhibitors) have been identified as additional options for hormone receptor (HR)- and HER2-positive patients.	Lapatinib	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	140-156
20847826-5	2010	Furthermore, chemotherapy-free regimens (trastuzumab or lapatinib plus aromatase inhibitors) have been identified as additional options for hormone receptor (HR)- and HER2-positive patients.	Lapatinib	56-65	nuclear receptor subfamily 4 group A member 1	Homo sapiens	158-160
20847826-5	2010	Furthermore, chemotherapy-free regimens (trastuzumab or lapatinib plus aromatase inhibitors) have been identified as additional options for hormone receptor (HR)- and HER2-positive patients.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
20847830-0	2010	Lapatinib - Member of a New Generation of ErbB-Targeting Drugs.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	42-46
20847830-3	2010	The small molecule lapatinib is a dual receptor tyrosine kinase inhibitor of both ErbBl and ErbB2.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-97
20847831-0	2010	Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-46
20847831-0	2010	Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
20847831-3	2010	As demonstrated in the EGF30008 trial, a combined targeted strategy with letrozole and lapatinib significantly increased progression-free survival and clinical benefit rates in patients with metastatic breast cancer that co-expresses ER and ErbB2.	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	241-246
20847929-0	2010	Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-34
20847929-3	2010	Therefore, several cooperative groups and academic centers have initiated trials investigating lapatinib in the treatment of early-stage ErbB2 (HER2)-overexpressing breast cancer.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-142
20847929-3	2010	Therefore, several cooperative groups and academic centers have initiated trials investigating lapatinib in the treatment of early-stage ErbB2 (HER2)-overexpressing breast cancer.	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
20736298-0	2010	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-47
20736298-11	2010	These data continue to support the efficacy of lapatinib in patients with HER-2(+) MBC.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
20798196-0	2010	Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.	Lapatinib	147-156	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-35
20798196-12	2010	CONCLUSION: The addition of lapatinib to letrozole led to a significantly longer PFS interval while maintaining QOL during treatment, when compared with letrozole alone, thus confirming the clinical benefit of the combination therapy in the HR(+) HER-2(+) MBC patient population.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	247-252
20156908-0	2010	Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	58-74
20156908-1	2010	OBJECTIVE: To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC).	Lapatinib	71-80	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-141
20156908-1	2010	OBJECTIVE: To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC).	Lapatinib	71-80	epidermal growth factor receptor	Homo sapiens	156-188
20156908-10	2010	CONCLUSIONS: The addition of lapatinib to letrozole is well tolerated and leads to a significantly greater PFS time, ORR, and CBR than with letrozole alone in women with MBC who coexpress HR and HER-2.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	195-200
20200040-3	2010	Novel agents include monoclonal antibodies such as pertuzumab, which bind to receptors on the cell surface, and tyrosine kinase inhibitors (TKIs) such as lapatinib, which target intracellular pathways such as that of the epidermal growth factor receptor.	Lapatinib	154-163	epidermal growth factor receptor	Homo sapiens	221-253
20009104-3	2009	Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).	Lapatinib	64-73	epidermal growth factor receptor	Homo sapiens	49-53
20072830-4	2010	Lapatinib is a novel dual tyrosine kinase inhibitor, blocking HER1 and HER2 tyrosine kinase activity by binding to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	62-66
20072830-4	2010	Lapatinib is a novel dual tyrosine kinase inhibitor, blocking HER1 and HER2 tyrosine kinase activity by binding to the ATP-binding site of the receptor"s intracellular domain.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
20016816-12	2009	Using secreted Gluc, we localized systemic metastases by BLI and quantitatively monitored the total viable metastatic tumor burden by blood Gluc assay during the course of treatment with lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2.	Lapatinib	187-196	epidermal growth factor receptor	Homo sapiens	234-238
20016816-12	2009	Using secreted Gluc, we localized systemic metastases by BLI and quantitatively monitored the total viable metastatic tumor burden by blood Gluc assay during the course of treatment with lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2.	Lapatinib	187-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	243-247
19536776-0	2009	The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.	Lapatinib	46-55	epidermal growth factor receptor	Mus musculus	9-13
19536776-0	2009	The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Mus musculus	14-19
19536776-2	2009	Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	60-92
19536776-2	2009	Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	94-98
19536776-2	2009	Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	104-109
19536776-5	2009	Lapatinib potently inhibited the growth of a HER-2 overexpressing gastric cancer cell line and demonstrated moderate activity in gastric and colon cancer cells with detectable HER-2 expression.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	45-50
19536776-5	2009	Lapatinib potently inhibited the growth of a HER-2 overexpressing gastric cancer cell line and demonstrated moderate activity in gastric and colon cancer cells with detectable HER-2 expression.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	176-181
20009104-3	2009	Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).	Lapatinib	64-73	epidermal growth factor receptor	Homo sapiens	88-92
20009104-3	2009	Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).	Lapatinib	64-73	sterol regulatory element binding transcription factor 1	Homo sapiens	205-248
20009104-3	2009	Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).	Lapatinib	64-73	sterol regulatory element binding transcription factor 1	Homo sapiens	250-257
19749798-1	2009	Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapatinib).	Lapatinib	14-23	epidermal growth factor receptor	Homo sapiens	161-165
19749798-1	2009	Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapatinib).	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
19749798-1	2009	Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapatinib).	Lapatinib	203-212	epidermal growth factor receptor	Homo sapiens	161-165
19749798-1	2009	Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapatinib).	Lapatinib	203-212	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
19923317-8	2009	Lapatinib, an oral small-molecule inhibitor of human epidermal growth factor receptors-1 and -2, has been shown, when combined with capecitabine, to improve progression-free survival in patients with advanced metastatic breast cancer who had progressed on prior therapy.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-95
20071309-2	2009	Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	74-106
20300449-2	2009	There are currently two HER2-targeted therapies approved for clinical use, the monoclonal HER2 antibody trastuzumab and the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
20300449-2	2009	There are currently two HER2-targeted therapies approved for clinical use, the monoclonal HER2 antibody trastuzumab and the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib.	Lapatinib	165-174	epidermal growth factor receptor	Homo sapiens	124-128
20300449-6	2009	Identification and clinical validation of molecular predictors of response to trastuzumab and lapatinib is critical for further personalizing treatment and improving clinical benefit for patients whose tumors over-express HER2.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	222-226
19934303-12	2009	Knockdown of TSC2 resulted in HER2-independent activation of mTOR and dampened the response to trastuzumab and lapatinib.	Lapatinib	111-120	TSC complex subunit 2	Homo sapiens	13-17
19934303-13	2009	Treatment with the HER2 inhibitor lapatinib decreased phosphorylated S6 and growth in TSC2-expressing cells but not in TSC2-knockdown cells.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
19934303-13	2009	Treatment with the HER2 inhibitor lapatinib decreased phosphorylated S6 and growth in TSC2-expressing cells but not in TSC2-knockdown cells.	Lapatinib	34-43	TSC complex subunit 2	Homo sapiens	86-90
19854117-11	2009	Additionally, over-expression of the membrane protein drug transporter, P-glycoprotein (P-gp) a common cancer drug resistance mechanism, greatly reduces the cellular accumulation of dasatinib but not of lapatinib.	Lapatinib	203-212	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
19854117-11	2009	Additionally, over-expression of the membrane protein drug transporter, P-glycoprotein (P-gp) a common cancer drug resistance mechanism, greatly reduces the cellular accumulation of dasatinib but not of lapatinib.	Lapatinib	203-212	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
20071309-2	2009	Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	114-119
20071309-2	2009	Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
20071309-2	2009	Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-135
20071309-7	2009	In a pivotal phase III trial, a combination of lapatinib and capecitabine almost doubled time to disease progression when compared to capecitabine alone (8.4 vs. 4.1 months) in women with HER2/ErbB2-positive advanced or metastatic breast cancer previously treated with anthracyclin, taxanes and trastuzumab.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-192
20071309-7	2009	In a pivotal phase III trial, a combination of lapatinib and capecitabine almost doubled time to disease progression when compared to capecitabine alone (8.4 vs. 4.1 months) in women with HER2/ErbB2-positive advanced or metastatic breast cancer previously treated with anthracyclin, taxanes and trastuzumab.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-198
19858400-0	2009	Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
19853943-0	2009	Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.	Lapatinib	13-22	zinc fingers and homeoboxes 2	Homo sapiens	108-111
19853943-0	2009	Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.	Lapatinib	13-22	mitogen-activated protein kinase kinase 7	Homo sapiens	115-118
19853943-0	2009	Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.	Lapatinib	13-22	mitogen-activated protein kinase 1	Homo sapiens	122-125
19853943-0	2009	Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.	Lapatinib	13-22	mitogen-activated protein kinase kinase 7	Homo sapiens	252-255
19853943-0	2009	Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.	Lapatinib	193-202	mitogen-activated protein kinase kinase 7	Homo sapiens	252-255
19853943-1	2009	BACKGROUND AND PURPOSE: We recently showed that lapatinib, an EGFR/HER2 inhibitor, radiosensitized breast cancer cells of the basal and HER2+ subtypes.	Lapatinib	48-57	epidermal growth factor receptor	Homo sapiens	62-66
19853943-1	2009	BACKGROUND AND PURPOSE: We recently showed that lapatinib, an EGFR/HER2 inhibitor, radiosensitized breast cancer cells of the basal and HER2+ subtypes.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
19853943-1	2009	BACKGROUND AND PURPOSE: We recently showed that lapatinib, an EGFR/HER2 inhibitor, radiosensitized breast cancer cells of the basal and HER2+ subtypes.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
19853943-3	2009	MATERIALS AND METHODS: Response of EGFR downstream signaling pathways was assessed by Western blot and clonogenic cell survival assays in breast tumor cells after irradiation (5Gy), lapatinib, CI-1040, or combined treatment.	Lapatinib	182-191	epidermal growth factor receptor	Homo sapiens	35-39
19786658-0	2009	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Lapatinib	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	104-120
19786658-2	2009	This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).	Lapatinib	42-51	epidermal growth factor receptor	Homo sapiens	95-127
19786658-2	2009	This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-172
19786658-2	2009	This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
19786658-2	2009	This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).	Lapatinib	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	245-261
19786658-5	2009	Results In HR-positive, HER2-positive patients (n = 219), addition of lapatinib to letrozole significantly reduced the risk of disease progression versus letrozole-placebo (hazard ratio [HR] = 0.71; 95% CI, 0.53 to 0.96; P = .019); median PFS was 8.2 v 3.0 months, respectively.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
19858400-3	2009	Lapatinib is a dual inhibitor of HER2 and epidermal growth factor receptor kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
19786658-10	2009	CONCLUSION: This trial demonstrated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and clinical benefit rates in patients with MBC that coexpresses HR and HER2.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	198-202
19752719-1	2009	The aim of this study was to investigate, at preclinical level, efflux pump modulation induced by lapatinib, a small-molecule dual inhibitor of the epidermal growth factor receptor (EGFR), in HER2-negative or HER2-positive breast cancer cell lines (SkBr3 and BRC230).	Lapatinib	98-107	epidermal growth factor receptor	Homo sapiens	148-180
19844234-10	2009	Patients with tumours harbouring an H1047R PIK3CA mutation or low expression of PTEN derived clinical benefit from lapatinib.	Lapatinib	115-124	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	43-49
19844234-10	2009	Patients with tumours harbouring an H1047R PIK3CA mutation or low expression of PTEN derived clinical benefit from lapatinib.	Lapatinib	115-124	phosphatase and tensin homolog	Homo sapiens	80-84
19844234-11	2009	CONCLUSION: Lapatinib monotherapy had shown anti-tumour activity in Japanese patients with HER2-positive MBC that relapsed after trastuzumab-based therapy, including those with brain metastases.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
19853943-4	2009	RESULTS: In SUM102 cells, an EGFR+ basal breast cancer cell line, exposure to ionizing radiation elicited strong activation of ERK1/2 and JNK, which was blocked by lapatinib, and weak/no activation of p38, AKT or STAT3.	Lapatinib	164-173	mitogen-activated protein kinase 3	Homo sapiens	127-133
19853943-4	2009	RESULTS: In SUM102 cells, an EGFR+ basal breast cancer cell line, exposure to ionizing radiation elicited strong activation of ERK1/2 and JNK, which was blocked by lapatinib, and weak/no activation of p38, AKT or STAT3.	Lapatinib	164-173	mitogen-activated protein kinase 8	Homo sapiens	138-141
19853943-6	2009	Lapatinib-mediated radiosensitization of SUM102 cells was completely abrogated with expression of constitutively active Raf.	Lapatinib	0-9	zinc fingers and homeoboxes 2	Homo sapiens	120-123
19853943-8	2009	CONCLUSIONS: These data suggest that radiosensitization by lapatinib is mediated largely through inhibition of MEK/ERK and that direct inhibition of this pathway may provide an additional avenue of radiosensitization in EGFR+ or HER2+ breast cancers.	Lapatinib	59-68	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
19853943-8	2009	CONCLUSIONS: These data suggest that radiosensitization by lapatinib is mediated largely through inhibition of MEK/ERK and that direct inhibition of this pathway may provide an additional avenue of radiosensitization in EGFR+ or HER2+ breast cancers.	Lapatinib	59-68	mitogen-activated protein kinase 1	Homo sapiens	115-118
19853943-8	2009	CONCLUSIONS: These data suggest that radiosensitization by lapatinib is mediated largely through inhibition of MEK/ERK and that direct inhibition of this pathway may provide an additional avenue of radiosensitization in EGFR+ or HER2+ breast cancers.	Lapatinib	59-68	epidermal growth factor receptor	Homo sapiens	220-224
19853943-8	2009	CONCLUSIONS: These data suggest that radiosensitization by lapatinib is mediated largely through inhibition of MEK/ERK and that direct inhibition of this pathway may provide an additional avenue of radiosensitization in EGFR+ or HER2+ breast cancers.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	229-233
19287304-0	2009	Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-77
19287304-13	2009	Lapatinib plus capecitabine seems to have clinical activity in HER2-positive brain metastases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
19826350-3	2009	These discoveries have led to the strategic development of several kinds of EGFR inhibitors, five of which have gained US Food and Drug Administration approval for the treatment of patients with non-small-cell lung cancer (gefitinib and erlotinib), metastatic colorectal cancer (cetuximab and panitumumab), head and neck (cetuximab), pancreatic cancer (erlotinib) and breast (lapatinib) cancer.	Lapatinib	376-385	epidermal growth factor receptor	Homo sapiens	76-80
19752719-1	2009	The aim of this study was to investigate, at preclinical level, efflux pump modulation induced by lapatinib, a small-molecule dual inhibitor of the epidermal growth factor receptor (EGFR), in HER2-negative or HER2-positive breast cancer cell lines (SkBr3 and BRC230).	Lapatinib	98-107	epidermal growth factor receptor	Homo sapiens	182-186
19752719-1	2009	The aim of this study was to investigate, at preclinical level, efflux pump modulation induced by lapatinib, a small-molecule dual inhibitor of the epidermal growth factor receptor (EGFR), in HER2-negative or HER2-positive breast cancer cell lines (SkBr3 and BRC230).	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	192-196
19752719-1	2009	The aim of this study was to investigate, at preclinical level, efflux pump modulation induced by lapatinib, a small-molecule dual inhibitor of the epidermal growth factor receptor (EGFR), in HER2-negative or HER2-positive breast cancer cell lines (SkBr3 and BRC230).	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	209-213
19752719-3	2009	Lapatinib was active in the HER2-overexpressing cell line, SkBr3, but not in BRC230 cell line, which does not express HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
19752719-5	2009	Simultaneous exposure to lapatinib and caelyx in SkBr3 cell line produced an additive cytotoxic effect with dephosphorylation of HER2 and EGFR, an upregulation of p21, and an induction of apoptosis through dephosphorylation of BAD and caspase cleavage.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
19752719-5	2009	Simultaneous exposure to lapatinib and caelyx in SkBr3 cell line produced an additive cytotoxic effect with dephosphorylation of HER2 and EGFR, an upregulation of p21, and an induction of apoptosis through dephosphorylation of BAD and caspase cleavage.	Lapatinib	25-34	epidermal growth factor receptor	Homo sapiens	138-142
19752719-5	2009	Simultaneous exposure to lapatinib and caelyx in SkBr3 cell line produced an additive cytotoxic effect with dephosphorylation of HER2 and EGFR, an upregulation of p21, and an induction of apoptosis through dephosphorylation of BAD and caspase cleavage.	Lapatinib	25-34	H3 histone pseudogene 16	Homo sapiens	163-166
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	23-32	epidermal growth factor receptor	Homo sapiens	169-173
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	169-173
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	169-173
19752719-8	2009	Our data indicate that lapatinib used in combination with caelyx is active in HER2-expressing cells, probably because of lapatinib-induced dephosphorylation of the HER2-EGFR pathway, and also in non-HER2-expressing cells, possibly because lapatinib blocks efflux pump activity, increasing the length of time of intracellular exposure to caelyx and thereby increasing its cytotoxic effect.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
19748186-6	2009	Of these emerging therapies, the dual tyrosine kinase receptor inhibitor against EGFR and HER2, lapatinib (Tyverb/Tykerb) has shown the most promise to date.	Lapatinib	96-105	epidermal growth factor receptor	Homo sapiens	81-85
19748186-6	2009	Of these emerging therapies, the dual tyrosine kinase receptor inhibitor against EGFR and HER2, lapatinib (Tyverb/Tykerb) has shown the most promise to date.	Lapatinib	114-120	epidermal growth factor receptor	Homo sapiens	81-85
19823038-0	2009	Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.	Lapatinib	29-38	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	14-19
19748186-6	2009	Of these emerging therapies, the dual tyrosine kinase receptor inhibitor against EGFR and HER2, lapatinib (Tyverb/Tykerb) has shown the most promise to date.	Lapatinib	107-113	epidermal growth factor receptor	Homo sapiens	81-85
19823038-0	2009	Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.	Lapatinib	62-71	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	14-19
19895239-0	2009	Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
19823038-1	2009	Prior studies demonstrated that resistance to the ERBB1/2 inhibitor Lapatinib in HCT116 cells was mediated by increased MCL-1 expression.	Lapatinib	68-77	epidermal growth factor receptor	Homo sapiens	50-57
19823038-1	2009	Prior studies demonstrated that resistance to the ERBB1/2 inhibitor Lapatinib in HCT116 cells was mediated by increased MCL-1 expression.	Lapatinib	68-77	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	120-125
19823038-3	2009	The BCL-2 family antagonist Obatoclax (GX15-070), that inhibits BCL-2/BCL-X(L)/MCL-1 function, enhanced Lapatinib toxicity in parental HCT116 and Lapatinib adapted HCT116 cells.	Lapatinib	104-113	BCL2 apoptosis regulator	Homo sapiens	4-9
19823038-3	2009	The BCL-2 family antagonist Obatoclax (GX15-070), that inhibits BCL-2/BCL-X(L)/MCL-1 function, enhanced Lapatinib toxicity in parental HCT116 and Lapatinib adapted HCT116 cells.	Lapatinib	146-155	BCL2 apoptosis regulator	Homo sapiens	4-9
19823038-5	2009	The promotion of Lapatinib toxicity by GX15-070 correlated with increased cytosolic levels of apoptosis inducing factor (AIF) and expression of ATG8 (LC3), and the formation of large vesicles that intensely stained for a transfected LC3-GFP construct.	Lapatinib	17-26	apoptosis inducing factor mitochondria associated 1	Homo sapiens	94-119
19823038-5	2009	The promotion of Lapatinib toxicity by GX15-070 correlated with increased cytosolic levels of apoptosis inducing factor (AIF) and expression of ATG8 (LC3), and the formation of large vesicles that intensely stained for a transfected LC3-GFP construct.	Lapatinib	17-26	apoptosis inducing factor mitochondria associated 1	Homo sapiens	121-124
19823038-5	2009	The promotion of Lapatinib toxicity by GX15-070 correlated with increased cytosolic levels of apoptosis inducing factor (AIF) and expression of ATG8 (LC3), and the formation of large vesicles that intensely stained for a transfected LC3-GFP construct.	Lapatinib	17-26	GABA type A receptor associated protein like 1	Homo sapiens	144-148
19823038-5	2009	The promotion of Lapatinib toxicity by GX15-070 correlated with increased cytosolic levels of apoptosis inducing factor (AIF) and expression of ATG8 (LC3), and the formation of large vesicles that intensely stained for a transfected LC3-GFP construct.	Lapatinib	17-26	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	150-153
19823038-5	2009	The promotion of Lapatinib toxicity by GX15-070 correlated with increased cytosolic levels of apoptosis inducing factor (AIF) and expression of ATG8 (LC3), and the formation of large vesicles that intensely stained for a transfected LC3-GFP construct.	Lapatinib	17-26	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	233-236
19823038-8	2009	Collectively, our data demonstrate that Obatoclax mediated inhibition of MCL-1 rapidly enhances Lapatinib toxicity in tumor cells via a toxic form of autophagy and via AIF release from the mitochondrion.	Lapatinib	96-105	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	73-78
19895239-1	2009	Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	77-81
19895239-1	2009	Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	82-87
19895239-1	2009	Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
19895239-1	2009	Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
19895239-2	2009	Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
19791830-1	2009	Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2).	Lapatinib	19-25	epidermal growth factor receptor	Homo sapiens	157-161
19881954-2	2009	The recently developed small molecule, lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor-2 receptor tyrosine kinase inhibitor, might improve this situation.	Lapatinib	39-48	epidermal growth factor receptor	Homo sapiens	57-89
19881954-2	2009	The recently developed small molecule, lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor-2 receptor tyrosine kinase inhibitor, might improve this situation.	Lapatinib	39-48	epidermal growth factor receptor	Homo sapiens	91-95
19881954-2	2009	The recently developed small molecule, lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor-2 receptor tyrosine kinase inhibitor, might improve this situation.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-137
19863462-1	2009	Lapatinib is an oral, small-molecule, dual kinase inhibitor that targets both HER2 and the EGF receptor.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
19863462-2	2009	Lapatinib was approved in June 2008 in Europe for the treatment of advanced HER2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
19881954-0	2009	Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.	Lapatinib	97-106	epidermal growth factor receptor	Homo sapiens	28-60
19791830-0	2009	Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
19791830-1	2009	Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	157-161
19791830-1	2009	Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2).	Lapatinib	19-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
19791830-1	2009	Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
19791830-1	2009	Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2).	Lapatinib	11-17	epidermal growth factor receptor	Homo sapiens	157-161
19791830-2	2009	In the EU, lapatinib in combination with capecitabine is indicated for the treatment of women with HER2-overexpressing, advanced or metastatic breast cancer that has progressed after treatment with regimens that include anthracyclines, taxanes and, in the metastatic setting, trastuzumab.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
19791830-1	2009	Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2).	Lapatinib	11-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
19791830-3	2009	The orally administered combination of lapatinib and capecitabine was a more effective treatment than capecitabine alone, and was a generally well tolerated, conveniently administered combination for women with trastuzumab-refractory, HER2-positive advanced or metastatic breast cancer in a clinical trial.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	235-239
19718025-6	2009	Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 4	Homo sapiens	33-38
19828406-6	2009	Examples of approved targeted agents in breast cancer include agents targeting the human epidermal growth factor receptor 2 (HER2), such as trastuzumab, lapatinib and the anti-VEGF bevacizumab.	Lapatinib	153-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-123
19828406-6	2009	Examples of approved targeted agents in breast cancer include agents targeting the human epidermal growth factor receptor 2 (HER2), such as trastuzumab, lapatinib and the anti-VEGF bevacizumab.	Lapatinib	153-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
19153829-0	2009	Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
19153829-1	2009	The randomized phase III trial EGF100151 demonstrated that the combination of lapatinib plus capecitabine (L + C) significantly improved time to progression (TTP) compared with capecitabine alone (C) in heavily pretreated patients with HER2+ (ErbB2+) advanced or metastatic breast cancer.	Lapatinib	78-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	236-240
19153829-12	2009	The addition of lapatinib to capecitabine significantly increases TTP without any evidence of a deleterious effect on patients" QOL, confirming its clinical benefit in this heavily pretreated patient population with advanced HER2+ breast cancer that has progressed on trastuzumab therapy.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	225-229
19846022-0	2009	Lapatinib for the treatment of HER2-overexpressing breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
19718025-6	2009	Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib.	Lapatinib	140-149	epidermal growth factor receptor	Homo sapiens	33-37
19554571-1	2009	BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Mus musculus	82-86
19554571-1	2009	BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Mus musculus	91-96
19554571-1	2009	BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.	Lapatinib	12-21	epidermal growth factor receptor	Mus musculus	157-161
19554571-1	2009	BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Mus musculus	166-171
19554571-1	2009	BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Mus musculus	166-171
19554571-10	2009	CONCLUSIONS: Lapatinib has little activity against the xenografts of the PPTP"s in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition.	Lapatinib	13-22	epidermal growth factor receptor	Mus musculus	183-187
19554571-10	2009	CONCLUSIONS: Lapatinib has little activity against the xenografts of the PPTP"s in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Mus musculus	188-193
19737952-3	2009	Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	29-61
19169683-1	2009	PURPOSE: To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC).	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-105
19671800-0	2009	Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
19671800-0	2009	Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.	Lapatinib	19-28	AXL receptor tyrosine kinase	Homo sapiens	91-94
19671800-1	2009	HER2-directed therapies, such as trastuzumab and lapatinib, are important treatments for breast cancer.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
19671800-3	2009	We isolated and characterized multiple lapatinib-resistant, HER2-positive, estrogen receptor (ER)-positive breast cancer clones derived from lapatinib-sensitive BT474 cells by chronic exposure to lapatinib.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
19671800-6	2009	Furthermore, small interfering RNA to AXL, estrogen deprivation, or fulvestrant, an ER antagonist, decreases AXL expression and restores sensitivity to lapatinib in these cells.	Lapatinib	152-161	AXL receptor tyrosine kinase	Homo sapiens	38-41
19671800-7	2009	Taken together, these data provide scientific evidence to assess the expression of AXL in HER2-positive, ER-positive patients who have progressed on either lapatinib or trastuzumab and to test the combination of HER2-targeted agents and GSK1363089 in the clinic.	Lapatinib	156-165	AXL receptor tyrosine kinase	Homo sapiens	83-86
19671800-7	2009	Taken together, these data provide scientific evidence to assess the expression of AXL in HER2-positive, ER-positive patients who have progressed on either lapatinib or trastuzumab and to test the combination of HER2-targeted agents and GSK1363089 in the clinic.	Lapatinib	156-165	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
19737952-3	2009	Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
19737952-3	2009	Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-74
19525314-2	2009	The anti-ErbB-2 monoclonal antibody (mAb) trastuzumab and the dual epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor lapatinib are effective in patients with breast cancer that overexpresses ErbB-2.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-106
19846022-1	2009	This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of lapatinib for the treatment of advanced or metastatic HER2-overexpressing breast cancer based upon a review of the manufacturer"s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
19846022-11	2009	In sensitivity analyses the ICER for lapatinib plus capecitabine compared with capecitabine monotherapy or vinorelbine monotherapy was robust to variation in assumptions.	Lapatinib	37-46	cAMP responsive element modulator	Homo sapiens	28-32
19525314-2	2009	The anti-ErbB-2 monoclonal antibody (mAb) trastuzumab and the dual epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor lapatinib are effective in patients with breast cancer that overexpresses ErbB-2.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-106
19620793-2	2009	Anti-HER agents such as trastuzumab and lapatinib are known to exhibit significant antitumor activities in human HER2-positive breast cancers.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
19620495-1	2009	PURPOSE: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	42-74
19620495-1	2009	PURPOSE: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	76-80
19620495-1	2009	PURPOSE: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-126
19620495-1	2009	PURPOSE: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
19620495-1	2009	PURPOSE: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
19620495-9	2009	RESULTS: Lapatinib improved median EFS in HER2-amplified, ER- or PR-positive MBC (n = 36; 5.7 v 4.5 months; P = .351); benefit was greater and statistically significant in HER2-amplified, ER-negative, PR-negative MBC (n = 42; 8.3 v 5.0 months; P = .007).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
19620495-9	2009	RESULTS: Lapatinib improved median EFS in HER2-amplified, ER- or PR-positive MBC (n = 36; 5.7 v 4.5 months; P = .351); benefit was greater and statistically significant in HER2-amplified, ER-negative, PR-negative MBC (n = 42; 8.3 v 5.0 months; P = .007).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-176
19309723-0	2009	Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.	Lapatinib	142-151	epidermal growth factor receptor	Homo sapiens	66-70
19309723-0	2009	Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
19309723-7	2009	CONCLUSIONS: HER2 to CEP17 FISH ratio may predict which patients with MSGT have an increased likelihood to benefit from lapatinib.	Lapatinib	120-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
19309723-8	2009	The finding of HER2:CEP17 ratio as a predictive marker of efficacy to lapatinib warrants further investigation.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
19518076-8	2009	The potencies of the small molecule EGFR kinase inhibitors erlotinib and lapatinib for various forms of EGFR were measured, and the therapeutic and mechanistic implications of these results considered.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	36-40
19518076-8	2009	The potencies of the small molecule EGFR kinase inhibitors erlotinib and lapatinib for various forms of EGFR were measured, and the therapeutic and mechanistic implications of these results considered.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	104-108
19399906-2	2009	This study assessed lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and HER-2, as second-line therapy in patients with locally advanced or metastatic TCC.	Lapatinib	20-29	epidermal growth factor receptor	Homo sapiens	67-99
19399906-2	2009	This study assessed lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and HER-2, as second-line therapy in patients with locally advanced or metastatic TCC.	Lapatinib	20-29	epidermal growth factor receptor	Homo sapiens	101-105
19574203-0	2009	mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).	Lapatinib	168-177	mechanistic target of rapamycin kinase	Homo sapiens	0-4
19574203-0	2009	mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).	Lapatinib	168-177	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
19574203-1	2009	The small molecule HER2 tyrosine kinase inhibitor (TKI) lapatinib (Tykerb) is approved for the therapy of patients with HER2-positive breast carcinomas who have progressed on trastuzumab (Herceptin).	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
19574203-5	2009	As hyperactivation of the pharmacologically targetable PI3K/mTOR/p70S6K1 axis appears to be central to the occurrence of lapatinib resistance, preclinical data showing enhanced antitumour effects when combining lapatinib with mTOR inhibitors (e.g., rapamycin analogues and NVP-BEZ235) highlight the importance of translational work to yield clinically useful regimens capable of delaying or treating lapatinib resistance.	Lapatinib	121-130	mechanistic target of rapamycin kinase	Homo sapiens	60-64
19574203-5	2009	As hyperactivation of the pharmacologically targetable PI3K/mTOR/p70S6K1 axis appears to be central to the occurrence of lapatinib resistance, preclinical data showing enhanced antitumour effects when combining lapatinib with mTOR inhibitors (e.g., rapamycin analogues and NVP-BEZ235) highlight the importance of translational work to yield clinically useful regimens capable of delaying or treating lapatinib resistance.	Lapatinib	211-220	mechanistic target of rapamycin kinase	Homo sapiens	60-64
19574203-5	2009	As hyperactivation of the pharmacologically targetable PI3K/mTOR/p70S6K1 axis appears to be central to the occurrence of lapatinib resistance, preclinical data showing enhanced antitumour effects when combining lapatinib with mTOR inhibitors (e.g., rapamycin analogues and NVP-BEZ235) highlight the importance of translational work to yield clinically useful regimens capable of delaying or treating lapatinib resistance.	Lapatinib	211-220	mechanistic target of rapamycin kinase	Homo sapiens	60-64
19252432-1	2009	HER2 is an important predictive marker for response to trastuzumab and lapatinib in breast cancer.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
19513552-6	2009	Furthermore, the effect of the HER2-tyrosine kinase inhibitor lapatinib on FoxM1 in HER2 positive breast cancer cells was investigated.	Lapatinib	62-71	forkhead box M1	Homo sapiens	75-80
19513552-6	2009	Furthermore, the effect of the HER2-tyrosine kinase inhibitor lapatinib on FoxM1 in HER2 positive breast cancer cells was investigated.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
19513552-11	2009	Indeed, treatment of breast cancer cells with lapatinib reduced FoxM1 expression at protein, mRNA and gene promoter levels.	Lapatinib	46-55	forkhead box M1	Homo sapiens	64-69
19254954-7	2009	Lapatinib, a clinically active EGFR inhibitor, significantly reversed the epidermal growth factor-induced cisplatin resistance.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
19529774-0	2009	Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
19529774-0	2009	Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
19529774-0	2009	Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.	Lapatinib	0-9	thymidylate synthetase	Homo sapiens	73-93
19529774-0	2009	Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	137-141
19529774-0	2009	Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
19529774-4	2009	METHODOLOGY AND PRINCIPAL FINDINGS: In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2 downregulates TS via inhibition of the nuclear translocation of EGFR and HER2.	Lapatinib	71-80	epidermal growth factor receptor	Homo sapiens	96-100
19529774-4	2009	METHODOLOGY AND PRINCIPAL FINDINGS: In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2 downregulates TS via inhibition of the nuclear translocation of EGFR and HER2.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
19529774-4	2009	METHODOLOGY AND PRINCIPAL FINDINGS: In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2 downregulates TS via inhibition of the nuclear translocation of EGFR and HER2.	Lapatinib	71-80	thymidylate synthetase	Homo sapiens	124-126
19529774-4	2009	METHODOLOGY AND PRINCIPAL FINDINGS: In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2 downregulates TS via inhibition of the nuclear translocation of EGFR and HER2.	Lapatinib	71-80	epidermal growth factor receptor	Homo sapiens	174-178
19529774-4	2009	METHODOLOGY AND PRINCIPAL FINDINGS: In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2 downregulates TS via inhibition of the nuclear translocation of EGFR and HER2.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	183-187
19529774-5	2009	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells.	Lapatinib	144-153	thymidylate synthetase	Homo sapiens	116-118
19529774-5	2009	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells.	Lapatinib	144-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-184
19529774-8	2009	The translocation of EGFR and HER2 into the nucleus and the subsequent activation of the TS promoter were inhibited by lapatinib.	Lapatinib	119-128	epidermal growth factor receptor	Homo sapiens	21-25
19529774-8	2009	The translocation of EGFR and HER2 into the nucleus and the subsequent activation of the TS promoter were inhibited by lapatinib.	Lapatinib	119-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
19529774-8	2009	The translocation of EGFR and HER2 into the nucleus and the subsequent activation of the TS promoter were inhibited by lapatinib.	Lapatinib	119-128	thymidylate synthetase	Homo sapiens	89-91
19529774-9	2009	CONCLUSIONS AND SIGNIFICANCE: These results demonstrate that lapatinib inhibits the nuclear translocation of EGFR and HER2 and downregulates TS, thus sensitizing cancer cells to fluoropyrimidine.	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	109-113
19529774-9	2009	CONCLUSIONS AND SIGNIFICANCE: These results demonstrate that lapatinib inhibits the nuclear translocation of EGFR and HER2 and downregulates TS, thus sensitizing cancer cells to fluoropyrimidine.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-122
19529774-9	2009	CONCLUSIONS AND SIGNIFICANCE: These results demonstrate that lapatinib inhibits the nuclear translocation of EGFR and HER2 and downregulates TS, thus sensitizing cancer cells to fluoropyrimidine.	Lapatinib	61-70	thymidylate synthetase	Homo sapiens	141-143
19479664-3	2009	There are three small molecule EGFR kinase inhibitor drugs in clinical use (gefitinib, erlotinib and lapatinib), and several others are currently undergoing clinical development.	Lapatinib	101-110	epidermal growth factor receptor	Homo sapiens	31-35
19483734-2	2009	Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway.	Lapatinib	120-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
19483734-2	2009	Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway.	Lapatinib	120-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
19426700-4	2009	The influence of lapatinib pre-treatment on intestinal P-gp expression was investigated by Western blot analysis.	Lapatinib	17-26	phosphoglycolate phosphatase	Mus musculus	55-59
19426700-10	2009	A 38.5% significant decrease of P-gp expression was observed in duodenum segment in lapatinib pre-treated group as compared with control group.	Lapatinib	84-93	phosphoglycolate phosphatase	Mus musculus	32-36
19426700-11	2009	In conclusion, lapatinib enhanced everolimus absorption by decreasing intestinal P-gp expression.	Lapatinib	15-24	phosphoglycolate phosphatase	Mus musculus	81-85
19509167-8	2009	The GDC-0941 and lapatinib combination further showed that inhibition of HER2 activity was essential for maximum combinatorial efficacy.	Lapatinib	17-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
19179558-0	2009	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
19179558-1	2009	BACKGROUND: This phase II study evaluated the efficacy and safety of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer that progressed during prior trastuzumab therapy.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-136
19179558-1	2009	BACKGROUND: This phase II study evaluated the efficacy and safety of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer that progressed during prior trastuzumab therapy.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
19179558-9	2009	CONCLUSIONS: Single-agent lapatinib has clinical activity with manageable toxic effects in HER2-overexpressing breast cancer that progressed on trastuzumab-containing therapy.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
19394894-0	2009	Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-43
19394894-3	2009	Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor tyrosine kinases, previously had a 50% response rate in a cohort of 30 patients with HER2-overexpressing (HER2+) recurrent or anthracycline-refractory inflammatory breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	161-165
19394894-3	2009	Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor tyrosine kinases, previously had a 50% response rate in a cohort of 30 patients with HER2-overexpressing (HER2+) recurrent or anthracycline-refractory inflammatory breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-186
19394894-4	2009	We aimed to assess efficacy of lapatinib in an expanded cohort of patients with relapsed or refractory HER2+ disease.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
19394894-18	2009	INTERPRETATION: Lapatinib monotherapy is a potentially effective treatment for relapsed or refractory HER2+ inflammatory breast cancer.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
19008049-6	2009	The use of lapatinib, a dual tyrosine kinase inhibitor of both HER1 and HER2, in combination with capecitabine in the second-line treatment of HER2-positive patients with metastatic breast cancer previously treated with trastuzumab has been established.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	63-67
19461171-4	2009	Lapatinib proves effective for trastuzumab-resistant HER2-overexpressing breast cancer and also for brain metastasis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
19371315-1	2009	AIMS: To characterize the impact of potent CYP3A4 inhibition and induction on lapatinib pharmacokinetics.	Lapatinib	78-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
19371315-9	2009	CONCLUSIONS: Systemic exposure to lapatinib was significantly altered by potent inhibition and induction of CYP3A4.	Lapatinib	34-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
19442060-7	2009	More recent anti-HER-2 strategies involve targeting its tyrosine kinase domain; for example, lapatinib (Tykerb) is a dual HER-2 and EGFR tyrosine kinase inhibitor and has shown efficacy as a single agent and in combination with other therapeutics.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-22
19442060-7	2009	More recent anti-HER-2 strategies involve targeting its tyrosine kinase domain; for example, lapatinib (Tykerb) is a dual HER-2 and EGFR tyrosine kinase inhibitor and has shown efficacy as a single agent and in combination with other therapeutics.	Lapatinib	93-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-127
19255302-0	2009	Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-106
18600445-1	2009	PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	140-172
18600445-1	2009	PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	174-178
18600445-1	2009	PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	180-185
18600445-1	2009	PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	192-196
18600445-1	2009	PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	198-203
19008049-6	2009	The use of lapatinib, a dual tyrosine kinase inhibitor of both HER1 and HER2, in combination with capecitabine in the second-line treatment of HER2-positive patients with metastatic breast cancer previously treated with trastuzumab has been established.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
19008049-6	2009	The use of lapatinib, a dual tyrosine kinase inhibitor of both HER1 and HER2, in combination with capecitabine in the second-line treatment of HER2-positive patients with metastatic breast cancer previously treated with trastuzumab has been established.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
19346299-8	2009	The efficacy results for the more recently approved small molecule HER-1/HER-2 kinase inhibitor lapatinib are also presented along with a more limited review of markers of resistance for this agent.	Lapatinib	96-105	epidermal growth factor receptor	Homo sapiens	67-72
19287975-0	2009	Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
19287975-4	2009	Here, we show that the dual inhibitor of ErbB receptors, lapatinib, enhances cytostatic and induces cytotoxic effects of GTC in two bladder cancer cell lines which differ with regard to expression levels of proteins taking part in the ErbB pathway.	Lapatinib	57-66	epidermal growth factor receptor	Homo sapiens	41-45
19287975-4	2009	Here, we show that the dual inhibitor of ErbB receptors, lapatinib, enhances cytostatic and induces cytotoxic effects of GTC in two bladder cancer cell lines which differ with regard to expression levels of proteins taking part in the ErbB pathway.	Lapatinib	57-66	epidermal growth factor receptor	Homo sapiens	235-239
19287975-5	2009	Lapatinib inhibited phosphorylation of ErbB receptors and also reduced the level of phosphorylated AKT.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	39-43
19287975-5	2009	Lapatinib inhibited phosphorylation of ErbB receptors and also reduced the level of phosphorylated AKT.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	99-102
19287975-7	2009	In RT112 cells, which express high levels of ErbB receptors and harbour wild-type p53, combined GTC/lapatinib treatment resulted in the phosphorylation of p53 at Ser46 and accumulation of sub-G1 cell populations.	Lapatinib	100-109	epidermal growth factor receptor	Homo sapiens	45-49
19287975-7	2009	In RT112 cells, which express high levels of ErbB receptors and harbour wild-type p53, combined GTC/lapatinib treatment resulted in the phosphorylation of p53 at Ser46 and accumulation of sub-G1 cell populations.	Lapatinib	100-109	tumor protein p53	Homo sapiens	82-85
19287975-7	2009	In RT112 cells, which express high levels of ErbB receptors and harbour wild-type p53, combined GTC/lapatinib treatment resulted in the phosphorylation of p53 at Ser46 and accumulation of sub-G1 cell populations.	Lapatinib	100-109	tumor protein p53	Homo sapiens	155-158
19346299-8	2009	The efficacy results for the more recently approved small molecule HER-1/HER-2 kinase inhibitor lapatinib are also presented along with a more limited review of markers of resistance for this agent.	Lapatinib	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
19276373-4	2009	The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity.	Lapatinib	158-167	microRNA 205	Homo sapiens	22-29
19060928-0	2009	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
19365626-5	2009	Lapatinib, an orally available HER1- and HER2-targeted tyrosine kinase inhibitor, represents one such notable innovation.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
19365626-5	2009	Lapatinib, an orally available HER1- and HER2-targeted tyrosine kinase inhibitor, represents one such notable innovation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
19365626-6	2009	Lapatinib is currently being evaluated in both the adjuvant and metastatic settings and was recently approved by the United States Food and Drug Administration in combination with capecitabine, for the treatment of women with HER2-positive, pretreated, metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	226-230
19275756-6	2009	Preclinical experiments, clinical experience with the use of trastuzumab beyond progression, and a recent phase III clinical trial with Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, demonstrate that the HER-2 signaling axis remains an important therapeutic target even after progression on trastuzumab.	Lapatinib	136-145	epidermal growth factor receptor	Homo sapiens	154-158
19275756-6	2009	Preclinical experiments, clinical experience with the use of trastuzumab beyond progression, and a recent phase III clinical trial with Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, demonstrate that the HER-2 signaling axis remains an important therapeutic target even after progression on trastuzumab.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-164
19275756-6	2009	Preclinical experiments, clinical experience with the use of trastuzumab beyond progression, and a recent phase III clinical trial with Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, demonstrate that the HER-2 signaling axis remains an important therapeutic target even after progression on trastuzumab.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	213-218
19228746-3	2009	Lapatinib, an epidermal growth factor receptor/HER2 inhibitor, was associated with regressions of CNS lesions in a small phase 2 trial.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	14-46
19228746-3	2009	Lapatinib, an epidermal growth factor receptor/HER2 inhibitor, was associated with regressions of CNS lesions in a small phase 2 trial.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
19228746-15	2009	Further studies of lapatinib-based regimens for CNS metastases from HER2+ breast cancer are warranted.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
19418111-2	2009	Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2, is approved for the treatment of metastatic breast cancer patients after failure of prior anthracycline, taxanes and trastuzumab therapies in combination with capecitabine.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	47-51
19418111-2	2009	Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2, is approved for the treatment of metastatic breast cancer patients after failure of prior anthracycline, taxanes and trastuzumab therapies in combination with capecitabine.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
19365520-9	2009	Given signal pathway complexity and HER family member cooperation, it may be better to simultaneously target a number of these receptors (e.g. HER1/HER2 by lapatinib).	Lapatinib	156-165	epidermal growth factor receptor	Homo sapiens	143-147
19365520-9	2009	Given signal pathway complexity and HER family member cooperation, it may be better to simultaneously target a number of these receptors (e.g. HER1/HER2 by lapatinib).	Lapatinib	156-165	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
19259796-1	2009	Although the development of trastuzumab and lapatinib has improved the outlook for women with HER-2 positive breast cancer, resistance to HER-2 targeted therapy is a growing clinical dilemma.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-99
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	epidermal growth factor receptor	Homo sapiens	235-239
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 3	Homo sapiens	249-253
19060928-7	2009	Lapatinib-induced accumulation of HER2 and trastuzumab-mediated downregulation of HER2 was also observed in vivo, where the combination of the two agents triggered complete tumor remissions in all cases after 10 days of treatment.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
19060928-7	2009	Lapatinib-induced accumulation of HER2 and trastuzumab-mediated downregulation of HER2 was also observed in vivo, where the combination of the two agents triggered complete tumor remissions in all cases after 10 days of treatment.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
19060928-8	2009	Accumulation of HER2 at the cell surface by lapatinib enhanced immune-mediated trastuzumab-dependent cytotoxicity.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20
19060928-0	2009	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
19060928-1	2009	Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-55
19060928-1	2009	Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
19060928-1	2009	Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
19060928-4	2009	Lapatinib, given alone or in combination with trastuzumab to HER2-overexpressing breast cancer cells SKBR3 and MCF7-HER2, inhibited HER2 phosphorylation, prevented receptor ubiquitination and resulted in a marked accumulation of inactive receptors at the cell surface.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
19060928-4	2009	Lapatinib, given alone or in combination with trastuzumab to HER2-overexpressing breast cancer cells SKBR3 and MCF7-HER2, inhibited HER2 phosphorylation, prevented receptor ubiquitination and resulted in a marked accumulation of inactive receptors at the cell surface.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
19060928-6	2009	By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
19563669-14	2009	Moreover, siRNA-based depletion of XIAP or use of a Smac mimetic to target multiple IAPs increased apoptosis in response to the ErbB antagonists, Trastuzumab, Lapatinib or Gefitinib in Her2-overexpressing BT474 cells, or Gefitinib in EGFR-overexpressing MDAMB468 cells.	Lapatinib	159-168	X-linked inhibitor of apoptosis	Homo sapiens	35-39
19117341-0	2009	Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-49
19117341-1	2009	BACKGROUND: A recent clinical trial demonstrated that the addition of lapatinib to capecitabine in the treatment of HER-2-positive advanced breast cancer (ABC) significantly increases median time to progression.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-121
19056914-0	2009	An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).	Lapatinib	159-168	phosphoglycolate phosphatase	Mus musculus	32-46
19056914-0	2009	An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).	Lapatinib	159-168	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-83
19056914-1	2009	Lapatinib is a tyrosine kinase inhibitor approved for use in combination with capecitabine to treat advanced or metastatic breast cancers overexpressing human epidermal receptor 2 (ErbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-186
19056914-2	2009	This work investigated the role of P-glycoprotein (Pgp; the protein from the Mdr1a/b gene) and breast cancer resistance protein (Bcrp; the protein from the Bcrp1 gene) in modulating the central nervous system penetration of lapatinib at steady-state conditions in FVBn mice (wild-type), Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)/Bcrp1(-/-) knockout mice.	Lapatinib	224-233	phosphoglycolate phosphatase	Mus musculus	35-49
19056914-5	2009	In contrast, Mdr1a/b(-/-)/Bcrp1(-/-) triple knockout mice had a 40-fold higher brain-to-plasma ratio (ratio range from 1.2 to 1.7), suggesting that Pgp and Bcrp work in concert to limit the brain-to-plasma ratio of lapatinib in mice.	Lapatinib	215-224	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	13-18
19056914-5	2009	In contrast, Mdr1a/b(-/-)/Bcrp1(-/-) triple knockout mice had a 40-fold higher brain-to-plasma ratio (ratio range from 1.2 to 1.7), suggesting that Pgp and Bcrp work in concert to limit the brain-to-plasma ratio of lapatinib in mice.	Lapatinib	215-224	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
19056914-5	2009	In contrast, Mdr1a/b(-/-)/Bcrp1(-/-) triple knockout mice had a 40-fold higher brain-to-plasma ratio (ratio range from 1.2 to 1.7), suggesting that Pgp and Bcrp work in concert to limit the brain-to-plasma ratio of lapatinib in mice.	Lapatinib	215-224	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
19052038-0	2009	Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.	Lapatinib	53-62	epidermal growth factor receptor	Homo sapiens	110-123
19052038-0	2009	Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.	Lapatinib	64-72	epidermal growth factor receptor	Homo sapiens	110-123
19052038-1	2009	OBJECTIVE: The Phase I dose-escalation study was conducted to evaluate the safety and pharmacokinetics of lapatinib (GW572016), a dual ErbB-1 and -2 inhibitor, in Japanese patients with solid tumors that generally express ErbB-1 and/or overexpress ErbB-2.	Lapatinib	106-115	epidermal growth factor receptor	Homo sapiens	135-148
19141783-0	2009	Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.	Lapatinib	10-19	estrogen receptor 1 (alpha)	Mus musculus	42-59
19141783-1	2009	Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	53-85
19141783-1	2009	Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	87-91
19141783-1	2009	Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	97-102
19141783-6	2009	Among MMTV-erbB2 mice treated for 5 months (n = 20 mice per group), those treated with lapatinib had fewer premalignant lesions and noninvasive cancers in their mammary glands than those treated with vehicle (P = .02).	Lapatinib	87-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-16
19141783-7	2009	Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	89-93
19141783-7	2009	Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
19141783-7	2009	Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib.	Lapatinib	0-9	cyclin D1	Homo sapiens	126-135
19141783-7	2009	Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib.	Lapatinib	0-9	epiregulin	Homo sapiens	140-150
19141783-7	2009	Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib.	Lapatinib	0-9	interferon alpha inducible protein 27	Homo sapiens	183-186
19141783-8	2009	Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients.	Lapatinib	72-81	cyclin D1	Homo sapiens	6-15
19141783-8	2009	Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients.	Lapatinib	72-81	epiregulin	Homo sapiens	17-27
19141783-8	2009	Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients.	Lapatinib	72-81	interferon alpha inducible protein 27	Homo sapiens	33-36
19141783-9	2009	These data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer.	Lapatinib	24-33	estrogen receptor 1 (alpha)	Mus musculus	77-79
20877672-4	2009	Lapatinib targets HER-2 and EGFR.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-23
20877672-4	2009	Lapatinib targets HER-2 and EGFR.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	28-32
19563669-14	2009	Moreover, siRNA-based depletion of XIAP or use of a Smac mimetic to target multiple IAPs increased apoptosis in response to the ErbB antagonists, Trastuzumab, Lapatinib or Gefitinib in Her2-overexpressing BT474 cells, or Gefitinib in EGFR-overexpressing MDAMB468 cells.	Lapatinib	159-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
18936791-4	2009	This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.	Lapatinib	236-245	epidermal growth factor receptor	Homo sapiens	311-316
20110044-8	2009	In a Phase III trial comparing lapatinib plus capecitabine with capecitabine alone in HER2+ patients with advanced breast cancer that had progressed after trastuzumab therapy, the median time to progression was 8.4 months with combination therapy, compared with 4.4 months with capecitabine alone (P < 0.001).	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
19593514-0	2009	Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
20110044-0	2009	Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	41-73
20110044-0	2009	Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-118
20110044-1	2009	BACKGROUND: Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) tyrosine kinases.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	79-111
20110044-1	2009	BACKGROUND: Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) tyrosine kinases.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	113-117
20110044-1	2009	BACKGROUND: Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) tyrosine kinases.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-163
20110044-1	2009	BACKGROUND: Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) tyrosine kinases.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
20110044-2	2009	In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine in the treatment of advanced breast cancer overexpressing HER2 (HER2+).	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
20110044-2	2009	In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine in the treatment of advanced breast cancer overexpressing HER2 (HER2+).	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
20110044-7	2009	A Phase II trial of lapatinib monotherapy in 39 HER2+ patients with breast cancer and brain metastases yielded 1 partial response, although 15.4% of patients had stable disease for > or =16 weeks.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
18936791-4	2009	This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.	Lapatinib	236-245	erb-b2 receptor tyrosine kinase 2	Homo sapiens	321-326
18774637-0	2008	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	63-67
20130423-4	2009	Accordingly, the ErbB receptor family with their most prominent members EGFR and HER-2 represents validated targets for anti-cancer therapy, and anti-ErbB MoAbs (cetuximab, panitumumab, and trastuzumab) and TKIs (gefitinib, erlotinib, and lapatinib) have now been approved for the treatment of advanced colorectal cancer, squamous cell carcinoma of the head and neck, advanced non-small-cell lung cancer, as well as pancreatic and breast cancer.	Lapatinib	239-248	epidermal growth factor receptor	Homo sapiens	17-21
18774637-0	2008	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
18774637-2	2008	Lapatinib is a dual inhibitor of the epidermal growth factor receptor and HER2 tyrosine kinase.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
19094209-8	2008	Small interfering RNA-induced depletion of HER2 protein and lapatinib-induced blockade of HER2 tyrosine kinase activity both significantly prevented EVOO polyphenols-induced cytotoxicity.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
18774637-4	2008	Lapatinib induced selective and potent growth inhibition in two HER2-amplified gastric cancer cell lines (SNU-216 and NCI-N87).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
18774637-5	2008	Lapatinib inhibited the phosphorylation of HER2, EGFR and downstream signaling proteins, resulting in G1 arrest in both cell lines with down-regulation of cMyc and induction of p27kip1.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
18774637-5	2008	Lapatinib inhibited the phosphorylation of HER2, EGFR and downstream signaling proteins, resulting in G1 arrest in both cell lines with down-regulation of cMyc and induction of p27kip1.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	49-53
18774637-5	2008	Lapatinib inhibited the phosphorylation of HER2, EGFR and downstream signaling proteins, resulting in G1 arrest in both cell lines with down-regulation of cMyc and induction of p27kip1.	Lapatinib	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	155-159
18774637-5	2008	Lapatinib inhibited the phosphorylation of HER2, EGFR and downstream signaling proteins, resulting in G1 arrest in both cell lines with down-regulation of cMyc and induction of p27kip1.	Lapatinib	0-9	cyclin dependent kinase inhibitor 1B	Homo sapiens	177-184
18774637-6	2008	Lapatinib also induced apoptosis in NCI-N87 which has high HER2 amplification ratio.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
19562083-3	2008	Currently available EGFR-inhibiting drugs include the tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib, and lapatinib, which are administered orally and interfere with the intracellular tyrosine kinase domain, and the monoclonal antibodies (mAbs) cetuximab and panitumumab, which are administered intravenously and interfere with extracellular ligand binding.	Lapatinib	114-123	epidermal growth factor receptor	Homo sapiens	20-24
19047115-2	2008	EXPERIMENTAL DESIGN: In available breast cancer tissue from EGF30001 (paclitaxel +/- lapatinib in HER-2-negative/unknown metastatic breast cancer, n = 579) and EGF100151 (capecitabine +/- lapatinib in HER-2-positive metastatic breast cancer, n = 399), HER-2 gene amplification by fluorescence in situ hybridization (FISH), HER-2 mRNA by reverse transcription-PCR (RT-PCR), HER-2 protein expression by HercepTest immunohistochemistry (IHC), epidermal growth factor receptor (EGFR) mRNA level by RT-PCR, and EGFR protein by IHC were analyzed and compared with clinical outcome.	Lapatinib	85-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
19192581-7	2008	Recently, lapatinib, a tyrosine kinase inhibitor, was registered by EMEA for patients with a HER2 positive tumor after previous treatment with anthracyclines, taxanes and trastuzumab.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
19047149-8	2008	Using clinically relevant EGFR inhibitors, erlotinib and lapatinib, we found that inhibition of EGFR activation effectively inhibited leptin- and IGF-I-induced invasion and migration of breast cancer cells.	Lapatinib	57-66	epidermal growth factor receptor	Homo sapiens	96-100
19047149-8	2008	Using clinically relevant EGFR inhibitors, erlotinib and lapatinib, we found that inhibition of EGFR activation effectively inhibited leptin- and IGF-I-induced invasion and migration of breast cancer cells.	Lapatinib	57-66	leptin	Homo sapiens	134-140
19047149-8	2008	Using clinically relevant EGFR inhibitors, erlotinib and lapatinib, we found that inhibition of EGFR activation effectively inhibited leptin- and IGF-I-induced invasion and migration of breast cancer cells.	Lapatinib	57-66	insulin like growth factor 1	Homo sapiens	146-151
19047149-10	2008	Our findings indicate the possibility of using EGFR inhibitors erlotinib and lapatinib to counter the procancerous effects of leptin and IGF-I in breast cancers.	Lapatinib	77-86	epidermal growth factor receptor	Homo sapiens	47-51
19047149-10	2008	Our findings indicate the possibility of using EGFR inhibitors erlotinib and lapatinib to counter the procancerous effects of leptin and IGF-I in breast cancers.	Lapatinib	77-86	leptin	Homo sapiens	126-132
19047149-10	2008	Our findings indicate the possibility of using EGFR inhibitors erlotinib and lapatinib to counter the procancerous effects of leptin and IGF-I in breast cancers.	Lapatinib	77-86	insulin like growth factor 1	Homo sapiens	137-142
19047120-2	2008	The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial.	Lapatinib	138-147	erb-b2 receptor tyrosine kinase 2	Mus musculus	123-127
19047120-6	2008	RESULTS: Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts.	Lapatinib	9-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
19047120-6	2008	RESULTS: Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts.	Lapatinib	9-18	phosphoglycolate phosphatase	Mus musculus	64-67
19047115-10	2008	Although a significant correlation with lapatinib responsiveness was observed among "HER-2-negative" breast cancer patients in the large, high-volume commercial reference laboratory, this was not confirmed in the academic reference/research laboratory.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
19047115-11	2008	CONCLUSIONS: Women with HER-2-positive metastatic breast cancer benefit from lapatinib, whereas women with HER-2-negative metastatic breast cancer derive no incremental benefit from lapatinib.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-29
19013786-3	2008	Examples of approved targeted agents in breast cancer include agents directed against the human epidermal growth factor receptor 2 (HER2) such as trastuzumab and lapatinib and the anti-VEGF bevacizumab.	Lapatinib	162-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
18188694-1	2008	PURPOSE: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	74-106
18188694-1	2008	PURPOSE: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	108-112
18188694-1	2008	PURPOSE: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	124-156
18188694-1	2008	PURPOSE: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
18188694-2	2008	Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
18188694-10	2008	CONCLUSION: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
19046108-3	2008	Lapatinib is an orally active, reversible, small-molecule tyrosine kinase inhibitor that potently inhibits both HER1 and HER2 tyrosine kinase activity.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	112-116
18955454-1	2008	PURPOSE: Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2-positive locally advanced or metastatic breast cancer (MBC).	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	56-88
18955454-1	2008	PURPOSE: Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2-positive locally advanced or metastatic breast cancer (MBC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-146
18955454-2	2008	This phase III trial evaluated the efficacy of lapatinib in HER-2-negative and HER-2-uncharacterized MBC.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-65
18955454-7	2008	In 86 HER-2-positive patients (15%), treatment with paclitaxel-lapatinib resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel-placebo.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-11
18955454-13	2008	However, first-line therapy with paclitaxel-lapatinib significantly improved clinical outcomes in HER-2-positive patients.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
19046108-3	2008	Lapatinib is an orally active, reversible, small-molecule tyrosine kinase inhibitor that potently inhibits both HER1 and HER2 tyrosine kinase activity.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
19010894-0	2008	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Lapatinib	57-66	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-29
19034632-3	2008	HER2 overexpression is a validated therapeutic target, as shown by the clinical efficacy of trastuzumab and lapatinib.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
19034632-4	2008	However, only 25-30% of patients with HER2-overexpressing tumors respond to single-agent trastuzumab or lapatinib, and resistance develops even in responding patients.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
19010894-0	2008	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Lapatinib	57-66	mechanistic target of rapamycin kinase	Homo sapiens	102-106
19010894-0	2008	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Lapatinib	57-66	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	107-136
19010894-3	2008	Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance to lapatinib, a recently approved anti-HER2 tyrosine kinase inhibitor.	Lapatinib	151-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	187-191
19010894-4	2008	Here, we have identified the tumor suppressor PTEN as a modulator of lapatinib sensitivity in vitro and in vivo.	Lapatinib	69-78	phosphatase and tensin homolog	Homo sapiens	46-50
19010894-5	2008	In addition, we show that two dominant activating mutations in PIK3CA (E545K and H1047R), which are prevalent in breast cancer, also confer resistance to lapatinib.	Lapatinib	154-163	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	63-69
19010894-6	2008	Furthermore, we show that phosphatidylinositol 3-kinase (PI3K)-induced lapatinib resistance can be abrogated through the use of NVP-BEZ235, a dual inhibitor of PI3K/mTOR.	Lapatinib	71-80	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	26-55
19010894-6	2008	Furthermore, we show that phosphatidylinositol 3-kinase (PI3K)-induced lapatinib resistance can be abrogated through the use of NVP-BEZ235, a dual inhibitor of PI3K/mTOR.	Lapatinib	71-80	mechanistic target of rapamycin kinase	Homo sapiens	165-169
19010894-7	2008	Our data show that deregulation of the PI3K pathway, either through loss-of-function mutations in PTEN or dominant activating mutations in PIK3CA, leads to lapatinib resistance, which can be effectively reversed by NVP-BEZ235.	Lapatinib	156-165	phosphatase and tensin homolog	Homo sapiens	98-102
19010894-7	2008	Our data show that deregulation of the PI3K pathway, either through loss-of-function mutations in PTEN or dominant activating mutations in PIK3CA, leads to lapatinib resistance, which can be effectively reversed by NVP-BEZ235.	Lapatinib	156-165	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	139-145
18849320-0	2008	FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.	Lapatinib	27-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-142
18829547-0	2008	Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	105-161
18829547-0	2008	Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.	Lapatinib	11-17	ATP binding cassette subfamily B member 1	Homo sapiens	105-161
18829547-0	2008	Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.	Lapatinib	19-27	ATP binding cassette subfamily B member 1	Homo sapiens	105-161
18829547-1	2008	Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	99-131
18829547-1	2008	Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	133-138
18829547-1	2008	Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	142-147
18829547-1	2008	Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-158
18829547-3	2008	The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters.	Lapatinib	56-65	ATP binding cassette subfamily B member 1	Homo sapiens	135-159
18829547-3	2008	The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters.	Lapatinib	56-65	ATP binding cassette subfamily B member 1	Homo sapiens	161-166
18829547-3	2008	The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters.	Lapatinib	56-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	172-196
18829547-3	2008	The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters.	Lapatinib	56-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	198-203
18829547-4	2008	Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells.	Lapatinib	24-33	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
18829547-4	2008	Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells.	Lapatinib	24-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-90
18829547-6	2008	Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E(2)17betaG by ABCG2.	Lapatinib	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
18829547-6	2008	Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E(2)17betaG by ABCG2.	Lapatinib	14-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	109-114
18829547-6	2008	Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E(2)17betaG by ABCG2.	Lapatinib	14-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	199-204
18829547-7	2008	Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner.	Lapatinib	13-22	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
18829547-7	2008	Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner.	Lapatinib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	72-77
18829547-7	2008	Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner.	Lapatinib	13-22	ATP binding cassette subfamily B member 1	Homo sapiens	113-118
18829547-7	2008	Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner.	Lapatinib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	122-127
18829547-9	2008	Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice.	Lapatinib	13-22	ATP binding cassette subfamily B member 1	Homo sapiens	106-111
18829547-10	2008	Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function.	Lapatinib	26-35	ATP binding cassette subfamily B member 1	Homo sapiens	45-50
18829547-10	2008	Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function.	Lapatinib	26-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-61
18980964-1	2008	Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-39
18980964-1	2008	Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
18980964-1	2008	Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy.	Lapatinib	189-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-39
18980964-1	2008	Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy.	Lapatinib	189-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
18980964-1	2008	Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy.	Lapatinib	198-204	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-39
18980964-1	2008	Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy.	Lapatinib	198-204	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
18980964-4	2008	Instead, acquired resistance to lapatinib seems to be mediated by redundant survival pathways that are activated as a consequence of marked inhibition of ErbB2 kinase activity.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-159
18980964-5	2008	For example, inhibition of phosphatidylinositol3 kinase-Akt in lapatinib-treated cells leads to derepression of FOXO3A, a transcription factor that up-regulates estrogen receptor (ER) signaling, resulting in a switch in the regulation of survival factors (e.g., survivin) and cell survival from ErbB2 alone to ER and ErbB2 in resistant cells.	Lapatinib	63-72	AKT serine/threonine kinase 1	Homo sapiens	56-59
18980964-5	2008	For example, inhibition of phosphatidylinositol3 kinase-Akt in lapatinib-treated cells leads to derepression of FOXO3A, a transcription factor that up-regulates estrogen receptor (ER) signaling, resulting in a switch in the regulation of survival factors (e.g., survivin) and cell survival from ErbB2 alone to ER and ErbB2 in resistant cells.	Lapatinib	63-72	forkhead box O3	Homo sapiens	112-118
18980964-5	2008	For example, inhibition of phosphatidylinositol3 kinase-Akt in lapatinib-treated cells leads to derepression of FOXO3A, a transcription factor that up-regulates estrogen receptor (ER) signaling, resulting in a switch in the regulation of survival factors (e.g., survivin) and cell survival from ErbB2 alone to ER and ErbB2 in resistant cells.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	295-300
18980964-5	2008	For example, inhibition of phosphatidylinositol3 kinase-Akt in lapatinib-treated cells leads to derepression of FOXO3A, a transcription factor that up-regulates estrogen receptor (ER) signaling, resulting in a switch in the regulation of survival factors (e.g., survivin) and cell survival from ErbB2 alone to ER and ErbB2 in resistant cells.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	317-322
18980964-6	2008	In this review, we discuss the effects of lapatinib on signaling networks in ErbB2+ breast cancer cells to elucidate potential mechanisms of therapeutic resistance and strategies to overcome or prevent its development.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-82
18762792-1	2008	Lapatinib is an oral dual inhibitor of EGFR and HER2, the coexpression of which is associated with metastatic disease in patients with renal cell carcinoma.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	39-43
18762792-1	2008	Lapatinib is an oral dual inhibitor of EGFR and HER2, the coexpression of which is associated with metastatic disease in patients with renal cell carcinoma.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
18762792-2	2008	A recent randomized phase III trial of lapatinib versus hormone therapy was conducted in patients with cytokine-refractory metastatic renal cell carcinoma and tumors overexpressing EGFR and/or HER2.	Lapatinib	39-48	epidermal growth factor receptor	Homo sapiens	181-185
18762792-2	2008	A recent randomized phase III trial of lapatinib versus hormone therapy was conducted in patients with cytokine-refractory metastatic renal cell carcinoma and tumors overexpressing EGFR and/or HER2.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-197
18762792-5	2008	A nonsignificant numerical advantage in time to progression was observed in patients with EGFR overexpression in the primary tumor (immunohistochemistry score 3+), suggesting that lapatinib could be of benefit in this subset of patients.	Lapatinib	180-189	epidermal growth factor receptor	Homo sapiens	90-94
18588508-7	2008	Importantly, the presence of C797S with T790M in the same EGFR allele conferred complete resistance to erlotinib, lapatinib and CI-1033.	Lapatinib	114-123	epidermal growth factor receptor	Homo sapiens	58-62
18952552-9	2008	Lapatinib, a dual tyrosine kinase inhibitor against HER1 and HER2, has been approved in combination with capecitabine for HER2-overexpressing advanced or metastatic breast cancer, which has progressed following previous anthracycline, taxane, and trastuzumab therapy.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	52-56
18952552-9	2008	Lapatinib, a dual tyrosine kinase inhibitor against HER1 and HER2, has been approved in combination with capecitabine for HER2-overexpressing advanced or metastatic breast cancer, which has progressed following previous anthracycline, taxane, and trastuzumab therapy.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
18952552-9	2008	Lapatinib, a dual tyrosine kinase inhibitor against HER1 and HER2, has been approved in combination with capecitabine for HER2-overexpressing advanced or metastatic breast cancer, which has progressed following previous anthracycline, taxane, and trastuzumab therapy.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
18952558-1	2008	BACKGROUND: Patients with HER2-positive breast cancer whose disease has become resistant to the anti-HER2 monoclonal antibody trastuzumab can benefit from lapatinib, a dual epidermal growth factor receptor/HER2 tyrosine kinase (TK) inhibitor.	Lapatinib	155-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
18952558-1	2008	BACKGROUND: Patients with HER2-positive breast cancer whose disease has become resistant to the anti-HER2 monoclonal antibody trastuzumab can benefit from lapatinib, a dual epidermal growth factor receptor/HER2 tyrosine kinase (TK) inhibitor.	Lapatinib	155-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
18952558-9	2008	For these patients, there is evidence from a large randomized trial that effective HER2 targeting can be accomplished by inhibiting the HER2 TK activity with lapatinib.	Lapatinib	158-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
18952558-9	2008	For these patients, there is evidence from a large randomized trial that effective HER2 targeting can be accomplished by inhibiting the HER2 TK activity with lapatinib.	Lapatinib	158-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
18803447-6	2008	On the other hand, the dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor lapatinib has been the first drug to be approved in combination with capecitabine for the treatment of patients who progress on trastuzumab-based therapies.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-101
18823221-5	2008	Lapatinib is an oral dual tyrosine kinase inhibitor against members of the human epidermal growth factor receptor (HER) family (HER1 or epidermal growth factor receptor [EGFR], and HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	81-113
18823221-5	2008	Lapatinib is an oral dual tyrosine kinase inhibitor against members of the human epidermal growth factor receptor (HER) family (HER1 or epidermal growth factor receptor [EGFR], and HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	128-132
18823221-5	2008	Lapatinib is an oral dual tyrosine kinase inhibitor against members of the human epidermal growth factor receptor (HER) family (HER1 or epidermal growth factor receptor [EGFR], and HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	136-168
18823221-5	2008	Lapatinib is an oral dual tyrosine kinase inhibitor against members of the human epidermal growth factor receptor (HER) family (HER1 or epidermal growth factor receptor [EGFR], and HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	170-174
18823221-5	2008	Lapatinib is an oral dual tyrosine kinase inhibitor against members of the human epidermal growth factor receptor (HER) family (HER1 or epidermal growth factor receptor [EGFR], and HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185
18849320-1	2008	On March 13, 2007, the U.S. Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-190
18849320-1	2008	On March 13, 2007, the U.S. Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab.	Lapatinib	66-75	epidermal growth factor receptor	Homo sapiens	195-201
18849320-1	2008	On March 13, 2007, the U.S. Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab.	Lapatinib	66-75	epidermal growth factor receptor	Homo sapiens	285-317
18768996-2	2008	SUMMARY: Lapatinib is a small-molecule tyrosine kinase inhibitor that dually targets human epidermal growth factor receptors 1 and 2 (HER2).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-132
18768996-9	2008	CONCLUSION: Lapatinib has demonstrated efficacy in combination with capecitabine in patients with previously treated HER2-positive metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
18768996-2	2008	SUMMARY: Lapatinib is a small-molecule tyrosine kinase inhibitor that dually targets human epidermal growth factor receptors 1 and 2 (HER2).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
18768996-5	2008	Combination therapy with lapatinib and capecitabine has demonstrated superior time to progression compared with capecitabine monotherapy for the treatment of HER2-positive metastatic breast cancer refractory to anthracycline-, taxane-, and trastuzumab-containing regimens.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
18728660-0	2008	Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.	Lapatinib	20-29	twist family bHLH transcription factor 1	Homo sapiens	2-7
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-32
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	Lapatinib	126-135	epidermal growth factor receptor	Homo sapiens	97-101
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
18728660-1	2008	The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC).	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
18544666-5	2008	Lapatinib was competent to inhibit basal and epidermal growth factor (EGF)-stimulated ERBB1 phosphorylation in adapted cells.	Lapatinib	0-9	epidermal growth factor	Homo sapiens	45-68
18757423-9	2008	Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.	Lapatinib	26-35	epidermal growth factor receptor	Homo sapiens	59-63
18757423-9	2008	Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73
18757423-9	2008	Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-77
18757423-9	2008	Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-146
18757423-9	2008	Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-150
18757423-10	2008	Combining the INCB7839 second-generation sheddase inhibitor with lapatinib prevented the growth of HER-2/neu-positive BT474-SC1 human breast cancer xenografts in vivo.	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-104
18757423-10	2008	Combining the INCB7839 second-generation sheddase inhibitor with lapatinib prevented the growth of HER-2/neu-positive BT474-SC1 human breast cancer xenografts in vivo.	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-108
18544666-0	2008	Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.	Lapatinib	0-9	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	61-66
18544666-0	2008	Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.	Lapatinib	0-9	BCL2 antagonist/killer 1	Homo sapiens	92-95
18544666-2	2008	Lapatinib inhibited radiation-induced activation of ERBB1/2, extracellular signal-regulated kinases 1/2, and AKT, and radiosensitized HCT116 cells.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	52-112
18544666-5	2008	Lapatinib was competent to inhibit basal and epidermal growth factor (EGF)-stimulated ERBB1 phosphorylation in adapted cells.	Lapatinib	0-9	epidermal growth factor	Homo sapiens	70-73
18544666-5	2008	Lapatinib was competent to inhibit basal and epidermal growth factor (EGF)-stimulated ERBB1 phosphorylation in adapted cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	86-91
18544666-7	2008	However, in neither parental nor adapted cells did expression of dominant-negative ERBB1 and dominant-negative ERBB2 recapitulate the cell death-promoting effects of lapatinib.	Lapatinib	166-175	epidermal growth factor receptor	Homo sapiens	83-88
18544666-7	2008	However, in neither parental nor adapted cells did expression of dominant-negative ERBB1 and dominant-negative ERBB2 recapitulate the cell death-promoting effects of lapatinib.	Lapatinib	166-175	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-116
18544666-9	2008	Overexpression of BCL-XL protected parental cells from lapatinib toxicity.	Lapatinib	55-64	BCL2 like 1	Homo sapiens	18-24
18544666-10	2008	Knockdown of MCL-1 expression enhanced lapatinib toxicity in adapted cells that was reverted by knockdown of BAK expression.	Lapatinib	39-48	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-18
18664652-3	2008	We examined the efficacy of lapatinib, an inhibitor of the epidermal growth factor receptor (EGFR) and HER2 kinases, for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasis.	Lapatinib	28-37	epidermal growth factor receptor	Mus musculus	59-91
21127749-2	2008	Lapatinib is a potent dual inhibitor of HER-2 and EGFR.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-45
21127749-2	2008	Lapatinib is a potent dual inhibitor of HER-2 and EGFR.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	50-54
21127749-9	2008	Results from these studies suggest that the main benefit from lapatinib is in the HER-2 positive breast cancer population.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-87
21127749-11	2008	Lapatinib may have a specific role in treating HER-2 positive CNS metastases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
18594499-0	2008	Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.	Lapatinib	72-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
18594499-3	2008	Lapatinib is an oral receptor tyrosine kinase inhibitor that targets HER2 and the EGFR.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
18594499-3	2008	Lapatinib is an oral receptor tyrosine kinase inhibitor that targets HER2 and the EGFR.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	82-86
18594499-5	2008	In a pivotal phase III trial, a combination of lapatinib and capecitabine significantly decreased the risk of disease progression relative to capecitabine alone in women with HER2-positive advanced or metastatic breast cancer previously treated with anthracyclines, taxanes, and trastuzumab.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
18594499-9	2008	These features make lapatinib an ideal agent to evaluate more fully in HER2-positive metastatic and early-stage breast cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
18719096-7	2008	Furthermore, overexpression of Brk conferred resistance to the ability of Lapatinib, an ErbB2 kinase inhibitor, to inhibit ErbB2-induced proliferation.	Lapatinib	74-83	protein tyrosine kinase 6	Homo sapiens	31-34
18719096-7	2008	Furthermore, overexpression of Brk conferred resistance to the ability of Lapatinib, an ErbB2 kinase inhibitor, to inhibit ErbB2-induced proliferation.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-93
18719096-7	2008	Furthermore, overexpression of Brk conferred resistance to the ability of Lapatinib, an ErbB2 kinase inhibitor, to inhibit ErbB2-induced proliferation.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
18664652-3	2008	We examined the efficacy of lapatinib, an inhibitor of the epidermal growth factor receptor (EGFR) and HER2 kinases, for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasis.	Lapatinib	28-37	epidermal growth factor receptor	Mus musculus	93-97
18664652-3	2008	We examined the efficacy of lapatinib, an inhibitor of the epidermal growth factor receptor (EGFR) and HER2 kinases, for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasis.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Mus musculus	103-107
18664652-7	2008	RESULTS: In vitro, lapatinib inhibited the phosphorylation of EGFR, HER2, and downstream signaling proteins; cell proliferation; and migration in 231-BR cells (both with and without HER2).	Lapatinib	19-28	epidermal growth factor receptor	Mus musculus	62-66
18664652-7	2008	RESULTS: In vitro, lapatinib inhibited the phosphorylation of EGFR, HER2, and downstream signaling proteins; cell proliferation; and migration in 231-BR cells (both with and without HER2).	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Mus musculus	68-72
18664652-7	2008	RESULTS: In vitro, lapatinib inhibited the phosphorylation of EGFR, HER2, and downstream signaling proteins; cell proliferation; and migration in 231-BR cells (both with and without HER2).	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Mus musculus	182-186
18664652-10	2008	Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001).	Lapatinib	157-166	erb-b2 receptor tyrosine kinase 2	Mus musculus	65-69
18664652-10	2008	Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001).	Lapatinib	157-166	erb-b2 receptor tyrosine kinase 2	Mus musculus	80-84
18664652-10	2008	Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001).	Lapatinib	157-166	erb-b2 receptor tyrosine kinase 2	Mus musculus	80-84
18664652-11	2008	CONCLUSIONS: Lapatinib is the first HER2-directed drug to be validated in a preclinical model for activity against brain metastases of breast cancer.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Mus musculus	36-40
18462377-2	2008	Recent reports suggest activity of erlotinib, an ErbB1 inhibitor, and lapatinib, a dual inhibitor of ErbB1 and ErbB2, in hepatocellular carcinoma (HCC).	Lapatinib	70-79	epidermal growth factor receptor	Homo sapiens	101-106
18803986-8	2008	Lapatinib is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not HER2.	Lapatinib	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-61
18803986-8	2008	Lapatinib is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not HER2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	114-118
18803986-16	2008	CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases.	Lapatinib	13-22	epidermal growth factor receptor	Homo sapiens	50-54
18803986-16	2008	CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
18803986-19	2008	Lapatinib"s efficacy in other malignancies that overexpress EGFR and/or HER2 is under evaluation.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	60-64
18803986-19	2008	Lapatinib"s efficacy in other malignancies that overexpress EGFR and/or HER2 is under evaluation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
18803986-0	2008	Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	37-69
18803986-1	2008	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	51-83
18803986-1	2008	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	85-89
18803986-1	2008	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-135
18803986-1	2008	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
18462377-2	2008	Recent reports suggest activity of erlotinib, an ErbB1 inhibitor, and lapatinib, a dual inhibitor of ErbB1 and ErbB2, in hepatocellular carcinoma (HCC).	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-116
18644997-2	2008	Lapatinib is a selective competitive inhibitor of both the HER2 and EGFR tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
18644997-2	2008	Lapatinib is a selective competitive inhibitor of both the HER2 and EGFR tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	68-72
18644997-3	2008	Although lapatinib showed significant activity in patients with HER2-positive breast cancer, the role of EGFR in the response of breast cancer to lapatinib has not been defined.	Lapatinib	146-155	epidermal growth factor receptor	Homo sapiens	105-109
18644997-4	2008	Here, we examined the role of EGFR expression levels in the sensitivity of HER2-overexpressing breast cancer cells to lapatinib.	Lapatinib	118-127	epidermal growth factor receptor	Homo sapiens	30-34
18644997-4	2008	Here, we examined the role of EGFR expression levels in the sensitivity of HER2-overexpressing breast cancer cells to lapatinib.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
18644997-5	2008	Depletion of EGFR by EGFR small-interfering RNA knockdown did not affect lapatinib sensitivity in these cells, whereas treated HER2 siRNA knockdown cells became more resistant to lapatinib.	Lapatinib	179-188	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
18594201-3	2008	ErbB2 signaling can also be blocked using small molecule tyrosine kinase inhibitors, like Lapatinib, that compete with ATP for binding at the ErbB2 catalytic kinase domain.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
18297114-2	2008	Five EGFR inhibitors, two monoclonal antibodies and three TKIs, have recently gained FDA approval in oncology (cetuximab, panitumumab, erlotinib, gefitinib and lapatinib).	Lapatinib	160-169	epidermal growth factor receptor	Homo sapiens	5-9
18594201-3	2008	ErbB2 signaling can also be blocked using small molecule tyrosine kinase inhibitors, like Lapatinib, that compete with ATP for binding at the ErbB2 catalytic kinase domain.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-147
18283035-0	2008	A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
18386291-7	2008	Furthermore, EGFR inhibitors gefitinib and lapatinib abrogated hypersensitivity of MAPK signaling and cooperated with PTEN expression to inhibit cell growth in both monolayer and anchorage-independent conditions.	Lapatinib	43-52	epidermal growth factor receptor	Homo sapiens	13-17
18386291-7	2008	Furthermore, EGFR inhibitors gefitinib and lapatinib abrogated hypersensitivity of MAPK signaling and cooperated with PTEN expression to inhibit cell growth in both monolayer and anchorage-independent conditions.	Lapatinib	43-52	phosphatase and tensin homolog	Homo sapiens	118-122
18283037-10	2008	Lapatinib-resistant MCF-7/HER2-Lap10 cells, which are capable of growing in the continuous presence of 10 microM lapatinib without significant effects on cell viability, notably exhibited a lapatinib-insensitive hyperphosphorylation of p70S6K1.	Lapatinib	190-199	LAP	Homo sapiens	0-3
18283035-0	2008	A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
18283037-11	2008	Rapamycin cotreatment suppressed p70S6K1 hyperactivation and synergistically resensitized MCF-7/HER2-Lap10 cells to lapatinib (>20-fold increase in lapatinib-induced cytotoxicity; CI(50) = 0.175 < 1.0 = additivity).	Lapatinib	116-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
18283037-11	2008	Rapamycin cotreatment suppressed p70S6K1 hyperactivation and synergistically resensitized MCF-7/HER2-Lap10 cells to lapatinib (>20-fold increase in lapatinib-induced cytotoxicity; CI(50) = 0.175 < 1.0 = additivity).	Lapatinib	116-125	LAP	Homo sapiens	101-104
18283035-1	2008	BACKGROUND: The efficacy and tolerability of the epidermal growth factor receptor/human epidermal growth factor receptor type 2 (HER2) tyrosine kinase inhibitor lapatinib in refractory metastatic breast cancer were assessed.	Lapatinib	161-170	epidermal growth factor receptor	Homo sapiens	88-120
18283037-12	2008	CONCLUSIONS: Serine-threonine kinase p70S6K1, a marker for mTOR activity that regulates protein translation, constitutes a specific biomarker for the biological effects of the dual-HER1/HER2 inhibitor lapatinib.	Lapatinib	201-210	mechanistic target of rapamycin kinase	Homo sapiens	59-63
18283037-12	2008	CONCLUSIONS: Serine-threonine kinase p70S6K1, a marker for mTOR activity that regulates protein translation, constitutes a specific biomarker for the biological effects of the dual-HER1/HER2 inhibitor lapatinib.	Lapatinib	201-210	epidermal growth factor receptor	Homo sapiens	181-185
18283037-12	2008	CONCLUSIONS: Serine-threonine kinase p70S6K1, a marker for mTOR activity that regulates protein translation, constitutes a specific biomarker for the biological effects of the dual-HER1/HER2 inhibitor lapatinib.	Lapatinib	201-210	erb-b2 receptor tyrosine kinase 2	Homo sapiens	186-190
18283037-13	2008	The clinical implications of our data are that the efficacy of lapatinib might be enhanced with therapies that target the mTOR pathway.	Lapatinib	63-72	mechanistic target of rapamycin kinase	Homo sapiens	122-126
18283035-1	2008	BACKGROUND: The efficacy and tolerability of the epidermal growth factor receptor/human epidermal growth factor receptor type 2 (HER2) tyrosine kinase inhibitor lapatinib in refractory metastatic breast cancer were assessed.	Lapatinib	161-170	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
18283035-5	2008	Both assessments established that approximately 6% of HER2-positive patients derived clinical benefit from lapatinib, being progression free for >/=6 months.	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
18283035-10	2008	CONCLUSIONS: Lapatinib monotherapy had modest clinical activity in HER2-positive metastatic breast cancer that progressed on prior trastuzumab regimens.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
18283037-0	2008	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.	Lapatinib	150-159	mechanistic target of rapamycin kinase	Homo sapiens	48-52
18283037-14	2008	Rapamycin analogues such as CCI-779 (Temsirolimus) and RAD001 (Everolimus) may warrant further clinical evaluation to effectively delay or prevent the development of acquired resistance to lapatinib in HER2-positive breast cancer patients.	Lapatinib	189-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
18283037-0	2008	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.	Lapatinib	150-159	epidermal growth factor receptor	Homo sapiens	114-118
18283037-0	2008	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.	Lapatinib	150-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
18283037-2	2008	Here, we took advantage of a semiquantitative protein array technology to identify intracellular oncogenic kinases that distinctively correlate with breast cancer cell sensitivity/resistance to the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)).	Lapatinib	239-248	epidermal growth factor receptor	Homo sapiens	203-207
18283037-2	2008	Here, we took advantage of a semiquantitative protein array technology to identify intracellular oncogenic kinases that distinctively correlate with breast cancer cell sensitivity/resistance to the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)).	Lapatinib	239-248	erb-b2 receptor tyrosine kinase 2	Homo sapiens	208-212
18283037-5	2008	A model of acquired resistance to lapatinib (MCF-7/HER2-Lap10 cells) was established by chronically exposing MCF-7/HER2 cells to increasing concentrations of lapatinib for >10 months.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
18283037-5	2008	A model of acquired resistance to lapatinib (MCF-7/HER2-Lap10 cells) was established by chronically exposing MCF-7/HER2 cells to increasing concentrations of lapatinib for >10 months.	Lapatinib	34-43	LAP	Homo sapiens	56-59
18283037-6	2008	RESULTS: Treatment of MCF-7/HER2 cells with either trastuzumab or lapatinib similarly impaired HER2-enhanced activation status (i.e. phosphorylation) of the mitogen-activated protein kinases, c-Jun N-terminal kinases 1-3 and p38alpha/beta/gamma/delta and of the serine/threonine kinases AKT, glycogen synthase kinase-3, p90 ribosomal s6 kinase1/2, and mitogen- and stress-activated protein kinase1/2.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
18283037-6	2008	RESULTS: Treatment of MCF-7/HER2 cells with either trastuzumab or lapatinib similarly impaired HER2-enhanced activation status (i.e. phosphorylation) of the mitogen-activated protein kinases, c-Jun N-terminal kinases 1-3 and p38alpha/beta/gamma/delta and of the serine/threonine kinases AKT, glycogen synthase kinase-3, p90 ribosomal s6 kinase1/2, and mitogen- and stress-activated protein kinase1/2.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
18283037-6	2008	RESULTS: Treatment of MCF-7/HER2 cells with either trastuzumab or lapatinib similarly impaired HER2-enhanced activation status (i.e. phosphorylation) of the mitogen-activated protein kinases, c-Jun N-terminal kinases 1-3 and p38alpha/beta/gamma/delta and of the serine/threonine kinases AKT, glycogen synthase kinase-3, p90 ribosomal s6 kinase1/2, and mitogen- and stress-activated protein kinase1/2.	Lapatinib	66-75	mitogen-activated protein kinase 8	Homo sapiens	192-220
18283037-6	2008	RESULTS: Treatment of MCF-7/HER2 cells with either trastuzumab or lapatinib similarly impaired HER2-enhanced activation status (i.e. phosphorylation) of the mitogen-activated protein kinases, c-Jun N-terminal kinases 1-3 and p38alpha/beta/gamma/delta and of the serine/threonine kinases AKT, glycogen synthase kinase-3, p90 ribosomal s6 kinase1/2, and mitogen- and stress-activated protein kinase1/2.	Lapatinib	66-75	mitogen-activated protein kinase 14	Homo sapiens	225-233
18283037-6	2008	RESULTS: Treatment of MCF-7/HER2 cells with either trastuzumab or lapatinib similarly impaired HER2-enhanced activation status (i.e. phosphorylation) of the mitogen-activated protein kinases, c-Jun N-terminal kinases 1-3 and p38alpha/beta/gamma/delta and of the serine/threonine kinases AKT, glycogen synthase kinase-3, p90 ribosomal s6 kinase1/2, and mitogen- and stress-activated protein kinase1/2.	Lapatinib	66-75	cellular inhibitor of PP2A	Homo sapiens	320-323
18283037-8	2008	Conversely, lapatinib treatment caused a drastic decrease in the phosphorylation of p70S6K1 at ERK1/2-regulated sites (Thr(421)/Ser(424)) and, as a consequence, p70S6K1 activity measured by its phospho-Thr(389) levels was abolished.	Lapatinib	12-21	mitogen-activated protein kinase 3	Homo sapiens	95-101
18283037-9	2008	The mTOR inhibitor rapamycin was found to supraadditively increase lapatinib efficacy in MCF-7/HER2 cells [ approximately 10-fold enhancement; combination index (CI(50)) = 0.243 < 1.0 = additivity, P < 0.001] but not in p70S6K1 gene-amplified MCF-7 parental cells ( approximately 1.3-fold enhancement; CI(50) = 0.920 congruent with 1.0 = additivity).	Lapatinib	67-76	mechanistic target of rapamycin kinase	Homo sapiens	4-8
18283037-9	2008	The mTOR inhibitor rapamycin was found to supraadditively increase lapatinib efficacy in MCF-7/HER2 cells [ approximately 10-fold enhancement; combination index (CI(50)) = 0.243 < 1.0 = additivity, P < 0.001] but not in p70S6K1 gene-amplified MCF-7 parental cells ( approximately 1.3-fold enhancement; CI(50) = 0.920 congruent with 1.0 = additivity).	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
18283037-10	2008	Lapatinib-resistant MCF-7/HER2-Lap10 cells, which are capable of growing in the continuous presence of 10 microM lapatinib without significant effects on cell viability, notably exhibited a lapatinib-insensitive hyperphosphorylation of p70S6K1.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
18283037-10	2008	Lapatinib-resistant MCF-7/HER2-Lap10 cells, which are capable of growing in the continuous presence of 10 microM lapatinib without significant effects on cell viability, notably exhibited a lapatinib-insensitive hyperphosphorylation of p70S6K1.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
18283037-10	2008	Lapatinib-resistant MCF-7/HER2-Lap10 cells, which are capable of growing in the continuous presence of 10 microM lapatinib without significant effects on cell viability, notably exhibited a lapatinib-insensitive hyperphosphorylation of p70S6K1.	Lapatinib	113-122	LAP	Homo sapiens	0-3
17653858-2	2008	Clinical therapeutic decisions in the treatment of patients with HER2 positive metastatic breast cancer are based on appropriate patient selection, the clinical situation, and data related to the available therapeutic agents trastuzumab and lapatinib.	Lapatinib	241-250	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
18533085-1	2008	OBJECTIVE: To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR (ERBB1) and HER2 inhibitor, using prospective data collected in 44 clinical studies.	Lapatinib	44-53	epidermal growth factor receptor	Homo sapiens	92-96
18533085-1	2008	OBJECTIVE: To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR (ERBB1) and HER2 inhibitor, using prospective data collected in 44 clinical studies.	Lapatinib	44-53	epidermal growth factor receptor	Homo sapiens	98-103
18533085-1	2008	OBJECTIVE: To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR (ERBB1) and HER2 inhibitor, using prospective data collected in 44 clinical studies.	Lapatinib	44-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
18445819-3	2008	In this study, we aimed to test directly in human breast cancers the effect of conventional chemotherapy or lapatinib (an epidermal growth factor receptor [EGFR]/HER2 pathway inhibitor) on this tumorigenic CD44(>) and CD24(>/low) cell population.	Lapatinib	108-117	epidermal growth factor receptor	Homo sapiens	122-154
18445819-3	2008	In this study, we aimed to test directly in human breast cancers the effect of conventional chemotherapy or lapatinib (an epidermal growth factor receptor [EGFR]/HER2 pathway inhibitor) on this tumorigenic CD44(>) and CD24(>/low) cell population.	Lapatinib	108-117	epidermal growth factor receptor	Homo sapiens	156-160
18445819-3	2008	In this study, we aimed to test directly in human breast cancers the effect of conventional chemotherapy or lapatinib (an epidermal growth factor receptor [EGFR]/HER2 pathway inhibitor) on this tumorigenic CD44(>) and CD24(>/low) cell population.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
18445819-3	2008	In this study, we aimed to test directly in human breast cancers the effect of conventional chemotherapy or lapatinib (an epidermal growth factor receptor [EGFR]/HER2 pathway inhibitor) on this tumorigenic CD44(>) and CD24(>/low) cell population.	Lapatinib	108-117	CD44 molecule (Indian blood group)	Homo sapiens	206-210
18445819-3	2008	In this study, we aimed to test directly in human breast cancers the effect of conventional chemotherapy or lapatinib (an epidermal growth factor receptor [EGFR]/HER2 pathway inhibitor) on this tumorigenic CD44(>) and CD24(>/low) cell population.	Lapatinib	108-117	CD24 molecule	Homo sapiens	221-225
18458039-0	2008	Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-64
18458039-1	2008	PURPOSE: This study (EGF20009) assessed the efficacy and tolerability of two lapatinib administration schedules as first-line monotherapy in women with ErbB2-amplified locally advanced or metastatic breast cancer.	Lapatinib	77-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-157
18458039-9	2008	CONCLUSION: Lapatinib demonstrated clinical activity and was well tolerated as first-line therapy in ErbB2-amplified locally advanced or metastatic breast cancer.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
18458039-10	2008	This study supports further evaluation of lapatinib in first-line and early-stage ErbB2-overexpressing breast cancer.	Lapatinib	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-87
18467719-1	2008	PURPOSE: Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER-2) tyrosine kinases with demonstrated activity in patients with HER-2-positive breast cancer.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	56-88
18467719-1	2008	PURPOSE: Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER-2) tyrosine kinases with demonstrated activity in patients with HER-2-positive breast cancer.	Lapatinib	9-18	epidermal growth factor receptor	Homo sapiens	90-94
18467719-1	2008	PURPOSE: Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER-2) tyrosine kinases with demonstrated activity in patients with HER-2-positive breast cancer.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-136
18467719-1	2008	PURPOSE: Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER-2) tyrosine kinases with demonstrated activity in patients with HER-2-positive breast cancer.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-143
18467719-1	2008	PURPOSE: Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER-2) tyrosine kinases with demonstrated activity in patients with HER-2-positive breast cancer.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	206-211
18467719-2	2008	In the current phase III open-label trial, lapatinib was compared with hormone therapy (HT) in patients with advanced renal cell carcinoma (RCC) that express EGFR and/or HER-2.	Lapatinib	43-52	epidermal growth factor receptor	Homo sapiens	158-162
18467719-7	2008	In a biomarker analysis of patients with EGFR-overexpressed tumors (3+ by immunohistochemistry [IHC]; n = 241) median TTP was 15.1 weeks for lapatinib versus 10.9 weeks for HT (HR = 0.76; P = .06), and median OS was 46.0 weeks for lapatinib versus 37.9 weeks for HT (HR = 0.69; P = .02).	Lapatinib	141-150	epidermal growth factor receptor	Homo sapiens	41-45
17653858-5	2008	Lapatinib, an oral small molecule tyrosine kinase inhibitor has more recently become available (in 2007), approved for used in combination with capecitabine for patients with HER2 positive metastatic disease that has progressed on trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
18421051-0	2008	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Lapatinib	18-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-106
18487908-5	2008	Lapatinib combined with capecitabine showed efficacy against HER2-positive metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
18561551-6	2008	If a tumor overexpresses HER2, targeted treatment with trastuzumab (Herceptin) or lapatinib (Tykerb) is possible.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
18561551-6	2008	If a tumor overexpresses HER2, targeted treatment with trastuzumab (Herceptin) or lapatinib (Tykerb) is possible.	Lapatinib	93-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
18421051-3	2008	We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases.	Lapatinib	40-49	epidermal growth factor receptor	Homo sapiens	72-104
18421051-3	2008	We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases.	Lapatinib	40-49	epidermal growth factor receptor	Homo sapiens	106-110
18421051-3	2008	We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-121
18421051-3	2008	We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-145
18413807-2	2008	Previous studies of lapatinib, a selective dual-kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2 tyrosine kinases, have shown predictable relationships between the activity of these target genes and response.	Lapatinib	20-29	epidermal growth factor receptor	Homo sapiens	68-100
18413839-0	2008	EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-40
18413839-2	2008	We report the prospective discovery of ErbB2 mutations that confer resistance to the small-molecule inhibitor lapatinib.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44
18413839-4	2008	RESULTS: Lapatinib resistance screens identified mutations at 16 different ErbB2 amino acid residues, with 12 mutated amino acids mapping to the kinase domain.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-80
18413839-7	2008	ErbB2 T798I imparts the strongest lapatinib resistance effect and is analogous to the epidermal growth factor receptor T790M, ABL T315I, and cKIT T670I gatekeeper mutations that are associated with clinical drug resistance.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
18413839-8	2008	ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Mus musculus	0-5
18413839-8	2008	ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	227-232
18413839-8	2008	ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers.	Lapatinib	203-212	erb-b2 receptor tyrosine kinase 2	Mus musculus	0-5
18413839-8	2008	ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers.	Lapatinib	203-212	erb-b2 receptor tyrosine kinase 2	Homo sapiens	227-232
18413839-9	2008	The epidermal growth factor receptor/ErbB2/vascular endothelial growth factor receptor inhibitor EXEL-7647 was found to inhibit almost all lapatinib resistance-associated mutations.	Lapatinib	139-148	epidermal growth factor receptor	Homo sapiens	4-36
18413839-9	2008	The epidermal growth factor receptor/ErbB2/vascular endothelial growth factor receptor inhibitor EXEL-7647 was found to inhibit almost all lapatinib resistance-associated mutations.	Lapatinib	139-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-42
18413839-10	2008	Furthermore, no ErbB2 mutations were found to be associated with EXEL-7647 resistance and lapatinib sensitivity.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-21
18216274-1	2008	Lapatinib [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, GW572016, Tykerb] is a tyrosine kinase inhibitor approved for use in combination with capecitabine to treat advanced or metastatic breast cancers overexpressing HER2 (ErbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	289-293
18216274-1	2008	Lapatinib [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, GW572016, Tykerb] is a tyrosine kinase inhibitor approved for use in combination with capecitabine to treat advanced or metastatic breast cancers overexpressing HER2 (ErbB2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	295-300
18216274-5	2008	Lapatinib is a substrate for the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP).	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
18216274-5	2008	Lapatinib is a substrate for the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP).	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
18216274-5	2008	Lapatinib is a substrate for the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP).	Lapatinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-110
18216274-5	2008	Lapatinib is a substrate for the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP).	Lapatinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	112-116
18216274-6	2008	Furthermore, lapatinib is an inhibitor (IC(50) values 0.025-5 muM) of Pgp, BCRP, and organic anion transporting polypeptide 1B1 (a hepatic uptake transporter).	Lapatinib	13-22	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
18216274-6	2008	Furthermore, lapatinib is an inhibitor (IC(50) values 0.025-5 muM) of Pgp, BCRP, and organic anion transporting polypeptide 1B1 (a hepatic uptake transporter).	Lapatinib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	75-79
18216274-9	2008	In contrast, systemic exposure of lapatinib after oral dosing was unchanged when efflux by Pgp and BCRP was absent from the gastrointestinal tract.	Lapatinib	34-43	ATP binding cassette subfamily B member 1	Homo sapiens	91-94
18216274-9	2008	In contrast, systemic exposure of lapatinib after oral dosing was unchanged when efflux by Pgp and BCRP was absent from the gastrointestinal tract.	Lapatinib	34-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	99-103
18621618-0	2008	Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
18375904-5	2008	We suggest an atomic-level mechanism for the poor efficacy of lapatinib against tumors with activating EGFR kinase domain point mutations compared with the efficacy of gefitinib and erlotinib, and demonstrate how structural insights help our understanding of acquired resistance to these agents.	Lapatinib	62-71	epidermal growth factor receptor	Homo sapiens	103-107
18413807-2	2008	Previous studies of lapatinib, a selective dual-kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2 tyrosine kinases, have shown predictable relationships between the activity of these target genes and response.	Lapatinib	20-29	epidermal growth factor receptor	Homo sapiens	102-106
18413807-2	2008	Previous studies of lapatinib, a selective dual-kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2 tyrosine kinases, have shown predictable relationships between the activity of these target genes and response.	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
18413807-6	2008	This study shows that biomarkers predictive for lapatinib sensitivity, including the previously described copy number gains of EGFR and HER2, can be discovered using novel genomic assays in an unbiased manner.	Lapatinib	48-57	epidermal growth factor receptor	Homo sapiens	127-131
18413807-6	2008	This study shows that biomarkers predictive for lapatinib sensitivity, including the previously described copy number gains of EGFR and HER2, can be discovered using novel genomic assays in an unbiased manner.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
18334972-0	2008	Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
18622912-2	2008	Lapatinib, an oral HER2-tyrosine kinase inhibitor, showed activity in patients with breast cancer progression after trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
18334972-0	2008	Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	39-43
18334972-1	2008	In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer.	Lapatinib	55-64	epidermal growth factor receptor	Homo sapiens	99-103
18334972-1	2008	In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
18334972-7	2008	Lapatinib exerts growth inhibition in a PTEN-independent manner.	Lapatinib	0-9	phosphatase and tensin homolog	Homo sapiens	40-44
18334972-9	2008	In contrast, lapatinib-resistant cell lines exhibited high androgen receptor (AR) levels or epithelial-to-mesenchymal transition (post-EMT) features.	Lapatinib	13-22	androgen receptor	Homo sapiens	59-76
18334972-9	2008	In contrast, lapatinib-resistant cell lines exhibited high androgen receptor (AR) levels or epithelial-to-mesenchymal transition (post-EMT) features.	Lapatinib	13-22	androgen receptor	Homo sapiens	78-80
18334972-9	2008	In contrast, lapatinib-resistant cell lines exhibited high androgen receptor (AR) levels or epithelial-to-mesenchymal transition (post-EMT) features.	Lapatinib	13-22	IL2 inducible T cell kinase	Homo sapiens	135-138
18334972-11	2008	These observations provide a clear biologic rational to test lapatinib as a single agent or in combination with chemotherapy in endometrial cancer with HER2 overexpression.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
18334972-12	2008	Expression of EGFR, its ligands, HER3, AR, and post-EMT markers warrant further evaluation to help define patients with HER2-nonoverexpressing endometrial cancer most likely to benefit from lapatinib.	Lapatinib	190-199	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
18347147-5	2008	A reversible EGFR and HER2 TKI, lapatinib, decreased Stat3 activation by blocking heterodimerization of EGFR and HER2, which led to a modest increase in the inhibitory effect on gefitinib-resistant T790M cells.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	13-17
19707428-0	2008	Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-69
19707428-0	2008	Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
19707428-1	2008	Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	52-90
19707428-1	2008	Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	92-96
19707428-1	2008	Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-153
19707428-1	2008	Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-159
19707428-2	2008	Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP).	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-110
18777950-7	2008	More recently, small-molecule tyrosine kinase inhibitors such as lapatinib have been investigated for the treatment of ErbB2-positive metastatic breast cancer.	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-124
18212337-0	2008	Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.	Lapatinib	164-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-111
18212337-0	2008	Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.	Lapatinib	164-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-118
18212337-2	2008	Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor (EGFR) and human EGFR 2 (HER-2), demonstrated clinical activity in four of five IBC patients in phase I trials.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	43-75
18212337-2	2008	Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor (EGFR) and human EGFR 2 (HER-2), demonstrated clinical activity in four of five IBC patients in phase I trials.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	77-81
18212337-2	2008	Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor (EGFR) and human EGFR 2 (HER-2), demonstrated clinical activity in four of five IBC patients in phase I trials.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	93-97
18212337-2	2008	Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor (EGFR) and human EGFR 2 (HER-2), demonstrated clinical activity in four of five IBC patients in phase I trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
18212337-10	2008	Within cohort A, phosphorylated (p) HER-3 and lack of p53 expression predicted for response to lapatinib (P < .05).	Lapatinib	95-104	erb-b2 receptor tyrosine kinase 3	Homo sapiens	36-41
18212337-10	2008	Within cohort A, phosphorylated (p) HER-3 and lack of p53 expression predicted for response to lapatinib (P < .05).	Lapatinib	95-104	tumor protein p53	Homo sapiens	54-57
18212337-13	2008	CONCLUSION: Lapatinib is well tolerated with clinical activity in heavily pretreated HER-2+, but not EGFR+/HER-2-, IBC.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-91
18212337-13	2008	CONCLUSION: Lapatinib is well tolerated with clinical activity in heavily pretreated HER-2+, but not EGFR+/HER-2-, IBC.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
18212337-15	2008	These findings warrant further investigation of lapatinib monotherapy or combination therapy in HER-2+ IBC.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-102
18347147-5	2008	A reversible EGFR and HER2 TKI, lapatinib, decreased Stat3 activation by blocking heterodimerization of EGFR and HER2, which led to a modest increase in the inhibitory effect on gefitinib-resistant T790M cells.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
18347147-5	2008	A reversible EGFR and HER2 TKI, lapatinib, decreased Stat3 activation by blocking heterodimerization of EGFR and HER2, which led to a modest increase in the inhibitory effect on gefitinib-resistant T790M cells.	Lapatinib	32-41	signal transducer and activator of transcription 3	Homo sapiens	53-58
18347147-5	2008	A reversible EGFR and HER2 TKI, lapatinib, decreased Stat3 activation by blocking heterodimerization of EGFR and HER2, which led to a modest increase in the inhibitory effect on gefitinib-resistant T790M cells.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	104-108
18347147-5	2008	A reversible EGFR and HER2 TKI, lapatinib, decreased Stat3 activation by blocking heterodimerization of EGFR and HER2, which led to a modest increase in the inhibitory effect on gefitinib-resistant T790M cells.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
18347147-6	2008	In addition to lapatinib, the anti-EGFR antibody, cetuximab, induced down-regulation of EGFR and apoptotic cell death in T790M cells.	Lapatinib	15-24	epidermal growth factor receptor	Homo sapiens	35-39
18347147-8	2008	Taken together, these data suggest that treatment with a combination of lapatinib and cetuximab, which induces dimeric dissociation and EGFR down-regulation, appears to be an effective strategy for treatment of patients with EGFR TKI-resistant NSCLC.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	136-140
18347147-8	2008	Taken together, these data suggest that treatment with a combination of lapatinib and cetuximab, which induces dimeric dissociation and EGFR down-regulation, appears to be an effective strategy for treatment of patients with EGFR TKI-resistant NSCLC.	Lapatinib	72-81	epidermal growth factor receptor	Homo sapiens	225-229
18708732-2	2008	Trastuzumab and lapatinib are 2 agents that have gained FDA approval for treating Her-2/neu-positive breast cancer.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-87
18334220-2	2008	We report here crystal structures of the ErbB4 kinase domain in active and lapatinib-inhibited forms.	Lapatinib	75-84	erb-b2 receptor tyrosine kinase 4	Mus musculus	41-46
18334220-5	2008	Lapatinib binds to an inactive form of the ErbB4 kinase in a mode equivalent to its interaction with the EGF receptor.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 4	Mus musculus	43-48
18334220-6	2008	All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 4	Mus musculus	4-9
18334220-6	2008	All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Mus musculus	80-84
18334220-6	2008	All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Mus musculus	85-90
18334220-6	2008	All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 4	Mus musculus	4-9
18334220-6	2008	All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Mus musculus	80-84
18334220-6	2008	All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets.	Lapatinib	98-107	erb-b2 receptor tyrosine kinase 2	Mus musculus	85-90
18211286-11	2008	This FASN-triggered HER1/HER2-breast cancer-like phenotype was specifically inhibitable either by FASN inhibitor C75 or by Tyr-kinase inhibitors (TKIs) gefitinib (Iressa) and lapatinib (Tykerb) but not by chemotherapeutic agents such as cisplatin.	Lapatinib	175-184	fatty acid synthase	Homo sapiens	5-9
18211286-11	2008	This FASN-triggered HER1/HER2-breast cancer-like phenotype was specifically inhibitable either by FASN inhibitor C75 or by Tyr-kinase inhibitors (TKIs) gefitinib (Iressa) and lapatinib (Tykerb) but not by chemotherapeutic agents such as cisplatin.	Lapatinib	175-184	epidermal growth factor receptor	Homo sapiens	20-24
18211286-11	2008	This FASN-triggered HER1/HER2-breast cancer-like phenotype was specifically inhibitable either by FASN inhibitor C75 or by Tyr-kinase inhibitors (TKIs) gefitinib (Iressa) and lapatinib (Tykerb) but not by chemotherapeutic agents such as cisplatin.	Lapatinib	186-192	fatty acid synthase	Homo sapiens	5-9
18211286-11	2008	This FASN-triggered HER1/HER2-breast cancer-like phenotype was specifically inhibitable either by FASN inhibitor C75 or by Tyr-kinase inhibitors (TKIs) gefitinib (Iressa) and lapatinib (Tykerb) but not by chemotherapeutic agents such as cisplatin.	Lapatinib	186-192	epidermal growth factor receptor	Homo sapiens	20-24
18211286-12	2008	Transient overexpression of FASN dramatically increased HBL100 breast epithelial cells" sensitivity to cytotoxic effects of C75, gefitinib and lapatinib (approximately 8, 10 and > 15 times, respectively), while significantly decreasing (approximately 3 times) cisplatin efficacy.	Lapatinib	143-152	fatty acid synthase	Homo sapiens	28-32
18199554-0	2008	Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.	Lapatinib	107-116	epidermal growth factor receptor	Homo sapiens	17-49
18199554-0	2008	Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
18199554-1	2008	The goal of this study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2) on interactions with the dual tyrosine kinase inhibitor lapatinib.	Lapatinib	239-248	epidermal growth factor receptor	Homo sapiens	120-152
18199554-1	2008	The goal of this study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2) on interactions with the dual tyrosine kinase inhibitor lapatinib.	Lapatinib	239-248	epidermal growth factor receptor	Homo sapiens	154-158
18199554-1	2008	The goal of this study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2) on interactions with the dual tyrosine kinase inhibitor lapatinib.	Lapatinib	239-248	epidermal growth factor receptor	Homo sapiens	159-164
18199554-1	2008	The goal of this study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2) on interactions with the dual tyrosine kinase inhibitor lapatinib.	Lapatinib	239-248	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
18199554-1	2008	The goal of this study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2) on interactions with the dual tyrosine kinase inhibitor lapatinib.	Lapatinib	239-248	erb-b2 receptor tyrosine kinase 2	Homo sapiens	176-181
18199554-3	2008	The point mutations G719C and L861Q had minor effects on lapatinib K(i)s, whereas EGFR mutations L858R and del15 had a higher K(i) for lapatinib than wild-type EGFR.	Lapatinib	135-144	epidermal growth factor receptor	Homo sapiens	82-86
18199554-4	2008	Structural analysis of wild-type EGFR-lapatinib complexes and modeling of the EGFR mutants were consistent with these data, suggesting that loss of structural flexibility and possible stabilization of the active-like conformation could interfere with lapatinib binding, particularly to the EGFR deletion mutants.	Lapatinib	38-47	epidermal growth factor receptor	Homo sapiens	33-37
18199554-4	2008	Structural analysis of wild-type EGFR-lapatinib complexes and modeling of the EGFR mutants were consistent with these data, suggesting that loss of structural flexibility and possible stabilization of the active-like conformation could interfere with lapatinib binding, particularly to the EGFR deletion mutants.	Lapatinib	251-260	epidermal growth factor receptor	Homo sapiens	78-82
18199554-4	2008	Structural analysis of wild-type EGFR-lapatinib complexes and modeling of the EGFR mutants were consistent with these data, suggesting that loss of structural flexibility and possible stabilization of the active-like conformation could interfere with lapatinib binding, particularly to the EGFR deletion mutants.	Lapatinib	251-260	epidermal growth factor receptor	Homo sapiens	78-82
18199554-5	2008	Furthermore, EGFR deletion mutants were relatively resistant to lapatinib-mediated inhibition of receptor autophosphorylation in recombinant cells expressing the variants, whereas EGFR point mutations had a modest or no effect.	Lapatinib	64-73	epidermal growth factor receptor	Homo sapiens	13-17
18199554-6	2008	Of note, EGFR T790M, a receptor variant found in patients with gefitinib-resistant NSCLC, was also resistant to lapatinib-mediated inhibition of receptor autophosphorylation.	Lapatinib	112-121	epidermal growth factor receptor	Homo sapiens	9-13
18199554-7	2008	Two HER2 insertional variants found in NSCLC were less sensitive to lapatinib inhibition than two HER2 point mutants.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
18199554-8	2008	The effects of lapatinib on the proliferation of human NSCLC tumor cell lines expressing wild-type or variant EGFR and HER2 cannot be explained solely on the basis of the biochemical activity or receptor autophosphorylation in recombinant cells.	Lapatinib	15-24	epidermal growth factor receptor	Homo sapiens	110-114
18199554-8	2008	The effects of lapatinib on the proliferation of human NSCLC tumor cell lines expressing wild-type or variant EGFR and HER2 cannot be explained solely on the basis of the biochemical activity or receptor autophosphorylation in recombinant cells.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
20824003-0	2008	Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib.	Lapatinib	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-51
18409020-1	2008	Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
20824004-0	2008	Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-56
18366956-0	2008	The emerging role of lapatinib in HER2-positive breast cancer.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
18366956-2	2008	Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
18708732-2	2008	Trastuzumab and lapatinib are 2 agents that have gained FDA approval for treating Her-2/neu-positive breast cancer.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-91
17827454-3	2007	Several EGFR inhibitors have recently gained US Food and Drug Administration approval for cancer therapy in the United States (and many other countries), including the mAbs cetuximab and panitumumab, and the small molecule TKIs gefitinib, erlotinib, and lapatinib.	Lapatinib	254-263	epidermal growth factor receptor	Homo sapiens	8-12
18054677-5	2007	Because cellular mechanisms can arise that can block the efficacy of this approach (and result in clinical resistance), recent research has led to the development of lapatinib, a targeted therapy that can act on HER2 inside the cell to disrupt the signaling pathways thought to be part of tumorigenic mechanisms.	Lapatinib	166-175	erb-b2 receptor tyrosine kinase 2	Homo sapiens	212-216
18269773-11	2007	Lapatinib, a new target agent that simultaneously inhibits both HER2 and epidermal growth factor receptor tyrosine kinases has been shown to be active in trastuzumab-resistant MBC.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
17714070-1	2007	Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	21-27
19707333-6	2007	Recently, a tyrosine kinase inhibitor, lapatinib, that targets both ErbB1 and ErbB2, has also shown activity in metastatic breast cancer.	Lapatinib	39-48	epidermal growth factor receptor	Homo sapiens	68-73
19707333-6	2007	Recently, a tyrosine kinase inhibitor, lapatinib, that targets both ErbB1 and ErbB2, has also shown activity in metastatic breast cancer.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-83
17350323-7	2007	ErbB1 and ErbB2 are also frequently overexpressed in salivary gland cancers and this has provided the rationale for clinical trials with trastuzumab, cetuximab, gefitinib, lapatinib.	Lapatinib	172-181	epidermal growth factor receptor	Homo sapiens	0-5
17761983-0	2007	Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.	Lapatinib	18-27	epidermal growth factor receptor	Homo sapiens	55-87
17761983-0	2007	Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.	Lapatinib	18-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-100
17761983-2	2007	This phase II study was conducted to determine the antitumor activity of lapatinib, a dual inhibitor of EGFR and erbB2 tyrosine kinase activity, in MSGTs.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	104-108
17761983-2	2007	This phase II study was conducted to determine the antitumor activity of lapatinib, a dual inhibitor of EGFR and erbB2 tyrosine kinase activity, in MSGTs.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-118
17892419-5	2007	Recently, lapatinib, a small molecule dual inhibitor of both HER2 and EGF receptors, has been developed to expand the options for treating HER-positive breast cancer.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
17350323-7	2007	ErbB1 and ErbB2 are also frequently overexpressed in salivary gland cancers and this has provided the rationale for clinical trials with trastuzumab, cetuximab, gefitinib, lapatinib.	Lapatinib	172-181	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-15
17679920-0	2007	Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
17673607-1	2007	Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	77-83
17673607-1	2007	Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-94
17673607-2	2007	Lapatinib has been shown to have activity in ErbB-2-overexpressing breast cancer in several phase II and III clinical trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-51
17545611-5	2007	Inhibition of HER2 activation by the tyrosine kinase inhibitor lapatinib led to decreased levels of PKCalpha phosphorylation, clearly indicating a cross-talk between PKCalpha and HER2 molecules.	Lapatinib	63-72	protein kinase C alpha	Homo sapiens	100-108
17545611-5	2007	Inhibition of HER2 activation by the tyrosine kinase inhibitor lapatinib led to decreased levels of PKCalpha phosphorylation, clearly indicating a cross-talk between PKCalpha and HER2 molecules.	Lapatinib	63-72	protein kinase C alpha	Homo sapiens	166-174
17545611-5	2007	Inhibition of HER2 activation by the tyrosine kinase inhibitor lapatinib led to decreased levels of PKCalpha phosphorylation, clearly indicating a cross-talk between PKCalpha and HER2 molecules.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
17699871-9	2007	Both inhibitors as well as the dual EGFR/HER2 inhibitor, lapatinib, induced apoptosis of the HR cells in culture.	Lapatinib	57-66	epidermal growth factor receptor	Homo sapiens	36-40
17699871-9	2007	Both inhibitors as well as the dual EGFR/HER2 inhibitor, lapatinib, induced apoptosis of the HR cells in culture.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	91-123
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	125-129
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-175
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-189
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	231-235
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	240-244
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	22-28	epidermal growth factor receptor	Homo sapiens	91-123
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	22-28	epidermal growth factor receptor	Homo sapiens	125-129
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	22-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-175
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	22-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	30-38	epidermal growth factor receptor	Homo sapiens	91-123
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	30-38	epidermal growth factor receptor	Homo sapiens	125-129
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	30-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-175
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	30-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	30-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-189
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	30-38	epidermal growth factor receptor	Homo sapiens	231-235
17635524-1	2007	OBJECTIVE: Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (ErbB2), inhibits population growth of selected EGFR and HER2 overexpressing cell lines.	Lapatinib	30-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	240-244
17635524-2	2007	Previous studies with a small number of cell lines suggest a correlation between overexpression of EGFR and/or HER2 and sensitivity to growth inhibition by lapatinib; however, the precise determinants of lapatinib selectivity for tumour and/or other cells remain unclear.	Lapatinib	156-165	epidermal growth factor receptor	Homo sapiens	99-103
17635524-2	2007	Previous studies with a small number of cell lines suggest a correlation between overexpression of EGFR and/or HER2 and sensitivity to growth inhibition by lapatinib; however, the precise determinants of lapatinib selectivity for tumour and/or other cells remain unclear.	Lapatinib	156-165	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
17635524-2	2007	Previous studies with a small number of cell lines suggest a correlation between overexpression of EGFR and/or HER2 and sensitivity to growth inhibition by lapatinib; however, the precise determinants of lapatinib selectivity for tumour and/or other cells remain unclear.	Lapatinib	204-213	epidermal growth factor receptor	Homo sapiens	99-103
17635524-2	2007	Previous studies with a small number of cell lines suggest a correlation between overexpression of EGFR and/or HER2 and sensitivity to growth inhibition by lapatinib; however, the precise determinants of lapatinib selectivity for tumour and/or other cells remain unclear.	Lapatinib	204-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
17635524-4	2007	Using statistical tools to analyse the data, a model describing the relationship between lapatinib IC(50) (the response variable) and EGFR and HER2 expression and tissue type (explanatory variables) was derived.	Lapatinib	89-98	epidermal growth factor receptor	Homo sapiens	134-138
17635524-4	2007	Using statistical tools to analyse the data, a model describing the relationship between lapatinib IC(50) (the response variable) and EGFR and HER2 expression and tissue type (explanatory variables) was derived.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
17635524-5	2007	CONCLUSION: The results suggest that simultaneous consideration of EGFR and HER2 expression, as well as tissue type yields the best determinant of lapatinib selectivity in cultured cells.	Lapatinib	147-156	epidermal growth factor receptor	Homo sapiens	67-71
17635524-5	2007	CONCLUSION: The results suggest that simultaneous consideration of EGFR and HER2 expression, as well as tissue type yields the best determinant of lapatinib selectivity in cultured cells.	Lapatinib	147-156	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
18472989-3	2007	Lapatinib is a novel dual receptor tyrosine kinase inhibitor that is a selective and potent inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, both of which are growth promoting factors overexpressed in some breast cancers.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	105-111
18472989-3	2007	Lapatinib is a novel dual receptor tyrosine kinase inhibitor that is a selective and potent inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, both of which are growth promoting factors overexpressed in some breast cancers.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-122
18472989-4	2007	Cell-based assays have proven lapatinib to be a potent inhibitor of ErbB-1 and ErbB-2 activation and breast cancer cell proliferation.	Lapatinib	30-39	epidermal growth factor receptor	Homo sapiens	68-74
18472989-4	2007	Cell-based assays have proven lapatinib to be a potent inhibitor of ErbB-1 and ErbB-2 activation and breast cancer cell proliferation.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-85
18472989-5	2007	In pharmacokinetic studies, lapatinib has shown mostly linear elimination kinetics over the daily dose range of 10-1600 mg and is metabolized by CYP3A4/5 and CYP2C19.	Lapatinib	28-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	145-151
18472989-5	2007	In pharmacokinetic studies, lapatinib has shown mostly linear elimination kinetics over the daily dose range of 10-1600 mg and is metabolized by CYP3A4/5 and CYP2C19.	Lapatinib	28-37	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	158-165
17591827-2	2007	Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	80-112
17591827-2	2007	Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	114-118
17591827-2	2007	Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	119-124
17591827-2	2007	Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
17591827-2	2007	Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR/ErbB1) and HER2/ErbB2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-140
17545611-5	2007	Inhibition of HER2 activation by the tyrosine kinase inhibitor lapatinib led to decreased levels of PKCalpha phosphorylation, clearly indicating a cross-talk between PKCalpha and HER2 molecules.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
17513611-1	2007	Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	59-91
17593621-5	2007	Recent results from trials of the dual HER-2 and EGFR tyrosine kinase inhibitor, lapatinib, also show very promising results in HER-2-positive breast cancer.	Lapatinib	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44
17593621-5	2007	Recent results from trials of the dual HER-2 and EGFR tyrosine kinase inhibitor, lapatinib, also show very promising results in HER-2-positive breast cancer.	Lapatinib	81-90	epidermal growth factor receptor	Homo sapiens	49-53
17593621-5	2007	Recent results from trials of the dual HER-2 and EGFR tyrosine kinase inhibitor, lapatinib, also show very promising results in HER-2-positive breast cancer.	Lapatinib	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-133
17489737-1	2007	Pharmaceutical companies have developed targeted therapies such as trastuzumab and lapatinib for human epidermal growth factor receptor (HER)2/neu-positive tumors, while others have developed antiepidermal growth factor receptor (EGFR) therapies, such as tarceva and erbitux for EGFR-positive tumors.	Lapatinib	83-92	epidermal growth factor receptor	Homo sapiens	103-135
17489737-1	2007	Pharmaceutical companies have developed targeted therapies such as trastuzumab and lapatinib for human epidermal growth factor receptor (HER)2/neu-positive tumors, while others have developed antiepidermal growth factor receptor (EGFR) therapies, such as tarceva and erbitux for EGFR-positive tumors.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-142
17489737-1	2007	Pharmaceutical companies have developed targeted therapies such as trastuzumab and lapatinib for human epidermal growth factor receptor (HER)2/neu-positive tumors, while others have developed antiepidermal growth factor receptor (EGFR) therapies, such as tarceva and erbitux for EGFR-positive tumors.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-146
17555368-7	2007	A Phase I trial of gemcitabine with the EGFR/Her-2 inhibitor, lapatinib, is completed.	Lapatinib	62-71	epidermal growth factor receptor	Homo sapiens	40-44
17555368-7	2007	A Phase I trial of gemcitabine with the EGFR/Her-2 inhibitor, lapatinib, is completed.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-50
17513611-1	2007	Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	93-98
17513611-1	2007	Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-109
17513611-1	2007	Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials.	Lapatinib	11-19	epidermal growth factor receptor	Homo sapiens	59-91
17513611-1	2007	Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials.	Lapatinib	11-19	epidermal growth factor receptor	Homo sapiens	93-98
17513611-1	2007	Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials.	Lapatinib	11-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-109
17513611-4	2007	Responsive cell lines, BT474 and SKBr3, constitutively overexpress ErbB2 and show an IC(50) of 25 or 32 nmol/L for lapatinib, respectively.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-72
17513611-6	2007	Cells responsive to lapatinib exhibited strong differential effects on multiple genes in the AKT pathway.	Lapatinib	20-29	AKT serine/threonine kinase 1	Homo sapiens	93-96
17513611-7	2007	After 12 h of exposure to 1.0 micromol/L of lapatinib, AKT1, MAPK9, HSPCA, IRAK1, and CCND1 transcripts were down-regulated 7- to 25-fold in responsive BT474 and SKBr3 cells.	Lapatinib	44-53	AKT serine/threonine kinase 1	Homo sapiens	55-59
17513611-7	2007	After 12 h of exposure to 1.0 micromol/L of lapatinib, AKT1, MAPK9, HSPCA, IRAK1, and CCND1 transcripts were down-regulated 7- to 25-fold in responsive BT474 and SKBr3 cells.	Lapatinib	44-53	mitogen-activated protein kinase 9	Homo sapiens	61-66
17513611-7	2007	After 12 h of exposure to 1.0 micromol/L of lapatinib, AKT1, MAPK9, HSPCA, IRAK1, and CCND1 transcripts were down-regulated 7- to 25-fold in responsive BT474 and SKBr3 cells.	Lapatinib	44-53	heat shock protein 90 alpha family class A member 2, pseudogene	Homo sapiens	68-73
17513611-7	2007	After 12 h of exposure to 1.0 micromol/L of lapatinib, AKT1, MAPK9, HSPCA, IRAK1, and CCND1 transcripts were down-regulated 7- to 25-fold in responsive BT474 and SKBr3 cells.	Lapatinib	44-53	interleukin 1 receptor associated kinase 1	Homo sapiens	75-80
17513611-7	2007	After 12 h of exposure to 1.0 micromol/L of lapatinib, AKT1, MAPK9, HSPCA, IRAK1, and CCND1 transcripts were down-regulated 7- to 25-fold in responsive BT474 and SKBr3 cells.	Lapatinib	44-53	cyclin D1	Homo sapiens	86-91
17513611-8	2007	In contrast, lapatinib weakly down-regulated the AKT pathway in nonresponsive breast cancer cell lines (<5-fold down-regulation of most genes in the pathway).	Lapatinib	13-22	AKT serine/threonine kinase 1	Homo sapiens	49-52
17513611-9	2007	Furthermore, the proapoptotic gene FOXO3A, which is negatively regulated by AKT, was up-regulated 7- and 25-fold in lapatinib-responsive SKBr3 and BT474 cells, respectively.	Lapatinib	116-125	forkhead box O3	Homo sapiens	35-41
17513611-9	2007	Furthermore, the proapoptotic gene FOXO3A, which is negatively regulated by AKT, was up-regulated 7- and 25-fold in lapatinib-responsive SKBr3 and BT474 cells, respectively.	Lapatinib	116-125	AKT serine/threonine kinase 1	Homo sapiens	76-79
17513611-10	2007	Phosphorylated Akt and Akt-mediated phosphorylation of FOXO3A also decreased in responsive breast cancer cell lines exposed to lapatinib.	Lapatinib	127-136	AKT serine/threonine kinase 1	Homo sapiens	15-18
17513611-10	2007	Phosphorylated Akt and Akt-mediated phosphorylation of FOXO3A also decreased in responsive breast cancer cell lines exposed to lapatinib.	Lapatinib	127-136	AKT serine/threonine kinase 1	Homo sapiens	23-26
17513611-10	2007	Phosphorylated Akt and Akt-mediated phosphorylation of FOXO3A also decreased in responsive breast cancer cell lines exposed to lapatinib.	Lapatinib	127-136	forkhead box O3	Homo sapiens	55-61
17407594-4	2007	A therapeutic strategy that has been used to block HER2 function is the small molecule tyrosine kinase inhibitor lapatinib.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
17407594-5	2007	Using human mammary epithelial cells that overexpress HER2, we determined the anti-proliferative effect of lapatinib through measuring the total cell number and analyzing the cell cycle distribution.	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
17283152-3	2007	Here, we show that lapatinib, a small-molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, exerts its antitumor activity in a PTEN-independent manner.	Lapatinib	19-28	epidermal growth factor receptor	Homo sapiens	60-65
17341725-0	2007	Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
17113234-4	2007	Her2 amplification and/or overexpression are highly predictive of response to HER2-targeted compounds such as trastuzumab and lapatinib but have been inconsistent predictors of response to cytotoxic chemotherapy.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
17113234-4	2007	Her2 amplification and/or overexpression are highly predictive of response to HER2-targeted compounds such as trastuzumab and lapatinib but have been inconsistent predictors of response to cytotoxic chemotherapy.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
17283152-3	2007	Here, we show that lapatinib, a small-molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, exerts its antitumor activity in a PTEN-independent manner.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-75
17283152-3	2007	Here, we show that lapatinib, a small-molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, exerts its antitumor activity in a PTEN-independent manner.	Lapatinib	19-28	phosphatase and tensin homolog	Homo sapiens	129-133
17283152-4	2007	Steady-state phosphorylated ErbB2 (p-ErbB2) and p-Akt (S473) protein levels were inhibited within 30 min following lapatinib but not in response to trastuzumab in BT474 and Au565 cells (two ErbB2-overexpressing breast cancer cell lines that are sensitive to the proapoptotic effects of lapatinib).	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
17283152-4	2007	Steady-state phosphorylated ErbB2 (p-ErbB2) and p-Akt (S473) protein levels were inhibited within 30 min following lapatinib but not in response to trastuzumab in BT474 and Au565 cells (two ErbB2-overexpressing breast cancer cell lines that are sensitive to the proapoptotic effects of lapatinib).	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-42
17283152-4	2007	Steady-state phosphorylated ErbB2 (p-ErbB2) and p-Akt (S473) protein levels were inhibited within 30 min following lapatinib but not in response to trastuzumab in BT474 and Au565 cells (two ErbB2-overexpressing breast cancer cell lines that are sensitive to the proapoptotic effects of lapatinib).	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-42
17283152-4	2007	Steady-state phosphorylated ErbB2 (p-ErbB2) and p-Akt (S473) protein levels were inhibited within 30 min following lapatinib but not in response to trastuzumab in BT474 and Au565 cells (two ErbB2-overexpressing breast cancer cell lines that are sensitive to the proapoptotic effects of lapatinib).	Lapatinib	286-295	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33
17283152-8	2007	In addition, lapatinib inhibited Akt phosphorylation in MDA-MB-468 cells, an ErbB1-expressing/ErbB2 non-overexpressing breast cancer line, despite their PTEN-null status.	Lapatinib	13-22	epidermal growth factor receptor	Homo sapiens	77-82
17283152-8	2007	In addition, lapatinib inhibited Akt phosphorylation in MDA-MB-468 cells, an ErbB1-expressing/ErbB2 non-overexpressing breast cancer line, despite their PTEN-null status.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-99
17283152-8	2007	In addition, lapatinib inhibited Akt phosphorylation in MDA-MB-468 cells, an ErbB1-expressing/ErbB2 non-overexpressing breast cancer line, despite their PTEN-null status.	Lapatinib	13-22	phosphatase and tensin homolog	Homo sapiens	153-157
17283152-9	2007	Moreover, patients with ErbB2-overexpressing inflammatory breast cancers responded to lapatinib monotherapy regardless of PTEN status.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-29
17283152-10	2007	Thus, lapatinib seems to exert its antitumor activity in ErbB2-overexpressing breast cancers in a PTEN-independent manner.	Lapatinib	6-15	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-62
17283152-10	2007	Thus, lapatinib seems to exert its antitumor activity in ErbB2-overexpressing breast cancers in a PTEN-independent manner.	Lapatinib	6-15	phosphatase and tensin homolog	Homo sapiens	98-102
17250463-0	2007	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
17208435-5	2007	Lapatinib, a TKI of EGFR and HER2, has shown clinical benefit in trastuzumab refractory breast cancer and is poised for FDA approval.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	20-24
17208435-5	2007	Lapatinib, a TKI of EGFR and HER2, has shown clinical benefit in trastuzumab refractory breast cancer and is poised for FDA approval.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
17250463-0	2007	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	78-110
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	112-116
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	128-132
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	78-110
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	112-116
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	128-132
17250463-1	2007	Lapatinib (GW 572016) is an oral inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), which are both frequently altered in human malignant tumors.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
17250463-5	2007	Phase II studies showed that lapatinib has meaningful clinical activity in the setting of HER2-positive advanced breast cancer patients.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
17203189-3	2007	Lapatinib, a reversible inhibitor of both EGFR and HER-2/neu, has shown some success in achieving clinical responses in heavily pretreated advanced cancer patients.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	42-46
17203189-10	2007	A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines.	Lapatinib	99-108	epidermal growth factor receptor	Homo sapiens	83-87
17308062-0	2007	Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.	Lapatinib	0-9	insulin like growth factor 1	Homo sapiens	85-113
17308062-3	2007	In the current study, we show that the dual epidermal growth factor receptor (EGFR)/human EGFR-2 (HER2) kinase inhibitor lapatinib induces apoptosis in trastuzumab-resistant cells derived from the HER2-overexpressing SKBR3 breast cancer line.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	44-76
17308062-3	2007	In the current study, we show that the dual epidermal growth factor receptor (EGFR)/human EGFR-2 (HER2) kinase inhibitor lapatinib induces apoptosis in trastuzumab-resistant cells derived from the HER2-overexpressing SKBR3 breast cancer line.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	78-82
17308062-3	2007	In the current study, we show that the dual epidermal growth factor receptor (EGFR)/human EGFR-2 (HER2) kinase inhibitor lapatinib induces apoptosis in trastuzumab-resistant cells derived from the HER2-overexpressing SKBR3 breast cancer line.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	90-94
17308062-3	2007	In the current study, we show that the dual epidermal growth factor receptor (EGFR)/human EGFR-2 (HER2) kinase inhibitor lapatinib induces apoptosis in trastuzumab-resistant cells derived from the HER2-overexpressing SKBR3 breast cancer line.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
17308062-3	2007	In the current study, we show that the dual epidermal growth factor receptor (EGFR)/human EGFR-2 (HER2) kinase inhibitor lapatinib induces apoptosis in trastuzumab-resistant cells derived from the HER2-overexpressing SKBR3 breast cancer line.	Lapatinib	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	197-201
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	20-24
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	98-101
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	0-9	insulin like growth factor 1	Homo sapiens	186-214
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	0-9	insulin like growth factor 1	Homo sapiens	216-221
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	0-9	insulin like growth factor 1	Homo sapiens	363-368
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	161-170	AKT serine/threonine kinase 1	Homo sapiens	98-101
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	161-170	insulin like growth factor 1	Homo sapiens	186-214
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	161-170	insulin like growth factor 1	Homo sapiens	216-221
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	161-170	insulin like growth factor 1	Homo sapiens	363-368
17308062-4	2007	Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase [corrected] Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody alphaIR3.	Lapatinib	324-333	insulin like growth factor 1	Homo sapiens	216-221
17308062-5	2007	As increased IGF-I receptor signaling has been implicated in trastuzumab resistance, our data strongly support further study of lapatinib as a potential therapeutic in breast cancers that have progressed on trastuzumab.	Lapatinib	128-137	insulin like growth factor 1 receptor	Homo sapiens	13-27
17203189-10	2007	A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-93
17203189-10	2007	A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Mus musculus	94-97
17203189-3	2007	Lapatinib, a reversible inhibitor of both EGFR and HER-2/neu, has shown some success in achieving clinical responses in heavily pretreated advanced cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-60
17203189-8	2007	EGFR/HER-2/neu tyrosine kinase inhibitors (lapatinib and GW2974) were combined with Bcl-2 inhibitors (HA14-1 or GX15-070) and the anti-proliferative effects were determined by the MTT tetrazolium dye assay.	Lapatinib	43-52	epidermal growth factor receptor	Homo sapiens	0-4
17320695-2	2007	Lapatinib is an oral, small molecule, reversible dual inhibitor of ErbB1 (epidermal growth factor receptor) and ErbB2 (HER2) tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	67-72
17320695-2	2007	Lapatinib is an oral, small molecule, reversible dual inhibitor of ErbB1 (epidermal growth factor receptor) and ErbB2 (HER2) tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	74-106
17320695-2	2007	Lapatinib is an oral, small molecule, reversible dual inhibitor of ErbB1 (epidermal growth factor receptor) and ErbB2 (HER2) tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-117
17320695-2	2007	Lapatinib is an oral, small molecule, reversible dual inhibitor of ErbB1 (epidermal growth factor receptor) and ErbB2 (HER2) tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
17060407-0	2007	Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	119-124
17547474-8	2007	Novel therapeutics, such as lapatinib, an oral tyrosine kinase inhibitor, which blocks both the epidermal growth factor receptor and HER2 receptor has recently been approved by the US FDA.	Lapatinib	28-37	epidermal growth factor receptor	Homo sapiens	96-128
17547474-8	2007	Novel therapeutics, such as lapatinib, an oral tyrosine kinase inhibitor, which blocks both the epidermal growth factor receptor and HER2 receptor has recently been approved by the US FDA.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
17402790-6	2007	Lapatinib is a tyrosine kinase inhibitor, blocking tryosine kinase domains of both epidermal growth factor receptor and HER-2.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	83-115
17402790-6	2007	Lapatinib is a tyrosine kinase inhibitor, blocking tryosine kinase domains of both epidermal growth factor receptor and HER-2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-125
17485900-2	2007	Lapatinib, an orally administered dual inhibitor of ErbB1 (EGFR) and ErbB2 (HER2) receptor tyrosine kinases has shown promising results for metastatic breast cancer (MBC).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	52-57
17485900-2	2007	Lapatinib, an orally administered dual inhibitor of ErbB1 (EGFR) and ErbB2 (HER2) receptor tyrosine kinases has shown promising results for metastatic breast cancer (MBC).	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	59-63
17485900-2	2007	Lapatinib, an orally administered dual inhibitor of ErbB1 (EGFR) and ErbB2 (HER2) receptor tyrosine kinases has shown promising results for metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-74
17485900-2	2007	Lapatinib, an orally administered dual inhibitor of ErbB1 (EGFR) and ErbB2 (HER2) receptor tyrosine kinases has shown promising results for metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
17485900-5	2007	Large randomized trials using lapatinib following chemotherapy and surgery are ongoing for early stage HER2-overexpressing breast cancer.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
17060407-0	2007	Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-134
17060407-1	2007	BACKGROUND: To evaluate the role of FDG-PET in assessing anti-tumor efficacy of molecular targeted drugs, we prospectively performed FDG-PET and CT for response evaluation in patients treated with lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinases.	Lapatinib	197-206	epidermal growth factor receptor	Homo sapiens	228-233
16894399-0	2006	Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	19-23
17192538-0	2006	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
17192538-1	2006	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	60-92
17192538-1	2006	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
17192538-1	2006	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-135
17192538-1	2006	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
17110623-1	2006	Lapatinib is an oral receptor tyrosine kinase inhibitor, targeting both the ErbB-1 and ErbB-2 receptors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	76-82
17110623-1	2006	Lapatinib is an oral receptor tyrosine kinase inhibitor, targeting both the ErbB-1 and ErbB-2 receptors.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-93
17001557-5	2006	But new therapeutic agents, as e. g. lapatinib, are promising in the treatment of HER-2 positive breast cancer even if trastuzumab is failing.	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-87
16843263-5	2006	The HER2 inhibitors lapatinib, trastuzumab, and CI-1033 inhibited growth of H1781 cells and cells expressing exogenous HER2(YVMA).	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
16843263-5	2006	The HER2 inhibitors lapatinib, trastuzumab, and CI-1033 inhibited growth of H1781 cells and cells expressing exogenous HER2(YVMA).	Lapatinib	20-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
16894399-3	2006	Phase I clinical trials have shown that lapatinib is well tolerated, with mild diarrhea and rash the most frequent toxicities, and early evidence of clinical efficacy has been reported especially in HER2-positive breast cancer.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	199-203
17192538-9	2006	CONCLUSIONS: Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
16934227-4	2006	We have shown that the RTK inhibitor GW282974A (an analogue of GW2016; lapatinib) is effective in chemosensitisation of drug resistant EGFR over-expressing cells giving rise to a synergistic effect when used in combination with either cisplatin or paclitaxel in chemosensitivity assays.	Lapatinib	71-80	ret proto-oncogene	Homo sapiens	23-26
16934227-4	2006	We have shown that the RTK inhibitor GW282974A (an analogue of GW2016; lapatinib) is effective in chemosensitisation of drug resistant EGFR over-expressing cells giving rise to a synergistic effect when used in combination with either cisplatin or paclitaxel in chemosensitivity assays.	Lapatinib	71-80	epidermal growth factor receptor	Homo sapiens	135-139
17092403-1	2006	We report the case of a woman who conceived while being treated on a phase I clinical trial with lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, for metastatic breast cancer.	Lapatinib	97-106	epidermal growth factor receptor	Homo sapiens	128-160
17092403-1	2006	We report the case of a woman who conceived while being treated on a phase I clinical trial with lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, for metastatic breast cancer.	Lapatinib	97-106	epidermal growth factor receptor	Homo sapiens	162-166
17092403-1	2006	We report the case of a woman who conceived while being treated on a phase I clinical trial with lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, for metastatic breast cancer.	Lapatinib	97-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-180
16940802-8	2006	5"-Deoxy-5-fluorouridine with GW282974X demonstrated global synergy, both in high and low expressing epidermal growth factor receptor breast cancer cell lines.	Lapatinib	30-39	epidermal growth factor receptor	Homo sapiens	101-133
16894399-0	2006	Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
16894399-1	2006	Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	65-97
16894399-1	2006	Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	99-103
16894399-1	2006	Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-149
16894399-1	2006	Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
16894399-2	2006	Preclinical data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo.	Lapatinib	33-42	epidermal growth factor receptor	Homo sapiens	112-116
16894399-2	2006	Preclinical data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
16894399-2	2006	Preclinical data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo.	Lapatinib	200-209	epidermal growth factor receptor	Homo sapiens	112-116
16452222-5	2006	Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
16682622-4	2006	Analysis of baseline gene expression in acquired lapatinib-resistant and parental cells indicates estrogen receptor (ER) signaling involvement in the development of resistance.	Lapatinib	49-58	estrogen receptor 1	Homo sapiens	98-115
16682622-4	2006	Analysis of baseline gene expression in acquired lapatinib-resistant and parental cells indicates estrogen receptor (ER) signaling involvement in the development of resistance.	Lapatinib	49-58	estrogen receptor 1	Homo sapiens	117-119
16682622-5	2006	Using gene interference, we confirm that acquired resistance to lapatinib is mediated by a switch in cell survival dependence and regulation of a key antiapoptotic mediator from ErbB2 alone to codependence upon ER and ErbB2 rather than loss of ErbB2 expression or insensitivity of ErbB2 signaling to lapatinib.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	178-183
16682622-5	2006	Using gene interference, we confirm that acquired resistance to lapatinib is mediated by a switch in cell survival dependence and regulation of a key antiapoptotic mediator from ErbB2 alone to codependence upon ER and ErbB2 rather than loss of ErbB2 expression or insensitivity of ErbB2 signaling to lapatinib.	Lapatinib	64-73	estrogen receptor 1	Homo sapiens	211-213
16682622-5	2006	Using gene interference, we confirm that acquired resistance to lapatinib is mediated by a switch in cell survival dependence and regulation of a key antiapoptotic mediator from ErbB2 alone to codependence upon ER and ErbB2 rather than loss of ErbB2 expression or insensitivity of ErbB2 signaling to lapatinib.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	218-223
16682622-5	2006	Using gene interference, we confirm that acquired resistance to lapatinib is mediated by a switch in cell survival dependence and regulation of a key antiapoptotic mediator from ErbB2 alone to codependence upon ER and ErbB2 rather than loss of ErbB2 expression or insensitivity of ErbB2 signaling to lapatinib.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	218-223
16682622-5	2006	Using gene interference, we confirm that acquired resistance to lapatinib is mediated by a switch in cell survival dependence and regulation of a key antiapoptotic mediator from ErbB2 alone to codependence upon ER and ErbB2 rather than loss of ErbB2 expression or insensitivity of ErbB2 signaling to lapatinib.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	218-223
16682622-6	2006	Increased ER signaling in response to lapatinib is enhanced by the activation of factors facilitating the transcriptional activity of ER, notably FOXO3a and caveolin-1.	Lapatinib	38-47	estrogen receptor 1	Homo sapiens	10-12
16682622-6	2006	Increased ER signaling in response to lapatinib is enhanced by the activation of factors facilitating the transcriptional activity of ER, notably FOXO3a and caveolin-1.	Lapatinib	38-47	estrogen receptor 1	Homo sapiens	134-136
16682622-6	2006	Increased ER signaling in response to lapatinib is enhanced by the activation of factors facilitating the transcriptional activity of ER, notably FOXO3a and caveolin-1.	Lapatinib	38-47	forkhead box O3	Homo sapiens	146-152
16682622-6	2006	Increased ER signaling in response to lapatinib is enhanced by the activation of factors facilitating the transcriptional activity of ER, notably FOXO3a and caveolin-1.	Lapatinib	38-47	caveolin 1	Homo sapiens	157-167
16682622-7	2006	Importantly, we confirm that lapatinib induces ER signaling in tumor biopsies from patients with ErbB2-overexpressing breast cancers receiving lapatinib therapy.	Lapatinib	29-38	estrogen receptor 1	Homo sapiens	47-49
16682622-7	2006	Importantly, we confirm that lapatinib induces ER signaling in tumor biopsies from patients with ErbB2-overexpressing breast cancers receiving lapatinib therapy.	Lapatinib	29-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-102
16682622-7	2006	Importantly, we confirm that lapatinib induces ER signaling in tumor biopsies from patients with ErbB2-overexpressing breast cancers receiving lapatinib therapy.	Lapatinib	143-152	estrogen receptor 1	Homo sapiens	47-49
16682622-7	2006	Importantly, we confirm that lapatinib induces ER signaling in tumor biopsies from patients with ErbB2-overexpressing breast cancers receiving lapatinib therapy.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-102
16452222-0	2006	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-72
16452222-0	2006	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Lapatinib	49-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-72
16452222-1	2006	Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	54-86
16452222-1	2006	Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	88-92
16452222-1	2006	Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
16452222-5	2006	Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-105
16452222-1	2006	Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.	Lapatinib	11-19	epidermal growth factor receptor	Homo sapiens	54-86
16452222-1	2006	Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.	Lapatinib	11-19	epidermal growth factor receptor	Homo sapiens	88-92
16452222-1	2006	Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.	Lapatinib	11-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
16452222-2	2006	Here, we explore the therapeutic potential of lapatinib by testing its effect on tumor cell growth in a panel of 31 characterized human breast cancer cell lines, including trastuzumab-conditioned HER-2-positive cell lines.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	196-201
16452222-5	2006	Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation.	Lapatinib	12-21	zinc fingers and homeoboxes 2	Homo sapiens	107-110
16452222-5	2006	Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation.	Lapatinib	12-21	AKT serine/threonine kinase 1	Homo sapiens	112-115
16452222-5	2006	Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation.	Lapatinib	12-21	mitogen-activated protein kinase 1	Homo sapiens	121-124
16452222-8	2006	For the combination of lapatinib plus trastuzumab, synergistic drug interactions were observed in four different HER-2-overexpressing cell lines.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-118
16452222-10	2006	These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab.	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-135
16452223-5	2006	Alternatively, inhibition of ErbB2 signaling using lapatinib (GW572016), a reversible small-molecule inhibitor of ErbB1/ErbB2 tyrosine kinases, at pharmacologically relevant concentrations, leads to marked inhibition of survivin protein with subsequent apoptosis.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-34
16452223-5	2006	Alternatively, inhibition of ErbB2 signaling using lapatinib (GW572016), a reversible small-molecule inhibitor of ErbB1/ErbB2 tyrosine kinases, at pharmacologically relevant concentrations, leads to marked inhibition of survivin protein with subsequent apoptosis.	Lapatinib	51-60	epidermal growth factor receptor	Homo sapiens	114-119
16452223-5	2006	Alternatively, inhibition of ErbB2 signaling using lapatinib (GW572016), a reversible small-molecule inhibitor of ErbB1/ErbB2 tyrosine kinases, at pharmacologically relevant concentrations, leads to marked inhibition of survivin protein with subsequent apoptosis.	Lapatinib	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-125
16452223-5	2006	Alternatively, inhibition of ErbB2 signaling using lapatinib (GW572016), a reversible small-molecule inhibitor of ErbB1/ErbB2 tyrosine kinases, at pharmacologically relevant concentrations, leads to marked inhibition of survivin protein with subsequent apoptosis.	Lapatinib	62-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-34
16452223-5	2006	Alternatively, inhibition of ErbB2 signaling using lapatinib (GW572016), a reversible small-molecule inhibitor of ErbB1/ErbB2 tyrosine kinases, at pharmacologically relevant concentrations, leads to marked inhibition of survivin protein with subsequent apoptosis.	Lapatinib	62-70	epidermal growth factor receptor	Homo sapiens	114-119
16452223-5	2006	Alternatively, inhibition of ErbB2 signaling using lapatinib (GW572016), a reversible small-molecule inhibitor of ErbB1/ErbB2 tyrosine kinases, at pharmacologically relevant concentrations, leads to marked inhibition of survivin protein with subsequent apoptosis.	Lapatinib	62-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-125
16452223-9	2006	Importantly, the clinical relevance of these findings was illustrated in patients with ErbB2-overexpressing breast cancer whose clinical response to lapatinib was associated with marked inhibition of survivin in their tumors.	Lapatinib	149-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-92
19364051-3	2005	The targeted blockade of HER2 activity with monoclonal antibodies (e.g., trastuzumab [Herceptin]) and small-molecule tyrosine kinase inhibitors (e.g., lapatinib) results in the inhibition of tumor growth in HER2-positive cancers.	Lapatinib	151-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
16397255-0	2006	Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.	Lapatinib	86-94	epidermal growth factor receptor	Homo sapiens	12-16
16397255-0	2006	Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.	Lapatinib	86-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-26
16397255-0	2006	Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.	Lapatinib	86-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
16397255-8	2006	In contrast, GW572016 suppressed the activation of EGFR, ErbB2, MAPK, and AKT in a concentration-dependent manner.	Lapatinib	13-21	epidermal growth factor receptor	Homo sapiens	51-55
16397255-8	2006	In contrast, GW572016 suppressed the activation of EGFR, ErbB2, MAPK, and AKT in a concentration-dependent manner.	Lapatinib	13-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-62
16397255-8	2006	In contrast, GW572016 suppressed the activation of EGFR, ErbB2, MAPK, and AKT in a concentration-dependent manner.	Lapatinib	13-21	AKT serine/threonine kinase 1	Homo sapiens	74-77
15684311-0	2005	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.	Lapatinib	33-42	epidermal growth factor receptor	Homo sapiens	70-75
16091755-0	2005	Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.	Lapatinib	10-19	epidermal growth factor receptor	Homo sapiens	62-67
16091755-0	2005	Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
16091755-0	2005	Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.	Lapatinib	21-29	epidermal growth factor receptor	Homo sapiens	62-67
16091755-0	2005	Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.	Lapatinib	21-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
16091755-2	2005	Here, apoptosis of ErbB2-overexpressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and (ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-24
16091755-2	2005	Here, apoptosis of ErbB2-overexpressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and (ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein.	Lapatinib	86-95	epidermal growth factor receptor	Homo sapiens	113-118
16091755-2	2005	Here, apoptosis of ErbB2-overexpressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and (ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
16091755-2	2005	Here, apoptosis of ErbB2-overexpressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and (ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
16091755-2	2005	Here, apoptosis of ErbB2-overexpressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and (ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
16091755-3	2005	Treating ErbB2-overexpressing breast cancer cell lines with a relatively low concentration of lapatinib alone resulted in a minimal increase in tumor cell apoptosis with an associated decrease in steady-state protein levels of p-ErbB2, p-Akt, p-Erk1/2, and notably survivin, compared to baseline.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-14
16091755-3	2005	Treating ErbB2-overexpressing breast cancer cell lines with a relatively low concentration of lapatinib alone resulted in a minimal increase in tumor cell apoptosis with an associated decrease in steady-state protein levels of p-ErbB2, p-Akt, p-Erk1/2, and notably survivin, compared to baseline.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	229-234
16091755-3	2005	Treating ErbB2-overexpressing breast cancer cell lines with a relatively low concentration of lapatinib alone resulted in a minimal increase in tumor cell apoptosis with an associated decrease in steady-state protein levels of p-ErbB2, p-Akt, p-Erk1/2, and notably survivin, compared to baseline.	Lapatinib	94-103	mitogen-activated protein kinase 3	Homo sapiens	245-251
15955900-1	2005	PURPOSE: This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.	Lapatinib	131-140	epidermal growth factor receptor	Homo sapiens	169-174
15955900-1	2005	PURPOSE: This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.	Lapatinib	131-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-198
15955900-1	2005	PURPOSE: This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.	Lapatinib	142-150	epidermal growth factor receptor	Homo sapiens	169-174
15857287-9	2005	Lapatinib, a dual EGFR/HER2 TK inhibitors, is particularly promising in breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
15857287-9	2005	Lapatinib, a dual EGFR/HER2 TK inhibitors, is particularly promising in breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
15833875-5	2005	We used two independent methods, expression of intracellular single-chain antibody against HER-2 and treatment with a novel dual EGFR/HER-2 kinase inhibitor GW572016 (lapatinib).	Lapatinib	157-165	epidermal growth factor receptor	Homo sapiens	129-133
15833875-5	2005	We used two independent methods, expression of intracellular single-chain antibody against HER-2 and treatment with a novel dual EGFR/HER-2 kinase inhibitor GW572016 (lapatinib).	Lapatinib	157-165	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-139
15833875-5	2005	We used two independent methods, expression of intracellular single-chain antibody against HER-2 and treatment with a novel dual EGFR/HER-2 kinase inhibitor GW572016 (lapatinib).	Lapatinib	167-176	epidermal growth factor receptor	Homo sapiens	129-133
15833875-5	2005	We used two independent methods, expression of intracellular single-chain antibody against HER-2 and treatment with a novel dual EGFR/HER-2 kinase inhibitor GW572016 (lapatinib).	Lapatinib	167-176	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-139
15833875-6	2005	Expression of intracellular HER-2 antibody scFv-5R and treatment with GW572016 inhibited HER-2 signaling.	Lapatinib	70-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-94
15833875-9	2005	GW572016 was more potent in its ability to inhibit PSA expression and AR recruitment and histone acetylation than the EGFR-selective kinase inhibitor ZD1839 (gefitinib), consistent with the HER-2 kinase playing the major role in AR regulation.	Lapatinib	0-8	kallikrein related peptidase 3	Homo sapiens	51-54
15833875-9	2005	GW572016 was more potent in its ability to inhibit PSA expression and AR recruitment and histone acetylation than the EGFR-selective kinase inhibitor ZD1839 (gefitinib), consistent with the HER-2 kinase playing the major role in AR regulation.	Lapatinib	0-8	androgen receptor	Homo sapiens	70-72
15833875-9	2005	GW572016 was more potent in its ability to inhibit PSA expression and AR recruitment and histone acetylation than the EGFR-selective kinase inhibitor ZD1839 (gefitinib), consistent with the HER-2 kinase playing the major role in AR regulation.	Lapatinib	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	190-195
15833875-9	2005	GW572016 was more potent in its ability to inhibit PSA expression and AR recruitment and histone acetylation than the EGFR-selective kinase inhibitor ZD1839 (gefitinib), consistent with the HER-2 kinase playing the major role in AR regulation.	Lapatinib	0-8	androgen receptor	Homo sapiens	229-231
15684311-0	2005	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.	Lapatinib	33-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-85
15684311-1	2005	PURPOSE: This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies.	Lapatinib	66-75	epidermal growth factor receptor	Homo sapiens	144-149
15684311-1	2005	PURPOSE: This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-162
15684311-11	2005	CONCLUSION: Lapatinib exhibited preliminary evidence of biologic and clinical activity in ErbB1 and/or ErbB2-overexpressing tumors.	Lapatinib	12-21	epidermal growth factor receptor	Homo sapiens	90-95
15684311-11	2005	CONCLUSION: Lapatinib exhibited preliminary evidence of biologic and clinical activity in ErbB1 and/or ErbB2-overexpressing tumors.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108
15665275-0	2005	The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	9-14
15755991-7	2005	Basal proliferation in the absence of growth factors was also inhibited by GW572016 to a greater extent than ZD1839, suggesting that low level HER2/HER3 activation perhaps by an autocrine pathway contributes to the proliferation signal.	Lapatinib	75-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
15755991-7	2005	Basal proliferation in the absence of growth factors was also inhibited by GW572016 to a greater extent than ZD1839, suggesting that low level HER2/HER3 activation perhaps by an autocrine pathway contributes to the proliferation signal.	Lapatinib	75-83	erb-b2 receptor tyrosine kinase 3	Homo sapiens	148-152
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	184-192	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	184-192	erb-b2 receptor tyrosine kinase 3	Homo sapiens	37-41
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	184-192	androgen receptor	Homo sapiens	43-45
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	184-192	epidermal growth factor receptor	Homo sapiens	143-147
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	184-192	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	184-192	epidermal growth factor receptor	Homo sapiens	214-218
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	194-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	194-203	erb-b2 receptor tyrosine kinase 3	Homo sapiens	37-41
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	194-203	epidermal growth factor receptor	Homo sapiens	143-147
15755991-6	2005	Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib).	Lapatinib	194-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
15665275-10	2005	In addition to inhibiting mitogenic signaling and cell cycle progression, lapatinib inhibited estrogen-stimulated ER transcriptional activity and cooperated with tamoxifen to further reduce ER-dependent transcription.	Lapatinib	74-83	estrogen receptor 1	Homo sapiens	114-116
15665275-10	2005	In addition to inhibiting mitogenic signaling and cell cycle progression, lapatinib inhibited estrogen-stimulated ER transcriptional activity and cooperated with tamoxifen to further reduce ER-dependent transcription.	Lapatinib	74-83	estrogen receptor 1	Homo sapiens	190-192
15665275-11	2005	Lapatinib in combination with tamoxifen effectively inhibited the growth of tamoxifen-resistant ErbB2 overexpressing MCF-7 mammary tumor xenografts.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-101
15665275-0	2005	The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
15665275-0	2005	The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.	Lapatinib	43-51	epidermal growth factor receptor	Homo sapiens	9-14
15665275-0	2005	The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.	Lapatinib	43-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
15665275-5	2005	Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models.	Lapatinib	50-59	epidermal growth factor receptor	Homo sapiens	27-32
15665275-5	2005	Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
15665275-5	2005	Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models.	Lapatinib	50-59	estrogen receptor 1	Homo sapiens	109-111
15665275-5	2005	Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models.	Lapatinib	61-69	epidermal growth factor receptor	Homo sapiens	27-32
15665275-5	2005	Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models.	Lapatinib	61-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
15665275-5	2005	Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models.	Lapatinib	61-69	estrogen receptor 1	Homo sapiens	109-111
15528979-0	2005	Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.	Lapatinib	77-85	epidermal growth factor receptor	Homo sapiens	94-98
22500146-14	2005	Patients with tumors overexpressing ErbB1 and/or ErbB2 are likely to benefit from lapatinib treatment.	Lapatinib	82-91	epidermal growth factor receptor	Homo sapiens	36-41
22500146-14	2005	Patients with tumors overexpressing ErbB1 and/or ErbB2 are likely to benefit from lapatinib treatment.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-54
15528979-0	2005	Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.	Lapatinib	77-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-104
15528979-1	2005	GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent.	Lapatinib	0-8	epidermal growth factor receptor	Homo sapiens	19-23
15528979-1	2005	GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent.	Lapatinib	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-29
12964069-1	2003	Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.	Lapatinib	0-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-31
15374980-0	2004	A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.	Lapatinib	65-73	epidermal growth factor receptor	Homo sapiens	23-55
15374980-0	2004	A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.	Lapatinib	75-84	epidermal growth factor receptor	Homo sapiens	23-55
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	0-8	epidermal growth factor receptor	Homo sapiens	122-154
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	0-8	epidermal growth factor receptor	Homo sapiens	156-160
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	0-8	epidermal growth factor receptor	Homo sapiens	162-169
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-180
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	10-19	epidermal growth factor receptor	Homo sapiens	122-154
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	10-19	epidermal growth factor receptor	Homo sapiens	156-160
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	10-19	epidermal growth factor receptor	Homo sapiens	162-169
15374980-1	2004	GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-180
15374980-2	2004	We determined the crystal structure of EGFR bound to GW572016.	Lapatinib	53-61	epidermal growth factor receptor	Homo sapiens	39-43
15374980-4	2004	Surprisingly, we found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).	Lapatinib	28-36	epidermal growth factor receptor	Homo sapiens	105-109
15374980-4	2004	Surprisingly, we found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).	Lapatinib	28-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-120
15374980-4	2004	Surprisingly, we found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).	Lapatinib	28-36	epidermal growth factor receptor	Homo sapiens	155-159
14967461-9	2004	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).	Lapatinib	143-151	epidermal growth factor receptor	Homo sapiens	205-237
14633707-8	2003	Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.	Lapatinib	66-74	epidermal growth factor receptor	Rattus norvegicus	9-13
14633707-8	2003	Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.	Lapatinib	66-74	epidermal growth factor receptor	Rattus norvegicus	33-37
14633707-10	2003	Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer.	Lapatinib	97-105	epidermal growth factor receptor	Rattus norvegicus	89-93
14633707-11	2003	The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.	Lapatinib	99-107	epidermal growth factor receptor	Rattus norvegicus	126-130
14633707-11	2003	The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.	Lapatinib	99-107	epidermal growth factor receptor	Rattus norvegicus	266-270
16020981-2	2005	We examined the efficacy of GW572016 (lapatinib), a dual inhibitor of ErbB1/ErbB2 with a panel of 10 MPM cell lines.	Lapatinib	28-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-81
15374980-8	2004	The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.	Lapatinib	67-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-93
14751502-0	2004	Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	Lapatinib	42-50	epidermal growth factor receptor	Homo sapiens	54-58
14751502-0	2004	Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	Lapatinib	42-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
14751502-4	2004	RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	Lapatinib	9-17	epidermal growth factor receptor	Homo sapiens	63-67
14751502-4	2004	RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	Lapatinib	9-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
14751502-5	2004	GW572016 radiosensitized EGFR-overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization.	Lapatinib	0-8	epidermal growth factor receptor	Homo sapiens	25-29
14751502-7	2004	Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of GW572016 to inhibit downstream ERK and Akt activation, despite inhibition of HER2 phosphorylation.	Lapatinib	86-94	mitogen-activated protein kinase 1	Homo sapiens	117-120
14751502-7	2004	Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of GW572016 to inhibit downstream ERK and Akt activation, despite inhibition of HER2 phosphorylation.	Lapatinib	86-94	AKT serine/threonine kinase 1	Homo sapiens	125-128
14751502-9	2004	CONCLUSION: GW572016 potently inhibits receptor phosphorylation in either EGFR- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.	Lapatinib	12-20	epidermal growth factor receptor	Homo sapiens	74-79
14751502-9	2004	CONCLUSION: GW572016 potently inhibits receptor phosphorylation in either EGFR- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.	Lapatinib	12-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
14737100-0	2004	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.	Lapatinib	165-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-15
14737100-0	2004	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.	Lapatinib	165-173	epidermal growth factor receptor	Homo sapiens	137-141
14737100-0	2004	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.	Lapatinib	165-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-34
14737100-5	2004	GW572016, a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.	Lapatinib	0-8	epidermal growth factor receptor	Homo sapiens	51-55
14737100-5	2004	GW572016, a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.	Lapatinib	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-65
14737100-6	2004	Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.	Lapatinib	63-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-33
14737100-6	2004	Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.	Lapatinib	63-71	epidermal growth factor receptor	Homo sapiens	39-43
14737100-6	2004	Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.	Lapatinib	63-71	mitogen-activated protein kinase 3	Homo sapiens	121-127
14737100-6	2004	Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.	Lapatinib	63-71	AKT serine/threonine kinase 1	Homo sapiens	137-140
14737100-7	2004	Increased phosphorylation of p95ErbB2 and AKT in response to HRG was abrogated to varying degrees by GW572016.	Lapatinib	101-109	AKT serine/threonine kinase 1	Homo sapiens	42-45
15163842-0	2004	Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.	Lapatinib	108-117	epidermal growth factor receptor	Homo sapiens	86-90
15163842-0	2004	Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-97
15163842-2	2004	The novel dual EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib (GlaxoSmithKline; Research Triangle Park, NC) has been shown to inhibit tumor cell growth in vitro and in xenograft models for a variety of human tumors.	Lapatinib	53-62	epidermal growth factor receptor	Homo sapiens	15-19
15163842-2	2004	The novel dual EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib (GlaxoSmithKline; Research Triangle Park, NC) has been shown to inhibit tumor cell growth in vitro and in xenograft models for a variety of human tumors.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-26
12964069-1	2003	Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.	Lapatinib	0-20	epidermal growth factor receptor	Homo sapiens	36-40
12964069-1	2003	Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.	Lapatinib	0-20	heparan sulfate proteoglycan 2	Homo sapiens	111-114
33766630-9	2021	In general, NRG1/ErbB pathway was activated by TOCP while combined treatment with lapatinib attenuated TOCP-induced NRG1/ErbB signaling cascade.	Lapatinib	82-91	neuregulin 1	Mus musculus	116-120
12214266-0	2002	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Lapatinib	23-31	epidermal growth factor receptor	Homo sapiens	91-95
12214266-0	2002	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Lapatinib	23-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-101
12214266-0	2002	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Lapatinib	23-31	mitogen-activated protein kinase 3	Homo sapiens	117-123
12214266-0	2002	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Lapatinib	23-31	AKT serine/threonine kinase 1	Homo sapiens	128-131
12214266-2	2002	Here we show that a small molecule, GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines.	Lapatinib	36-44	epidermal growth factor receptor	Homo sapiens	69-73
12214266-2	2002	Here we show that a small molecule, GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines.	Lapatinib	36-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-83
12214266-2	2002	Here we show that a small molecule, GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines.	Lapatinib	36-44	epidermal growth factor receptor	Homo sapiens	146-150
12214266-2	2002	Here we show that a small molecule, GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines.	Lapatinib	36-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-160
12214266-3	2002	GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively.	Lapatinib	0-8	epidermal growth factor receptor	Homo sapiens	54-58
12214266-3	2002	GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively.	Lapatinib	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-68
12214266-3	2002	GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively.	Lapatinib	0-8	mitogen-activated protein kinase 3	Homo sapiens	98-104
12214266-3	2002	GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively.	Lapatinib	0-8	AKT serine/threonine kinase 1	Homo sapiens	109-112
12214266-6	2002	These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts.	Lapatinib	50-58	epidermal growth factor receptor	Homo sapiens	93-97
12214266-6	2002	These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts.	Lapatinib	50-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-104
12214266-6	2002	These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts.	Lapatinib	50-58	mitogen-activated protein kinase 3	Homo sapiens	106-112
12214266-6	2002	These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts.	Lapatinib	50-58	AKT serine/threonine kinase 1	Homo sapiens	117-120
12214266-7	2002	Erk1/2 and AKT represent potential biomarkers to assess the clinical activity of GW572016.	Lapatinib	81-89	mitogen-activated protein kinase 3	Homo sapiens	0-6
12214266-7	2002	Erk1/2 and AKT represent potential biomarkers to assess the clinical activity of GW572016.	Lapatinib	81-89	AKT serine/threonine kinase 1	Homo sapiens	11-14
12214266-8	2002	Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.	Lapatinib	65-73	AKT serine/threonine kinase 1	Homo sapiens	24-27
12214266-8	2002	Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.	Lapatinib	65-73	epidermal growth factor receptor	Homo sapiens	31-35
12214266-8	2002	Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.	Lapatinib	65-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44
33766630-3	2021	Our previous study discovered that a neuropathic OP, tri-o-cresyl phosphate (TOCP) activated NRG1/ErbB signaling pathway in both spinal cord and sciatic nerve of hens during the formation of OPIDN and lapatinib, a non-selective antagonist of ErbB1 and ErbB2 receptors, alleviated the toxicity.	Lapatinib	201-210	neuregulin 1	Gallus gallus	93-97
33766630-3	2021	Our previous study discovered that a neuropathic OP, tri-o-cresyl phosphate (TOCP) activated NRG1/ErbB signaling pathway in both spinal cord and sciatic nerve of hens during the formation of OPIDN and lapatinib, a non-selective antagonist of ErbB1 and ErbB2 receptors, alleviated the toxicity.	Lapatinib	201-210	epidermal growth factor receptor	Mus musculus	98-102
33766630-9	2021	In general, NRG1/ErbB pathway was activated by TOCP while combined treatment with lapatinib attenuated TOCP-induced NRG1/ErbB signaling cascade.	Lapatinib	82-91	epidermal growth factor receptor	Mus musculus	121-125
33766630-10	2021	The results implied that NRG1/ErbB system may predominately play functional role in spinal cord (central nervous system) but not in sciatic nerves (peripheral nervous system) of mouse subjected to neurotoxic OP, which was confirmed by the study in vitro that lapatinib was not able to attenuate TOCP-induced neurotoxicity in rodent Schwann cell line RSC 96 cells.	Lapatinib	259-268	neuregulin 1	Mus musculus	25-29
33766630-10	2021	The results implied that NRG1/ErbB system may predominately play functional role in spinal cord (central nervous system) but not in sciatic nerves (peripheral nervous system) of mouse subjected to neurotoxic OP, which was confirmed by the study in vitro that lapatinib was not able to attenuate TOCP-induced neurotoxicity in rodent Schwann cell line RSC 96 cells.	Lapatinib	259-268	epidermal growth factor receptor	Mus musculus	30-34
33771774-5	2021	On pain recurrence after the trial, he was prescribed the oral EGFR-Is erlotinib, gefitinib, and lapatinib without relief.	Lapatinib	97-106	epidermal growth factor receptor	Homo sapiens	63-67
33033492-1	2020	Lapatinib and trastuzumab (Herceptin) are targeted therapies designed for patients with HER2+ breast tumors.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
33801244-4	2021	We clarify that lapatinib, a dual inhibitor for EGFR and ERBB2, promoted autophagy in cells expressing only EGFR but inhibited autophagy in cells expressing only ERBB2.	Lapatinib	16-25	epidermal growth factor receptor	Homo sapiens	48-52
33801244-4	2021	We clarify that lapatinib, a dual inhibitor for EGFR and ERBB2, promoted autophagy in cells expressing only EGFR but inhibited autophagy in cells expressing only ERBB2.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-62
33801244-4	2021	We clarify that lapatinib, a dual inhibitor for EGFR and ERBB2, promoted autophagy in cells expressing only EGFR but inhibited autophagy in cells expressing only ERBB2.	Lapatinib	16-25	epidermal growth factor receptor	Homo sapiens	108-112
33801244-4	2021	We clarify that lapatinib, a dual inhibitor for EGFR and ERBB2, promoted autophagy in cells expressing only EGFR but inhibited autophagy in cells expressing only ERBB2.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-167
33033492-9	2020	Our results indicate that transcriptional similarity of biological pathways can be used to predict lapatinib and trastuzumab response in HER2+ breast cancer.	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
32795383-3	2020	METHODS: To investigate a potential protective effect of adipocyte-conditioned medium on HER2 positive breast cancer cells exposed to tyrosine kinase inhibitors (TKI) such as lapatinib, we analyzed the sensitivity of HER2 positive breast cancer models in vitro and in vivo on SCID mice in the presence or absence of adipocytes or adipocyte-conditioned medium.	Lapatinib	175-184	erb-b2 receptor tyrosine kinase 2	Mus musculus	89-93
24503803-6	2013	Further study will be needed to evaluate in the clinic the combination of lapatinib and an m-TOR inhibitor as a treatment approach in HER2 overexpressing breast cancer that shows a poor response to trastuzumab.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
25441421-6	2015	The addition of trastuzumab, pertuzumab, bevacizumab, or lapatinib to chemotherapy significantly (P < .05) improved objective response rate (ORR), time to failure (TTF), and overall survival (OS) in patients with HER2-positive (HER2(+)) disease.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	216-220
25441421-6	2015	The addition of trastuzumab, pertuzumab, bevacizumab, or lapatinib to chemotherapy significantly (P < .05) improved objective response rate (ORR), time to failure (TTF), and overall survival (OS) in patients with HER2-positive (HER2(+)) disease.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	231-235
25441421-7	2015	Trastuzumab or lapatinib combined with endocrine therapy significantly (P < .05) improved ORR, time to progression (TTP), and progression-free survival (PFS) in patients with HER2(+) and HR(+) disease.	Lapatinib	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	178-182
25441421-8	2015	In patients with HER2-negative (HER2(-)) cancer, bevacizumab or lapatinib added to chemotherapy significantly (P < .05), improved ORR but did not prolong PFS and OS (P > .05).	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21
25441421-8	2015	In patients with HER2-negative (HER2(-)) cancer, bevacizumab or lapatinib added to chemotherapy significantly (P < .05), improved ORR but did not prolong PFS and OS (P > .05).	Lapatinib	64-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
23689990-0	2015	Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.	Lapatinib	139-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
23689990-1	2015	BACKGROUND: The results from a phase III trial conducted outside of Japan demonstrated a significant improvement in time to progression (TTP) when lapatinib was combined with capecitabine compared with capecitabine alone in patients with HER2-positive advanced or metastatic breast cancer.	Lapatinib	147-156	erb-b2 receptor tyrosine kinase 2	Homo sapiens	238-242
23689990-8	2015	CONCLUSIONS: Lapatinib in combination with capecitabine in Japanese HER2-positive breast cancer patients was well tolerated.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
24503798-0	2013	18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
24503798-1	2013	Targeted therapies against HER2 (trastuzumab, lapatinib) have improved the efficacy of treatment and the outcome of patients with HER2-positive breast cancer.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
24503798-2	2013	Lapatinib is a tyrosine kinase inhibitor targeting EGFR1 and HER2: it binds the intracellular domain of these receptors and blocks their downstream signaling pathways.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
24503802-0	2013	Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.	Lapatinib	69-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
24503803-5	2013	Lapatinib may have the potential to convert trastuzumab-refractory tumors to trastuzumab-sensitive tumors in HER2-positive breast cancer by upregulation of the cell surface expression of HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
18490651-0	2008	Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-126
18490651-1	2008	PURPOSE: The combination of lapatinib and trastuzumab has been observed to have a synergistic, antiproliferative effect against ErbB2-positive breast cancer cells in vitro.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-133
34957911-3	2021	Currently available HER2 inhibitor lapatinib targets the ATP binding site of the cytoplasmic kinase domain, blocking autophosphorylation and activation of HER-2.	Lapatinib	35-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
34718243-8	2022	Recently, the DETECT III trial has shown that patients with HER2 negative metastatic breast cancer and HER2 positive CTCs may benefit from targeted anti-HER2 treatment with lapatinib.	Lapatinib	173-182	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
34718243-8	2022	Recently, the DETECT III trial has shown that patients with HER2 negative metastatic breast cancer and HER2 positive CTCs may benefit from targeted anti-HER2 treatment with lapatinib.	Lapatinib	173-182	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
34718243-8	2022	Recently, the DETECT III trial has shown that patients with HER2 negative metastatic breast cancer and HER2 positive CTCs may benefit from targeted anti-HER2 treatment with lapatinib.	Lapatinib	173-182	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
34958115-4	2022	Previously, we have reported that the combination of epidermal growth factor receptor/HER2 inhibitor lapatinib and sphingosine analog fingolimod (FTY720) confers a significant cytostatic effect in lung cancer cells.	Lapatinib	101-110	epidermal growth factor receptor	Homo sapiens	53-85
34958115-4	2022	Previously, we have reported that the combination of epidermal growth factor receptor/HER2 inhibitor lapatinib and sphingosine analog fingolimod (FTY720) confers a significant cytostatic effect in lung cancer cells.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
34958115-9	2022	Additionally, the cytotoxic effect of lapatinib was enhanced by hydroxychloroquine or the CDK4/6 inhibitor abemaciclib, both of which induce lysosomal dysfunction.	Lapatinib	38-47	cyclin dependent kinase 4	Homo sapiens	90-96
34939319-3	2022	Although compound 6b showed higher cytotoxicity, compound 4b exhibited better inhibitory activity towards the EGFR pathway than compound 6b as represented by the significant reduction in the EGFR kinase activity and the levels of phosho-EGFR and phosho-AKT when compared to lapatinib as a reference standard.	Lapatinib	274-283	epidermal growth factor receptor	Homo sapiens	110-114
34957911-3	2021	Currently available HER2 inhibitor lapatinib targets the ATP binding site of the cytoplasmic kinase domain, blocking autophosphorylation and activation of HER-2.	Lapatinib	35-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-160
34894465-2	2022	Trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine have markedly extended HER2 breast cancer survival but current knowledge on how these HER2-targeted agents induce interstitial lung disease is still poorly defined due to limited cases in the literature.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
34808043-0	2021	Binding Mechanism between Acetylcholinesterase and Drugs Pazopanib and Lapatinib: Biochemical and Biophysical Studies.	Lapatinib	71-80	acetylcholinesterase (Cartwright blood group)	Homo sapiens	26-46
34808043-3	2021	In this work, interaction and inhibition studies through spectroscopic and computational techniques to evaluate the binding effectiveness of lapatinib and pazopanib TKIs to acetylcholinesterase (AChE) are reported.	Lapatinib	141-150	acetylcholinesterase (Cartwright blood group)	Homo sapiens	173-193
34808043-3	2021	In this work, interaction and inhibition studies through spectroscopic and computational techniques to evaluate the binding effectiveness of lapatinib and pazopanib TKIs to acetylcholinesterase (AChE) are reported.	Lapatinib	141-150	acetylcholinesterase (Cartwright blood group)	Homo sapiens	195-199
34808043-6	2021	The fluorescence suppression studies indicate a static mechanism for lapatinib-AChE and pazopanib-AChE systems, with a binding constant in the order of 105 M-1.	Lapatinib	69-78	acetylcholinesterase (Cartwright blood group)	Homo sapiens	79-83
34808043-6	2021	The fluorescence suppression studies indicate a static mechanism for lapatinib-AChE and pazopanib-AChE systems, with a binding constant in the order of 105 M-1.	Lapatinib	69-78	acetylcholinesterase (Cartwright blood group)	Homo sapiens	98-102
34808043-7	2021	The obtained thermodynamic parameters reveal interactions driven by van der Waals forces and hydrogen bonds in the lapatinib-AChE system (DeltaH  and DeltaS  < 0).	Lapatinib	115-124	acetylcholinesterase (Cartwright blood group)	Homo sapiens	125-129
34844517-0	2021	The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
34944900-5	2021	ERalpha-positive breast cancer cells that developed resistance showed greatly reduced ERalpha levels and responsiveness to fulvestrant and a 10-fold increased sensitivity to lapatinib, suggesting that targeting rewired processes in the resistant state may provide benefits and prolong anticancer effectiveness.	Lapatinib	174-183	estrogen receptor 1	Homo sapiens	0-7
34896211-5	2022	Inhibition of ERBB2 and IGF2BP2 by lapatinib robustly rescued the PTCSR cells from acquired dedifferentiation.	Lapatinib	35-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-19
34896211-5	2022	Inhibition of ERBB2 and IGF2BP2 by lapatinib robustly rescued the PTCSR cells from acquired dedifferentiation.	Lapatinib	35-44	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	24-31
34101105-0	2021	HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 3	Homo sapiens	0-4
34101105-0	2021	HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 3	Homo sapiens	47-51
34101105-0	2021	HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
34101105-7	2021	PROCEDURES: In a panel of HER2+ breast cancer cell lines treated with the HER2 inhibitor lapatinib, we evaluate changes in HER3 expression and viability.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
34101105-7	2021	PROCEDURES: In a panel of HER2+ breast cancer cell lines treated with the HER2 inhibitor lapatinib, we evaluate changes in HER3 expression and viability.	Lapatinib	89-98	erb-b2 receptor tyrosine kinase 3	Homo sapiens	123-127
34101105-8	2021	Mouse HER2+ breast cancer models treated with lapatinib were imaged with a peptide-based HER3-specific PET imaging agent (68Ga)HER3P1 to assess for dynamic changes in tumoral HER3 expression and uptake confirmed by biodistribution.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Mus musculus	6-10
34101105-9	2021	Subsequently, HER2+ cell lines were treated with the HER2 inhibitor lapatinib as well HER3-specific siRNA to assess for changes in viability and correlate with HER3 expression upregulation.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Mus musculus	53-57
34101105-11	2021	RESULTS: Lapatinib treatment of a panel of HER2+ breast cancer cell lines increased HER3 expression in the lapatinib-resistant cell line MDA-MB 453 but not the lapatinib-resistant cell-line HCC-1569.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
34101105-11	2021	RESULTS: Lapatinib treatment of a panel of HER2+ breast cancer cell lines increased HER3 expression in the lapatinib-resistant cell line MDA-MB 453 but not the lapatinib-resistant cell-line HCC-1569.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 3	Homo sapiens	84-88
34101105-11	2021	RESULTS: Lapatinib treatment of a panel of HER2+ breast cancer cell lines increased HER3 expression in the lapatinib-resistant cell line MDA-MB 453 but not the lapatinib-resistant cell-line HCC-1569.	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 3	Homo sapiens	84-88
34101105-12	2021	Evaluation of (68Ga)HER3P1 uptake in mice implanted with the HER2+ breast cancer cell lines MDA-MB453 or HCC-1569 prior to and after treatment with lapatinib demonstrated a significant increase in MDA-MB453 tumors only, consistent with in vitro findings.	Lapatinib	148-157	erb-b2 receptor tyrosine kinase 2	Mus musculus	61-65
34101105-13	2021	The additional knockdown of HER3 increased therapeutic efficacy of lapatinib only in MDA-MB453 cells, but not in HCC-1569 cells.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 3	Homo sapiens	28-32
34830108-9	2021	Cell growth and invasion/migration are also decreased in cells with single/combined knockdowns of EGFR and SQSTM1 or in SQSTM1-knockdown cells without EGFR kinase inhibitor Lapatinib treatment compared to that in scrambled cells.	Lapatinib	173-182	epidermal growth factor receptor	Homo sapiens	151-155
34585713-4	2021	The ideas were as follows: (1) using liposome as a nano-delivery system for HER2 inhibitor (lapatinib; LAP) to reduce the toxicity; (2) modifying the capsule with T7 peptide for specific targeted delivery to the tumor cells, and (3) enabling the capsule with the pH-sensitive ability and triggering sustained drug release at extracellular weakly acidic microenvironment to emerge toxicity in tumors and to improve curative effects.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
34585713-4	2021	The ideas were as follows: (1) using liposome as a nano-delivery system for HER2 inhibitor (lapatinib; LAP) to reduce the toxicity; (2) modifying the capsule with T7 peptide for specific targeted delivery to the tumor cells, and (3) enabling the capsule with the pH-sensitive ability and triggering sustained drug release at extracellular weakly acidic microenvironment to emerge toxicity in tumors and to improve curative effects.	Lapatinib	92-101	LAP	Homo sapiens	103-106
34535639-5	2021	The ERBB1/2 inhibitor, lapatinib, led to the reversal of the aberrant ARE-mediated process in ERBB2-amplified breast cancer cells.	Lapatinib	23-32	epidermal growth factor receptor	Homo sapiens	4-11
34413161-3	2021	Mice were orally administered lapatinib to inhibit BCRP in vivo, and plasma samples were assessed by liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS), with all-ion fragmentation acquisition, and quantified by LC-MS/MS.	Lapatinib	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-55
34413161-8	2021	After adding parent compounds to the apical side of induced pluripotent stem cell-derived small intestinal epithelial-like cells, DS, GS, and ES in the basal compartment significantly increased in the presence of lapatinib and febuxostat, suggesting the inhibition of intestinal BCRP.	Lapatinib	213-222	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	279-283
34709124-5	2021	Based on docking energy (<= -9.00 kcal mol-1), four drugs (Celecoxib, Glipizide, Lapatinib, and Sitagliptin) were identified as potential inhibitors of TACE, with binding affinities up to 106-107 M-1.	Lapatinib	81-90	ADAM metallopeptidase domain 17	Homo sapiens	152-156
34482024-5	2021	A high KA by Ab6 and Ab6-mediated increased anti-proliferative effects against NCI-H1838 or BT474 were also respectively observed in the presence of Erlotinib (HER1 inhibitor) or Lapatinib (HER1/HER2 inhibitor).	Lapatinib	179-188	epidermal growth factor receptor	Homo sapiens	190-194
34482024-5	2021	A high KA by Ab6 and Ab6-mediated increased anti-proliferative effects against NCI-H1838 or BT474 were also respectively observed in the presence of Erlotinib (HER1 inhibitor) or Lapatinib (HER1/HER2 inhibitor).	Lapatinib	179-188	erb-b2 receptor tyrosine kinase 2	Homo sapiens	195-199
34722261-6	2021	ERBB-2 mutation with L755S and V842I indicates resistance to trastuzumab, while that with L755S and K753I indicates resistance to lapatinib; these mutations maybe sensitive to pan-HER tyrosine-kinase inhibitors.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-6
34722261-6	2021	ERBB-2 mutation with L755S and V842I indicates resistance to trastuzumab, while that with L755S and K753I indicates resistance to lapatinib; these mutations maybe sensitive to pan-HER tyrosine-kinase inhibitors.	Lapatinib	130-139	TXK tyrosine kinase	Homo sapiens	184-199
34382727-7	2021	Our study not only identified miRNA-221 as a pivotal factor conferring the acquired resistance of HER2-positive breast cancer cells to lapatinib through negatively regulating p27kip1 expression but also suggested Src inhibition as a potential strategy to overcome lapatinib resistance.	Lapatinib	264-273	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	213-216
34376577-6	2021	Lapatinib, a tyrosine kinase inhibitor that targets HER2, and siRNA-mediated knockdown of HER2 similarly suppressed cancer cell growth in vitro.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
34589134-2	2021	Administration of lapatinib with capecitabine is an effective treatment for HER2-positive metastatic BC.	Lapatinib	18-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
34589134-10	2021	In addition, Western blotting revealed that the expressions of HER-2, p-HER-2, AKT, p-AKT, ERK, and p-ERK were downregulated by lapatinib-sulforaphane treatment.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-68
34589134-10	2021	In addition, Western blotting revealed that the expressions of HER-2, p-HER-2, AKT, p-AKT, ERK, and p-ERK were downregulated by lapatinib-sulforaphane treatment.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
34589134-10	2021	In addition, Western blotting revealed that the expressions of HER-2, p-HER-2, AKT, p-AKT, ERK, and p-ERK were downregulated by lapatinib-sulforaphane treatment.	Lapatinib	128-137	AKT serine/threonine kinase 1	Homo sapiens	79-82
34589134-10	2021	In addition, Western blotting revealed that the expressions of HER-2, p-HER-2, AKT, p-AKT, ERK, and p-ERK were downregulated by lapatinib-sulforaphane treatment.	Lapatinib	128-137	AKT serine/threonine kinase 1	Homo sapiens	86-89
34589134-10	2021	In addition, Western blotting revealed that the expressions of HER-2, p-HER-2, AKT, p-AKT, ERK, and p-ERK were downregulated by lapatinib-sulforaphane treatment.	Lapatinib	128-137	EPH receptor B2	Homo sapiens	91-94
34589134-10	2021	In addition, Western blotting revealed that the expressions of HER-2, p-HER-2, AKT, p-AKT, ERK, and p-ERK were downregulated by lapatinib-sulforaphane treatment.	Lapatinib	128-137	EPH receptor B2	Homo sapiens	102-105
34481907-3	2021	To assess this, we used lapatinib ditosylate (LAP), an anti-cancer drug that inhibits MPC-1 through suppression of estrogen-related receptor alpha (ERR-alpha), in D-galactose/ovariectomized rats.	Lapatinib	24-44	mitochondrial pyruvate carrier 1	Rattus norvegicus	86-91
34481907-3	2021	To assess this, we used lapatinib ditosylate (LAP), an anti-cancer drug that inhibits MPC-1 through suppression of estrogen-related receptor alpha (ERR-alpha), in D-galactose/ovariectomized rats.	Lapatinib	24-44	estrogen related receptor, alpha	Rattus norvegicus	115-146
34481907-3	2021	To assess this, we used lapatinib ditosylate (LAP), an anti-cancer drug that inhibits MPC-1 through suppression of estrogen-related receptor alpha (ERR-alpha), in D-galactose/ovariectomized rats.	Lapatinib	24-44	estrogen related receptor, alpha	Rattus norvegicus	148-157
34481907-3	2021	To assess this, we used lapatinib ditosylate (LAP), an anti-cancer drug that inhibits MPC-1 through suppression of estrogen-related receptor alpha (ERR-alpha), in D-galactose/ovariectomized rats.	Lapatinib	46-49	mitochondrial pyruvate carrier 1	Rattus norvegicus	86-91
34481907-3	2021	To assess this, we used lapatinib ditosylate (LAP), an anti-cancer drug that inhibits MPC-1 through suppression of estrogen-related receptor alpha (ERR-alpha), in D-galactose/ovariectomized rats.	Lapatinib	46-49	estrogen related receptor, alpha	Rattus norvegicus	115-146
34481907-3	2021	To assess this, we used lapatinib ditosylate (LAP), an anti-cancer drug that inhibits MPC-1 through suppression of estrogen-related receptor alpha (ERR-alpha), in D-galactose/ovariectomized rats.	Lapatinib	46-49	estrogen related receptor, alpha	Rattus norvegicus	148-157
34153400-0	2021	Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
34153400-3	2021	In the current study, we find that Melatonin sensitizes HER2-positive breast cancer cells to the dual tyrosine kinase inhibitor Lapatinib in vitro.	Lapatinib	128-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
34153400-7	2021	Meanwhile, Lapatinib resistant HER2-positive breast cancer cells (LapR) display lower basal expression levels of UPR genes and enhanced tolerance to EnR stress with attenuated response to Brefeldin A and Tunicamycin.	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
34620206-9	2021	RESULTS: Besides differing in sensitivities to trastuzumab, the different cellular models also showed distinct response to other anti-HER2 drugs (lapatinib, neratinib, pertuzumab and T-DM1) used in the clinic.	Lapatinib	146-155	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
34382727-0	2021	MiR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer.	Lapatinib	16-25	microRNA 221	Homo sapiens	0-7
34382727-0	2021	MiR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer.	Lapatinib	16-25	cyclin dependent kinase inhibitor 1B	Homo sapiens	62-69
34382727-0	2021	MiR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
34382727-1	2021	Development of acquired resistance to lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, severely limited the duration of clinical response in advanced HER2-driven breast cancer patients.	Lapatinib	38-47	epidermal growth factor receptor	Homo sapiens	56-60
34382727-1	2021	Development of acquired resistance to lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, severely limited the duration of clinical response in advanced HER2-driven breast cancer patients.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
34382727-1	2021	Development of acquired resistance to lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, severely limited the duration of clinical response in advanced HER2-driven breast cancer patients.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
34382727-2	2021	Although the compensatory activation of PI3K/Akt survival signal has been proposed to cause the acquired lapatinib resistance; however, the comprehensive molecular mechanisms remain required to develop more efficient strategies to circumvent this therapeutic difficulty.	Lapatinib	105-114	AKT serine/threonine kinase 1	Homo sapiens	45-48
34382727-3	2021	In this study, we found that suppression of HER2 by lapatinib still led to the Akt inactivation and elevation of FOX3a protein level but failed to induce the expression of their downstream pro-apoptotic effector p27kip1 , a cyclin-dependent kinase inhibitor.	Lapatinib	52-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
34382727-3	2021	In this study, we found that suppression of HER2 by lapatinib still led to the Akt inactivation and elevation of FOX3a protein level but failed to induce the expression of their downstream pro-apoptotic effector p27kip1 , a cyclin-dependent kinase inhibitor.	Lapatinib	52-61	AKT serine/threonine kinase 1	Homo sapiens	79-82
34382727-4	2021	The elevation of miR-221 was found to contribute to the development of the acquired lapatinib resistance by targeting p27kip1 expression.	Lapatinib	84-93	microRNA 221	Homo sapiens	17-24
34382727-4	2021	The elevation of miR-221 was found to contribute to the development of the acquired lapatinib resistance by targeting p27kip1 expression.	Lapatinib	84-93	cyclin dependent kinase inhibitor 1B	Homo sapiens	118-125
34382727-5	2021	Furthermore, the upregulation of miR-221 was mediated by the lapatinib-induced Src family tyrosine kinase and subsequent NF-kB activations.	Lapatinib	61-70	microRNA 221	Homo sapiens	33-40
34382727-5	2021	Furthermore, the upregulation of miR-221 was mediated by the lapatinib-induced Src family tyrosine kinase and subsequent NF-kB activations.	Lapatinib	61-70	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	79-82
34382727-6	2021	The reversal of miR-221 upregulation and p27kip1 downregulation by Src inhibitor, dasatinib, can overcome lapatinib resistance.	Lapatinib	106-115	microRNA 221	Homo sapiens	16-23
34382727-6	2021	The reversal of miR-221 upregulation and p27kip1 downregulation by Src inhibitor, dasatinib, can overcome lapatinib resistance.	Lapatinib	106-115	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	67-70
34382727-7	2021	Our study not only identified miRNA-221 as a pivotal factor conferring the acquired resistance of HER2-positive breast cancer cells to lapatinib through negatively regulating p27kip1 expression but also suggested Src inhibition as a potential strategy to overcome lapatinib resistance.	Lapatinib	135-144	microRNA 221	Homo sapiens	30-39
34382727-7	2021	Our study not only identified miRNA-221 as a pivotal factor conferring the acquired resistance of HER2-positive breast cancer cells to lapatinib through negatively regulating p27kip1 expression but also suggested Src inhibition as a potential strategy to overcome lapatinib resistance.	Lapatinib	135-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
34382727-7	2021	Our study not only identified miRNA-221 as a pivotal factor conferring the acquired resistance of HER2-positive breast cancer cells to lapatinib through negatively regulating p27kip1 expression but also suggested Src inhibition as a potential strategy to overcome lapatinib resistance.	Lapatinib	135-144	cyclin dependent kinase inhibitor 1B	Homo sapiens	175-182
34382727-7	2021	Our study not only identified miRNA-221 as a pivotal factor conferring the acquired resistance of HER2-positive breast cancer cells to lapatinib through negatively regulating p27kip1 expression but also suggested Src inhibition as a potential strategy to overcome lapatinib resistance.	Lapatinib	135-144	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	213-216
34382727-7	2021	Our study not only identified miRNA-221 as a pivotal factor conferring the acquired resistance of HER2-positive breast cancer cells to lapatinib through negatively regulating p27kip1 expression but also suggested Src inhibition as a potential strategy to overcome lapatinib resistance.	Lapatinib	264-273	microRNA 221	Homo sapiens	30-39
34382727-7	2021	Our study not only identified miRNA-221 as a pivotal factor conferring the acquired resistance of HER2-positive breast cancer cells to lapatinib through negatively regulating p27kip1 expression but also suggested Src inhibition as a potential strategy to overcome lapatinib resistance.	Lapatinib	264-273	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
34535639-5	2021	The ERBB1/2 inhibitor, lapatinib, led to the reversal of the aberrant ARE-mediated process in ERBB2-amplified breast cancer cells.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-99
34535639-8	2021	Lapatinib accelerated the ARE-mRNA decay for several ERBB2-regulated genes.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-58
34435487-3	2021	In vitro biological studies indicated that 3a showed strong cytotoxicity and EGFR enzyme inhibitory activity and effectively reversed lapatinib-mediated resistance of MDA-MB-231 cells via inhibiting triple-negative breast cancer (TNBC) cell stemness and the AKT/ERK signaling pathway.	Lapatinib	134-143	AKT serine/threonine kinase 1	Homo sapiens	258-261
34545713-8	2021	RESULTS: Four kinase inhibitors (lapatinib, PD169316, sunitinib, gefitinib) significantly increased ALA-PpIX fluorescence and PDT response in TNBC cells with ABCG2 activity, but not in MCF10A nontumor breast epithelial cell line without ABCG2 activity.	Lapatinib	33-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	158-163
34451888-3	2021	In this study, we first identified FDA-approved compounds with similar structures in the DrugBank to lapatinib and gefitinib, two known inhibitors of EGFR and HER2.	Lapatinib	101-110	epidermal growth factor receptor	Homo sapiens	150-154
34459788-11	2021	Targeted treatment of ERBB2 using lapatinib could attenuate apatinib resistance.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-27
34575017-7	2021	Decreased HER2 expression was correlated with increased EMT phenotype, inactivated chromatin and lower response to lapatinib.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
34575017-9	2021	Our results suggest that ERBB2 gene silencing by epigenetic regulation during EMT may be a mechanism of de novo resistance of HER2-positive breast cancer cells to trastuzumab and lapatinib.	Lapatinib	179-188	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-30
34575017-9	2021	Our results suggest that ERBB2 gene silencing by epigenetic regulation during EMT may be a mechanism of de novo resistance of HER2-positive breast cancer cells to trastuzumab and lapatinib.	Lapatinib	179-188	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
34399705-10	2021	CONCLUSIONS: Our study suggests that loss-of-function mutations of CSK and PTEN cause lapatinib resistance by re-activating MAPK and PI3K pathways, and further proved these two pathways are druggable targets.	Lapatinib	86-95	C-terminal Src kinase	Homo sapiens	67-70
34399705-10	2021	CONCLUSIONS: Our study suggests that loss-of-function mutations of CSK and PTEN cause lapatinib resistance by re-activating MAPK and PI3K pathways, and further proved these two pathways are druggable targets.	Lapatinib	86-95	phosphatase and tensin homolog	Homo sapiens	75-79
34399705-11	2021	Inhibiting the two pathways synergistically are effective to overcome lapatinib resistance in HER2-amplified GC.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
34399705-12	2021	This study provides insights for understanding the resistant mechanism of HER2 targeted therapy and novel strategies that may ultimately overcome resistance or limited efficacy of lapatinib treatment for subset of HER2 amplified GC.	Lapatinib	180-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
34399705-12	2021	This study provides insights for understanding the resistant mechanism of HER2 targeted therapy and novel strategies that may ultimately overcome resistance or limited efficacy of lapatinib treatment for subset of HER2 amplified GC.	Lapatinib	180-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	214-218
34545713-13	2021	As an FDA-approved kinase inhibitor for breast cancer treatment, lapatinib is ready to be used in combination with ALA for therapeutic enhancement in tumors with elevated ABCG2 activity.	Lapatinib	65-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	171-176
34126209-4	2021	Lapatinib (LAP) has been approved by the FDA in combination with other anticancer agents for the treatment of HER2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
34126209-4	2021	Lapatinib (LAP) has been approved by the FDA in combination with other anticancer agents for the treatment of HER2-positive breast cancer.	Lapatinib	11-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
34157442-0	2021	Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells.	Lapatinib	51-60	glutathione peroxidase 4	Homo sapiens	14-18
34157442-0	2021	Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells.	Lapatinib	51-60	mechanistic target of rapamycin kinase	Homo sapiens	22-26
34157442-4	2021	In the present study, we studied the role of Glutathione peroxidase 4 (GPX4) and mammalian target of rapamycin (mTOR) in regulation of lung cancer cells response to Lapatinib (Lap).	Lapatinib	165-174	glutathione peroxidase 4	Homo sapiens	45-69
34157442-4	2021	In the present study, we studied the role of Glutathione peroxidase 4 (GPX4) and mammalian target of rapamycin (mTOR) in regulation of lung cancer cells response to Lapatinib (Lap).	Lapatinib	165-174	glutathione peroxidase 4	Homo sapiens	71-75
34157442-4	2021	In the present study, we studied the role of Glutathione peroxidase 4 (GPX4) and mammalian target of rapamycin (mTOR) in regulation of lung cancer cells response to Lapatinib (Lap).	Lapatinib	165-174	mechanistic target of rapamycin kinase	Homo sapiens	81-110
34157442-4	2021	In the present study, we studied the role of Glutathione peroxidase 4 (GPX4) and mammalian target of rapamycin (mTOR) in regulation of lung cancer cells response to Lapatinib (Lap).	Lapatinib	165-174	mechanistic target of rapamycin kinase	Homo sapiens	112-116
34157442-10	2021	Mechanistically, upregulation of GPX4 was due to enhanced activation of mTORC1 in Lap resistant NSCLC cells.	Lapatinib	82-85	glutathione peroxidase 4	Mus musculus	33-37
34157442-10	2021	Mechanistically, upregulation of GPX4 was due to enhanced activation of mTORC1 in Lap resistant NSCLC cells.	Lapatinib	82-85	CREB regulated transcription coactivator 1	Mus musculus	72-78
34157442-13	2021	In vivo experiments also indicated that silencing of GPX4 enhanced the anticancer effect of Lap via promoting ferroptosis.	Lapatinib	92-95	glutathione peroxidase 4	Mus musculus	53-57
34399705-0	2021	A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.	Lapatinib	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
34399705-3	2021	Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, is an effective agent to treat HER2-amplified breast cancer but it failed in gastric cancer (GC) clinical trials.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	18-22
34399705-3	2021	Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, is an effective agent to treat HER2-amplified breast cancer but it failed in gastric cancer (GC) clinical trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
34399705-3	2021	Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, is an effective agent to treat HER2-amplified breast cancer but it failed in gastric cancer (GC) clinical trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
34399705-4	2021	However, the molecular mechanism of lapatinib resistance in HER2-amplified GC is not well studied.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
34399705-5	2021	METHODS: We employed an unbiased, genome-scale screening with pooled CRISPR library on HER2-amplified GC cell lines to identify genes that are associated with resistance to lapatinib.	Lapatinib	173-182	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
34399705-7	2021	RESULTS: We found that loss of function of CSK or PTEN conferred lapatinib resistance in HER2-amplified GC cell lines NCI-N87 and OE19, respectively.	Lapatinib	65-74	C-terminal Src kinase	Homo sapiens	43-46
34399705-7	2021	RESULTS: We found that loss of function of CSK or PTEN conferred lapatinib resistance in HER2-amplified GC cell lines NCI-N87 and OE19, respectively.	Lapatinib	65-74	phosphatase and tensin homolog	Homo sapiens	50-54
34399705-9	2021	Furthermore, in vitro and in vivo pharmacological study has shown that lapatinib resistance by the loss of function of CSK or PTEN, could be overcome by lapatinib combined with the PI3K inhibitor copanlisib and MEK inhibitor trametinib.	Lapatinib	71-80	C-terminal Src kinase	Homo sapiens	119-122
34399705-9	2021	Furthermore, in vitro and in vivo pharmacological study has shown that lapatinib resistance by the loss of function of CSK or PTEN, could be overcome by lapatinib combined with the PI3K inhibitor copanlisib and MEK inhibitor trametinib.	Lapatinib	71-80	phosphatase and tensin homolog	Homo sapiens	126-130
34399705-9	2021	Furthermore, in vitro and in vivo pharmacological study has shown that lapatinib resistance by the loss of function of CSK or PTEN, could be overcome by lapatinib combined with the PI3K inhibitor copanlisib and MEK inhibitor trametinib.	Lapatinib	71-80	mitogen-activated protein kinase kinase 7	Homo sapiens	211-214
34399705-9	2021	Furthermore, in vitro and in vivo pharmacological study has shown that lapatinib resistance by the loss of function of CSK or PTEN, could be overcome by lapatinib combined with the PI3K inhibitor copanlisib and MEK inhibitor trametinib.	Lapatinib	153-162	C-terminal Src kinase	Homo sapiens	119-122
34399705-9	2021	Furthermore, in vitro and in vivo pharmacological study has shown that lapatinib resistance by the loss of function of CSK or PTEN, could be overcome by lapatinib combined with the PI3K inhibitor copanlisib and MEK inhibitor trametinib.	Lapatinib	153-162	phosphatase and tensin homolog	Homo sapiens	126-130
34451888-3	2021	In this study, we first identified FDA-approved compounds with similar structures in the DrugBank to lapatinib and gefitinib, two known inhibitors of EGFR and HER2.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
34344439-11	2021	RESULTS: Treatment with HER2-targeted therapy reveals that mutations in the kinase domain (H1047R) but not the helical domain (E545K) increase resistance to lapatinib.	Lapatinib	157-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
34347777-0	2021	Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	34-39
34347777-11	2021	We observed synergy when we combined poziotinib or lapatinib with paclitaxel in resistant TOV-21G and OVCAR3 cells.	Lapatinib	51-60	carbonic anhydrase 3	Homo sapiens	102-108
34347777-13	2021	Furthermore, we demonstrated direct inhibition of paclitaxel-induced ABCB1 transporter activity by both lapatinib and poziotinib.	Lapatinib	104-113	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
34347777-14	2021	In conclusion, lapatinib and poziotinib combined with paclitaxel synergizes to inhibit the proliferation of ABCB1-overexpressing ovarian cancer cells in vitro.	Lapatinib	15-24	ATP binding cassette subfamily B member 1	Homo sapiens	108-113
34344439-12	2021	Mechanistically, sustained AKT signaling drives lapatinib resistance in cells with the kinase domain mutation, as demonstrated by staining for the intracellular product of PI3-kinase, PIP3.	Lapatinib	48-57	AKT serine/threonine kinase 1	Homo sapiens	27-30
34153715-0	2021	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-53
34239043-0	2021	A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.	Lapatinib	56-65	snail family transcriptional repressor 2	Homo sapiens	2-7
34239043-0	2021	A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.	Lapatinib	56-65	pseudopodium enriched atypical kinase 1	Homo sapiens	8-13
34239043-0	2021	A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.	Lapatinib	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
34239043-0	2021	A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.	Lapatinib	56-65	inhibin subunit beta A	Homo sapiens	14-19
34239043-5	2021	Furthermore, mesenchymal stem cells (MSCs) and cancer-associated fibroblasts (CAFs) express high PEAK1 protein levels and potentiate tumorigenesis, lapatinib resistance and metastasis of HER2-positive breast cancer cells in a PEAK1-dependent manner.	Lapatinib	148-157	pseudopodium enriched atypical kinase 1	Homo sapiens	226-231
34239043-6	2021	Analysis of PEAK1-dependent secreted factors from MSCs revealed INHBA/activin-A as a necessary factor in the conditioned media of PEAK1-expressing MSCs that promotes lapatinib resistance.	Lapatinib	166-175	pseudopodium enriched atypical kinase 1	Homo sapiens	12-17
34239043-6	2021	Analysis of PEAK1-dependent secreted factors from MSCs revealed INHBA/activin-A as a necessary factor in the conditioned media of PEAK1-expressing MSCs that promotes lapatinib resistance.	Lapatinib	166-175	inhibin subunit beta A	Homo sapiens	64-69
34239043-6	2021	Analysis of PEAK1-dependent secreted factors from MSCs revealed INHBA/activin-A as a necessary factor in the conditioned media of PEAK1-expressing MSCs that promotes lapatinib resistance.	Lapatinib	166-175	pseudopodium enriched atypical kinase 1	Homo sapiens	130-135
34295807-0	2021	Circular RNA circ-MMP11 Contributes to Lapatinib Resistance of Breast Cancer Cells by Regulating the miR-153-3p/ANLN Axis.	Lapatinib	39-48	anillin, actin binding protein	Homo sapiens	112-116
34239043-7	2021	Single-cell CycIF analysis of MSC-breast cancer cell co-cultures identified enrichment of p-Akthigh/p-gH2AXlow, MCL1high/p-gH2AXlow and GRP78high/VIMhigh breast cancer cell subpopulations by the presence of PEAK1-expressing MSCs and lapatinib treatment.	Lapatinib	233-242	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	112-116
34239043-7	2021	Single-cell CycIF analysis of MSC-breast cancer cell co-cultures identified enrichment of p-Akthigh/p-gH2AXlow, MCL1high/p-gH2AXlow and GRP78high/VIMhigh breast cancer cell subpopulations by the presence of PEAK1-expressing MSCs and lapatinib treatment.	Lapatinib	233-242	heat shock protein family A (Hsp70) member 5	Homo sapiens	136-141
34367947-7	2021	Moreover, an HER2-enriched subtype predicted higher pCR rates irrespective of HER2-targeted agents (trastuzumab, lapatinib, pertuzumab, or T-DM1); chemotherapy agents (taxane-based, or anthracyclines plus taxane-based); endocrine therapy and hormone receptor (all the differences were statistically significant (P all <= 0.001)).	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
34253170-6	2021	Additionally, lapatinib enhances cell sensitivity to metformin, and knockdown of REDD1 and Sestrin2 decreased cell sensitivity to metformin and lapatinib.	Lapatinib	144-153	DNA damage inducible transcript 4	Homo sapiens	81-86
34253170-6	2021	Additionally, lapatinib enhances cell sensitivity to metformin, and knockdown of REDD1 and Sestrin2 decreased cell sensitivity to metformin and lapatinib.	Lapatinib	144-153	sestrin 2	Homo sapiens	91-99
34238922-11	2021	While adding lapatinib reversed gemcitabine resistance induced by exosomal ANXA6.	Lapatinib	13-22	annexin A6	Homo sapiens	75-80
34820552-8	2022	We tested the ability of this strategy to synergize with the anticancer efficacy of lapatinib, an inhibitor of EGFR/HER1/HER2-assocated kinase.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	111-115
34820552-8	2022	We tested the ability of this strategy to synergize with the anticancer efficacy of lapatinib, an inhibitor of EGFR/HER1/HER2-assocated kinase.	Lapatinib	84-93	epidermal growth factor receptor	Homo sapiens	116-120
34820552-8	2022	We tested the ability of this strategy to synergize with the anticancer efficacy of lapatinib, an inhibitor of EGFR/HER1/HER2-assocated kinase.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
34820552-9	2022	These studies show that blockade of amino acid entry amplifies the anticancer effect of lapatinib via interference with mTOR signaling, promotion of apoptosis, and suppression of cell proliferation and metastasis.	Lapatinib	88-97	mechanistic target of rapamycin kinase	Homo sapiens	120-124
34327214-8	2021	In the pseudovirus assay, imatinib and lapatinib had IC50 values below 10 muM, while candesartan cilexetil had an IC50 value of approximately 67 microM against Mpro in a FRET-based activity assay.	Lapatinib	39-48	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	160-164
34295807-3	2021	This study is designed to explore the role and mechanism of circ-MMP11 in lapatinib resistance in breast cancer.	Lapatinib	74-83	matrix metallopeptidase 11	Homo sapiens	65-70
34295807-12	2021	Furthermore, circ-MMP11 knockdown promoted lapatinib sensitivity by repressing cell viability, colony number, migration, invasion, and boosting apoptosis in LR breast cancer cells.	Lapatinib	43-52	matrix metallopeptidase 11	Homo sapiens	18-23
34295807-16	2021	And circ-MMP11 functioned as a sponge of miR-153-3p to regulate ANLN expression, thereby promoting lapatinib resistance in breast cancer cells, providing therapeutic targets for the treatment of breast cancer.	Lapatinib	99-108	matrix metallopeptidase 11	Homo sapiens	9-14
34295807-16	2021	And circ-MMP11 functioned as a sponge of miR-153-3p to regulate ANLN expression, thereby promoting lapatinib resistance in breast cancer cells, providing therapeutic targets for the treatment of breast cancer.	Lapatinib	99-108	anillin, actin binding protein	Homo sapiens	64-68
34115243-6	2021	Cardiotoxicity rates of other HER2-targeted treatments, such as pertuzumab, T-DM1, lapatinib, neratinib, tucatinib, trastuzumab deruxtecan, and margetuximab, appear to be significantly lower as reported in the pivotal trials which led to their approval.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
34214965-0	2021	Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
34290605-0	2021	Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells.	Lapatinib	60-69	heat shock protein 90 alpha family class A member 1	Homo sapiens	28-33
34290605-0	2021	Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells.	Lapatinib	88-97	heat shock protein 90 alpha family class A member 1	Homo sapiens	28-33
34290605-1	2021	Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	29-33
34290605-1	2021	Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
34290605-1	2021	Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
34290605-5	2021	The joint administration of ganetespib and lapatinib depleted the aberrant nuclear transcription factor STAT3, a mediator of the cell cycle and apoptosis-related pathways that is probably involved in the lapatinib resistance of HER2-positive breast cancer cells.	Lapatinib	43-52	signal transducer and activator of transcription 3	Homo sapiens	104-109
34290605-5	2021	The joint administration of ganetespib and lapatinib depleted the aberrant nuclear transcription factor STAT3, a mediator of the cell cycle and apoptosis-related pathways that is probably involved in the lapatinib resistance of HER2-positive breast cancer cells.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	228-232
34290605-5	2021	The joint administration of ganetespib and lapatinib depleted the aberrant nuclear transcription factor STAT3, a mediator of the cell cycle and apoptosis-related pathways that is probably involved in the lapatinib resistance of HER2-positive breast cancer cells.	Lapatinib	204-213	signal transducer and activator of transcription 3	Homo sapiens	104-109
34290605-5	2021	The joint administration of ganetespib and lapatinib depleted the aberrant nuclear transcription factor STAT3, a mediator of the cell cycle and apoptosis-related pathways that is probably involved in the lapatinib resistance of HER2-positive breast cancer cells.	Lapatinib	204-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	228-232
34893156-8	2021	Finally, the HLA-DQA1*02:01 allele is significantly associated with the occurrence of liver toxicity events in patients receiving lapatinib.	Lapatinib	130-139	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	13-21
34214965-0	2021	Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
34159337-3	2021	Among the hits was lapatinib, an approved inhibitor of the ErbB family of receptor tyrosine kinases.	Lapatinib	19-28	epidermal growth factor receptor	Homo sapiens	59-63
34267653-6	2021	More importantly, Pim1 inhibitor overcame the resistance of breast cancer cells to HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	114-123	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	18-22
34267653-6	2021	More importantly, Pim1 inhibitor overcame the resistance of breast cancer cells to HER2 tyrosine kinase inhibitor lapatinib.	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
34267653-7	2021	In summary, downregulation of HER2 by targeting Pim1 may be a promising and effective therapeutic approach not only for anti-cancer growth but also for circumventing lapatinib resistance in HER2-positive breast cancer patients.	Lapatinib	166-175	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
34267653-7	2021	In summary, downregulation of HER2 by targeting Pim1 may be a promising and effective therapeutic approach not only for anti-cancer growth but also for circumventing lapatinib resistance in HER2-positive breast cancer patients.	Lapatinib	166-175	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	48-52
34159337-4	2021	Lapatinib and other pan-ErbB inhibitors suppress replication of SARS-CoV-2 and unrelated viruses with a high barrier to resistance.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	24-28
34159337-5	2021	ErbB4, but not lapatinib"s cancer targets ErbB1 and ErbB2, is required for SARS-CoV-2 entry and encephalitis alphavirus infection and is a molecular target mediating lapatinib"s antiviral effect.	Lapatinib	166-175	erb-b2 receptor tyrosine kinase 4	Homo sapiens	0-5
34159337-6	2021	In human lung organoids, lapatinib protects from SARS-CoV-2-induced activation of pathways implicated in non-infectious acute lung injury and fibrosis downstream of ErbBs (p38-MAPK, MEK/ERK, and AKT/mTOR), pro-inflammatory cytokine production, and epithelial barrier injury.	Lapatinib	25-34	mitogen-activated protein kinase 14	Homo sapiens	172-180
34159337-6	2021	In human lung organoids, lapatinib protects from SARS-CoV-2-induced activation of pathways implicated in non-infectious acute lung injury and fibrosis downstream of ErbBs (p38-MAPK, MEK/ERK, and AKT/mTOR), pro-inflammatory cytokine production, and epithelial barrier injury.	Lapatinib	25-34	mitogen-activated protein kinase kinase 7	Homo sapiens	182-185
34159337-6	2021	In human lung organoids, lapatinib protects from SARS-CoV-2-induced activation of pathways implicated in non-infectious acute lung injury and fibrosis downstream of ErbBs (p38-MAPK, MEK/ERK, and AKT/mTOR), pro-inflammatory cytokine production, and epithelial barrier injury.	Lapatinib	25-34	mitogen-activated protein kinase 1	Homo sapiens	186-189
34159337-6	2021	In human lung organoids, lapatinib protects from SARS-CoV-2-induced activation of pathways implicated in non-infectious acute lung injury and fibrosis downstream of ErbBs (p38-MAPK, MEK/ERK, and AKT/mTOR), pro-inflammatory cytokine production, and epithelial barrier injury.	Lapatinib	25-34	AKT serine/threonine kinase 1	Homo sapiens	195-198
34159337-6	2021	In human lung organoids, lapatinib protects from SARS-CoV-2-induced activation of pathways implicated in non-infectious acute lung injury and fibrosis downstream of ErbBs (p38-MAPK, MEK/ERK, and AKT/mTOR), pro-inflammatory cytokine production, and epithelial barrier injury.	Lapatinib	25-34	mechanistic target of rapamycin kinase	Homo sapiens	199-203
34200751-8	2021	In the drug-screening test, the miR-30 family sensitized the HER2-positive HCC1954 cell line to lapatinib (p < 10-2) and HCC1937, MDA-MB-361, MDA-MB-436 and CAL120 to doxorubicin (p < 10-4) with an opposite impact on MCF7.	Lapatinib	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
34141791-1	2021	BACKGROUND: Capecitabine is used in combination with lapatinib as palliative treatment for human epidermal growth factor receptor 2 - positive metastatic breast cancer.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-131
34204236-2	2021	Lapatinib is a tyrosine kinase inhibitor that works by blocking the phosphorylation of the receptor HER2.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	100-104
35390338-7	2022	We also showed that a clinically used kinase inhibitor lapatinib could be repurposed for therapeutic enhancement of ALA due to its potent ABCG2 inhibitory activity.	Lapatinib	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	138-143
34074257-4	2021	METHODS: To determine novel mechanisms of EGFR/HER2 therapy resistance in breast cancer, gefitinib or lapatinib resistant variants were created from SKBR3 breast cancer cells.	Lapatinib	102-111	epidermal growth factor receptor	Homo sapiens	42-46
34074257-4	2021	METHODS: To determine novel mechanisms of EGFR/HER2 therapy resistance in breast cancer, gefitinib or lapatinib resistant variants were created from SKBR3 breast cancer cells.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
34093999-11	2021	These observed effects were comparable to lapatinib treatment, a clinically used inhibitor of HER1 and 2 receptors phosphorylation.	Lapatinib	42-51	epidermal growth factor receptor	Homo sapiens	94-104
34342244-0	2021	The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
34342244-0	2021	The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
34342244-1	2021	BACKGROUND: The aim of this study was to evaluate the effectiveness of lapatinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-124
34342244-1	2021	BACKGROUND: The aim of this study was to evaluate the effectiveness of lapatinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
34342244-9	2021	Lapatinib could be used as an alternative selection for HER2-positive metastasic breast cancer patients when there is disease progression after trastuzumab or pyrotinib treatment, which is used as part of China"s national health insurance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
35617997-0	2022	Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib.	Lapatinib	71-80	high mobility group box 1	Homo sapiens	10-15
35617997-1	2022	The application of lapatinib, a widely used dual inhibitor of human epidermal growth factor receptor 1 (EGFR/ERBB1) and 2 (HER2/ERBB2), has been seriously limited due to cutaneous toxicity.	Lapatinib	19-28	epidermal growth factor receptor	Homo sapiens	104-108
35617997-1	2022	The application of lapatinib, a widely used dual inhibitor of human epidermal growth factor receptor 1 (EGFR/ERBB1) and 2 (HER2/ERBB2), has been seriously limited due to cutaneous toxicity.	Lapatinib	19-28	epidermal growth factor receptor	Homo sapiens	109-114
34350378-1	2021	Background: We hypothesized that the addition of receptor tyrosine kinase inhibitors (RTKis, e.g., lapatinib, erlotinib, cetuximab, bevacizumab, panitumumab) to radiotherapy-based treatment for solid tumors does not increase overall survival but may increase toxicity.	Lapatinib	99-108	ret proto-oncogene	Homo sapiens	49-73
34272718-4	2021	Specifically, a case is presented in which reduced glutathione (GSH) was included in an experiment with human liver S9 fraction to trap reactive metabolites generated from cytochrome P450-mediated metabolism of lapatinib and its O-dealkylated metabolite, M1 (question 1).	Lapatinib	211-220	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-187
35617997-1	2022	The application of lapatinib, a widely used dual inhibitor of human epidermal growth factor receptor 1 (EGFR/ERBB1) and 2 (HER2/ERBB2), has been seriously limited due to cutaneous toxicity.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
35617997-1	2022	The application of lapatinib, a widely used dual inhibitor of human epidermal growth factor receptor 1 (EGFR/ERBB1) and 2 (HER2/ERBB2), has been seriously limited due to cutaneous toxicity.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-133
35617997-7	2022	Therefore, restoring HMGB1 expression might be an effective remedy against lapatinib-induced cutaneous toxicity.	Lapatinib	75-84	high mobility group box 1	Homo sapiens	21-26
35617997-8	2022	Finally, we found that saikosaponin A could significantly rescue the reduced HMGB1 transcription, which could alleviate lapatinib-induced DNA damage, inhibit keratinocyte apoptosis and further prevent the toxicity of lapatinib in mice.	Lapatinib	120-129	high mobility group box 1	Mus musculus	77-82
35617997-8	2022	Finally, we found that saikosaponin A could significantly rescue the reduced HMGB1 transcription, which could alleviate lapatinib-induced DNA damage, inhibit keratinocyte apoptosis and further prevent the toxicity of lapatinib in mice.	Lapatinib	217-226	high mobility group box 1	Mus musculus	77-82
35390338-0	2022	Inhibition of ABCG2 transporter by lapatinib enhances 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy response in human glioma cell lines.	Lapatinib	35-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	14-19
35390338-8	2022	Our study reveals ABCG2 as an important biological determinant of PpIX fluorescence in glioma cells and suggests ABCG2 inhibition with lapatinib as a promising therapeutic enhancement approach.	Lapatinib	135-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	18-23
35390338-8	2022	Our study reveals ABCG2 as an important biological determinant of PpIX fluorescence in glioma cells and suggests ABCG2 inhibition with lapatinib as a promising therapeutic enhancement approach.	Lapatinib	135-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	113-118
35448925-3	2022	Among them, targeted drugs for HER-2 included trastuzumab, pertuzumab, T-DM1, RC48-ADC, lapatinib, pyrotinib, allitinib, sipatinib, seratinib.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-36
35549881-10	2022	Lapatinib and monoclonal antibodies like trastuzumab have been used for the dual inhibition of ErbB1 and ErbB2 in the treatment of various cancers.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	95-100
35549881-10	2022	Lapatinib and monoclonal antibodies like trastuzumab have been used for the dual inhibition of ErbB1 and ErbB2 in the treatment of various cancers.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-110
35503682-9	2022	Furthermore, HER2 allosteric mutants with enhanced covalent homodimerization were characterized by altered pharmacology that reduces the activity of existing anti-HER2 agents, including the monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib.	Lapatinib	256-265	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
35503682-9	2022	Furthermore, HER2 allosteric mutants with enhanced covalent homodimerization were characterized by altered pharmacology that reduces the activity of existing anti-HER2 agents, including the monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib.	Lapatinib	256-265	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
35572995-11	2022	She was given trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (dual tyrosine kinase inhibitor of the EGFR/HER2 pathway).	Lapatinib	62-71	epidermal growth factor receptor	Homo sapiens	111-115
35572995-11	2022	She was given trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (dual tyrosine kinase inhibitor of the EGFR/HER2 pathway).	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
35014203-9	2022	Lapatinib may decrease the apoptotic effects in cardiomyocytes by altering the effects of trastuzumab on BCL-X proteins.	Lapatinib	0-9	BCL2 like 1	Homo sapiens	105-110
35395805-7	2022	Additionally, the patients with TET1 mutations were found to be more sensitive to lapatinib and 5-fluorouracil.	Lapatinib	82-91	tet methylcytosine dioxygenase 1	Homo sapiens	32-36
35463361-0	2022	Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
35463361-0	2022	Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	73-78
35463361-2	2022	However, whether or not lapatinib (an oral tyrosine kinase inhibitor selective for inhibition of HER2), or a combination of lapatinib and gemcitabine, exerts inhibitory effects on HER2-overexpressed CCA is still unclear.	Lapatinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
35463361-2	2022	However, whether or not lapatinib (an oral tyrosine kinase inhibitor selective for inhibition of HER2), or a combination of lapatinib and gemcitabine, exerts inhibitory effects on HER2-overexpressed CCA is still unclear.	Lapatinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-184
35463361-2	2022	However, whether or not lapatinib (an oral tyrosine kinase inhibitor selective for inhibition of HER2), or a combination of lapatinib and gemcitabine, exerts inhibitory effects on HER2-overexpressed CCA is still unclear.	Lapatinib	124-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-184
35463361-5	2022	The synergistic effect of lapatinib and gemcitabine was interpreted by docking analysis, ABCB1-associated ATPase assay, rhodamine transport assay and LC-MS/MS analyses.	Lapatinib	26-35	ATP binding cassette subfamily B member 1	Homo sapiens	89-94
35463361-8	2022	Lapatinib exerts a dual effect on HER2-overexpressed CCA, suppressing the growth of CCA cells by inhibiting HER2 and HER2-dependent downstream signaling pathways while inhibiting ABCB1 transporter function, allowing for the accumulation of active gemcitabine metabolites within cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
35463361-8	2022	Lapatinib exerts a dual effect on HER2-overexpressed CCA, suppressing the growth of CCA cells by inhibiting HER2 and HER2-dependent downstream signaling pathways while inhibiting ABCB1 transporter function, allowing for the accumulation of active gemcitabine metabolites within cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
35463361-8	2022	Lapatinib exerts a dual effect on HER2-overexpressed CCA, suppressing the growth of CCA cells by inhibiting HER2 and HER2-dependent downstream signaling pathways while inhibiting ABCB1 transporter function, allowing for the accumulation of active gemcitabine metabolites within cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
35463361-8	2022	Lapatinib exerts a dual effect on HER2-overexpressed CCA, suppressing the growth of CCA cells by inhibiting HER2 and HER2-dependent downstream signaling pathways while inhibiting ABCB1 transporter function, allowing for the accumulation of active gemcitabine metabolites within cells.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	179-184
35463361-9	2022	Conclusions: Our data demonstrates that lapatinib can not only inhibit growth of CCA overexpressing HER2, but can also circumvent ABCB1-mediated chemoresistance after gemcitabine treatment.	Lapatinib	40-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
35463361-9	2022	Conclusions: Our data demonstrates that lapatinib can not only inhibit growth of CCA overexpressing HER2, but can also circumvent ABCB1-mediated chemoresistance after gemcitabine treatment.	Lapatinib	40-49	ATP binding cassette subfamily B member 1	Homo sapiens	130-135
35158093-4	2022	To address this, we have undertaken a mass spectrometry approach to identify phosphoproteins specific for ErbB2 using the inhibitors Lapatinib and CP724714 in ovarian cancer cells.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111
35158093-8	2022	The activity of aldose reductase in reducing NADPH as a substrate was significantly higher in EGF stimulated cells which was inhibited by Lapatinib and CP724714 but not by Geftinib (EGFR inhibitor).	Lapatinib	138-147	aldo-keto reductase family 1 member B	Homo sapiens	16-32
35158093-9	2022	MARCKS was phosphorylated on stimulation of SKOV-3 cells with EGF that was inhibited by Lapatinib and CP724714 which was dependent on the kinase activity of ErbB2.	Lapatinib	88-97	myristoylated alanine rich protein kinase C substrate	Homo sapiens	0-6
35158093-9	2022	MARCKS was phosphorylated on stimulation of SKOV-3 cells with EGF that was inhibited by Lapatinib and CP724714 which was dependent on the kinase activity of ErbB2.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-162
35431974-6	2022	Our findings suggest that PTPRO is not only able to serve as an independent prognostic indicator, but upregulating PTPRO can also reverse the lapatinib resistance of ERBB2-positive breast cancer.	Lapatinib	142-151	protein tyrosine phosphatase, receptor type, O	Mus musculus	115-120
35276440-3	2022	METHODS: We conducted a meta-analysis of randomized phase II/III studies testing lapatinib + trastuzumab in combination with neoadjuvant chemotherapy for human epidermal growth factor receptor (HER2)-positive early breast cancer (BC).	Lapatinib	81-90	epidermal growth factor receptor	Homo sapiens	160-192
35276440-3	2022	METHODS: We conducted a meta-analysis of randomized phase II/III studies testing lapatinib + trastuzumab in combination with neoadjuvant chemotherapy for human epidermal growth factor receptor (HER2)-positive early breast cancer (BC).	Lapatinib	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
35431974-0	2022	Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance.	Lapatinib	104-113	protein tyrosine phosphatase receptor type O	Homo sapiens	21-26
35431974-6	2022	Our findings suggest that PTPRO is not only able to serve as an independent prognostic indicator, but upregulating PTPRO can also reverse the lapatinib resistance of ERBB2-positive breast cancer.	Lapatinib	142-151	erb-b2 receptor tyrosine kinase 2	Mus musculus	166-171
35431974-1	2022	Despite the initial benefit from treating ERBB2-positive breast cancer with tyrosine kinase inhibitor lapatinib, resistance develops inevitably.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-47
35270029-4	2022	We hypothesize that treating ER+ letrozole-resistant T47D breast cancer cells (T47DaromLR) with a combination of 10 muM glyceollin and 0.5 muM lapatinib (a dual EGFR/HER2 inhibitor) will decrease cell proliferation through induction of apoptosis.	Lapatinib	143-152	epidermal growth factor receptor	Homo sapiens	161-165
35431974-2	2022	Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs), is inversely correlated with the aggressiveness of multiple malignancies, we decided to explore the correlation between PTPRO and lapatinib resistance in ERBB2-positive breast cancer.	Lapatinib	287-296	protein tyrosine phosphatase receptor type O	Homo sapiens	24-68
35431974-2	2022	Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs), is inversely correlated with the aggressiveness of multiple malignancies, we decided to explore the correlation between PTPRO and lapatinib resistance in ERBB2-positive breast cancer.	Lapatinib	287-296	protein tyrosine phosphatase receptor type O	Homo sapiens	70-75
35431974-2	2022	Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs), is inversely correlated with the aggressiveness of multiple malignancies, we decided to explore the correlation between PTPRO and lapatinib resistance in ERBB2-positive breast cancer.	Lapatinib	287-296	protein tyrosine phosphatase receptor type O	Homo sapiens	277-282
35431974-2	2022	Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs), is inversely correlated with the aggressiveness of multiple malignancies, we decided to explore the correlation between PTPRO and lapatinib resistance in ERBB2-positive breast cancer.	Lapatinib	287-296	erb-b2 receptor tyrosine kinase 2	Homo sapiens	311-316
35356262-4	2022	Specifically, this study investigated the efficacy of pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer (NCT04899128).	Lapatinib	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
35356262-14	2022	Conclusion: Pyrotinib-based therapy has the potential to improve survival in patients with lapatinib-resistant HER2-positive metastatic breast cancer, including those with brain metastases.	Lapatinib	91-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
35270029-4	2022	We hypothesize that treating ER+ letrozole-resistant T47D breast cancer cells (T47DaromLR) with a combination of 10 muM glyceollin and 0.5 muM lapatinib (a dual EGFR/HER2 inhibitor) will decrease cell proliferation through induction of apoptosis.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
35182693-5	2022	In HepG2 cells, lapatinib and imatinib raised the lysosomal pH and destabilized the lysosomal membrane, thereby impairing lysosomal proteolytic activity such as cathepsin B processing.	Lapatinib	16-25	cathepsin B	Homo sapiens	161-172
35267416-6	2022	The overexpression or chronic lapatinib-induced upregulation of AnxA6 in AnxA6-low TNBC cells reversed the quiescent/lypolytic phenotype to a more lipogenic/glycolytic phenotype with gluconeogenic precursors as additional metabolites.	Lapatinib	30-39	annexin A6	Homo sapiens	64-69
35267416-6	2022	The overexpression or chronic lapatinib-induced upregulation of AnxA6 in AnxA6-low TNBC cells reversed the quiescent/lypolytic phenotype to a more lipogenic/glycolytic phenotype with gluconeogenic precursors as additional metabolites.	Lapatinib	30-39	annexin A6	Homo sapiens	73-78
35216393-11	2022	Lapatinib was identified as a potent drug for LUAD in the context of low KCNQ1.	Lapatinib	0-9	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	73-78
35248133-4	2022	METHODS: We performed siRNA knockdown screens of genes differentially expressed between lapatinib-responsive and -resistant HER2+ breast cancer cells, which corresponded largely to luminal versus basal subtypes.	Lapatinib	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	124-128
35248133-6	2022	RESULTS: Knockdown of one of the genes, INHBA, significantly slowed growth and increased sensitivity to lapatinib in multiple basal HER2+ cell lines in both 2-d and 3-d cultures, but had no effect in luminal HER2+ cells.	Lapatinib	104-113	inhibin subunit beta A	Homo sapiens	40-45
35248133-6	2022	RESULTS: Knockdown of one of the genes, INHBA, significantly slowed growth and increased sensitivity to lapatinib in multiple basal HER2+ cell lines in both 2-d and 3-d cultures, but had no effect in luminal HER2+ cells.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
35177646-7	2022	Inhibition of either ErbB2 with lapatinib as a tyrosine kinase inhibitor or ErbB3 with TX1-85-1 or siRNAs arrested cell proliferation, inhibited the in vitro tumorigenicity, and lead to loss of stemness in the converting cells.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-26
35173243-5	2022	In our study, it was shown the micelles modified with Angiopep-2 had high loading efficiency of paclitaxel and lapatinib (Ang-MIC-PTX/LP).	Lapatinib	111-120	angiogenin	Homo sapiens	122-125
34898356-0	2022	Lapatinib induces mitochondrial dysfunction to enhance oxidative stress and ferroptosis in doxorubicin-induced cardiomyocytes via inhibition of PI3K/Akt signaling pathway.	Lapatinib	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	149-152
35159006-8	2022	Lastly, we found that the PRCP inhibitor caused synergistic killing of TNBC cells when combined with the EGFR and ErbB2 inhibitor lapatinib.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
35144424-4	2022	We investigated the efficacy of pyrotinib, a new irreversible tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor, HER2, and HER4, in lapatinib-resistant HER2-positive MBC patients.	Lapatinib	157-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
35144424-5	2022	METHODS: This is a retrospective observational study including lapatinib-resistant HER2-positive MBC patients who received pyrotinib-based treatment.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
35046829-0	2021	Corrigendum: Neuroprotective Effects of the Anti-Cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis.	Lapatinib	61-70	glutathione peroxidase 4	Homo sapiens	114-138
33727095-5	2021	Hence, this study aims to explore the molecular signaling pathways and the efficacy of treatment with lapatinib ditosylate (LAP), as one of EGFR-TKIs that has not yet been investigated in AD, on cognitive decline induced by ovariectomy (OVX) with chronic administration of D-galactose (D-gal) in female Wistar albino rats.	Lapatinib	102-122	epidermal growth factor receptor	Rattus norvegicus	140-144
33727095-5	2021	Hence, this study aims to explore the molecular signaling pathways and the efficacy of treatment with lapatinib ditosylate (LAP), as one of EGFR-TKIs that has not yet been investigated in AD, on cognitive decline induced by ovariectomy (OVX) with chronic administration of D-galactose (D-gal) in female Wistar albino rats.	Lapatinib	124-127	epidermal growth factor receptor	Rattus norvegicus	140-144
33982768-0	2021	[Corrigendum] Lapatinib-induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro.	Lapatinib	14-23	signal transducer and activator of transcription 3	Homo sapiens	86-91
33735711-6	2021	The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM).	Lapatinib	167-176	epidermal growth factor receptor	Homo sapiens	87-91
34045483-1	2021	Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
34035375-3	2021	We report that responsive HER2 + breast cancer cell lines had a higher number of miRNAs with altered expression after treatment with trastuzumab and lapatinib compared to poorly responsive cell lines.	Lapatinib	149-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
34035375-4	2021	To evaluate whether miRNAs can sensitize HER2 + cells to treatment, we performed a high-throughput screen of 1626 miRNA mimics and inhibitors in combination with trastuzumab and lapatinib in HER2 + breast cancer cells.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-195
34034468-8	2021	Lapatinib, a small-molecule HER inhibitor similar to neratinib, has shown some effects on the treatment of HR-positive and HER-2 positive patients with advanced breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
33980863-3	2021	HER2+ cell line responses to inhibition with lapatinib were analyzed by RNAseq and ChIPseq to characterize transcriptional and epigenetic changes.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
33980863-4	2021	Motif analysis of lapatinib-responsive genomic regions implicated the pioneer transcription factor FOXA1 as a mediator of adaptive responses.	Lapatinib	18-27	forkhead box A1	Homo sapiens	99-104
33980863-5	2021	Lapatinib in combination with FOXA1 depletion led to dysregulation of enhancers, impaired adaptive upregulation of HER3, and decreased proliferation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 3	Homo sapiens	115-119
33951110-1	2021	Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2.	Lapatinib	107-116	BCL2 apoptosis regulator	Homo sapiens	39-44
33951110-1	2021	Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2.	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-144
33951110-3	2021	We detected BCL2 mRNA upregulation in both HER2+/ER- as well as HER2+/ER+ patient tumors treated with lapatinib or trastuzumab.	Lapatinib	102-111	BCL2 apoptosis regulator	Homo sapiens	12-16
33951110-3	2021	We detected BCL2 mRNA upregulation in both HER2+/ER- as well as HER2+/ER+ patient tumors treated with lapatinib or trastuzumab.	Lapatinib	102-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
33951110-6	2021	BCL-2 upregulation was evident within the majority of lapatinib-treated HER2+/ER+ tumors and was often coupled with increased ER expression and decreased proliferation.	Lapatinib	54-63	BCL2 apoptosis regulator	Homo sapiens	0-5
33951110-6	2021	BCL-2 upregulation was evident within the majority of lapatinib-treated HER2+/ER+ tumors and was often coupled with increased ER expression and decreased proliferation.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
33951110-6	2021	BCL-2 upregulation was evident within the majority of lapatinib-treated HER2+/ER+ tumors and was often coupled with increased ER expression and decreased proliferation.	Lapatinib	54-63	epiregulin	Homo sapiens	73-75
33951110-6	2021	BCL-2 upregulation was evident within the majority of lapatinib-treated HER2+/ER+ tumors and was often coupled with increased ER expression and decreased proliferation.	Lapatinib	54-63	epiregulin	Homo sapiens	78-80
33951110-8	2021	Together, these results provide clinical validation of the BCL-2 induction associated with the adaptive response to lapatinib and support evaluation of BCL-2 inhibitors within the context of lapatinib and other HER2-targeted receptor tyrosine kinase inhibitors.	Lapatinib	116-125	BCL2 apoptosis regulator	Homo sapiens	59-64
34016991-2	2021	Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib.	Lapatinib	125-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
33652033-7	2021	Furthermore, inhibition of ErbB2 phosphorylation with lapatinib in CMECs revealed that QLQX-induced downregulation of Ang II-activated autophagy and apoptosis was ErbB2 phosphorylation-dependent via the AKT-FoxO3a axis.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-32
33957015-7	2021	To prevent the progression, lapatinib and vinorelbine were reintroduced and transient increases in alanine aminotransferase and gamma-glutamyl transpeptidase were observed.	Lapatinib	28-37	glutamic--pyruvic transaminase	Homo sapiens	99-123
33957015-7	2021	To prevent the progression, lapatinib and vinorelbine were reintroduced and transient increases in alanine aminotransferase and gamma-glutamyl transpeptidase were observed.	Lapatinib	28-37	inactive glutathione hydrolase 2	Homo sapiens	128-157
33939112-6	2021	Using 2nd line HER2 inhibitor lapatinib resistant 3-dimensional model systems, we assessed the effects of the drugs on ErbB2 positive breast cancer spheroids and developed a high-throughput invasion assay for HER2 positive ovarian cancer organoids for further evaluation.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
33939112-7	2021	RESULTS: We identified Auranofin, Colchicine, Monensin, Niclosamide, Podophyllotoxin, Quinacrine and Thiostrepton as efficient inhibitors of invasive growth of 2nd line HER2 inhibitor lapatinib resistant breast cancer spheroids and ovarian cancer organoids.	Lapatinib	184-193	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
33928964-2	2021	In this study we demonstrate the potential of SEIRA microscopy for highlighting the very subtle secondary structure modifications associated with the binding of Lapatinib, a tyrosine kinase inhibitor (TKI), to epidermal growth factor receptor (EGFR), a well-known driver of tumorigenesis in pathological settings such as lung, breast and brain cancers.	Lapatinib	161-170	epidermal growth factor receptor	Homo sapiens	210-242
33862249-4	2021	Trastuzumab-based therapy has long been the mainstay of systemic therapy and over the last two decades other HER2-targeted agents including lapatinib, pertuzumab and trastuzumab emtansine, have been introduced in the clinical practice.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
33514658-6	2021	Neutralization of ERBB2 signaling with ERBB2 tyrosine kinase inhibitors (i.e., lapatinib, afatinib, and neratinib) increases apoptotic cell death and reduces human engraftment of MDS cells in mice at 21 weeks post-transplantation.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-23
33514658-6	2021	Neutralization of ERBB2 signaling with ERBB2 tyrosine kinase inhibitors (i.e., lapatinib, afatinib, and neratinib) increases apoptotic cell death and reduces human engraftment of MDS cells in mice at 21 weeks post-transplantation.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44
33933113-8	2021	All HER2-positive cell lines except SNU16 were sensitive to lapatinib (IC50s 0.04 microM-1.5 microM).	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
33928964-2	2021	In this study we demonstrate the potential of SEIRA microscopy for highlighting the very subtle secondary structure modifications associated with the binding of Lapatinib, a tyrosine kinase inhibitor (TKI), to epidermal growth factor receptor (EGFR), a well-known driver of tumorigenesis in pathological settings such as lung, breast and brain cancers.	Lapatinib	161-170	epidermal growth factor receptor	Homo sapiens	244-248
33857297-3	2021	This project, namely "PathTurbEr" (Pathway Perturbation Driver) uses the GE dataset derived from the lapatinib (an EGFR/HER dual inhibitor) sensitive and resistant samples from breast cancer cell lines (SKBR3).	Lapatinib	101-110	epidermal growth factor receptor	Homo sapiens	115-119
33607208-6	2021	We found that the UbcH5b-p62 axis confers TNBC cells resistance to lapatinib by promoting autophagy.	Lapatinib	67-76	nucleoporin 62	Mus musculus	25-28
33907275-6	2021	We observed the lapatinib-induced compensatory upregulation of HER3 signaling in many types of HER2-amplified cancers, although with much variability.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 3	Homo sapiens	63-67
33907275-6	2021	We observed the lapatinib-induced compensatory upregulation of HER3 signaling in many types of HER2-amplified cancers, although with much variability.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
33919468-7	2021	Altogether, our results suggested that anti-HER2 mAbs could become useful in the treatment of FMC, particularly, if combined with lapatinib, since drug-resistance seems to be rare.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
33857297-4	2021	Differential expression analysis revealed 512 differentially expressed genes (DEGs) and their pathway enrichment revealed 13 highly perturbed singalling pathways in lapatinib resistance, including PI3K-AKT, Chemokine, Hippo and TGF-$\beta $ singalling pathways.	Lapatinib	165-174	AKT serine/threonine kinase 1	Homo sapiens	202-205
33857297-4	2021	Differential expression analysis revealed 512 differentially expressed genes (DEGs) and their pathway enrichment revealed 13 highly perturbed singalling pathways in lapatinib resistance, including PI3K-AKT, Chemokine, Hippo and TGF-$\beta $ singalling pathways.	Lapatinib	165-174	transforming growth factor alpha	Homo sapiens	228-238
33398673-9	2021	Additional gene expression studies indicated that co-targeting the EGFR and Wnt/beta-catenin pathways with lapatinib and XAV939 (a tankyrase inhibitor) promoted mesenchymal to epithelial transition (MET).	Lapatinib	107-116	epidermal growth factor receptor	Homo sapiens	67-71
33398673-9	2021	Additional gene expression studies indicated that co-targeting the EGFR and Wnt/beta-catenin pathways with lapatinib and XAV939 (a tankyrase inhibitor) promoted mesenchymal to epithelial transition (MET).	Lapatinib	107-116	catenin beta 1	Homo sapiens	80-92
33398673-9	2021	Additional gene expression studies indicated that co-targeting the EGFR and Wnt/beta-catenin pathways with lapatinib and XAV939 (a tankyrase inhibitor) promoted mesenchymal to epithelial transition (MET).	Lapatinib	107-116	SAFB like transcription modulator	Homo sapiens	199-202
33785053-9	2021	Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
33795761-5	2021	Novel drug-transporter interactions were discovered, such as lapatinib and gefitinib with ABCA1, olaparib and NVPADW742 with ABCC3, and gefitinib and AZ628 with SLC4A4.	Lapatinib	61-70	ATP binding cassette subfamily A member 1	Homo sapiens	90-95
33795761-5	2021	Novel drug-transporter interactions were discovered, such as lapatinib and gefitinib with ABCA1, olaparib and NVPADW742 with ABCC3, and gefitinib and AZ628 with SLC4A4.	Lapatinib	61-70	ATP binding cassette subfamily C member 3	Homo sapiens	125-130
33795761-5	2021	Novel drug-transporter interactions were discovered, such as lapatinib and gefitinib with ABCA1, olaparib and NVPADW742 with ABCC3, and gefitinib and AZ628 with SLC4A4.	Lapatinib	61-70	solute carrier family 4 member 4	Homo sapiens	161-167
33785053-10	2021	After RANKL stimulation, lapatinib-resistant cells show increased NF-kappaB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer.	Lapatinib	25-34	TNF superfamily member 11	Homo sapiens	6-11
33785053-10	2021	After RANKL stimulation, lapatinib-resistant cells show increased NF-kappaB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer.	Lapatinib	25-34	nuclear factor kappa B subunit 1	Homo sapiens	66-75
33785053-10	2021	After RANKL stimulation, lapatinib-resistant cells show increased NF-kappaB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer.	Lapatinib	25-34	TNF superfamily member 11	Homo sapiens	6-10
33785053-10	2021	After RANKL stimulation, lapatinib-resistant cells show increased NF-kappaB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	195-199
33785053-11	2021	Overactivation of the RANK signaling pathway enhances ERK and NF-kappaB signaling and increases lapatinib resistance in different HER2-positive breast cancer cell lines, whereas RANK loss sensitizes lapatinib-resistant cells to the drug.	Lapatinib	96-105	TNF superfamily member 11	Homo sapiens	22-26
33785053-11	2021	Overactivation of the RANK signaling pathway enhances ERK and NF-kappaB signaling and increases lapatinib resistance in different HER2-positive breast cancer cell lines, whereas RANK loss sensitizes lapatinib-resistant cells to the drug.	Lapatinib	199-208	TNF superfamily member 11	Homo sapiens	178-182
33785053-15	2021	CONCLUSIONS: Our data support a physical and functional link between RANK and HER2 signaling in breast cancer and demonstrate that increased RANK signaling may contribute to the development of lapatinib resistance through NF-kappaB activation.	Lapatinib	193-202	TNF superfamily member 11	Homo sapiens	141-145
33785053-15	2021	CONCLUSIONS: Our data support a physical and functional link between RANK and HER2 signaling in breast cancer and demonstrate that increased RANK signaling may contribute to the development of lapatinib resistance through NF-kappaB activation.	Lapatinib	193-202	nuclear factor kappa B subunit 1	Homo sapiens	222-231
33785053-9	2021	Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells.	Lapatinib	181-190	TNF superfamily member 11	Homo sapiens	105-109
33785053-9	2021	Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
33785053-9	2021	Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
33785053-9	2021	Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells.	Lapatinib	224-233	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
33473169-2	2021	The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive breast cancer.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
33755862-6	2021	The dual-HER2 blockade with trastuzumab plus either pertuzumab or lapatinib led to complete and durable responses in 5 (62.5%) out of 8 models, including one tumor bearing a concomitant HER2 mutation.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
33755862-6	2021	The dual-HER2 blockade with trastuzumab plus either pertuzumab or lapatinib led to complete and durable responses in 5 (62.5%) out of 8 models, including one tumor bearing a concomitant HER2 mutation.	Lapatinib	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	186-190
33742063-2	2021	We here investigate changes in tumour-immune contexture, as assessed by stromal tumour-infiltrating lymphocytes (sTILs) and by multiplexed spatial cellular phenotyping, during treatment with lapatinib-trastuzumab in HER2+ BC patients (PAMELA trial).	Lapatinib	191-200	erb-b2 receptor tyrosine kinase 2	Homo sapiens	216-220
33936677-0	2021	Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma.	Lapatinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
33842315-11	2021	A functional role of STEAP4 intervention was established in HER2 overexpressing BC by pharmacological studies, where blockage of the STEAP4 pathway with an iron chelator (Deferiprone) in combination with the HER2 inhibitor Lapatinib led to a significant reduction in cell growth in vitro.	Lapatinib	223-232	STEAP4 metalloreductase	Homo sapiens	21-27
33842315-11	2021	A functional role of STEAP4 intervention was established in HER2 overexpressing BC by pharmacological studies, where blockage of the STEAP4 pathway with an iron chelator (Deferiprone) in combination with the HER2 inhibitor Lapatinib led to a significant reduction in cell growth in vitro.	Lapatinib	223-232	erb-b2 receptor tyrosine kinase 2	Homo sapiens	208-212
33842315-12	2021	Furthermore, siRNA mediated knockdown of STEAP4 also suppressed cell proliferation and enhanced the inhibition of Lapatinib in HER2 overexpressing BC, confirming its potential oncogenic role in BC.	Lapatinib	114-123	STEAP4 metalloreductase	Homo sapiens	41-47
33842315-12	2021	Furthermore, siRNA mediated knockdown of STEAP4 also suppressed cell proliferation and enhanced the inhibition of Lapatinib in HER2 overexpressing BC, confirming its potential oncogenic role in BC.	Lapatinib	114-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
33085768-2	2021	The Collaborative Ependymoma Research Network (CERN) conducted a prospective phase II clinical trial of dose-dense temozolomide and lapatinib, targeting the unmethylated MGMT promoter status and increased expression of ErbB2 (HER2) and ErbB1 (EGFR) in ependymomas.	Lapatinib	132-141	O-6-methylguanine-DNA methyltransferase	Homo sapiens	170-174
33085768-2	2021	The Collaborative Ependymoma Research Network (CERN) conducted a prospective phase II clinical trial of dose-dense temozolomide and lapatinib, targeting the unmethylated MGMT promoter status and increased expression of ErbB2 (HER2) and ErbB1 (EGFR) in ependymomas.	Lapatinib	132-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	219-224
33085768-2	2021	The Collaborative Ependymoma Research Network (CERN) conducted a prospective phase II clinical trial of dose-dense temozolomide and lapatinib, targeting the unmethylated MGMT promoter status and increased expression of ErbB2 (HER2) and ErbB1 (EGFR) in ependymomas.	Lapatinib	132-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	226-230
33085768-2	2021	The Collaborative Ependymoma Research Network (CERN) conducted a prospective phase II clinical trial of dose-dense temozolomide and lapatinib, targeting the unmethylated MGMT promoter status and increased expression of ErbB2 (HER2) and ErbB1 (EGFR) in ependymomas.	Lapatinib	132-141	epidermal growth factor receptor	Homo sapiens	236-241
33085768-2	2021	The Collaborative Ependymoma Research Network (CERN) conducted a prospective phase II clinical trial of dose-dense temozolomide and lapatinib, targeting the unmethylated MGMT promoter status and increased expression of ErbB2 (HER2) and ErbB1 (EGFR) in ependymomas.	Lapatinib	132-141	epidermal growth factor receptor	Homo sapiens	243-247
33376146-0	2021	Detoxication vs. Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib.	Lapatinib	43-52	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	63-69
33376146-0	2021	Detoxication vs. Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib.	Lapatinib	124-133	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	63-69
33376146-4	2021	In the present study, reaction phenotyping experiments using human recombinant UGT enzymes and enzyme-selective chemical inhibitors demonstrated that UGT1A1 was the major hepatic UGT enzyme involved in lapatinib M1 glucuronidation.	Lapatinib	202-211	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	79-82
33376146-4	2021	In the present study, reaction phenotyping experiments using human recombinant UGT enzymes and enzyme-selective chemical inhibitors demonstrated that UGT1A1 was the major hepatic UGT enzyme involved in lapatinib M1 glucuronidation.	Lapatinib	202-211	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	150-156
33376146-4	2021	In the present study, reaction phenotyping experiments using human recombinant UGT enzymes and enzyme-selective chemical inhibitors demonstrated that UGT1A1 was the major hepatic UGT enzyme involved in lapatinib M1 glucuronidation.	Lapatinib	202-211	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	150-153
33376146-11	2021	In addition to P450-mediated bioactivation, we report that multiple non-P450 pathways are involved in the biotransformation of the primary phenolic metabolite of lapatinib in vitro, including glucuronidation, sulfation, and aldehyde oxidase-mediated oxidation.	Lapatinib	162-171	aldehyde oxidase 1	Homo sapiens	224-240
33376146-12	2021	UGT1A1 was identified as the major hepatic enzyme involved in lapatinib M1 glucuronidation, which may limit hepatic exposure to the potentially toxic quinoneimine.	Lapatinib	62-71	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
33559918-2	2021	Some HER2 mutations are activating, and they represent a mechanism of resistance to conventional anti-HER2 therapies such as trastuzumab and lapatinib.	Lapatinib	141-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
33429148-3	2021	RESULTS: We identified that CDK12, co-amplified with HER2 in a high frequency, is powerful to sensitise or resensitise HER2-positive breast cancer to anti-HER2 TKIs lapatinib, evidenced by patient-derived organoids in vitro and cell-derived xenograft or patient-derived xenograft in vivo.	Lapatinib	165-174	cyclin dependent kinase 12	Homo sapiens	28-33
33429148-3	2021	RESULTS: We identified that CDK12, co-amplified with HER2 in a high frequency, is powerful to sensitise or resensitise HER2-positive breast cancer to anti-HER2 TKIs lapatinib, evidenced by patient-derived organoids in vitro and cell-derived xenograft or patient-derived xenograft in vivo.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
33429148-3	2021	RESULTS: We identified that CDK12, co-amplified with HER2 in a high frequency, is powerful to sensitise or resensitise HER2-positive breast cancer to anti-HER2 TKIs lapatinib, evidenced by patient-derived organoids in vitro and cell-derived xenograft or patient-derived xenograft in vivo.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
33429148-3	2021	RESULTS: We identified that CDK12, co-amplified with HER2 in a high frequency, is powerful to sensitise or resensitise HER2-positive breast cancer to anti-HER2 TKIs lapatinib, evidenced by patient-derived organoids in vitro and cell-derived xenograft or patient-derived xenograft in vivo.	Lapatinib	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
33429148-4	2021	Exploring mechanisms, we found that inhibition of CDK12 attenuated PI3K/AKT signal, which usually serves as an oncogenic driver and is reactivated when HER2-positive breast cancers develop resistance to lapatinib.	Lapatinib	203-212	cyclin dependent kinase 12	Homo sapiens	50-55
33429148-4	2021	Exploring mechanisms, we found that inhibition of CDK12 attenuated PI3K/AKT signal, which usually serves as an oncogenic driver and is reactivated when HER2-positive breast cancers develop resistance to lapatinib.	Lapatinib	203-212	AKT serine/threonine kinase 1	Homo sapiens	72-75
33429148-5	2021	Combining CDK12 inhibition exerted additional suppression on p-AKT activation induced by anti-HER2 TKIs lapatinib treatment.	Lapatinib	104-113	cyclin dependent kinase 12	Homo sapiens	10-15
33429148-5	2021	Combining CDK12 inhibition exerted additional suppression on p-AKT activation induced by anti-HER2 TKIs lapatinib treatment.	Lapatinib	104-113	AKT serine/threonine kinase 1	Homo sapiens	63-66
33429148-5	2021	Combining CDK12 inhibition exerted additional suppression on p-AKT activation induced by anti-HER2 TKIs lapatinib treatment.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
33574423-2	2021	Lapatinib, an FDA-approved drug for cancer treatment, has recently been identified as an mPGES-1 inhibitor.	Lapatinib	0-9	prostaglandin E synthase	Mus musculus	89-96
33559918-2	2021	Some HER2 mutations are activating, and they represent a mechanism of resistance to conventional anti-HER2 therapies such as trastuzumab and lapatinib.	Lapatinib	141-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
33559918-8	2021	A case of de novo metastatic breast cancer harboring both HER2 amplification and the L755S mutation in an untreated breast primary tumor displayed clinical resistance to standard trastuzumab- or lapatinib-based therapies but good responses to T-DM1 and T-DXd.	Lapatinib	195-204	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
33150390-0	2021	EGFR/ErbB2 targeting lapatinib therapy for aggressive prolactinomas.	Lapatinib	21-30	epidermal growth factor receptor	Homo sapiens	0-4
33122343-3	2021	Using clinical data, we examined the impact of lapatinib on HER2/EGFR expression levels and NK cell gene signatures.	Lapatinib	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
33122343-3	2021	Using clinical data, we examined the impact of lapatinib on HER2/EGFR expression levels and NK cell gene signatures.	Lapatinib	47-56	epidermal growth factor receptor	Homo sapiens	65-69
33122343-4	2021	We investigated the ability of three TKIs (lapatinib, afatinib, neratinib) to alter HER2/immune-related protein levels in pre-clinical models of HER2+ and HER2-low breast cancer, and the subsequent effects on trastuzumab/pertuzumab-mediated ADCC.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
33122343-9	2021	RESULTS: Lapatinib significantly increased membrane HER2 levels, while afatinib and neratinib significantly decreased levels in all pre-clinical models.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
33122343-10	2021	Single agent lapatinib increased HER2 or EGFR levels in 10/11 (91%) tumor samples.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
33122343-10	2021	Single agent lapatinib increased HER2 or EGFR levels in 10/11 (91%) tumor samples.	Lapatinib	13-22	epidermal growth factor receptor	Homo sapiens	41-45
33492449-8	2021	RESULTS: FaDu cells pretreated with MRP1 inhibitors exhibited significantly higher radioactivity than those without inhibitor treatment (cyclosporine A: 6.91 +- 0.27, lapatinib: 10.03 +- 0.47, MK-571: 10.15 +- 0.44%dose/mg protein, p < 0.01).	Lapatinib	167-176	ATP binding cassette subfamily C member 1	Homo sapiens	36-40
33492449-9	2021	In the in vivo PET study, the SUVmean ratio in tumors [calculated as after treatment (2nd PET scan)/before treatment of MRP1 inhibitors (1st PET scan)] of the mice treated with MRP1 inhibitors was significantly higher than those of control mice (cyclosporine A: 2.6 +- 0.7, lapatinib: 2.2 +- 0.7, MK-571: 2.2 +- 0.7, control: 1.2 +- 0.2, p < 0.05).	Lapatinib	274-283	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	120-124
33492449-9	2021	In the in vivo PET study, the SUVmean ratio in tumors [calculated as after treatment (2nd PET scan)/before treatment of MRP1 inhibitors (1st PET scan)] of the mice treated with MRP1 inhibitors was significantly higher than those of control mice (cyclosporine A: 2.6 +- 0.7, lapatinib: 2.2 +- 0.7, MK-571: 2.2 +- 0.7, control: 1.2 +- 0.2, p < 0.05).	Lapatinib	274-283	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	177-181
33259822-8	2021	By a structure-activity relationship study, we found that SOD1 decreased the formation of quinoneimines from flufenamic acid and tolfenamic acid, but did not affect those produced from acetaminophen, amodiaquine, diclofenac, and lapatinib.	Lapatinib	229-238	superoxide dismutase 1	Homo sapiens	58-62
33150390-0	2021	EGFR/ErbB2 targeting lapatinib therapy for aggressive prolactinomas.	Lapatinib	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-10
32585059-1	2020	Lapatinib (LAP) is an anticancer drug, which is metabolized to the N- and O-dealkylated products (N-LAP and O-LAP, respectively).	Lapatinib	0-9	LAP	Homo sapiens	11-14
33569405-12	2021	Conclusions: The results of this study suggest that patients with HER2-positive MBC with trastuzumab and lapatinib failure can benefit from subsequent pyrotinib treatment and tolerate this treatment well, especially those who have benefited from previous lapatinib treatment or those who have no liver metastasis.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
33569405-12	2021	Conclusions: The results of this study suggest that patients with HER2-positive MBC with trastuzumab and lapatinib failure can benefit from subsequent pyrotinib treatment and tolerate this treatment well, especially those who have benefited from previous lapatinib treatment or those who have no liver metastasis.	Lapatinib	255-264	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
33069758-9	2021	Furthermore, suppression of expression or activation of VGLL1 enhances the therapeutic effects of lapatinib.	Lapatinib	98-107	vestigial like family member 1	Homo sapiens	56-61
33314925-0	2020	HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
33314925-0	2020	HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
33362556-0	2020	Neuroprotective Effects of the Anti-cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis.	Lapatinib	48-57	glutathione peroxidase 4	Mus musculus	101-125
33362556-8	2020	In the ferroptotic cell death model, lapatinib exerted neuroprotection via restoring glutathione peroxidase 4 (GPX4).	Lapatinib	37-46	glutathione peroxidase 4	Mus musculus	85-109
33362556-8	2020	In the ferroptotic cell death model, lapatinib exerted neuroprotection via restoring glutathione peroxidase 4 (GPX4).	Lapatinib	37-46	glutathione peroxidase 4	Mus musculus	111-115
33362556-10	2020	In a mouse model of KA-triggered seizure, it was also validated that lapatinib blocked GPX4-dependent ferroptosis.	Lapatinib	69-78	glutathione peroxidase 4	Mus musculus	87-91
33362556-11	2020	It is concluded that lapatinib has neuroprotective potential against epileptic seizures via suppressing GPX4-mediated ferroptosis.	Lapatinib	21-30	glutathione peroxidase 4	Mus musculus	104-108
32815004-3	2021	Although hepatotoxicity is its main side effect, it makes sense to investigate the ability of LAP to induce photosensitivity reactions bearing in mind that BRAF (serine/threonine-protein kinase B-Raf) inhibitors display a considerable phototoxic potential and that afloqualone, a quinazoline-marketed drug, causes photodermatosis.	Lapatinib	94-97	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	156-160
32815004-3	2021	Although hepatotoxicity is its main side effect, it makes sense to investigate the ability of LAP to induce photosensitivity reactions bearing in mind that BRAF (serine/threonine-protein kinase B-Raf) inhibitors display a considerable phototoxic potential and that afloqualone, a quinazoline-marketed drug, causes photodermatosis.	Lapatinib	94-97	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	162-199
33371069-5	2020	Both lapatinib and pyrotinib potentially target EGFR and/or HER2, but in some instances, induces different responses of patients with EGFR and/or HER2 mutations.	Lapatinib	5-14	epidermal growth factor receptor	Homo sapiens	48-52
33371069-5	2020	Both lapatinib and pyrotinib potentially target EGFR and/or HER2, but in some instances, induces different responses of patients with EGFR and/or HER2 mutations.	Lapatinib	5-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
33371069-5	2020	Both lapatinib and pyrotinib potentially target EGFR and/or HER2, but in some instances, induces different responses of patients with EGFR and/or HER2 mutations.	Lapatinib	5-14	epidermal growth factor receptor	Homo sapiens	134-138
33371069-5	2020	Both lapatinib and pyrotinib potentially target EGFR and/or HER2, but in some instances, induces different responses of patients with EGFR and/or HER2 mutations.	Lapatinib	5-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
33371069-27	2020	CONCLUSION: This case report demonstrates that EGFR-ZNF880 fusion and EGFR E114K mutations may contribute or lead to the formation of a special HER2 dimer, which is rapidly resistant to lapatinib but sensitive to pyrotinib.	Lapatinib	186-195	epidermal growth factor receptor	Homo sapiens	47-51
33371069-27	2020	CONCLUSION: This case report demonstrates that EGFR-ZNF880 fusion and EGFR E114K mutations may contribute or lead to the formation of a special HER2 dimer, which is rapidly resistant to lapatinib but sensitive to pyrotinib.	Lapatinib	186-195	zinc finger protein 880	Homo sapiens	52-58
33371069-27	2020	CONCLUSION: This case report demonstrates that EGFR-ZNF880 fusion and EGFR E114K mutations may contribute or lead to the formation of a special HER2 dimer, which is rapidly resistant to lapatinib but sensitive to pyrotinib.	Lapatinib	186-195	epidermal growth factor receptor	Homo sapiens	70-74
33371069-27	2020	CONCLUSION: This case report demonstrates that EGFR-ZNF880 fusion and EGFR E114K mutations may contribute or lead to the formation of a special HER2 dimer, which is rapidly resistant to lapatinib but sensitive to pyrotinib.	Lapatinib	186-195	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
33087324-7	2020	Strikingly, the combinatorial treatment with Lapatinib (dual kinase inhibitor of EGFR (ERBB1) and ERBB2) and Thiostrepton (FOXM1 inhibitor) reduced growth and peritoneal spread of ovarian cancer cells more effectively than either single agent treatment in vivo.	Lapatinib	45-54	epidermal growth factor receptor	Homo sapiens	81-85
33087324-7	2020	Strikingly, the combinatorial treatment with Lapatinib (dual kinase inhibitor of EGFR (ERBB1) and ERBB2) and Thiostrepton (FOXM1 inhibitor) reduced growth and peritoneal spread of ovarian cancer cells more effectively than either single agent treatment in vivo.	Lapatinib	45-54	epidermal growth factor receptor	Homo sapiens	87-92
33087324-7	2020	Strikingly, the combinatorial treatment with Lapatinib (dual kinase inhibitor of EGFR (ERBB1) and ERBB2) and Thiostrepton (FOXM1 inhibitor) reduced growth and peritoneal spread of ovarian cancer cells more effectively than either single agent treatment in vivo.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
32585059-1	2020	Lapatinib (LAP) is an anticancer drug, which is metabolized to the N- and O-dealkylated products (N-LAP and O-LAP, respectively).	Lapatinib	0-9	LAP	Homo sapiens	98-103
32585059-1	2020	Lapatinib (LAP) is an anticancer drug, which is metabolized to the N- and O-dealkylated products (N-LAP and O-LAP, respectively).	Lapatinib	0-9	LAP	Homo sapiens	100-103
33447230-5	2020	Accepted options include treatment with trastuzumab beyond progression, in combination with a broad variety of single-agent chemotherapies used sequentially, or lapatinib (an HER2-targeting tyrosine kinase inhibitor [TKI]) in combination with either trastuzu-mab or capecitabine.	Lapatinib	161-170	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
33154776-0	2020	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
32919890-0	2020	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
32919890-1	2020	BACKGROUND: ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab.	Lapatinib	202-211	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-17
32919890-1	2020	BACKGROUND: ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab.	Lapatinib	202-211	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
33154776-1	2020	The aim of the present study was to determine the efficacy and safety of lapatinib-based treatment for patients with human epidermal growth factor receptor-2-positive (HER2+) metastatic breast cancer (MBC).	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-157
33154776-1	2020	The aim of the present study was to determine the efficacy and safety of lapatinib-based treatment for patients with human epidermal growth factor receptor-2-positive (HER2+) metastatic breast cancer (MBC).	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-172
33154776-2	2020	The aim of the present real-world study was to investigate the medical records and follow-up information of 92 patients with HER2+ MBC who received a lapatinib-based regimen at the recurrent/metastatic stage, 78 of whom had been pretreated with trastuzumab.	Lapatinib	150-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
33154776-8	2020	Multivariate analysis revealed that the line of lapatinib-based treatment and its combination with capecitabine or a different agent were independent prognostic factors for the median PFS in patients with HER2+ MBC.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
33154776-10	2020	Therefore, the findings of the present study suggested that lapatinib-based treatment is effective in patients with HER2+ MBC (even in trastuzumab-pretreated patients), and the combination of lapatinib with capecitabine may be recommended due to its good efficacy, convenience and tolerability.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
33147005-0	2020	Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization.	Lapatinib	135-144	ATP binding cassette subfamily B member 1	Homo sapiens	10-24
33222246-12	2021	CM272 markedly reduced CCA cells proliferation and synergized with Cisplatin and the ERBB-targeted inhibitor Lapatinib.	Lapatinib	109-118	epidermal growth factor receptor	Homo sapiens	85-89
33183223-5	2020	Using non-small cell lung cancer as a case study, we show that interaction terms that capture associations between drugs, pathways, and mutant kinases quantitatively contribute to the response of two EGFR inhibitors (afatinib and lapatinib).	Lapatinib	230-239	epidermal growth factor receptor	Homo sapiens	200-204
32959525-4	2020	Bicompartmental nanoparticles delivering a synergistic combination of lapatinib and paclitaxel result in increased activity against HER2+ breast cancer cells.	Lapatinib	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
32910476-0	2020	Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.	Lapatinib	66-75	CD274 molecule	Homo sapiens	13-18
32910476-1	2020	BACKGROUND: The purpose of this retrospective biomarker study of the Canadian Cancer Trials Group (CCTG) MA.31 randomized phase 3 trial (lapatinib vs trastuzumab) of HER2-positive metastatic breast cancer (MBC) was to evaluate the prognostic and predictive biomarker utility of pretreatment serum programmed death ligand 1 (PD-L1) levels.	Lapatinib	137-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
32910476-6	2020	However, within the trastuzumab arm, a higher continuous pretreatment serum PD-L1 level was significant for shorter OS (hazard ratio [HR], 3.85; P = .04), but within the lapatinib arm, pretreatment serum PD-L1 was not associated with OS (P = .37).	Lapatinib	170-179	CD274 molecule	Homo sapiens	76-81
32910476-8	2020	There was a significant interaction between treatment arm and continuous serum PD-L1 (bootstrap method; P = .0025): at or above 214.2 pg/mL (the 89th percentile), serum PD-L1 was associated with significantly shorter OS with trastuzumab treatment versus lapatinib treatment.	Lapatinib	254-263	CD274 molecule	Homo sapiens	169-174
32910476-9	2020	CONCLUSIONS: In the CCTG MA.31 trial, serum PD-L1 was a significant predictive factor: a higher pretreatment serum PD-L1 level was associated with shorter OS with trastuzumab treatment but with longer OS with lapatinib treatment.	Lapatinib	209-218	CD274 molecule	Homo sapiens	44-49
32910476-9	2020	CONCLUSIONS: In the CCTG MA.31 trial, serum PD-L1 was a significant predictive factor: a higher pretreatment serum PD-L1 level was associated with shorter OS with trastuzumab treatment but with longer OS with lapatinib treatment.	Lapatinib	209-218	CD274 molecule	Homo sapiens	115-120
33240815-0	2020	Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-70
33240815-1	2020	Background: Intracranial activity of lapatinib has been demonstrated in several studies in patients with human epidermal growth factor receptor-2 positive breast cancers (HER-2+ BC).	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-145
33240815-1	2020	Background: Intracranial activity of lapatinib has been demonstrated in several studies in patients with human epidermal growth factor receptor-2 positive breast cancers (HER-2+ BC).	Lapatinib	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-176
33240815-20	2020	Conclusions: Lapatinib has shown intracranial activity and yielded better survival for HER-2+ BC patients with BMs.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-92
32956836-2	2020	Several inhibitors targeting EGFR/HER2 signaling, including FDA-approved lapatinib and gefitinib as well as a novel dual tyrosine kinase inhibitor (TKI) sapitinib, showed greater therapeutic efficacies.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	29-33
32956836-2	2020	Several inhibitors targeting EGFR/HER2 signaling, including FDA-approved lapatinib and gefitinib as well as a novel dual tyrosine kinase inhibitor (TKI) sapitinib, showed greater therapeutic efficacies.	Lapatinib	73-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
33021725-3	2020	Today, several anti-HER2 agents are in clinical use including: the monoclonal antibodies trastuzumab and pertuzumab; the small molecule inhibitors lapatinib, neratinib, and tucatinib; and the antibody-drug conjugates ado-trastuzumab emtansine and trastuzumab deruxtecan, in some jurisdictions.	Lapatinib	147-156	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
32919134-5	2020	Notably, the most active antitumor compounds 39 and 40 represented the most potent inhibitors to EGFR with IC50 values of 24.58 and 30.42 nM respectively in comparison with 17.38 nM for lapatinib as a standard drug.	Lapatinib	186-195	epidermal growth factor receptor	Homo sapiens	97-101
32800546-3	2020	Lapatinib, a tyrosine-kinase inhibitor, blocks the activation of the HER1 and HER2 tyrosine kinase to inhibit the activation of downstream signaling pathways and thus inhibit tumor survival and proliferation.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
33113620-2	2020	Lapatinib, pyrotinib and neratinib, as ErbB family TKIs, have been approved by National Medical Products Administration and applied in the treatment of HER-2 positive breast cancer in China.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-43
33113620-2	2020	Lapatinib, pyrotinib and neratinib, as ErbB family TKIs, have been approved by National Medical Products Administration and applied in the treatment of HER-2 positive breast cancer in China.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-157
32800546-0	2020	Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.	Lapatinib	15-24	forkhead box O3	Homo sapiens	120-126
32800546-0	2020	Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.	Lapatinib	15-24	NAD(P)H quinone dehydrogenase 1	Homo sapiens	127-131
32800546-0	2020	Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.	Lapatinib	75-84	forkhead box O3	Homo sapiens	120-126
33194604-3	2020	We report a case of a 40-year-old woman with both HER2- and EGFR-amplified metastatic colon cancer, who developed refractory disease resistant to multiline therapies (including trastuzumab with lapatinib) but achieved a remarkable response after pyrotinib treatment.	Lapatinib	194-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
33194604-3	2020	We report a case of a 40-year-old woman with both HER2- and EGFR-amplified metastatic colon cancer, who developed refractory disease resistant to multiline therapies (including trastuzumab with lapatinib) but achieved a remarkable response after pyrotinib treatment.	Lapatinib	194-203	epidermal growth factor receptor	Homo sapiens	60-64
32800546-8	2020	The results of Western blot showed that in tumor tissues of mice transplanted with BT-474 cells, the expression levels of FOXO3a and NQO1 protein in the luteolin group, lapatinib group, and lapatinib + luteolin group were all obviously upregulated, the mice transplanted with ZR-75-1 cells exhibited similar results.	Lapatinib	169-178	NAD(P)H quinone dehydrogenase 1	Homo sapiens	133-137
32800546-0	2020	Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.	Lapatinib	75-84	NAD(P)H quinone dehydrogenase 1	Homo sapiens	127-131
32800546-3	2020	Lapatinib, a tyrosine-kinase inhibitor, blocks the activation of the HER1 and HER2 tyrosine kinase to inhibit the activation of downstream signaling pathways and thus inhibit tumor survival and proliferation.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	69-73
32800546-9	2020	These data suggest that the combination of lapatinib and luteolin may inhibit HER2+ human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2+ human breast cancer xenografts.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
32800546-9	2020	These data suggest that the combination of lapatinib and luteolin may inhibit HER2+ human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2+ human breast cancer xenografts.	Lapatinib	43-52	forkhead box O3	Homo sapiens	150-156
32800546-9	2020	These data suggest that the combination of lapatinib and luteolin may inhibit HER2+ human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2+ human breast cancer xenografts.	Lapatinib	43-52	NAD(P)H quinone dehydrogenase 1	Homo sapiens	161-165
32800546-9	2020	These data suggest that the combination of lapatinib and luteolin may inhibit HER2+ human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2+ human breast cancer xenografts.	Lapatinib	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
32988919-7	2020	CONCLUSION: Mutations in TP53 and PIK3CA hotspot at exon 9 may be potential negative predictors of ER+HER2+ BC treated with neoadjuvant letrozole and lapatinib, while MLL2 inactivating mutation might confer therapeutic benefit in these patients.	Lapatinib	150-159	tumor protein p53	Homo sapiens	25-29
32707209-2	2020	Herein, a tailor-made 2,3-dimethylmaleic-anhydride-poly(ethylene glycol)-epsilon-poly-l-lysine-doxorubicin /lapatinib polymeric nanoplatform (DMMA-P-DOX/LAP) for synergistically eliminating breast cancer is developed by encapsulating lapatinib into dual-pH responsive charge switchable biopolymer-doxorubicin conjugate nanoparticles.	Lapatinib	108-117	LAP	Homo sapiens	153-156
32988919-7	2020	CONCLUSION: Mutations in TP53 and PIK3CA hotspot at exon 9 may be potential negative predictors of ER+HER2+ BC treated with neoadjuvant letrozole and lapatinib, while MLL2 inactivating mutation might confer therapeutic benefit in these patients.	Lapatinib	150-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
32988919-7	2020	CONCLUSION: Mutations in TP53 and PIK3CA hotspot at exon 9 may be potential negative predictors of ER+HER2+ BC treated with neoadjuvant letrozole and lapatinib, while MLL2 inactivating mutation might confer therapeutic benefit in these patients.	Lapatinib	150-159	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	34-40
32988919-7	2020	CONCLUSION: Mutations in TP53 and PIK3CA hotspot at exon 9 may be potential negative predictors of ER+HER2+ BC treated with neoadjuvant letrozole and lapatinib, while MLL2 inactivating mutation might confer therapeutic benefit in these patients.	Lapatinib	150-159	estrogen receptor 1	Homo sapiens	99-101
33202212-5	2020	HER2-specific therapy includes monoclonal antibodies and low-molecular weight inhibitors of tyrosine kinase receptors, such as lapatinib, neratinib, and pyrotinib.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
32320483-9	2020	In line, we also identified lapatinib, a dual EGFR/HER2 inhibitor, as another CYP3A4 inducer only active in 3D spheroid culture.	Lapatinib	28-37	epidermal growth factor receptor	Homo sapiens	46-50
32320483-9	2020	In line, we also identified lapatinib, a dual EGFR/HER2 inhibitor, as another CYP3A4 inducer only active in 3D spheroid culture.	Lapatinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
32320483-9	2020	In line, we also identified lapatinib, a dual EGFR/HER2 inhibitor, as another CYP3A4 inducer only active in 3D spheroid culture.	Lapatinib	28-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
32378049-0	2020	Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
32378049-6	2020	Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
32378049-6	2020	Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	53-85
32378049-6	2020	Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
32378049-6	2020	Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting.	Lapatinib	0-3	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
32378049-6	2020	Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting.	Lapatinib	0-3	epidermal growth factor receptor	Homo sapiens	53-85
32378049-6	2020	Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting.	Lapatinib	0-3	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
32378049-14	2020	Hence, the combinational therapy in which Lap suppresses the low-dose effect of Dox in SKBR3 cells may provide an effective intervention strategy for reducing the risk of metastasis in HER2-positive breast cancers.	Lapatinib	42-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
32582968-0	2020	Lapatinib-induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro.	Lapatinib	0-9	signal transducer and activator of transcription 3	Mus musculus	72-77
33841528-10	2020	Finally, according on molecular docking analysis, lapatinib-ERBB2 and eugenol-ESR1 exhibited highest and lowest binding energy, respectively.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-65
32873927-3	2020	HER2-targeted therapies (lapatinib, neratinib, tucatinib and trastuzumab emtansine), alone or in combination, yield a number of intracranial responses in patients with HER2-positive breast cancer brain metastases.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
33013420-1	2020	Lapatinib, targeting the human epidermal growth factor receptor family members HER1 and HER2, has been approved by the US Food and Drug Administration for use in metastatic HER2-positive breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-63
33013420-1	2020	Lapatinib, targeting the human epidermal growth factor receptor family members HER1 and HER2, has been approved by the US Food and Drug Administration for use in metastatic HER2-positive breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	79-83
33013420-1	2020	Lapatinib, targeting the human epidermal growth factor receptor family members HER1 and HER2, has been approved by the US Food and Drug Administration for use in metastatic HER2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
33013420-1	2020	Lapatinib, targeting the human epidermal growth factor receptor family members HER1 and HER2, has been approved by the US Food and Drug Administration for use in metastatic HER2-positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-177
33013420-2	2020	However, resistance to lapatinib remains a common challenge to HER2-positive metastatic breast cancer.	Lapatinib	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
33013420-3	2020	Until now, the molecular mechanisms of acquired resistance to lapatinib (ALR) have remained unclear.	Lapatinib	62-71	growth factor, augmenter of liver regeneration	Homo sapiens	73-76
32507561-9	2020	(4) To use specific treatments for very selected populations, such as trastuzumab/lapatinib in mCRC human epidermal growth factor receptor 2-positive, immunotherapy in microsatellite instability, intrahepatic therapies in limited disease or primarily located in the liver, although the main recommendation is to include patients in clinical trials.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-140
32988996-1	2020	BACKGROUND: HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib.	Lapatinib	219-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
32988996-1	2020	BACKGROUND: HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib.	Lapatinib	219-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
32086952-9	2020	As CDK7 inhibitors are currently under clinical evaluation in patients, our data suggestion the addition of the TKI ponatinib or lapatinib in CDK7 inhibitor clinical trials in patients.	Lapatinib	129-138	cyclin dependent kinase 7	Homo sapiens	142-146
32942617-0	2020	HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.	Lapatinib	56-65	estrogen receptor 1	Homo sapiens	110-112
32942617-0	2020	HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.	Lapatinib	86-95	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
32942617-0	2020	HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.	Lapatinib	86-95	estrogen receptor 1	Homo sapiens	110-112
32942617-0	2020	HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.	Lapatinib	86-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
32942617-1	2020	Lapatinib, a Human Epidermal growth factor Receptor 2 (HER2)-targeting therapy in HER2-overexpressing breast cancer, has been widely used clinically, but the prognosis is still poor because most patients acquire resistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-53
32942617-1	2020	Lapatinib, a Human Epidermal growth factor Receptor 2 (HER2)-targeting therapy in HER2-overexpressing breast cancer, has been widely used clinically, but the prognosis is still poor because most patients acquire resistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
32942617-1	2020	Lapatinib, a Human Epidermal growth factor Receptor 2 (HER2)-targeting therapy in HER2-overexpressing breast cancer, has been widely used clinically, but the prognosis is still poor because most patients acquire resistance.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
32942617-6	2020	Analysis of the protein interaction network in two resistant cell lines with different lapatinib resistance mechanisms showed that HSP90 protein was commonly increased.	Lapatinib	87-96	heat shock protein 90 alpha family class A member 1	Homo sapiens	131-136
32942617-9	2020	These results suggest that HSP90 inhibitors in patients with lapatinib-resistant Estrogen Receptor (ER) (+) HER2 (+) breast cancer are promising therapeutics for future clinical trials.	Lapatinib	61-70	heat shock protein 90 alpha family class A member 1	Homo sapiens	27-32
32942617-9	2020	These results suggest that HSP90 inhibitors in patients with lapatinib-resistant Estrogen Receptor (ER) (+) HER2 (+) breast cancer are promising therapeutics for future clinical trials.	Lapatinib	61-70	estrogen receptor 1	Homo sapiens	81-98
32942617-9	2020	These results suggest that HSP90 inhibitors in patients with lapatinib-resistant Estrogen Receptor (ER) (+) HER2 (+) breast cancer are promising therapeutics for future clinical trials.	Lapatinib	61-70	epiregulin	Homo sapiens	100-103
32942617-9	2020	These results suggest that HSP90 inhibitors in patients with lapatinib-resistant Estrogen Receptor (ER) (+) HER2 (+) breast cancer are promising therapeutics for future clinical trials.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
33005299-0	2020	Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-52
33005299-8	2020	Finally, a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutation was identified at the time of tumor progression, which may explain the acquired resistance to lapatinib.	Lapatinib	185-194	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	11-81
33005299-9	2020	CONCLUSION: This is the first case report of HER2-positive RAS/BRAF wild-type metastatic CRC patient responding to lapatinib monotherapy.	Lapatinib	115-124	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
33005299-9	2020	CONCLUSION: This is the first case report of HER2-positive RAS/BRAF wild-type metastatic CRC patient responding to lapatinib monotherapy.	Lapatinib	115-124	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	63-67
32582968-1	2020	The present study was designed to ascertain whether lapatinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), affects ovarian reserve and fertility potential in a mouse model.	Lapatinib	52-61	epidermal growth factor receptor	Mus musculus	94-126
32582968-1	2020	The present study was designed to ascertain whether lapatinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), affects ovarian reserve and fertility potential in a mouse model.	Lapatinib	52-61	epidermal growth factor receptor	Mus musculus	128-132
32582968-9	2020	This lack of effect of lapatinib on ovarian function may be due to the activation of the STAT3 signaling pathway that counteracts the inhibitory effects of lapatinib on EGF receptors.	Lapatinib	156-165	signal transducer and activator of transcription 3	Mus musculus	89-94
32771039-11	2020	More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib and/or the SRC inhibitor dasatinib.	Lapatinib	176-185	estrogen receptor 1 (alpha)	Mus musculus	69-73
32771039-11	2020	More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib and/or the SRC inhibitor dasatinib.	Lapatinib	176-185	coiled-coil domain containing 170	Mus musculus	74-81
32771039-11	2020	More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib and/or the SRC inhibitor dasatinib.	Lapatinib	176-185	erb-b2 receptor tyrosine kinase 2	Homo sapiens	161-165
32601199-3	2020	Here, we show that fibroblasts counteract the cytotoxic effects of HER2 kinase-targeted therapy in a subset of HER2+ breast cancer cell lines and allow cancer cells to proliferate in the presence of the HER2 kinase inhibitor lapatinib.	Lapatinib	225-234	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
32905515-0	2020	Combination of carbon-ion beam and dual tyrosine kinase inhibitor, lapatinib, effectively destroys HER2 positive breast cancer stem-like cells.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
32905515-6	2020	Carbon-ion beam combined with lapatinib significantly enhanced apoptosis and carbon-ion beam alone dose-dependently increased autophagy-related expression of Beclin1 and in combination with lapatinib greatly enhanced ATG7 expression at protein levels.	Lapatinib	190-199	autophagy related 7	Homo sapiens	217-221
32905515-8	2020	Altogether, combination of carbon-ion beam irradiation and lapatinib has a high potential to kill HER2-positive breast CSCs, causing severe irreparable DNA damage, enhanced autophagy, and apoptosis.	Lapatinib	59-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
32905036-7	2020	Tyrosine kinase overexpression can be treated with lapatinib, which has also been approved for improving survival and is used in combination with capecitabine.	Lapatinib	51-60	TXK tyrosine kinase	Homo sapiens	0-15
32905036-10	2020	For a long time, only two agents, trastuzumab and lapatinib, have been approved by the Food and Drug Administration (FDA) for the treatment of HER2 positive breast cancers.	Lapatinib	50-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
32905036-12	2020	Lapatinib was approved by the FDA in 2007 for HER2 positive breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50
32478891-9	2020	One patient with V659E responded well to ERBB2 inhibitor lapatinib plus capecitabine as well as subsequent afatinib treatment upon progression.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-46
32601199-7	2020	Expression of activated AKT in tumor cells recapitulates the effects of fibroblasts resulting in sustained MTOR signaling and poor lapatinib response.	Lapatinib	131-140	AKT serine/threonine kinase 1	Homo sapiens	24-27
32580684-7	2021	The results have shown that Doxorubicin, Neratinib maleate, Epirubicin, and Lapatinib Ditosylate have good interaction with GPR116 binding site.	Lapatinib	76-96	adhesion G protein-coupled receptor F5	Homo sapiens	124-130
32727239-0	2020	CORRIGENDUM to "Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma".	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
32555923-2	2020	Here, the optimal surface charge (-28 mV) and particle size (51 nm) enabled the acid-labile hyaluronic acid pullulan prodrug (HPP)-doxorubicin (Dox)/lapatinib (Lap) conjugate to circulate in the blood for a lengthy period of time and enhance the electron paramagnetic resonance effect, while the targeted molecule hyaluronic acid accelerated CD44 receptor-mediated 4T1 cell internalization.	Lapatinib	149-158	CD44 antigen	Mus musculus	342-346
32555923-2	2020	Here, the optimal surface charge (-28 mV) and particle size (51 nm) enabled the acid-labile hyaluronic acid pullulan prodrug (HPP)-doxorubicin (Dox)/lapatinib (Lap) conjugate to circulate in the blood for a lengthy period of time and enhance the electron paramagnetic resonance effect, while the targeted molecule hyaluronic acid accelerated CD44 receptor-mediated 4T1 cell internalization.	Lapatinib	160-163	CD44 antigen	Mus musculus	342-346
32694997-1	2020	The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity.	Lapatinib	39-48	ret proto-oncogene	Homo sapiens	4-28
32694997-3	2020	The effect of lapatinib on the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, the major cellular defense pathway against oxidative stress, has so far not been studied in detail.	Lapatinib	14-23	kelch like ECH associated protein 1	Homo sapiens	31-66
32694997-3	2020	The effect of lapatinib on the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, the major cellular defense pathway against oxidative stress, has so far not been studied in detail.	Lapatinib	14-23	kelch like ECH associated protein 1	Homo sapiens	68-73
32694997-3	2020	The effect of lapatinib on the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, the major cellular defense pathway against oxidative stress, has so far not been studied in detail.	Lapatinib	14-23	NFE2 like bZIP transcription factor 2	Homo sapiens	75-118
32694997-3	2020	The effect of lapatinib on the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, the major cellular defense pathway against oxidative stress, has so far not been studied in detail.	Lapatinib	14-23	NFE2 like bZIP transcription factor 2	Homo sapiens	120-124
32694997-4	2020	In the present study, we show that lapatinib (2-20 microM) activates the Keap1-Nrf2 pathway in HepG2 cells, a hepatocellular carcinoma-derived cell line, in a concentration-dependent manner upon 24 h of treatment.	Lapatinib	35-44	kelch like ECH associated protein 1	Homo sapiens	73-78
32694997-4	2020	In the present study, we show that lapatinib (2-20 microM) activates the Keap1-Nrf2 pathway in HepG2 cells, a hepatocellular carcinoma-derived cell line, in a concentration-dependent manner upon 24 h of treatment.	Lapatinib	35-44	NFE2 like bZIP transcription factor 2	Homo sapiens	79-83
32694997-5	2020	Lapatinib stabilized the transcription factor Nrf2 at concentrations >=5 microM and caused its nuclear translocation.	Lapatinib	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	46-50
32694997-6	2020	Well-established Nrf2 regulated genes (Nqo1, Gsta1, Gclc, and Gclm) were upregulated at lapatinib concentrations >=10 microM.	Lapatinib	88-97	NFE2 like bZIP transcription factor 2	Homo sapiens	17-21
32694997-6	2020	Well-established Nrf2 regulated genes (Nqo1, Gsta1, Gclc, and Gclm) were upregulated at lapatinib concentrations >=10 microM.	Lapatinib	88-97	NAD(P)H quinone dehydrogenase 1	Homo sapiens	39-43
32694997-6	2020	Well-established Nrf2 regulated genes (Nqo1, Gsta1, Gclc, and Gclm) were upregulated at lapatinib concentrations >=10 microM.	Lapatinib	88-97	glutathione S-transferase alpha 1	Homo sapiens	45-50
32694997-6	2020	Well-established Nrf2 regulated genes (Nqo1, Gsta1, Gclc, and Gclm) were upregulated at lapatinib concentrations >=10 microM.	Lapatinib	88-97	glutamate-cysteine ligase catalytic subunit	Homo sapiens	52-56
32694997-6	2020	Well-established Nrf2 regulated genes (Nqo1, Gsta1, Gclc, and Gclm) were upregulated at lapatinib concentrations >=10 microM.	Lapatinib	88-97	glutamate-cysteine ligase modifier subunit	Homo sapiens	62-66
32694997-9	2020	Furthermore, the gene expression of mitochondrial Glrx2 and SOD2 were increased upon lapatinib treatment, which was also observed for the mitochondrial SOD2 protein content.	Lapatinib	85-94	glutaredoxin 2	Homo sapiens	50-55
32694997-9	2020	Furthermore, the gene expression of mitochondrial Glrx2 and SOD2 were increased upon lapatinib treatment, which was also observed for the mitochondrial SOD2 protein content.	Lapatinib	85-94	superoxide dismutase 2	Homo sapiens	60-64
32694997-9	2020	Furthermore, the gene expression of mitochondrial Glrx2 and SOD2 were increased upon lapatinib treatment, which was also observed for the mitochondrial SOD2 protein content.	Lapatinib	85-94	superoxide dismutase 2	Homo sapiens	152-156
32694997-10	2020	In conclusion, lapatinib treatment for 24 h activated the Keap1-Nrf2 pathway in HepG2 cells starting at 10 muM, which is a clinically relevant concentration.	Lapatinib	15-24	kelch like ECH associated protein 1	Homo sapiens	58-63
32694997-10	2020	In conclusion, lapatinib treatment for 24 h activated the Keap1-Nrf2 pathway in HepG2 cells starting at 10 muM, which is a clinically relevant concentration.	Lapatinib	15-24	NFE2 like bZIP transcription factor 2	Homo sapiens	64-68
32576928-5	2020	By using the DREAM-in-CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19.	Lapatinib	36-45	potassium voltage-gated channel interacting protein 3	Homo sapiens	13-18
32576928-5	2020	By using the DREAM-in-CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19.	Lapatinib	36-45	prostaglandin E synthase	Mus musculus	81-88
32545895-1	2020	Over the last few decades, improved knowledge of oncogenic activation mechanisms of HER2 protein has led to the development of HER2 targeted therapies that are currently commonly used in HER2-positive advanced breast cancer, such as trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab emtansine.	Lapatinib	246-255	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
32545895-1	2020	Over the last few decades, improved knowledge of oncogenic activation mechanisms of HER2 protein has led to the development of HER2 targeted therapies that are currently commonly used in HER2-positive advanced breast cancer, such as trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab emtansine.	Lapatinib	246-255	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
32545895-1	2020	Over the last few decades, improved knowledge of oncogenic activation mechanisms of HER2 protein has led to the development of HER2 targeted therapies that are currently commonly used in HER2-positive advanced breast cancer, such as trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab emtansine.	Lapatinib	246-255	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
32547705-3	2020	We hypothesize that poor penetration of the blood-brain barrier by previously tested EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as afateninb, erlotinib, gefitinib, and lapatinib played a role in their limited efficacy.	Lapatinib	174-183	epidermal growth factor receptor	Homo sapiens	85-89
32547705-3	2020	We hypothesize that poor penetration of the blood-brain barrier by previously tested EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as afateninb, erlotinib, gefitinib, and lapatinib played a role in their limited efficacy.	Lapatinib	174-183	epidermal growth factor receptor	Homo sapiens	118-122
32139271-1	2020	Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (~15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase inhibitor (TKI) drugs (eg, lapatinib and neratinib), all of which have dramatically changed the prognosis for this aggressive subtype of breast cancer.	Lapatinib	287-296	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-54
32517054-0	2020	Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.	Lapatinib	67-76	TXK tyrosine kinase	Homo sapiens	115-130
32517054-5	2020	This new family of compounds combines two fragments: the drug fragment is a lapatinib group, which inhibits the tyrosine kinase receptor activity, and an icosahedral boron cluster used as agents for neutron capture therapy (BNCT).	Lapatinib	76-85	TXK tyrosine kinase	Homo sapiens	112-127
32694900-2	2020	Due to limited real-world data, we evaluate the effectiveness of anti-human epidermal growth factor receptor 2 (HER2) therapy (lapatinib or trastuzumab) plus chemotherapy or chemotherapy alone in patients who were previously treated with trastuzumab-containing regimens and investigate factors associated with effectiveness.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-110
32694900-2	2020	Due to limited real-world data, we evaluate the effectiveness of anti-human epidermal growth factor receptor 2 (HER2) therapy (lapatinib or trastuzumab) plus chemotherapy or chemotherapy alone in patients who were previously treated with trastuzumab-containing regimens and investigate factors associated with effectiveness.	Lapatinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
32694900-8	2020	Results: After a median follow-up of 26.2 (range, 2.0-56.0) months, PFS significantly improved with anti-HER2 therapy compared with chemotherapy alone: median 6.0 months with lapatinib [95% confidence interval (95% CI), 4.53-7.47], 4.5 months with trastuzumab (95% CI, 3.99-5.01)vs. 3.0 months with chemotherapy alone (95% CI, 2.42-3.58); stratified hazard ratio (HR)=0.70, 95% CI, 0.60-0.81; P<0.0001.	Lapatinib	175-184	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
32139271-1	2020	Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (~15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase inhibitor (TKI) drugs (eg, lapatinib and neratinib), all of which have dramatically changed the prognosis for this aggressive subtype of breast cancer.	Lapatinib	287-296	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
32528877-10	2020	In addition, although lapatinib and crizotinib have a high P-gp inhibitory activity, we found that co-treatment with crizotinib and vincristine (VIC) did not have much of a sensitization effect on KBV20C cells, whereas lapatinib had a high sensitization effect on VIC-treated KBV20C cells.	Lapatinib	22-31	phosphoglycolate phosphatase	Mus musculus	59-63
32563955-1	2020	Her2-dependent breast cancer is treated with pharmacological drugs (eg, Herceptin, lapatinib) that target Her2 signaling.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
32563955-1	2020	Her2-dependent breast cancer is treated with pharmacological drugs (eg, Herceptin, lapatinib) that target Her2 signaling.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
32563955-8	2020	We also found that 1.5 mumol/L curcumin strongly potentiated lapatinib inhibition of Her2-Akt pathway signaling, and more so for pAkt, when combined with quercetin plus OptiBerry (CQO).	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
32563955-8	2020	We also found that 1.5 mumol/L curcumin strongly potentiated lapatinib inhibition of Her2-Akt pathway signaling, and more so for pAkt, when combined with quercetin plus OptiBerry (CQO).	Lapatinib	61-70	AKT serine/threonine kinase 1	Homo sapiens	90-93
33354548-12	2020	Four patients with ERBB2 amplification received trastuzumab and/or lapatinib, showed partial response, and maintained response beyond 12 weeks.	Lapatinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-24
33354548-14	2020	Three patients with ERBB3 mutations showed response to lapatinib-capecitabine.	Lapatinib	55-64	erb-b2 receptor tyrosine kinase 3	Homo sapiens	20-25
33354548-18	2020	Responses are seen with lapatinib in concurrent ERBB2 mutation and amplification.	Lapatinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-53
33354548-19	2020	ERBB3 mutation showed response to lapatinib.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 3	Homo sapiens	0-5
31177402-0	2020	The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.	Lapatinib	107-116	ATP binding cassette subfamily B member 1	Homo sapiens	45-59
31177402-1	2020	Background Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC).	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
31177402-1	2020	Background Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC).	Lapatinib	11-20	epidermal growth factor receptor	Homo sapiens	108-112
31177402-1	2020	Background Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC).	Lapatinib	11-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
31177402-3	2020	The aim of this study was to investigate the effects of elacridar, an ABCB1 and ABCG2 inhibitor, on the brain and cerebrospinal fluid uptake of lapatinib.	Lapatinib	144-153	ATP binding cassette subfamily B member 1	Homo sapiens	70-75
31177402-3	2020	The aim of this study was to investigate the effects of elacridar, an ABCB1 and ABCG2 inhibitor, on the brain and cerebrospinal fluid uptake of lapatinib.	Lapatinib	144-153	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	80-85
31177402-5	2020	Lapatinib concentrations in the blood plasma (BP), cerebrospinal fluid (CSF) and brain tissue (BT) were measured by liquid chromatography coupled with tandem mass spectrometry.	Lapatinib	0-9	colony stimulating factor 2	Homo sapiens	72-75
31177402-6	2020	Results Elacridar significantly increased lapatinib penetration into the CSF and BT (Cmax increase of 136.4% and 54.7% and AUC0-  increase of 53.7% and 86.5%, respectively).	Lapatinib	42-51	colony stimulating factor 2	Homo sapiens	73-83
31177402-9	2020	The inhibition of ABCB1 and ABCG2 transporters by elacridar substantially enhanced the penetration of lapatinib into the CSF and BT.	Lapatinib	102-111	ATP binding cassette subfamily B member 1	Homo sapiens	18-23
31177402-9	2020	The inhibition of ABCB1 and ABCG2 transporters by elacridar substantially enhanced the penetration of lapatinib into the CSF and BT.	Lapatinib	102-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	28-33
31177402-9	2020	The inhibition of ABCB1 and ABCG2 transporters by elacridar substantially enhanced the penetration of lapatinib into the CSF and BT.	Lapatinib	102-111	colony stimulating factor 2	Homo sapiens	121-131
32329582-3	2020	We show here that the anti-HER3 antibody-drug conjugate EV20/MMAF exerted potent anti-tumoral properties against several models of primary resistance and secondary resistance to common anti-HER2 available therapies, including trastuzumab, lapatinib, neratinib, and trastuzumab-emtansine.	Lapatinib	239-248	erb-b2 receptor tyrosine kinase 3	Mus musculus	27-31
32274564-0	2020	Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.	Lapatinib	17-26	KRAS proto-oncogene, GTPase	Homo sapiens	60-64
32139324-4	2020	Compounds 1e and 1h were identified as lead compounds which displayed almost 3-4 times more potent inhibition of EGFR and HER2 than the approved drug lapatinib.	Lapatinib	150-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
32365111-5	2020	Lapatinib-induced SG formation correlates with the inhibition of general translation initiation which involves the phosphorylation of the translation initiation factor eIF2alpha through the kinase PERK.	Lapatinib	0-9	eukaryotic translation initiation factor 2A	Homo sapiens	168-177
32365111-5	2020	Lapatinib-induced SG formation correlates with the inhibition of general translation initiation which involves the phosphorylation of the translation initiation factor eIF2alpha through the kinase PERK.	Lapatinib	0-9	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	197-201
32365111-6	2020	Disrupting PERK-SG formation by PERK depletion experiments sensitizes resistant breast cancer cells to Lapatinib.	Lapatinib	103-112	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	11-15
32365111-6	2020	Disrupting PERK-SG formation by PERK depletion experiments sensitizes resistant breast cancer cells to Lapatinib.	Lapatinib	103-112	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	32-36
32368385-6	2020	Trastuzumab, pertuzumab, T-DM1, and lapatinib are commonly recommended as a single agent (along with chemotherapy) or in combinations of anti-HER2 agents in neoadjuvant, adjuvant and metastatic settings according to National Comprehensive Cancer Network (NCCN) guidelines.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-146
32108439-0	2020	Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study.	Lapatinib	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
32108439-0	2020	Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study.	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
32108439-1	2020	Lapatinib is widely used in the later lines treatment of HER2 positive metastatic breast cancer (MBC).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
32490320-12	2020	The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMODeltahepa/JNKDeltahepa mice.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Mus musculus	109-136
32490320-12	2020	The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMODeltahepa/JNKDeltahepa mice.	Lapatinib	53-62	erb-b2 receptor tyrosine kinase 2	Mus musculus	138-143
32490320-12	2020	The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMODeltahepa/JNKDeltahepa mice.	Lapatinib	53-62	epidermal growth factor receptor	Mus musculus	149-153
32490320-13	2020	Lapatinib effectively inhibited cystogenesis, improved transaminases, and effectively blocked EGFR-Raf-MEK-ERK signaling.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	94-98
32490320-13	2020	Lapatinib effectively inhibited cystogenesis, improved transaminases, and effectively blocked EGFR-Raf-MEK-ERK signaling.	Lapatinib	0-9	midkine	Mus musculus	103-106
32490320-13	2020	Lapatinib effectively inhibited cystogenesis, improved transaminases, and effectively blocked EGFR-Raf-MEK-ERK signaling.	Lapatinib	0-9	mitogen-activated protein kinase 1	Mus musculus	107-110
31462705-8	2020	A low dose of THZ1 displayed potent synergy with the HER2 inhibitor lapatinib in HER2iR BC cells in vitro.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
31765734-2	2020	One of them, lapatinib, is used once advanced tumors become refractory to the HER2 antibody trastuzumab.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
32019194-3	2020	Here composite nanocrystals of PTX and LAPA (cNC) were designed with a ratio of 2:1 (w/w), which was their intracellular ratio at the best synergistic efficacy on a drug-resistant cancer cell line (MCF-7/ADR).	Lapatinib	39-43	aldo-keto reductase family 1 member B	Homo sapiens	204-207
33176309-2	2020	Lapatinib simultaneously inhibits EGFR and HER2, leading to apoptosis.	Lapatinib	0-9	epidermal growth factor receptor	Mus musculus	34-38
33176309-2	2020	Lapatinib simultaneously inhibits EGFR and HER2, leading to apoptosis.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	43-47
31037288-10	2020	Following lapatinib and trastuzumab, the HER2-E/ERBB2-high group showed a higher pCR rate compared to the rest (44.5% [95% CI = 35.4-53.9%] vs. 11.6% [95% CI = 6.9-18.0%]; adjusted odds ratio [OR]=6.05 [95%CI=3.10-11.80]; P&lt;0.001).	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
31037288-10	2020	Following lapatinib and trastuzumab, the HER2-E/ERBB2-high group showed a higher pCR rate compared to the rest (44.5% [95% CI = 35.4-53.9%] vs. 11.6% [95% CI = 6.9-18.0%]; adjusted odds ratio [OR]=6.05 [95%CI=3.10-11.80]; P&lt;0.001).	Lapatinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-53
32256585-4	2020	Drugs such as trastuzumab, pertuzumab, lapatinib, neratinib, and the more recent afatinib target the deregulation of HER2 expression.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
32231738-0	2020	Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine.	Lapatinib	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
32231738-1	2020	Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (ABC) patients.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	223-257
32231738-1	2020	Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (ABC) patients.	Lapatinib	112-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	259-263
32231738-8	2020	In HER2-positive ABC patients initiating lapatinib plus capecitabine, consideration should be given to more closely monitoring patients at risk of nausea and vomiting, while rash and hand foot syndrome are AE associated with improved survival.	Lapatinib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
32195186-1	2020	Introduction: Combination of trastuzumab (T) and lapatinib (L) has been showed to significantly improve the prognosis of HER2+ heavily pretreated metastatic breast cancer (MBC).	Lapatinib	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
32309387-1	2020	Background: Lapatinib is approved for the treatment of metastatic HER2-overexpressed breast cancer with capecitabine after progress on anthracycline, taxane, and trastuzumab in China.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
31559601-6	2020	To understand the inhibitory effects of the active ligands against HER2 over expressed breast cancer cell lines, all inhibitors and the control compound, lapatinib, were docked into the active site of HER2 enzyme performed using Ligand Fit docking engine and PMF scoring function.	Lapatinib	154-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	201-205
31203575-0	2020	A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
31203575-1	2020	PURPOSE: To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L. MATERIALS AND METHODS: We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L-T.	Lapatinib	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
31383939-1	2020	Associations between HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity have been reported.	Lapatinib	40-49	major histocompatibility complex, class II, DR beta 1	Homo sapiens	21-29
31383939-3	2020	Studies investigating associations between HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity were systematically searched in PubMed, Human Genome Epidemiology Network, and the Cochrane Library.	Lapatinib	62-71	major histocompatibility complex, class II, DR beta 1	Homo sapiens	43-51
31383939-4	2020	Primary outcomes were the associations between HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity.	Lapatinib	66-75	major histocompatibility complex, class II, DR beta 1	Homo sapiens	47-55
31383939-5	2020	Overall odds ratios (ORs) with the corresponding 95%CIs were calculated using a random-effect model to determine the associations between HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity.	Lapatinib	157-166	major histocompatibility complex, class II, DR beta 1	Homo sapiens	138-146
31383939-6	2020	A clear association between HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity was identified in our analyses.	Lapatinib	47-56	major histocompatibility complex, class II, DR beta 1	Homo sapiens	28-36
31383939-10	2020	Since HLA-DRB1*07:01 is associated with lapatinib-induced hepatotoxicity, genetic screening of HLA-DRB1*07:01 in breast cancer patients prior to lapatinib therapy is warranted for patient safety.	Lapatinib	40-49	major histocompatibility complex, class II, DR beta 1	Homo sapiens	6-14
31383939-10	2020	Since HLA-DRB1*07:01 is associated with lapatinib-induced hepatotoxicity, genetic screening of HLA-DRB1*07:01 in breast cancer patients prior to lapatinib therapy is warranted for patient safety.	Lapatinib	145-154	major histocompatibility complex, class II, DR beta 1	Homo sapiens	95-103
31959756-3	2020	Here we evaluate gene expression data before, during and after neoadjuvant treatment with lapatinib and trastuzumab in HER2+/HER2-E tumors of the PAMELA trial and breast cancer cell lines.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
31959756-3	2020	Here we evaluate gene expression data before, during and after neoadjuvant treatment with lapatinib and trastuzumab in HER2+/HER2-E tumors of the PAMELA trial and breast cancer cell lines.	Lapatinib	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
33463944-16	2020	This chapter will explore various HER2 TKIs- lapatinib, neratinib, afatinib, sapitinib, CP-724,714, dacomitinib, tucatinib, pyrotinib, and poziotinib as promising clinical tools in sensitizing resistant cancers to HER2 antibodies.	Lapatinib	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
31462705-8	2020	A low dose of THZ1 displayed potent synergy with the HER2 inhibitor lapatinib in HER2iR BC cells in vitro.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-85
31111958-7	2019	Consequently, TSA synergizes with lapatinib, a tyrosine kinase inhibitor of HER2, to suppress breast cancer in vitro and in rodent models.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
31445021-1	2019	We have demonstrated previously that the kinase inhibitors (KIs) lapatinib, pazopanib, regorafenib and sorafenib are potent inhibitors of UGT1A1 and UGTs 1A7-1A10.	Lapatinib	65-74	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	138-144
31704817-3	2019	MATERIALS AND METHODS: We examined the anti-tumor activity of lapatinib and afatinib, that are reversible and irreversible TKIs, in HER2 gene-amplified trastuzumab-sensitive and - resistant gastric cancer cells (GLM-1 and GLM-1HerR2) in vitro and in vivo.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
31704817-0	2019	Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells.	Lapatinib	25-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
31477168-2	2019	Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel has shown efficacy in patients with metastatic HER2-positive breast cancer.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
31372791-9	2019	CONCLUSIONS: Our study demonstrated that concomitant use of H2 blockers and CYP3A4 inducers was associated with lapatinib-induced hepatotoxicity.	Lapatinib	112-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
31163957-0	2019	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.	Lapatinib	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
31163957-5	2019	Potential relationships between tumor mRNA levels of HER2 and response to lapatinib-based therapy were also explored.	Lapatinib	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
31211468-12	2019	Notably, a high expression level of ES3 in HER2-positive breast tumor tissues motivated us to investigate the effect of HER2 on ES3 expression by blocking HER2 activity with lapatinib.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
31211468-12	2019	Notably, a high expression level of ES3 in HER2-positive breast tumor tissues motivated us to investigate the effect of HER2 on ES3 expression by blocking HER2 activity with lapatinib.	Lapatinib	174-183	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
31636810-0	2019	Lysosomal Destabilizing Drug Siramesine and the Dual Tyrosine Kinase Inhibitor Lapatinib Induce a Synergistic Ferroptosis through Reduced Heme Oxygenase-1 (HO-1) Levels.	Lapatinib	79-88	heme oxygenase 1	Homo sapiens	138-154
31636810-0	2019	Lysosomal Destabilizing Drug Siramesine and the Dual Tyrosine Kinase Inhibitor Lapatinib Induce a Synergistic Ferroptosis through Reduced Heme Oxygenase-1 (HO-1) Levels.	Lapatinib	79-88	heme oxygenase 1	Homo sapiens	156-160
31538230-1	2019	PURPOSE: This phase I trial evaluated the maximum tolerated dose, safety and preliminary efficacy of lapatinib, a HER1, HER2 dual kinase inhibitor plus bortezomib, a proteasome inhibitor, in adult patients with advanced malignancies.	Lapatinib	101-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
31538230-6	2019	Biomarker analysis showed upregulation of p27 expression with lapatinib and the combination.	Lapatinib	62-71	dynactin subunit 6	Homo sapiens	42-45
31492693-0	2019	Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.	Lapatinib	55-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-34
31492693-2	2019	We have previously shown that cytochromes P450 CYP3A4 and CYP3A5 quantitatively contribute to lapatinib bioactivation, leading to formation of a reactive, potentially toxic quinone imine.	Lapatinib	94-103	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	58-64
31492693-3	2019	CYP3A5 is highly polymorphic; however, the impact of CYP3A5 polymorphism on lapatinib metabolism has not been fully established.	Lapatinib	76-85	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	53-59
31492693-4	2019	The goal of this study was to determine the effect of CYP3A5 genotype and individual variation in CYP3A activity on the metabolic activation of lapatinib using human-relevant in vitro systems.	Lapatinib	144-153	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	54-60
31492693-4	2019	The goal of this study was to determine the effect of CYP3A5 genotype and individual variation in CYP3A activity on the metabolic activation of lapatinib using human-relevant in vitro systems.	Lapatinib	144-153	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-59
31492693-5	2019	Lapatinib metabolism was examined using CYP3A5-genotyped human liver microsomes and cryopreserved human hepatocytes.	Lapatinib	0-9	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	40-46
31492693-8	2019	Further, the relative contributions of CYP3A4 and CYP3A5 to lapatinib O-debenzylation were estimated using selective chemical inhibitors of CYP3A.	Lapatinib	60-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
31492693-8	2019	Further, the relative contributions of CYP3A4 and CYP3A5 to lapatinib O-debenzylation were estimated using selective chemical inhibitors of CYP3A.	Lapatinib	60-69	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	50-56
31492693-8	2019	Further, the relative contributions of CYP3A4 and CYP3A5 to lapatinib O-debenzylation were estimated using selective chemical inhibitors of CYP3A.	Lapatinib	60-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-44
31492693-9	2019	The results from this study demonstrated that lapatinib O-debenzylation and quinone imine-GSH conjugate formation were highly correlated with hepatic CYP3A activity, as measured by midazolam 1"-hydroxylation.	Lapatinib	46-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-155
31492693-10	2019	CYP3A4 played a dominant role in lapatinib bioactivation in all liver tissues evaluated.	Lapatinib	33-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
31492693-11	2019	The CYP3A5 contribution to lapatinib bioactivation varied by individual donor and was dependent on CYP3A5 genotype and activity.	Lapatinib	27-36	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	4-10
31492693-11	2019	The CYP3A5 contribution to lapatinib bioactivation varied by individual donor and was dependent on CYP3A5 genotype and activity.	Lapatinib	27-36	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	99-105
31492693-12	2019	CYP3A5 contributed approximately 20%-42% to lapatinib O-debenzylation in livers from CYP3A5 expressers.	Lapatinib	44-53	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
31492693-12	2019	CYP3A5 contributed approximately 20%-42% to lapatinib O-debenzylation in livers from CYP3A5 expressers.	Lapatinib	44-53	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	85-91
31492693-13	2019	These findings indicate that individual CYP3A activity, not CYP3A5 genotype alone, is a key determinant of lapatinib bioactivation and likely influences exposure to reactive metabolites.	Lapatinib	107-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-45
31492693-13	2019	These findings indicate that individual CYP3A activity, not CYP3A5 genotype alone, is a key determinant of lapatinib bioactivation and likely influences exposure to reactive metabolites.	Lapatinib	107-116	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	60-66
31492693-14	2019	SIGNIFICANCE STATEMENT: This study is the first to examine the effect of CYP3A5 genotype, total CYP3A activity, and CYP3A5-selective activity on lapatinib bioactivation in individual human liver tissues.	Lapatinib	145-154	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	73-79
31492693-14	2019	SIGNIFICANCE STATEMENT: This study is the first to examine the effect of CYP3A5 genotype, total CYP3A activity, and CYP3A5-selective activity on lapatinib bioactivation in individual human liver tissues.	Lapatinib	145-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-78
31492693-14	2019	SIGNIFICANCE STATEMENT: This study is the first to examine the effect of CYP3A5 genotype, total CYP3A activity, and CYP3A5-selective activity on lapatinib bioactivation in individual human liver tissues.	Lapatinib	145-154	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	116-122
31492693-15	2019	The results of this investigation indicate that lapatinib bioactivation via oxidative O-debenzylation is highly correlated with total hepatic CYP3A activity, and not CYP3A5 genotype alone.	Lapatinib	48-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-147
31492693-15	2019	The results of this investigation indicate that lapatinib bioactivation via oxidative O-debenzylation is highly correlated with total hepatic CYP3A activity, and not CYP3A5 genotype alone.	Lapatinib	48-57	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	166-172
31492693-16	2019	These findings provide insight into the individual factors, namely, CYP3A activity, that may affect individual exposure to reactive, potentially toxic metabolites of lapatinib.	Lapatinib	166-175	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-73
31431454-7	2019	HER2 V659E cPAC cell lines displayed constitutive phosphorylation of AKT and significantly higher sensitivity to the HER2 inhibitors lapatinib and neratinib relative to HER2-wild-type cell lines (IC50 &lt; 200 nmol/L in HER2 V659E vs. IC50 &gt; 2,500 nmol/L in HER2 WT).Conclusions: This study creates a foundation for molecular understanding of and drug development for canine lung cancer.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	0-4
31431454-7	2019	HER2 V659E cPAC cell lines displayed constitutive phosphorylation of AKT and significantly higher sensitivity to the HER2 inhibitors lapatinib and neratinib relative to HER2-wild-type cell lines (IC50 &lt; 200 nmol/L in HER2 V659E vs. IC50 &gt; 2,500 nmol/L in HER2 WT).Conclusions: This study creates a foundation for molecular understanding of and drug development for canine lung cancer.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	117-121
31431454-7	2019	HER2 V659E cPAC cell lines displayed constitutive phosphorylation of AKT and significantly higher sensitivity to the HER2 inhibitors lapatinib and neratinib relative to HER2-wild-type cell lines (IC50 &lt; 200 nmol/L in HER2 V659E vs. IC50 &gt; 2,500 nmol/L in HER2 WT).Conclusions: This study creates a foundation for molecular understanding of and drug development for canine lung cancer.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	117-121
31431454-7	2019	HER2 V659E cPAC cell lines displayed constitutive phosphorylation of AKT and significantly higher sensitivity to the HER2 inhibitors lapatinib and neratinib relative to HER2-wild-type cell lines (IC50 &lt; 200 nmol/L in HER2 V659E vs. IC50 &gt; 2,500 nmol/L in HER2 WT).Conclusions: This study creates a foundation for molecular understanding of and drug development for canine lung cancer.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	117-121
31431454-7	2019	HER2 V659E cPAC cell lines displayed constitutive phosphorylation of AKT and significantly higher sensitivity to the HER2 inhibitors lapatinib and neratinib relative to HER2-wild-type cell lines (IC50 &lt; 200 nmol/L in HER2 V659E vs. IC50 &gt; 2,500 nmol/L in HER2 WT).Conclusions: This study creates a foundation for molecular understanding of and drug development for canine lung cancer.	Lapatinib	133-142	erb-b2 receptor tyrosine kinase 2	Canis lupus familiaris	117-121
31234033-4	2019	Lapatinib induced cytotoxicity on MDA-MB-231 cell line by elevating the concentration and its IC50 value was 32.5 muM after 24 h. Lapatinib increased apoptotic cells and micronuclei in binucleated cells gradually by increasing the concentration for 24 h. The EGFR protein expression was reduced by double fold that expressed in non-treated cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	259-263
31234033-4	2019	Lapatinib induced cytotoxicity on MDA-MB-231 cell line by elevating the concentration and its IC50 value was 32.5 muM after 24 h. Lapatinib increased apoptotic cells and micronuclei in binucleated cells gradually by increasing the concentration for 24 h. The EGFR protein expression was reduced by double fold that expressed in non-treated cells.	Lapatinib	130-139	epidermal growth factor receptor	Homo sapiens	259-263
31234033-5	2019	Lapatinib enhanced deletion of EGFR gene signals highly significantly from the lowest concentration.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	31-35
31234033-6	2019	Alternatively, lapatinib amplified signals of TP53 gene effectively by raising the concentration.	Lapatinib	15-24	tumor protein p53	Homo sapiens	46-50
30273693-5	2019	The transactivation of the EGFR and HER2 was inhibited by gefitinib or lapatinib (tyrosine kinase inhibitors), PACAP (6-38) (PAC1 antagonist), N-acetylcysteine (NAC is an anti-oxidant) or dipheyleneiodonium (DPI is an inhibitor of Nox and Duox enzymes).	Lapatinib	71-80	epidermal growth factor receptor	Homo sapiens	27-31
30273693-5	2019	The transactivation of the EGFR and HER2 was inhibited by gefitinib or lapatinib (tyrosine kinase inhibitors), PACAP (6-38) (PAC1 antagonist), N-acetylcysteine (NAC is an anti-oxidant) or dipheyleneiodonium (DPI is an inhibitor of Nox and Duox enzymes).	Lapatinib	71-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-40
31477168-2	2019	Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel has shown efficacy in patients with metastatic HER2-positive breast cancer.	Lapatinib	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
31477168-14	2019	CONCLUSION: In early-stage HER2-positive breast cancer, the neoadjuvant treatment with T-DM1, lapatinib, and nab-paclitaxel was more effective than the standard treatment, particularly in the ER-positive cohort.	Lapatinib	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
31477168-14	2019	CONCLUSION: In early-stage HER2-positive breast cancer, the neoadjuvant treatment with T-DM1, lapatinib, and nab-paclitaxel was more effective than the standard treatment, particularly in the ER-positive cohort.	Lapatinib	94-103	estrogen receptor 1	Homo sapiens	28-30
31125894-2	2019	The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors.	Lapatinib	107-116	epidermal growth factor receptor	Homo sapiens	154-158
31492560-8	2019	FINDINGS: Induced expression of constitutively active SYK130E reduced cellular response to EGFR/ERBB2 inhibitor, lapatinib.	Lapatinib	113-122	epidermal growth factor receptor	Homo sapiens	91-95
31492560-8	2019	FINDINGS: Induced expression of constitutively active SYK130E reduced cellular response to EGFR/ERBB2 inhibitor, lapatinib.	Lapatinib	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-101
30590459-0	2019	Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.	Lapatinib	0-9	annexin A6	Homo sapiens	18-28
30590459-0	2019	Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	108-112
30590459-4	2019	Here, we demonstrate that prolong (>3 days) treatment of AnxA6-low TNBC cells with lapatinib led to AnxA6 upregulation and accumulation of cholesterol in late endosomes.	Lapatinib	83-92	annexin A6	Homo sapiens	57-62
30590459-4	2019	Here, we demonstrate that prolong (>3 days) treatment of AnxA6-low TNBC cells with lapatinib led to AnxA6 upregulation and accumulation of cholesterol in late endosomes.	Lapatinib	83-92	annexin A6	Homo sapiens	100-105
30590459-5	2019	Basal extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation was EGFR independent and significantly higher in lapatinib-resistant MDA-MB-468 (LAP-R) cells.	Lapatinib	121-130	mitogen-activated protein kinase 1	Homo sapiens	6-51
30590459-5	2019	Basal extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation was EGFR independent and significantly higher in lapatinib-resistant MDA-MB-468 (LAP-R) cells.	Lapatinib	121-130	mitogen-activated protein kinase 3	Homo sapiens	53-59
30590459-5	2019	Basal extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation was EGFR independent and significantly higher in lapatinib-resistant MDA-MB-468 (LAP-R) cells.	Lapatinib	121-130	epidermal growth factor receptor	Homo sapiens	76-80
30590459-5	2019	Basal extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation was EGFR independent and significantly higher in lapatinib-resistant MDA-MB-468 (LAP-R) cells.	Lapatinib	121-130	LAP	Homo sapiens	153-156
30590459-7	2019	Inhibition of lapatinib-induced upregulation of AnxA6 by RNA interference (A6sh) or withdrawal lapatinib from LAP-R cells not only reversed the accumulation of cholesterol in late endosomes but also led to enrichment of plasma membranes with cholesterol, restored EGFR-dependent activation of ERK1/2 and sensitized the cells to lapatinib.	Lapatinib	14-23	annexin A6	Homo sapiens	48-53
30590459-7	2019	Inhibition of lapatinib-induced upregulation of AnxA6 by RNA interference (A6sh) or withdrawal lapatinib from LAP-R cells not only reversed the accumulation of cholesterol in late endosomes but also led to enrichment of plasma membranes with cholesterol, restored EGFR-dependent activation of ERK1/2 and sensitized the cells to lapatinib.	Lapatinib	14-23	epidermal growth factor receptor	Homo sapiens	264-268
30590459-7	2019	Inhibition of lapatinib-induced upregulation of AnxA6 by RNA interference (A6sh) or withdrawal lapatinib from LAP-R cells not only reversed the accumulation of cholesterol in late endosomes but also led to enrichment of plasma membranes with cholesterol, restored EGFR-dependent activation of ERK1/2 and sensitized the cells to lapatinib.	Lapatinib	14-23	mitogen-activated protein kinase 3	Homo sapiens	293-299
30590459-7	2019	Inhibition of lapatinib-induced upregulation of AnxA6 by RNA interference (A6sh) or withdrawal lapatinib from LAP-R cells not only reversed the accumulation of cholesterol in late endosomes but also led to enrichment of plasma membranes with cholesterol, restored EGFR-dependent activation of ERK1/2 and sensitized the cells to lapatinib.	Lapatinib	95-104	LAP	Homo sapiens	110-113
30590459-7	2019	Inhibition of lapatinib-induced upregulation of AnxA6 by RNA interference (A6sh) or withdrawal lapatinib from LAP-R cells not only reversed the accumulation of cholesterol in late endosomes but also led to enrichment of plasma membranes with cholesterol, restored EGFR-dependent activation of ERK1/2 and sensitized the cells to lapatinib.	Lapatinib	95-104	LAP	Homo sapiens	110-113
31377477-1	2019	BACKGROUND: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti-human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel.	Lapatinib	12-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	203-207
30590459-8	2019	These data suggest that lapatinib-induced AnxA6 expression and accumulation of cholesterol in late endosomes constitute an adaptive mechanism for EGFR-expressing TNBC cells to overcome prolong treatment with EGFR-targeted TKIs and can be exploited as an option to inhibit and/or monitor the frequently observed acquired resistance to these drugs.	Lapatinib	24-33	annexin A6	Homo sapiens	42-47
30590459-8	2019	These data suggest that lapatinib-induced AnxA6 expression and accumulation of cholesterol in late endosomes constitute an adaptive mechanism for EGFR-expressing TNBC cells to overcome prolong treatment with EGFR-targeted TKIs and can be exploited as an option to inhibit and/or monitor the frequently observed acquired resistance to these drugs.	Lapatinib	24-33	epidermal growth factor receptor	Homo sapiens	146-150
30590459-8	2019	These data suggest that lapatinib-induced AnxA6 expression and accumulation of cholesterol in late endosomes constitute an adaptive mechanism for EGFR-expressing TNBC cells to overcome prolong treatment with EGFR-targeted TKIs and can be exploited as an option to inhibit and/or monitor the frequently observed acquired resistance to these drugs.	Lapatinib	24-33	epidermal growth factor receptor	Homo sapiens	208-212
31125894-2	2019	The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors.	Lapatinib	107-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
31219517-0	2019	Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
31187169-12	2019	This study confirms the need for caution in patients with solid tumors treated with lapatinib, and who are concomitantly receiving drugs that are strong CYP3A inhibitors and/or prolong the QTc.	Lapatinib	84-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-158
31357743-0	2019	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.	Lapatinib	30-39	E1A binding protein p300	Homo sapiens	0-5
31357743-0	2019	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.	Lapatinib	30-39	sirtuin 1	Homo sapiens	10-17
31357743-0	2019	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.	Lapatinib	30-39	forkhead box O3	Homo sapiens	67-72
31357743-6	2019	In addition, using SIRT1/6 specific siRNAs and chemical inhibitor, we also found that sirtuin 1 and -6 (SIRT1 and -6) play a part in fine-tuning FOXO3 acetylation and lapatinib sensitivity.	Lapatinib	167-176	sirtuin 1	Homo sapiens	19-24
31357743-2	2019	In this study, using the BT474 breast cancer cells and a recently established lapatinib resistant (BT474-LapR) cell line, we observed that higher FOXO3 and acetylated (Ac)-FOXO3 levels correlate with lapatinib sensitivity.	Lapatinib	78-87	forkhead box O3	Homo sapiens	146-151
31357743-6	2019	In addition, using SIRT1/6 specific siRNAs and chemical inhibitor, we also found that sirtuin 1 and -6 (SIRT1 and -6) play a part in fine-tuning FOXO3 acetylation and lapatinib sensitivity.	Lapatinib	167-176	sirtuin 1	Homo sapiens	86-102
31357743-2	2019	In this study, using the BT474 breast cancer cells and a recently established lapatinib resistant (BT474-LapR) cell line, we observed that higher FOXO3 and acetylated (Ac)-FOXO3 levels correlate with lapatinib sensitivity.	Lapatinib	78-87	forkhead box O3	Homo sapiens	172-177
31357743-6	2019	In addition, using SIRT1/6 specific siRNAs and chemical inhibitor, we also found that sirtuin 1 and -6 (SIRT1 and -6) play a part in fine-tuning FOXO3 acetylation and lapatinib sensitivity.	Lapatinib	167-176	sirtuin 1	Homo sapiens	104-116
31357743-2	2019	In this study, using the BT474 breast cancer cells and a recently established lapatinib resistant (BT474-LapR) cell line, we observed that higher FOXO3 and acetylated (Ac)-FOXO3 levels correlate with lapatinib sensitivity.	Lapatinib	200-209	forkhead box O3	Homo sapiens	146-151
31357743-8	2019	Collectively, our results suggest the involvement of FOXO3 acetylation in regulating lapatinib sensitivity of HER2-positive breast cancers.	Lapatinib	85-94	forkhead box O3	Homo sapiens	53-58
31357743-2	2019	In this study, using the BT474 breast cancer cells and a recently established lapatinib resistant (BT474-LapR) cell line, we observed that higher FOXO3 and acetylated (Ac)-FOXO3 levels correlate with lapatinib sensitivity.	Lapatinib	200-209	forkhead box O3	Homo sapiens	172-177
31340525-4	2019	This study showed that four epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) (gefitinib, erlotinib, lapatinib, and afatinib) were transported from tumor cells as substrates of ABCG2.	Lapatinib	123-132	epidermal growth factor receptor	Homo sapiens	89-93
31340525-4	2019	This study showed that four epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) (gefitinib, erlotinib, lapatinib, and afatinib) were transported from tumor cells as substrates of ABCG2.	Lapatinib	123-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	199-204
31142682-3	2019	HER2 is a promising therapeutic target of these tumors, and HER2-targeted drugs, such as trastuzumab and lapatinib, have improved the outcome of these patients.	Lapatinib	105-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
31262849-0	2019	A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.	Lapatinib	76-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
31312984-0	2019	Theoretical study on the mechanism of N- and alpha-carbon oxidation of lapatinib catalyzed by cytochrome P450 monooxygenase.	Lapatinib	71-80	cytochrome P450 family 20 subfamily A member 1	Homo sapiens	94-123
31312984-4	2019	In this study, the N- and alpha-carbon oxidation processes of lapatinib catalyzed by CYP3A4 were explored by density functional theory method.	Lapatinib	62-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
30624609-0	2019	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.	Lapatinib	197-206	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-6
31262849-4	2019	Vinorelbine and lapatinib is a combination used in later-line treatment of metastatic HER2-positive breast cancer.	Lapatinib	16-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
31262849-5	2019	The current article presents a systematic review and meta-analysis of prospective series of the vinorelbine/lapatinib doublet for efficacy and toxicity in metastatic HER2-positive breast cancer.	Lapatinib	108-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
31262849-10	2019	Vinorelbine/ lapatinib combination regimen may serve as an option for pre-treated patients with metastatic HER2-positive breast cancer.	Lapatinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
30977027-0	2019	Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-73
30977027-1	2019	PURPOSE: Lapatinib (L) is approved in combination with capecitabine or letrozole for patients with trastuzumab-resistant HER2-positive metastatic breast cancer (MBC).	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
31528467-0	2019	A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-79
31262905-6	2019	In a detailed quantitative analysis using lower doses, we demonstrated that lapatinib, with high P-gp inhibitory activity, yielded the best pairing for sensitizing P-gp-overexpressing KBV20C cells to vincristine.	Lapatinib	76-85	ATP binding cassette subfamily B member 1	Homo sapiens	97-101
31262905-6	2019	In a detailed quantitative analysis using lower doses, we demonstrated that lapatinib, with high P-gp inhibitory activity, yielded the best pairing for sensitizing P-gp-overexpressing KBV20C cells to vincristine.	Lapatinib	76-85	ATP binding cassette subfamily B member 1	Homo sapiens	164-168
31262905-8	2019	Lapatinib was shown to have a higher P-gp-inhibitory activity than verapamil, even at lower doses, indicating that its sensitizing of cells to vincristine involves its P-gp-inhibitory effects.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
31262905-8	2019	Lapatinib was shown to have a higher P-gp-inhibitory activity than verapamil, even at lower doses, indicating that its sensitizing of cells to vincristine involves its P-gp-inhibitory effects.	Lapatinib	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	168-172
31170116-4	2019	Although phase 2 trial data support the use of the combination of trastuzumab and lapatinib with chemotherapy in HER2-positive colorectal cancer, the patient"s benefit from targeted treatment of HER2-positive biliary or pancreatic neoplasms is currently unclear, and further clinical trials are necessary.	Lapatinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
30880293-0	2019	Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.	Lapatinib	0-9	pro-opiomelanocortin-alpha	Mus musculus	24-28
30880293-5	2019	We investigated the effect of a potent dual tyrosine kinase inhibitor, lapatinib, on ACTH production and cell proliferation in AtT-20 mouse corticotroph tumor cells.	Lapatinib	71-80	pro-opiomelanocortin-alpha	Mus musculus	85-89
30880293-6	2019	Lapatinib decreased proopiomelanocortin (Pomc) mRNA levels and ACTH levels in AtT-20 cells and also inhibited cell proliferation, induced apoptosis, and decreased pituitary tumor-transforming gene 1 (Pttg1), a hallmark of pituitary tumors, mRNA levels.	Lapatinib	0-9	pro-opiomelanocortin-alpha	Mus musculus	20-39
30880293-6	2019	Lapatinib decreased proopiomelanocortin (Pomc) mRNA levels and ACTH levels in AtT-20 cells and also inhibited cell proliferation, induced apoptosis, and decreased pituitary tumor-transforming gene 1 (Pttg1), a hallmark of pituitary tumors, mRNA levels.	Lapatinib	0-9	pro-opiomelanocortin-alpha	Mus musculus	41-45
30880293-6	2019	Lapatinib decreased proopiomelanocortin (Pomc) mRNA levels and ACTH levels in AtT-20 cells and also inhibited cell proliferation, induced apoptosis, and decreased pituitary tumor-transforming gene 1 (Pttg1), a hallmark of pituitary tumors, mRNA levels.	Lapatinib	0-9	pro-opiomelanocortin-alpha	Mus musculus	63-67
30880293-6	2019	Lapatinib decreased proopiomelanocortin (Pomc) mRNA levels and ACTH levels in AtT-20 cells and also inhibited cell proliferation, induced apoptosis, and decreased pituitary tumor-transforming gene 1 (Pttg1), a hallmark of pituitary tumors, mRNA levels.	Lapatinib	0-9	pituitary tumor-transforming gene 1	Mus musculus	163-198
30880293-6	2019	Lapatinib decreased proopiomelanocortin (Pomc) mRNA levels and ACTH levels in AtT-20 cells and also inhibited cell proliferation, induced apoptosis, and decreased pituitary tumor-transforming gene 1 (Pttg1), a hallmark of pituitary tumors, mRNA levels.	Lapatinib	0-9	pituitary tumor-transforming gene 1	Mus musculus	200-205
30880293-10	2019	Lapatinib also significantly decreased Pomc and Pttg1 mRNA levels in the tumor and plasma ACTH and corticosterone levels in vivo.	Lapatinib	0-9	pro-opiomelanocortin-alpha	Mus musculus	39-43
30880293-10	2019	Lapatinib also significantly decreased Pomc and Pttg1 mRNA levels in the tumor and plasma ACTH and corticosterone levels in vivo.	Lapatinib	0-9	pituitary tumor-transforming gene 1	Mus musculus	48-53
30880293-10	2019	Lapatinib also significantly decreased Pomc and Pttg1 mRNA levels in the tumor and plasma ACTH and corticosterone levels in vivo.	Lapatinib	0-9	pro-opiomelanocortin-alpha	Mus musculus	90-94
30880293-11	2019	Thus, lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.	Lapatinib	6-15	pro-opiomelanocortin-alpha	Mus musculus	30-34
31209328-5	2019	RESULTS: Lapatinib increased intratumoral HER2 protein, which encouraged resistance to this treatment in mouse models.	Lapatinib	9-18	erb-b2 receptor tyrosine kinase 2	Mus musculus	42-46
31209328-6	2019	Sera from CRPC patients following lapatinib treatment demonstrated increased HER2 levels.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	34-43	epidermal growth factor receptor	Homo sapiens	157-161
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	80-89	epidermal growth factor receptor	Homo sapiens	157-161
31209328-7	2019	Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
31209328-8	2019	Knockdown of HER2 and ErbB3, but not EGFR, sensitised CRPC cells to lapatinib.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
31209328-8	2019	Knockdown of HER2 and ErbB3, but not EGFR, sensitised CRPC cells to lapatinib.	Lapatinib	68-77	erb-b2 receptor tyrosine kinase 3	Homo sapiens	22-27
31059070-0	2019	Fingolimod sensitizes EGFR wild-type non-small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.	Lapatinib	73-82	epidermal growth factor receptor	Homo sapiens	22-26
31528467-9	2019	Conclusion: We treated a patient with LM from primary HER2-positive breast cancer who responded well to lapatinib plus capecitabine.	Lapatinib	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
31460159-2	2019	The dual EGFR/HER2 kinase inhibitor lapatinib has shown promising clinical results, but its limitations have also led to the resistance and activation of tumor survival pathways.	Lapatinib	36-45	epidermal growth factor receptor	Homo sapiens	9-13
31460159-2	2019	The dual EGFR/HER2 kinase inhibitor lapatinib has shown promising clinical results, but its limitations have also led to the resistance and activation of tumor survival pathways.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
31460159-4	2019	Two of these compounds were shown to be more effective than lapatinib at the inhibition of HER2 autophosphorylation of Y1248.	Lapatinib	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
31164152-6	2019	HER2-amplified cells were treated with several agents including anti-EGFR antibodies (cetuximab, SYM004 and MM151); anti-HER2 (trastuzumab, pertuzumab and lapatinib) inhibitors; anti-HER3 (duligotuzumab) inhibitors; and MEK and PI3KCA inhibitors, such as refametinib and pictilisib, as single agents and in combination.	Lapatinib	155-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
31097774-1	2019	BACKGROUND: Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops.	Lapatinib	168-177	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
31097774-1	2019	BACKGROUND: Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops.	Lapatinib	168-177	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
31097774-2	2019	In a preclinical model, an HDAC inhibitor epigenetically reversed the resistance of cancer cells to trastuzumab and showed synergistic efficacy with lapatinib in inhibiting growth of trastuzumab-resistant HER2-positive (HER2+) breast cancer.	Lapatinib	149-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
31097774-2	2019	In a preclinical model, an HDAC inhibitor epigenetically reversed the resistance of cancer cells to trastuzumab and showed synergistic efficacy with lapatinib in inhibiting growth of trastuzumab-resistant HER2-positive (HER2+) breast cancer.	Lapatinib	149-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	220-224
31097774-10	2019	DISCUSSION: This study identified the MTD of the entinostat, lapatinib, and trastuzumab combination that provided acceptable tolerability and anti-tumour activity in heavily pre-treated patients with HER2+ metastatic breast cancer, supporting a confirmatory trial.	Lapatinib	61-70	metallothionein 1E	Homo sapiens	38-41
31097774-10	2019	DISCUSSION: This study identified the MTD of the entinostat, lapatinib, and trastuzumab combination that provided acceptable tolerability and anti-tumour activity in heavily pre-treated patients with HER2+ metastatic breast cancer, supporting a confirmatory trial.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	200-204
31076567-7	2019	We observed synergistic effects on KatoIII cells as well as three additional gastric cancer cell lines with FGFR2 amplification when AZD4547 was combined with small molecular inhibitors Cpd22 and lapatinib targeting ILK and EGFR/HER2, respectively.	Lapatinib	196-205	integrin linked kinase	Homo sapiens	216-219
30903140-0	2019	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.	Lapatinib	79-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
30903140-4	2019	PATIENTS AND METHODS: Baseline HER2+ tumors from patients treated with neoadjuvant lapatinib plus trastuzumab (with endocrine therapy for estrogen receptor (ER)+ tumors) in TBCRC006 (NCT00548184) were evaluated in a central laboratory for HER2 amplification by FISH (n=56).	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
31106632-0	2019	Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma.	Lapatinib	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
31106632-6	2019	This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib, it can effectively target brain metastasis.	Lapatinib	132-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
31141894-2	2019	Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
31141894-2	2019	Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer.	Lapatinib	54-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
31141894-3	2019	Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	24-56
31141894-3	2019	Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	58-62
31141894-3	2019	Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	63-68
31141894-3	2019	Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	69-73
31141894-3	2019	Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
31141894-3	2019	Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
31141894-3	2019	Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
31076567-7	2019	We observed synergistic effects on KatoIII cells as well as three additional gastric cancer cell lines with FGFR2 amplification when AZD4547 was combined with small molecular inhibitors Cpd22 and lapatinib targeting ILK and EGFR/HER2, respectively.	Lapatinib	196-205	epidermal growth factor receptor	Homo sapiens	224-228
31076567-7	2019	We observed synergistic effects on KatoIII cells as well as three additional gastric cancer cell lines with FGFR2 amplification when AZD4547 was combined with small molecular inhibitors Cpd22 and lapatinib targeting ILK and EGFR/HER2, respectively.	Lapatinib	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	229-233
31092430-0	2019	Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways.	Lapatinib	0-9	amphiregulin	Homo sapiens	19-31
30726965-11	2019	CONCLUSION: The addition of concurrent lapatinib to SRS was associated with improved complete response rates among patients with HER2-positive brain metastases.	Lapatinib	39-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
31092430-0	2019	Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways.	Lapatinib	0-9	mitogen-activated protein kinase 3	Homo sapiens	92-98
31092430-0	2019	Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	103-106
31092430-3	2019	Lapatinib is a potent EGFR and human epidermal growth factor receptor 2 (HER2) inhibitor that inhibits cell proliferation and induces apoptosis in various human cancer cells.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	22-26
31092430-3	2019	Lapatinib is a potent EGFR and human epidermal growth factor receptor 2 (HER2) inhibitor that inhibits cell proliferation and induces apoptosis in various human cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-71
31092430-3	2019	Lapatinib is a potent EGFR and human epidermal growth factor receptor 2 (HER2) inhibitor that inhibits cell proliferation and induces apoptosis in various human cancer cells.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
31092430-9	2019	Moreover, AREG treatment stimulated BeWo cell proliferation by activating ERK1/2 and PI3K/AKT signaling pathways, which was blocked by lapatinib.	Lapatinib	135-144	amphiregulin	Homo sapiens	10-14
31092430-9	2019	Moreover, AREG treatment stimulated BeWo cell proliferation by activating ERK1/2 and PI3K/AKT signaling pathways, which was blocked by lapatinib.	Lapatinib	135-144	AKT serine/threonine kinase 1	Homo sapiens	90-93
31024833-4	2019	Lapatinib is an important alternative to treat tumors that presents this phenotype due to its ability to inhibit tyrosine kinase residues associated with HER1 and HER2 receptors.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	154-158
31024833-4	2019	Lapatinib is an important alternative to treat tumors that presents this phenotype due to its ability to inhibit tyrosine kinase residues associated with HER1 and HER2 receptors.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
30957209-5	2019	Patients with HER2-positive disease have a number of treatment options, including ado-trastuzumab emtansine (TDM1) or lapatinib-capecitabine, and there is emerging evidence of the efficacy of neratinib- and tucatinib-based chemotherapy combinations in the CNS.	Lapatinib	118-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
30987650-3	2019	The latter can be induced by target-based agents such as Lapatinib, an anti-HER2 tyrosine kinase inhibitor (TKI) largely used in breast cancer treatment.	Lapatinib	57-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
30987650-4	2019	METHODS: Here we investigate whether G6PD inhibition causes autophagy alteration, which can potentiate Lapatinib effect on cancer cells.	Lapatinib	103-112	glucose-6-phosphate dehydrogenase	Homo sapiens	37-41
30987650-7	2019	We generated a cell line overexpressing G6PD and performed synergism studies on cell growth inhibition induced by Lapatinib and Polydatin using the median effect by Chou-Talay.	Lapatinib	114-123	glucose-6-phosphate dehydrogenase	Homo sapiens	40-44
30987650-11	2019	Cells engineered to overexpress G6PD became resilient to autophagy and resistant to lapatinib.	Lapatinib	84-93	glucose-6-phosphate dehydrogenase	Homo sapiens	32-36
30987650-12	2019	On the other hand, G6PD inhibition synergistically increased lapatinib-induced cytotoxic effect on cancer cells, while autophagy blockade abolished this effect.	Lapatinib	61-70	glucose-6-phosphate dehydrogenase	Homo sapiens	19-23
30907562-0	2019	Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.	Lapatinib	27-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
30959904-0	2019	Cytotoxic Effect of Paclitaxel and Lapatinib Co-Delivered in Polylactide-co-Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells.	Lapatinib	35-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-115
30665034-9	2019	Additionally compounds 4b, 7a and 9 showed more potent activity against EGFR than Lapatinib, their IC50 values are from 0.019 to 0.026 microM while IC50 of Lapatinib is 0.028 microM.	Lapatinib	156-165	epidermal growth factor receptor	Homo sapiens	72-76
30538297-7	2019	In selected HER2-positive breast-cancer cells, we demonstrate synergistic interactions between KDM5-inh1 and HER2-targeting agents (trastuzumab and lapatinib).	Lapatinib	148-157	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
30538297-7	2019	In selected HER2-positive breast-cancer cells, we demonstrate synergistic interactions between KDM5-inh1 and HER2-targeting agents (trastuzumab and lapatinib).	Lapatinib	148-157	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
30898150-9	2019	However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models.	Lapatinib	131-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-113
30504425-3	2019	EXPERIMENTAL DESIGN: We generated lapatinib- and trastuzumab-resistant clones deriving from two different HER2-amplified gastric cancer cell lines.	Lapatinib	34-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
30260048-10	2019	Thus, inhibiting ErbB1 and ErbB2 by lapatinib or blocking cell division by paclitaxel or their combination causes significant trabecular bone loss and bone marrow adiposity involving a switch in osteogenesis/adipogenesis potential, altered expression of some major molecules of the Wnt/beta-catenin signalling pathway, and increased recruitment of bone-resorbing osteoclasts.	Lapatinib	36-45	epidermal growth factor receptor	Rattus norvegicus	17-22
30260048-10	2019	Thus, inhibiting ErbB1 and ErbB2 by lapatinib or blocking cell division by paclitaxel or their combination causes significant trabecular bone loss and bone marrow adiposity involving a switch in osteogenesis/adipogenesis potential, altered expression of some major molecules of the Wnt/beta-catenin signalling pathway, and increased recruitment of bone-resorbing osteoclasts.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	27-32
30260048-3	2019	This study examined the effects of individual or combination treatments with breast cancer drugs lapatinib (a dual ErbB1/ErbB2 inhibitor) and paclitaxel (a microtubule-stabilizing cytotoxic agent) on bone and bone marrow of rats.	Lapatinib	97-106	epidermal growth factor receptor	Rattus norvegicus	115-120
30907562-1	2019	This study aimed to evaluate the clinical efficacy of trastuzumab combined with lapatinib in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-150
30907562-1	2019	This study aimed to evaluate the clinical efficacy of trastuzumab combined with lapatinib in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
30842786-1	2019	Lapatinib is a small molecule inhibitor of EGFR (HER1) and ERBB2 (HER2) receptors, which is used for treatment of advanced or metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-64
30842786-0	2019	LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib.	Lapatinib	85-94	serine peptidase inhibitor, Kunitz type 1	Homo sapiens	18-24
30842786-1	2019	Lapatinib is a small molecule inhibitor of EGFR (HER1) and ERBB2 (HER2) receptors, which is used for treatment of advanced or metastatic breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
30842786-0	2019	LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib.	Lapatinib	85-94	prostaglandin D2 receptor	Homo sapiens	25-28
30842786-4	2019	We found that the expression of EGFR/ERBB2 and activation of ERBB pathway was significantly related to Lapatinib sensitivity.	Lapatinib	103-112	epidermal growth factor receptor	Homo sapiens	32-36
30842786-1	2019	Lapatinib is a small molecule inhibitor of EGFR (HER1) and ERBB2 (HER2) receptors, which is used for treatment of advanced or metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	43-47
30842786-1	2019	Lapatinib is a small molecule inhibitor of EGFR (HER1) and ERBB2 (HER2) receptors, which is used for treatment of advanced or metastatic breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	49-53
30842786-4	2019	We found that the expression of EGFR/ERBB2 and activation of ERBB pathway was significantly related to Lapatinib sensitivity.	Lapatinib	103-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-42
30842786-4	2019	We found that the expression of EGFR/ERBB2 and activation of ERBB pathway was significantly related to Lapatinib sensitivity.	Lapatinib	103-112	epidermal growth factor receptor	Homo sapiens	37-41
30842786-12	2019	In further experiments, GIHCG knockdown enhanced cancer cell susceptibility to Lapatinib, while high level of SPINT1-AS1 was a sensitive biomarker of NCI-N87 and MCF7 cancer cells to Lapatinib.	Lapatinib	183-192	serine peptidase inhibitor, Kunitz type 1	Homo sapiens	110-116
30842786-12	2019	In further experiments, GIHCG knockdown enhanced cancer cell susceptibility to Lapatinib, while high level of SPINT1-AS1 was a sensitive biomarker of NCI-N87 and MCF7 cancer cells to Lapatinib.	Lapatinib	183-192	prostaglandin D2 receptor	Homo sapiens	117-120
30842786-13	2019	In conclusions, lncRNAs GIHCG and SPINT1-AS1 were involved in regulating Lapatinib sensitivity.	Lapatinib	73-82	serine peptidase inhibitor, Kunitz type 1	Homo sapiens	34-40
30842786-13	2019	In conclusions, lncRNAs GIHCG and SPINT1-AS1 were involved in regulating Lapatinib sensitivity.	Lapatinib	73-82	prostaglandin D2 receptor	Homo sapiens	41-44
30781364-8	2019	Combined sub-effective treatments of OC-LP resulted in synergistic anti-proliferative effects against the HER2-positive BT-474 and SK-BR-3 breast cancer cell lines, compared to OC or LP monotherapy.	Lapatinib	40-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
30781364-9	2019	Antibody array and Western blot analysis showed that combined OC-LP treatment significantly inhibited EGFR, HER2, and c-Met receptor activation, as well as multiple downstream signaling proteins, compared to individual OC or LP treatment.	Lapatinib	65-67	epidermal growth factor receptor	Homo sapiens	102-106
30781364-0	2019	(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.	Lapatinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-74
30781364-5	2019	Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	39-43
30786890-7	2019	The synergistic effects of lovastatin with the ErbB2 inhibitor lapatinib were evaluated using an ErbB2-positive breast cancer xenograft mouse model.	Lapatinib	63-72	erb-b2 receptor tyrosine kinase 2	Mus musculus	47-52
30781364-9	2019	Antibody array and Western blot analysis showed that combined OC-LP treatment significantly inhibited EGFR, HER2, and c-Met receptor activation, as well as multiple downstream signaling proteins, compared to individual OC or LP treatment.	Lapatinib	65-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
30781364-5	2019	Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
30781364-9	2019	Antibody array and Western blot analysis showed that combined OC-LP treatment significantly inhibited EGFR, HER2, and c-Met receptor activation, as well as multiple downstream signaling proteins, compared to individual OC or LP treatment.	Lapatinib	65-67	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	118-123
30781364-5	2019	Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
30781364-5	2019	Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer.	Lapatinib	11-13	epidermal growth factor receptor	Homo sapiens	39-43
30786890-11	2019	Lovastatin also synergized with lapatinib to strongly suppress the in vivo growth of ErbB2-positive breast cancer xenografts.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Mus musculus	85-90
30781364-12	2019	Activated c-Met, EGFR, HER2, and protein kinase B (AKT) were significantly suppressed in combination-treated mice tumors, compared to OC or LP monotherapy.	Lapatinib	140-142	thymoma viral proto-oncogene 1	Mus musculus	51-54
30781364-5	2019	Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer.	Lapatinib	11-13	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
30781364-5	2019	Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer.	Lapatinib	11-13	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
30781364-6	2019	HER2-Positive tumor cells can escape targeted therapies like LP effects by overexpressing c-Met.	Lapatinib	61-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
30738402-3	2019	Lapatinib is a small-molecule dual HER2/epidermal growth factor receptor inhibitor that has demonstrated intracranial activity against HER2+ breast cancer brain metastases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
30781364-6	2019	HER2-Positive tumor cells can escape targeted therapies like LP effects by overexpressing c-Met.	Lapatinib	61-63	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	90-95
30566834-1	2019	CD44 receptor and mitochondria targeting hyaluronic acid-d-alpha-tocopherol succinate-(4-carboxybutyl)triphenyl phosphonium bromide (HA-TS-TPP)-based nanoparticles (NPs) were designed for the delivery of lapatinib (LPT) to triple-negative breast cancer (TNBC).	Lapatinib	204-213	CD44 molecule (Indian blood group)	Homo sapiens	0-4
30566834-1	2019	CD44 receptor and mitochondria targeting hyaluronic acid-d-alpha-tocopherol succinate-(4-carboxybutyl)triphenyl phosphonium bromide (HA-TS-TPP)-based nanoparticles (NPs) were designed for the delivery of lapatinib (LPT) to triple-negative breast cancer (TNBC).	Lapatinib	215-218	CD44 molecule (Indian blood group)	Homo sapiens	0-4
30611900-2	2019	This methodology was successfully applied to two different clinically relevant combinations, gemcitabine/doxorubicin (Gem/Dox) and gemcitabine/lapatinib (Gem/Lap), showing a certain degree of universality of the synthetic methodology.	Lapatinib	143-152	LAP	Homo sapiens	158-161
30743996-4	2019	We found that lapatinib treatment resulted in phenotypic alterations consistent with a senescent phenotype and strong SA-beta-gal activity in HER2-positive cell lines.	Lapatinib	14-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-146
30743996-5	2019	Lapatinib-induced senescence was associated with elevated levels of p15 and p27 but was not dependent on the expression of p16 or p21.	Lapatinib	0-9	cyclin dependent kinase inhibitor 2B	Homo sapiens	68-71
30738402-3	2019	Lapatinib is a small-molecule dual HER2/epidermal growth factor receptor inhibitor that has demonstrated intracranial activity against HER2+ breast cancer brain metastases.	Lapatinib	0-9	epidermal growth factor receptor	Homo sapiens	40-72
30743996-5	2019	Lapatinib-induced senescence was associated with elevated levels of p15 and p27 but was not dependent on the expression of p16 or p21.	Lapatinib	0-9	interferon alpha inducible protein 27	Homo sapiens	76-79
30738402-3	2019	Lapatinib is a small-molecule dual HER2/epidermal growth factor receptor inhibitor that has demonstrated intracranial activity against HER2+ breast cancer brain metastases.	Lapatinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-139
30738402-17	2019	CONCLUSIONS: For patients with HER2+ breast cancer brain metastases, the use of lapatinib concurrently with SRS improved local control of brain metastases, without an increased rate of radiation necrosis.	Lapatinib	80-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
30743996-6	2019	Restoring wild type p53 activity either by transfection or by treatment with APR-246, a molecule which reactivates mutant p53, blocked lapatinib-induced senescence and caused increased cell death.	Lapatinib	135-144	tumor protein p53	Homo sapiens	20-23
30743996-6	2019	Restoring wild type p53 activity either by transfection or by treatment with APR-246, a molecule which reactivates mutant p53, blocked lapatinib-induced senescence and caused increased cell death.	Lapatinib	135-144	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	77-80
30743996-6	2019	Restoring wild type p53 activity either by transfection or by treatment with APR-246, a molecule which reactivates mutant p53, blocked lapatinib-induced senescence and caused increased cell death.	Lapatinib	135-144	tumor protein p53	Homo sapiens	122-125
30743996-7	2019	In contrast to lapatinib, SA-beta-gal activity was not induced by exposing the cells to trastuzumab as a single agent but co-administration of lapatinib and trastuzumab induced senescence, as did treatment of the cells with the irreversible HER2 TKIs neratinib and afatinib.	Lapatinib	143-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	241-245
30738402-19	2019	In patients who underwent SRS for HER2+ breast cancer brain metastases, the use of lapatinib at any time point in the therapy course was associated with a survival benefit.	Lapatinib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
30242055-6	2019	Thy1-low cells are sensitive to the EGFR/HER2 dual inhibitor lapatinib.	Lapatinib	61-70	Thy-1 cell surface antigen	Homo sapiens	0-4
30711950-2	2019	Interestingly, our previous study unexpectedly showed that full-length HBx sensitized HCC cells to lapatinib by up-regulating erb-b2 receptor tyrosine kinase 3 (ERBB3).	Lapatinib	99-108	X protein	Hepatitis B virus	71-74
30711950-2	2019	Interestingly, our previous study unexpectedly showed that full-length HBx sensitized HCC cells to lapatinib by up-regulating erb-b2 receptor tyrosine kinase 3 (ERBB3).	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 3	Homo sapiens	126-159
30711950-2	2019	Interestingly, our previous study unexpectedly showed that full-length HBx sensitized HCC cells to lapatinib by up-regulating erb-b2 receptor tyrosine kinase 3 (ERBB3).	Lapatinib	99-108	erb-b2 receptor tyrosine kinase 3	Homo sapiens	161-166
30711950-3	2019	We further aimed to map the exact motif within the HBx sequence responsible for lapatinib sensitization.	Lapatinib	80-89	X protein	Hepatitis B virus	51-54
30711950-4	2019	MATERIALS AND METHODS: The exact motif responsible for the lapatinib sensitization was assessed by construction of various fragments of HBx.	Lapatinib	59-68	X protein	Hepatitis B virus	136-139
30711950-6	2019	RESULTS: Our investigation found that lapatinib sensitivity and up-regulation of ERBB3 promoter activity were observed only in HCC cells expressing C-terminal residues of HBx.	Lapatinib	38-47	X protein	Hepatitis B virus	171-174
30711950-7	2019	Furthermore, C-terminal HBx peptide induced ERBB3 protein expression and sensitivity to lapatinib.	Lapatinib	88-97	X protein	Hepatitis B virus	24-27
30711950-8	2019	CONCLUSION: These results not only indicate that the C-terminus of HBx is required for lapatinib sensitivity, but also provide clues to developing a predictive biomarker for response of HCC to lapatinib in the future.	Lapatinib	87-96	X protein	Hepatitis B virus	67-70
30711950-8	2019	CONCLUSION: These results not only indicate that the C-terminus of HBx is required for lapatinib sensitivity, but also provide clues to developing a predictive biomarker for response of HCC to lapatinib in the future.	Lapatinib	193-202	X protein	Hepatitis B virus	67-70
30242055-6	2019	Thy1-low cells are sensitive to the EGFR/HER2 dual inhibitor lapatinib.	Lapatinib	61-70	epidermal growth factor receptor	Homo sapiens	36-40
30242055-6	2019	Thy1-low cells are sensitive to the EGFR/HER2 dual inhibitor lapatinib.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
30675314-4	2019	Furthermore, it was identified that activations of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways in 4T1 TS conferred drug-resistance to doxorubicin (Dox) and lapatinib (Lapa).	Lapatinib	221-230	signal transducer and activator of transcription 3	Mus musculus	55-105
30675314-4	2019	Furthermore, it was identified that activations of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways in 4T1 TS conferred drug-resistance to doxorubicin (Dox) and lapatinib (Lapa).	Lapatinib	221-230	signal transducer and activator of transcription 3	Mus musculus	107-112
30675314-4	2019	Furthermore, it was identified that activations of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways in 4T1 TS conferred drug-resistance to doxorubicin (Dox) and lapatinib (Lapa).	Lapatinib	221-230	thymoma viral proto-oncogene 1	Mus musculus	136-139
30675314-4	2019	Furthermore, it was identified that activations of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways in 4T1 TS conferred drug-resistance to doxorubicin (Dox) and lapatinib (Lapa).	Lapatinib	232-236	signal transducer and activator of transcription 3	Mus musculus	55-105
30675314-4	2019	Furthermore, it was identified that activations of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways in 4T1 TS conferred drug-resistance to doxorubicin (Dox) and lapatinib (Lapa).	Lapatinib	232-236	signal transducer and activator of transcription 3	Mus musculus	107-112
30675314-4	2019	Furthermore, it was identified that activations of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways in 4T1 TS conferred drug-resistance to doxorubicin (Dox) and lapatinib (Lapa).	Lapatinib	232-236	thymoma viral proto-oncogene 1	Mus musculus	136-139
30867824-13	2019	CXCL5 was also induced in RCC by chloroquine and in a model of HER2 positive breast cancer cell lines after acute or chronic treatment with lapatinib.	Lapatinib	140-149	C-X-C motif chemokine ligand 5	Homo sapiens	0-5
30343043-5	2019	The effects of berberine and lapatinib on MAPK and PI3K pathways in MDA-MB231 and MCF-7 cells were evaluated using immunoflorescence assays, and the amounts of phosphorylated kinases were compared to total kinases after treating with different concentrations of berberine.	Lapatinib	29-38	mitogen-activated protein kinase 3	Homo sapiens	42-46
30343043-8	2019	Also, lapatinib strongly activated AKT but suppressed EGFR in MDA-MB231 cells.	Lapatinib	6-15	AKT serine/threonine kinase 1	Homo sapiens	35-38
30343043-8	2019	Also, lapatinib strongly activated AKT but suppressed EGFR in MDA-MB231 cells.	Lapatinib	6-15	epidermal growth factor receptor	Homo sapiens	54-58
30343043-10	2019	CONCLUSION: By way of its multikinase inhibitory effects, berberine might be a useful replacement for lapatinib, an EGFR inhibitor which can cause acquired drug resistance in patients.	Lapatinib	102-111	epidermal growth factor receptor	Homo sapiens	116-120
30867824-13	2019	CXCL5 was also induced in RCC by chloroquine and in a model of HER2 positive breast cancer cell lines after acute or chronic treatment with lapatinib.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
30729097-5	2019	This study evaluates the role of survivin in IGF1R-mediated lapatinib resistance.	Lapatinib	60-69	insulin like growth factor 1 receptor	Homo sapiens	45-50
30729097-6	2019	Using HNSCC cell lines FaDu and SCC25, survivin expression increased and lapatinib sensitivity decreased with IGF1R activation.	Lapatinib	73-82	insulin like growth factor 1 receptor	Homo sapiens	110-115
30729097-10	2019	These results demonstrate that enhanced survivin expression correlates with IGF1R-mediated lapatinib resistance in HNSCC cells and suggest that regulation of survivin expression may be a key mechanistic element in IGF1R-based therapeutic resistance.	Lapatinib	91-100	insulin like growth factor 1 receptor	Homo sapiens	76-81
30729097-10	2019	These results demonstrate that enhanced survivin expression correlates with IGF1R-mediated lapatinib resistance in HNSCC cells and suggest that regulation of survivin expression may be a key mechanistic element in IGF1R-based therapeutic resistance.	Lapatinib	91-100	insulin like growth factor 1 receptor	Homo sapiens	214-219
30463939-8	2019	Inhibition of ezrin synergizes with lapatinib in a PKCalpha-dependent fashion to inhibit proliferation and promote apoptosis in HER2-positive breast cancer cells.	Lapatinib	36-45	ezrin	Homo sapiens	14-19
30463939-8	2019	Inhibition of ezrin synergizes with lapatinib in a PKCalpha-dependent fashion to inhibit proliferation and promote apoptosis in HER2-positive breast cancer cells.	Lapatinib	36-45	protein kinase C alpha	Homo sapiens	51-59
30463939-8	2019	Inhibition of ezrin synergizes with lapatinib in a PKCalpha-dependent fashion to inhibit proliferation and promote apoptosis in HER2-positive breast cancer cells.	Lapatinib	36-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
30657766-0	2019	Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib.	Lapatinib	62-71	negative elongation factor complex member C/D	Homo sapiens	0-3
30657766-3	2019	The targeted anti-cancer agent, lapatinib, is a small molecule inhibitor that directly interferes with EGFR (HER-1)and HER-2 signaling, and indirectly reduces HER-3 signaling, thus suppressing important downstream events.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	103-107
30657766-3	2019	The targeted anti-cancer agent, lapatinib, is a small molecule inhibitor that directly interferes with EGFR (HER-1)and HER-2 signaling, and indirectly reduces HER-3 signaling, thus suppressing important downstream events.	Lapatinib	32-41	epidermal growth factor receptor	Homo sapiens	109-114
30657766-3	2019	The targeted anti-cancer agent, lapatinib, is a small molecule inhibitor that directly interferes with EGFR (HER-1)and HER-2 signaling, and indirectly reduces HER-3 signaling, thus suppressing important downstream events.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-124
30657766-3	2019	The targeted anti-cancer agent, lapatinib, is a small molecule inhibitor that directly interferes with EGFR (HER-1)and HER-2 signaling, and indirectly reduces HER-3 signaling, thus suppressing important downstream events.	Lapatinib	32-41	erb-b2 receptor tyrosine kinase 3	Homo sapiens	159-164
30657766-7	2019	Lapatinib-sensitive SKBR3, MDA-MB-468 and BT474 cells were incubated with Th1 cytokines, lapatinib, or both.	Lapatinib	0-9	negative elongation factor complex member C/D	Homo sapiens	74-77
30657766-10	2019	Interestingly, when lapatinib resistant lines MDA-MB-453 and JIMT-1 were tested, it was found that the presence of Th1 cytokines appeared to enhance sensitivity for lapatinib-induced metabolic suppression and induction of apoptotic cell death, nearly abrogating drug resistance.	Lapatinib	20-29	negative elongation factor complex member C/D	Homo sapiens	115-118
30657766-10	2019	Interestingly, when lapatinib resistant lines MDA-MB-453 and JIMT-1 were tested, it was found that the presence of Th1 cytokines appeared to enhance sensitivity for lapatinib-induced metabolic suppression and induction of apoptotic cell death, nearly abrogating drug resistance.	Lapatinib	165-174	negative elongation factor complex member C/D	Homo sapiens	115-118